
<html lang="en"     class="pb-page"  data-request-id="9f355e0e-da5e-49f9-b081-465d2f4727c0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-19;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c00345;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthetic Approaches to New Drugs Approved during 2018" /></meta><meta name="dc.Creator" content="Andrew C.  Flick" /></meta><meta name="dc.Creator" content="Carolyn A.  Leverett" /></meta><meta name="dc.Creator" content="Hong X.  Ding" /></meta><meta name="dc.Creator" content="Emma  McInturff" /></meta><meta name="dc.Creator" content="Sarah J.  Fink" /></meta><meta name="dc.Creator" content="Christopher J.  Helal" /></meta><meta name="dc.Creator" content="Jacob C.  DeForest" /></meta><meta name="dc.Creator" content="Peter D.  Morse" /></meta><meta name="dc.Creator" content="Subham  Mahapatra" /></meta><meta name="dc.Creator" content="Christopher J.  O’Donnell" /></meta><meta name="dc.Description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while ..." /></meta><meta name="Description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 27, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00345" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00345" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00345" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00345" /></link>
        
    
    

<title>Synthetic Approaches to New Drugs Approved during 2018 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00345" /></meta><meta property="og:title" content="Synthetic Approaches to New Drugs Approved during 2018" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0076.jpeg" /></meta><meta property="og:description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 39 new chemical entities approved for the first time globally in 2018." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00345"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00345">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00345&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00345&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00345&amp;href=/doi/10.1021/acs.jmedchem.0c00345" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 10652-10704</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00222" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00352" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthetic Approaches to New Drugs Approved during 2018</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Andrew C. Flick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew C. Flick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda California, Inc., 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+C.++Flick">Andrew C. Flick</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carolyn A. Leverett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carolyn A. Leverett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carolyn+A.++Leverett">Carolyn A. Leverett</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong X. Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong X. Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacodia (Beijing) Co., Ltd., Beijing 100085, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong+X.++Ding">Hong X. Ding</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emma McInturff</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emma McInturff</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emma++McInturff">Emma McInturff</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0426-3089" title="Orcid link">http://orcid.org/0000-0003-0426-3089</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah J. Fink</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah J. Fink</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda Pharmaceutical Company Limited, 125 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+J.++Fink">Sarah J. Fink</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher J. Helal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. Helal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biogen, 115 Broadway Avenue, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++Helal">Christopher J. Helal</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jacob C. DeForest</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jacob C. DeForest</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jacob+C.++DeForest">Jacob C. DeForest</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter D. Morse</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter D. Morse</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+D.++Morse">Peter D. Morse</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Subham Mahapatra</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Subham Mahapatra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Subham++Mahapatra">Subham Mahapatra</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath9">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Christopher J. O’Donnell</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. O’Donnell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 860-405-4976. Email: <a href="/cdn-cgi/l/email-protection#fe9d968c978d8a918e969b8cd094d0919a9190909b9292be8e9897849b8cd09d9193"><span class="__cf_email__" data-cfemail="46252e342f353229362e2334682c682922292828232a2a0636202f3c23346825292b">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++O%E2%80%99Donnell">Christopher J. O’Donnell</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath10">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1004-7139" title="Orcid link">http://orcid.org/0000-0003-1004-7139</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00345&amp;href=/doi/10.1021%2Facs.jmedchem.0c00345" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 10652–10704</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 27, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 February 2020</li><li><span class="item_label"><b>Published</b> online</span>27 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 October 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00345" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00345</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10652%26pageCount%3D53%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndrew%2BC.%2BFlick%252C%2BCarolyn%2BA.%2BLeverett%252C%2BHong%2BX.%2BDing%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D19%26contentID%3Dacs.jmedchem.0c00345%26title%3DSynthetic%2BApproaches%2Bto%2BNew%2BDrugs%2BApproved%2Bduring%2B2018%26numPages%3D53%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10704%26publicationDate%3DOctober%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00345"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">12061</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00345" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthetic Approaches to New Drugs Approved during 2018&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;C. Flick&quot;},{&quot;first_name&quot;:&quot;Carolyn&quot;,&quot;last_name&quot;:&quot;A. Leverett&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;X. Ding&quot;},{&quot;first_name&quot;:&quot;Emma&quot;,&quot;last_name&quot;:&quot;McInturff&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;J. Fink&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. Helal&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;C. DeForest&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;D. Morse&quot;},{&quot;first_name&quot;:&quot;Subham&quot;,&quot;last_name&quot;:&quot;Mahapatra&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. O’Donnell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;10652-10704&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00345&quot;},&quot;abstract&quot;:&quot;New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 39 new chemical entities approved for the first time globally in 2018.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00345&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00345" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00345&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00345" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00345&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00345" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00345&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00345&amp;href=/doi/10.1021/acs.jmedchem.0c00345" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00345" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00345" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00345%26sid%3Dliteratum%253Aachs%26pmid%3D32338902%26genre%3Darticle%26aulast%3DFlick%26date%3D2020%26atitle%3DSynthetic%2BApproaches%2Bto%2BNew%2BDrugs%2BApproved%2Bduring%2B2018%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D19%26spage%3D10652%26epage%3D10704%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291650" title="Alcohols">Alcohols</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/jmcmar.2020.63.issue-19/20201008/jmcmar.2020.63.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0076.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0076.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 39 new chemical entities approved for the first time globally in 2018.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="quote"><p class="first">The most fruitful basis for the discovery of a new drug is to start with an old drug.</p><div class="attrib">Sir James Whyte Black, Winner of the 1988 Nobel Prize in Medicine<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div></div><div class="NLM_p">Because drugs can have structural homology across similar biological targets, it is widely believed that the knowledge of new chemical entities and approaches to their construction will enhance the ability to discover new drugs more efficiently. This annual review, which is now in its 17th installment,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> presents synthetic routes for 39 new molecular entities that were approved for the first time by a governing body anywhere in the world during the 2018 calendar year (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Each drug is prefaced by a brief introduction summarizing the relevant pharmacology or differentiating features of the medicine.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> New indications for previously launched medications, new combinations or formulations of existing drugs, and drugs synthesized entirely by biological processes or peptide synthesizers have been excluded from coverage. For organizational purposes, drugs presented in this review are categorized into the following therapeutic areas: antibiotic and antifungal, anti-infective, cardiovascular and hematologic, gastrointestinal, inflammation and immunology, metabolic, oncology, ophthalmologic, rare disease, reproductive, and urinary tract. Within each of these therapeutic areas, drugs are ordered alphabetically by generic name. It is important to note that a drug’s process-scale synthetic approach is often not explicitly disclosed at the time of this review’s publication. In some cases, only a discovery-scale or a general synthetic approach capable of delivering the active pharmaceutical ingredient (API) has been made available. Nonetheless, the synthetic sequences described in this review have all been previously reported in either patent or public chemical literature and, to the best of our assessment, represent scalable routes originating from commercially available starting materials (as determined by explicit statement or inferred by experimental detail).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0001.jpeg" id="gr72" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0002.jpeg" id="GRAPHIC-d7e318-autogenerated" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0003.jpeg" id="GRAPHIC-d7e319-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of 39 NCEs approved in 2018.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0001.jpeg jm0c00345_0002.jpeg jm0c00345_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Antibiotic and Antifungal Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60734" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60734" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Eravacycline (Xerava)</h3><div class="NLM_p">Eravacycline belongs to the tetracycline class of antibiotics and was approved by the United States Food and Drug Administration (USFDA) for the treatment of complicated intra-abdominal infections in patients aged 18 years and older. Eravacycline is a fully synthetic broad-spectrum antibiotic that exhibits potent activity against both Gram-positive and Gram-negative bacterial strains, including many that have acquired tetracycline-specific resistant mechanisms.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Eravacycline was discovered and developed by Tetraphase Pharmaceuticals and was licensed to Everest Medicines for commercialization in many eastern Asian countries.</div><div class="NLM_p">Two other tetracycline antibiotics, sarecycline and omadacycline, were also approved this year, but both molecules were prepared from previously approved tetracyclines that were ultimately obtained via fermentation. Eravacycline is a fully synthetic tetracycline, and a highly convergent route for its preparation was first described by the laboratory of Professor Andrew Myers at Harvard University.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> This route was later refined at Tetraphase Pharmaceuticals, leading to the discovery and development of eravacycline.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The route described has been published in the primary and patent literature on multikilogram scale.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Retrosynthetically, eravacycline (<b>I</b>) was envisioned to be derived via a Michael addition–Dieckmann cyclization reaction between the anion of compound <b>1</b> and Michael acceptor <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Tricyclic intermediate <b>2</b> was envisioned to come from addition of the anion of isoxazole <b>4</b> to the aldehyde <b>3</b>, followed by an intramolecular Diels–Alder reaction to set the carbon framework of <b>2</b>. Isoxazole <b>4</b> was envisioned to come from dimethyl maleate, and the chiral vinyl amine stereocenter was set via an Ellman sulfinamide auxiliary.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0004.jpeg" id="gr73" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Retrosynthetic approach to eravacycline.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The preparation of the chiral isoxazole <b>4</b> is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'cit8c'); return false;" href="javascript:void(0);" class="ref cit8c">(8c)</a> Dimethyl maleate (<b>5</b>) was treated with bromine in the presence of azo-bis(isobutyronitrile) (AIBN) and ultraviolet light to give dibromide <b>6</b> in 92% yield. Condensation of <b>6</b> with hydroxyurea in the presence of potassium <i>tert</i>-butoxide provided isoxazole <b>7</b> in 66% yield. Benzylation of the hydroxy group of <b>7</b> followed by DIBAL reduction of the ester gave aldehyde <b>8</b> in high yield over the two steps. Condensation of <b>8</b> with (<i>S</i>)-<i>tert</i>-butylsulfinylamide (Ellman’s auxiliary) in the presence of copper(II) sulfate provided chiral sulfinimine <b>9</b> in 85% yield. After reaction optimization, <b>9</b> was treated with vinylmagnesium chloride in the presence of methyllithium and zinc chloride to give <b>10</b> in 95% yield (99.3:0.7 dr). The <i>tert</i>-butylsulfinyl group was removed under acidic conditions. The resulting primary amine was treated with formaldehyde in the presence of sodium acetate and then reduced using a picoline–borane complex to give the dimethylamine coupling partner <b>4</b> in 88% yield for the two-step sequence (96.0% ee). The ee was enhanced to 99.0% by tartrate salt formation, giving <b>4</b>·tartrate in 91% yield.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Eravacycline Isoxazole <b>4</b> (<b>4</b>·Tartrate)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The preparation of the tricyclic Michael acceptor enone <b>2</b> is described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.<a onclick="showRef(event, 'cit8b'); return false;" href="javascript:void(0);" class="ref cit8b">(8b)</a> Treating <b>4</b>·tartrate with sodium hydroxide provided the free base <b>4</b>, which was reacted with tetramethylpiperidine (TMP) magnesium chloride–lithium chloride complex to effect the direct magnesiation of <b>4</b> on the oxazole ring, with no competing allylic metalation. This intermediate was reacted with aldehyde <b>3</b> to give alcohols <b>11a/11b</b> in 95% yield (3.57:1 dr). Heating the mixture of <b>11a/11b</b> in DMSO, DIPEA, butylated hydroxytoluene, and isopropyl acetate effected the intramolecular Diels–Alder reaction to give a mixture of <i>endo</i> products (<b>12a/12b</b>), arising from <b>11a</b>, and a mixture of <i>exo</i> products (<b>12c/12d</b>), arising from <b>11b</b>. This mixture of alcohols <b>12a</b>–<b>d</b> was oxidized with sulfur trioxide pyridine complex to give ketones <b>13a/13b</b> in 99.1:0.9 dr and 74% overall yield from <b>11a/b</b>. Treating <b>13a/13b</b> with boron trichloride efficiently effected demethylation of the methyl enol ether, which spontaneously underwent ring opening to provide enone <b>14</b> in high yield. Protection of the resulting alcohol as its tributylsilyl ether followed by recrystallization from isopropyl alcohol provided the tricyclic Michael acceptor coupling partner <b>2</b> in 88% yield.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0016.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Construction of Eravacycline Tricyclic Michael Acceptor Enone <b>2</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The preparation of intermediate <b>1</b> is described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.<a onclick="showRef(event, 'cit6c'); return false;" href="javascript:void(0);" class="ref cit6c">(6c)</a> Compound <b>15</b> was treated initially with LDA and then quenched with methyl iodide to give arene <b>16</b>. Formation of the acid chloride of <b>16</b> followed by reaction with phenol provided the corresponding ester, making way for methyl ether cleavage with boron tribromide to provide phenol <b>17</b>. Nitration of <b>17</b> and protection of the phenol as a benzyl ether gave nitroarene <b>18</b>. Reduction of the nitro group with sodium bisulfite provided aniline <b>19</b> in 83% from compound <b>15</b>. Amine <b>19</b> was reacted with benzyl bromide to produce the dibenzylamine-protected coupling partner <b>1</b> in 80% yield.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0027.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Dibenzyl Amine Protected Coupling Partner <b>1</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The completion of the synthesis of eravacycline (<b>I</b>) is described in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>.<a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">(8a)</a> Compound <b>1</b> was treated with LDA followed by compound <b>2</b> to promote the desired intermolecular Michael addition. The resulting Michael adduct was then treated with lithium bis(trimethylsilyl)amide (LHMDS) to induce an intramolecular Dieckmann cyclization, which gave compound <b>20</b> in 94% yield. The silyl protecting group was removed using hydrofluoric acid, and the resulting intermediate was treated with hydrogen and palladium on carbon. These conditions resulted in the removal of the dibenzylamine and benzyl ether protecting groups, which further gave rise to the opening of the oxazole ring to ultimately arrive at compound <b>21</b> in 89% yield for the two step sequence. Compound <b>21</b> was then reacted with acid chloride <b>22</b> to furnish eravacycline <b>I</b> in 89% yield.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0038.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Final Assembly of Eravacycline (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.2.  Fosravuconazole <span class="smallcaps smallerCapital">l</span>-Lysine Ethanolate (Nailin)</h3><div class="NLM_p">Fosravuconazole <span class="smallcaps smallerCapital">l</span>-lysine ethanolate (F-RVCZ) is an orally administered, broad-spectrum antifungal drug approved in Japan for the treatment of onychomycosis in 2018.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> F-RVCZ is a prodrug of ravuconazole with improved solubility and oral bioavailability.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Originally discovered by Eisai,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> ravuconazole was licensed to Bristol-Myers Squibb (BMS) for worldwide development, excluding Japan, in 1996. However, BMS terminated development of the drug in 2004, and Eisai reacquired the worldwide development, manufacturing, and marketing rights. The antifungal activities of ravuconazole, like other azole drugs, derive from the inhibition of ergosterol biosynthesis and block the 14α-demethylation pathway present in many strains of yeasts and molds.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The lowering of ergosterol levels leads to accumulation of 14α-methyl sterols, which impairs normal structure and functions of cell membranes, ultimately resulting in growth inhibition or death of fungal cells. F-RCVZ exhibited higher efficacy (higher initial cure rates and lower recurrence rates), an improved safety-profile (lower hepatic functional disorders), and improved dosing regimen (once daily for 12 weeks) over existing standards of care such as terbinafine and itraconazole.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">In addition to several disclosures describing the gram-scale synthesis of ravuconazole and related precursors,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> a robust plant-scale preparation has been described by researchers at BMS (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This route utilized lactate <b>23</b> as a starting material for the preparation of arylpropanone <b>26</b>. First, methyl ester <b>23</b> was converted to a morpholine amide in the presence of catalytic sodium methoxide. The alcohol was subsequently protected to generate tetrahydropyranyl ether <b>24</b>. Use of real-time infrared reaction monitoring allowed for safe formation of Grignard reagent <b>25</b> from the corresponding bromide, which was then reacted with amide <b>24</b> to furnish aryl ketone <b>26</b> after aqueous acetic acid quench. Corey–Chaykovsky epoxidation and subsequent epoxide opening were performed in a single-step, telescoped process. Once epoxidation was complete, heating the reaction mixture to 90 °C triggered a triazole-mediated epoxide-opening sequence to form alcohol <b>28</b>. The stereochemical outcome of the epoxide-forming step is dictated by the adjacent chiral center, providing <b>27</b> in 8.6:1 dr. Removal of the tetrahydropyranyl protecting group within <b>28</b> generated an intermediate diol which was converted to trisubstituted epoxide <b>29</b> via selective mesylation of the secondary alcohol. Generation of lithium cyanide <i>in situ</i> from acetone cyanohydrin <b>30</b> and LHMDS followed by subsequent addition to epoxide <b>29</b> delivered the α-cyano alcohol <b>31</b> in 90% yield, which was subsequently converted to thioamide monohydrate salt <b>33</b> by treatment with diethyl dithiophosphate <b>32</b> and sulfuric acid. Condensation of the thioamide <b>33</b> with 2-bromo-4′-cyanoacetophenone <b>34</b> in hot ethanol resulted in thiazole formation which completed the preparation of ravuconazole (<b>35</b>).</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0049.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Ravuconazole (<b>35</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Conversion of ravuconazole to the highly water-soluble prodrug fosravuconazole <span class="smallcaps smallerCapital">l</span>-lysine ethanolate (<b>II</b>) has been described by the scientists at Eisai (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> First, ravuconazole (<b>35</b>) was O-alkylated with di-<i>tert</i>-butyl chloromethylphosphate <b>36</b> to furnish phosphate ester <b>37</b>. Subjection of ester <b>37</b> to trifluoroacetic acid (TFA) and aqueous sodium hydroxide provided the free acid, which was subsequently converted to fosravuconazole <span class="smallcaps smallerCapital">l</span>-lysine ethanolate (<b>II</b>).</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0060.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Fosravuconazole <span class="smallcaps smallerCapital">l</span>-Lysine Ethanolate (<b>II</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">2.3.  Omadacycline (Nuzyra)</h3><div class="NLM_p">Omadacycline belongs to the aminomethylcycline class of tetracycline antibiotics and was approved by the USFDA for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Discovered and developed by Paratek Pharmaceuticals, omadacycline was licensed to Bayer, Merck, and Novartis over the course of its clinical development. Ultimately the rights were returned to Paratek, who collaborated with Zai Lab (Shanghai) Co., Ltd. to commercialize the drug in China.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">A number of syntheses of omadacycline have been published, and the largest scale route is described in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. This route advantageously began with minocycline (<b>38</b>, <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>) which is a tetracyclic antibiotic drug first patented in 1961.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Minocycline was condensed with <i>N</i>-(hydroxymethyl)phthalimide (<b>39</b>) in the presence of triflic acid to give a mixture of the 9-phthalimidomethyl analogs <b>40</b> and <b>41</b> in approximately a 60:40 ratio. This mixture was treated with methylamine, which resulted in hydrolysis of the phthalimide to give an unreported distribution of methylamine analogs <b>42</b> and <b>43</b>. This mixture was then treated with pivaldehyde under catalytic hydrogenation conditions to affect the reductive amination at position N-9, followed by concomitant removal of the hemiaminal group on the amide, furnishing omadacycline (<b>III</b>) in 15–18% yield for the overall process after conversion to the tosylate salt.</div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0071.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0071.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Omadacycline <b>III</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0071.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">2.4.  Plazomicin (Zemdri)</h3><div class="NLM_p">Originally discovered by California-based Ionis Pharmaceuticals and later developed by Achaogen, plazomicin was approved by the USFDA in 2018 for the treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including pyelonephritis. The drug, a next-generation aminoglycoside that is delivered by injection, was acquired by Cipla as part of an auction of Achaogen assets after the American firm filed for chapter 11 bankruptcy.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> As a structural derivative of the anti-infective aminoglycoside sisomycin, plazomicin is a neoglycoside that is highly active against a variety of bacterial pathogens, including many of the Gram-negative rods that are implicated in cUTIs. Plazomicin is not affected by most aminoglycoside-modifying enzymes and retains activity against multidrug-resistant (MDR) isolates known as carbapenem-resistant enterobacteriaceae (CRE).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Two synthetic routes to plazomicin have been reported, both of which originate from commercial sisomicin (<b>44</b>, <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>) and vary only by differential protection of the sisomicin amines.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Sisomicin was treated with an ion-exchange resin which furnished trifluoroacetamide <b>45</b> after reaction with ethyl trifluorothioacetate. Zinc acetate and benzyloxycarbonyl succinimide provided the corresponding Cbz-protected intermediate <b>46</b> in a 35% yield from <b>44</b>. Amide coupling and removal of the trifluoroacetate group yielded glycoside <b>48</b>, which then underwent reductive amination, benzoyl ester cleavage, and global Cbz removal under hydrogenative conditions to give rise to plazomicin (<b>IV</b>).<a onclick="showRef(event, 'cit21c cit21d'); return false;" href="javascript:void(0);" class="ref cit21c cit21d">(21c,d)</a></div><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0074.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0074.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Plazomicin (<b>IV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0074.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">2.5.  Sarecycline Hydrochloride (Seysara)</h3><div class="NLM_p">Sarecycline belongs to the tetracycline class of antibiotics and was approved by the USFDA for the oral treatment of inflammatory lesions of non-nodular, moderate-to-severe acne vulgaris in patients at least 9 years old. Sarecycline was discovered at Paratek Pharmaceuticals and licensed to Warner Chilcott, which was later acquired by Allergan. Allergan completed the development and launch of the drug before rights were acquired by Almarall S.A. in 2018.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">To date, there are no publications describing the discovery of sarecycline. The only reported synthetic route to the drug, performed on small scale by Paratek, is described in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Iodination of commercially available sancycline <b>51</b> with <i>N</i>-iodosuccinimide followed by HPLC purification provided iodosancycline <b>52</b> as the trifluoroacetate salt (no yield reported). Carbonylation of <b>52</b> in the presence of palladium acetate and Xantphos followed by treatment with triethylsilane provided the corresponding aldehyde, which was treated with trifluoracetic acid to provide formylsancycline trifluoroacetate <b>53</b>.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Condensation of <b>53</b> with <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride, reduction with sodium cyanoborohydride, and treatment with hydrochloric acid provided sarecycline hydrochloride (<b>V</b>) in 23% yield for the three-step sequence.</div><figure id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0075.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0075.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Sarecycline Hydrochloride (<b>V</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0075.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">3.  Anti-infective Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">3.1.  Baloxavir Marboxil (Xofluza)</h3><div class="NLM_p">In 2018, baloxavir marboxil received its first approval by the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) for the treatment of influenza A or B virus infections.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Later the same year, the drug was also approved by the USFDA for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 h.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Baloxavir marboxil was discovered by Shionogi, who licensed their rights to Roche in February 2016 for development and commercialization except in Taiwan and Japan (Shionogi maintained its rights in these two countries).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Baloxavir is a novel cap-dependent endonuclease inhibitor that blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. This is in contrast to neuraminidase inhibitors, which impair viral release from infected host cells.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">Shionogi has reported two unique synthetic approaches to baloxavir, each of which originate from different starting materials.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The route expected to be most scalable is depicted in <a class="ref internalNav" href="#sch10" aria-label="Schemes 10">Schemes 10</a>, <a class="ref internalNav" href="#sch11" aria-label="11">11</a>, and <a class="ref internalNav" href="#sch12" aria-label="12">12</a>. This approach strategically hinges upon union of a piperazine tricyclic core and a tricyclic diaryl mercaptan.<a onclick="showRef(event, 'cit28b'); return false;" href="javascript:void(0);" class="ref cit28b">(28b)</a> Acid <b>54</b> was methylated and then subjected to Boc-hydrazine under weakly acidic conditions to furnish ester <b>55</b> which was reacted with amine <b>58</b> to afford racemic hemihydrate <b>59</b>. Amine <b>58</b> can be prepared by the alkylation of phthalimidyl alcohol <b>56</b> with bromide <b>57</b>, followed by hydrazine-mediated phthalimide cleavage.</div><figure id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Assembly of Baloxavir Piperazine Heterocyclic Core <b>59</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Construction of Baloxavir Benzothiepine <b>62</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch12" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Final Assembly of Baloxavir Marboxil (<b>VI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Separately, benzothiepine <b>62</b> was constructed as outlined in <a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>. Benzoic acid <b>60</b> was <i>o-</i>lithiated prior to quench with DMF. The lactone in <b>61</b> was formed upon acidification with D-CSA. Intramolecular Friedel–Crafts followed by acidification and reduction furnished benzothiepine alcohol <b>62</b> in 73% yield.</div><div class="NLM_p last">The final steps in the assembly of baloxavir marboxil are described in <a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>. Enantiomeric resolution of <b>59</b> was performed by reacting <b>59</b> with commercial chiral acid <b>63</b> followed by recrystallization from warm ethyl acetate. The diastereomer corresponding to the desired geometry was then collected and treated with DBU which provided enantiomerically enriched free base <b>64</b>. Although this reaction was exemplified on kilogram-scale, the chiral purity was not reported. The benzyl ether within <b>64</b> was then converted to the corresponding <i>n</i>-hexyl ether using <i>n</i>-hexanol and isopropylmagnesium chloride, making way for isolation of tosylate salt <b>65</b> after treatment with <i>p</i>-TsOH. Next, <b>62</b> was subjected to propylphosphonic anhydride (T3P) under acidic conditions and coupled with fragment <b>65</b> to form the core structure of baloxavir marboxil. Subsequent treatment with base and methanesulfonic acid led to the formation of mesylate salt <b>66</b>. Removal of the <i>n</i>-hexyl ether was facilitated by lithium chloride in warm NMP, followed by isolation of phenol <b>67</b> upon precipitation from a warm acetonitrile/water mixture. Subsequent alkylation with alkyl chloride <b>68</b> preceded careful treatment with acid to furnish baloxavir marboxil (<b>VI</b>).</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">3.2.  Bictegravir (Bictarvy)</h3><div class="NLM_p">Bictegravir, discovered by Gilead, was approved in 2018 as part of a combination therapy involving bictegravir, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infections.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> This was based on a phase 3 clinical trial where the combination of bictegravir, emtricitabine, and tenofovir alafenamide was shown to be better tolerated than previous single-tablet regimens.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Bictegravir belongs to a class of antiretroviral drugs known as integrase strand transfer inhibitors (INSTIs). Compounds of this class inhibit HIV-1 integrase (IN), which plays a central role in viral replication by catalyzing the insertion of viral cDNA into the genome of the host.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">Process chemists at Gilead have disclosed a seven-step route to bictegravir.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Although yields were not reported for this sequence, the approach allowed for the late-state installation of chiral aminocyclopentanol <b>78</b> (<a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>). The synthesis began with condensation of Meldrum’s acid (<b>69</b>) and methoxyacetic acid <b>70</b> in the presence of pivaloyl chloride, giving rise to intermediate <b>71</b>. Subjection of <b>71</b> to benzylamine <b>72</b> and TFA ultimately furnished β-ketoamide <b>73</b>. Treatment with DMF–DMA followed by condensation with dimethyl acetal <b>74</b> furnished vinylogous amide <b>75</b>, making way for a cyclization reaction to generate  pyridone <b>77</b> by treatment with dimethyl oxalate (<b>76</b>) and sodium methoxide. Acetal deprotection was followed by treatment with <i>syn</i>-aminopentanol <b>78</b> under basic conditions. This annulation arose from amide bond formation between primary amine <b>78</b> and the methyl ester within <b>77</b>, followed by condensation with the pendant acetal, allowing for arrival at aminal <b>79</b>, establishing the polycyclic core of bictegravir. Magnesium bromide-mediated demethylation furnished bictegravir (<b>VII</b>).</div><figure id="sch13" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0009.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Bictegravir (<b>VII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The preparation of s<i>yn</i>-aminopentanol <b>78</b> has been described on gram scale by the Chinese firm Anhui Twisun Hi-Tech Pharmaceutical Co., Ltd. in <a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Commercial cyclopentanoic acid <b>80</b> was converted to the corresponding Weinreb amide <b>81</b> which was then exposed to methylmagnesium bromide, giving rise to ketone <b>82</b>. Subjection of <b>82</b> to Baeyer–Villiger oxidation conditions resulted in a rearrangement product whereby the more substituted carbon of the ketone underwent rearrangement, presumably with retention of stereochemical configuration.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Subsequent treatment with base and finally acidic removal of the Boc group provided aminopentanol <b>78</b>. Although yields were reported for this sequence, stereoselectivity was not.</div><figure id="sch14" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0010.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Preparation of Bictegravir <i>syn</i>-Aminopentanol <b>78</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">3.3.  Danoprevir (Ganovo)</h3><div class="NLM_p">Danoprevir is an orally available hepatitis C virus nonstructural protein 3 (NS3) protease inhibitor approved in 2018 in China for treatment-naive patients with noncirrhotic genotype 1b chronic hepatitis C.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Discovered by InterMune Inc. and Array Biopharma Inc., the rights to license danoprevir were acquired by Roche in 2006, who later partnered with Aslectis for the co-development and commercialization of the drug in China.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Hepatitis C is reported to affect roughly 1.6% of the population globally and 4.4% of the population in China, with the genotype 1b predominating in China.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Protease activity of hepatitis C NS3 is crucial for viral replication. Danoprevir inhibits the NS3 protease active site through a two-step binding mechanism that involves an initial collision complex that rapidly isomerizes to a highly stable complex displaying unusually slow dissociation.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> With a calculated complex half-life of roughly 5 h, the observed binding kinetics distinguish danoprevir from other related macrocyclic inhibitors of NS3. Danoprevir is also a substrate of cytochrome P4503A. To maximize its effectiveness, danoprevir is coadministered with the CYP3A inhibitor/inducer ritonavir, as well as the antiviral drugs peginterferon alfa-2a and ribavirin, both of which are also currently used to treat hepatitis C.</div><div class="NLM_p">A synthetic approach to danoprevir sodium was initially reported in a series of three patents disclosed in 2005.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> A slightly different route derived from the same starting cyclopropyl aminoester was published in 2014.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> To date no explicit scale synthesis has been reported. However, scientists at Boehringer-Ingelheim have reported a concise approach to the building block cyclopropyl aminoester <b>87</b> (a substructural component of several macrocyclic antiviral drugs) on multikilogram scale, and this approach is described in <a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The hydrochloride salt of ethyl glycine <b>83</b> was condensed with benzaldehyde to form imine <b>84</b>, making way for a cyclative dialkylation with 2-butene-1,4-dibromide <b>85</b> through a sequential S<sub>N</sub>2–S<sub>N</sub>2′ reaction. Acidic hydrolysis of the imine and <i>N</i>-Boc protection yielded racemic vinylcylopropane <b>86</b> in 65–70% yield over three steps. Enzymatic resolution using Alcalase 2.4L allowed for selective saponification of the undesired (1<i>S</i>,2<i>R</i>)-carboxylate, providing the desired (1<i>R</i>,2<i>S</i>) enantiomer <b>87</b> in quantitative conversion (including mass recovery of the acid).</div><figure id="sch15" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0011.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Preparation of Danoprevir Cyclopropyl Aminoester <b>87</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of danoprevir continued with deprotection of the amine within <b>87</b> to give <b>88</b> and amide formation mediated by hexafluorophosphate azabenzotriazole tetramethyluronium (HATU) with carboxylic acid <b>89</b> (<a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>). This was followed by a second Boc-deprotection step to afford amino alcohol <b>90</b> in 80% yield over the three-step sequence. HATU-mediated amide coupling with commercial carboxylic acid <b>91</b> provided alkene <b>92</b>, which, when treated with Hoveyda first generation metathesis catalyst <b>93</b>, afforded macrocycle <b>94</b> in 52% yield. Carbonyldiimidazole (CDI)-mediated coupling of <b>94</b> and isoindoline <b>95</b> followed by basic hydrolysis yielded carboxylic acid <b>96</b>. This acid was then reacted with CDI and cyclopropylsulfonamide <b>97</b>, furnishing danoprevir (<b>VIII</b>).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><figure id="sch16" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0012.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Danoprevir (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">3.4.  Doravirine (Pifelto)</h3><div class="NLM_p">Doravirine, also referred to as MK-1439 or “DOR”, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) discovered and developed by Merck.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The drug was approved in 2018 by the USFDA for the treatment of HIV-1 in appropriate patients.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The once-daily dosed drug, like all NNRTIs, inhibits viral DNA synthesis by binding to an allosteric site located about 10 Å from the polymerase active site of the HIV-1 reverse transcriptase.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Doravirine has demonstrated significant antiviral activity against a broad range of NNRTI-resistance associated mutations that are increasingly found in treatment-naive patients while exhibiting an improved safety-profile over existing standard-of-care regimens such as ritonavir, darunavir, and efavirenz.</div><div class="NLM_p">A considerable number of accounts related to the preparation of doravirine and related analogs have been published,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and a robust, kilogram-scale synthesis of the drug has been described by researchers at Merck (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Strategically, this scale route was designed to proceed through substrates that would minimize the evolution of doravirine byproducts that arose from polymethylation and polycyanation, which were challenging to remove by methods other than chromatography. Toward this end, an iridium-catalyzed <i>meta</i>-borylation–oxidation protocol converted iodochlorobenzene <b>98</b> to phenol <b>99</b>, which then participated in an S<sub>N</sub>Ar reaction with pyridine <b>100</b> to arrive at diaryl ether <b>101</b>. Basic hydrolysis of <b>101</b> followed by recrystallization gave rise to 2-pyridinol <b>102</b> in 87% yield from <b>98</b>. Next, introduction of the nitrile using copper cyanide in NMP was achieved under relatively mild conditions. The authors note that keeping the temperature under 110 °C was critical for suppressing undesired bis-cyanation products and that the iodide was chosen over the analogous bromide to further help ensure selectivity for the desired mononitrile product <b>103</b>. Alkylation of <b>103</b> with 5-(chloromethyl)-2,4-dihydro-3<i>H</i>-1,2,4-triazol-3-one (<b>104</b>) was possible under mild conditions to give 2-pyridone <b>105</b> in 81% yield after recrystallization. Although <b>104</b> is commercially available, reports of its preparation have also been previously published.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Lastly, after screening a variety of methylation conditions, <b>105</b> was treated with iodomethane and potassium carbonate in cool NMP, furnishing doravirine (<b>IX</b>) in 68% yield, with minimal overmethylation products observed.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><figure id="sch17" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0013.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Doravirine (<b>IX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">3.5.  Moxidectin (Moxidectin)</h3><div class="NLM_p">Moxidectin was developed by the nonprofit firm Medicines Development for Global Health (MDGH) and was approved by the USFDA in 2018 for the treatment of river blindness, also called onchocerciasis, in patients aged 12 years and older.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> River blindness is caused by the larvae (microfilariae) of a parasitic worm <i>Onchocerca volvulus</i> which manifests as severe itching, disfiguring skin conditions, and visual impairment, including permanent blindness.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Nearly 200 million people are at risk of river blindness, with 99% of patients living in sub-Saharan Africa. Although the actual mechanism of action is unknown, studies with other nematodes suggest that moxidectin binds to a parasite’s glutamate-gated ion channels (GluCl), γ-aminobutyric acid (GABA) receptors, and/or ATP-binding cassette (ABC) transporters.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> This induces increased permeability that leads to an influx of chloride ions and results into flaccid paralysis of the parasite. Moxidectin is active against microfilariae of <i>Onchocerca volvulus</i> but does not kill the adult worms. The drug has a longer half-life than ivermectin, the current standard of care, and offers an alternative for managing antiparasitic drug resistance.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">Moxidectin is a 16-membered macrocyclic lactone of the milbemycin class, which presents significant synthetic challenges structurally.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> However, the starting material for the synthesis of the drug is highly functionalized macrolactone nemadectin (<b>106</b>), a fermentation product of <i>Streptomyces cyanogriseus</i> ssp. <i>noncyanogenus</i>.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Although several Chinese patents have been filed describing the conversion of nemadectin to moxidectin,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> the route described in the most detail is presented in <a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>.<a onclick="showRef(event, 'cit52d'); return false;" href="javascript:void(0);" class="ref cit52d">(52d)</a> Selective protection of the nemadectin C-25 allylic hydroxyl group with 4-chlorophenoxy acetyl chloride <b>107</b> furnished <b>108</b>. The choice of this protecting group was driven by improved stability and simpler purification (recrystallization) of the intermediates. The remaining C-10 secondary alcohol in <b>108</b> was oxidized using modified Pfitzner–Moffat conditions using phenyl phosphorodichloridate (<b>109</b>) to yield ketone <b>110</b>.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Oxime formation and selective saponification of the ester protecting group furnished moxidectin (<b>X</b>). It should be noted that the oxime retains the (<i>E</i>)-configuration throughout the final two steps of the synthesis of the molecule.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><figure id="sch18" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0014.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Moxidectin (<b>X</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">3.6.  Tafenoquine (Krintafel)</h3><div class="NLM_p">Tafenoquine is an orally active antimalarial therapy targeting <i>Plasmodium vivax</i> in patients 16 years of age and older. It is available in both preventative dose-loading regimens and radical cure dosages.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Developed by the Walter Reed Army Institute of Research in the 1980s, tafenoquine (also known as WR 238605) was described as possessing both tissue and blood schizonticidal activity.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The exact mechanism of action of tafenoquine, which is a racemate, is unknown. However, current evidence suggests that tafenoquine may inhibit hematin polymerization<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> and induce apoptosis in select strains.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Tafenoquine is currently being developed by GlaxoSmithKline (GSK) in collaboration with Medicines for Malaria Venture, 60° Pharmaceutical, Knight Therapeutics, and the United States Army.</div><div class="NLM_p">Multiple synthetic routes to tafenoquine have been reported in patents, which have been reviewed.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> A 2003 patent describes the process chemistry route to access tafenoquine, and this approach is described in <a class="ref internalNav" href="#sch19" aria-label="Schemes 19">Schemes 19</a> and <a class="ref internalNav" href="#sch20" aria-label="20">20</a>.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a><i>p</i>-Anisidine <b>111</b> was heated in xylenes and ethyl acetoacetate to give aniline <b>112</b> in 87% yield, which was converted to quinoline <b>113</b> via a sulfuric acid-mediated dehydrative condensation reaction. Quinoline <b>113</b> was subsequently chlorinated with phosphorus oxychloride and sulfuryl chloride to arrive at dichloroquinoline <b>114</b>. Methoxide addition, treatment with triethylphosphine in base, and subsequent nitration converted <b>114</b> to nitroquinoline <b>115</b>.</div><figure id="sch19" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0015.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Preparation of Tafenoquine Nitroquinoline Intermediate <b>115</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch20" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0017.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of Tafenoquine (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">This highly activated quinoline was subjected to a substitution reaction with phenol <b>116</b> under basic conditions. Next, treatment with Darco KB and hydrazine-promoted nitroreduction gave amine <b>117</b> in a 73% yield for the three step sequence (<a class="ref internalNav" href="#sch20" aria-label="Scheme 20">Scheme 20</a>). Alkylation of <b>117</b> with commercial iodide <b>118</b> was performed in a mixture of warm NMP and diisopropylamine followed by hydrazine-mediated conversion of the phthalimide to the corresponding primary amine. Sequential exposure to potassium hydroxide and succinic acid completed the synthesis of tafenoquine (<b>XI</b>) in 63% from <b>119</b>.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">3.7.  Tecovirimat (Tpoxx)</h3><div class="NLM_p">Tecovirimat, which was developed by SIGA Technologies and the United States Department of Health and Human Services Biomedical Advances Research and Development Authority, is the first oral treatment for smallpox. Although smallpox was eradicated due to effective vaccination practices, many people worldwide are now unvaccinated. Because health authorities believe that a single case of the disease could trigger a global health emergency, the identification of this small molecule therapy was intended to serve as a countermeasure. Initiated by a biodefense effort from the National Institute of Allergy and Infectious Disease, tecovirimat was identified by screening libraries of over 300,000 known compounds for their ability to interfere with replication of vaccinia or cowpox. The mechanism of action of tecovirimat likely involves the F13L gene of the vaccinia virus, which encodes a membrane protein that is required for extracelullar virus production.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Tecovirimat was approved under the USFDA’s Animal Rule, as clinical studies in humans were not ethical or feasible.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> This led to several challenges, as the variola virus that causes smallpox has only been observed in humans. As a result, it was necessary to use three animal models: rabbitpox virus in rabbits, ectromelia virus (mousepox), and monkeypox in non-human primates.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Upon approval, tecovirimat became part of the U.S. Government’s Strategic National Stockpile.</div><div class="NLM_p">An efficient, three-step synthetic route to tecovirimat, shown in <a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>, was demonstrated on a small scale.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Diels–Alder cycloaddition of cycloheptatriene <b>120</b> and maleic anhydride <b>121</b> in refluxing xylenes formed the fused tricyclic core in a single step and a 4:1 product ratio, favoring the expected <b>122</b>-<i>endo</i> isomer, which could be isolated by recrystallization from MTBE. Reaction of this fused anhydride with 4-(trifluoromethyl)benzohydrazide <b>123</b> in a mixture of alcohols proceeded without inversion or epimerization of the stereocenters.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Recrystallization from EtOAc/water facilitated isolation of tecovirimat (<b>XII</b>) as the hydrate.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><figure id="sch21" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0018.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of Tecovirimat (<b>XII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">4.  Cardiovascular and Hematologic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00562" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00562" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">4.1.  Avatrombopag Maleate (Doptelet)</h3><div class="NLM_p">Avatrombopag is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. It was first approved by the USFDA in May 2018 and subsequently approved by the European Medicine Agency (EMA) in June 2019.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> Originally developed by Astellas, avatrombopag’s development rights have been transferred between a number of firms, most recently Dova Pharmaceuticals (an affiliate of PBM Capital). In March 2018, Dova entered into an agreement (through AkaRx) to grant Shanghai Fosun Pharma the exclusive development and distribution rights of the drug in mainland China and Hong Kong.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><div class="NLM_p">A large scale synthetic route to avatrombopag, as well as crystalline form protocols, have been reported in a series of patents from Astellas.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> As described in <a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>, bromination of 1-(4-chlorothiophen-2-yl)ethenone (<b>124</b>) gave bromide <b>125</b>. Condensation with thiourea produced thiazolamine <b>126</b> in 46% yield over two steps. Thiazolamine <b>126</b> was brominated with <i>N</i>-bromosuccinimide (NBS) in DMF, making way for nucleophilic aromatic substitution with 1-cyclohexylpiperazine (<b>127</b>) to provide <b>128</b> in 34% overall yield. Amide bond formation with 5,6-dichloronicotinic acid (<b>129</b>) was accomplished by activation with phosphorus oxychloride to give nicotinamide <b>130</b> in 83% yield. A second nucleophilic aromatic substitution with ethyl isonipecotate <b>131</b>, followed by hydrolysis, provided avatrombopag (<b>132</b>).<a onclick="showRef(event, 'cit70a'); return false;" href="javascript:void(0);" class="ref cit70a">(70a)</a> Salt formation was demonstrated on 20 kg scale using maleic acid in a mixture of DMSO/acetone/water (2:2:1) to obtain avatrombopag maleate (<b>XIII</b>) in 85% yield.<a onclick="showRef(event, 'cit70b cit70c'); return false;" href="javascript:void(0);" class="ref cit70b cit70c">(70b,c)</a></div><figure id="sch22" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0019.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of Avatrombopag Maleate (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41">4.2.  Revefenacin (Yupelri)</h3><div class="NLM_p">Developed by Theravance Biopharma and Mylan, revefenacin is a long-acting muscarinic antagonist approved by the USFDA in 2018 for the treatment of chronic obstructive pulmonary disease (COPD).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Administered as an inhaled solution, the drug was first licensed to GSK from Theravance in 2004. However, the developing rights were returned to Theravance in 2009 due to incompatibility with GSK’s proprietary inhaler device.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Revefenacin binds competitively and reversibly to the muscarinic M<sub>3</sub> receptors in the airway smooth muscle which inhibits bronchoconstriction and increases bronchodilation.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div><div class="NLM_p">Three patent applications have been filed by Theravance describing the synthesis and solid form considerations with respect to revefenacin.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The approach to the drug’s construction essentially involves a linear sequence which began with heating piperidine <b>133</b> and isocyanate <b>134</b> together (neat) to 70 °C (<a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a>). Subsequent treatment with acid, transfer hydrogenation, and pH adjustment (pH ∼12) ultimately furnished carbamate <b>135</b> in 99% yield over the four-step sequence. Next, reductive amination with glycine derivative <b>136</b> followed by hydrogenolytic removal of the Cbz group and recrystallization in isopropyl alcohol produced <b>137</b> in 96% yield over the three steps. Amide bond formation with acid <b>138</b>, pH adjustment, and a reductive amination reaction with isonipecotamide <b>140</b> completed the assembly of the molecule. Aqueous base workup and subjection to isopropyl alcohol gave rise to revefenacin (<b>XIV</b>) in 88% yield from aldehyde <b>139</b>.<a onclick="showRef(event, 'cit73b'); return false;" href="javascript:void(0);" class="ref cit73b">(73b)</a></div><figure id="sch23" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0020.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Revefenacin (<b>XIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">4.3.  Roxadustat (Ai Rui Zhuo)</h3><div class="NLM_p">Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor for the treatment of anemia in patients with dialysis-dependent chronic kidney disease (CKD).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The drug was developed by FibroGen, in collaboration with Astellas and AstraZeneca, and was approved in China in December 2018 as first-in-class potent HIF-PHD inhibitor.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> HIF-PHD enzymes regulate the degradation of transcription factors in the HIF family under normal oxygen conditions. Inhibition of these enzymes stabilizes HIF and enhances its activity, leading to an increase in endogenous erythropoietin (EPO) production, allowing erythropoiesis to occur.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The drug also increases iron bioavailability by suppressing peptide hormone hepcidin levels, thus ameliorating anemia by boosting the body’s natural oxygen-sensing and response system without the need of intravenous iron supplementation. Roxadustat can also be prescribed to patients who use hemodialysis or peritoneal dialysis.</div><div class="NLM_p">A surge of patents published in 2017 and 2018 described several unique synthetic routes to roxadustat.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> FibroGen reported the first small scale synthesis of roxadustat in 2004,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and in 2014 this same organization devised a robust kilogram-scale route which is depicted in <a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The nine-step synthetic sequence commenced with 5-bromophthalide <b>141</b>, which was converted to 5-phenoxyphthalide <b>142</b> via a modified Ullman-type coupling.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The reaction was performed on 85 kg scale. The γ-lactone <b>142</b> was opened to furnish an acid chloride intermediate which delivered methyl ester <b>143</b> upon treatment with MeOH. Substitution of benzyl chloride <b>143</b> with <i>p</i>-toluenesulfonylglycine methyl ester (<b>144</b>) was carried out under Finkelstein conditions to produce intermediate <b>145</b>, which then underwent base-mediated cyclization and subsequent aromatization to produce isoquinoline <b>146</b> in 58% yield from <b>142</b>. Regiospecific Mannich aminomethylation of isoquinoline <b>146</b> was achieved with bis(dimethylamino)methane <b>147</b> in acetic acid to furnish dimethylaminomethyl intermediate <b>148</b>, which was subsequently activated with acetic anhydride to replace the dimethylamino group with an acetoxy moiety. The reaction yielded the intended isoquinolinol <b>150</b>. The undesired bis-acetoxy adduct <b>149</b> could be recycled to generate additional <b>150</b> upon treatment with morpholine. Reduction of the acetoxy group under hydrogenation conditions yielded <b>151</b>, and this intermediate was converted to roxadustat (<b>XV</b>) via treatment with glycine <b>152</b> and sodium methoxide.</div><figure id="sch24" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0021.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of Roxadustat (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">5.  Gastrointestinal Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46">5.1.  Elobixibat Hydrate (Goofice)</h3><div class="NLM_p">Elobixibat is a highly potent, first-in-class inhibitor of ileal bile acid transport and approved for the treatment of chronic idiopathic constipation, a disorder that affects approximately 14% of adults. Elobixibat was developed by EA Pharma (a subsidiary of Eisai Co.) and Mochida and was approved by the Japanese PMDA in 2018.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> The drug interrupts enterohepatic circulation of bile while increasing the delivery of bile acids to the colon. These circumstances improve colonic motility and mucosal fluid secretion, resulting in an overall reduction of completely spontaneous bowel movements.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Interestingly, multiple biochemical pathways are reported to impact this disease state (e.g., 5-HT<sub>4</sub>, guanylate cyclase C receptor), necessitating additional studies prior to the drug’s approval in the United States.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a></div><div class="NLM_p">A complete synthetic route to elobixibat is not explicitly disclosed in peer-reviewed or patent literature. However, a series of patents from AstraZeneca describe the conversion of an advanced intermediate to the API through a general synthetic route.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> To date, however, no yields or specific reaction details are associated with the preparation of the early stage intermediate sulfone <b>160</b>, but a general approach described by authors from AstraZeneca is depicted in <a class="ref internalNav" href="#sch25" aria-label="Scheme 25">Scheme 25</a>.</div><figure id="sch25" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0022.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. General Route to Elobixibat Sulfone <b>160</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Aminobenzothiazole <b>153</b> was hydrolyzed using potassium hydroxide to give mercaptophenol <b>154</b>, which then underwent a tandem alkylation/lactam formation with α,α-disubstituted-β-halopropanoic acid <b>155</b> to form benzothiazepine <b>156</b>. Copper-catalyzed installation of the <i>N</i>-phenyl group with an unspecified halobenzene (halogen represented by “X” within structure <b>157</b>) preceded reduction of the carbonyl group which resulted in amine <b>159</b>. This amine was oxidized to sulfone <b>160</b> using either hydrogen peroxide or trifluoroacetic acid (TFAA).<a onclick="showRef(event, 'cit82a'); return false;" href="javascript:void(0);" class="ref cit82a">(82a)</a></div><div class="NLM_p">A milligram- to gram-scale conversion of phenol <b>160</b> to elobixibat is described in the patent literature. This takes place via sequential aminoester installations, as is depicted in <a class="ref internalNav" href="#sch26" aria-label="Scheme 26">Scheme 26</a>.<a onclick="showRef(event, 'cit82c'); return false;" href="javascript:void(0);" class="ref cit82c">(82c)</a> Phenol <b>160</b> was alkylated using ethyl bromoacetate (<b>161</b>) to provide ester <b>162</b>, which was saponified with sodium hydroxide to yield acid <b>163</b>. Aromatic substitution involving sodium methanethiolate prior to amide coupling with (<i>R</i>)-2-phenylglycine methyl ester hydrochloride mediated by 2-(1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU) delivered aminoester <b>165</b> in high yield. Saponification of the ester gave acid <b>166</b> which was followed by coupling with <i>tert</i>-butyl glycinate with <b>166</b> and subsequent TFA-mediated <i>tert</i>-butyl cleavage to furnish elobixibat hydrate (<b>XVI</b>) in 85% yield.</div><figure id="sch26" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0023.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of Elobixibat Hydrate (<b>XVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49">5.2.  Tegoprazan</h3><div class="NLM_p">Tegoprazan (<b>XVII</b>), discovered by Pfizer and developed by RaQualia Pharma and CJ Healthcare, has an orthogonal mechanism of action to first-line treatments for gastroesophageal reflux disease (GERD) such that it is a reversible and potassium-competitive acid blocker of the H<sup>+</sup>/K<sup>+</sup> ATPase.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> In phase III clinical trials, once-daily dosing of the drug (50 mg or 100 mg) to patients with erosive esophagitis demonstrated noninferiority to esomeprazole (40 mg per day) in both healing and tolerability, supporting its approval in Korea in 2018.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Tegoprazan therefore represents an alternative treatment approach to proton pump inhibitors (PPIs) such as esomeprazole, lansoprazole, omeprazole, and rabeprazole.</div><div class="NLM_p">The most likely scalable synthesis of tegoprazan has been described in an original patent filed by RaQualia (<a class="ref internalNav" href="#sch27" aria-label="Scheme 27">Scheme 27</a>).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Key challenges in the preparation of the drug are the construction of the tetrasubstituted aryl core and efficient introduction of the enantiomerically pure chromanol side chain. Starting with phenol <b>168</b>, deprotonation of the phenol led to enhanced nucleophilicity, enabling selective O-benzylation. Bromination with NBS <i>para</i> to the aniline functionality afforded <b>169</b>, an intermediate that contained four appropriately placed functional groups present in the heterocyclic core. Acetylation of aniline <b>169</b> generated a precursor to the methyl benzimidazole, which was then subjected to palladium-catalyzed cyanation of the aryl bromide at high temperature under microwave irradiation to yield <b>170</b>. Iron-catalyzed reduction of the nitro group and concomitant condensation with the proximal <i>N</i>-acetyl functionality secured benzimidazole <b>171</b>. Hydrolysis of the nitrile required forcing conditions, most likely due to the benzimidazole N–H functionality. Coupling of the resulting carboxylic acid with dimethylamine hydrochloride afforded amide <b>172</b>. To make way for chromanol side chain addition, benzimidazole <b>172</b> was first protected as the tosylate prior to benzyl group removal via hydrogenolysis to give tosyl benzimidazole <b>173</b>. Treatment of <b>173</b> and enantiomerically pure alcohol <b>174</b> (<a class="ref internalNav" href="#sch28" aria-label="Scheme 28">Scheme 28</a>) in tri-<i>n</i>-butylphosphine with 1,1′-(azodicarbonyl)dipiperidine (ADDP) followed by silica gel purification and recrystallization afforded ether <b>175</b> in high enantiomeric excess and good yield. Removal of the tosyl group under basic conditions provided tegoprazan (<b>XVII</b>) in 87% yield (>99% ee).</div><figure id="sch27" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0024.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of Tegoprazan (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch28" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0025.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. Preparation of Tegoprazan Chromanol <b>174</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Chromanol <b>174</b> was prepared by the condensation of 3,5-difluorophenol (<b>176</b>) with methyl propiolate using tetrabutylammonium fluoride (TBAF) as a base, affording <b>177</b> as a 1:1 mixture of <i>E</i> and <i>Z</i> enol ethers. Reduction of the double bond using catalytic hydrogenation and treatment with triflic acid facilitated an intramolecular Friedel–Crafts acylation to yield chromanone <b>178</b> in good yield for each step. Asymmetric reduction of ketone <b>178</b> with oxazaborolidine catalyst <b>179</b> using borane–dimethyl sulfide as the stoichiometric reductant provided alcohol <b>174</b> in 88% yield and 86% ee, which could be further resolved to >99% ee upon recrystallization. A variant of this route has been developed to provide <b>174</b> in increased yield via conversion of <b>178</b> to the chromenone, asymmetric reduction, and hydrogenation of the double bond, although the value of the two additional steps is not clear relative to the one-step process exemplified in <a class="ref internalNav" href="#sch28" aria-label="Scheme 28">Scheme 28</a>.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">6.  Inflammation and Immunology Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73864" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73864" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53">6.1.  Elagolix Sodium (Orlissa)</h3><div class="NLM_p">Elagolix was developed by AbbVie and Neurocrine Biosciences and approved by the USFDA in July 2018 for the treatment of women with endometriosis, a chronic disease resulting in intermenstrual bleeding, nonmenstrual pelvic pain, and pain during menstruation, intercourse, urination, and defecation.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Elagolix is a gonadotropin-releasing hormone (GnRH) antagonist, which is active by suppression of luteinizing hormone and follicle-stimulating hormone. Because GnRH-antagonists reduce estrogen release, these drugs are less prone to side effects related to complete estrogen suppression, such as bone mineral density loss.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> On the basis of the outcome of phase III clinic trial, women who were treated with elagolix showed improvements in productivity at work and less absenteeism, as well as a significant decrease in reported levels of fatigue.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><div class="NLM_p">Neurocrine Biosciences, Inc. has published multiple synthetic routes to elagolix, with both a milligram and multikilogram scale demonstration.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The synthetic route shown in <a class="ref internalNav" href="#sch29" aria-label="Scheme 29">Scheme 29</a> represents the most likely process scale route, beginning with the condensation of urea <b>180</b> and <i>tert</i>-butyl acetoacetate (<b>181</b>) under acidic conditions to generate uracil <b>182</b>. Iodination of the uracil using iodine monochloride provided <b>183</b> in 90% yield, followed by a Suzuki coupling with arylboronic acid <b>184</b>. These conditions provided <b>185</b> in high yield and were demonstrated on a multikilogram scale. Alkylation of uracil <b>185</b> with mesylate <b>187</b> (formed by reaction of (−)-<i>N</i>-Boc-<span class="smallcaps smallerCapital">d</span>-α-phenylglycinol with methanesulfonyl chloride (<b>186</b>)) followed by an acidic workup gave rise to the polysubstituted uracil core <b>188</b>. Alkylation of the primary amine with ethyl 4-bromobutyrate enabled access to ester <b>189</b>, which required filtration through a plug of silica gel for purification. Treatment of the ethyl ester with ethanolic sodium hydroxide followed by heptane recrystallization provided the target compound elagolix sodium (<b>XVIII</b>) in 78% yield.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><figure id="sch29" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0026.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Synthesis of Elagolix Sodium (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55">6.2.  Fostamatinib (Tavalisse)</h3><div class="NLM_p">Fostamatinib was approved by the USFDA in 2018 for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have not demonstrated sufficient response to prior treatment.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Although fostamatinib is marketed by Rigel Pharmaceuticals, the company has been involved in licensing agreements with AstraZeneca for development of the drug for other indications, including rheumatoid arthritis.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Fostamatinib functions as an inhibitor of spleen tyrosine kinase (SYK),<a onclick="showRef(event, 'cit91b ref93'); return false;" href="javascript:void(0);" class="ref cit91b ref93">(91b,93)</a> a key regulator of signal transduction pathways that are involved in various autoimmune diseases.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Fostamatinb inhibits Fcγ receptor (FcγR)-mediated signal transduction, preventing cytoskeletal rearrangement which results in decreased platelet destruction.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Due to low aqueous solubility of the drug’s active form (R406), fostamatinib is marketed as a methylene phosphonate prodrug which undergoes conversion to the active metabolite of the drug in the gut.<a onclick="showRef(event, 'ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref95 ref96">(95,96)</a> In clinical trials, ITP patients (even those who did not previously respond to splenectomy, rituximab, and/or thrombopoietic agent treatments) demonstrated statistically significant responses when treated with fostamatinib.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> At present, studies involving the drug as a treatment for other indications such as IgA nephropathy and hemolytic anemia are ongoing.<a onclick="showRef(event, 'cit91b'); return false;" href="javascript:void(0);" class="ref cit91b">(91b)</a></div><div class="NLM_p">A large scale synthetic route to fostamatinib has been reported by Rigel Pharmaceuticals and is outlined in <a class="ref internalNav" href="#sch30" aria-label="Scheme 30">Scheme 30</a>.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Chlorination of pyrimidione <b>190</b> with POCl<sub>3</sub> required high temperature. Upon cooling, monosubstitution with aminopyridine <b>192</b> occurred regioselectively to provide pyrimidine <b>193</b> in 77% yield. Substituting chloropyrimidine <b>193</b> with amine <b>194</b> required heating in aqueous NMP to furnish intermediate <b>195</b> in 91% yield. Impressively, studies by AstraZeneca showed that conditions could provide <b>195</b> at over 500 kg in single batch reactions.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Installation of the phosphate side chain was demonstrated by alkylation of <b>195</b> with <i>tert</i>-butyl phosphate <b>196</b> under basic conditions. Phosphate <b>196</b> was prepared in a single step from chloromethyl sulfurochloridate (<b>199</b>) and potassium di-<i>tert</i>-butyl phosphate (<b>200</b>) as shown in <a class="ref internalNav" href="#sch31" aria-label="Scheme 31">Scheme 31</a>.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Extraction with <i>i</i>-PrOAc led to a solution of intermediate <b>197</b>, which was not isolated but instead heated with aqueous acetic acid which facilitated <i>tert</i>-butyl cleavage and precipitation of phosphonic acid intermediate <b>198</b> as an acetic acid solvate. Conversion to the DMF solvate enabled isolation of clean product in 88% yield after washing with MTBE. The final step of the synthesis was performed on 1 kg scale and was accomplished by reaction of the DMF solvate of <b>198</b> with triethylamine in <i>i</i>-PrOH at room temperature, filtration, and subjection of the filtrate solution to sodium 2-ethylhexanoate in water and <i>i</i>-PrOH. Fostamatinib hexahydrate (<b>XIX</b>) was isolated in 92% yield following precipitation from the reaction mixture.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><figure id="sch30" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0028.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. Synthesis of Fostamatinib (<b>XIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch31" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0029.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 31. Preparation of Fostamatinib <i>tert</i>-Butyl Phosphate <b>196</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">7.  Metabolic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07538" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07538" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59">7.1.  Evocalcet (Orkedia)</h3><div class="NLM_p">Evocalcet is an oral allosteric calcium-sensing receptor (CaSR) agonist discovered by Mitsubishi Tanabe Pharma Corporation and developed by Kyowa Kirin for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis. Secondary hyperparathyroidism is a common mineral and bone disorder in patients with chronic kidney disease.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Evocalcet acts on calcium receptors in parathyroid glands, effectively suppressing parathyroid hormone secretion through a similar mechanism of action as cinalcacet, a high volume calcimimetic produced by Amgen.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> When compared in a head-to-head phase III clinical trial, evocalcet demonstrated superior safety and efficacy while minimizing the upper gastrointestinal symptoms commonly associated with cinalcacet.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Evocalcet was granted approval for manufacturing and market by Japan’s Ministry of Health, Labor and Welfare (MHLW) in March 2018.</div><div class="NLM_p">The discovery synthesis of evocalcet was reported in a 2018 publication and patent disclosed by Kyowa Kirin and Mitsubishi Tanabe Pharma Corporation.<a onclick="showRef(event, 'ref99 ref102'); return false;" href="javascript:void(0);" class="ref ref99 ref102">(99,102)</a> The synthesis began with the activation of <i>N</i>-Boc pyrrolidinol <b>201</b> with triflic anhydride, followed by a nucleophilic displacement with (<i>R</i>)-(+)-1-(1-naphthyl)ethylamine (<b>202</b>), affording pyrrolidine <b>203</b> as a mixture of diastereomers. Treatment of the diastereomeric mixture with triphosgene and <i>t</i>-BuOH under forcing conditions formed the corresponding Boc-protected <i>syn</i>- and <i>anti</i>-diastereomers <b>204</b> and <b>205</b>, respectively, which were separable by column chromatography (<a class="ref internalNav" href="#sch32" aria-label="Scheme 32">Scheme 32</a>).</div><figure id="sch32" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0030.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 32. Synthesis of Evocalcet Aminopyrrolidines <b>204</b> and <b>205</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After the desired <i>syn</i>-aminopyrrolidine <b>204</b> was isolated, a global deprotection was performed with HCl in dioxane. The crude hydrochloride salts were then recrystallized from an EtOH and Et<sub>2</sub>O mixture, obtaining diamine <b>206</b> as a bis-hydrochloride salt and ethanol solvate in 94% yield over two steps. A subsequent palladium catalyzed Buchwald–Hartwig amination with pyrrolidine <b>206</b> and aryl bromide <b>207</b> furnished aniline <b>208</b> in 63% yield. Lastly, treatment of ester <b>208</b> with aqueous sodium hydroxide facilitated conversion to the carboxylic acid. A final recrystallization from EtOH afforded evocalcet (<b>XX</b>) in 73% yield over two steps, with a longest linear sequence of eight steps (<a class="ref internalNav" href="#sch33" aria-label="Scheme 33">Scheme 33</a>).</div><figure id="sch33" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0031.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 33. Synthesis of Evocalcet (<b>XX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch33"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">8.  Oncology Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22271" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22271" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63">8.1.  Anlotinib Dihydrochloride (Fu Ke Wei)</h3><div class="NLM_p">Anlotinib dihydrochloride, co-developed by Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories, was approved in China in 2018 for use as a single-therapy treatment of metastatic or locally advanced non-small-cell lung cancer (NSCLC) in patients who have experienced disease progression or recurrence after at least two lines of systemic chemotherapy treatments.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The drug serves as a multitargeting tyrosine kinase inhibitor, leading to inhibition of many vascular endothelial growth factor (VEGFR) tyrosine kinases, platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptors (FGFRs), and tyrosine kinase receptor c-kit,<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> which are known for their critical role in regulating tumor angiogenesis and tumor cell proliferation.<a onclick="showRef(event, 'ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref104 ref105">(104,105)</a> Because the availability of effective first- and second-line therapies for NSCLC is often limited, an increasing need for new third-line therapies currently exists.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Toward this end, anlotinib has now shown improved progression-free survival (PFS) and overall response rate (ORR) compared to drugs having a similar mechanism of action.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107,108)</a> The drug is also currently undergoing clinical trials involving treatment of metastatic renal cancer, soft tissue sarcomas, and a variety of carcinomas.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">Although reagents, conditions, and yields for the published synthetic route to anlotinib dihydrochloride described by Advenchen Laboratories<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> and Jiangsu Chia-Tai Tianqing Pharmaceutical Co.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> possibly correspond to a discovery route, a scalable synthesis likely involves the commercial fragments (or related derivatives) shown in <a class="ref internalNav" href="#sch34" aria-label="Scheme 34">Scheme 34</a>: quinoline <b>209</b>, indole <b>210</b>, and cyclopropyl carbamate <b>213</b>. Substitution of the chloride within <b>209</b> with phenol <b>210</b> was facilitated by DMAP in refluxing dioxane, and this was followed by removal of the benzyl protecting group by transfer hydrogenation. Alkylation with mesylate <b>213</b> (arising from alcohol <b>212</b>) furnished the anlotinib core. Removal of the CBz protecting group followed by acidification and recrystallization of the salt in cold ethanol provided anlotinib dihydrochloride (<b>XXI</b>) in a variety of crystal polymorphs.<a onclick="showRef(event, 'cit110a'); return false;" href="javascript:void(0);" class="ref cit110a">(110a)</a></div><figure id="sch34" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0032.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 34. Synthesis of Anlotinib (<b>XXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch34"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65">8.2.  Apalutamide (Erleada)</h3><div class="NLM_p">Apalutamide was approved by the USFDA in 2018 for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC)<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> and represents the first drug approved by the USFDA for nmCRPC.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Initially discovered by the University of California,<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> the drug was licensed to Aragon Pharmaceuticals and later Johnson & Johnson (Janssen) after the company’s acquisition of Aragon in 2013.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Apalutamide is a next-generation, nonsteroidal androgen receptor (AR) antagonist, known to function by binding to the ligand-binding domain of the AR, ultimately inhibiting nuclear translocation, DNA binding, and AR-mediated transcription. Traditional treatment for metastatic prostate cancer has relied on androgen deprivation therapy (ADT), but resistance to the therapy is common, generally resulting in progression to castration-resistant forms of the disease.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> This resistance has spurred efforts for identifying novel and improved AR-based therapies,<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> and apalutamide was discovered as part of these efforts. As such, apalutamide has shown substantially improved AR binding affinity over bicalutamide.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> In clinical trials, nmCRPC patients treated with apalutamide exhibited substantially longer metastasis- and progression-free survival compared to placebo.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Several clinical trials remain ongoing with apalutamide relating to prostate cancer.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div><div class="NLM_p">Although a variety of tractable synthetic routes have been disclosed by several firms,<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Aragon and Janssen have published several syntheses of apalutamide demonstrated on scales of 50 g or larger.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> A plausible scale route outlined by Aragon is described in <a class="ref internalNav" href="#sch35" aria-label="Scheme 35">Scheme 35</a>.<a onclick="showRef(event, 'cit119b'); return false;" href="javascript:void(0);" class="ref cit119b">(119b)</a> 5-Nitro-3-(trifluoromethyl)pyridin-2-ol (<b>215</b>) underwent POBr<sub>3</sub>-mediated conversion to the 2-bromopyridine intermediate, followed by cyanation using sodium cyanide and copper(I) iodide in butyronitrile to provide cyanopyridyl intermediate <b>216</b>.<a onclick="showRef(event, 'cit119b'); return false;" href="javascript:void(0);" class="ref cit119b">(119b)</a> Chemoselective reduction of the nitro group within <b>216</b> involved a catalyst slurry (H<sub>3</sub>PO<sub>2</sub>, Pt/C, NH<sub>4</sub>VO<sub>3</sub>) in xylenes and butyronitrile under a hydrogen atmosphere.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> The resulting aminopyridine <b>217</b> was telescoped into a CDI-mediated coupling reaction with Boc-protected amino acid <b>218</b> to yield amide <b>219</b>, which was then purified by distillation. No yields were reported for the three-step telescoped conversion of <b>215</b> to <b>219</b>.<a onclick="showRef(event, 'cit119b'); return false;" href="javascript:void(0);" class="ref cit119b">(119b)</a> Boc cleavage using HCl in <i>i</i>-PrOH preceded an Ullman-type coupling with aryl bromide <b>231</b> giving rise to thiohydantoin precursor <b>232</b> in 84% yield. Lastly, exposure of <b>232</b> to 1,1′-thiocarbonylbis(pyridin-2(1<i>H</i>)-one) (<b>233</b>) and DMAP in warm DMA provided apalutamide (<b>XXII</b>) in 80% yield.<a onclick="showRef(event, 'cit119b'); return false;" href="javascript:void(0);" class="ref cit119b">(119b)</a></div><figure id="sch35" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0033.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 35. Synthesis of Apalutamide (<b>XXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch35"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67">8.3.  Binimetinib (Mektovi)</h3><div class="NLM_p">Binimetinib is a non-ATP competitive mitogen-activated protein kinase 1/2 (MEK1/2) inhibitor discovered by Array BioPharma and approved for use in combination with the BRAF inhibitor encorafenib (Braftovi) for the treatment of BRAF V600E/K mutant melanomas.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> While use of BRAF inhibitors alone provides efficacy in BRAF mutant malignancies including 40–50% of metastatic melanomas, re-emergence of disease is common.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> A mechanistic understanding of this finding has emerged: in patients treated with BRAF inhibitors, concomitant inhibition of wild-type BRAF paradoxically leads to activation of the mitogen-activated protein kinase (MAPK) pathway, resulting in resistance and the development of keratoacanthomas and squamous cell carcinomas. Supplementing Braftovi therapy with binimetinib blocks MAPK-induced MEK1/2 signaling resulting in increased progression-free survival (PFS) and overall survival (OS) compared to encorafenib or vemurafenib (another BRAF inhibitor).<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Binimetinib is currently marketed in the U.S. by Pfizer after its acquisition of Array BioPharma in 2019.</div><div class="NLM_p">The most recent and largest demonstrated scale (0.1 mol) route to binimetinib avoids the use of silica gel chromatography and is described in <a class="ref internalNav" href="#sch36" aria-label="Scheme 36">Scheme 36</a>.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> A noteworthy aspect of this sequence is the effective introduction and functionalization of multiple reactive nitrogen atoms in building the pentasubstituted benzoyl core. Coupling of 2,3,4-trifluoro-5-nitrobenzoic acid (<b>234</b>) with <i>O</i>-alkylhydroxylamine <b>235</b> using CDI and diisopropylethylamine afforded alkoxyamide <b>236</b> in high yield. Ammonium hydroxide displacement of the activated fluorine atoms within <b>236</b> required pressurized conditions employing a steel bomb to furnish <b>237</b>. Benzimidazole formation was then realized by subjecting nitroaniline <b>237</b> to formic acid and palladium hydroxide on carbon providing <b>238</b> after recrystallization from EtOAc and heptane. An impressive palladium-catalyzed arylation of <b>238</b> with 1-iodo-4-bromo-2-fluorobenzene (<b>239</b>) exclusively provided the hindered primary aniline in the presence of the unsubstituted benzimidazole and amide <i>N</i>-H functionalities, giving <b>240</b> in good conversion following recrystallization from EtOAc and heptane. A second chemoselective functionalization, methylation of the benzimidazole N-1 position, was cleanly affected using methyl iodide and K<sub>2</sub>CO<sub>3</sub> in DMF. Recrystallization from MeOH yielded the penultimate intermediate that was directly treated with excess aqueous phosphoric acid in acetonitrile for <i>tert</i>-butyl ether cleavage.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Recrystallization gave binimetinib (<b>XXIII</b>) in 56% yield over the two steps.</div><figure id="sch36" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Scheme 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0034.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 36. Synthesis of Binimetinib (<b>XXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch36"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69">8.4.  Dacomitinib (Vizimpro)</h3><div class="NLM_p">Dacomitinib, developed by Pfizer, is an orally administered irreversible tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) family. The drug also binds to EGFR/HER1, HER2, and HER4.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The drug was approved by the USFDA in September 2018 for first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations, as detected by a USFDA-approved test. Second-generation EGFR TKIs including dacomitinib have been designed as pan-HER inhibitors to overcome issues of acquired resistance associated with first-generation EGFR TKIs, which include gefitinib and erlotinib.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> In a phase III clinical trial, dacomitinib prolonged progression-free survival compared to gefitinib.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Accounts of the medicinal chemistry discovery<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> and process development<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> optimization of dacomitinib have been published in the primary literature.</div><div class="NLM_p">The commercial process for the synthesis of dacomitinib, as reported by authors from Pfizer and described in <a class="ref internalNav" href="#sch37" aria-label="Scheme 37">Scheme 37</a>, involves an efficient three-step, two-isolation sequence that delivered dacomitinib in an impressive 58% overall yield.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Hydrogenative reduction of nitroarene <b>241</b> provided aniline <b>242</b> as a solution in acetonitrile, which was carried forward into the next step without purification. Amidation of aniline <b>242</b> with butenoic acid <b>243</b>, synthesized in two steps from bromide <b>246</b> (<a class="ref internalNav" href="#sch38" aria-label="Scheme 38">Scheme 38</a>),<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> was facilitated by T3P and 2,6-lutidine in acetonitrile. A reverse quench with aqueous NaOH was subsequently performed to minimize hydrolysis of the formamidine group upon workup. A seeded, cooling crystallization from a mixture of acetonitrile and toluene then provided amide <b>244</b> in 75% over two steps. While the discovery routes to dacomitinib carried quinazoline intermediates through multiple steps, this approach was challenging on process scale due to the low solubility of quinazolines in organic solvents. Formation of the quinazoline in the final step ameliorated this problem. Toward this end, intermediate <b>244</b> underwent a Dimroth rearrangement in the presence of aniline <b>245</b> to provide dacomitinib (<b>XXIV</b>). As both <b>245</b> and dacomitinib are each unstable under the high temperatures typically employed for Dimroth rearrangements (e.g., refluxing HOAc), these conditions were optimized to proceed at lower temperatures. This reaction represents one of few reported examples of a Dimroth reaction occurring under such mild conditions.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> The reaction ultimately occurred at 30 °C in neat acetic acid using 2 equiv of aniline <b>245</b> to increase the reaction rate. The reaction was quenched with 2-MeTHF and NaOH, neutralized with triethylamine, and the dacomitinib hydrate was isolated by a seeded crystallization.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><figure id="sch37" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Scheme 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0035.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 37. Synthesis of Dacomitinib (<b>XXIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch38" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Scheme 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0036.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 38. Synthesis of Dacomitinib Butanoic Acid <b>243</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch38"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72">8.5.  Duvelisib Monohydrate (Copiktra)</h3><div class="NLM_p">Duvelisib monoydrate was approved by the USFDA in 2018 as a treatment for either chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma in patients where at least two other treatments have failed.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> The drug is a dual-inhibitor of phosphoinositide 3-kinase (PI3K) γ and δ, members of a family of signal-transducing enzymes that are involved in regulating numerous cellular processes relating to cell growth and survival.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> As one of the most commonly activated signaling pathways in human cancer, this pathway has become a popular target for oncology therapeutic development.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> After initial development by Intellikine and further work by Infinity Pharmaceuticals, duvelisib monohydrate was licensed to Verastem Oncology in 2016 for commercialization.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div><div class="NLM_p">A kilogram-scale synthesis of duvelisib was disclosed in a 2011 patent application from Intellikine and relies upon the THP-protected purine <b>249</b>, available in a single step from widely available chloropurine <b>247</b> and dihydropyran <b>248</b>, <a class="ref internalNav" href="#sch39" aria-label="Scheme 39">Scheme 39</a>.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Preparation of the heterocyclic architecture of the drug began with benzoic acid <b>250</b> (<a class="ref internalNav" href="#sch40" aria-label="Scheme 40">Scheme 40</a>), which was activated with thionyl chloride and treated with aniline to give benzamide <b>251</b>. In an impressive telescoped sequence, <b>251</b> was treated with isopropylmagnesium chloride in chilled THF. In a separate reactor, Weinreb amide <b>253</b> (accessible from <span class="smallcaps smallerCapital">l</span>-alanine (<b>252</b>)) was simultaneously treated with <i>n</i>-hexyllithium. These separate solutions were then combined to give rise to intermediate <b>254</b>, which was then quenched with HCl, resulting in Boc deprotection and cyclization to give isoquinolone <b>255</b>, albeit with an erosion of enantiopurity (84% ee). A salt resolution by treatment with <span class="smallcaps smallerCapital">d</span>-tartaric acid in methanol, filtration, and treatment with ammonium hydroxide improved the enantiomeric excess of <b>255</b> to >99% while delivering an overall yield of 60% from <b>251</b>. The purine fragment was then installed by S<sub>N</sub>Ar with <b>249</b>. Acidic THP removal, pH adjustment with ammonium hydroxide, and isolation from DCM preceded a recrystallization in isopropanol and water to give duvelisib (<b>XXV</b>) in the desired solid form after drying.</div><figure id="sch39" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Scheme 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0037.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 39. Preparation of Duvelisib Purine <b>249</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch40" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Scheme 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0039.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 40. Synthesis of Duvelisib Monohydrate (<b>XXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch40"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75">8.6.  Encorafenib (Braftovi)</h3><div class="NLM_p">Encorafenib was approved by the USFDA in 2018 as a combination treatment with binimetinib for unresectable or metastatic melanoma.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Encorafenib is a BRAF inhibitor, and detection of a BRAF V600E or BRAF V600K mutation in tumor specimens is required prior to treatment.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Approximately 50% of melanomas are found to contain an activating BRAF V600 mutation.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Combination therapies combining a BRAF inhibitor and an MEK inhibitor have become the standard of care for patients in such cases.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> While initial response rates are often highly promising, treatment resistance and progression occur in approximately 80% of cases within 3 years. In clinical trials, patients given the combination of encorafenib and binimetinib had an increased progression-free survival (PFS) and overall survival (OS) compared to encorafenib or vemurafenib, a USFDA-approved treatment for late-stage melanoma.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Encorafenib is currently marketed in the U.S. by Pfizer after its acquisition of Array BioPharma in 2019.</div><div class="NLM_p">A synthesis of encorafenib was disclosed by Novartis.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> The convergent route hinged upon the construction of the central pyrazole core, onto which substituted aryl and heteroaryl groups were appended.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> (<i>S</i>)-(−)-1,2-Diaminopropane dihydrochloride (<b>257</b>, <a class="ref internalNav" href="#sch41" aria-label="Scheme 41">Scheme 41</a>) was treated with potassium carbonate to form the free base, followed by sequential addition of benzyl chloroformate and methyl chloroformate to give bis-carbamate <b>258</b>. Hydrogenation with palladium on carbon then provided the chiral carbamate fragment <b>259</b>. Preparation of encorafenib also necessitated the construction of an aryl boronate ester, and this approach began with formylation of 2-bromo-4-chloro-1-fluorobenzene (<b>260</b>) to give benzaldehyde <b>261</b> (<a class="ref internalNav" href="#sch42" aria-label="Scheme 42">Scheme 42</a>). Oxidation to the carboxylic acid followed by Curtius rearrangement delivered Boc-aniline <b>262</b>, which was then then converted to boronic ester <b>263</b> under Miyaura conditions involving bis(pinacolato)diboron. Synthesis of the pyrazole core began with benzyl protection of isopropylhydrazine <b>264</b> (<a class="ref internalNav" href="#sch43" aria-label="Scheme 43">Scheme 43</a>) followed by alkylation with (ethoxyethylidine)malononitrile. Acid-promoted cyclization furnished aminopyrazole <b>265</b>. Methyl ketone formation made way for a Sandmeyer conversion of the pendant amine to the corresponding iodide, providing iodopyrazole <b>266</b>. The methyl ketone was then converted to 2-aminopyrimidine <b>268</b> in two steps: first, by the addition of Brederick’s reagent (<b>267</b>) and, second, by cyclization with guanidine. Formal hydrolysis to the pyrimidone was accomplished with a second Sandmeyer reaction, and subjection to phosphorus oxychloride and carbamate <b>259</b> ultimately delivered ethylenediamine <b>269</b>. After Suzuki cross-coupling with boronic ester <b>263</b>, intermediate <b>270</b> was acidified to reveal the aniline, which was then treated with methanesulfonyl chloride to generate the bis-mesylated form of the drug target. Careful exposure to sodium hydroxide and subsequent acidification resulted in selective monosulfonyl deprotection to furnish encorafenib (<b>XXVI</b>).</div><figure id="sch41" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Scheme 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0040.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 41. Synthesis of Encorafenib Carbamate <b>259</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch42" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Scheme 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0041.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 42. Synthesis of Encorafenib Boronate Ester <b>263</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch43" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Scheme 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0042.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 43. Synthesis of Encorafenib (<b>XXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch43"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79">8.7.  Fruquintinib (Elunate)</h3><div class="NLM_p">Fruquintinib, a highly potent and selective vascular endothelial growth factor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor disclosed by Hutchinson MediPharma, was approved in China during 2018 for the treatment of solid tumors.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The drug was approved for the treatment of metastatic colorectal cancer for patients who had at least two prior failed treatments involving systemic antineoplastic therapies.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Several additional clinical trials are currently underway evaluating fruquintnib for the treatment of advanced gastric cancer and advanced non-small-cell lung cancer.</div><div class="NLM_p">Although a discovery or process chemistry route for the synthesis of fruquintinib has yet to be disclosed, several U.S.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> and Chinese patents<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> have been filed relating to the isolation of various crystalline forms of the drug. A generic reaction for the final transformation was reported in two patents,<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> which involves the S<sub>N</sub>Ar reaction between chloroquinazoline <b>271</b> and phenol <b>272</b>, affording fruquintinib in 85% yield (<a class="ref internalNav" href="#sch44" aria-label="Scheme 44">Scheme 44</a>).</div><figure id="sch44" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Scheme 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0043.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 44. Synthesis of of Fruquintinib (<b>XXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch44"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81">8.8.  Gilteritinib (Xospata)</h3><div class="NLM_p">Gilteritinib, co-developed by Astellas and Kotobuki Pharmaceuticals,<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> is a dual FMS-like tyrosine kinase 3 (FLT3)/AXL inhibitor approved in Japan for the treatment of anaplastic lymphoma kinase (ALK) and relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation. Gilteritinib also binds to and inhibits the wild-type and mutant forms of ALK, preventing cell proliferation in cancer cell types that overexpress the mutation.<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148,149)</a> In November 2018, the USFDA approved the drug for treatment of adults with relapsed FLT3 positive refractory AML as detected by a USFDA-approved test.<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148,149)</a></div><div class="NLM_p">Although a synthesis of gilteritinib has been reported by Astellas, no yields were reported throughout the synthetic sequence.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> A separate approach has been reported in a Chinese patent in greater detail and is described in <a class="ref internalNav" href="#sch45" aria-label="Scheme 45">Scheme 45</a>.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Chloropyrazine <b>273</b> was treated with aminopyran <b>274</b> in the presence of base. The resulting aminopyrazine <b>275</b> underwent a palladium-catalyzed amination reaction with aniline <b>276</b>, a subunit that is present in Ariad’s ALK/EGFR dual inhibitor brigatinib approved in 2017.<a onclick="showRef(event, 'cit2p ref152'); return false;" href="javascript:void(0);" class="ref cit2p ref152">(2p,152)</a> The resulting nitrile <b>277</b> underwent hydrolysis to furnish gilteritinib (<b>XXVIII</b>) in 85% yield.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div><figure id="sch45" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Scheme 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0044.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 45. Synthesis of Gilteritinib (<b>XXVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch45"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83">8.9.  Glasdegib (Daurismo)</h3><div class="NLM_p">Glasdegib was approved in 2018 for treatment of newly diagnosed acute myeloid leukemia (AML) patients at least 75 years of age who are not appropriate candidates for intensive induction chemotherapy.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> The drug, developed by Pfizer, was approved for use in combination with low doses of the anti-metabolite cytarabine. After receiving orphan drug designation for this indication in the U.S. and EU,<a onclick="showRef(event, 'cit153b'); return false;" href="javascript:void(0);" class="ref cit153b">(153b)</a> glasdegib represents the first hedgehog (Hh) pathway inhibitor to be approved for AML in the U.S.<a onclick="showRef(event, 'cit153a'); return false;" href="javascript:void(0);" class="ref cit153a">(153a)</a> Clinical trials of previously untreated AML patients treated with glasdegib in combination with low doses of cytarabine showed significant reduction in risk of death and a 5-fold increased chance of obtaining complete remission versus those patients being treated with only cytabarine.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Glasdegib binds to and inhibits Smoothened (SMO),<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> a transmembrane protein of the same name which is a component of the hedgehog pathway, known to be critical for disease progression.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Because the hedgehog signaling pathway is known to play an important role in a variety of cancers,<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> it has attracted much interest as a potential avenue for developing new oncology therapies, and several other drugs targeting this pathway are approved for advanced basal cell carcinoma and being investigated for other indications.<a onclick="showRef(event, 'ref155 ref158'); return false;" href="javascript:void(0);" class="ref ref155 ref158">(155,158)</a> Glasdegib also received orphan drug status during 2017 in the United States for treatment of myelodysplastic syndrome (MDS), and clinical trials remain ongoing for this and other hematological malignancies worldwide.<a onclick="showRef(event, 'cit153a'); return false;" href="javascript:void(0);" class="ref cit153a">(153a)</a></div><div class="NLM_p">The scale synthesis of glasdegib has been described by researchers from Pfizer and involves a fascinating kinetic resolution–amination approach which is described in <a class="ref internalNav" href="#sch46" aria-label="Schemes 46">Schemes 46</a>–<a class="ref internalNav" href="#sch48" aria-label="48">48</a>. Methoxypyridine <b>278</b> was converted to the pyridinium salt <b>279</b> upon subjection to methyl triflate. Separately, benzimidazole <b>281</b>, which arose from tosylation of benzimidazole <b>280</b>, was lithiated, quenched with <b>279</b>, then immediately treated with aqueous H<sub>3</sub>PO<sub>4</sub> to yield enone <b>283</b> in 75% from <b>279</b>.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Subsequent 1,4-reduction with LiAl(O<i>t</i>-Bu)<sub>3</sub> and CuBr provided piperidone <b>284</b> in high yield (90%) with only trace amounts (<2%) of the over-reduced saturated piperidinol observed. Tosyl removal with hot HCl in THF provided dihydrochloride monohydrate salt <b>285</b> in 95% yield as a racemate.</div><figure id="sch46" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Scheme 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0045.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 46. Synthesis of Glasdegib Piperidone <b>285</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The key step of the synthesis relied on a dynamic kinetic resolution (DKR)-based enzymatic transamination process of the racemic mixture of (<i>S</i>)-<b>285</b> and (<i>R</i>)-<b>285</b> to provide the desired <i>anti</i>-amine <b>286</b> in high <i>anti</i>/<i>syn</i> ratio and high ee (<a class="ref internalNav" href="#sch47" aria-label="Scheme 47">Scheme 47</a>).<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> As such, treatment of <b>285</b> in DMSO/borate buffer (pH = 10) with transaminase enzyme ATA-036 led to >10:1 ratio of <i>anti</i>/<i>syn</i> amines <b>286</b> (99% ee). This transformation reportedly relied on specificity of the transaminase reaction to proceed only with the (<i>R</i>)-<b>285</b> isomer, with (<i>S</i>)-<b>285</b> instead undergoing a retro aza-Michael/aza-Michael racemization process (via <b>287</b>) to regenerate ketones (<i>S</i>)-<b>285</b> and (<i>R</i>)-<b>285</b> as a mixture with amine <b>286</b>. This mixture is then funneled back through the transamination process, ultimately providing amine <b>286</b> in 85% yield.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a></div><figure id="sch47" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Scheme 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0046.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 47. Transaminase Dynamic Kinetic Resolution (DKR) of Glasdegib Amine <b>286</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After completion of the transaminase DKR transformation, direct treatment of the reaction mixture with a solution of imidazole solvate <b>289</b> (prepared by reaction of aniline <b>288</b> with CDI and DBU as shown in <a class="ref internalNav" href="#sch48" aria-label="Scheme 48">Scheme 48</a>) provided glasdegib in free base form in 80% yield (98% purity) after precipitation from acetonitrile.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> This material could be converted directly to the corresponding maleate salt by stirring with maleic acid in aqueous <i>i</i>-PrOH at 60 °C, leading to 95% isolated yield of glasdegib (<b>XXIX</b>).<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div><figure id="sch48" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Scheme 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0047.jpeg" id="gr48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 48. Synthesis of Glasdegib (<b>XXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch48"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87">8.10.  Ivosidenib (Tibsovo)</h3><div class="NLM_p">Ivosidenib, a first-in-class oral inhibitor of mutated cytosolic isocitrate dehydrogenase 1 (IDH1) developed by Agios Pharmaceuticals, was approved by the USFDA in July 2018 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by a USFDA-approved test.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> IDH1 mutations have been identified in a variety of hematologic and solid tumors, conferring a gain of function in cancer cells and resulting in increased levels of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG plays a key contributory role in leukemia tumorigenesis.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Ivosidenib has been shown to reduce 2-HG levels, which are key contributors in leukemia tumorigenesis, and translated to durable remissions during clinical trials.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a></div><div class="NLM_p">While patents from Agios have described only a general procedure for the synthesis of ivosidenib, with no isolation details or yields,<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Teva Pharmaceuticals has published a process that provides the API in high chiral purity without column chromatography (<a class="ref internalNav" href="#sch49" aria-label="Scheme 49">Scheme 49</a>).<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Amine <b>290</b> was converted to the corresponding formamide by treatment with ethyl formate in the presence of triethylamine. Following partial evaporation of solvent, dehydration of the formamide (POCl<sub>3</sub>, Et<sub>3</sub>N) afforded isonitrile <b>291</b>, which was dissolved in trifluoroethanol and carried forward crude into the key Ugi reaction with imine <b>292</b> (preformed by condensation of aniline <b>296</b> with aldehyde <b>297</b>, as shown in <a class="ref internalNav" href="#sch50" aria-label="Scheme 50">Scheme 50</a>) and acid <b>293</b>. While the Ugi reaction provided the product as a mixture of diastereomers, a workup and crystallization procedure was developed for the isolation of desired diastereomer <b>294</b>. Acid/base extraction and treatment with piperidine allowed for isolation of pure <b>294</b> in >99.9% chiral purity and 27–31% yield from amine <b>290</b>. Buchwald–Hartwig coupling with 2-chloroisonicotinonitrile (<b>295</b>) followed by crystallization from EtOAc and <i>n</i>-heptane gave ivosidenib (<b>XXX</b>) in 91% yield.</div><figure id="sch49" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Scheme 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0048.jpeg" id="gr49" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 49. Synthesis of Ivosidenib (<b>XXX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch50" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Scheme 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0050.jpeg" id="gr50" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 50. Synthesis of Ivosidenib Imine <b>292</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch50"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90">8.11.  Larotrectinib (Viktrakvi)</h3><div class="NLM_p">Discovered by Array BioPharma and Loxo Oncology and later developed in collaboration with Bayer AG, larotrectinib was approved in November 2018 by the USFDA for the treatment of solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion that do not have a known acquired resistance mutation, are metastatic, or where surgical treatment is likely to result in morbidity.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> The drug is a highly potent, pan-TRK (TRKA, TRKB, and TRKC) inhibitor<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> and is the second drug approved for a tumor-agnostic indication.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Larotrectinib is the first drug of its kind to receive this designation at initial approval.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div><div class="NLM_p">A synthetic route to the larotrectinib was disclosed in a patent filed by Array Biopharma in 2017, and this approach is depicted in <a class="ref internalNav" href="#sch51" aria-label="Scheme 51">Scheme 51</a>.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> The synthesis began with condensation of 2,5-difluorobenzaldehyde (<b>298</b>) with Ellman’s auxiliary to form transient sulfinyl imine <b>299</b>, which was then treated with the Grignard reagent formed from alkyl bromide <b>300</b>. This sequence gave rise to sulfinamide <b>301</b> in 81% yield over 2 steps, although no diastereoselectivity was reported. Treatment with TFA and triethylsilane triggered removal of the chiral auxiliary and concomitant deprotection–cyclization to form pyrrolidine <b>302</b>, which was isolated as the <span class="smallcaps smallerCapital">d</span>-(+)-maleate salt. S<sub>N</sub>Ar reaction of pyrrolidine <b>302</b> with nitropyrazolopyridimine <b>303</b> formed intermediate arene <b>304</b>. No yield of <b>304</b> was reported.</div><figure id="sch51" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Scheme 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0051.jpeg" id="gr51" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 51. Synthesis of Larotrectinib Pyrazolopyrimidine <b>304</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch51"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The final sequence to furnish larotrectinib involved nitro reduction of <b>304</b> to form aminopyrazolopyrimidine <b>305</b> (<a class="ref internalNav" href="#sch52" aria-label="Scheme 52">Scheme 52</a>), which was isolated as a fumarate salt in 83% yield. Exposure to phenyl chloroformate, pyrrolidinol <b>307</b>, then sulfuric acid provided larotrectinib (<b>XXXI</b>) as the hydrogen sulfate salt in 92% yield.</div><figure id="sch52" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Scheme 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0052.jpeg" id="gr52" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 52. Synthesis of Larotrectinib (<b>XXXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch52"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93">8.12.  Lorlatinib (Lorbrena)</h3><div class="NLM_p">Identification of oncogenic echinoderm microtuble associated protein like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements and c-ros oncogene 1 (cROS) in non-small-cell lung cancer (NSCLC) has led to the identification of multiple first-line tyrosine kinase inhibitors that have made a major impact on treatment of this genetically defined cancer.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Tumor progression emerges due to both brain metastases and resistance mutations, with the ALK G1202R mutant being particularly challenging to address with first and second generation therapies.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Lorlatinib, developed by Pfizer, is a macrocyclic ALK and cROS inhibitor that readily penetrates the blood–brain barrier and demonstrates significant activity against multiple ALK mutations including G1202R, demonstrating the ability to address both of these issues.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Clinical trials of patients with ALK mutations whose tumors progressed on one or more ALK inhibitor therapies showed significantly improved ORRs and PFS when taking lorlatinib in comparison to existing kinase inhibitor therapies.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Additionally, significant response to lorlatinib was seen in patients with brain metastases.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div><div class="NLM_p">Structurally, lorlatinib presents considerable challenges with respect to efficient construction of the macrocycle. The reported largest scale synthesis utilizes a convergent approach, demonstrated by a Suzuki cross-coupling to afford a penultimate intermediate and subsequent amide macrolactamization to yield the core structure. This approach incorporates many of the key transformations and bond disconnections developed in the discovery synthesis, with subsequent process optimization used to enable efficient production of kilogram quantities. A gram-scale synthesis of the aminomethyl pyrazole fragment commenced with bis-bromination of pyrazole ester <b>308</b> (<a class="ref internalNav" href="#sch53" aria-label="Scheme 53">Scheme 53</a>).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Protected methylamine equivalent <b>310</b> was introduced by treatment with sodium hydride and subsequent addition to <b>309</b> to yield intermediate <b>311</b>. Conversion of ester <b>311</b> to nitrile <b>312</b> was accomplished using a high-yielding, three-step sequence employing ester hydrolysis, conversion of the resulting acid to a primary amide, and finally dehydration of the primary amide to nitrile <b>312</b>.</div><figure id="sch53" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Scheme 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0053.jpeg" id="gr53" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 53. Preparation of Lorlatinib Aminopyrazole Fragment <b>312</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Enantioselective reduction of commercial ketone <b>313</b> (<a class="ref internalNav" href="#sch54" aria-label="Scheme 54">Scheme 54</a>) was explored with a variety of chemical reagents (CBS reduction, DIP-Cl), but ultimately a biocatalytic solution was identified from screening a diverse set of ketoreductases.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> After optimization, the reduction proceeded in high yield and essentially complete enantioselectivity on >200 kg to yield <b>314</b>. The key pyridine ether bond was formed by activation of the chiral secondary alcohol as the methanesulfonate ester followed by S<sub>N</sub>2 displacement with 2-amino-3-hydroxypyridine (<b>315</b>) to afford <b>316</b>. Carbonylation of the aryl iodide to methyl ester <b>317</b> was affected by palladium in the presence of carbon monoxide and MeOH. To generate the Suzuki coupling precursor, <b>317</b> was brominated on the pyridine <i>para</i> to the amino group, followed by bis-Boc protection of the amino group, then Miyaura borylation to give <b>318</b>. Although Suzuki coupling of <b>318</b> and <b>312</b> was plagued by homocoupling of <b>318</b>,<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> slow addition of <b>318</b> in a toluene solution to a solution of <b>312</b>, palladium catalyst, and CsF in an aqueous toluene mixture at reflux suppressed the side reaction to <3%, enabling high yields of <b>319</b>. Acidic removal of the three Boc groups followed by neutralization and nitrile-sparing ester hydrolysis with KOTMS led to the precipitation of <b>320</b> as a crystalline solid. Macrocyclic amidation was affected by slow addition of a DMF solution of <b>320</b> over 14 h into a dilute solution of HATU and triethylamine in EtOAc, which served to minimize intermolecular coupling. Following aqueous workup, treatment with acetic acid led to crystallization and isolation of the acetic acid solvate of lorlatinib (<b>XXXII</b>) in 56% yield and >99.2% purity.</div><figure id="sch54" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Scheme 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0054.jpeg" id="gr54" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 54. Synthesis of Lorlatinib (<b>XXXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch54"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96">8.13.  Plitidepsin (Aplidin)</h3><div class="NLM_p">Plitidepsin, also known as dehydrodidemnin B, is a macrocyclic marine natural product originally isolated nearly 40 years ago from the tunicate <i>aplidium albicans</i>.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> The drug showed potent antiproliferative effects in cancer cells and <i>in vivo</i> tumor models in early studies.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> While plitidepsin has demonstrated a broad range of pleiotropic effects in cells, interaction with the translation elongation factor eEF1A2 has been proposed to be the primary mechanism of action.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> When Pharma Mar advanced plitidepsin into clinical trials as a combination treatment with dexamethasone, patients with relapsed/refractory multiple myeloma showed significant improvement in ORR, PFS, and overall survival versus patients treated only with dexamethasone.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> These data supported approval in Australia in 2018.</div><div class="NLM_p">The synthetic route to plitidepsin reported on largest scale is shown in <a class="ref internalNav" href="#sch55" aria-label="Schemes 55">Schemes 55</a>–<a class="ref internalNav" href="#sch59" aria-label="59">59</a>. This route employed a convergent approach whereby construction of two main fragments yielded a linear precursor which then underwent macrolactamization prior to final introduction of peptidic side chains.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> The synthesis of the first fragment commenced with the protected bis-peptide <b>321</b>, which was treated with HCl in dioxane to remove the Boc group, affording <b>322</b> (<a class="ref internalNav" href="#sch55" aria-label="Scheme 55">Scheme 55</a>). Next, reductive debenzylation of keto ester <b>323</b> (whose preparation is described in <a class="ref internalNav" href="#sch56" aria-label="Scheme 56">Scheme 56</a>) made way for direct coupling with <b>322</b> under standard amide forming conditions to yield <b>324</b>. Fluoride-mediated TBS removal was followed by esterification with acid <b>325</b> (whose preparation is described in <a class="ref internalNav" href="#sch57" aria-label="Scheme 57">Scheme 57</a>), and simultaneous cleavage of Boc and silyl protecting groups with HCl generated <b>326</b>.</div><figure id="sch55" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Scheme 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0055.jpeg" id="gr55" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 55. Assembly of Plitidepsin Peptidic Fragment <b>326</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch55"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch56" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Scheme 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0056.jpeg" id="gr56" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 56. Preparation of Plitidepsin Ketoester Fragment <b>323</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch57" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Scheme 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0057.jpeg" id="gr57" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 57. Preparation of Plitidepsin Carboxylic Acid <b>325</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch57"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of <b>323</b> started with bis-silylation of <b>327</b> followed by selective silyl ester hydrolysis to provide <b>328</b> in high yield. Activation of <b>328</b> with CDI formed an acyl imidazole species that underwent treatment with the lithium enolate of benzyl acetate to afford keto ester <b>329</b>. Deprotonation followed by exposure to iodomethane generated malonate <b>323</b> as a mixture of diastereomers.</div><div class="NLM_p">Preparation of <b>325</b> started with the conversion of <i>N</i>-Boc isoleucine (<b>330</b>) to keto ester <b>331</b> (<a class="ref internalNav" href="#sch57" aria-label="Scheme 57">Scheme 57</a>). KBH<sub>4</sub>-mediated reduction of the ketone within <b>331</b> was completed in high yield and diastereoselectivity, and silylation of the resultant alcohol yielded <b>332</b>. Deprotection of the ester was accomplished with catalytic hydrogenation to give <b>325</b> in good yield.</div><div class="NLM_p">Synthesis of <b>338</b>, the second fragment necessary for coupling with <b>326</b>, started with protected threonine derivative <b>333</b> (<a class="ref internalNav" href="#sch58" aria-label="Scheme 58">Scheme 58</a>). Intermediate <b>333</b> was esterified via S<sub>N</sub>2 reaction of the carboxylate with bromoacetophenone, yielding <b>334</b>. The protected tyrosine intermediate <b>335</b> was N-alkylated under phase transfer conditions to give phenethylamine <b>336</b>, which was then esterified with <b>334</b> to afford <b>337</b> in high yield. Selective removal of the phenacyl ester was made possible upon exposure to zinc and acetic acid, generating <b>338</b> in 74% yield.</div><figure id="sch58" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Scheme 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0058.jpeg" id="gr58" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 58. Construction of Plitidepsin Peptide Fragment <b>338</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Preparation of the macrocyclization precursor was performed by coupling of <b>326</b> and <b>338</b> using well-established amide bond forming methods to afford <b>339</b> (<a class="ref internalNav" href="#sch59" aria-label="Scheme 59">Scheme 59</a>). Hydrogenation using Pearlman’s catalyst proceeded in high yield, revealing the acid and secondary amine groups used to form macrocycle <b>340</b>. The ring-closing reaction was performed by treatment with HATU, HOAt, and NMM under high dilution, resulting in macrocycle <b>340</b> in 68% yield, and forming the core structure of plitidepsin. Importantly, the β-keto ester stereocenter, carried forward as a mixture of diastereomers in the linear precursor, was set during the macrocyclization process to yield a single stereoisomer. A high-yielding, three-step process to convert <b>340</b> to <b>343</b> consisted of Boc removal under acidic conditions to liberate the primary amine, coupling of Cbz-protected <i>N</i>-Me amino acid <b>342</b> (formed by selective N-methylation of <b>341</b> using NaH and MeI in THF) to the primary amine, and finally, hydrogenolytic cleavage of the Cbz group. Coupling of the proline-derived acid <b>343</b> to <b>344</b> using diisopropylcarbodiimide (DIC) completed the synthesis of plitidepsin (<b>XXXIII</b>).</div><figure id="sch59" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Scheme 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0059.jpeg" id="gr59" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 59. Final Assembly of Plitidepsin (<b>XXXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To generate <b>344</b>, proline benzyl ester <b>345</b> was coupled with pyruvic acid to yield <b>346</b>, followed by conversion of the benzyl ester to the acid via hydrogenation (<a class="ref internalNav" href="#sch60" aria-label="Scheme 60">Scheme 60</a>).</div><figure id="sch60" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Scheme 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0061.jpeg" id="gr60" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 60. Construction of Plitidepsin Amino Acid Derivative <b>344</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch60"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103">8.14.  Pyrotinib Maleate (Airuini)</h3><div class="NLM_p">Pyrotinib maleate, an oral irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) developed by Hengrui Pharmaceutical, received conditional approval in China in August 2018 for the treatment of HER2-positive, advanced, or metastatic breast cancer in combination with capecitabine in patients previously treated with anthracycline or taxane chemotherapy.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> Structurally, pyrotinib is similar to neratinib, which is also approved for the treatment of HER2-positive breast cancer, differing in terminal amine substitution of the Michael acceptor covalent-binding warhead. An account of the discovery and development of pyrotinib, focused primarily on modifications of the left-side 2-butenoyl side chain of neratinib, has been published.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> The terminal methylpyrrolidine group within pyrotinib demonstrated improvements in cellular potency, favorable PK profiles, <i>in vivo</i> antitumor efficacy, and safety profile.</div><div class="NLM_p">The process-scale synthesis of cyanoquinoline <b>347</b>, which is a commercially available intermediate for pyrotinib and neratinib, likely follows the route to neratinib published by scientists from Wyeth,<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> as described in an earlier edition of this annual review.<a onclick="showRef(event, 'cit2p'); return false;" href="javascript:void(0);" class="ref cit2p">(2p)</a> From aminoquinoline <b>347</b>, acylation to introduce the side chain rapidly provided access to pyrotinib freebase (<b>349</b>, <a class="ref internalNav" href="#sch61" aria-label="Scheme 61">Scheme 61</a>). A patent from Hengrui describes two kilogram-scale approaches to this acylation: (1) amidation of acid <b>348</b> with EEDQ in NMP; (2) via the corresponding acid chloride of <b>348</b>.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> While the acid chloride route required column chromatography, the EEDQ conditions allowed for chromatography-free isolation of pyrotinib in 80% yield and high purity following acid/base extraction and crystallization from ethanol and acetone. Subsequent treatment with maleic acid in ethanol and crystallization from diethyl ether provided pyrotinib maleate (<b>XXXIV)</b> in 79% yield.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a></div><figure id="sch61" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Scheme 61</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0062.jpeg" id="gr61" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 61. Synthesis of Pyrotinib Maleate (<b>XXXIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch61"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Acid <b>348</b> was generated on kiloscale in four steps from <i>N</i>-Boc-<span class="smallcaps smallerCapital">d</span>-prolinol (<b>350</b>, <a class="ref internalNav" href="#sch62" aria-label="Scheme 62">Scheme 62</a>).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Following oxidation to the corresponding aldehyde, a Horner–Wadsworth–Emmons (HWE) reaction with triethyl phosphonoacetate gave α,β-unsaturated ester <b>351</b> in 45% yield. Reduction of <i>N</i>-Boc to <i>N</i>-Me in the presence of paraformaldehyde and formic acid followed by ester hydrolysis generated acid <b>348</b>.</div><figure id="sch62" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Scheme 62</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0063.jpeg" id="gr62" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 62. Synthesis of Pyrotinib Acid <b>348</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch62"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106">8.15.  Talazoparib (Talzenna)</h3><div class="NLM_p">Talazoparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor discovered by BioMarin and developed by Pfizer, was approved by the USFDA in October 2018 for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer, as detected by a USFDA-approved companion diagnostic.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> PARP enzymes play a critical role in repair of DNA single-strand breaks; PARP inhibition in BRCA1 and BRCA2 mutation carriers results in accumulation of DNA damage, leading to cell death.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> In addition to catalytic inhibition, PARP inhibitors have been shown to “trap” PARP enzymes on damaged DNA, inducing cytotoxicity by interfering with DNA repair and replication via PARP-DNA complexes.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Despite a comparable ability to inhibit PARP catalysis, talazoparib is approximately 100-fold more potent at trapping PARP-DNA complexes compared to other PARP inhibitors in clinical development, including olaparib and rucaparib, and achieves antitumor responses in preclinical models as a single agent at much lower concentrations.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a></div><div class="NLM_p">BioMarin has published several routes to talazoparib in the patent literature.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> The most likely scale route has been exemplified on kiloscale through enantiopure intermediate <b>356</b>.<a onclick="showRef(event, 'cit192a cit192b cit192c'); return false;" href="javascript:void(0);" class="ref cit192a cit192b cit192c">(192a−c)</a> Interestingly, the approach to <b>356</b> was inspired by a fortuitous byproduct observed during the discovery of talazoparib.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Condensation of isobenzofuranone <b>352</b> and aldehyde <b>353</b> in the presence of triethylamine and acetic anhydride gave rise to compound <b>354</b> in 75% yield. Acid-catalyzed ring opening of lactone <b>354</b> with methanol provided keto-ester <b>355</b>. Both <b>354</b> and <b>355</b> were isolated by precipitation and filtration following solvent exchange, avoiding column chromatography. While the mechanistic details of the cascade reaction sequence that converted <b>355</b> to <b>356</b> has to date not been disclosed, the mechanism presumably proceeds via <i>in situ</i> nitro reduction, imine formation with 4-fluorobenzaldehyde, and Mannich-like intramolecular attack by the proximal triazolylacetic ketone to deliver the racemic heterocycle <b>356</b>. The <i>trans</i> relative configuration of ring substituents was the major product obtained, which could be isolated by crystallization in 81% yield. Chiral separation was reported on kiloscale using either SFC (83% yield, 97% purity) or simulated moving bed (SMB) (productivity greater than 6 (kg feed/day)/kg chiral stationary phase). The initial route relied on chiral separation via SFC on talazoparib itself; however, owing to the improved solubility of the racemate <b>356</b> compared to the API, chiral separation of racemic <b>356</b> was found to improve separation efficiency and scalability. Scientists from Guangzhou Wellhealth Biopharmaceutical Co. have reported an alternative resolution of talazoparib on a smaller scale that avoids chiral separation, instead using <span class="smallcaps smallerCapital">d</span>-(−)-tartaric acid to isolate a late-stage intermediate.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> Treatment of <b>356</b> with hydrazine monohydrate secured the tricyclic core in 77% yield, which was then converted to the tosylate salt to give talazoparib (<b>XXXV</b>; <a class="ref internalNav" href="#sch63" aria-label="Scheme 63">Scheme 63</a>).</div><figure id="sch63" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Scheme 63</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0064.jpeg" id="gr63" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 63. Synthesis of Talazoparib Tosylate (<b>XXXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch63"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i108">9.  Ophthalmologic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109">9.1.  Omidenepag Isopropyl (Eybelis)</h3><div class="NLM_p">Omidenepag isopropyl, which is administered as a 0.002% ophthalmic solution, was approved in Japan in 2018 for the treatment of glaucoma and ocular hypertension.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Discovered and developed by Santen, the drug was designed as an isopropyl ester to allow for increased passive permeability to the corneal epithelium, where the physiologic pH of this compartment would convert the molecule to the corresponding carboxylate, revealing a potent and selective prostaglandin E<sub>2</sub> (h-EP2) receptor agonist.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Omidenpag isopropyl, also referred to as OMDI, lowered intraocular pressure (IOP) in preclinical trials at significantly low concentrations (0.0006%) in a dose-dependent manner in monkeys, suggesting that the drug could offer an alternative treatment option to prostaglandin F (FP) receptor agonists.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> The drug, whose structure evolved from a small-molecule EP2 agonist originally published by researchers at Pfizer,<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> is currently undergoing clinical trial investigation in the United States as a 0.002% once-daily solution, in comparison to a twice-daily 0.5% timolol maleate solution, for the treatment of ocular hypertension.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></div><div class="NLM_p">Two patent applications disclosed by the Japanese firm Ube Industries, Ltd. have described a process synthesis of omidenepag isopropyl.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Reacting <i>p</i>-cyanofluorobenzene (<b>357</b>) with pyrazole in the presence of base, borane reduction of the nitrile, and acid–base workup led to <b>358</b> in 83% across the three-step sequence (<a class="ref internalNav" href="#sch64" aria-label="Scheme 64">Scheme 64</a>). Next, subjection of sulfonic acid <b>359</b> to triflic anhydride prior to exposure to <b>358</b> under basic conditions yielded sulfonamine <b>360</b>. Lastly, reaction with <b>361</b> (arising from exposure of <b>362</b> in <a class="ref internalNav" href="#sch65" aria-label="Scheme 65">Scheme 65</a> to sulfonic acid in warm aqueous isopropanol, giving <b>363</b> and subsequent treatment with thionyl chloride and aqueous base) under basic conditions in refluxing acetonitrile furnished omidenepag isopropyl (<b>XXXVI</b>) in an impressive 98% yield. It should be noted in <a class="ref internalNav" href="#sch65" aria-label="Scheme 65">Scheme 65</a> that although <i>tert</i>-butyl nicotinate <b>362</b> is commercially available, the source of this starting material was not specified in the Ube patent.<a onclick="showRef(event, 'cit197b'); return false;" href="javascript:void(0);" class="ref cit197b">(197b)</a></div><figure id="sch64" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Scheme 64</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0065.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0065.jpeg" id="gr64" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 64. Synthesis of Omidenepag Isopropyl (<b>XXXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch64"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch65" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Scheme 65</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0066.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0066.jpeg" id="gr65" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 65. Synthesis of Omidenepag Isopropyl Chloromethylpyridine <b>361</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0066.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch65"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i112">10.  Rare Diseases Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113">10.1.  Tezacaftor (Symdeko)</h3><div class="NLM_p">In 2018, the USFDA approved tezacaftor as a combination therapy with ivacaftor (a USFDA approved drug in 2012)<a onclick="showRef(event, 'cit2k ref198'); return false;" href="javascript:void(0);" class="ref cit2k ref198">(2k,198)</a> for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del gene mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Discovered and developed by Vertex Pharmaceuticals, tezacaftor is a broad-acting CFTR corrector that facilitates the cellular processing and trafficking of normal CFTR and multiple mutant CFTR, including F508del, thereby increasing the amount of CFTR protein at the cell surface.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> Ivacaftor is a CFTR potentiator that enhances chloride ion transport by potentiating the channel gating activity of CFTR protein. Ivacaftor potentiates the CFTR protein delivered to the cell surface by tezacaftor, leading to further enhancement of chloride ion transport than either agent can achieve alone.<a onclick="showRef(event, 'cit200a'); return false;" href="javascript:void(0);" class="ref cit200a">(200a)</a> One of the major differentiators of tezacaftor over other CFTR correctors is that tezacaftor is not a CYP3A4 enzyme inducer and does not interfere with ivacaftor’s metabolic pathways.<a onclick="showRef(event, 'ref201 ref202'); return false;" href="javascript:void(0);" class="ref ref201 ref202">(201,202)</a> In June 2019, the USFDA approved tezacaftor/ivacaftor combination therapy for the treatment of pediatric patients aged 6 years and older with CF who have certain genetic mutations.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a></div><div class="NLM_p">Multiple patent applications have been filed by scientists at Vertex describing the preparation of tezacaftor, and all of which outline similar reaction sequences.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> The route depicted here has been chosen based on higher reported scale, better efficiency, and lesser step counts.<a onclick="showRef(event, 'cit204f'); return false;" href="javascript:void(0);" class="ref cit204f">(204f)</a> The convergent synthetic strategy utilizes a late-stage amide bond formation to unite two key fragments. Preparation of the acid fragment <b>368</b> commenced with the palladium-catalyzed decarboxylative arylation involving ethyl cyanoacetate <b>365</b> with aryl bromide <b>364</b> in the presence of a bulky phosphine ligand (<a class="ref internalNav" href="#sch66" aria-label="Scheme 66">Scheme 66</a>). The reaction yielded benzonitrile <b>366</b> in 66% yield after acidification. Cyclopropanation of <b>366</b> via double alkylation of ethylene fragment <b>367</b> in the presence of a phase transfer catalyst followed by basic hydrolysis delivered carboxylic acid <b>368</b>, which was purified by recrystallization from hot toluene.</div><figure id="sch66" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Scheme 66</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0067.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0067.jpeg" id="gr66" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 66. Synthesis of Tezacaftor Cyclopropylacetic Acid <b>368</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch66"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Synthesis of the indole subunit began with regioselective bromination of 3-fluoro-4-nitroaniline (<b>369</b>) to arene <b>370</b> (<a class="ref internalNav" href="#sch67" aria-label="Scheme 67">Scheme 67</a>). Lewis acid-catalyzed epoxide ring opening of (<i>R</i>)-glycidyl benzyl ether (<b>371</b>) by aniline <b>370</b> followed by reduction of the nitro group furnished hydroxy <i>p</i>-phenylenediamine <b>372</b>, which was isolated as the <i>p</i>-TsOH salt. The salt was treated with aqueous NaHCO<sub>3</sub> in DCM to generate free base <b>372</b> prior to the next step. It should be noted that the yields for conversion of <b>370</b> to <b>372</b> were not reported by the authors. A Sonogashira coupling between aryl bromide <b>372</b> and terminal alkyne <b>373</b> (whose synthesis is described in <a class="ref internalNav" href="#sch68" aria-label="Scheme 68">Scheme 68</a>) followed by a Larock-type cyclization completed the preparation of aminoindole subunit <b>374</b>. To unite key subunits <b>368</b> and <b>374</b>, the carboxylic acid <b>368</b> was first converted to an acid chloride and then reacted with aminoindole <b>374</b> to deliver bis-benzyl protected tezacaftor. Finally, global deprotection via palladium-catalyzed hydrogenation furnished tezacaftor (<b>XXXVII</b>) in 68–84% yield (based on <b>374</b>).</div><figure id="sch67" data-index="69" class="article__inlineFigure"><h2 class="fig-label">Scheme 67</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0068.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0068.jpeg" id="gr67" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 67. Synthesis of Tezacaftor (<b>XXXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0068.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch67"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch68" data-index="70" class="article__inlineFigure"><h2 class="fig-label">Scheme 68</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0069.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0069.jpeg" id="gr68" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 68. Synthesis of Tezacaftor Alkyne <b>373</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0069.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch68"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Preparation of alkyne <b>373</b> is described in <a class="ref internalNav" href="#sch68" aria-label="Scheme 68">Scheme 68</a>. First, propargyl alcohol <b>375</b> was converted to propargyl chloride <b>376</b> by treatment with aqueous HCl. A Grignard reagent was generated from chloride <b>376</b> and subsequently alkylated with benzyl chloromethyl ether <b>377</b>. Removal of the trimethylsilyl moiety generated the terminal alkyne <b>373</b>.</div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i117">11.  Reproductive Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36563" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36563" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118">11.1.  Segesterone Acetate (Annovera)</h3><div class="NLM_p">Segesterone acetate is a progestin hormonal contraceptive that was developed by The Population Council and has been available since 2000. In 2018, it was approved as a combination therapy with ethinyl estradiol, marketed under the brand name Annovera.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> This drug represents the first in a new class of contraceptives, as it is administered as a silicone ring that can be inserted by the patient and does not require refrigeration and whose duration of action lasts for an entire year.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> These factors are all especially beneficial for providing effective contraception in limited-resource settings and developing nations.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a></div><div class="NLM_p">Although detailed synthetic routes to segesterone acetate are sparsely available, a 1997 paper from The Population Council<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> cited earlier work by Mehrof et al.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> and Schwars et al.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> for a general synthetic approach to the compound. A 2013 patent by the same group disclosed an updated and concise synthesis involving nucleophilic addition of an acetylene equivalent into a ketone followed by hydration to obtain the desired functionality.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> The route began with 19-norandrostenedione (<b>378</b>, <a class="ref internalNav" href="#sch69" aria-label="Scheme 69">Scheme 69</a>). In a two-step, one-pot procedure, the enone was converted to the enol ether using trimethyl orthoformate, followed by formylation of the remaining ketone to provide <b>379</b> in an 80% yield over two steps. Next, trimethysilylacetylene was deprotonated using LiHMDS in THF prior to subjection to <b>379</b>. After the addition was complete, the reaction was allowed to warm to room temperature, and the TMS group was removed with potassium carbonate to generate <b>380</b>. The alkyne was then hydrated under acidic conditions to the corresponding ketone <b>381</b>. The next series of reactions enabled inversion of configuration at the congested C-17 center. Treatment of alcohol <b>381</b> with phenylsulfuryl chloride resulted in chloride displacement and a 2,3-sigmatropic rearrangement to arrive at sulfoxide <b>382</b>. Subjection of the enone of <b>382</b> to trimethoxyphosphine and triethylamine, followed by treatment with hypochlorous acetic anhydride conditions, induced a Mislow–Evans rearrangement to complete the preparation of segesterone acetate (<b>XXXVIII</b>).</div><figure id="sch69" data-index="71" class="article__inlineFigure"><h2 class="fig-label">Scheme 69</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0070.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0070.jpeg" id="gr69" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 69. Synthesis of Segesterone Acetate (<b>XXXVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0070.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch69"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i120">12.  Urinary Tract Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07088" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07088" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec12_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121">12.1.  Vibegron (Beova)</h3><div class="NLM_p">Vibegron is a selective β3 adrenergic receptor (β<sub>3</sub>AR) agonist approved in Japan during 2018 for the treatment of overactive bladder (OAB).<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> The drug, originally discovered by Merck,<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> was developed jointly by Kyorin Pharmaceutical Co., Ltd. and Kissei Pharmaceutical Co., Ltd. and is currently undergoing clinical trials for OAB in the United States and Europe.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> Vibegron represents the third β<sub>3</sub>AR agonist to be examined in clinical trials for OAB, the other two being Astellas’ mirabegron (approved in 2012) and GSK and AltheRx’s solabegron (currently in phase II trials).<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> Vibegron differentiates from mirabegron such that it offers an enhanced safety profile (reportedly driven by its selectivity against other adrenergic receptors and CYP3A4 and CYP2D6 inhibition/induction) and offers an improved dosing regimen in comparison to solabegron (once daily versus twice daily, which was used in a phase II efficacy study).<a onclick="showRef(event, 'ref213 ref214'); return false;" href="javascript:void(0);" class="ref ref213 ref214">(213,214)</a> Vibegron evolved from structural modifications to a previously discovered Merck β<sub>3</sub>AR agonist, MK-0634, which progressed into preclinical studies for the treatment of obesity in the early 2000s and has since been discontinued. Vibegron differs from previously reported acyclic β-hydroxylamine β<sub>3</sub>AR agonists in that it possesses a unique <i>cis</i>-pyrrolidine moiety linking the C-2 and C-5 substituents, resulting in improved pharmacological properties,<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> but simultaneously increases the complexity of the drug structure and synthesis.</div><div class="NLM_p">Several reports describing the construction of vibegron have been published.<a onclick="showRef(event, 'ref213 ref215'); return false;" href="javascript:void(0);" class="ref ref213 ref215">(213,215)</a> A concise manufacturing-scale synthesis of the drug was reported by Merck in 2018 in which the authors engineered a dynamic kinetic resolution (DKR) that efficiently established a challenging amino alcohol stereorelationship within an early stage intermediate (<b>386</b>, <a class="ref internalNav" href="#sch70" aria-label="Scheme 70">Scheme 70</a>) and later influenced the incumbent C-2 and C-5 pyrrolidine stereocenters within the API structure.<a onclick="showRef(event, 'cit215a'); return false;" href="javascript:void(0);" class="ref cit215a">(215a)</a> This elegant synthetic approach is described in <a class="ref internalNav" href="#sch70" aria-label="Schemes 70">Schemes 70</a> and <a class="ref internalNav" href="#sch71" aria-label="71">71</a>. Oxidation of commercial pentynol <b>383</b> (<a class="ref internalNav" href="#sch70" aria-label="Scheme 70">Scheme 70</a>) followed by a Strecker reaction and Boc-protection furnished racemic aminonitrile <b>384</b>.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> Grignard addition to the nitrile followed by acidic workup generated racemic ketones <b>385</b> in 95%. Because epimerization of the Boc-protected amine stereocenter within <b>385</b> was observed under basic conditions, a ketoreductase (KRED-p301) was engineered to selectively facilitate reaction of cofactor sodium nicotinamide adenine dinucleotide phosphate (NADPNa) with (<i>R</i>)-<b>385</b> within a pH range capable of facilitating both epimerization and reduction of the ketone.<a onclick="showRef(event, 'cit215a'); return false;" href="javascript:void(0);" class="ref cit215a">(215a)</a> In practice, the catalytic conditions developed efficiently converted (<i>R</i>)-<b>385</b> to amino alcohol <b>386</b>. The reaction proceeded in 95% conversion with >99.4% ee and with a diastereomeric ratio greater than 100:1.</div><figure id="sch70" data-index="72" class="article__inlineFigure"><h2 class="fig-label">Scheme 70</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0072.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0072.jpeg" id="gr70" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 70. Synthesis of Vibegron Progenitor Aminoalcohol <b>386</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0072.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch70"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch71" data-index="73" class="article__inlineFigure"><h2 class="fig-label">Scheme 71</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0073.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0073.jpeg" id="gr71" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 71. Synthesis of Vibegron (<b>XXXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0073.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch71"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Subjection of <b>386</b> to Sonagashira conditions followed by treatment with acid delivered disubstituted alkyne <b>387</b> as the corresponding HCl salt. Warming <b>387</b> in the presence of Hunig’s base facilitated an intramolecular cyclization reaction to produce crude pyrrolidinol <b>388</b> which was converted to the corresponding silyl ether prior to hydrogenation. The authors reason that the bulky silyl ether imparted good selectivity (95:5 dr) during the hydrogenation step. Upon workup of the hydrogenation, the silyl functionality was removed, resulting in an overall conversion of <b>387</b> to <b>390</b> in 80% yield.<a onclick="showRef(event, 'cit215a'); return false;" href="javascript:void(0);" class="ref cit215a">(215a)</a> Reaction of aniline <b>390</b> with commercial carboxylate <b>391</b> under conventional amide-bond forming conditions secured vibegron (<b>XXXIX</b>) in 93% yield.</div></div></div><div id="sec13" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i124">13.  Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, the pharmaceutical industry continued its trend of considerable productivity with respect to annual small molecule drug approvals. These 39 new medicines (which include highly functionalized macrocycles, compounds containing multiple asymmetric centers, and complex heterocyclic systems) represent an architecturally diverse set of molecules that address disease states worldwide across a wide range of therapeutic areas. Fascinatingly, the scale preparation of these drugs relied upon synthetic methodologies spanning the full breadth of known chemical reactions ranging from engineered biocatalytic reactions aided by molecular modeling technologies to transformations first discovered in the 19th century. Clever utility of metal-catalyzed reactions proved critical to establishing structural motifs within the 2018 class of drugs, further emphasizing the expanding importance of this technology particularly toward the scale preparation of API and to an expanded scope of bonds that are capable of being fashioned in this manner. The architectural complexity within these drugs gives clear evidence that medicinal chemists are becoming empowered to explore structurally challenging motifs in the early discovery stages, further reinforcing the industry’s embrace of complex chemical space. As we embark upon a new decade of drug discovery, new biological targets and opportunities will emerge. As this expansion continues, the demands to reach higher levels of complexity more quickly will be asked of the modern medicinal and process chemist. Innovative synthetic technologies and creative, artistic approaches will continue to inspire and deliver the medicines of the future.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00345" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70817" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70817" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. O’Donnell</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1004-7139" title="Orcid link">http://orcid.org/0000-0003-1004-7139</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c8aba0baa1bbbca7b8a0adbae6a2e6a7aca7a6a6ada4a488b8aea1b2adbae6aba7a5"><span class="__cf_email__" data-cfemail="294a415b405a5d4659414c5b074307464d4647474c454569594f40534c5b074a4644">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew C. Flick</span> - <span class="hlFld-Affiliation affiliation">Takeda
California, Inc., 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolyn A. Leverett</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong X. Ding</span> - <span class="hlFld-Affiliation affiliation">Pharmacodia
(Beijing) Co., Ltd., Beijing 100085, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emma McInturff</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0426-3089" title="Orcid link">http://orcid.org/0000-0003-0426-3089</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah J. Fink</span> - <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceutical Company Limited, 125 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. Helal</span> - <span class="hlFld-Affiliation affiliation">Biogen, 115 Broadway Avenue, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob C. DeForest</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter D. Morse</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Subham Mahapatra</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41436" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41436" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="74" class="article__inlineFigure"><h2 class="fig-label">Andrew C. Flick</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=BIO-d7e4779-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Andrew C. Flick</b> earned a B.A. in Chemistry from Lake Forest College. After associate-level appointments at Abbott Laboratories and Array BioPharma, he joined Professor Albert Padwa’s laboratory at Emory University. After completing his Ph.D. studies on dipolar cycloaddition approaches to alkaloid natural product total synthesis, he joined Pfizer where he was involved with numerous medicinal chemistry projects within the Neurosciences, Rare Diseases, and Inflammation & Immunology therapeutic areas. As a synthesis team lead, his contributions led to the discovery of the transcription factor inhibitor PF-06763809, which is currently undergoing clinical trials for the treatment of psoriasis. Andy recently joined Takeda California’s GI Drug Discovery Unit and has authored over 40 peer-reviewed publications and patents.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="75" class="article__inlineFigure"><h2 class="fig-label">Carolyn A. Leverett</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=BIO-d7e4784-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Carolyn Leverett</b> began her career at Pfizer in 2012, focusing on the development of microtubule inhibitor-based payloads for use as antibody–drug conjugates. She currently works in the Discovery Sciences research group, exploring the use of protein degrader-based therapies for treating a variety of disease areas. Carolyn obtained her B.S. in Chemistry from North Carolina State University. She completed her doctoral studies with Professor Albert Padwa at Emory University in Atlanta, GA, working on total synthesis of several piperidine-based natural products and the alkaloid minfiensine. Prior to joining Pfizer she was a Postdoctoral Fellow working with Professor Daniel Romo at Texas A&M University, exploring new applications of nucleophile-catalyzed aldol lactonization reactions.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="76" class="article__inlineFigure"><h2 class="fig-label">Hong X. Ding</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=BIO-d7e4789-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hong X. Ding</b> obtained a B.S. in Pharmaceutics in 2001 and a Ph.D. in Medicinal Chemistry in 2006 from Zhejiang University in Hangzhou, China. Hongxia is the cofounder and Chief Executive Officer of Pharmacodia, a leading pharmaceutical big data company in China, which is an online platform (<a href="http://www.pharmacodia.com" class="extLink">http://www.pharmacodia.com</a>) providing big data and information service in the pharmaceutical R&D field. In 2010–2013, Hong Xia joined Shenogen Pharma Group, a China-based biotech company as a senior director of the R&D department. Before Shenogen, Hong Xia worked in BioDuro since 2006, as senior group leader and senior research scientist.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="77" class="article__inlineFigure"><h2 class="fig-label">Emma McInturff</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=BIO-d7e4797-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Emma McInturff</b> obtained a B.S. in Chemistry from Boise State University and a Ph.D. from the University of Texas at Austin, working in the laboratory of Professor Mike Krische on ruthenium catalyzed carbonyl addition methodology development. She joined Pfizer process chemistry in Groton, CT, in 2014.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="78" class="article__inlineFigure"><h2 class="fig-label">Sarah J. Fink</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=BIO-d7e4802-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sarah J. Fink</b> obtained a B.A. in Chemistry and English literature from Williams College, followed by a Ph.D. in Organic Chemistry from the University of Cambridge with Professor Ian Paterson. Her thesis work focused on the total synthesis of aplyronine C. After a fellowship for young international scientists at Shanghai Institute of Materia Medica, Sarah joined BioDuro in Shanghai in 2014, where she was a scientist and chemistry group leader for integrated drug discovery projects in multiple therapeutic areas. She relocated with BioDuro to Boston in early 2017, where she provided medicinal chemistry and scientific project management support for collaborations with pharma and biotech as an associate director for integrated programs. Sarah recently joined Takeda’s Rare Disease Drug Discovery Unit.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="79" class="article__inlineFigure"><h2 class="fig-label">Christopher J. Helal</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=BIO-d7e4807-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christopher J. Helal</b> received his B.S. in Chemistry at the Ohio State University in 1991 and carried out his doctoral studies at Harvard University with Professor Elias J. Corey. He joined Pfizer in 1997 in Groton, CT, working in neuroscience medicinal chemistry. He supported the metabolic disease research area and led an enabling technologies team that included biocatalysis, flow chemistry, single-electron chemistry, reaction optimization, and parallel synthesis. He currently leads the medicinal chemistry group at Biogen, focusing on neuroscience indications.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="80" class="article__inlineFigure"><h2 class="fig-label">Jacob C. DeForest</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=BIO-d7e4812-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jacob C. DeForest</b> received his B.A. in Chemistry from Pepperdine University under the supervision of Professor Matt Joyner in 2012. He completed his Ph.D. in Chemistry at the University of California, Irvine, in 2017 working with Professor Scott Rychnovsky on the total synthesis of alkaloid natural products. He is currently a process chemist at Pfizer.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="81" class="article__inlineFigure"><h2 class="fig-label">Peter D. Morse</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=BIO-d7e4817-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Peter D. Morse</b> obtained a B.Sc. in Structural Biology and Chemistry from the University of Connecticut in 2010. He then obtained his Ph.D. at the University of North Carolina at Chapel Hill, working with Professor David Nicewicz in 2015. After postdoctoral studies with Professor Timothy Jamison at MIT, he joined the Applied Synthesis Technology group at Pfizer in 2017.</p></figure></div><div class="bio" rid="ath9"><figure id="ath9" data-index="82" class="article__inlineFigure"><h2 class="fig-label">Subham Mahapatra</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=BIO-d7e4822-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Subham Mahapatra</b> received his M.Sc. in Chemistry from Indian Institute of Technology Bombay, Mumbai, and earned his Ph.D. from Oregon State University, Corvallis, where he completed the first total syntheses of natural products amphidinolides C and F. Subsequently, Subham’s postdoctoral research with Professor Barry Trost at Stanford University was focused on the development of a new C–H activation method for the generation of π-allyl intermediates. Later, Subham picked up a second postdoctoral position in the laboratory of Professor Seth Herzon at Yale University where he worked on the total synthesis of lomaiviticin A. Subham joined Pfizer in 2017. Currently, he is a Senior Scientist (medicinal chemistry) in the Internal Medicine Department and his research focuses on cardiovascular and metabolic disease areas.</p></figure></div><div class="bio" rid="ath10"><figure id="ath10" data-index="83" class="article__inlineFigure"><h2 class="fig-label">Christopher J. O’Donnell</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=BIO-d7e4827-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christopher J. O’Donnell</b> obtained a B.S. in Chemistry from the University of Illinois Urbana—Champaign and a Ph.D. in Organic Chemistry from the University of Wisconsin. After postdoctoral research at the University of California—Irvine, he joined Pfizer in 1999 in the Neuroscience Medicinal Chemistry group. As a scientist, project leader, and manager in these areas, he has led project teams to the nomination of over 10 clinical candidates. In 2010, Chris moved to the Oncology Medicinal Chemistry group to build the Antibody Drug Conjugate chemistry group, and his team has nominated 11 conjugates for clinical development. In 2018, Chris moved to the Pfizer Ventures team where he makes and manages equity investments for Pfizer. Chris is an author/inventor of 75 peer-reviewed journal articles and patent applications.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Ac</td><td class="NLM_def"><p class="first last">acetyl</p></td></tr><tr><td class="NLM_term">ADDP</td><td class="NLM_def"><p class="first last">1,1′-(azodicarbonyl)dipiperidine</p></td></tr><tr><td class="NLM_term">AIBN</td><td class="NLM_def"><p class="first last">2,2′-azobis(isobutyronitrile)</p></td></tr><tr><td class="NLM_term">aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">BHT</td><td class="NLM_def"><p class="first last">butylated hydroxytoluene</p></td></tr><tr><td class="NLM_term">BINAP</td><td class="NLM_def"><p class="first last">2,2′-bis(diphenylphosphino)-1,1′-dinaphthalene</p></td></tr><tr><td class="NLM_term">Bn</td><td class="NLM_def"><p class="first last">benzyl</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>N</i>-<i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">2,2′-bpy</td><td class="NLM_def"><p class="first last">2,2′-bipyridyl</p></td></tr><tr><td class="NLM_term">Bu</td><td class="NLM_def"><p class="first last">butyl</p></td></tr><tr><td class="NLM_term"><i>n</i>-Bu</td><td class="NLM_def"><p class="first last"><i>n-</i>butyl</p></td></tr><tr><td class="NLM_term">TTBP·HBF<sub>4</sub></td><td class="NLM_def"><p class="first last">tri-<i>tert</i>-butylphosphonium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">cat.</td><td class="NLM_def"><p class="first last">catalytic</p></td></tr><tr><td class="NLM_term">Cbz</td><td class="NLM_def"><p class="first last">benzyloxycarbonyl</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">COD</td><td class="NLM_def"><p class="first last">1,5-cyclooctadiene</p></td></tr><tr><td class="NLM_term">conc</td><td class="NLM_def"><p class="first last">concentrated</p></td></tr><tr><td class="NLM_term">CPME</td><td class="NLM_def"><p class="first last">cyclopentyl methyl ether</p></td></tr><tr><td class="NLM_term">CSA</td><td class="NLM_def"><p class="first last">camphorsulfonic acid</p></td></tr><tr><td class="NLM_term">Cy</td><td class="NLM_def"><p class="first last">cyclohexyl</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last">1,3-dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">de</td><td class="NLM_def"><p class="first last">diastereomeric excess</p></td></tr><tr><td class="NLM_term">dr</td><td class="NLM_def"><p class="first last">diastereomeric ratio</p></td></tr><tr><td class="NLM_term">DIBAL</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr><tr><td class="NLM_term">DIC</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-diisopropylcarbodiimide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DIP-Cl</td><td class="NLM_def"><p class="first last">B-chlorodiisopinocampheylborane, (+)-Ipc<sub>2</sub>BCl</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">1,2-dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMF–DMA</td><td class="NLM_def"><p class="first last">dimethylformamide–dimethylacetal</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DPPA</td><td class="NLM_def"><p class="first last">diphenylphosphoryl azide</p></td></tr><tr><td class="NLM_term">dppb</td><td class="NLM_def"><p class="first last">1,4-bis(diphenylphosphino)butane</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-ferrocenediyl-bis(diphenylphosphine)</p></td></tr><tr><td class="NLM_term">dr</td><td class="NLM_def"><p class="first last">diastereomeric ratio</p></td></tr><tr><td class="NLM_term">dtbpf</td><td class="NLM_def"><p class="first last">1,1′-bis(di-<i>tert</i>-butylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropal)-<i>N</i>-ethylcarbodiimide</p></td></tr><tr><td class="NLM_term">ee</td><td class="NLM_def"><p class="first last">enantiomeric excess</p></td></tr><tr><td class="NLM_term">EEDQ</td><td class="NLM_def"><p class="first last">2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last">(2-(1<i>H</i>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">Hex</td><td class="NLM_def"><p class="first last">hexyl</p></td></tr><tr><td class="NLM_term"><i>n</i>-Hex</td><td class="NLM_def"><p class="first last"><i>n</i>-hexyl</p></td></tr><tr><td class="NLM_term">HMDS</td><td class="NLM_def"><p class="first last">hexamethyldisilazane</p></td></tr><tr><td class="NLM_term">HOAc</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">HOAt</td><td class="NLM_def"><p class="first last">1-hydroxy-7-azabenzotriazole</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole hydrate</p></td></tr><tr><td class="NLM_term"><i>i-</i>Pr</td><td class="NLM_def"><p class="first last">isopropyl</p></td></tr><tr><td class="NLM_term"><i>i-</i>PrOH</td><td class="NLM_def"><p class="first last">isopropyl alcohol</p></td></tr><tr><td class="NLM_term">KOTMS</td><td class="NLM_def"><p class="first last">potassium trimethylsilanolate</p></td></tr><tr><td class="NLM_term">LAH</td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term">LHMDS</td><td class="NLM_def"><p class="first last">lithium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term"><i>m</i>-CPBA</td><td class="NLM_def"><p class="first last">3-chloroperoxybenzoic acid</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">methyl ethyl ketone</p></td></tr><tr><td class="NLM_term">MeTHF</td><td class="NLM_def"><p class="first last">2-methyltetrahydrofuran</p></td></tr><tr><td class="NLM_term">MIBK</td><td class="NLM_def"><p class="first last">methyl isobutyl ketone</p></td></tr><tr><td class="NLM_term">Ms</td><td class="NLM_def"><p class="first last">methylsulfonyl, mesyl</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">molecular sieves</p></td></tr><tr><td class="NLM_term">MTBE</td><td class="NLM_def"><p class="first last">methyl <i>tert</i>-butyl ether</p></td></tr><tr><td class="NLM_term"><i>n</i>-Pr</td><td class="NLM_def"><p class="first last"><i>n</i>-propyl</p></td></tr><tr><td class="NLM_term">NADP</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">NADPNa</td><td class="NLM_def"><p class="first last">sodium nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">NMO</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine <i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffered saline</p></td></tr><tr><td class="NLM_term">PCC</td><td class="NLM_def"><p class="first last">pyridinium chlorochromate</p></td></tr><tr><td class="NLM_term">Ph</td><td class="NLM_def"><p class="first last">phenyl</p></td></tr><tr><td class="NLM_term">PhCH<sub>3</sub></td><td class="NLM_def"><p class="first last">toluene</p></td></tr><tr><td class="NLM_term">Pin</td><td class="NLM_def"><p class="first last">pinacolato</p></td></tr><tr><td class="NLM_term">PLP</td><td class="NLM_def"><p class="first last">pyridoxal-5-phosphate</p></td></tr><tr><td class="NLM_term">PPA</td><td class="NLM_def"><p class="first last">polyphosphoric acid</p></td></tr><tr><td class="NLM_term">PPTS</td><td class="NLM_def"><p class="first last">pyridinium <i>p</i>-toluenesulfonate</p></td></tr><tr><td class="NLM_term"><i>p</i>-TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">py</td><td class="NLM_def"><p class="first last">pyridine</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">Su</td><td class="NLM_def"><p class="first last">succinimide</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last">1-propanephosphonic acid cyclic</p></td></tr><tr><td class="NLM_term">TBAB</td><td class="NLM_def"><p class="first last">tetrabutylammonium bromide</p></td></tr><tr><td class="NLM_term">TBAC</td><td class="NLM_def"><p class="first last">tetrabutylammonium chloride</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">TBAHS</td><td class="NLM_def"><p class="first last">tetrabutylammonium hydrogen sulfate</p></td></tr><tr><td class="NLM_term">TBAI</td><td class="NLM_def"><p class="first last">tetrabutylammonium iodide</p></td></tr><tr><td class="NLM_term">TBS</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>,<i>N</i>-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term"><i>t</i>-Bu</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl</p></td></tr><tr><td class="NLM_term">TEMPO</td><td class="NLM_def"><p class="first last">2,2,6,6-tetramethylpiperidine 1-oxyl</p></td></tr><tr><td class="NLM_term">Tf</td><td class="NLM_def"><p class="first last">triflic, trifluoromethanesulfonyl</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TFAA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid anhydride</p></td></tr><tr><td class="NLM_term">TFE</td><td class="NLM_def"><p class="first last">2,2,2-trifluoroethanol</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyranyl</p></td></tr><tr><td class="NLM_term">TMEDA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>,<i>N</i>′<i>,N</i>′-tetramethylethylenediamine</p></td></tr><tr><td class="NLM_term">TMP</td><td class="NLM_def"><p class="first last">tetramethylpiperidine</p></td></tr><tr><td class="NLM_term">TMS</td><td class="NLM_def"><p class="first last">trimethylsilyl</p></td></tr><tr><td class="NLM_term">Tr</td><td class="NLM_def"><p class="first last">trityl, triphenylmethyl</p></td></tr><tr><td class="NLM_term">Ts</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonyl</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i136">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 216 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raju, T. N. K.</span></span> <span> </span><span class="NLM_article-title">The Nobel Chronicles. 1988: James Whyte Black, (B 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1022</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)74775-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0140-6736%2805%2974775-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10768469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=1022&author=T.+N.+K.+Raju&title=The+Nobel+Chronicles.+1988%3A+James+Whyte+Black%2C+%28B+1924%29%2C+Gertrude+Elion+%281918-99%29%2C+and+George+H+Hitchings+%281905-98%29&doi=10.1016%2FS0140-6736%2805%2974775-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)</span></div><div class="casAuthors">Raju T N</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9208</span>),
    <span class="NLM_cas:pages">1022</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTWLVzWjiD66qcneEtCi92fW6udTcc2eY61vJJ348ZOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D&md5=c89d64b40317d0d0cb4a76c1cceecb58</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974775-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974775-9%26sid%3Dliteratum%253Aachs%26aulast%3DRaju%26aufirst%3DT.%2BN.%2BK.%26atitle%3DThe%2520Nobel%2520Chronicles.%25201988%253A%2520James%2520Whyte%2520Black%252C%2520%2528B%25201924%2529%252C%2520Gertrude%2520Elion%2520%25281918-99%2529%252C%2520and%2520George%2520H%2520Hitchings%2520%25281905-98%2529%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D1022%26doi%3D10.1016%2FS0140-6736%2805%2974775-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2002 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.2174/1389557043487457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F1389557043487457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=14965293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=207-233&author=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2002+New+Drugs&doi=10.2174%2F1389557043487457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2002 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-233</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  Therefore, it is important to be acquainted with these new structures as well as their syntheses.  To these ends, this review covers the syntheses of 28 NCEs marketed in 2002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGx8Y2c3smk7Vg90H21EOLACvtfcHk0lhBQWV1aNX42Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D&md5=d93f443a242964b39e822ecb12ddacad</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.2174%2F1389557043487457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043487457%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202002%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D207%26epage%3D233%26doi%3D10.2174%2F1389557043487457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2003 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2174/1389557043402900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F1389557043402900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=15579116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1105-1125&author=K.+K.-C.+Liuauthor=J.+Liauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2003+New+Drugs&doi=10.2174%2F1389557043402900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2003 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Li, Jin; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1125</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing new future drugs.  To these ends, this review covers the syntheses of 23 NCEs marketed in 2003.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLauPqC1hEzbVg90H21EOLACvtfcHk0lgqZZoTKACiLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO&md5=f3f6acd4fefd93ede895369105d1cefb</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F1389557043402900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043402900%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202003%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1105%26epage%3D1125%26doi%3D10.2174%2F1389557043402900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2004 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1144</span>, <span class="refDoi"> DOI: 10.2174/138955705774933329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138955705774933329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=16375759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1133-1144&author=J.+Liauthor=K.+K.-C.+Liuauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2004+New+Drugs&doi=10.2174%2F138955705774933329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2004 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1144</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as leads for designing future drugs.  To this end, this review covers the syntheses of 12 NCEs marketed in 2004, such as azacitidine, duloxetine hydrochloride, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXh0-pEnN47Vg90H21EOLACvtfcHk0lgqZZoTKACiLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P&md5=9593b6bfb38f08160e1b198f53b70a53</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.2174%2F138955705774933329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774933329%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202004%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1133%26epage%3D1144%26doi%3D10.2174%2F138955705774933329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2005 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.2174/138955707780363800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138955707780363800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=17430228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-450&author=S.+M.+Sakyaauthor=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2005+New+Drugs&doi=10.2174%2F138955707780363800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2005 new drugs</span></div><div class="casAuthors">Sakya, Subas M.; Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-450</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 22 NCEs marketed in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_TvNK-ZG2LVg90H21EOLACvtfcHk0lhYYEv-bfjpww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D&md5=cdbab18a11647fe6089fc6c6ded6ede9</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.2174%2F138955707780363800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707780363800%26sid%3Dliteratum%253Aachs%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202005%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D450%26doi%3D10.2174%2F138955707780363800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2006 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.2174/138955707782795629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138955707782795629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=18220978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1255-1269&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=J.+Li&title=Synthetic+Approaches+to+the+2006+New+Drugs&doi=10.2174%2F138955707782795629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2006 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1255-1269</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 16 NCEs marketed in 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX9HJKV9Z-pLVg90H21EOLACvtfcHk0lhYYEv-bfjpww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K&md5=4d0a4be2d4e258c11f73792380a40078</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.2174%2F138955707782795629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707782795629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202006%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1255%26epage%3D1269%26doi%3D10.2174%2F138955707782795629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2007 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.2174/138955708786786435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138955708786786435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=19075810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1526-1548&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2007+New+Drugs&doi=10.2174%2F138955708786786435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2007 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1526-1548</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review covers the syntheses of 19 new chem. entities (NCEs) marketed in 2007.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These NCEs provide insights into mol. recognition and also serve as leads for designing future new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2ujHwEzjb7Vg90H21EOLACvtfcHk0lg2N0bCdmRj5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D&md5=b2e378b89f153b6374a4aa375cf65fd7</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.2174%2F138955708786786435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708786786435%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202007%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1526%26epage%3D1548%26doi%3D10.2174%2F138955708786786435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2008 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1675</span>, <span class="refDoi"> DOI: 10.2174/138955709791012201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138955709791012201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20088782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1655-1675&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2008+New+Drugs&doi=10.2174%2F138955709791012201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2gR"><div class="casContent"><span class="casTitleNuber">2g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2008 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1655-1675</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 18 NCEs marketed in 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyNqyXXeUK7Vg90H21EOLACvtfcHk0ljUOGGKs-7pog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D&md5=7c21b476dd957ab5b90c98502ee0ec2a</span></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.2174%2F138955709791012201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709791012201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202008%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1655%26epage%3D1675%26doi%3D10.2174%2F138955709791012201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2009 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2010.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=21256756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1136-1154&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=J.+Li&title=Synthetic+Approaches+to+the+2009+New+Drugs&doi=10.1016%2Fj.bmc.2010.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2hR"><div class="casContent"><span class="casTitleNuber">2h</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2009 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1154</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 21 NCEs marketed in 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhM07bPdVyP7Vg90H21EOLACvtfcHk0ljUOGGKs-7pog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D&md5=132426fbdd026496e573cb26110b559b</span></div><a href="/servlet/linkout?suffix=cit2h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202009%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1136%26epage%3D1154%26doi%3D10.1016%2Fj.bmc.2010.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2010 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2011.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=22261026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1155-1174&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=H.+X.+Ding&title=Synthetic+Approaches+to+the+2010+New+Drugs&doi=10.1016%2Fj.bmc.2011.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2iR"><div class="casContent"><span class="casTitleNuber">2i</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2010 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Ding, Hong X.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1155-1174</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4x86l05yfrVg90H21EOLACvtfcHk0li4yfjK1MOWLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D&md5=e4a5130168e87de1a00a090241a54412</span></div><a href="/servlet/linkout?suffix=cit2i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202010%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1155%26epage%3D1174%26doi%3D10.1016%2Fj.bmc.2011.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2011 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=23623674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&author=H.+X.+Dingauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2011+New+Drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2jR"><div class="casContent"><span class="casTitleNuber">2j</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2011 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2795-2825</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 26 NCEs that were launched in the world in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4leMAGdR_wLVg90H21EOLACvtfcHk0li4yfjK1MOWLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D&md5=07079afb3ea7459e73455de425e5d756</span></div><a href="/servlet/linkout?suffix=cit2j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202011%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2k"><span><span class="NLM_label">(k) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2012 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2014.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=24629448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2005-2032&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2012+New+Drugs&doi=10.1016%2Fj.bmc.2014.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2kR"><div class="casContent"><span class="casTitleNuber">2k</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2012 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent a privileged structure for a particular biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two addnl. drugs which were launched at the end of 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C7y-_vIFErVg90H21EOLACvtfcHk0ljIzLm-ttO2uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D&md5=bb629a07ee4cfa5efe4f8b2ca0003410</span></div><a href="/servlet/linkout?suffix=cit2k&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202012%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2005%26epage%3D2032%26doi%3D10.1016%2Fj.bmc.2014.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2013 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2015.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=25797159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1895-1922&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2013+New+Drugs&doi=10.1016%2Fj.bmc.2015.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2lR"><div class="casContent"><span class="casTitleNuber">2l</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2013 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1895-1922</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83u4l4iyn9LVg90H21EOLACvtfcHk0lit-Yhk852rGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D&md5=b64a1ec20260b828d7f6de0e0a1319b0</span></div><a href="/servlet/linkout?suffix=cit2l&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202013%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D1895%26epage%3D1922%26doi%3D10.1016%2Fj.bmc.2015.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27020685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2mR"><div class="casContent"><span class="casTitleNuber">2m</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2014 new drugs</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1937-1980</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkq2WCDEAgbVg90H21EOLACvtfcHk0liHEyNEDcGxzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D&md5=a5ce03081110edb2b616006c73d14650</span></div><a href="/servlet/linkout?suffix=cit2m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2015</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6480</span>– <span class="NLM_lpage">6515</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2n&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6480-6515&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2015&doi=10.1021%2Facs.jmedchem.7b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2nR"><div class="casContent"><span class="casTitleNuber">2n</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2015</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K. -C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6480-6515</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 29 new chem. entities (NCEs) that were approved for the first time in 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5OCn9h-Lu07Vg90H21EOLACvtfcHk0ljkkdnqOOd23Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D&md5=b10c1f677c2f4a216b11a4c89e8b3683</span></div><a href="/servlet/linkout?suffix=cit2n&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00010%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202015%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6480%26epage%3D6515%26doi%3D10.1021%2Facs.jmedchem.7b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2o"><span><span class="NLM_label">(o) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to New Drugs Approved During 2016</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7004</span>– <span class="NLM_lpage">7031</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2o&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7004-7031&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+New+Drugs+Approved+During+2016&doi=10.1021%2Facs.jmedchem.8b00260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2oR"><div class="casContent"><span class="casTitleNuber">2o</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to New Drugs Approved During 2016</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7004-7031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review discusses the published syntheses of the nineteen new chem. entities approved for the first time by a governing body anywhere in the world in 2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr16l1kfs1KlbVg90H21EOLACvtfcHk0lgDgKxNZ8m71Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D&md5=183bbabe40dbfd7b7cfbcd94fd55f0d0</span></div><a href="/servlet/linkout?suffix=cit2o&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00260%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520New%2520Drugs%2520Approved%2520During%25202016%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7004%26epage%3D7031%26doi%3D10.1021%2Facs.jmedchem.8b00260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2p"><span><span class="NLM_label">(p) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInturff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2017</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7340</span>– <span class="NLM_lpage">7382</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2p&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Wqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7340-7382&author=A.+C.+Flickauthor=C.+A.+Leverettauthor=H.+X.+Dingauthor=E.+McInturffauthor=S.+J.+Finkauthor=C.+J.+Helalauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2017&doi=10.1021%2Facs.jmedchem.9b00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2pR"><div class="casContent"><span class="casTitleNuber">2p</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2017</span></div><div class="casAuthors">Flick, Andrew C.; Leverett, Carolyn A.; Ding, Hong X.; McInturff, Emma; Fink, Sarah J.; Helal, Christopher J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7340-7382</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 31 new chem. entities approved for the first time globally in 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozpSoktvArg7Vg90H21EOLACvtfcHk0lgDgKxNZ8m71Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Wqt7g%253D&md5=83863eeaaadfcaab14c45e0ace932455</span></div><a href="/servlet/linkout?suffix=cit2p&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00196%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DMcInturff%26aufirst%3DE.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202017%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7340%26epage%3D7382%26doi%3D10.1021%2Facs.jmedchem.9b00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graul, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruces, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, M.</span></span> <span> </span><span class="NLM_article-title">The Year’s New Drugs & Biologics 2018: Part I</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">35</span>, <span class="refDoi"> DOI: 10.1358/dot.2019.55.1.2959663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdot.2019.55.1.2959663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cfhtFWqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=35&author=A.+I.+Graulauthor=P.+Pinaauthor=E.+Crucesauthor=M.+Stringer&title=The+Year%E2%80%99s+New+Drugs+%26+Biologics+2018%3A+Part+I&doi=10.1358%2Fdot.2019.55.1.2959663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The year's new drugs and biologics 2018: Part I</span></div><div class="casAuthors">Graul A I; Pina P; Cruces E; Stringer M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-87</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Sixty-four new drugs and biologics reached their first global markets in 2018, the greatest number in at least a decade.  In addition, 19 important new line extensions (new indications, new combinations or new formulations of previously marketed drugs) were introduced over the course of 2018.  Twenty-three other new products and new line extensions were approved but not launched before December 31.  As has been the trend in recent years, oncology was the most active therapeutic area in terms of new launches, with cancer drugs accounting for 25% of all novel drugs and biologics introduced worldwide last year.  Eight first-in-class agents were launched for the first time in 2018, including the first RNA interference agent as well as the photo-finish approval and rollout of the first three members of a radically different class of non-vasoconstricting antimigraine agents, the anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies.  Twenty-nine of the drugs launched last year were designated orphan drugs, reflecting the continued upswing in investment in the area of neglected diseases.  This is especially true in the U.S., which welcomed 25 of the newly launched orphan drugs.  Overall, the U.S. was the most active market for new drugs and biologics, accounting for two-thirds of all new launches in 2018.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa2AZtp5SCeIYPsCkJIw00fW6udTcc2eYWhtTt4Xk_Wbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfhtFWqtg%253D%253D&md5=047c9e036c80b4dbb94c9bb6d144fabb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1358%2Fdot.2019.55.1.2959663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2019.55.1.2959663%26sid%3Dliteratum%253Aachs%26aulast%3DGraul%26aufirst%3DA.%2BI.%26aulast%3DPina%26aufirst%3DP.%26aulast%3DCruces%26aufirst%3DE.%26aulast%3DStringer%26aufirst%3DM.%26atitle%3DThe%2520Year%25E2%2580%2599s%2520New%2520Drugs%2520%2526%2520Biologics%25202018%253A%2520Part%2520I%26jtitle%3DDrugs%2520Today%26date%3D2019%26volume%3D55%26spage%3D35%26doi%3D10.1358%2Fdot.2019.55.1.2959663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span>For a more
detailed description of the medicinal chemistry strategy, preclinical
and clinical pharmacology of these drugs, see the following: <span> </span><span class="NLM_article-title">To Market, To Market—2018</span>. In  <i>2019
Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>, Ed.; <span class="NLM_publisher-name">ACS Division of Medicinal Chemistry</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, <span class="NLM_year">2019</span>; Vol.  <span class="NLM_volume">54</span>, pp  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">596</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=469-596&author=J.+J.+Bronson&title=2019%0AMedicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTo%2520Market%252C%2520To%2520Market%25E2%2580%25942018%26btitle%3D2019%250AMedicinal%2520Chemistry%2520Reviews%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26pub%3DACS%2520Division%2520of%2520Medicinal%2520Chemistry%26date%3D2019%26volume%3D54%26spage%3D469%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, A.</span></span> <span> </span><span class="NLM_article-title">Eravacycline</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1358/dof.2014.039.04.2135181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdof.2014.039.04.2135181" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=247-256&author=S.+Chopraauthor=A.+Dasgupta&title=Eravacycline&doi=10.1358%2Fdof.2014.039.04.2135181"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1358%2Fdof.2014.039.04.2135181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2014.039.04.2135181%26sid%3Dliteratum%253Aachs%26aulast%3DChopra%26aufirst%3DS.%26aulast%3DDasgupta%26aufirst%3DA.%26atitle%3DEravacycline%26jtitle%3DDrugs%2520Future%26date%3D2014%26volume%3D39%26spage%3D247%26epage%3D256%26doi%3D10.1358%2Fdof.2014.039.04.2135181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Eravacycline: A Review in Complicated Intra-Abdominal Infections</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01067-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-01067-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30783960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=315-324&author=L.+J.+Scott&title=Eravacycline%3A+A+Review+in+Complicated+Intra-Abdominal+Infections&doi=10.1007%2Fs40265-019-01067-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Eravacycline: A Review in Complicated Intra-Abdominal Infections</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">315-324</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Eravacycline (Xerava), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-pos. and -neg. bacterial strains expressing certain common tetracycline-specific acquired resistance mechanisms.  In vitro, eravacycline exhibits potent activity against a broad spectrum of clin. relevant Gram-pos. and -neg. aerobic and anaerobic bacteria.  I.v. eravacycline is approved in several countries for the treatment of complicated intra-abdominal infections (cIAIs) in adult patients.  In two pivotal double-blind, multinational trials in this patient population, eravacycline (infusion ≈ 1 h) was noninferior to i.v. ertapenem or meropenem at the test-of-cure visit in terms of clin. response rates in all prespecified populations.  Eravacycline had an acceptable tolerability profile, with infusion site reactions, nausea, vomiting and diarrhoea the most commonly reported adverse reactions, most of which were of mild to moderate severity.  Given its broad spectrum of activity against common clin. relevant pathogens (including those expressing certain tetracycline- and other antibacterial-specific acquired resistance mechanisms) and its more potent in vitro activity and better tolerability profile than tigecycline, eravacycline provides a novel emerging option for the treatment of adult patients with cIAIs, esp. as empirical therapy when coverage of resistant pathogens is required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpakHQfiT0eebVg90H21EOLACvtfcHk0lhgdVf61Wejjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrY%253D&md5=3f0eef4a8789cc5a8dd0ff6ee9dc6a18</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01067-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01067-3%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DEravacycline%253A%2520A%2520Review%2520in%2520Complicated%2520Intra-Abdominal%2520Infections%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D315%26epage%3D324%26doi%3D10.1007%2Fs40265-019-01067-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenitsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorityala, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagace-Wiens, P. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoban, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlowsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0545-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-016-0545-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=26863149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=567-588&author=G.+G.+Zhanelauthor=D.+Cheungauthor=H.+Adamauthor=S.+Zelenitskyauthor=A.+Goldenauthor=F.+Schweizerauthor=B.+Gorityalaauthor=P.+R.+S.+Lagace-Wiensauthor=A.+Walktyauthor=A.+S.+Ginauthor=D.+J.+Hobanauthor=J.+A.+Karlowsky&title=Review+of+Eravacycline%2C+a+Novel+Fluorocycline+Antibacterial+Agent&doi=10.1007%2Fs40265-016-0545-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent</span></div><div class="casAuthors">Zhanel, George G.; Cheung, Doris; Adam, Heather; Zelenitsky, Sheryl; Golden, Alyssa; Schweizer, Frank; Gorityala, Bala; Lagace-Wiens, Philippe R. S.; Walkty, Andrew; Gin, Alfred S.; Hoban, Daryl J.; Karlowsky, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">567-588</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Eravacycline is an investigational, synthetic fluorocycline antibacterial agent that is structurally similar to tigecycline with two modifications to the D-ring of its tetracycline core: a fluorine atom replaces the dimethylamine moiety at C-7 and a pyrrolidinoacetamido group replaces the 2-tertiary-Bu glycylamido at C-9.  Like other tetracyclines, eravacycline inhibits bacterial protein synthesis through binding to the 30S ribosomal subunit.  Eravacycline demonstrates broad-spectrum antimicrobial activity against Gram-pos., Gram-neg., and anaerobic bacteria with the exception of Pseudomonas aeruginosa.  Eravacycline is two- to fourfold more potent than tigecycline vs. Gram-pos. cocci and two- to eightfold more potent than tigecycline vs. Gram-neg. bacilli.  I.v. eravacycline demonstrates linear pharmacokinetics that have been described by a four-compartment model.  Oral bioavailability of eravacycline is estd. at 28 % (range 26-32 %) and a single oral dose of 200 mg achieves a max. plasma concn. (Cmax) and area under the plasma concn.-time curve from 0 to infinity (AUC0-∞) of 0.23 ± 0.04 mg/L and 3.34 ± 1.11 mg·h/L, resp.  A population pharmacokinetic study of i.v. (IV) eravacycline demonstrated a mean steady-state vol. of distribution (Vss) of 320 L or 4.2 L/kg, a mean terminal elimination half-life (t1/2) of 48 h, and a mean total clearance (CL) of 13.5 L/h.  In a neutropenic murine thigh infection model, the pharmacodynamic parameter that demonstrated the best correlation with antibacterial response was the ratio of area under the plasma concn.-time curve over 24 h to the min. inhibitory concn. (AUC0-24h/MIC).  Several animal model studies including mouse systemic infection, thigh infection, lung infection, and pyelonephritis models have been published and demonstrated the in vivo efficacy of eravacycline.  A phase II clin. trial evaluating the efficacy and safety of eravacycline in the treatment of community-acquired complicated intra-abdominal infection (cIAI) has been published as well, and phase III clin. trials in cIAI and complicated urinary tract infection (cUTI) have been completed.  The eravacycline phase III program, known as IGNITE (Investigating Gram-Neg. Infections Treated with Eravacycline), investigated its safety and efficacy in cIAI (IGNITE 1) and cUTI (IGNITE 2).  Eravacycline met the primary endpoint in IGNITE 1, while data anal. for IGNITE 2 is currently ongoing.  Common adverse events reported in phase I-III studies included gastrointestinal effects such as nausea and vomiting.  Eravacycline is a promising i.v. and oral fluorocycline that may offer an alternative treatment option for patients with serious infections, particularly those caused by multidrug-resistant Gram-neg. pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppVXX7DWzsV7Vg90H21EOLACvtfcHk0lhgdVf61Wejjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGrsr8%253D&md5=ae7ad3f07bc0c2652e0b0257f63a5d52</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0545-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0545-8%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DCheung%26aufirst%3DD.%26aulast%3DAdam%26aufirst%3DH.%26aulast%3DZelenitsky%26aufirst%3DS.%26aulast%3DGolden%26aufirst%3DA.%26aulast%3DSchweizer%26aufirst%3DF.%26aulast%3DGorityala%26aufirst%3DB.%26aulast%3DLagace-Wiens%26aufirst%3DP.%2BR.%2BS.%26aulast%3DWalkty%26aufirst%3DA.%26aulast%3DGin%26aufirst%3DA.%2BS.%26aulast%3DHoban%26aufirst%3DD.%2BJ.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DReview%2520of%2520Eravacycline%252C%2520a%2520Novel%2520Fluorocycline%2520Antibacterial%2520Agent%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D567%26epage%3D588%26doi%3D10.1007%2Fs40265-016-0545-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brubaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, A. G.</span></span> <span> </span><span class="NLM_article-title">A Practical, Enantioselective Synthetic Route to a Key Precursor to the Tetracycline Antibiotics</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3523</span>– <span class="NLM_lpage">3525</span>, <span class="refDoi"> DOI: 10.1021/ol071377d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol071377d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovF2murs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=3523-3525&author=J.+D.+Brubakerauthor=A.+G.+Myers&title=A+Practical%2C+Enantioselective+Synthetic+Route+to+a+Key+Precursor+to+the+Tetracycline+Antibiotics&doi=10.1021%2Fol071377d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">A Practical, Enantioselective Synthetic Route to a Key Precursor to the Tetracycline Antibiotics</span></div><div class="casAuthors">Brubaker, Jason D.; Myers, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3523-3525</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic dihydronaphthoisoxazoledione I (R = tert-butyldimethylsilyl), an intermediate in the convergent prepn. of tetracycline antibiotics and their analogs, is prepd. in five steps and 29% overall yield from 3-methoxy-2-furancarboxaldehyde (prepd. in one step from 3-methoxyfuran) and 3-benzyloxy-5-isoxazolecarboxaldehyde (II; prepd. in two steps from com. available material, no data); using this route, up to 40 g of material have been prepd. at a time.  Enantioselective addn. of divinylzinc to II in the presence of a nonracemic lithium morpholinylethanolate derived from (1S,2R)-norephedrine followed by mesylation of the nonracemic secondary alc. and substitution of the mesylate with dimethylamine provides α-vinylisoxazolemethylamine III (R1 = H) in 93% ee; divinylzinc is prepd. in situ from vinylmagnesium bromide and zinc chloride as a soln. which may be stored for up to 2 mo with no loss of yield or enantioselectivity in subsequent addn.  III (R1 = H) is also prepd. in five steps from II by addn. of vinylmagnesium bromide, enzymic resoln. of the racemic secondary alc. with Amano AK lipase and vinyl acetate, hydrolysis of the acetate, mesylation of the alc., and substitution of the mesylate with dimethylamine.  Regioselective lithiation of III (R1 = H) and addn. to 3-methoxy-2-furancarboxaldehyde, stereoselective thermal intramol. Diels-Alder cycloaddn. in the presence of diisopropylethylamine and 4-methyl-2,6-di-tert-butylphenol, and Swern oxidn. of the intermediate alcs. provides the nonracemic oxanaphthoisoxazolone IV in 57% yield; lithiation and iodination of III (R = H) to give III (R1 = I) followed by metalation with isopropylmagnesium chloride and addn. to 3-methoxy-2-furancarboxaldehyde gives the intermediate alcs. and their Diels-Alder adducts with higher diastereoselectivities than direct lithiation of III (R = H) followed by addn.  Boron trichloride-mediated cleavage of the Me and bicyclic ethers of IV followed by silylation yields I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgcix7f7WugLVg90H21EOLACvtfcHk0liMh7WrAw2ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovF2murs%253D&md5=7bc12de97d04ee79631c7f38c0b15d91</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1021%2Fol071377d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol071377d%26sid%3Dliteratum%253Aachs%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DMyers%26aufirst%3DA.%2BG.%26atitle%3DA%2520Practical%252C%2520Enantioselective%2520Synthetic%2520Route%2520to%2520a%2520Key%2520Precursor%2520to%2520the%2520Tetracycline%2520Antibiotics%26jtitle%3DOrg.%2520Lett.%26date%3D2007%26volume%3D9%26spage%3D3523%26epage%3D3525%26doi%3D10.1021%2Fol071377d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Charest, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brubaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, A. G.</span></span> <span> </span><span class="NLM_article-title">A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1126/science.1109755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1126%2Fscience.1109755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=15831754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOnt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=395-398&author=M.+G.+Charestauthor=C.+D.+Lernerauthor=J.+D.+Brubakerauthor=D.+R.+Siegelauthor=A.+G.+Myers&title=A+Convergent+Enantioselective+Route+to+Structurally+Diverse+6-Deoxytetracycline+Antibiotics&doi=10.1126%2Fscience.1109755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics</span></div><div class="casAuthors">Charest, Mark G.; Lerner, Christian D.; Brubaker, Jason D.; Siegel, Dionicio R.; Myers, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5720</span>),
    <span class="NLM_cas:pages">395-398</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Complex antibiotics based on natural products are almost invariably prepd. by semisynthesis, or chem. transformation of the isolated natural products.  This approach greatly limits the range of accessible structures that might be studied as new antibiotic candidates.  Here the authors report a short and enantioselective synthetic route to a diverse range of 6-deoxytetracycline antibiotics, e.g. I·HCl.  The common feature of this class is a scaffold of four linearly fused rings, labeled A through D.  The authors targeted not a single compd. but a group of structures with the D ring as a site of structural variability.  A late-stage, diastereoselective C-ring construction was used to couple structurally varied D-ring precursors with an AB precursor contg. much of the essential functionality for binding to the bacterial ribosome.  Five derivs. were synthesized from benzoic acid in yields ranging from 5 to 7% over 14 to 15 steps, and a sixth, (-)-doxycycline hydrochloride (I·HCl), was synthesized in 8.3% yield over 18 steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr34sWE_oyu0LVg90H21EOLACvtfcHk0liMh7WrAw2ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOnt70%253D&md5=7050921817cf4f1bae760215eaf1a7b3</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1126%2Fscience.1109755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1109755%26sid%3Dliteratum%253Aachs%26aulast%3DCharest%26aufirst%3DM.%2BG.%26aulast%3DLerner%26aufirst%3DC.%2BD.%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DSiegel%26aufirst%3DD.%2BR.%26aulast%3DMyers%26aufirst%3DA.%2BG.%26atitle%3DA%2520Convergent%2520Enantioselective%2520Route%2520to%2520Structurally%2520Diverse%25206-Deoxytetracycline%2520Antibiotics%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D395%26epage%3D398%26doi%3D10.1126%2Fscience.1109755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, A. G.</span>; <span class="NLM_string-name">Kummer, D. A.</span>; <span class="NLM_string-name">Li, D.</span>; <span class="NLM_string-name">Hecker, E.</span>; <span class="NLM_string-name">Dion, A.</span>; <span class="NLM_string-name">Wright, P. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Tetracyclines and Intermediates for the Treatment of Infection</span>. <span class="NLM_patent">WO 2010126607A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+G.+Myers&author=D.+A.+Kummer&author=D.+Li&author=E.+Hecker&author=A.+Dion&author=P.+M.+Wright&title=Synthesis+of+Tetracyclines+and+Intermediates+for+the+Treatment+of+Infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DA.%2BG.%26atitle%3DSynthesis%2520of%2520Tetracyclines%2520and%2520Intermediates%2520for%2520the%2520Treatment%2520of%2520Infection%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwoody, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plamondon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, J. A.</span></span> <span> </span><span class="NLM_article-title">Fluorocyclines. 1. 7-Fluoro-9-Pyrrolidinoacetamido-6-Demethyl-6-Deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1021/jm201465w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201465w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Smu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=597-605&author=X.-Y.+Xiaoauthor=D.+K.+Huntauthor=J.+Zhouauthor=R.+B.+Clarkauthor=N.+Dunwoodyauthor=C.+Fyfeauthor=T.+H.+Grossmanauthor=W.+J.+O%E2%80%99Brienauthor=L.+Plamondonauthor=M.+Ronnauthor=C.+Sunauthor=W.-Y.+Zhangauthor=J.+A.+Sutcliffe&title=Fluorocyclines.+1.+7-Fluoro-9-Pyrrolidinoacetamido-6-Demethyl-6-Deoxytetracycline%3A+A+Potent%2C+Broad+Spectrum+Antibacterial+Agent&doi=10.1021%2Fjm201465w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent</span></div><div class="casAuthors">Xiao, Xiao-Yi; Hunt, Diana K.; Zhou, Jingye; Clark, Roger B.; Dunwoody, Nick; Fyfe, Corey; Grossman, Trudy H.; O'Brien, William J.; Plamondon, Louis; Ronn, Magnus; Sun, Cuixiang; Zhang, Wu-Yan; Sutcliffe, Joyce A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">597-605</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This and the accompanying report (DOI: 10.1021/jm201467r) describe the design, synthesis, and evaluation of a new generation of tetracycline antibacterial agents, 7-fluoro-9-substituted-6-demethyl-6-deoxytetracyclines ("fluorocyclines"), accessible through a recently developed total synthesis approach.  These fluorocyclines possess potent antibacterial activities against multidrug resistant (MDR) Gram-pos. and Gram-neg. pathogens.  One of the fluorocyclines, 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline (I, also known as TP-434, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference, Boston, MA, Sept. 12-15, 2010, poster F1-2157), is currently undergoing phase 2 clin. trials in patients with complicated intra-abdominal infections (cIAI).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ3aZPFmJBmrVg90H21EOLACvtfcHk0liMh7WrAw2ctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Smu7fL&md5=b976b79734bf90689531f4f584b0f78c</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1021%2Fjm201465w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201465w%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DX.-Y.%26aulast%3DHunt%26aufirst%3DD.%2BK.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DR.%2BB.%26aulast%3DDunwoody%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DC.%26aulast%3DGrossman%26aufirst%3DT.%2BH.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DW.%2BJ.%26aulast%3DPlamondon%26aufirst%3DL.%26aulast%3DRonn%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.-Y.%26aulast%3DSutcliffe%26aufirst%3DJ.%2BA.%26atitle%3DFluorocyclines.%25201.%25207-Fluoro-9-Pyrrolidinoacetamido-6-Demethyl-6-Deoxytetracycline%253A%2520A%2520Potent%252C%2520Broad%2520Spectrum%2520Antibacterial%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D597%26epage%3D605%26doi%3D10.1021%2Fjm201465w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwoody, N.</span></span> <span> </span><span class="NLM_article-title">A Divergent Route to Eravacycline</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">936</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.6b02442</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.6b02442" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCgs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2017&pages=936-943&author=W.-Y.+Zhangauthor=Q.+Cheauthor=S.+Crawfordauthor=M.+Ronnauthor=N.+Dunwoody&title=A+Divergent+Route+to+Eravacycline&doi=10.1021%2Facs.joc.6b02442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">A Divergent Route to Eravacycline</span></div><div class="casAuthors">Zhang, Wu-Yan; Che, Qinglin; Crawford, Scott; Ronn, Magnus; Dunwoody, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">936-943</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A convergent route to eravacycline has been developed by employing Michael-Dieckmann cyclization between an enone and a fully built and protected left-hand piece (LHP).  After construction of the core eravacycline structure, a deprotection reaction was developed, allowing for the isoxazole ring opening and global deprotection to be achieved in one pot.  The LHP is synthesized from readily available 4-fluoro-3-methylphenol in six steps featuring a palladium-catalyzed Ph carboxylation in the last step.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondgEBWx4BQ7Vg90H21EOLACvtfcHk0lggzYGppI8tSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCgs77O&md5=af27209be4307456ae44237d9002e623</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.6b02442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.6b02442%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.-Y.%26aulast%3DChe%26aufirst%3DQ.%26aulast%3DCrawford%26aufirst%3DS.%26aulast%3DRonn%26aufirst%3DM.%26aulast%3DDunwoody%26aufirst%3DN.%26atitle%3DA%2520Divergent%2520Route%2520to%2520Eravacycline%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2017%26volume%3D82%26spage%3D936%26epage%3D943%26doi%3D10.1021%2Facs.joc.6b02442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Xiao, X.-Y.</span>; <span class="NLM_string-name">Plamondon, L.</span>; <span class="NLM_string-name">Hunt, D. K.</span>; <span class="NLM_string-name">Clark, R. B.</span>; <span class="NLM_string-name">Zahler, R. B.</span></span> <span> </span><span class="NLM_article-title">Preparation of C7-Fluoro Substituted Tetracycline Compounds as Antibacterial Agents</span>. <span class="NLM_patent">WO2010017470A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Zhou&author=X.-Y.+Xiao&author=L.+Plamondon&author=D.+K.+Hunt&author=R.+B.+Clark&author=R.+B.+Zahler&title=Preparation+of+C7-Fluoro+Substituted+Tetracycline+Compounds+as+Antibacterial+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520C7-Fluoro%2520Substituted%2520Tetracycline%2520Compounds%2520as%2520Antibacterial%2520Agents%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwoody, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilicky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.-Y.</span></span> <span> </span><span class="NLM_article-title">Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">838</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1021/op4000219</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op4000219" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=838-845&author=M.+Ronnauthor=Z.+Zhuauthor=P.+C.+Hoganauthor=W.-Y.+Zhangauthor=J.+Niuauthor=C.+E.+Katzauthor=N.+Dunwoodyauthor=O.+Gilickyauthor=Y.+Dengauthor=D.+K.+Huntauthor=M.+Heauthor=C.-L.+Chenauthor=C.+Sunauthor=R.+B.+Clarkauthor=X.-Y.+Xiao&title=Process+R%26D+of+Eravacycline%3A+The+First+Fully+Synthetic+Fluorocycline+in+Clinical+Development&doi=10.1021%2Fop4000219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development</span></div><div class="casAuthors">Ronn, Magnus; Zhu, Zhijian; Hogan, Philip C.; Zhang, Wu-Yan; Niu, John; Katz, Christopher E.; Dunwoody, Nicholas; Gilicky, Olga; Deng, Yonghong; Hunt, Diana K.; He, Minsheng; Chen, Chi-Li; Sun, Cuixiang; Clark, Roger B.; Xiao, Xiao-Yi</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">838-845</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Process research and development of the first fully synthetic broad spectrum 7-fluorotetracycline in clin. development is described.  The process utilizes two key intermediates in a convergent approach.  The key transformation is a Michael-Dieckmann reaction between a suitable substituted arom. moiety and a key cyclohexenone deriv.  Subsequent deprotection and acylation provide the desired active pharmaceutical ingredient in good overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXTEZ7pkV0WrVg90H21EOLACvtfcHk0lggzYGppI8tSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gs7s%253D&md5=d591ae52db9e104cae0839b2e3b348c7</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fop4000219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop4000219%26sid%3Dliteratum%253Aachs%26aulast%3DRonn%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHogan%26aufirst%3DP.%2BC.%26aulast%3DZhang%26aufirst%3DW.-Y.%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DKatz%26aufirst%3DC.%2BE.%26aulast%3DDunwoody%26aufirst%3DN.%26aulast%3DGilicky%26aufirst%3DO.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DHunt%26aufirst%3DD.%2BK.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DC.-L.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DClark%26aufirst%3DR.%2BB.%26aulast%3DXiao%26aufirst%3DX.-Y.%26atitle%3DProcess%2520R%2526D%2520of%2520Eravacycline%253A%2520The%2520First%2520Fully%2520Synthetic%2520Fluorocycline%2520in%2520Clinical%2520Development%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2013%26volume%3D17%26spage%3D838%26epage%3D845%26doi%3D10.1021%2Fop4000219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilicky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwoody, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, M.</span></span> <span> </span><span class="NLM_article-title">Process Research and Development of TP-808: A Key Intermediate for the Manufacture of Synthetic Tetracyclines</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVWht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=377-386&author=W.-Y.+Zhangauthor=C.-L.+Chenauthor=M.+Heauthor=Z.+Zhuauthor=P.+Hoganauthor=O.+Gilickyauthor=N.+Dunwoodyauthor=M.+Ronn&title=Process+Research+and+Development+of+TP-808%3A+A+Key+Intermediate+for+the+Manufacture+of+Synthetic+Tetracyclines&doi=10.1021%2Facs.oprd.7b00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Process Research and Development of TP-808: A Key Intermediate for the Manufacture of Synthetic Tetracyclines</span></div><div class="casAuthors">Zhang, Wu-Yan; Chen, Chi-Li; He, Minsheng; Zhu, Zhijian; Hogan, Philip; Gilicky, Olga; Dunwoody, Nicholas; Ronn, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">377-386</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Process research, development, and manuf. of TP-808 (I), a key intermediate for the discovery and manuf. of tetracycline analogs, is described.  The process used for the prepn. of I avoids chromatog. purifications and has been substantially improved over the previously reported prepn.  The robustness of the process was demonstrated in a 76.1 kg manufg. campaign with 56% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgcvtwzUdmn7Vg90H21EOLACvtfcHk0lggzYGppI8tSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVWht7c%253D&md5=39788986d026b955611ca5ee9376e8c7</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00003%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.-Y.%26aulast%3DChen%26aufirst%3DC.-L.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHogan%26aufirst%3DP.%26aulast%3DGilicky%26aufirst%3DO.%26aulast%3DDunwoody%26aufirst%3DN.%26aulast%3DRonn%26aufirst%3DM.%26atitle%3DProcess%2520Research%2520and%2520Development%2520of%2520TP-808%253A%2520A%2520Key%2520Intermediate%2520for%2520the%2520Manufacture%2520of%2520Synthetic%2520Tetracyclines%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D377%26epage%3D386%26doi%3D10.1021%2Facs.oprd.7b00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafrance, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilicky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwoody, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, M.</span></span> <span> </span><span class="NLM_article-title">Process Research and Development of an Enantiomerically Enriched Allylic Amine, One of the Key Intermediates for the Manufacture of Synthetic Tetracyclines</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1784</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.5b00274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=1784-1795&author=W.-Y.+Zhangauthor=P.+C.+Hoganauthor=C.-L.+Chenauthor=J.+Niuauthor=Z.+Wangauthor=D.+Lafranceauthor=O.+Gilickyauthor=N.+Dunwoodyauthor=M.+Ronn&title=Process+Research+and+Development+of+an+Enantiomerically+Enriched+Allylic+Amine%2C+One+of+the+Key+Intermediates+for+the+Manufacture+of+Synthetic+Tetracyclines&doi=10.1021%2Facs.oprd.5b00274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Process Research and Development of an Enantiomerically Enriched Allylic Amine, One of the Key Intermediates for the Manufacture of Synthetic Tetracyclines</span></div><div class="casAuthors">Zhang, Wu-Yan; Hogan, Philip C.; Chen, Chi-Li; Niu, John; Wang, Zhimin; Lafrance, Danny; Gilicky, Olga; Dunwoody, Nicholas; Ronn, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1784-1795</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A robust, cost-effective, and high yielding manufg. process for enantiomerically enriched (S)-allylic amine I, a key intermediate for fully synthetic tetracyclines have been developed.  Two novel and scalable asym. vinylations resulting in high-to-excellent stereoselectivity have been developed for the key step.  The final product is purified by an efficient crystn. of a L-tartaric salt.  The process described has been used to manuf. ∼350 kg of the tartaric salt of I with 99.0% ee in 8 steps (35% overall yield) from cheap and readily available di-Me maleate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpflsR7C6Ehf7Vg90H21EOLACvtfcHk0liBJaTZnKgxsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7jN&md5=5f46cd3c6b37577215c9372412850c39</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00274%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.-Y.%26aulast%3DHogan%26aufirst%3DP.%2BC.%26aulast%3DChen%26aufirst%3DC.-L.%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLafrance%26aufirst%3DD.%26aulast%3DGilicky%26aufirst%3DO.%26aulast%3DDunwoody%26aufirst%3DN.%26aulast%3DRonn%26aufirst%3DM.%26atitle%3DProcess%2520Research%2520and%2520Development%2520of%2520an%2520Enantiomerically%2520Enriched%2520Allylic%2520Amine%252C%2520One%2520of%2520the%2520Key%2520Intermediates%2520for%2520the%2520Manufacture%2520of%2520Synthetic%2520Tetracyclines%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D1784%26epage%3D1795%26doi%3D10.1021%2Facs.oprd.5b00274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><a href="https://www.eisai.com/news/2018/news201806.html" class="extLink">https://www.eisai.com/news/2018/news201806.html</a> (accessed Dec
3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.eisai.com%2Fnews%2F2018%2Fnews201806.html+%28accessed+Dec%0A3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span> <span> </span><span class="NLM_article-title">Potential of Ravuconazole and Its Prodrugs as the New Oraltherapeutics for Onychomycosis</span>. <i>Med. Mycol. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">E93</span>– <span class="NLM_lpage">E110</span>, <span class="refDoi"> DOI: 10.3314/mmj.16-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.3314%2Fmmj.16-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27904057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVClsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=E93-E110&author=H.+Yamaguchi&title=Potential+of+Ravuconazole+and+Its+Prodrugs+as+the+New+Oraltherapeutics+for+Onychomycosis&doi=10.3314%2Fmmj.16-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Potential of ravuconazole and its prodrugs as the new oral therapeutics for onychomycosis</span></div><div class="casAuthors">Yamaguchi, Hideyo</div><div class="citationInfo"><span class="NLM_cas:title">Medical Mycology Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e93-e110</span>CODEN:
                <span class="NLM_cas:coden">MMJEB4</span>;
        ISSN:<span class="NLM_cas:issn">2185-6486</span>.
    
            (<span class="NLM_cas:orgname">Nippon Ishinkin Gakkai</span>)
        </div><div class="casAbstract">A review.  Onychomycosis is a fungal infection of the nail app. caused by dermatophytes, Candida and nondermatophytic molds.  It is highly prevalent in the general population worldwide and also responsible for significant morbidity and complications and does not usually cure itself.  Thus, the condition needs to be treated in view of phys. and psychol. problems produced.  Currently, oral medications using terbinafine are the most effective therapy, but it has relatively limited therapeutic success, particularly for long-term management.  Such existing oral therapies are assocd. with high recurrence rates and treatment failure, as well as with potential adverse events and drug-drug interactions.  In the light of these issues, development of more efficacious and safer alternatives for the treatment of onychomycosis is warranted.  Ravuconazole and its prodrugs are promising new drug candidates for oral therapy of onychomycosis, among which a water-sol. prodrug, mono-lysine phosphoester deriv. (E1224 or BFE1224) is in the most advanced stage of clin. development: a Phase II dose-finding study has been successfully completed and Phase III comparative studies are in progress in Japan.  This review aims to summarize our current status of knowledge and information on ravuconazole and its prodrugs, particularly BFE1224, as the potential oral treatment option for onychomycosis.  It also summarize the clin. features of onychomycosis with particular stress on its etiol., epidemiol., and current therapeutic options and their limitations.  Given its clin. usefulness.  BFE1224 may become a valuable addn. to the current armamentarium for the treatment of onychomycosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHkpAaDzjBlrVg90H21EOLACvtfcHk0liBJaTZnKgxsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVClsbzI&md5=8a12fc3102afed5c1eff2444a5180ce8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3314%2Fmmj.16-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3314%252Fmmj.16-00006%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DH.%26atitle%3DPotential%2520of%2520Ravuconazole%2520and%2520Its%2520Prodrugs%2520as%2520the%2520New%2520Oraltherapeutics%2520for%2520Onychomycosis%26jtitle%3DMed.%2520Mycol.%2520J.%26date%3D2016%26volume%3D57%26spage%3DE93%26epage%3DE110%26doi%3D10.3314%2Fmmj.16-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyosawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsu, K.</span></span> <span> </span><span class="NLM_article-title">In Vitro and in Vivo Antifungal Activities of ER-30346, a Novel Oral Triazole with a Broad Antifungal Spectrum</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2242</span>, <span class="refDoi"> DOI: 10.1128/AAC.40.10.2237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1128%2FAAC.40.10.2237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=8891121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK28XmtVCgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=2237-2242&author=K.+Hataauthor=J.+Kimuraauthor=H.+Mikiauthor=T.+Toyosawaauthor=T.+Nakamuraauthor=K.+Katsu&title=In+Vitro+and+in+Vivo+Antifungal+Activities+of+ER-30346%2C+a+Novel+Oral+Triazole+with+a+Broad+Antifungal+Spectrum&doi=10.1128%2FAAC.40.10.2237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum</span></div><div class="casAuthors">Hata, Katsura; Kimura, Junko; Miki, Hikari; Toyosawa, Toshio; Nakamura, Toshihiro; Katsu, Kanemasa</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2237-2242</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">ER-30346 is a novel oral triazole with a broad spectrum of potent activity against a wide range of fungi.  ER-30346, with MICs at which 90% of the strains tested are inhibited (MIC90s) ranging from 0.025 to 0.78 μg/mL, was 4 to 32 times more active than itraconazole, fluconazole, and amphotericin B against Candida albicans, Candida parapsilosis, and Candida glabrata.  Against Candida tropicalis, ER-30346, with an MIC90 of 12.5 μg/mL, was 2 to >8 times more active than itraconazole and fluconazole, but was 16 times less active than amphotericin B.  ER-30346 (MIC90, 0.78 μg/mL) was four to eight times more active than fluconazole and amphotericin B and had activity comparable to that of itraconazole against Trichosporon beigelli.  The MIC90s of ER-30346 were 0.10 μg/mL for Cryptococcus neoformans and 0.39 μg/mL for Aspergillus fumigatus.  ER-30346 was 2 to 8 times more active than itraconazole and amphotericin B and 32 to >256 times more active than fluconazole.  ER-30346 also showed good activity against dermatophytes, with MICs ranging from 0.05 to 0.39 μg/mL, and its activity was comparable to or 2 to 16 times higher than those of itraconazole and amphotericin B and >32 times higher an that of fluconazole.  In vivo activity was evaluated with systemic infections in mice.  Against systemic candidiasis and cryptococcosis, ER-30346 was comparable in efficacy to fluconazole and was more effective than itraconazole.  Of the drugs tested, ER-30346 was the most effective drug against systemic aspergillosis.  The authors studied the levels of ER-30346 in mouse plasma.  The max. concn. of drug in plasma and the area under the concn.-time curve for ER-30346 showed good linearity over a range of doses from 2 to 40 mg/kg of body wt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouenlKs4-WUrVg90H21EOLACvtfcHk0liBJaTZnKgxsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtVCgsb8%253D&md5=d73bc07b2ce8ab19b50220bcfc43b770</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.40.10.2237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.40.10.2237%26sid%3Dliteratum%253Aachs%26aulast%3DHata%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DJ.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DToyosawa%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DKatsu%26aufirst%3DK.%26atitle%3DIn%2520Vitro%2520and%2520in%2520Vivo%2520Antifungal%2520Activities%2520of%2520ER-30346%252C%2520a%2520Novel%2520Oral%2520Triazole%2520with%2520a%2520Broad%2520Antifungal%2520Spectrum%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26spage%3D2237%26epage%3D2242%26doi%3D10.1128%2FAAC.40.10.2237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubouchi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Fosravuconazole L-Lysine Ethanolate, a Novel Oral Triazole Antifungal Agent, for the Treatment of Onychomycosis: A Multicenter, Double-Blind, Randomized Phase III Study</span>. <i>J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1151</span>– <span class="NLM_lpage">1159</span>, <span class="refDoi"> DOI: 10.1111/1346-8138.14607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1111%2F1346-8138.14607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30156314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=1151-1159&author=S.+Watanabeauthor=I.+Tsubouchiauthor=A.+Okubo&title=Efficacy+and+Safety+of+Fosravuconazole+L-Lysine+Ethanolate%2C+a+Novel+Oral+Triazole+Antifungal+Agent%2C+for+the+Treatment+of+Onychomycosis%3A+A+Multicenter%2C+Double-Blind%2C+Randomized+Phase+III+Study&doi=10.1111%2F1346-8138.14607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study</span></div><div class="casAuthors">Watanabe, Shinichi; Tsubouchi, Ichiro; Okubo, Akihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1151-1159</span>CODEN:
                <span class="NLM_cas:coden">JDMYAG</span>;
        ISSN:<span class="NLM_cas:issn">0385-2407</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Fosravuconazole L-lysine ethanolate (F-RVCZ) is a prodrug of ravuconazole, a novel triazole antifungal agent, exerting broad and potent antifungal activity.  The efficacy and safety of F-RVCZ, compared with a placebo, were investigated in a multicenter, double-blind, randomized study of Japanese onychomycosis patients with 25% or more clin. involvement of the target toenail.  Subjects (n = 153) were randomly assigned to receive F-RVCZ (100 mg RVCZ,n = 101) or placebo (n = 52) p.o. once daily for 12 wk.  The primary end-point was the rate of complete cure (clin. cure [0% clin. involvement of the target toenail] plus mycol. cure [neg. potassium hydroxide examn.]) at week 48 (36-wk post-treatment visit).  Secondary end-points were changes over time in the efficacy and mycol. effect of F-RVCZ.  Safety was also evaluated.  The complete cure rate at week 48 was significantly higher with F-RVCZ (59.4%, 60/101) than the placebo (5.8%, 3/52) in the full anal. set (P < 0.001).  The mycol. cure rate at week 48 was also significantly higher with F-RVCZ (82.0%, 73/89) than the placebo (20.0%, 10/50, P < 0.001).  Regarding safety, adverse events were obsd. in 83.2% (84/101) and 80.8% (42/52), and adverse drug reactions (ADR) in 23.8% (24/101) and 3.8% (2/52) of F-RVCZ and placebo subjects, resp.  ADR were mild to moderate in severity, with none being serious.  F-RVCZ (equiv. to 100 mg ravuconazole) administrated once daily for 12 wk was more effective than placebo and tolerable in patients with onychomycosis, suggesting it to be a promising drug for onychomycosis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKwqaKpIELq7Vg90H21EOLACvtfcHk0lhFU2UI7gb-Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7%252FO&md5=716f4254981a5528fb4ac58ba997bbdc</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1111%2F1346-8138.14607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1346-8138.14607%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DS.%26aulast%3DTsubouchi%26aufirst%3DI.%26aulast%3DOkubo%26aufirst%3DA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Fosravuconazole%2520L-Lysine%2520Ethanolate%252C%2520a%2520Novel%2520Oral%2520Triazole%2520Antifungal%2520Agent%252C%2520for%2520the%2520Treatment%2520of%2520Onychomycosis%253A%2520A%2520Multicenter%252C%2520Double-Blind%252C%2520Randomized%2520Phase%2520III%2520Study%26jtitle%3DJ.%2520Dermatol.%26date%3D2018%26volume%3D45%26spage%3D1151%26epage%3D1159%26doi%3D10.1111%2F1346-8138.14607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Torrico, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Vega, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinazo, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schijman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strub-Wourgaft, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, I.</span></span> <span> </span><span class="NLM_article-title">Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-Concept, Randomised, Placebo-Controlled Trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30538-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS1473-3099%2817%2930538-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29352704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=419-430&author=F.+Torricoauthor=J.+Gasconauthor=L.+Ortizauthor=C.+Alonso-Vegaauthor=M.-J.+Pinazoauthor=A.+Schijmanauthor=I.+C.+Almeidaauthor=F.+Alvesauthor=N.+Strub-Wourgaftauthor=I.+Ribeiro&title=Treatment+of+Adult+Chronic+Indeterminate+Chagas+Disease+with+Benznidazole+and+Three+E1224+Dosing+Regimens%3A+A+Proof-of-Concept%2C+Randomised%2C+Placebo-Controlled+Trial&doi=10.1016%2FS1473-3099%2817%2930538-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial</span></div><div class="casAuthors">Torrico, Faustino; Gascon, Joaquim; Ortiz, Lourdes; Alonso-Vega, Cristina; Pinazo, Maria-Jesus; Schijman, Alejandro; Almeida, Igor C.; Alves, Fabiana; Strub-Wourgaft, Nathalie; Ribeiro, Isabela</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chagas disease is a major neglected vector-borne disease.  In this study, we investigated the safety and efficacy of three oral E1224 (a water-sol. ravuconazole prodrug) regimens and benznidazole vs. placebo in adult chronic indeterminate Chagas disease.  In this proof-of-concept, double-blind, randomised phase 2 clin. trial, we recruited adults (18-50 years) with confirmed diagnosis of Trypanosoma cruzi infection from two outpatient units in Bolivia.  Patients were randomised with a computer-generated randomisation list, which was stratified by center and used a block size of ten.  Patients were randomly assigned (1:1:1:1:1) to five oral treatment groups: high-dose E1224 (duration 8 wk, total dose 4000 mg), low-dose E1224 (8 wk, 2000 mg), short-dose E1224 (4 wk + 4 wk placebo, 2400 mg), benznidazole (60 days, 5 mg/kg per day), or placebo (8 wk, E1224-matched tablets).  Double-blinding was limited to the E1224 and placebo arms, and assessors were masked to all treatment allocations.  The primary efficacy endpoint was parasitol. response to E1224 at the end of treatment, assessed by PCR.  The secondary efficacy endpoints were parasitol. response to benznidazole at end of treatment, assessed by PCR; sustainability of parasitol. response until 12 mo; parasite clearance and changes in parasite load; incidence of conversion to neg. response in conventional and non-conventional (antigen trypomastigote chemiluminescent ELISA [AT CL-ELISA]) serol. response; changes in levels of biomarkers; and complete response.  The primary anal. population consisted of all randomised patients by their assigned treatment arms.  This trial is registered with ClinicalTrials.gov, no. NCT01489228.  Between July 19, 2011, and July 26, 2012, we screened 560 participants with confirmed Chagas disease, of whom 231 were enrolled and assigned to high-dose E1224 (n = 45), low-dose E1224 (n = 48), short-dose E1224 (n = 46), benznidazole (n = 45), or placebo (n = 47).  Parasite clearance was obsd. with E1224 during the treatment phase, but no sustained response was seen with low-dose and short-dose regimens, whereas 13 patients (29%, 95% CI 16.4-44.3) had sustained response with the high-dose regimen compared with four (9%, 2.4-20.4) in the placebo group (p < 0.0001).  Benznidazole had a rapid and sustained effect on parasite clearance, with 37 patients (82%, 67.9-92.0) with sustained response at 12-mo follow-up.  After 1 wk of treatment, mean quant. PCR repeated measurements showed a significant redn. in parasite load in all treatment arms vs. placebo.  Parasite levels in the low-dose and short-dose E1224 groups gradually returned to placebo levels.  Both treatments were well tolerated.  Reversible, dose-dependent liver enzyme increases were seen with E1224 and benznidazole.  A 187 (81%) participants developed treatment-emergent adverse events and six (3%) developed treatment-emergent serious adverse events.  Treatment-emergent adverse events were headaches, nausea, pruritus, peripheral neuropathy, and hypersensitivity.  E1224 is the first new chem. entity developed for Chagas disease in decades.  E1224 displayed a transient, suppressive effect on parasite clearance, whereas benznidazole showed early and sustained efficacy until 12 mo of follow-up.  Despite PCR limitations, our results support increased diagnosis and access to benznidazole std. regimen, and provide a development roadmap for novel benznidazole regimens in monotherapy and in combinations with E1224.  Drugs for Neglected Diseases initiative.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqes8nnI-YsK7Vg90H21EOLACvtfcHk0lhFU2UI7gb-Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2hsbo%253D&md5=0d71e1af60fad81c14943af5e70ad8ad</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930538-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930538-8%26sid%3Dliteratum%253Aachs%26aulast%3DTorrico%26aufirst%3DF.%26aulast%3DGascon%26aufirst%3DJ.%26aulast%3DOrtiz%26aufirst%3DL.%26aulast%3DAlonso-Vega%26aufirst%3DC.%26aulast%3DPinazo%26aufirst%3DM.-J.%26aulast%3DSchijman%26aufirst%3DA.%26aulast%3DAlmeida%26aufirst%3DI.%2BC.%26aulast%3DAlves%26aufirst%3DF.%26aulast%3DStrub-Wourgaft%26aufirst%3DN.%26aulast%3DRibeiro%26aufirst%3DI.%26atitle%3DTreatment%2520of%2520Adult%2520Chronic%2520Indeterminate%2520Chagas%2520Disease%2520with%2520Benznidazole%2520and%2520Three%2520E1224%2520Dosing%2520Regimens%253A%2520A%2520Proof-of-Concept%252C%2520Randomised%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26spage%3D419%26epage%3D430%26doi%3D10.1016%2FS1473-3099%2817%2930538-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Q.</span></span> <span> </span><span class="NLM_article-title">Improved Chiral Synthesis of Ravuconazole</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1611</span>– <span class="NLM_lpage">1625</span>, <span class="refDoi"> DOI: 10.1080/00397910802563420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F00397910802563420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=1611-1625&author=L.+Xuauthor=M.+R.+Mullerauthor=X.+Yuauthor=B.-Q.+Zhu&title=Improved+Chiral+Synthesis+of+Ravuconazole&doi=10.1080%2F00397910802563420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Improved chiral synthesis of ravuconazole</span></div><div class="casAuthors">Xu, Lin; Muller, Marc R.; Yu, Xiong; Zhu, Bao-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1611-1625</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A short, elegant, and high yielding synthesis of ravuconazole is presented.  The key step of this synthesis is an enantioselective palladium-catalyzed chiral zinc-allene addn. reaction.  The starting materials are 2-chloro-1-(2,4-difluorophenyl)-ethanone and (R)-4-phenylbutyn-2-ol obtained from enzymic resoln. of its racemate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSPw1AMDMdoLVg90H21EOLACvtfcHk0lhFU2UI7gb-Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFCisLs%253D&md5=38be319861dd2dcd71374b3a1bd0e813</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1080%2F00397910802563420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397910802563420%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DL.%26aulast%3DMuller%26aufirst%3DM.%2BR.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DB.-Q.%26atitle%3DImproved%2520Chiral%2520Synthesis%2520of%2520Ravuconazole%26jtitle%3DSynth.%2520Commun.%26date%3D2009%26volume%3D39%26spage%3D1611%26epage%3D1625%26doi%3D10.1080%2F00397910802563420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruoka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaku, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakinuma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antifungal Activity of Novel Thiazole-Containing Triazole Antifungals. II. Optically Active ER-30346 and Its Derivatives</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1248/cpb.46.623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1248%2Fcpb.46.623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=9579038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK1cXisl2ns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1998&pages=623-630&author=A.+Tsuruokaauthor=Y.+Kakuauthor=H.+Kakinumaauthor=I.+Tsukadaauthor=M.+Yanagisawaauthor=K.+Naraauthor=T.+Naito&title=Synthesis+and+Antifungal+Activity+of+Novel+Thiazole-Containing+Triazole+Antifungals.+II.+Optically+Active+ER-30346+and+Its+Derivatives&doi=10.1248%2Fcpb.46.623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives</span></div><div class="casAuthors">Tsuruoka, Akihiko; Kaku, Yumiko; Kakinuma, Hiroyuki; Tsukada, Itaru; Yanagisawa, Manabu; Nara, Kazumasa; Naito, Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-630</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A series of novel thiazole-contg. triazole antifungals, I (R1 = Ph, 4-FC6H4, Q, etc.) and II (X = CH, N, Y = Cl, F, CSNH2, etc.), was synthesized and evaluated for antifungal activity against a variety of clin. isolated pathogenic fungi in vitro and against systemic candidosis in vivo.  These compds. showed potent antifungal activities in vitro and in vivo.  In particular, (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1 ,2,4-triazol-1-yl)-2-butanol (ER-30346) showed potent and well-balanced in vitro activities and potent in vivo efficacy, and had a good safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAnG45DQnQu7Vg90H21EOLACvtfcHk0liAwVnYfnjIow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisl2ns7Y%253D&md5=8d2a0ee78e21be39de46d661ebe5e588</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1248%2Fcpb.46.623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.46.623%26sid%3Dliteratum%253Aachs%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DKaku%26aufirst%3DY.%26aulast%3DKakinuma%26aufirst%3DH.%26aulast%3DTsukada%26aufirst%3DI.%26aulast%3DYanagisawa%26aufirst%3DM.%26aulast%3DNara%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520Antifungal%2520Activity%2520of%2520Novel%2520Thiazole-Containing%2520Triazole%2520Antifungals.%2520II.%2520Optically%2520Active%2520ER-30346%2520and%2520Its%2520Derivatives%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1998%26volume%3D46%26spage%3D623%26epage%3D630%26doi%3D10.1248%2Fcpb.46.623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibasaki, M.</span></span> <span> </span><span class="NLM_article-title">An Enantioselective Synthesis of the Key Intermediate for Triazole Antifungal Agents; Application to the Catalytic Asymmetric Synthesis of Efinaconazole (Jublia)</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">3272</span>– <span class="NLM_lpage">3278</span>, <span class="refDoi"> DOI: 10.1021/jo500369y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo500369y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=3272-3278&author=K.+Tamuraauthor=N.+Kumagaiauthor=M.+Shibasaki&title=An+Enantioselective+Synthesis+of+the+Key+Intermediate+for+Triazole+Antifungal+Agents%3B+Application+to+the+Catalytic+Asymmetric+Synthesis+of+Efinaconazole+%28Jublia%29&doi=10.1021%2Fjo500369y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">An Enantioselective Synthesis of the Key Intermediate for Triazole Antifungal Agents; Application to the Catalytic Asymmetric Synthesis of Efinaconazole (Jublia)</span></div><div class="casAuthors">Tamura, Keiji; Kumagai, Naoya; Shibasaki, Masakatsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3272-3278</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new synthetic route, the shortest reported to date, to access a key intermediate I for the synthesis of various triazole antifungal agents was developed.  The elusive tetrasubstituted stereogenic center that is essential in advanced triazole antifungal agents was constructed via the catalytic asym. cyanosilylation of a ketone.  The subsequent transformations were performed in two one-pot operations, enhancing the overall synthetic efficiency toward the intermediate.  This streamlined synthetic approach was successfully applied to efficient enantioselective syntheses of efinaconazole (II, Jublia) and ravuconazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUWAKjsfr3wbVg90H21EOLACvtfcHk0liAwVnYfnjIow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itL0%253D&md5=f1ddf3693a5ab8363c81b0b7bf61eae0</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Fjo500369y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo500369y%26sid%3Dliteratum%253Aachs%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DKumagai%26aufirst%3DN.%26aulast%3DShibasaki%26aufirst%3DM.%26atitle%3DAn%2520Enantioselective%2520Synthesis%2520of%2520the%2520Key%2520Intermediate%2520for%2520Triazole%2520Antifungal%2520Agents%253B%2520Application%2520to%2520the%2520Catalytic%2520Asymmetric%2520Synthesis%2520of%2520Efinaconazole%2520%2528Jublia%2529%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D3272%26epage%3D3278%26doi%3D10.1021%2Fjo500369y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, M.</span></span> <span> </span><span class="NLM_article-title">Process for the Manufacture of Enantiomerically Pure Antifungal Azoles as Ravuconazole and Isavuconazole</span>. <span class="NLM_patent">US20110087030A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Soukup&title=Process+for+the+Manufacture+of+Enantiomerically+Pure+Antifungal+Azoles+as+Ravuconazole+and+Isavuconazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSoukup%26aufirst%3DM.%26atitle%3DProcess%2520for%2520the%2520Manufacture%2520of%2520Enantiomerically%2520Pure%2520Antifungal%2520Azoles%2520as%2520Ravuconazole%2520and%2520Isavuconazole%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, M.</span></span> <span> </span><span class="NLM_article-title">Intermediate Halophenyl Derivatives and Their Use in a Process for Preparing Azole Derivatives</span>. <span class="NLM_patent">WO2003002498A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+Soukup&title=Intermediate+Halophenyl+Derivatives+and+Their+Use+in+a+Process+for+Preparing+Azole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSoukup%26aufirst%3DM.%26atitle%3DIntermediate%2520Halophenyl%2520Derivatives%2520and%2520Their%2520Use%2520in%2520a%2520Process%2520for%2520Preparing%2520Azole%2520Derivatives%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A. S. D.</span></span> <span> </span><span class="NLM_article-title">Process for Selectively Preparing (1H-1,2,4-Triazol-1-yl)alkanols, Hydrazinyl Alkanol Compound Produced by Said Process and Use Thereof</span>. <span class="NLM_patent">WO2015058272A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+S.+D.+Souza&title=Process+for+Selectively+Preparing+%281H-1%2C2%2C4-Triazol-1-yl%29alkanols%2C+Hydrazinyl+Alkanol+Compound+Produced+by+Said+Process+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSouza%26aufirst%3DA.%2BS.%2BD.%26atitle%3DProcess%2520for%2520Selectively%2520Preparing%2520%25281H-1%252C2%252C4-Triazol-1-yl%2529alkanols%252C%2520Hydrazinyl%2520Alkanol%2520Compound%2520Produced%2520by%2520Said%2520Process%2520and%2520Use%2520Thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A. S. D.</span>; <span class="NLM_string-name">Mendes, B. L. D. M. E.</span></span> <span> </span><span class="NLM_article-title">Process for Selectively Preparing (1H-1,2,4-Triazol-1-yl)alkanols, Hydrazinyl Alkanol Compound Produced by Said Process and Use Thereof</span>. <span class="NLM_patent">BR102013027313B1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+S.+D.+Souza&author=B.+L.+D.+M.+E.+Mendes&title=Process+for+Selectively+Preparing+%281H-1%2C2%2C4-Triazol-1-yl%29alkanols%2C+Hydrazinyl+Alkanol+Compound+Produced+by+Said+Process+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSouza%26aufirst%3DA.%2BS.%2BD.%26atitle%3DProcess%2520for%2520Selectively%2520Preparing%2520%25281H-1%252C2%252C4-Triazol-1-yl%2529alkanols%252C%2520Hydrazinyl%2520Alkanol%2520Compound%2520Produced%2520by%2520Said%2520Process%2520and%2520Use%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shalini, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drabu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P. K.</span></span> <span> </span><span class="NLM_article-title">Advances in Synthetic Approach to and Antifungal Activity of Triazoles</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.3762/bjoc.7.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.3762%2Fbjoc.7.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=21804864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvVKrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=668-677&author=K.+Shaliniauthor=N.+Kumarauthor=S.+Drabuauthor=P.+K.+Sharma&title=Advances+in+Synthetic+Approach+to+and+Antifungal+Activity+of+Triazoles&doi=10.3762%2Fbjoc.7.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13hR"><div class="casContent"><span class="casTitleNuber">13h</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in synthetic approach to and antifungal activity of triazoles</span></div><div class="casAuthors">Shalini, Kumari; Kumar, Nitin; Drabu, Sushma; Sharma, Pramod Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">668-677, No. 79</span>CODEN:
                <span class="NLM_cas:coden">BJOCBH</span>;
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    
            (<span class="NLM_cas:orgname">Beilstein-Institut zur Foerderung der Chemischen Wissenschaften</span>)
        </div><div class="casAbstract">A review.  Several five membered ring systems, e.g., triazole, oxadiazole dithiazole and thiadiazole with three heteroatoms at sym. or asym. positions have been studied because of their interesting pharmacol. properties.  In this article emphasis is placed on the synthetic development and pharmacol. activity of the triazole moiety which exhibits a broad spectrum of pharmacol. activity such as antifungal, antibacterial, anti-inflammatory and anticancer activity, etc.  Triazoles have increased our ability to treat many fungal infections, for example, candidiasis, cryptococcal meningitis, aspergillosis etc.  However, mortality due to these infections even with antifungal therapy is still unacceptably high.  Therefore, the development of new antifungal agents targeting specific fungal structures or functions is being actively pursued.  Rapid developments in mol. mycol. have led to a concd. search for more target antifungal agents.  Although a new era of antifungal therapy has begun, presenting challenges by systemic fungal diseases, the options for treatment will have greatly expanded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1hbxjMYkeALVg90H21EOLACvtfcHk0liAwVnYfnjIow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvVKrtbw%253D&md5=646e2ee7ddbf2b7bd9205a2b38a757a0</span></div><a href="/servlet/linkout?suffix=cit13h&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.7.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.7.79%26sid%3Dliteratum%253Aachs%26aulast%3DShalini%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DDrabu%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DP.%2BK.%26atitle%3DAdvances%2520in%2520Synthetic%2520Approach%2520to%2520and%2520Antifungal%2520Activity%2520of%2520Triazoles%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2011%26volume%3D7%26spage%3D668%26epage%3D677%26doi%3D10.3762%2Fbjoc.7.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruoka, A.</span></span> <span> </span><span class="NLM_article-title">ER-30346. Triazole Antifungal</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1358/dof.1996.021.01.333681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdof.1996.021.01.333681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK2sXjtVWktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1996&pages=20-24&author=T.+Naitoauthor=K.+Hataauthor=A.+Tsuruoka&title=ER-30346.+Triazole+Antifungal&doi=10.1358%2Fdof.1996.021.01.333681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13iR"><div class="casContent"><span class="casTitleNuber">13i</span><div class="casTitle"><span class="NLM_cas:atitle">ER-30346. Triazole antifungal</span></div><div class="casAuthors">Naito, Toshihiko; Hata, Katsura; Tsuruoka, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-24</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous</span>)
        </div><div class="casAbstract">A review with 8 refs. of synthesis, pharmacol. actions, pharmacokinetics, drug interactions, and toxicity of triazole ER-30346.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw5bY56qrk9bVg90H21EOLACvtfcHk0lg_vQ0CCdtCDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtVWktg%253D%253D&md5=fbd11a57e6d4c3e809b07842f1b006a5</span></div><a href="/servlet/linkout?suffix=cit13i&amp;dbid=16384&amp;doi=10.1358%2Fdof.1996.021.01.333681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.1996.021.01.333681%26sid%3Dliteratum%253Aachs%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DHata%26aufirst%3DK.%26aulast%3DTsuruoka%26aufirst%3DA.%26atitle%3DER-30346.%2520Triazole%2520Antifungal%26jtitle%3DDrugs%2520Future%26date%3D1996%26volume%3D21%26spage%3D20%26epage%3D24%26doi%3D10.1358%2Fdof.1996.021.01.333681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindrud, M. D.</span>; <span class="NLM_string-name">Kim, S.</span>; <span class="NLM_string-name">Wei, C.</span></span> <span> </span><span class="NLM_article-title">Sonic Impinging Jet Crystallization Apparatus and Process</span>. <span class="NLM_patent">WO2000044468A1</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=M.+D.+Lindrud&author=S.+Kim&author=C.+Wei&title=Sonic+Impinging+Jet+Crystallization+Apparatus+and+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLindrud%26aufirst%3DM.%2BD.%26atitle%3DSonic%2520Impinging%2520Jet%2520Crystallization%2520Apparatus%2520and%2520Process%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pesti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DelMonte, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discordia, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doubleday, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kacsur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muslehiddinoglu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olzog, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoraval, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totleben, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanyo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemishetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasylak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span> <span> </span><span class="NLM_article-title">The Process Development of Ravuconazole: An Efficient Multikilogram Scale Preparation of an Antifungal Agent</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1021/op900065c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op900065c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotl2ht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=716-728&author=J.+Pestiauthor=C.-K.+Chenauthor=L.+Spanglerauthor=A.+J.+DelMonteauthor=S.+Benoitauthor=D.+Berglundauthor=J.+Bienauthor=P.+Brodfuehrerauthor=Y.+Chanauthor=E.+Corbettauthor=C.+Costelloauthor=P.+DeMenaauthor=R.+P.+Discordiaauthor=W.+Doubledayauthor=Z.+Gaoauthor=S.+Gingrasauthor=J.+Grossoauthor=O.+Haasauthor=D.+Kacsurauthor=C.+Laiauthor=S.+Leungauthor=M.+Millerauthor=J.+Muslehiddinogluauthor=N.+Nguyenauthor=J.+Qiuauthor=M.+Olzogauthor=E.+Reiffauthor=D.+Thoravalauthor=M.+Totlebenauthor=D.+Vanyoauthor=P.+Vemishettiauthor=J.+Wasylakauthor=C.+Wei&title=The+Process+Development+of+Ravuconazole%3A+An+Efficient+Multikilogram+Scale+Preparation+of+an+Antifungal+Agent&doi=10.1021%2Fop900065c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The Process Development of Ravuconazole: An Efficient Multikilogram Scale Preparation of an Antifungal Agent</span></div><div class="casAuthors">Pesti, Jaan; Chen, Chien-Kuang; Spangler, Lori; DelMonte, Albert J.; Benoit, Serge; Berglund, Derek; Bien, Jeffrey; Brodfuehrer, Paul; Chan, Yeung; Corbett, Elisabeth; Costello, Carrie; DeMena, Paul; Discordia, Robert P.; Doubleday, Wendel; Gao, Zhinong; Gingras, Stephane; Grosso, John; Haas, Oscar; Kacsur, David; Lai, Chiajen; Leung, Simon; Miller, Melanie; Muslehiddinoglu, Jale; Nguyen, Nina; Qiu, Jun; Olzog, Martina; Reiff, Emily; Thoraval, Dominique; Totleben, Michael; Vanyo, Dale; Vemishetti, Purushotham; Wasylak, John; Wei, Chenkou</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">716-728</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a safe, robust process for the prepn. of ravuconazole (I), an antifungal agent, is described.  The discovery and development of procedures enabling the efficient synthesis of multikilogram quantities of I and the process demonstration through plant scale prepns. are presented.  A controlled means to prep. a Grignard reagent and utilization of Fourier Transform IR spectroscopy (FTIR) monitoring to safely conduct the reaction is featured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptVBPIsjDg3LVg90H21EOLACvtfcHk0lg_vQ0CCdtCDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotl2ht74%253D&md5=982f12e8bb7b3340606acb717e536eb6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fop900065c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop900065c%26sid%3Dliteratum%253Aachs%26aulast%3DPesti%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.-K.%26aulast%3DSpangler%26aufirst%3DL.%26aulast%3DDelMonte%26aufirst%3DA.%2BJ.%26aulast%3DBenoit%26aufirst%3DS.%26aulast%3DBerglund%26aufirst%3DD.%26aulast%3DBien%26aufirst%3DJ.%26aulast%3DBrodfuehrer%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DY.%26aulast%3DCorbett%26aufirst%3DE.%26aulast%3DCostello%26aufirst%3DC.%26aulast%3DDeMena%26aufirst%3DP.%26aulast%3DDiscordia%26aufirst%3DR.%2BP.%26aulast%3DDoubleday%26aufirst%3DW.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DGingras%26aufirst%3DS.%26aulast%3DGrosso%26aufirst%3DJ.%26aulast%3DHaas%26aufirst%3DO.%26aulast%3DKacsur%26aufirst%3DD.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DLeung%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMuslehiddinoglu%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DQiu%26aufirst%3DJ.%26aulast%3DOlzog%26aufirst%3DM.%26aulast%3DReiff%26aufirst%3DE.%26aulast%3DThoraval%26aufirst%3DD.%26aulast%3DTotleben%26aufirst%3DM.%26aulast%3DVanyo%26aufirst%3DD.%26aulast%3DVemishetti%26aufirst%3DP.%26aulast%3DWasylak%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DC.%26atitle%3DThe%2520Process%2520Development%2520of%2520Ravuconazole%253A%2520An%2520Efficient%2520Multikilogram%2520Scale%2520Preparation%2520of%2520an%2520Antifungal%2520Agent%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2009%26volume%3D13%26spage%3D716%26epage%3D728%26doi%3D10.1021%2Fop900065c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span>; <span class="NLM_string-name">Chen, C.-P. H.</span>; <span class="NLM_string-name">Fakes, M. G.</span>; <span class="NLM_string-name">Pendri, Y. R.</span>; <span class="NLM_string-name">Kiau, S.</span>; <span class="NLM_string-name">Vakkalagadda, B.</span></span> <span> </span><span class="NLM_article-title">Preparation of Mono-Lysine Salts of Azole Compounds as Fungicides</span>. <span class="NLM_patent">WO2006118351A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=Q.+Gao&author=C.-P.+H.+Chen&author=M.+G.+Fakes&author=Y.+R.+Pendri&author=S.+Kiau&author=B.+Vakkalagadda&title=Preparation+of+Mono-Lysine+Salts+of+Azole+Compounds+as+Fungicides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DQ.%26atitle%3DPreparation%2520of%2520Mono-Lysine%2520Salts%2520of%2520Azole%2520Compounds%2520as%2520Fungicides%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estivill, C.</span></span> <span> </span><span class="NLM_article-title">Omadacycline: Tetracycline Antibiotic</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1358/dof.2009.034.01.1324393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdof.2009.034.01.1324393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvVWhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=11-15&author=Y.+Wangauthor=R.+Castanerauthor=J.+Bolosauthor=C.+Estivill&title=Omadacycline%3A+Tetracycline+Antibiotic&doi=10.1358%2Fdof.2009.034.01.1324393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Amadacycline: tetracycline antibiotic</span></div><div class="casAuthors">Wang, Y.; Castaner, R.; Bolos, J.; Estivill, C.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-15</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Amadacycline (PTK-0796) is an aminomethylcycline antibiotic with a broad spectrum of antibacterial activity.  The agent showed potent in vitro activity against multidrug-resistant and -susceptible Gram-pos., Gram-neg., anaerobic and atypical bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and penicillin-resistant Streptococcus pneumoniae.  Amadacycline demonstrated superior in vivo activity to other antibiotics, including vancomycin, linezolid and minocycline, against infections caused by various bacterial pathogens and its activity was not affected by the presence of other antibiotics.  In patients with complicated skin and skin structure infections, amadacycline and linezolid showed comparable safety and efficacy profiles.  No discontinuations due to adverse events and no serious drug-related adverse events were reported in the amadacycline group.  Clin. trials of both oral and i.v. formulations of amadacycline have been completed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohbqe6FcpJSrVg90H21EOLACvtfcHk0lg1fNBdmoophg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvVWhurs%253D&md5=d0bf100a0f78f80dd80bd81e9b1567b8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1358%2Fdof.2009.034.01.1324393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2009.034.01.1324393%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCastaner%26aufirst%3DR.%26aulast%3DBolos%26aufirst%3DJ.%26aulast%3DEstivill%26aufirst%3DC.%26atitle%3DOmadacycline%253A%2520Tetracycline%2520Antibiotic%26jtitle%3DDrugs%2520Future%26date%3D2009%26volume%3D34%26spage%3D11%26epage%3D15%26doi%3D10.1358%2Fdof.2009.034.01.1324393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Omadacycline: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1931</span>– <span class="NLM_lpage">1937</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1015-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1015-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30471003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3crkt1Grsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1931-1937&author=A.+Markhamauthor=S.+J.+Keam&title=Omadacycline%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1015-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Omadacycline: First Global Approval</span></div><div class="casAuthors">Markham Anthony; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1931-1937</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Paratek Pharmaceuticals are developing omadacycline (NUZYRA®), a first-in-class orally active aminomethylcycline antibacterial, as a treatment for various bacterial infections.  The drug, which is available in intravenous and oral formulations, has a broad spectrum of antibacterial activity and was recently approved in the USA as a treatment for the treatment of community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults.  This article summarizes the milestones in the development of omadacycline leading to this first global approval for the treatment of CABP and ABSSSI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUPapfSmV6s7esJRIHUP1ofW6udTcc2eZxjRE9HUxvhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crkt1Grsg%253D%253D&md5=7d2f58c3468e05a04e52a57dc7a200c6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1015-2%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DOmadacycline%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1931%26epage%3D1937%26doi%3D10.1007%2Fs40265-018-1015-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartner, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvetovich, R. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis Development of an Aminomethylcycline Antibiotic Via an Electronically Tuned Acyliminium Friedel-Crafts Reaction</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6095</span>– <span class="NLM_lpage">6100</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2008.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.tetlet.2008.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVyis7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=6095-6100&author=J.+Y.+L.+Chungauthor=F.+W.+Hartnerauthor=R.+J.+Cvetovich&title=Synthesis+Development+of+an+Aminomethylcycline+Antibiotic+Via+an+Electronically+Tuned+Acyliminium+Friedel-Crafts+Reaction&doi=10.1016%2Fj.tetlet.2008.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis development of an aminomethylcycline antibiotic via an electronically tuned acyliminium Friedel-Crafts reaction</span></div><div class="casAuthors">Chung, John Y. L.; Hartner, Frederick W.; Cvetovich, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">6095-6100</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">With the goal of improving the synthetic efficiency, the development of a convergent synthesis of minocycline deriv. PTK0796 via an intermol. acyliminium Friedel-Crafts reaction (Tscherniac-Einhorn reaction) is described.  The entire C9 neopentylaminomethyl side chain was installed in one step using an electronically optimized chloromethylacyliminium precursor in 83% yield.  Deprotection and re-equilibration to the C4 α-epimer in the presence of CaCl2 and ethanolamine or NaOH afforded the target aminomethylcycline antibiotic.  The corresponding cryst. tosylate salt was found to exhibit improved solid state stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreS-zW9M_3PrVg90H21EOLACvtfcHk0lg1fNBdmoophg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVyis7%252FK&md5=1864f08e452659cd4004dceaabd72402</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2008.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2008.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DJ.%2BY.%2BL.%26aulast%3DHartner%26aufirst%3DF.%2BW.%26aulast%3DCvetovich%26aufirst%3DR.%2BJ.%26atitle%3DSynthesis%2520Development%2520of%2520an%2520Aminomethylcycline%2520Antibiotic%2520Via%2520an%2520Electronically%2520Tuned%2520Acyliminium%2520Friedel-Crafts%2520Reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D2008%26volume%3D49%26spage%3D6095%26epage%3D6100%26doi%3D10.1016%2Fj.tetlet.2008.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span>; <span class="NLM_string-name">Warchol, T.</span></span> <span> </span><span class="NLM_article-title">Methods for Synthesizing and Purifying Aminoalkyl Tetracycline Compounds</span>. <span class="NLM_patent">WO2008134048A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+Johnston&author=T.+Warchol&title=Methods+for+Synthesizing+and+Purifying+Aminoalkyl+Tetracycline+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%26atitle%3DMethods%2520for%2520Synthesizing%2520and%2520Purifying%2520Aminoalkyl%2520Tetracycline%2520Compounds%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steenbergen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villano, S.</span></span> <span> </span><span class="NLM_article-title">Discovery, Pharmacology, and Clinical Profile of Omadacycline, a Novel Aminomethylcycline Antibiotic</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6409</span>– <span class="NLM_lpage">6419</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.07.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2016.07.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27469981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cks7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=6409-6419&author=S.+K.+Tanakaauthor=J.+Steenbergenauthor=S.+Villano&title=Discovery%2C+Pharmacology%2C+and+Clinical+Profile+of+Omadacycline%2C+a+Novel+Aminomethylcycline+Antibiotic&doi=10.1016%2Fj.bmc.2016.07.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic</span></div><div class="casAuthors">Tanaka, S. Ken; Steenbergen, Judith; Villano, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6409-6419</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Omadacycline is novel, aminomethyl tetracycline antibiotic being developed for oral and i.v. administration for the treatment of community-acquired bacterial infections.  Omadacycline is characterized by an aminomethyl substituent at the C9 position of the core 6-member ring.  Modifications at this position result in an improved spectrum of antimicrobial activity by overcoming resistance known to affect older generation tetracyclines via ribosomal protection proteins and efflux pump mechanisms.  In vitro, omadacycline has activity against Gram-pos. and Gram-neg. aerobes, anaerobes, and atypical pathogens including Legionella and Chlamydia spp.  Omadacycline offers once daily oral and IV dosing and a clin. tolerability and safety profile that compares favorably with contemporary antibiotics used across serious community-acquired infections where resistance has rendered many less effective.  In studies in patients with complicated skin and skin structure infections, including those with MRSA infections, omadacycline exhibited an efficacy and tolerability profile that was comparable to linezolid.  Ongoing and planned clin. studies are evaluating omadacycline as monotherapy for treating serious community-acquired bacterial infections including Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP).  This review provides an overview of the discovery, microbiol., nonclin. data, and available clin. safety and efficacy data for omadacycline, with ref. to other contemporary tetracycline-derived antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2DRA8vvaNmbVg90H21EOLACvtfcHk0lg1fNBdmoophg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cks7nN&md5=d545e70f930e1213c2dc99f8142cdcc0</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.07.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.07.029%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DS.%2BK.%26aulast%3DSteenbergen%26aufirst%3DJ.%26aulast%3DVillano%26aufirst%3DS.%26atitle%3DDiscovery%252C%2520Pharmacology%252C%2520and%2520Clinical%2520Profile%2520of%2520Omadacycline%252C%2520a%2520Novel%2520Aminomethylcycline%2520Antibiotic%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D6409%26epage%3D6419%26doi%3D10.1016%2Fj.bmc.2016.07.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.fda.gov_drugs_new-2Ddrugs-2Dfda-2Dcders-2Dnew-2Dmolecular-2Dentities-2Dand-2Dnew-2Dtherapeutic-2Dbiological-2Dproducts_novel-2Ddrug-2Dapprovals-2D2018&amp;d=DwMFoQ&amp;c=UE1eNsedaKncO0Yl_u8bfw&amp;r=MKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s&amp;m=CVuOqytT8wbiBPnC7O4FpCDUO9pblLXS3us5ofOd6v4&amp;s=R3DCQACVOkMOAMrTxYddEgl3XJs1w-cCwklKJy_myRo&amp;e=" class="extLink">https://urldefense.proofpoint.com/v2/url?u=https-3A__www.fda.gov_drugs_new-2Ddrugs-2Dfda-2Dcders-2Dnew-2Dmolecular-2Dentities-2Dand-2Dnew-2Dtherapeutic-2Dbiological-2Dproducts_novel-2Ddrug-2Dapprovals-2D2018&d=DwMFoQ&c=UE1eNsedaKncO0Yl_u8bfw&r=MKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s&m=CVuOqytT8wbiBPnC7O4FpCDUO9pblLXS3us5ofOd6v4&s=R3DCQACVOkMOAMrTxYddEgl3XJs1w-cCwklKJy_myRo&e=</a> (accessed Dec 16, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__www.fda.gov_drugs_new-2Ddrugs-2Dfda-2Dcders-2Dnew-2Dmolecular-2Dentities-2Dand-2Dnew-2Dtherapeutic-2Dbiological-2Dproducts_novel-2Ddrug-2Dapprovals-2D2018%26d%3DDwMFoQ%26c%3DUE1eNsedaKncO0Yl_u8bfw%26r%3DMKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s%26m%3DCVuOqytT8wbiBPnC7O4FpCDUO9pblLXS3us5ofOd6v4%26s%3DR3DCQACVOkMOAMrTxYddEgl3XJs1w-cCwklKJy_myRo%26e%3D+%28accessed+Dec+16%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><a href="https://www.globenewswire.com/news-release/2019/06/06/1865709/0/en/Achaogen-Inc-Announces-Results-of-Auction-for-Substantially-All-Company-Assets.html" class="extLink">https://www.globenewswire.com/news-release/2019/06/06/1865709/0/en/Achaogen-Inc-Announces-Results-of-Auction-for-Substantially-All-Company-Assets.html</a> (accessed Jan 3, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2019%2F06%2F06%2F1865709%2F0%2Fen%2FAchaogen-Inc-Announces-Results-of-Auction-for-Substantially-All-Company-Assets.html+%28accessed+Jan+3%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Galani, I.</span></span> <span> </span><span class="NLM_article-title">Plazomicin: Aminoglycoside Antibiotic</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1358/dof.2014.039.01.2095267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdof.2014.039.01.2095267" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=25-35&author=I.+Galani&title=Plazomicin%3A+Aminoglycoside+Antibiotic&doi=10.1358%2Fdof.2014.039.01.2095267"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1358%2Fdof.2014.039.01.2095267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2014.039.01.2095267%26sid%3Dliteratum%253Aachs%26aulast%3DGalani%26aufirst%3DI.%26atitle%3DPlazomicin%253A%2520Aminoglycoside%2520Antibiotic%26jtitle%3DDrugs%2520Future%26date%3D2014%26volume%3D39%26spage%3D25%26epage%3D35%26doi%3D10.1358%2Fdof.2014.039.01.2095267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M. W.</span></span> <span> </span><span class="NLM_article-title">Plazomicin for the Treatment of Patients with Complicated Urinary Tract Infection</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1358/dot.2018.54.9.2874063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdot.2018.54.9.2874063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2017&pages=513-518&author=M.+W.+McCarthy&title=Plazomicin+for+the+Treatment+of+Patients+with+Complicated+Urinary+Tract+Infection&doi=10.1358%2Fdot.2018.54.9.2874063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1358%2Fdot.2018.54.9.2874063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2018.54.9.2874063%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DM.%2BW.%26atitle%3DPlazomicin%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Complicated%2520Urinary%2520Tract%2520Infection%26jtitle%3DDrugs%2520Today%26date%3D2017%26volume%3D54%26spage%3D513%26epage%3D518%26doi%3D10.1358%2Fdot.2018.54.9.2874063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Eljaaly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alharbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alshehri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogue, J. M.</span></span> <span> </span><span class="NLM_article-title">Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-1054-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-1054-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30723876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyis74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=243-269&author=K.+Eljaalyauthor=A.+Alharbiauthor=S.+Alshehriauthor=J.+K.+Ortwineauthor=J.+M.+Pogue&title=Plazomicin%3A+A+Novel+Aminoglycoside+for+the+Treatment+of+Resistant+Gram-Negative+Bacterial+Infections&doi=10.1007%2Fs40265-019-1054-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20cR"><div class="casContent"><span class="casTitleNuber">20c</span><div class="casTitle"><span class="NLM_cas:atitle">Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections</span></div><div class="casAuthors">Eljaaly, Khalid; Alharbi, Aisha; Alshehri, Samah; Ortwine, Jessica K.; Pogue, Jason M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-269</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Plazomicin is a novel semisynthetic parenteral aminoglycoside that inhibits bacterial protein synthesis.  It was approved by the United States Food and Drug Administration for use in adults with complicated urinary tract infections (cUTI), including pyelonephritis.  Plazomicin displays potent in vitro activity against Enterobacteriaceae, including both extended-spectrum β-lactamase-producing and carbapenem-resistant isolates.  Plazomicin's enhanced Enterobacteriaceae activity is due to its stability to commonly encountered aminoglycoside-modifying enzymes that compromise the activity of traditional aminoglycosides.  Plazomicin resistance in Enterobacteriaceae is via modification of the ribosomal binding site due to expression of 16S rRNA methyltransferases.  Plazomicin does not display improved activity over traditional aminoglycosides against other problematic resistant Gram-neg. bacteria, namely Pseudomonas aeruginosa and Acinetobacter baumannii.  Plazomicin has been assessed in two phase III randomized controlled trials.  The EPIC trial compared plazomicin and meropenem for the management of cUTI.  In this trial, plazomicin demonstrated superiority in composite cure (81.7% vs 70.1%; difference 11.6%; 95% confidence interval [CI] 2.7-25.7) at the test-of-cure visit, which was driven by enhanced sustained microbiol. eradication.  The CARE trial compared plazomicin-based and colistin-based combinations in patients with serious infections due to carbapenem-resistant Enterobacteriaceae (CRE).  In this anal., plazomicin-based combinations were assocd. with numerically decreased mortality or serious disease-related complications when compared with colistin-based combinations (23.5% vs 50%, resp.; 90% CI -0.7 to 51.2).  Furthermore, plazomicin was also assocd. with a lower incidence of nephrotoxicity than colistin.  However, small sample sizes limit the interpretation of the findings in the CARE trial.  Plazomicin is a novel aminoglycoside that offers clinicians an addnl. option for the management of CRE infections, with superior activity compared with traditional aminoglycosides and potentially improved efficacy and decreased toxicity compared with colistin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7IMMJ9KBAxLVg90H21EOLACvtfcHk0lg3O5JEpjO0Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyis74%253D&md5=e20938baf8656c6feb17be9e9c3e77b2</span></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-1054-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-1054-3%26sid%3Dliteratum%253Aachs%26aulast%3DEljaaly%26aufirst%3DK.%26aulast%3DAlharbi%26aufirst%3DA.%26aulast%3DAlshehri%26aufirst%3DS.%26aulast%3DOrtwine%26aufirst%3DJ.%2BK.%26aulast%3DPogue%26aufirst%3DJ.%2BM.%26atitle%3DPlazomicin%253A%2520A%2520Novel%2520Aminoglycoside%2520for%2520the%2520Treatment%2520of%2520Resistant%2520Gram-Negative%2520Bacterial%2520Infections%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D243%26epage%3D269%26doi%3D10.1007%2Fs40265-019-1054-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, P.-R.</span></span> <span> </span><span class="NLM_article-title">New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01112-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-01112-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30972660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWms7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=705-714&author=S.-S.+Jeanauthor=I.+M.+Gouldauthor=W.-S.+Leeauthor=P.-R.+Hsueh&title=New+Drugs+for+Multidrug-Resistant+Gram-Negative+Organisms%3A+Time+for+Stewardship&doi=10.1007%2Fs40265-019-01112-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20dR"><div class="casContent"><span class="casTitleNuber">20d</span><div class="casTitle"><span class="NLM_cas:atitle">New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship</span></div><div class="casAuthors">Jean, Shio-Shin; Gould, Ian M.; Lee, Wen-Sen; Hsueh, Po-Ren</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">705-714</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A gradual rise in drug-resistant trends among Gram-neg. organisms, esp. carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and extensively-drug-resistant (XDR) Acinetobacter baumannii, poses an enormous threat to healthcare systems worldwide.  In the last decade, many pharmaceutical companies have devoted enormous resources to the development of new potent antibiotics against XDR Gram-neg. pathogens, particularly CRE.  Some of these novel antibiotics against CRE strains are β-lactam/β-lactamase-inhibitor combination agents, while others belong to the non-β-lactam class.  Most of these antibiotics display good in vitro activity against the producers of Ambler class A, C, and D β-lactamase, although avibactam and vaborbactam are not active in vitro against metallo-β-lactamase (MβL) enzymes.  Nevertheless, in vitro efficacy against the producers of some or all class B enzymes (New Delhi MβL, Verona integron-encoded MβL, etc) has been shown with cefepime-zidebactam, aztreonam-avibactam, VNRX-5133, cefiderocol, plazomicin, and eravacycline.  As of Feburary 2019, drugs approved for treatment of some CRE-related infections by the US Food and Drug Administration included ceftazidime-avibactam, meropenem-vaborbactam, plazomicin, and eravacycline.  Although active against extended-spectrum and AmpC β-lactamase-producing Enterobacteriaceae, delafloxacin does not show in vitro activity against CRE.  Murepavadin is shown to be specifically active against CR- and colistin-resistant P. aeruginosa strains.  Despite successful development of novel antibiotics, strict implementation of an antibiotic stewardship policy in combination with the use of well-established phenotypic tests and novel multiplex PCR methods for detection of the most commonly encountered β-lactamases/carbapenemases in hospitals is important for prescribing effective antibiotics against CRE and decreasing the resistance burden due to CRE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9yoS5Y6hw97Vg90H21EOLACvtfcHk0lg3O5JEpjO0Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWms7nI&md5=e284e1d79d5a84abbb1418d00a153650</span></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01112-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01112-1%26sid%3Dliteratum%253Aachs%26aulast%3DJean%26aufirst%3DS.-S.%26aulast%3DGould%26aufirst%3DI.%2BM.%26aulast%3DLee%26aufirst%3DW.-S.%26aulast%3DHsueh%26aufirst%3DP.-R.%26atitle%3DNew%2520Drugs%2520for%2520Multidrug-Resistant%2520Gram-Negative%2520Organisms%253A%2520Time%2520for%2520Stewardship%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D705%26epage%3D714%26doi%3D10.1007%2Fs40265-019-01112-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagabhushan, T. L.</span></span> <span> </span><span class="NLM_article-title">Process for the Manufacture of 6′-N-Alkyl Derivatives of Sisomicin and Verdamicin; Novel Intermediates Useful Therein, and Novel 6′-N-Alkylverdamicins Prepared Thereby</span>. <span class="NLM_patent">US3997524A</span>, <span class="NLM_year">1976</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1976&author=T.+L.+Nagabhushan&title=Process+for+the+Manufacture+of+6%E2%80%B2-N-Alkyl+Derivatives+of+Sisomicin+and+Verdamicin%3B+Novel+Intermediates+Useful+Therein%2C+and+Novel+6%E2%80%B2-N-Alkylverdamicins+Prepared+Thereby"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNagabhushan%26aufirst%3DT.%2BL.%26atitle%3DProcess%2520for%2520the%2520Manufacture%2520of%25206%25E2%2580%25B2-N-Alkyl%2520Derivatives%2520of%2520Sisomicin%2520and%2520Verdamicin%253B%2520Novel%2520Intermediates%2520Useful%2520Therein%252C%2520and%2520Novel%25206%25E2%2580%25B2-N-Alkylverdamicins%2520Prepared%2520Thereby%26date%3D1976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggen, J.</span>; <span class="NLM_string-name">Goldblum, A. A.</span>; <span class="NLM_string-name">Linsell, M.</span>; <span class="NLM_string-name">Dozzo, P.</span>; <span class="NLM_string-name">Moser, H. E.</span>; <span class="NLM_string-name">Hildebrandt, D.</span>; <span class="NLM_string-name">Gliedt, M.</span></span> <span> </span><span class="NLM_article-title">Antibacterial Aminoglycoside Analogs</span>. <span class="NLM_patent">WO2009067692A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Aggen&author=A.+A.+Goldblum&author=M.+Linsell&author=P.+Dozzo&author=H.+E.+Moser&author=D.+Hildebrandt&author=M.+Gliedt&title=Antibacterial+Aminoglycoside+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAggen%26aufirst%3DJ.%26atitle%3DAntibacterial%2520Aminoglycoside%2520Analogs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Aggen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldblum, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dozzo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsell, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gliedt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrandt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlasichuk, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diokno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, H. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Spectrum of the Neoglycoside ACHN-490</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4642</span>, <span class="refDoi"> DOI: 10.1128/AAC.00572-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1128%2FAAC.00572-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20805391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCitrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=4636-4642&author=J.+B.+Aggenauthor=E.+S.+Armstrongauthor=A.+A.+Goldblumauthor=P.+Dozzoauthor=M.+S.+Linsellauthor=M.+J.+Gliedtauthor=D.+J.+Hildebrandtauthor=L.+A.+Feeneyauthor=A.+Kuboauthor=R.+D.+Matiasauthor=S.+Lopezauthor=M.+Gomezauthor=K.+B.+Wlasichukauthor=R.+Dioknoauthor=G.+H.+Millerauthor=H.+E.+Moser&title=Synthesis+and+Spectrum+of+the+Neoglycoside+ACHN-490&doi=10.1128%2FAAC.00572-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and spectrum of the neoglycoside ACHN-490</span></div><div class="casAuthors">Aggen, James B.; Armstrong, Eliana S.; Goldblum, Adam A.; Dozzo, Paola; Linsell, Martin S.; Gliedt, Micah J.; Hildebrandt, Darin J.; Feeney, Lee Ann; Kubo, Aya; Matias, Rowena D.; Lopez, Sara; Gomez, Marcela; Wlasichuk, Kenneth B.; Diokno, Raymond; Miller, George H.; Moser, Heinz E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4642</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">ACHN-490 is a neoglycoside, or "next-generation" aminoglycoside (AG), that has been identified as a potentially useful agent to combat drug-resistant bacteria emerging in hospitals and health care facilities around the world.  A focused medicinal chem. campaign produced a collection of over 400 sisomicin analogs from which ACHN-490 was selected.  The authors tested ACHN-490 against two panels of Gram-neg. and Gram-pos. pathogens, many of which harbored AG resistance mechanisms.  Unlike legacy AGs, ACHN-490 was active against strains expressing known AG-modifying enzymes, including the three most common such enzymes found in Enterobacteriaceae.  ACHN-490 inhibited the growth of AG-resistant Enterobacteriaceae (MIC90, ≤4 μg/mL), with the exception of Proteus mirabilis and indole-pos. Proteae (MIC90, 8 μg/mL and 16 μg/mL, resp.).  ACHN-490 was more active alone in vitro against Pseudomonas aeruginosa and Acinetobacter baumannii isolates with AG-modifying enzymes than against those with altered permeability/efflux.  The MIC90 of ACHN-490 against AG-resistant staphylococci was 2 μg/mL.  Due to its promising in vitro and in vivo profiles, ACHN-490 has been advanced into clin. development as a new antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqj0Wwd0mWDbVg90H21EOLACvtfcHk0lgaZetcVnEQuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCitrzO&md5=c30682c90423c6e2dfcaadf11ad7787e</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1128%2FAAC.00572-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00572-10%26sid%3Dliteratum%253Aachs%26aulast%3DAggen%26aufirst%3DJ.%2BB.%26aulast%3DArmstrong%26aufirst%3DE.%2BS.%26aulast%3DGoldblum%26aufirst%3DA.%2BA.%26aulast%3DDozzo%26aufirst%3DP.%26aulast%3DLinsell%26aufirst%3DM.%2BS.%26aulast%3DGliedt%26aufirst%3DM.%2BJ.%26aulast%3DHildebrandt%26aufirst%3DD.%2BJ.%26aulast%3DFeeney%26aufirst%3DL.%2BA.%26aulast%3DKubo%26aufirst%3DA.%26aulast%3DMatias%26aufirst%3DR.%2BD.%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DM.%26aulast%3DWlasichuk%26aufirst%3DK.%2BB.%26aulast%3DDiokno%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DG.%2BH.%26aulast%3DMoser%26aufirst%3DH.%2BE.%26atitle%3DSynthesis%2520and%2520Spectrum%2520of%2520the%2520Neoglycoside%2520ACHN-490%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D4636%26epage%3D4642%26doi%3D10.1128%2FAAC.00572-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, J. B.</span>; <span class="NLM_string-name">Miller, G. H.</span>; <span class="NLM_string-name">Aggen, J. B.</span>; <span class="NLM_string-name">Armstrong, E. S.</span></span> <span> </span><span class="NLM_article-title">Treatment of Urinary Tract Infections with Antibacterial Aminoglycoside Compounds</span>. <span class="NLM_patent">WO2010132777A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+B.+Bruss&author=G.+H.+Miller&author=J.+B.+Aggen&author=E.+S.+Armstrong&title=Treatment+of+Urinary+Tract+Infections+with+Antibacterial+Aminoglycoside+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBruss%26aufirst%3DJ.%2BB.%26atitle%3DTreatment%2520of%2520Urinary%2520Tract%2520Infections%2520with%2520Antibacterial%2520Aminoglycoside%2520Compounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, J. B.</span>; <span class="NLM_string-name">Miller, G. H.</span>; <span class="NLM_string-name">Aggen, J. B.</span>; <span class="NLM_string-name">Armstrong, E. S.</span></span> <span> </span><span class="NLM_article-title">Treatment of Klebsiella Pneumoniae Infections with Antibacterial Aminoglycoside Compounds</span>. <span class="NLM_patent">WO2010132770A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+B.+Bruss&author=G.+H.+Miller&author=J.+B.+Aggen&author=E.+S.+Armstrong&title=Treatment+of+Klebsiella+Pneumoniae+Infections+with+Antibacterial+Aminoglycoside+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBruss%26aufirst%3DJ.%2BB.%26atitle%3DTreatment%2520of%2520Klebsiella%2520Pneumoniae%2520Infections%2520with%2520Antibacterial%2520Aminoglycoside%2520Compounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Trend, R.</span>; <span class="NLM_string-name">Dappen, M.</span>; <span class="NLM_string-name">Henry, C. E.</span>; <span class="NLM_string-name">Goldblum, A. A.</span>; <span class="NLM_string-name">Aggen, J. B.</span>; <span class="NLM_string-name">Mendonca, R. F. d. J. G.</span>; <span class="NLM_string-name">Sardinha, J. C. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Antibacterial Aminoglycoside Analogs</span>. <span class="NLM_patent">WO2019079613A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=R.+Trend&author=M.+Dappen&author=C.+E.+Henry&author=A.+A.+Goldblum&author=J.+B.+Aggen&author=R.+F.+d.+J.+G.+Mendonca&author=J.+C.+F.+Sardinha&title=Synthesis+of+Antibacterial+Aminoglycoside+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTrend%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520Antibacterial%2520Aminoglycoside%2520Analogs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Sarecycline: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-1053-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-1053-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30659422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=325-329&author=E.+D.+Deeks&title=Sarecycline%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-1053-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Sarecycline: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-329</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Sarecycline (Seysara) is an oral, once-daily, tetracycline-class drug for which a tablet formulation is approved in the USA for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥ 9 years.  The drug was developed by Paratek and Allergen and later acquired by Almirall S.  A. (a Barcelona-based pharmaceutical company focused on medical dermatol.).  Sarceycline tablets were approved in early Oct. 2018 and are planned to be available for patients in Jan. 2019.  Sarecycline capsules have also been studied in the USA, but no recent reports of development have been identified for this formulation.  There are currently no clin. trials underway assessing sarecycline in rosacea.  This article summarizes the milestones in the development of sarecycline leading to this first approval for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBZ4V-bGzXl7Vg90H21EOLACvtfcHk0lj5yvDizC8RIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqt7o%253D&md5=e80aca5a735c13d2db53224be4844967</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-1053-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-1053-4%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DSarecycline%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D325%26epage%3D329%26doi%3D10.1007%2Fs40265-019-1053-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Abato, P.</span>; <span class="NLM_string-name">Assefa, H.</span>; <span class="NLM_string-name">Berniac, J.</span>; <span class="NLM_string-name">Bhatia, B.</span>; <span class="NLM_string-name">Bowser, T.</span>; <span class="NLM_string-name">Grier, M.</span>; <span class="NLM_string-name">Honeyman, L.</span>; <span class="NLM_string-name">Ismail, M.</span>; <span class="NLM_string-name">Kim, O. K.</span>; <span class="NLM_string-name">Nelson, M.</span>; <span class="NLM_string-name">Pan, J.</span>; <span class="NLM_string-name">Verma, A.</span></span> <span> </span><span class="NLM_article-title">Substituted Tetracycline Compounds for Treatment of Bacterial Infections and Neoplasms</span>. <span class="NLM_patent">WO2008079339A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+Abato&author=H.+Assefa&author=J.+Berniac&author=B.+Bhatia&author=T.+Bowser&author=M.+Grier&author=L.+Honeyman&author=M.+Ismail&author=O.+K.+Kim&author=M.+Nelson&author=J.+Pan&author=A.+Verma&title=Substituted+Tetracycline+Compounds+for+Treatment+of+Bacterial+Infections+and+Neoplasms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbato%26aufirst%3DP.%26atitle%3DSubstituted%2520Tetracycline%2520Compounds%2520for%2520Treatment%2520of%2520Bacterial%2520Infections%2520and%2520Neoplasms%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. L.</span>; <span class="NLM_string-name">McIntyre, L.</span></span> <span> </span><span class="NLM_article-title">Preparation of 7-Substituted Fused Ring Tetracycline Compounds as Antibiotics</span>. <span class="NLM_patent">WO2001087824A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=M.+L.+Nelson&author=L.+McIntyre&title=Preparation+of+7-Substituted+Fused+Ring+Tetracycline+Compounds+as+Antibiotics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DM.%2BL.%26atitle%3DPreparation%2520of%25207-Substituted%2520Fused%2520Ring%2520Tetracycline%2520Compounds%2520as%2520Antibiotics%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seyedi, F.</span>; <span class="NLM_string-name">Warchol, T.</span>; <span class="NLM_string-name">Grier, M.</span></span> <span> </span><span class="NLM_article-title">Methods for Synthesizing Substituted Tetracycline Compounds</span>. <span class="NLM_patent">WO2009009042A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=F.+Seyedi&author=T.+Warchol&author=M.+Grier&title=Methods+for+Synthesizing+Substituted+Tetracycline+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSeyedi%26aufirst%3DF.%26atitle%3DMethods%2520for%2520Synthesizing%2520Substituted%2520Tetracycline%2520Compounds%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span> <span> </span><span class="NLM_article-title">Baloxavir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0899-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0899-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29623652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVejsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=693-697&author=Y.-A.+Heo&title=Baloxavir%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0899-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Baloxavir: First Global Approval</span></div><div class="casAuthors">Heo, Young-A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">693-697</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Baloxavir marboxil (Xofluza; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi.  The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis.  In Feb. 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections.  Phase III development is underway in the USA, EU and other countries for this indication.  This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV1eFMLv6ePLVg90H21EOLACvtfcHk0lj5yvDizC8RIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVejsr0%253D&md5=1b11d92b5dc5807b6de1d1920ed1e4e5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0899-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0899-1%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26atitle%3DBaloxavir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D693%26epage%3D697%26doi%3D10.1007%2Fs40265-018-0899-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-influenza" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-influenza</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-drug-treat-influenza+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span> <span> </span><span class="NLM_article-title">Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1177/1060028019826565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1177%2F1060028019826565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30674196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2hsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=754-759&author=T.+Yang&title=Baloxavir+Marboxil%3A+The+First+Cap-Dependent+Endonuclease+Inhibitor+for+the+Treatment+of+Influenza&doi=10.1177%2F1060028019826565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza</span></div><div class="casAuthors">Yang, Tianrui</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">754-759</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To review the pharmacol., pharmacokinetics, clin. trials, and clin. implications of baloxavir marboxil.  Data Sources: A MEDLINE search was conducted using the terms baloxavir, baloxavir marboxil, cap-dependent endonuclease inhibitor, and polymerase acidic endonuclease inhibitor.  Addnl. data were obtained from the prescribing information and relevant guidelines.  Study Selection and Data Extn.: All clin. trials were included.  Data Synthesis: Baloxavir marboxil exploits a new mechanism of action of inhibiting cap-dependent endonuclease.  Baloxavir was shown to be superior compared with placebo and noninferior compared with oseltamivir with regard to the primary end point.  Baloxavir was well tolerated in the trials.  A second phase III study investigating high-risk patients was completed with pos. results.  However, the full article is not yet published.  Relevance to Patient Care and Clin. Practice: The small amt. of literature limits baloxavir's use in certain patient populations.  Baloxavir offers advantages such as single-dose regimen, eliminating adherence concerns and lack of cross-resistance, making it an alternative for resistant viruses.  Several uncertainties remain.  Baloxavir has not been studied in hospitalized patients, patients with symptoms for >48 h, or in combination with other antiviral agents.  Furthermore, resistance to baloxavir can develop after 1 dose.  Clin. studies are ongoing to evaluate baloxavir in young pediatric patients, hospitalized patients, and in combination therapy with neuraminidase inhibitors to further elucidate baloxavir's place in therapy.  Conclusion: Baloxavir is a new antiviral medication for the treatment of influenza.  Given the new mechanism of action, baloxavir may be useful in treating patients with resistant viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNvs3TXJOB27Vg90H21EOLACvtfcHk0ljS2-eTI4yQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2hsrfP&md5=bdf7716d61f468afc888890da50c47a7</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1177%2F1060028019826565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028019826565%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26atitle%3DBaloxavir%2520Marboxil%253A%2520The%2520First%2520Cap-Dependent%2520Endonuclease%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Influenza%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2019%26volume%3D53%26spage%3D754%26epage%3D759%26doi%3D10.1177%2F1060028019826565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Splawn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. C.</span></span> <span> </span><span class="NLM_article-title">Baloxavir Marboxil: A Novel Cap-Dependent Endonuclease (CEN) Inhibitor for the Treatment of Acute Uncomplicated Influenza</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1358/dot.2019.55.6.2999889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdot.2019.55.6.2999889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3MzhvV2qtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=359-366&author=S.+C.+Lockeauthor=L.+M.+Splawnauthor=J.+C.+Cho&title=Baloxavir+Marboxil%3A+A+Novel+Cap-Dependent+Endonuclease+%28CEN%29+Inhibitor+for+the+Treatment+of+Acute+Uncomplicated+Influenza&doi=10.1358%2Fdot.2019.55.6.2999889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza</span></div><div class="casAuthors">Locke S C; Splawn L M; Cho J C</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">359-366</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Baloxavir marboxil is a newly approved antiviral agent with activity against influenza via a novel mechanism of action of inhibition of cap-dependent endonuclease (CEN).  The novel agent was approved in October of 2018 in the United States for the treatment of acute uncomplicated influenza A and B in patients aged 12 years or older.  Baloxavir is given as a single weight-based dose of 40 mg orally once for patients weighing less than 80 kg and 80 mg orally once for those weighing 80 kg or more within 48 hours of symptom onset.  In comparison with current therapy, baloxavir is as effective in decreasing time to symptom alleviation as the drug of choice, oseltamivir, and significantly reduces viral load 1 day after treatment compared with placebo and oseltamivir.  In safety analyses baloxavir was well tolerated with only mild adverse events reported (nausea, headache, diarrhea, bronchitis, nasopharyngitis), thus providing a safe and reliable alternative option to current therapy for acute uncomplicated influenza.  Further studies are being conducted to evaluate the use of baloxavir in additional patient populations including pediatric patients less than 12 years of age and patients who are at high risk of complications related to influenza.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmeHYKxCnC5NXdcedVHT5tfW6udTcc2ea6ChfGLzMf_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzhvV2qtg%253D%253D&md5=e823e95a1a78fc9077331887c193e39a</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1358%2Fdot.2019.55.6.2999889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2019.55.6.2999889%26sid%3Dliteratum%253Aachs%26aulast%3DLocke%26aufirst%3DS.%2BC.%26aulast%3DSplawn%26aufirst%3DL.%2BM.%26aulast%3DCho%26aufirst%3DJ.%2BC.%26atitle%3DBaloxavir%2520Marboxil%253A%2520A%2520Novel%2520Cap-Dependent%2520Endonuclease%2520%2528CEN%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Acute%2520Uncomplicated%2520Influenza%26jtitle%3DDrugs%2520Today%26date%3D2019%26volume%3D55%26spage%3D359%26epage%3D366%26doi%3D10.1358%2Fdot.2019.55.6.2999889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, M.</span>; <span class="NLM_string-name">Tomita, K.</span>; <span class="NLM_string-name">Akiyama, T.</span>; <span class="NLM_string-name">Okano, A.</span>; <span class="NLM_string-name">Miyagawa, M.</span></span> <span> </span><span class="NLM_article-title">Substituted Polycyclic Pyridone Derivative and Prodrug Thereof</span>. <span class="NLM_patent">WO2016175224A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Kawai&author=K.+Tomita&author=T.+Akiyama&author=A.+Okano&author=M.+Miyagawa&title=Substituted+Polycyclic+Pyridone+Derivative+and+Prodrug+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DM.%26atitle%3DSubstituted%2520Polycyclic%2520Pyridone%2520Derivative%2520and%2520Prodrug%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shibahara, S.</span>; <span class="NLM_string-name">Fukui, N.</span>; <span class="NLM_string-name">Maki, T.</span>; <span class="NLM_string-name">Anan, K.</span></span> <span> </span><span class="NLM_article-title">Method for Producing Substituted Polycyclic Pyridone Derivative and Crystal of Same</span>. <span class="NLM_patent">WO2017221869A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Shibahara&author=N.+Fukui&author=T.+Maki&author=K.+Anan&title=Method+for+Producing+Substituted+Polycyclic+Pyridone+Derivative+and+Crystal+of+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShibahara%26aufirst%3DS.%26atitle%3DMethod%2520for%2520Producing%2520Substituted%2520Polycyclic%2520Pyridone%2520Derivative%2520and%2520Crystal%2520of%2520Same%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shishido, T.</span>; <span class="NLM_string-name">Noshi, T.</span>; <span class="NLM_string-name">Yamamoto, A.</span>; <span class="NLM_string-name">Kitano, M.</span></span> <span> </span><span class="NLM_article-title">Medicine for Treating Influenza Characterized by Comprising Combination of Cap-Dependent Endonuclease Inhibitor with Anti-Influenza Drug</span>. <span class="NLM_patent">WO2017104691A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=T.+Shishido&author=T.+Noshi&author=A.+Yamamoto&author=M.+Kitano&title=Medicine+for+Treating+Influenza+Characterized+by+Comprising+Combination+of+Cap-Dependent+Endonuclease+Inhibitor+with+Anti-Influenza+Drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShishido%26aufirst%3DT.%26atitle%3DMedicine%2520for%2520Treating%2520Influenza%2520Characterized%2520by%2520Comprising%2520Combination%2520of%2520Cap-Dependent%2520Endonuclease%2520Inhibitor%2520with%2520Anti-Influenza%2520Drug%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, M.</span>; <span class="NLM_string-name">Tomita, K.</span>; <span class="NLM_string-name">Akiyama, T.</span>; <span class="NLM_string-name">Okano, A.</span>; <span class="NLM_string-name">Miyagawa, M.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Compositions Containing Substituted Polycyclic Pyridone Derivatives and Prodrug Thereof</span>. <span class="NLM_patent">US2019169206A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Kawai&author=K.+Tomita&author=T.+Akiyama&author=A.+Okano&author=M.+Miyagawa&title=Pharmaceutical+Compositions+Containing+Substituted+Polycyclic+Pyridone+Derivatives+and+Prodrug+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DM.%26atitle%3DPharmaceutical%2520Compositions%2520Containing%2520Substituted%2520Polycyclic%2520Pyridone%2520Derivatives%2520and%2520Prodrug%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bam, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niedziela-Majka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yant, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukolj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazerwith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span> <span> </span><span class="NLM_article-title">Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7086</span>– <span class="NLM_lpage">7097</span>, <span class="refDoi"> DOI: 10.1128/AAC.01474-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1128%2FAAC.01474-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27645238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlWjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=7086-7097&author=M.+Tsiangauthor=G.+S.+Jonesauthor=J.+Goldsmithauthor=A.+Mulatoauthor=D.+Hansenauthor=E.+Kanauthor=L.+Tsaiauthor=R.+A.+Bamauthor=G.+Stepanauthor=K.+M.+Strayauthor=A.+Niedziela-Majkaauthor=S.+R.+Yantauthor=H.+Yuauthor=G.+Kukoljauthor=T.+Cihlarauthor=S.+E.+Lazerwithauthor=K.+L.+Whiteauthor=H.+Jin&title=Antiviral+Activity+of+Bictegravir+%28GS-9883%29%2C+a+Novel+Potent+HIV-1+Integrase+Strand+Transfer+Inhibitor+with+an+Improved+Resistance+Profile&doi=10.1128%2FAAC.01474-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile</span></div><div class="casAuthors">Tsiang, Manuel; Jones, Gregg S.; Goldsmith, Joshua; Mulato, Andrew; Hansen, Derek; Kan, Elaine; Tsai, Luong; Bam, Rujuta A.; Stepan, George; Stray, Kirsten M.; Niedziela-Majka, Anita; Yant, Stephen R.; Yu, Helen; Kukolj, George; Cihlar, Tomas; Lazerwith, Scott E.; White, Kirsten L.; Jin, Haolun</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7086-7097</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concn. [IC50] of 7.5 ± 0.3 nM) and HIV-1 integration in cells.  BIC exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T lymphocytes, with 50% effective concns. ranging from 1.5 to 2.4 nM and selectivity indexes up to 8,700 relative to cytotoxicity.  BIC exhibits synergistic in vitro antiviral effects in pairwise combinations with tenofovir alafenamide, emtricitabine, or darunavir and maintains potent antiviral activity against HIV-1 variants resistant to other classes of antiretrovirals.  BIC displayed an in vitro resistance profile that was markedly improved compared to the integrase strand transfer inhibitors (INSTIs) raltegravir (RAL) and elvitegravir (EVG), and comparable to that of dolutegravir (DTG), against nine INSTI-resistant site-directed HIV-1 mutants.  BIC displayed statistically improved antiviral activity relative to EVG, RAL, and DTG against a panel of 47 patient-derived HIV-1 isolates with highlevel INSTI resistance; 13 of 47 tested isolates exhibited >2-fold lower resistance to BIC than DTG.  In dose-escalation expts. conducted in vitro, BIC and DTG exhibited higher barriers to resistance than EVG, selecting for HIV-1 variants with reduced phenotypic susceptibility at days 71, 87, and 20, resp.  A recombinant virus with the BIC-selected M50I/R263K dual mutations in IN exhibited only 2.8-fold reduced susceptibility to BIC compared to wild-type virus.  All BIC-selected variants exhibited low to intermediate levels of cross-resistance to RAL, DTG, and EVG (<8-fold) but remained susceptible to other classes of antiretrovirals.  A high barrier to in vitro resistance emergence for both BIC and DTG was also obsd. in viral breakthrough studies in the presence of const. clin. relevant drug concns.  The overall virol. profile of BIC supports its ongoing clin. investigation in combination with other antiretroviral agents for both treatment-naive and -experienced HIV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC24EKhD8sNbVg90H21EOLACvtfcHk0ljgd744T1nBjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlWjt78%253D&md5=87a180a313ffaa8b03201b06a8c875ff</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.01474-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01474-16%26sid%3Dliteratum%253Aachs%26aulast%3DTsiang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DG.%2BS.%26aulast%3DGoldsmith%26aufirst%3DJ.%26aulast%3DMulato%26aufirst%3DA.%26aulast%3DHansen%26aufirst%3DD.%26aulast%3DKan%26aufirst%3DE.%26aulast%3DTsai%26aufirst%3DL.%26aulast%3DBam%26aufirst%3DR.%2BA.%26aulast%3DStepan%26aufirst%3DG.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DNiedziela-Majka%26aufirst%3DA.%26aulast%3DYant%26aufirst%3DS.%2BR.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DLazerwith%26aufirst%3DS.%2BE.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DJin%26aufirst%3DH.%26atitle%3DAntiviral%2520Activity%2520of%2520Bictegravir%2520%2528GS-9883%2529%252C%2520a%2520Novel%2520Potent%2520HIV-1%2520Integrase%2520Strand%2520Transfer%2520Inhibitor%2520with%2520an%2520Improved%2520Resistance%2520Profile%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D7086%26epage%3D7097%26doi%3D10.1128%2FAAC.01474-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1817</span>– <span class="NLM_lpage">1828</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1010-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1010-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30460547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1GgtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1817-1828&author=E.+D.+Deeks&title=Bictegravir%2FEmtricitabine%2FTenofovir+Alafenamide%3A+A+Review+in+HIV-1+Infection&doi=10.1007%2Fs40265-018-1010-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1817-1828</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Bictegravir is a new integrase strand transfer inhibitor (INSTI) with a high genetic barrier to the development of HIV-1 resistance.  The drug is co-formulated with the nucleos(t)ide reverse transcriptase inhibitors emtricitabine and tenofovir alafenamide (AF) in a single-tablet regimen (STR) for the once-daily treatment of HIV-1 infection in adults (bictegravir/emtricitabine/tenofovir AF; Biktarvy).  In phase 3 trials, bictegravir/emtricitabine/tenofovir AF was noninferior to dolutegravir-based therapy (dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir AF) in establishing virol. suppression in treatment-naive adults through 96 wk' treatment and, similarly, was noninferior to ongoing dolutegravir/abacavir/lamivudine or boosted elvitegravir- or protease inhibitor (PI)-based therapy in preventing virol. rebound over 48 wk in treatment-experienced patients.  No resistance emerged to any of the antiretrovirals in the STR.  Bictegravir/emtricitabine/tenofovir AF is generally well tolerated, requires no prior HLA-B*5701 testing (making it more suitable for 'rapid start' treatment), fulfils the antiretroviral regimen requirement for patients with hepatitis B virus (HBV) co-infection (i.e. contains tenofovir AF and emtricitabine, both of which are active against HBV) and can be used in renally impaired patients with creatinine clearance (CRCL) ≥ 30 mL/min.  Thus, although cost-effectiveness analyses would be beneficial, current data indicate that bictegravir/emtricitabine/tenofovir AF is a convenient initial and subsequent treatment option for adults with HIV-1 infection, including those co-infected with HBV, and provides the first non-pharmacol. boosted, INSTI-based, triple-combination STR suitable for patients with CRCL 30-50 mL/min.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9o4JdLQm3XLVg90H21EOLACvtfcHk0ljgd744T1nBjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1GgtbbK&md5=ffec7739b3a4dda20f945a8dd3539422</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1010-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1010-7%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DBictegravir%252FEmtricitabine%252FTenofovir%2520Alafenamide%253A%2520A%2520Review%2520in%2520HIV-1%2520Infection%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1817%26epage%3D1828%26doi%3D10.1007%2Fs40265-018-1010-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biemmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisicaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogolino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sechi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotriffer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">From Ligand to Complexes. Part 2. Remarks on Human Immunodeficiency Virus Type 1 Integrase Inhibition by Beta-Diketo Acid Metal Complexes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7253</span>– <span class="NLM_lpage">7264</span>, <span class="refDoi"> DOI: 10.1021/jm800893q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800893q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlejtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7253-7264&author=A.+Bacchiauthor=M.+Biemmiauthor=M.+Carcelliauthor=F.+Cartaauthor=C.+Compariauthor=E.+Fisicaroauthor=D.+Rogolinoauthor=M.+Sechiauthor=M.+Sippelauthor=C.+A.+Sotrifferauthor=T.+W.+Sanchezauthor=N.+Neamati&title=From+Ligand+to+Complexes.+Part+2.+Remarks+on+Human+Immunodeficiency+Virus+Type+1+Integrase+Inhibition+by+Beta-Diketo+Acid+Metal+Complexes&doi=10.1021%2Fjm800893q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">From Ligand to Complexes. Part 2. Remarks on Human Immunodeficiency Virus type 1 Integrase Inhibition by β-Diketo Acid Metal Complexes</span></div><div class="casAuthors">Bacchi, Alessia; Biemmi, Mariano; Carcelli, Mauro; Carta, Fabrizio; Compari, Carlotta; Fisicaro, Emilia; Rogolino, Dominga; Sechi, Mario; Sippel, Martin; Sotriffer, Christoph A.; Sanchez, Tino W.; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7253-7264</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previously, the authors synthesized a series of β-diketo acid metal complexes as novel HIV-1 integrase (IN) inhibitors (J. Med. Chem.2006, 46, 4248-4260).  Herein, a further extension of this study is reported.  First, detailed docking studies were performed to investigate the mode of binding in the active site of the free ligands and of their metal complexes.  Second, a series of potentiometric measurements were conducted for two diketo acids chosen as model ligands, with Mn2+ and Ca2+, to outline a speciation model.  Third, the authors designed and synthesized a new set of complexes with different stoichiometries and tested them in an in vitro assay specific for IN.  Finally, the authors obtained the first x-ray structure of a metal complex with HIV-1 IN inhibition activity.  Anal. of these results supports the hypothesis that the diketo acids could act as complexes and form complexes with the metal ions on the active site of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb91JhwTAFFrVg90H21EOLACvtfcHk0ljgd744T1nBjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlejtLvN&md5=db34155d02519041581c6021948172b8</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1021%2Fjm800893q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800893q%26sid%3Dliteratum%253Aachs%26aulast%3DBacchi%26aufirst%3DA.%26aulast%3DBiemmi%26aufirst%3DM.%26aulast%3DCarcelli%26aufirst%3DM.%26aulast%3DCarta%26aufirst%3DF.%26aulast%3DCompari%26aufirst%3DC.%26aulast%3DFisicaro%26aufirst%3DE.%26aulast%3DRogolino%26aufirst%3DD.%26aulast%3DSechi%26aufirst%3DM.%26aulast%3DSippel%26aufirst%3DM.%26aulast%3DSotriffer%26aufirst%3DC.%2BA.%26aulast%3DSanchez%26aufirst%3DT.%2BW.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DFrom%2520Ligand%2520to%2520Complexes.%2520Part%25202.%2520Remarks%2520on%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Integrase%2520Inhibition%2520by%2520Beta-Diketo%2520Acid%2520Metal%2520Complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7253%26epage%3D7264%26doi%3D10.1021%2Fjm800893q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sechi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisicaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogolino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gates, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derudas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mawsawi, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">From Ligand to Complexes: Inhibition of Human Immunodeficiency Virus Type 1 Integrase by Beta-Diketo Acid Metal Complexes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4248</span>– <span class="NLM_lpage">4260</span>, <span class="refDoi"> DOI: 10.1021/jm060193m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060193m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4248-4260&author=M.+Sechiauthor=A.+Bacchiauthor=M.+Carcelliauthor=C.+Compariauthor=E.+Duceauthor=E.+Fisicaroauthor=D.+Rogolinoauthor=P.+Gatesauthor=M.+Derudasauthor=L.+Q.+Al-Mawsawiauthor=N.+Neamati&title=From+Ligand+to+Complexes%3A+Inhibition+of+Human+Immunodeficiency+Virus+Type+1+Integrase+by+Beta-Diketo+Acid+Metal+Complexes&doi=10.1021%2Fjm060193m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">From Ligand to Complexes: Inhibition of Human Immunodeficiency Virus Type 1 Integrase by β-Diketo Acid Metal Complexes</span></div><div class="casAuthors">Sechi, Mario; Bacchi, Alessia; Carcelli, Mauro; Compari, Carlotta; Duce, Elenia; Fisicaro, Emilia; Rogolino, Dominga; Gates, Paul; Derudas, Marco; Al-Mawsawi, Laith Q.; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4248-4260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">β-Diketo acid-contg. compds. are a promising class of human immunodeficiency virus type 1 (HIV-1) integrase (IN) inhibitors.  Starting from the hypothesis that these inhibitors are able to coordinate ions in soln. before interacting on the active site, a series of potentiometric measurements have been performed to understand the coordination ability of the diketo acid pharmacophore toward the biol. relevant Mg2+.  Moreover, by using β-diketo acid/ester as model ligands with a set of divalent metal ions (Mg, Mn, Ni, Co, Cu, and Zn), the authors obtained a series of complexes and tested them for anti-HIV-1 IN activity.  Results demonstrate that the diketo acid functionality chelates divalent metal ions in soln., and complexes with metals in different stoichiometric ratios are isolated.  The authors postulate that the diketo acids act as complexes in their active form.  In particular, they predominantly form species such as Mg2L2+ and Mg2L2 (derived from diketo acids, H2L), and MgL+ and MgL2 (derived from diketo esters, HL) at physiol. pH.  Furthermore, the synthesized mono- and dimetallic complexes inhibited IN at a high nanomolar to low micromolar range, with metal dependency in the Ph diketo acid series.  Retrospective anal. suggests that the electronic properties of the arom. framework influence the metal-chelating ability of the diketo acid system.  Therefore, the difference in activities is related to the complexes they preferentially form in soln., and these findings are important for the design of a new generation of IN inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZMdzwfy_4y7Vg90H21EOLACvtfcHk0lijbZE4mrYnQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVSitrk%253D&md5=048fd84cfb2ec7652ed4dcdd9e160bb8</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1021%2Fjm060193m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060193m%26sid%3Dliteratum%253Aachs%26aulast%3DSechi%26aufirst%3DM.%26aulast%3DBacchi%26aufirst%3DA.%26aulast%3DCarcelli%26aufirst%3DM.%26aulast%3DCompari%26aufirst%3DC.%26aulast%3DDuce%26aufirst%3DE.%26aulast%3DFisicaro%26aufirst%3DE.%26aulast%3DRogolino%26aufirst%3DD.%26aulast%3DGates%26aufirst%3DP.%26aulast%3DDerudas%26aufirst%3DM.%26aulast%3DAl-Mawsawi%26aufirst%3DL.%2BQ.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DFrom%2520Ligand%2520to%2520Complexes%253A%2520Inhibition%2520of%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Integrase%2520by%2520Beta-Diketo%2520Acid%2520Metal%2520Complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4248%26epage%3D4260%26doi%3D10.1021%2Fjm060193m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, A.</span>; <span class="NLM_string-name">Enquist, J.</span>; <span class="NLM_string-name">Griggs, N.</span>; <span class="NLM_string-name">Hale, C.</span>; <span class="NLM_string-name">Ikemoto, N.</span>; <span class="NLM_string-name">Keaton, K. A.</span>; <span class="NLM_string-name">Kraft, M.</span>; <span class="NLM_string-name">Lazerwith, S. E.</span>; <span class="NLM_string-name">Leeman, M.</span>; <span class="NLM_string-name">Peng, Z.</span>; <span class="NLM_string-name">Schrier, K.</span>; <span class="NLM_string-name">Trinidad, J.</span>; <span class="NLM_string-name">van Herpt, J.</span>; <span class="NLM_string-name">Waltman, A. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Polycyclic-Carbamoylpyridone Compounds</span>. <span class="NLM_patent">US20150368264A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+Chiu&author=J.+Enquist&author=N.+Griggs&author=C.+Hale&author=N.+Ikemoto&author=K.+A.+Keaton&author=M.+Kraft&author=S.+E.+Lazerwith&author=M.+Leeman&author=Z.+Peng&author=K.+Schrier&author=J.+Trinidad&author=J.+van+Herpt&author=A.+W.+Waltman&title=Synthesis+of+Polycyclic-Carbamoylpyridone+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChiu%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520Polycyclic-Carbamoylpyridone%2520Compounds%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Review of Synthetic Routes and Final Forms of Integrase Inhibitors Dolutegravir, Cabotegravir, and Bictegravir</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVSmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=716-729&author=D.+L.+Hughes&title=Review+of+Synthetic+Routes+and+Final+Forms+of+Integrase+Inhibitors+Dolutegravir%2C+Cabotegravir%2C+and+Bictegravir&doi=10.1021%2Facs.oprd.9b00031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Review of Synthetic Routes and Final Forms of Integrase Inhibitors Dolutegravir, Cabotegravir, and Bictegravir</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">716-729</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Bictegravir and dolutegravir are two recently approved integrase inhibitors for the treatment of HIV.  A third inhibitor, cabotegravir, is in Phase 3 development.  As a continuation of a series of articles on synthetic routes to newly approved drugs, the current article reviews the patent and journal literature regarding synthetic routes and final forms of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR2U-hP-ajqLVg90H21EOLACvtfcHk0lijbZE4mrYnQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVSmt74%253D&md5=06d1a446aa8ebd38a086a4c94434c953</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00031%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DReview%2520of%2520Synthetic%2520Routes%2520and%2520Final%2520Forms%2520of%2520Integrase%2520Inhibitors%2520Dolutegravir%252C%2520Cabotegravir%252C%2520and%2520Bictegravir%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26spage%3D716%26epage%3D729%26doi%3D10.1021%2Facs.oprd.9b00031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span>; <span class="NLM_string-name">Zeng, Q.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing (1r,3s)-3-Aminocyclopentanol Hydrochloride</span>. <span class="NLM_patent">CN108774145A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=F.+Ye&author=Q.+Zeng&title=Method+for+Preparing+%281r%2C3s%29-3-Aminocyclopentanol+Hydrochloride"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DF.%26atitle%3DMethod%2520for%2520Preparing%2520%25281r%252C3s%2529-3-Aminocyclopentanol%2520Hydrochloride%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michelin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgarbossa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strukul, G.</span></span> <span> </span><span class="NLM_article-title">The Baeyer-Villiger Oxidation of Ketones: A Paradigm for the Role of Soft Lewis Acidity in Homogeneous Catalysis</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.ccr.2009.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SlsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2010&pages=646-660&author=R.+A.+Michelinauthor=P.+Sgarbossaauthor=A.+Scarsoauthor=G.+Strukul&title=The+Baeyer-Villiger+Oxidation+of+Ketones%3A+A+Paradigm+for+the+Role+of+Soft+Lewis+Acidity+in+Homogeneous+Catalysis&doi=10.1016%2Fj.ccr.2009.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The Baeyer-Villiger oxidation of ketones: A paradigm for the role of soft Lewis acidity in homogeneous catalysis</span></div><div class="casAuthors">Michelin, Rino A.; Sgarbossa, Paolo; Scarso, Alessandro; Strukul, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">646-660</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The Baeyer-Villiger oxidn. of ketones to the corresponding esters or lactones is a valuable transformation that has been upgraded several times over the last century, from the original use of monopersulfuric acid as oxidant to more atom efficient and environmentally friendly oxidants such as hydrogen peroxide.  This review has concd. mainly on Pt complexes as catalysts for the Baeyer-Villiger oxidn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqglAAQ68pLXLVg90H21EOLACvtfcHk0lijbZE4mrYnQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SlsLnN&md5=d5301a283029f3b4028239edb92353be</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DMichelin%26aufirst%3DR.%2BA.%26aulast%3DSgarbossa%26aufirst%3DP.%26aulast%3DScarso%26aufirst%3DA.%26aulast%3DStrukul%26aufirst%3DG.%26atitle%3DThe%2520Baeyer-Villiger%2520Oxidation%2520of%2520Ketones%253A%2520A%2520Paradigm%2520for%2520the%2520Role%2520of%2520Soft%2520Lewis%2520Acidity%2520in%2520Homogeneous%2520Catalysis%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2010%26volume%3D254%26spage%3D646%26epage%3D660%26doi%3D10.1016%2Fj.ccr.2009.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Danoprevir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1271</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0960-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0960-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30117020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFehsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1271-1276&author=A.+Markhamauthor=S.+J.+Keam&title=Danoprevir%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0960-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Danoprevir: First Global Approval</span></div><div class="casAuthors">Markham, Anthony; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1271-1276</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ascletis has developed danoprevir (Ganovo), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C.  Based on pos. results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently approved for marketing in China for the treatment of treatment-naive patients with non-cirrhotic genotype 1b chronic hepatitis C.  This article summarizes the milestones in the development of danoprevir leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfhWb3iJxXTLVg90H21EOLACvtfcHk0liR7dYwWedZoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFehsrnE&md5=df4922b885606bbf29853228c0822908</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0960-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0960-0%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DDanoprevir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1271%26epage%3D1276%26doi%3D10.1007%2Fs40265-018-0960-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gower, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razavi-Shearer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razavi, H.</span></span> <span> </span><span class="NLM_article-title">Global Epidemiology and Genotype Distribution of the Hepatitis C Virus Infection</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">S45</span>– <span class="NLM_lpage">S57</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2014.07.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.jhep.2014.07.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=25086286" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=S45-S57&author=E.+Gowerauthor=C.+Estesauthor=S.+Blachauthor=K.+Razavi-Shearerauthor=H.+Razavi&title=Global+Epidemiology+and+Genotype+Distribution+of+the+Hepatitis+C+Virus+Infection&doi=10.1016%2Fj.jhep.2014.07.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.07.027%26sid%3Dliteratum%253Aachs%26aulast%3DGower%26aufirst%3DE.%26aulast%3DEstes%26aufirst%3DC.%26aulast%3DBlach%26aufirst%3DS.%26aulast%3DRazavi-Shearer%26aufirst%3DK.%26aulast%3DRazavi%26aufirst%3DH.%26atitle%3DGlobal%2520Epidemiology%2520and%2520Genotype%2520Distribution%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520Infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D61%26spage%3DS45%26epage%3DS57%26doi%3D10.1016%2Fj.jhep.2014.07.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misialek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myszka, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiwert, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossen, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2559</span>– <span class="NLM_lpage">2568</span>, <span class="refDoi"> DOI: 10.1021/bi900038p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi900038p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFems7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=2559-2568&author=R.+Rajagopalanauthor=S.+Misialekauthor=S.+K.+Stevensauthor=D.+G.+Myszkaauthor=B.+J.+Brandhuberauthor=J.+A.+Ballardauthor=S.+W.+Andrewsauthor=S.+D.+Seiwertauthor=K.+Kossen&title=Inhibition+and+Binding+Kinetics+of+the+Hepatitis+C+Virus+NS3+Protease+Inhibitor+ITMN-191+Reveals+Tight+Binding+and+Slow+Dissociative+Behavior&doi=10.1021%2Fbi900038p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior</span></div><div class="casAuthors">Rajagopalan, Ravi; Misialek, Shawn; Stevens, Sarah K.; Myszka, David G.; Brandhuber, Barbara J.; Ballard, Joshua A.; Andrews, Steven W.; Seiwert, Scott D.; Kossen, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2559-2568</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The protease activity of hepatitis C virus nonstructural protein 3 (NS3) is essential for viral replication.  ITMN-191, a macrocyclic inhibitor of the NS3 protease active site, promotes rapid, multilog viral load redns. in chronic HCV patients.  Here, ITMN-191 is shown to be a potent inhibitor of NS3 with a two-step binding mechanism.  Progress curves are consistent with the formation of an initial collision complex (EI) that isomerizes to a highly stable complex (EI*) from which ITMN-191 dissocs. very slowly.  Ki, the dissocn. const. of EI, is 100 nM, and the rate const. for conversion of EI to EI* is 6.2 × 10-2 s-1.  Binding expts. using protein fluorescence confirm this isomerization rate.  From progress curve anal., the rate const. for dissocn. of ITMN-191 from the EI* complex is 3.8 × 10-5 s-1 with a calcd. complex half-life of ∼5 h and a true biochem. potency (Ki*) of ∼62 pM.  Surface plasmon resonance studies and assessment of enzyme reactivation following diln. of the EI* complex confirm slow dissocn. and suggest that the half-life may be considerably longer.  Abrogation of the tight binding and slow dissociative properties of ITMN-191 is obsd. with proteases that carry the R155K or D168A substitution, each of which is likely in drug resistant mutants.  Slow dissocn. is not obsd. with closely related macrocyclic inhibitors of NS3, suggesting that members of this class may display distinct binding kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOY26vXOrtJrVg90H21EOLACvtfcHk0liR7dYwWedZoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFems7k%253D&md5=5e985737f2627bd314b517f93b938336</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fbi900038p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900038p%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopalan%26aufirst%3DR.%26aulast%3DMisialek%26aufirst%3DS.%26aulast%3DStevens%26aufirst%3DS.%2BK.%26aulast%3DMyszka%26aufirst%3DD.%2BG.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DBallard%26aufirst%3DJ.%2BA.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DSeiwert%26aufirst%3DS.%2BD.%26aulast%3DKossen%26aufirst%3DK.%26atitle%3DInhibition%2520and%2520Binding%2520Kinetics%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520NS3%2520Protease%2520Inhibitor%2520ITMN-191%2520Reveals%2520Tight%2520Binding%2520and%2520Slow%2520Dissociative%2520Behavior%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D2559%26epage%3D2568%26doi%3D10.1021%2Fbi900038p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span>; <span class="NLM_string-name">Andrews, S. W.</span>; <span class="NLM_string-name">Condroski, K. R.</span>; <span class="NLM_string-name">Doherty, G. A.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Josey, J. A.</span>; <span class="NLM_string-name">Kennedy, A. L.</span>; <span class="NLM_string-name">Madduru, M. R.</span>; <span class="NLM_string-name">Stengel, P. J.</span>; <span class="NLM_string-name">Wenglowsky, S. M.</span>; <span class="NLM_string-name">Woodard, B. T.</span>; <span class="NLM_string-name">Woodard, L.</span></span> <span> </span><span class="NLM_article-title">Preparation of Macrocyclic Carboxylic Acid Derivatives as Inhibitors of HCV Replication</span>. <span class="NLM_patent">US20050267018A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=L.+M.+Blatt&author=S.+W.+Andrews&author=K.+R.+Condroski&author=G.+A.+Doherty&author=Y.+Jiang&author=J.+A.+Josey&author=A.+L.+Kennedy&author=M.+R.+Madduru&author=P.+J.+Stengel&author=S.+M.+Wenglowsky&author=B.+T.+Woodard&author=L.+Woodard&title=Preparation+of+Macrocyclic+Carboxylic+Acid+Derivatives+as+Inhibitors+of+HCV+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26atitle%3DPreparation%2520of%2520Macrocyclic%2520Carboxylic%2520Acid%2520Derivatives%2520as%2520Inhibitors%2520of%2520HCV%2520Replication%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span>; <span class="NLM_string-name">Wenglowsky, S. M.</span>; <span class="NLM_string-name">Andrews, S. W.</span>; <span class="NLM_string-name">Condroski, K. R.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Kennedy, A. L.</span>; <span class="NLM_string-name">Doherty, G. A.</span>; <span class="NLM_string-name">Josey, J. A.</span>; <span class="NLM_string-name">Stengel, P. J.</span>; <span class="NLM_string-name">Woodard, B. T.</span>; <span class="NLM_string-name">Madduru, M. R.</span></span> <span> </span><span class="NLM_article-title">Preparation of Macrocyclic Carboxylic Acids or Sulfonamides as Inhibitors of HCV Replication</span>. <span class="NLM_patent">WO2005095403A2</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=L.+M.+Blatt&author=S.+M.+Wenglowsky&author=S.+W.+Andrews&author=K.+R.+Condroski&author=Y.+Jiang&author=A.+L.+Kennedy&author=G.+A.+Doherty&author=J.+A.+Josey&author=P.+J.+Stengel&author=B.+T.+Woodard&author=M.+R.+Madduru&title=Preparation+of+Macrocyclic+Carboxylic+Acids+or+Sulfonamides+as+Inhibitors+of+HCV+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26atitle%3DPreparation%2520of%2520Macrocyclic%2520Carboxylic%2520Acids%2520or%2520Sulfonamides%2520as%2520Inhibitors%2520of%2520HCV%2520Replication%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit38c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span>; <span class="NLM_string-name">Wenglowsky, S. M.</span>; <span class="NLM_string-name">Andrews, S. W.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Kennedy, A. L.</span>; <span class="NLM_string-name">Condroski, K. R.</span>; <span class="NLM_string-name">Josey, J. A.</span>; <span class="NLM_string-name">Stengel, P. J.</span>; <span class="NLM_string-name">Madduru, M. R.</span>; <span class="NLM_string-name">Doherty, G. A.</span>; <span class="NLM_string-name">Woodard, B. T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Macrocyclic Carboxylic Acids and Acylsulfonamides as Inhibitors of HCV Replication</span>. <span class="NLM_patent">WO2005037214A2</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=L.+M.+Blatt&author=S.+M.+Wenglowsky&author=S.+W.+Andrews&author=Y.+Jiang&author=A.+L.+Kennedy&author=K.+R.+Condroski&author=J.+A.+Josey&author=P.+J.+Stengel&author=M.+R.+Madduru&author=G.+A.+Doherty&author=B.+T.+Woodard&title=Preparation+of+Macrocyclic+Carboxylic+Acids+and+Acylsulfonamides+as+Inhibitors+of+HCV+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26atitle%3DPreparation%2520of%2520Macrocyclic%2520Carboxylic%2520Acids%2520and%2520Acylsulfonamides%2520as%2520Inhibitors%2520of%2520HCV%2520Replication%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condroski, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serebryany, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenglowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madduru, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodard, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stengel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiwert, S. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4a Protease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1753</span>– <span class="NLM_lpage">1769</span>, <span class="refDoi"> DOI: 10.1021/jm400164c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400164c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFaku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1753-1769&author=Y.+Jiangauthor=S.+W.+Andrewsauthor=K.+R.+Condroskiauthor=B.+Buckmanauthor=V.+Serebryanyauthor=S.+Wenglowskyauthor=A.+L.+Kennedyauthor=M.+R.+Madduruauthor=B.+Wangauthor=M.+Lyonauthor=G.+A.+Dohertyauthor=B.+T.+Woodardauthor=C.+Lemieuxauthor=M.+G.+Doauthor=H.+Zhangauthor=J.+Ballardauthor=G.+Vigersauthor=B.+J.+Brandhuberauthor=P.+Stengelauthor=J.+A.+Joseyauthor=L.+Beigelmanauthor=L.+Blattauthor=S.+D.+Seiwert&title=Discovery+of+Danoprevir+%28ITMN-191%2FR7227%29%2C+a+Highly+Selective+and+Potent+Inhibitor+of+Hepatitis+C+Virus+%28HCV%29+NS3%2F4a+Protease&doi=10.1021%2Fjm400164c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease</span></div><div class="casAuthors">Jiang, Yutong; Andrews, Steven W.; Condroski, Kevin R.; Buckman, Brad; Serebryany, Vlad; Wenglowsky, Steve; Kennedy, April L.; Madduru, Machender R.; Wang, Bin; Lyon, Michael; Doherty, George A.; Woodard, Benjamin T.; Lemieux, Christine; Do, Mary Geck; Zhang, Hailong; Ballard, Joshua; Vigers, Guy; Brandhuber, Barbra J.; Stengel, Peter; Josey, John A.; Beigelman, Leonid; Blatt, Lawrence; Seiwert, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1753-1769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system.  Through structure-based drug design and optimization, macrocyclic peptidomimetic mols. bearing both a lipophilic P2 isoindoline carbamate and a P1/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepd. that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7).  Danoprevir (compd. 49) was selected as the clin. development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species.  X-ray crystallog. studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to the iterative structure-based design strategy of the authors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplS3sgoIBu_7Vg90H21EOLACvtfcHk0liwwabRW9-osg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFaku7w%253D&md5=2a979cd1202b9360bcef316dddd8382f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm400164c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400164c%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DCondroski%26aufirst%3DK.%2BR.%26aulast%3DBuckman%26aufirst%3DB.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DKennedy%26aufirst%3DA.%2BL.%26aulast%3DMadduru%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLyon%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DG.%2BA.%26aulast%3DWoodard%26aufirst%3DB.%2BT.%26aulast%3DLemieux%26aufirst%3DC.%26aulast%3DDo%26aufirst%3DM.%2BG.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DStengel%26aufirst%3DP.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DBlatt%26aufirst%3DL.%26aulast%3DSeiwert%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520of%2520Danoprevir%2520%2528ITMN-191%252FR7227%2529%252C%2520a%2520Highly%2520Selective%2520and%2520Potent%2520Inhibitor%2520of%2520Hepatitis%2520C%2520Virus%2520%2528HCV%2529%2520NS3%252F4a%2520Protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1753%26epage%3D1769%26doi%3D10.1021%2Fjm400164c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duceppe, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoneau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houpis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimroth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnaubelt, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (1r,2s)-1-Amino-2-Vinylcyclopropanecarboxylic Acid Vinyl-ACCA) Derivatives: Key Intermediates for the Preparation of Inhibitors of the Hepatitis C Virus NS3 Protease</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">5869</span>– <span class="NLM_lpage">5879</span>, <span class="refDoi"> DOI: 10.1021/jo050468q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo050468q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt12nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=5869-5879&author=P.+L.+Beaulieuauthor=J.+Gillardauthor=M.+D.+Baileyauthor=C.+Boucherauthor=J.-S.+Duceppeauthor=B.+Simoneauauthor=X.-J.+Wangauthor=L.+Zhangauthor=K.+Grozingerauthor=I.+Houpisauthor=V.+Farinaauthor=H.+Heimrothauthor=T.+Kruegerauthor=J.+Schnaubelt&title=Synthesis+of+%281r%2C2s%29-1-Amino-2-Vinylcyclopropanecarboxylic+Acid+Vinyl-ACCA%29+Derivatives%3A+Key+Intermediates+for+the+Preparation+of+Inhibitors+of+the+Hepatitis+C+Virus+NS3+Protease&doi=10.1021%2Fjo050468q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (1R,2S)-1-Amino-2-vinylcyclopropanecarboxylic Acid Vinyl-ACCA) Derivatives: Key Intermediates for the Preparation of Inhibitors of the Hepatitis C Virus NS3 Protease</span></div><div class="casAuthors">Beaulieu, Pierre L.; Gillard, James; Bailey, Murray D.; Boucher, Colette; Duceppe, Jean-Simon; Simoneau, Bruno; Wang, Xiao-Jun; Zhang, Li; Grozinger, Karl; Houpis, Ioannis; Farina, Vittorio; Heimroth, Heidi; Krueger, Thomas; Schnaubelt, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5869-5879</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(1R,2S)-1-Amino-2-vinylcyclopropanecarboxylic acid (vinyl-ACCA) is a key building block in the synthesis of BILN 2061, a potent inhibitor of hepatitis C virus NS3 and was recently shown to dramatically reduce viral load after administration to patients infected with HCV genotype 1.  The authors developed a scalable process that delivered derivs. of (1R,2S)-vinyl-ACCA in >99% enantiomeric excess.  The strategy included dialkylation of a glycine Schiff base using (E)-1,4-dibromo-2-butene as an electrophile to produce racemic vinyl-ACCA, which was subsequently resolved using a readily available, inexpensive esterase enzyme (Alcalase 2.4L).  Factors that affect diastereoselection in the initial dialkylation steps were examd. and the conditions were optimized to deliver the desired diastereomer selectively.  Product inhibition, which was encountered during the enzymic resoln. step, initially resulted in prolonged cycle times.  Enrichment of racemic vinyl-ACCA through a chem. resoln. via diastereomeric salt formation or the use of forcing conditions in the enzymic reaction both led to improvements in throughput and the development of a viable process.  Thus, multi-kilogram quantities of (1R,2S)-vinyl-ACCA were produced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMTSBIrZEPk7Vg90H21EOLACvtfcHk0liwwabRW9-osg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt12nur4%253D&md5=2165443a83201467dc3f8404758425cf</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjo050468q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo050468q%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DM.%2BD.%26aulast%3DBoucher%26aufirst%3DC.%26aulast%3DDuceppe%26aufirst%3DJ.-S.%26aulast%3DSimoneau%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DX.-J.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGrozinger%26aufirst%3DK.%26aulast%3DHoupis%26aufirst%3DI.%26aulast%3DFarina%26aufirst%3DV.%26aulast%3DHeimroth%26aufirst%3DH.%26aulast%3DKrueger%26aufirst%3DT.%26aulast%3DSchnaubelt%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%2520%25281r%252C2s%2529-1-Amino-2-Vinylcyclopropanecarboxylic%2520Acid%2520Vinyl-ACCA%2529%2520Derivatives%253A%2520Key%2520Intermediates%2520for%2520the%2520Preparation%2520of%2520Inhibitors%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520NS3%2520Protease%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D5869%26epage%3D5879%26doi%3D10.1021%2Fjo050468q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span>; <span class="NLM_string-name">Sherry, B. D.</span>; <span class="NLM_string-name">Gauthier, D. R.</span>; <span class="NLM_string-name">Campeau, L.-C.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Doravirine: An Investigational Next Generation Non-Nucleside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV</span>. In  <i>Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Magid, A. F.</span>; <span class="NLM_string-name">Pesti, J.</span>; <span class="NLM_string-name">Vaidyanathan, R.</span></span>, Eds.; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2016</span>; Vol.  <span class="NLM_volume">1239</span>, pp  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">205</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1239.ch007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=175-205&author=J.+D.+Burch&author=B.+D.+Sherry&author=D.+R.+Gauthier&author=L.-C.+Campeauauthor=A.+F.+Abdel-Magid&author=J.+Pesti&author=R.+Vaidyanathan&title=Comprehensive+Accounts+of+Pharmaceutical+Research+and+Development%3A+From+Discovery+to+Late-Stage+Process+Development+Volume+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1239.ch007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Fbk-2016-1239.ch007%26sid%3Dliteratum%253Aachs%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Doravirine%253A%2520An%2520Investigational%2520Next%2520Generation%2520Non-Nucleside%2520Reverse%2520Transcriptase%2520Inhibitor%2520%2528NNRTI%2529%2520for%2520the%2520Treatment%2520of%2520HIV%26btitle%3DComprehensive%2520Accounts%2520of%2520Pharmaceutical%2520Research%2520and%2520Development%253A%2520From%2520Discovery%2520to%2520Late-Stage%2520Process%2520Development%2520Volume%25201%26aulast%3DAbdel-Magid%26aufirst%3DA.%2BF.%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2016%26volume%3D1239%26spage%3D175%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colombier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. M.</span></span> <span> </span><span class="NLM_article-title">Doravirine: A Review</span>. <i>Curr. Opin. HIV AIDS</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1097/COH.0000000000000471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1097%2FCOH.0000000000000471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29794817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVemtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=308-314&author=M.+A.+Colombierauthor=J.+M.+Molina&title=Doravirine%3A+A+Review&doi=10.1097%2FCOH.0000000000000471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Doravirine: a review</span></div><div class="casAuthors">Colombier, Marie-Alice; Molina, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in HIV & AIDS</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">308-314</span>CODEN:
                <span class="NLM_cas:coden">COHABM</span>;
        ISSN:<span class="NLM_cas:issn">1746-630X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The current review addresses the role of doravirine (DOR), a novel once-daily nonnucleoside reverse transcriptase inhibitor (NNRTI) in first-line therapy at a time in which multiple options are available, and issues of antiviral efficacy, safety, simplicity and cost are crit. to make informed decisions.  DOR combination regimens have been tested in two large randomized double-blinded clin. trials in treatment-naive patients, showing noninferiority to ritonavir-boosted darunavir-based and efavirenz (EFV)-based regimens.  The main features of DOR are reviewed in this report including its antiviral activity, genetic barrier to resistance, safety, once-daily dosing and coformulation in a single tablet with tenofovir disoproxil fumarate and lamivudine.  DOR pharmacokinetics and drug-drug interactions are also reviewed as DOR can be given without food restriction and has no interaction with proton pump inhibitors.  DOR has shown a superior safety profile than EFV regarding neuropsychiatric and cutaneous adverse events.  DOR is currently being investigated in treatment-experienced patients and in those with transmitted NNRTI drug resistance.  DOR is a promising new NNRTI that could become the preferred drug in its class for treatment initiation.  DOR has shown excellent antiviral activity in treatment-naive patients, a better safety profile than EFV and a low potential for drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYEMuUgnObvbVg90H21EOLACvtfcHk0li91m2I9toorA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVemtrnF&md5=a3be79ea93dd338aaeadad905537df84</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1097%2FCOH.0000000000000471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOH.0000000000000471%26sid%3Dliteratum%253Aachs%26aulast%3DColombier%26aufirst%3DM.%2BA.%26aulast%3DMolina%26aufirst%3DJ.%2BM.%26atitle%3DDoravirine%253A%2520A%2520Review%26jtitle%3DCurr.%2520Opin.%2520HIV%2520AIDS%26date%3D2018%26volume%3D13%26spage%3D308%26epage%3D314%26doi%3D10.1097%2FCOH.0000000000000471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, D. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Characterization of Impurities of HIV NNRTI Doravirine by UHPLC-High Resolution Ms and Tandem Ms Analysis</span>. <i>J. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">968</span>, <span class="refDoi"> DOI: 10.1002/jms.3807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fjms.3807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27383410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs12gurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=959-968&author=L.+K.+Zhangauthor=R.+Yangauthor=H.+Shengauthor=R.+Helmyauthor=J.+Zhengauthor=Y.+Caoauthor=D.+R.+Gauthier&title=Characterization+of+Impurities+of+HIV+NNRTI+Doravirine+by+UHPLC-High+Resolution+Ms+and+Tandem+Ms+Analysis&doi=10.1002%2Fjms.3807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of impurities of HIV NNRTI Doravirine by UHPLC-high resolution MS and tandem MS analysis</span></div><div class="casAuthors">Zhang, Li-Kang; Yang, Ross; Sheng, Huaming; Helmy, Roy; Zheng, Jinjian; Cao, Yang; Gauthier, Donald R. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Mass Spectrometry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">959-968</span>CODEN:
                <span class="NLM_cas:coden">JMSPFJ</span>;
        ISSN:<span class="NLM_cas:issn">1076-5174</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">World Health Organization ests. that 34 million individuals globally are living with Human Immunodeficiency Virus (HIV).  Doravirine is a non-nucleoside reverse transcriptase inhibitors (NNRTI) being evaluated by Merck for the treatment of HIV-1 infection.  Drug regulation authorities require the purity of a pharmaceutical to be fully defined.  This is important to ensure that the pharmacol. and toxicol. effects are truly those of the drug substances and not because of the impurities.  Thus, understanding the drug impurity profiles is crit. to the safety and potency assessment of the drug candidate for clin. trials.  The impurity characterization can also provide useful information for crit. assessment of pharmaceutical processes.  Advances in mass spectrometry instrumentation and methods allow the identification of impurities in pharmaceuticals with a min. of sample material and increased sensitivity.  In this study, a rapid and sensitive method was developed for the structural detn. of the major impurities of doravirine.  The study utilizes ultra performance liq. chromatog.-high-resoln.-tandem mass spectrometry (UHPLC-HRMS/MS) techniques to perform structure elucidation of the unknown structures.  This approach has significant impact on impurity structural elucidation, and a total of five trace-level impurities of doravirine were characterized using the developed method.  Copyright © 2016 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkmg-gQgPhrVg90H21EOLACvtfcHk0li91m2I9toorA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs12gurnF&md5=98e8c5b41e32e1a6537acd99c84367a6</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1002%2Fjms.3807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjms.3807%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%2BK.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DSheng%26aufirst%3DH.%26aulast%3DHelmy%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DGauthier%26aufirst%3DD.%2BR.%26atitle%3DCharacterization%2520of%2520Impurities%2520of%2520HIV%2520NNRTI%2520Doravirine%2520by%2520UHPLC-High%2520Resolution%2520Ms%2520and%2520Tandem%2520Ms%2520Analysis%26jtitle%3DJ.%2520Mass%2520Spectrom.%26date%3D2016%26volume%3D51%26spage%3D959%26epage%3D968%26doi%3D10.1002%2Fjms.3807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit43b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, D. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Journet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangion, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschaen, D. M.</span></span> <span> </span><span class="NLM_article-title">Highly Efficient Synthesis of HIV NNRTI Doravirine</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1021/ol503625z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol503625z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFKlurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=1353-1356&author=D.+R.+Gauthierauthor=B.+D.+Sherryauthor=Y.+Caoauthor=M.+Journetauthor=G.+Humphreyauthor=T.+Itohauthor=I.+Mangionauthor=D.+M.+Tschaen&title=Highly+Efficient+Synthesis+of+HIV+NNRTI+Doravirine&doi=10.1021%2Fol503625z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43bR"><div class="casContent"><span class="casTitleNuber">43b</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Efficient Synthesis of HIV NNRTI Doravirine</span></div><div class="casAuthors">Gauthier, Donald R., Jr.; Sherry, Benjamin D.; Cao, Yang; Journet, Michel; Humphrey, Guy; Itoh, Tetsuji; Mangion, Ian; Tschaen, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1353-1356</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) doravirine I was prepd. using the aldol addn. of (E)-F3CCOCH:CHOEt with the aryloxyacetate 3-Cl-5-NCC6H3OCH2CO2Et in a continuous flow app. followed by elimination with trifluoroacetic anhydride and cyclocondensation with ammonia to give aryloxypyridinone II as the key step.  Aldol addn. of 3-Cl-5-NCC6H3OCH2CO2Et to F3CCOCH:CHOEt in the presence of potassium tert-amyloxide using a flow reactor at -20° for 1-60 s and quenching with aq. dipotassium phosphate followed by a batch elimination with trifluoroacetic anhydride and triethylamine and cyclocondensation with ammonia yielded II in 68% yield; alkylation with a (chloromethyl)-1,2,4-triazolone (prepd. in four steps from Ph chloroformate and glycolic acid) using diisopropylethylamine in NMP/tert-amyl alc. yielded I.  Conditions for the continuous flow aldol reaction were derived using microbatch snapshots of the flow process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod9R1eNic2TbVg90H21EOLACvtfcHk0li91m2I9toorA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFKlurk%253D&md5=4cb4a53d223195f05255992dfbac70e5</span></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.1021%2Fol503625z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol503625z%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DD.%2BR.%26aulast%3DSherry%26aufirst%3DB.%2BD.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DJournet%26aufirst%3DM.%26aulast%3DHumphrey%26aufirst%3DG.%26aulast%3DItoh%26aufirst%3DT.%26aulast%3DMangion%26aufirst%3DI.%26aulast%3DTschaen%26aufirst%3DD.%2BM.%26atitle%3DHighly%2520Efficient%2520Synthesis%2520of%2520HIV%2520NNRTI%2520Doravirine%26jtitle%3DOrg.%2520Lett.%26date%3D2015%26volume%3D17%26spage%3D1353%26epage%3D1356%26doi%3D10.1021%2Fol503625z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit43c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span>; <span class="NLM_string-name">Donald, R.</span>; <span class="NLM_string-name">Gauthier, J.</span>; <span class="NLM_string-name">Humphrey, G. R.</span>; <span class="NLM_string-name">Itoh, T.</span>; <span class="NLM_string-name">Journet, M.</span>; <span class="NLM_string-name">Qian, G.</span>; <span class="NLM_string-name">Sherry, B. D.</span>; <span class="NLM_string-name">Tschaen, D. M.</span></span> <span> </span><span class="NLM_article-title">Process for Making Reverse Transcriptase Inhibitors</span>. <span class="NLM_patent">WO2015084763A2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Cao&author=R.+Donald&author=J.+Gauthier&author=G.+R.+Humphrey&author=T.+Itoh&author=M.+Journet&author=G.+Qian&author=B.+D.+Sherry&author=D.+M.+Tschaen&title=Process+for+Making+Reverse+Transcriptase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26atitle%3DProcess%2520for%2520Making%2520Reverse%2520Transcriptase%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit43d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, T.</span>; <span class="NLM_string-name">Jeon, I.</span>; <span class="NLM_string-name">Mangion, I.</span>; <span class="NLM_string-name">Qian, G.</span>; <span class="NLM_string-name">Sherry, B. D.</span>; <span class="NLM_string-name">Gauthier, D. R.</span>; <span class="NLM_string-name">Cao, Y.</span></span> <span> </span><span class="NLM_article-title">Process for Making Reverse Transcriptase Inhibitors</span>. <span class="NLM_patent">WO2014089140A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=T.+Itoh&author=I.+Jeon&author=I.+Mangion&author=G.+Qian&author=B.+D.+Sherry&author=D.+R.+Gauthier&author=Y.+Cao&title=Process+for+Making+Reverse+Transcriptase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DT.%26atitle%3DProcess%2520for%2520Making%2520Reverse%2520Transcriptase%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit43e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asante-Appiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blouin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campeau, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauchon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chefson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromlish, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschenes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont-Gaudet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falgueyret, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forget, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvreau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plamondon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seliniotakis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Onge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truchon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducharme, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-1439, an Orally Bioavailable Non-Nucleoside Reverse Transcriptase Inhibitor Potent against a Wide Range of Resistant Mutant HIV Viruses</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmcl.2013.12.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=24412110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1yisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=917-922&author=B.+Coteauthor=J.+D.+Burchauthor=E.+Asante-Appiahauthor=C.+Baylyauthor=L.+Bedardauthor=M.+Blouinauthor=L.+C.+Campeauauthor=E.+Cauchonauthor=M.+Chanauthor=A.+Chefsonauthor=N.+Coulombeauthor=W.+Cromlishauthor=S.+Debnathauthor=D.+Deschenesauthor=K.+Dupont-Gaudetauthor=J.+P.+Falgueyretauthor=R.+Forgetauthor=S.+Gagneauthor=D.+Gauvreauauthor=M.+Girardinauthor=S.+Guiralauthor=E.+Langloisauthor=C.+S.+Liauthor=N.+Nguyenauthor=R.+Pappauthor=S.+Plamondonauthor=A.+Royauthor=S.+Royauthor=R.+Seliniotakisauthor=M.+St-Ongeauthor=S.+Ouelletauthor=P.+Tawaauthor=J.+F.+Truchonauthor=J.+Vaccaauthor=M.+Wronaauthor=Y.+Yanauthor=Y.+Ducharme&title=Discovery+of+MK-1439%2C+an+Orally+Bioavailable+Non-Nucleoside+Reverse+Transcriptase+Inhibitor+Potent+against+a+Wide+Range+of+Resistant+Mutant+HIV+Viruses&doi=10.1016%2Fj.bmcl.2013.12.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43eR"><div class="casContent"><span class="casTitleNuber">43e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses</span></div><div class="casAuthors">Cote, Bernard; Burch, Jason D.; Asante-Appiah, Ernest; Bayly, Chris; Bedard, Leanne; Blouin, Marc; Campeau, Louis-Charles; Cauchon, Elizabeth; Chan, Manuel; Chefson, Amandine; Coulombe, Nathalie; Cromlish, Wanda; Debnath, Smita; Deschenes, Denis; Dupont-Gaudet, Kristina; Falgueyret, Jean-Pierre; Forget, Robert; Gagne, Sebastien; Gauvreau, Danny; Girardin, Melina; Guiral, Sebastien; Langlois, Eric; Li, Chun Sing; Nguyen, Natalie; Papp, Rob; Plamondon, Serge; Roy, Amelie; Roy, Stephanie; Seliniotakis, Ria; St-Onge, Miguel; Ouellet, Stephane; Tawa, Paul; Truchon, Jean-Francois; Vacca, Joe; Wrona, Marc; Yan, Youwei; Ducharme, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">917-922</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of pyridone 36.  In cell cultures, this new NNRTI shows a superior potency profile against a range of wild type and clin. relevant, resistant mutant HIV viruses.  The overall favorable preclin. pharmacokinetic profile of 36 led to the prediction of a once daily low dose regimen in human.  NNRTI 36, now known as MK-1439, is currently in clin. development for the treatment of HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJff1LINDbQ7Vg90H21EOLACvtfcHk0ljm-L9mPm_RMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1yisw%253D%253D&md5=7d63ec63691d2d21eb29b8dd9c4c5e63</span></div><a href="/servlet/linkout?suffix=cit43e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.070%26sid%3Dliteratum%253Aachs%26aulast%3DCote%26aufirst%3DB.%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DBayly%26aufirst%3DC.%26aulast%3DBedard%26aufirst%3DL.%26aulast%3DBlouin%26aufirst%3DM.%26aulast%3DCampeau%26aufirst%3DL.%2BC.%26aulast%3DCauchon%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DM.%26aulast%3DChefson%26aufirst%3DA.%26aulast%3DCoulombe%26aufirst%3DN.%26aulast%3DCromlish%26aufirst%3DW.%26aulast%3DDebnath%26aufirst%3DS.%26aulast%3DDeschenes%26aufirst%3DD.%26aulast%3DDupont-Gaudet%26aufirst%3DK.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DForget%26aufirst%3DR.%26aulast%3DGagne%26aufirst%3DS.%26aulast%3DGauvreau%26aufirst%3DD.%26aulast%3DGirardin%26aufirst%3DM.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DLanglois%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DPapp%26aufirst%3DR.%26aulast%3DPlamondon%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DSeliniotakis%26aufirst%3DR.%26aulast%3DSt-Onge%26aufirst%3DM.%26aulast%3DOuellet%26aufirst%3DS.%26aulast%3DTawa%26aufirst%3DP.%26aulast%3DTruchon%26aufirst%3DJ.%2BF.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DWrona%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DDucharme%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520MK-1439%252C%2520an%2520Orally%2520Bioavailable%2520Non-Nucleoside%2520Reverse%2520Transcriptase%2520Inhibitor%2520Potent%2520against%2520a%2520Wide%2520Range%2520of%2520Resistant%2520Mutant%2520HIV%2520Viruses%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D917%26epage%3D922%26doi%3D10.1016%2Fj.bmcl.2013.12.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit43f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J.</span>; <span class="NLM_string-name">Cote, B.</span>; <span class="NLM_string-name">Nguyen, N.</span>; <span class="NLM_string-name">Li, C. S.</span>; <span class="NLM_string-name">St-Onge, M.</span>; <span class="NLM_string-name">Gauvreau, D.</span></span> <span> </span><span class="NLM_article-title">Non-Nucleoside Reverse Transcriptase Inhibitors</span>. <span class="NLM_patent">WO2011120133A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Burch&author=B.+Cote&author=N.+Nguyen&author=C.+S.+Li&author=M.+St-Onge&author=D.+Gauvreau&title=Non-Nucleoside+Reverse+Transcriptase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBurch%26aufirst%3DJ.%26atitle%3DNon-Nucleoside%2520Reverse%2520Transcriptase%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campeau, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvreau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardin, M. l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maligres, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, P. D.</span></span> <span> </span><span class="NLM_article-title">A Robust Kilo-Scale Synthesis of Doravirine</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1476</span>– <span class="NLM_lpage">1481</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00163</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00163" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSrtLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1476-1481&author=L.-C.+Campeauauthor=Q.+Chenauthor=D.+Gauvreauauthor=M.+l.+Girardinauthor=K.+Belykauthor=P.+Maligresauthor=G.+Zhouauthor=C.+Guauthor=W.+Zhangauthor=L.+Tanauthor=P.+D.+O%E2%80%99Shea&title=A+Robust+Kilo-Scale+Synthesis+of+Doravirine&doi=10.1021%2Facs.oprd.6b00163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Robust Kilo-Scale Synthesis of Doravirine</span></div><div class="casAuthors">Campeau, Louis-Charles; Chen, Qinghao; Gauvreau, Danny; Girardin, Melina; Belyk, Kevin; Maligres, Peter; Zhou, Guoyue; Gu, Chaozhan; Zhang, Wei; Tan, Lushi; O'Shea, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1476-1481</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Doravirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) currently in phase III clin. trials for the treatment of HIV infection.  Herein we describe a robust kilo-scale synthesis for its manuf.  The structure and origin of major impurities were detd. and their downstream fate-and-purge studied.  This resulted in a redesign of the route to introduce the key nitrile functionality via a copper mediated cyanation which allowed all impurities to be controlled to an acceptable level.  The improved synthesis was scaled to prep. ∼100 kg batches of doravirine to supply all preclin. and clin. studies up to phase III.  The synthesis affords high-quality material in a longest linear sequence of six steps and 37% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryg7zTXc5vMLVg90H21EOLACvtfcHk0livwkrlT3a-ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSrtLvL&md5=6d2ff3a82e01b6ddfb9de06bb756e36f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00163%26sid%3Dliteratum%253Aachs%26aulast%3DCampeau%26aufirst%3DL.-C.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DGauvreau%26aufirst%3DD.%26aulast%3DGirardin%26aufirst%3DM.%2Bl.%26aulast%3DBelyk%26aufirst%3DK.%26aulast%3DMaligres%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DGu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DP.%2BD.%26atitle%3DA%2520Robust%2520Kilo-Scale%2520Synthesis%2520of%2520Doravirine%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1476%26epage%3D1481%26doi%3D10.1021%2Facs.oprd.6b00163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span>; <span class="NLM_string-name">Xu, L.</span>; <span class="NLM_string-name">Makha, M.</span>; <span class="NLM_string-name">Sandoval, C. A.</span>; <span class="NLM_string-name">Huang, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of 3-Chloromethyl-1,2,4-triazoline-5-one</span>. <span class="NLM_patent">CN104628663A</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=W.+Yang&author=L.+Xu&author=M.+Makha&author=C.+A.+Sandoval&author=C.+Huang&title=Synthesis+Method+of+3-Chloromethyl-1%2C2%2C4-triazoline-5-one"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26atitle%3DSynthesis%2520Method%2520of%25203-Chloromethyl-1%252C2%252C4-triazoline-5-one%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cowden, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolling, U.-H.</span></span> <span> </span><span class="NLM_article-title">A New Synthesis of 1,2,4-Triazolin-5-ones: Application to the Convergent Synthesis of an NK1 Antagonist</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">8661</span>– <span class="NLM_lpage">8664</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)01548-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0040-4039%2800%2901548-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosVGhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2000&pages=8661-8664&author=C.+J.+Cowdenauthor=R.+D.+Wilsonauthor=B.+C.+Bishopauthor=I.+F.+Cottrellauthor=A.+J.+Daviesauthor=U.-H.+Dolling&title=A+New+Synthesis+of+1%2C2%2C4-Triazolin-5-ones%3A+Application+to+the+Convergent+Synthesis+of+an+NK1+Antagonist&doi=10.1016%2FS0040-4039%2800%2901548-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">A new synthesis of 1,2,4-triazolin-5-ones: application to the convergent synthesis of an NK1 antagonist</span></div><div class="casAuthors">Cowden, Cameron J.; Wilson, Robert D.; Bishop, Brian C.; Cottrell, Ian F.; Davies, Antony J.; Dolling, Ulf-H.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">8661-8664</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">3-Chloromethyl-1,2,4-triazolin-5-one (I) has been synthesized in a single step via the novel condensation of semicarbazide hydrochloride with ClCH2C(OMe)3.  Alkylation of the secondary amine fragment with I proceeds in 99% yield to afford the target NK1 antagonist II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxT3pfyW72z7Vg90H21EOLACvtfcHk0livwkrlT3a-ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosVGhu7g%253D&md5=f1377f6291373f2c2afcb4b598d5ca49</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2901548-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252901548-3%26sid%3Dliteratum%253Aachs%26aulast%3DCowden%26aufirst%3DC.%2BJ.%26aulast%3DWilson%26aufirst%3DR.%2BD.%26aulast%3DBishop%26aufirst%3DB.%2BC.%26aulast%3DCottrell%26aufirst%3DI.%2BF.%26aulast%3DDavies%26aufirst%3DA.%2BJ.%26aulast%3DDolling%26aufirst%3DU.-H.%26atitle%3DA%2520New%2520Synthesis%2520of%25201%252C2%252C4-Triazolin-5-ones%253A%2520Application%2520to%2520the%2520Convergent%2520Synthesis%2520of%2520an%2520NK1%2520Antagonist%26jtitle%3DTetrahedron%2520Lett.%26date%3D2000%26volume%3D41%26spage%3D8661%26epage%3D8664%26doi%3D10.1016%2FS0040-4039%2800%2901548-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wilby, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eissa, N. A.</span></span> <span> </span><span class="NLM_article-title">Clinical Pharmacokinetics and Drug Interactions of Doravirine. <i>Eur</i></span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1007/s13318-018-0497-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs13318-018-0497-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30047107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVarurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=637-644&author=K.+J.+Wilbyauthor=N.+A.+Eissa&title=Clinical+Pharmacokinetics+and+Drug+Interactions+of+Doravirine.+Eur&doi=10.1007%2Fs13318-018-0497-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46aR"><div class="casContent"><span class="casTitleNuber">46a</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetics and Drug Interactions of Doravirine</span></div><div class="casAuthors">Wilby, Kyle John; Eissa, Nesma Ahmed</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">637-644</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Springer France</span>)
        </div><div class="casAbstract">A review.  Doravirine is a new HIV-1 non-nucleoside reverse transcriptase inhibitor that has demonstrated a good efficacy and safety profile in clin. trials.  It has a therapeutic profile that makes it an attractive option for treatment of HIV-1 infection.  As such, there has been an increase in the published literature regarding the pharmacokinetics of doravirine and potential for drug-drug interactions.  This review aimed to identify pharmacokinetic literature pertaining to doravirine, used findings from the literature to summarize its pharmacokinetic profile, and finally evaluated literature describing actual and potential drug interactions.  Review findings show doravirine is well-absorbed, exhibits moderate protein binding activity, and is extensively metabolized by cytochrome P 450 enzymes (specifically CYP3A).  It has an elimination half-life of 12-21 h.  Gender, age, moderate hepatic impairment, and co-administration with food did not greatly alter doravirine's pharmacokinetic profile.  Drug interaction studies have shown doravirine does not affect the pharmacokinetics of dolutegravir or atorvastatin but may have its pharmacokinetics altered by rifampicin (rifampin) and other rifamycins (CYP3A inducers) and ritonavir (CYP3A inhibitor).  No clin. significant interactions were noted between doravirine and an antacid (aluminum-magnesium), pantoprazole, ledipasvir/sofosbuvir, or elbasvir/grazoprevir.  Further study is needed to better understand doravirine's efficacy and safety profile when co-administered with other agents known to be CYP inducers or inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-xmCP56FHa7Vg90H21EOLACvtfcHk0livwkrlT3a-ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVarurfN&md5=cd86e9f9e6a4dc45fa54e4d9f6824623</span></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=10.1007%2Fs13318-018-0497-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13318-018-0497-3%26sid%3Dliteratum%253Aachs%26aulast%3DWilby%26aufirst%3DK.%2BJ.%26aulast%3DEissa%26aufirst%3DN.%2BA.%26atitle%3DClinical%2520Pharmacokinetics%2520and%2520Drug%2520Interactions%2520of%2520Doravirine.%2520Eur%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2018%26volume%3D43%26spage%3D637%26epage%3D644%26doi%3D10.1007%2Fs13318-018-0497-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit46b"><span><span class="NLM_label">(b) </span><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=210867" class="extLink">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210867</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdaf%2Findex.cfm%3Fevent%3Doverview.process%26ApplNo%3D210867+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Opoku, N. O</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakajika, D. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanza, E. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mambandu, G. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyathirombo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigo, M. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasonia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masembe, S. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumbere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kataliko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larbelee, J. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kpawor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolay, K. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolay, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attah, S. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olipoh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halleux, C. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuesel, A. C</span></span> <span> </span><span class="NLM_article-title">Single Dose Moxidectin Versus Ivermectin for Onchocerca Volvulus Infection in Ghana, Liberia, and the Democratic Republic of the Congo: A Randomised, Controlled, Double-Blind Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1207</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)32844-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0140-6736%2817%2932844-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29361335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVehs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1207-1216&author=N.+O+Opokuauthor=D.+K+Bakajikaauthor=E.+M+Kanzaauthor=H.+Howardauthor=G.+L+Mambanduauthor=A.+Nyathiromboauthor=M.+M+Nigoauthor=K.+Kasoniaauthor=S.+L+Masembeauthor=M.+Mumbereauthor=K.+Katalikoauthor=J.+P+Larbeleeauthor=M.+Kpaworauthor=K.+M+Bolayauthor=F.+Bolayauthor=S.+Asareauthor=S.+K+Attahauthor=G.+Olipohauthor=M.+Vaillantauthor=C.+M+Halleuxauthor=A.+C+Kuesel&title=Single+Dose+Moxidectin+Versus+Ivermectin+for+Onchocerca+Volvulus+Infection+in+Ghana%2C+Liberia%2C+and+the+Democratic+Republic+of+the+Congo%3A+A+Randomised%2C+Controlled%2C+Double-Blind+Phase+3+Trial&doi=10.1016%2FS0140-6736%2817%2932844-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial</span></div><div class="casAuthors">Opoku, Nicholas O.; Bakajika, Didier K.; Kanza, Eric M.; Howard, Hayford; Mambandu, Germain L.; Nyathirombo, Amos; Nigo, Maurice M.; Kasonia, Kambale; Masembe, Safari L.; Mumbere, Mupenzi; Kataliko, Kambale; Larbelee, Jemmah P.; Kpawor, Mawolo; Bolay, Kpehe M.; Bolay, Fatorma; Attah, Simon K.; Vaillant, Michel; Halleux, Christine M.; Kuesel, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10154</span>),
    <span class="NLM_cas:pages">1207-1216</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The morbidity and socioeconomic effects of onchocerciasis, a parasitic disease that is primarily endemic in sub-Saharan Africa, have motivated large morbidity and transmission control programs.  Annual community-directed ivermectin treatment has substantially reduced prevalence.  Elimination requires intensified efforts, including more efficacious treatments.  We compared parasitol. efficacy and safety of moxidectin and ivermectin.  This double-blind, parallel group, superiority trial was done in four sites in Ghana, Liberia, and the Democratic Republic of the Congo.  We enrolled participants (aged ≥12 years) with at least 10 Onchocerca volvulus microfilariae per mg skin who were not co-infected with Loa loa or lymphatic filariasis microfilaremic.  Participants were randomly allocated, stratified by sex and level of infection, to receive a single oral dose of 8 mg moxidectin or 150μg/kg ivermectin as overencapsulated oral tablets.  The primary efficacy outcome was skin microfilariae d. 12 mo post treatment.  We used a mixed-effects model to test the hypothesis that the primary efficacy outcome in the moxidectin group was 50% or less than that in the ivermectin group.  The primary efficacy anal. population were all participants who received the study drug and completed 12-mo follow-up (modified intention to treat).  This study is registered with ClinicalTrials.gov, no. NCT00790998.  Between Apr. 22, 2009, and Jan 23, 2011, we enrolled and allocated 998 participants to moxidectin and 501 participants to ivermectin. 978 received moxidectin and 494 ivermectin, of which 947 and 480 were included in primary efficacy outcome analyses.  At 12 mo, skin microfilarial d. (microfilariae per mg of skin) was lower in the moxidectin group (adjusted geometric mean 0·6 [95% CI 0·3-1·0]) than in the ivermectin group (4·5 [3·5-5·9]; difference 3·9 [3·2-4·9], p<0·0001; treatment difference 86%).  Mazzotti (ie, efficacy-related) reactions occurred in 967 (99%) of 978 moxidectin-treated participants and in 478 (97%) of 494 ivermectin-treated participants, including ocular reactions (moxidectin 113 [12%] participants and ivermectin 47 [10%] participants), lab. reactions (788 [81%] and 415 [84%]), and clin. reactions (944 [97%] and 446 [90%]).  No serious adverse events were considered to be related to treatment.  Skin microfilarial loads (ie, parasite transmission reservoir) are lower after moxidectin treatment than after ivermectin treatment.  Moxidectin would therefore be expected to reduce parasite transmission between treatment rounds more than ivermectin could, thus accelerating progress towards elimination.  UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7ainnG-wbBbVg90H21EOLACvtfcHk0lhW1qxYnuyokg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVehs7w%253D&md5=b0d562e50a7e90a2592d0985cda69da6</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2932844-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252932844-1%26sid%3Dliteratum%253Aachs%26aulast%3DOpoku%26aufirst%3DN.%2BO%26aulast%3DBakajika%26aufirst%3DD.%2BK%26aulast%3DKanza%26aufirst%3DE.%2BM%26aulast%3DHoward%26aufirst%3DH.%26aulast%3DMambandu%26aufirst%3DG.%2BL%26aulast%3DNyathirombo%26aufirst%3DA.%26aulast%3DNigo%26aufirst%3DM.%2BM%26aulast%3DKasonia%26aufirst%3DK.%26aulast%3DMasembe%26aufirst%3DS.%2BL%26aulast%3DMumbere%26aufirst%3DM.%26aulast%3DKataliko%26aufirst%3DK.%26aulast%3DLarbelee%26aufirst%3DJ.%2BP%26aulast%3DKpawor%26aufirst%3DM.%26aulast%3DBolay%26aufirst%3DK.%2BM%26aulast%3DBolay%26aufirst%3DF.%26aulast%3DAsare%26aufirst%3DS.%26aulast%3DAttah%26aufirst%3DS.%2BK%26aulast%3DOlipoh%26aufirst%3DG.%26aulast%3DVaillant%26aufirst%3DM.%26aulast%3DHalleux%26aufirst%3DC.%2BM%26aulast%3DKuesel%26aufirst%3DA.%2BC%26atitle%3DSingle%2520Dose%2520Moxidectin%2520Versus%2520Ivermectin%2520for%2520Onchocerca%2520Volvulus%2520Infection%2520in%2520Ghana%252C%2520Liberia%252C%2520and%2520the%2520Democratic%2520Republic%2520of%2520the%2520Congo%253A%2520A%2520Randomised%252C%2520Controlled%252C%2520Double-Blind%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1207%26epage%3D1216%26doi%3D10.1016%2FS0140-6736%2817%2932844-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit47b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Awadzi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opoku, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazdins-Helds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuesel, A. C.</span></span> <span> </span><span class="NLM_article-title">A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca Volvulus Infection</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e2953</span>, (18 pp). <span class="refDoi"> DOI: 10.1371/journal.pntd.0002953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1371%2Fjournal.pntd.0002953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=24968000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ygtLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=e2953&author=K.+Awadziauthor=N.+O.+Opokuauthor=S.+K.+Attahauthor=J.+Lazdins-Heldsauthor=A.+C.+Kuesel&title=A+Randomized%2C+Single-Ascending-Dose%2C+Ivermectin-Controlled%2C+Double-Blind+Study+of+Moxidectin+in+Onchocerca+Volvulus+Infection&doi=10.1371%2Fjournal.pntd.0002953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection</span></div><div class="casAuthors">Awadzi, Kwablah; Opoku, Nicholas O.; Attah, Simon K.; Lazdins-Helds, Janis; Kuesel, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e2953/1-e2953/18, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Control of onchocerciasis as a public health problem in Africa relies on annual mass ivermectin distribution.  New tools are needed to achieve elimination of infection.  This study detd. in a small no. of Onchocerca volvulus infected individuals whether moxidectin, a veterinary anthelmintic, is safe enough to administer it in a future large study to further characterize moxidectin's safety and efficacy.  Effects on the parasite were also assessed.  Methodol./Principal Findings: Men and women from a forest area in South-eastern Ghana without ivermectin mass distribution received a single oral dose of 2 mg (N = 44), 4 mg (N = 45) or 8 mg (N = 38) moxidectin or 150 μg/kg ivermectin (N = 45) with 18 mo follow up.  All ivermectin and 97%-100% of moxidectin treated participants had Mazzotti reactions.  Statistically significantly higher percentages of participants treated with 8 mg moxidectin than participants treated with ivermectin experienced pruritus (87% vs. 56%), rash (63% vs. 42%), increased pulse rate (61% vs. 36%) and decreased mean arterial pressure upon 2 min standing still after ≥5 min supine relative to pre-treatment (61% vs. 27%).  These reactions resolved without treatment.  In the 8 mg moxidectin and ivermectin arms, the mean ± SD no. of microfilariae/mg skin were 22.9 ± 21.1 and 21.2 ± 16.4 pre-treatment and 0.0 ± 0.0 and 1.1 ± 4.2 at nadir reached 1 and 3 mo after treatment, resp.  At 6 mo, values were 0.0 ± 0.0 and 1.6 ± 4.5, at 12 mo 0.4 ± 0.9 and 3.4 ± 4.4 and at 18 mo 1.8 ± 3.3 and 4.0 ± 4.8, resp., in the 8 mg moxidectin and ivermectin arm.  The redn. from pre-treatment values was significantly higher after 8 mg moxidectin than after ivermectin treatment throughout follow up (p<0.01).  Conclusions/Significance: The 8 mg dose of moxidectin was safe enough to initiate the large study.  Provided its results confirm those from this study, availability of moxidectin to control programs could help them achieve onchocerciasis elimination objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt6NNNvsiF7LVg90H21EOLACvtfcHk0lhW1qxYnuyokg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ygtLbN&md5=83f752c91d9ea93e8c31cc8efe6416a2</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0002953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0002953%26sid%3Dliteratum%253Aachs%26aulast%3DAwadzi%26aufirst%3DK.%26aulast%3DOpoku%26aufirst%3DN.%2BO.%26aulast%3DAttah%26aufirst%3DS.%2BK.%26aulast%3DLazdins-Helds%26aufirst%3DJ.%26aulast%3DKuesel%26aufirst%3DA.%2BC.%26atitle%3DA%2520Randomized%252C%2520Single-Ascending-Dose%252C%2520Ivermectin-Controlled%252C%2520Double-Blind%2520Study%2520of%2520Moxidectin%2520in%2520Onchocerca%2520Volvulus%2520Infection%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2014%26volume%3D8%26spage%3De2953%26doi%3D10.1371%2Fjournal.pntd.0002953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cobb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckh, A.</span></span> <span> </span><span class="NLM_article-title">Moxidectin: A Review of Chemistry, Pharmacokinetics and Use in Horses</span>. <i>Parasites Vectors</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">S5</span>, <span class="refDoi"> DOI: 10.1186/1756-3305-2-S2-S5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1186%2F1756-3305-2-S2-S5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=19778466" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=S5&author=R.+Cobbauthor=A.+Boeckh&title=Moxidectin%3A+A+Review+of+Chemistry%2C+Pharmacokinetics+and+Use+in+Horses&doi=10.1186%2F1756-3305-2-S2-S5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1186%2F1756-3305-2-S2-S5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-3305-2-S2-S5%26sid%3Dliteratum%253Aachs%26aulast%3DCobb%26aufirst%3DR.%26aulast%3DBoeckh%26aufirst%3DA.%26atitle%3DMoxidectin%253A%2520A%2520Review%2520of%2520Chemistry%252C%2520Pharmacokinetics%2520and%2520Use%2520in%2520Horses%26jtitle%3DParasites%2520Vectors%26date%3D2009%26volume%3D2%26spage%3DS5%26doi%3D10.1186%2F1756-3305-2-S2-S5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prichard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lespine, A.</span></span> <span> </span><span class="NLM_article-title">Moxidectin and the Avermectins: Consanguinity but Not Identity</span>. <i>Int. J. Parasitol.: Drugs Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.ijpddr.2012.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.ijpddr.2012.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=24533275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BC2cfls1ehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=134-153&author=R.+Prichardauthor=C.+Menezauthor=A.+Lespine&title=Moxidectin+and+the+Avermectins%3A+Consanguinity+but+Not+Identity&doi=10.1016%2Fj.ijpddr.2012.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Moxidectin and the avermectins: Consanguinity but not identity</span></div><div class="casAuthors">Prichard Roger; Menez Cecile; Lespine Anne</div><div class="citationInfo"><span class="NLM_cas:title">International journal for parasitology. Drugs and drug resistance</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-53</span>
        ISSN:<span class="NLM_cas:issn">2211-3207</span>.
    </div><div class="casAbstract">The avermectins and milbemycins contain a common macrocyclic lactone (ML) ring, but are fermentation products of different organisms.  The principal structural difference is that avermectins have sugar groups at C13 of the macrocyclic ring, whereas the milbemycins are protonated at C13.  Moxidectin (MOX), belonging to the milbemycin family, has other differences, including a methoxime at C23.  The avermectins and MOX have broad-spectrum activity against nematodes and arthropods.  They have similar but not identical, spectral ranges of activity and some avermectins and MOX have diverse formulations for great user flexibility.  The longer half-life of MOX and its safety profile, allow MOX to be used in long-acting formulations.  Some important differences between MOX and avermectins in interaction with various invertebrate ligand-gated ion channels are known and could be the basis of different efficacy and safety profiles.  Modelling of IVM interaction with glutamate-gated ion channels suggest different interactions will occur with MOX.  Similarly, profound differences between MOX and the avermectins are seen in interactions with ABC transporters in mammals and nematodes.  These differences are important for pharmacokinetics, toxicity in animals with defective transporter expression, and probable mechanisms of resistance.  Resistance to the avermectins has become widespread in parasites of some hosts and MOX resistance also exists and is increasing.  There is some degree of cross-resistance between the avermectins and MOX, but avermectin resistance and MOX resistance are not identical.  In many cases when resistance to avermectins is noticed, MOX produces a higher efficacy and quite often is fully effective at recommended dose rates.  These similarities and differences should be appreciated for optimal decisions about parasite control, delaying, managing or reversing resistances, and also for appropriate anthelmintic combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSL5mESGuQZEE2yPDyEFiigfW6udTcc2eZFKbU3KV_Pobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfls1ehsQ%253D%253D&md5=960e3a7fb538f95e0a2772934af0929a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpddr.2012.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpddr.2012.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DPrichard%26aufirst%3DR.%26aulast%3DMenez%26aufirst%3DC.%26aulast%3DLespine%26aufirst%3DA.%26atitle%3DMoxidectin%2520and%2520the%2520Avermectins%253A%2520Consanguinity%2520but%2520Not%2520Identity%26jtitle%3DInt.%2520J.%2520Parasitol.%253A%2520Drugs%2520Drug%2520Resist.%26date%3D2012%26volume%3D2%26spage%3D134%26epage%3D153%26doi%3D10.1016%2Fj.ijpddr.2012.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lumaret, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errouissi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floate, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rombke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardhaugh, K.</span></span> <span> </span><span class="NLM_article-title">A Review on the Toxicity and Non-Target Effects of Macrocyclic Lactones in Terrestrial and Aquatic Environments</span>. <i>Curr. Pharm. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1004</span>– <span class="NLM_lpage">1060</span>, <span class="refDoi"> DOI: 10.2174/138920112800399257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138920112800399257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=22039795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns1eltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1004-1060&author=J.-P.+Lumaretauthor=F.+Errouissiauthor=K.+Floateauthor=J.+Rombkeauthor=K.+Wardhaugh&title=A+Review+on+the+Toxicity+and+Non-Target+Effects+of+Macrocyclic+Lactones+in+Terrestrial+and+Aquatic+Environments&doi=10.2174%2F138920112800399257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A review on the toxicity and non-target effects of macrocyclic lactones in terrestrial and aquatic environments</span></div><div class="casAuthors">Lumaret, Jean-Pierre; Errouissi, Faiek; Floate, Kevin; Rombke, Jorg; Wardhaugh, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1004-1060</span>CODEN:
                <span class="NLM_cas:coden">CPBUBP</span>;
        ISSN:<span class="NLM_cas:issn">1389-2010</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The avermectins, milbemycins and spinosyns are collectively referred to as macrocyclic lactones (MLs) which comprise several classes of chems. derived from cultures of soil micro-organisms.  These compds. are extensively and increasingly used in veterinary medicine and agriculture.  Due to their potential effects on non-target organisms, large amts. of information on their impact in the environment has been compiled in recent years, mainly caused by legal requirements related to their marketing authorization or registration.  The main objective of this paper is to critically review the present knowledge about the acute and chronic ecotoxicol. effects of MLs on organisms, mainly invertebrates, in the terrestrial and aquatic environment.  Detailed information is presented on the mode-of-action as well as the ecotoxicity of the most important compds. representing the three groups of MLs.  This information, based on more than 360 refs., is mainly provided in nine tables, presenting the effects of abamectin, ivermectin, eprinomectin, doramectin, emamectin, moxidectin, and spinosad on individual species of terrestrial and aquatic invertebrates as well as plants and algae.  Since dung dwelling organisms are particularly important non-targets, as they are exposed via dung from treated animals over their whole life-cycle, the information on the effects of MLs on dung communities is compiled in an addnl. table.  The results of this review clearly demonstrate that regarding environmental impacts many macrocyclic lactones are substances of high concern, particularly with larval instars of invertebrates.  Recent studies have also shown that susceptibility varies with life cycle stage and impacts can be mitigated by using MLs when these stages are not present.  However, information on the environmental impact of the MLs is scattered across a wide range of specialised scientific journals with research focusing mainly on ivermectin and to a lesser extent on abamectin doramectin and moxidectin.  By comparison, information on compds. such as eprinomectin, emamectin and selamectin is still relatively scarce.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXcE3YHuQiCLVg90H21EOLACvtfcHk0lirX01SU8pJWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns1eltLo%253D&md5=114cc1d8a05245f0cc5fb345b5091aac</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2174%2F138920112800399257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920112800399257%26sid%3Dliteratum%253Aachs%26aulast%3DLumaret%26aufirst%3DJ.-P.%26aulast%3DErrouissi%26aufirst%3DF.%26aulast%3DFloate%26aufirst%3DK.%26aulast%3DRombke%26aufirst%3DJ.%26aulast%3DWardhaugh%26aufirst%3DK.%26atitle%3DA%2520Review%2520on%2520the%2520Toxicity%2520and%2520Non-Target%2520Effects%2520of%2520Macrocyclic%2520Lactones%2520in%2520Terrestrial%2520and%2520Aquatic%2520Environments%26jtitle%3DCurr.%2520Pharm.%2520Biotechnol.%26date%3D2012%26volume%3D13%26spage%3D1004%26epage%3D1060%26doi%3D10.2174%2F138920112800399257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiala, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, D. B.</span></span> <span> </span><span class="NLM_article-title">Biosynthetic Origin of the Carbon Skeleton and Oxygen Atoms of the LL-F28249α, a Potent Antiparasitic Macrolide</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.42.398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.7164%2Fantibiotics.42.398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=2708133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaL1MXktVeru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1989&pages=398-406&author=H.+R.+Tsouauthor=Z.+H.+Ahmedauthor=R.+R.+Fialaauthor=M.+W.+Bullockauthor=G.+T.+Carterauthor=J.+J.+Goodmanauthor=D.+B.+Borders&title=Biosynthetic+Origin+of+the+Carbon+Skeleton+and+Oxygen+Atoms+of+the+LL-F28249%CE%B1%2C+a+Potent+Antiparasitic+Macrolide&doi=10.7164%2Fantibiotics.42.398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51aR"><div class="casContent"><span class="casTitleNuber">51a</span><div class="casTitle"><span class="NLM_cas:atitle">Biosynthetic origin of the carbon skeleton and oxygen atoms of the LL-F28249α, a potent antiparasitic macrolide</span></div><div class="casAuthors">Tsou, H. R.; Ahmed, Z. H.; Fiala, R. R.; Bullock, M. W.; Carter, G. T.; Goodman, J. J.; Borders, D. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">398-406</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">The biosynthesis of LL-F28249α (I) in a culture of Streptomyces cyanogriseus was studied using 13C-, 14C-, and 18O-labeled precursors.  A complete 13C-NMR spectrum of I was assigned.  Incorporation studies using 13-labeled precursors indicate that the C skeleton of I is derived from 7 acetate, 6 propionate, and one 2-methylpropionate units.  The origin of the O atoms of I was examd. by feeding [1-13C,18O2]acetate, [1-13C,18O2]propionate, [2-13C]acetate/18O2, and 18O2 sep. to the fermn. culture and analyzing the resulting labeled I samples by 13C-NMR, electron impact MS, and chem. ionization MS.  Of 8 O atoms in I, 4 are derived from acetate, 3 from propionate, and 1 from O2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrWVg6YkDLkLVg90H21EOLACvtfcHk0lirX01SU8pJWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXktVeru7o%253D&md5=fb4d1f9e5d1e8a49fe9f883f6086d1b9</span></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.42.398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.42.398%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DAhmed%26aufirst%3DZ.%2BH.%26aulast%3DFiala%26aufirst%3DR.%2BR.%26aulast%3DBullock%26aufirst%3DM.%2BW.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26aulast%3DGoodman%26aufirst%3DJ.%2BJ.%26aulast%3DBorders%26aufirst%3DD.%2BB.%26atitle%3DBiosynthetic%2520Origin%2520of%2520the%2520Carbon%2520Skeleton%2520and%2520Oxygen%2520Atoms%2520of%2520the%2520LL-F28249%25CE%25B1%252C%2520a%2520Potent%2520Antiparasitic%2520Macrolide%26jtitle%3DJ.%2520Antibiot.%26date%3D1989%26volume%3D42%26spage%3D398%26epage%3D406%26doi%3D10.7164%2Fantibiotics.42.398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit51b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Enhancing Nemadectin Production by Streptomyces Cyaneogriseus Ssp. Noncyanogenus through Quantitative Evaluation and Optimization of Dissolved Oxygen and Shear Force</span>. <i>Bioresour. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">180</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1016/j.biortech.2017.09.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.biortech.2017.09.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29414165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKqtbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=2018&pages=180-188&author=X.+Songauthor=Y.+Zhangauthor=J.+Xueauthor=C.+Liauthor=Z.+Wangauthor=Y.+Wang&title=Enhancing+Nemadectin+Production+by+Streptomyces+Cyaneogriseus+Ssp.+Noncyanogenus+through+Quantitative+Evaluation+and+Optimization+of+Dissolved+Oxygen+and+Shear+Force&doi=10.1016%2Fj.biortech.2017.09.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51bR"><div class="casContent"><span class="casTitleNuber">51b</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing nemadectin production by Streptomyces cyaneogriseus ssp. noncyanogenus through quantitative evaluation and optimization of dissolved oxygen and shear force</span></div><div class="casAuthors">Song, Xiaoqing; Zhang, Yun; Xue, Jiayun; Li, Chao; Wang, Zejian; Wang, Yonghong</div><div class="citationInfo"><span class="NLM_cas:title">Bioresource Technology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">180-188</span>CODEN:
                <span class="NLM_cas:coden">BIRTEB</span>;
        ISSN:<span class="NLM_cas:issn">0960-8524</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In this study, effects of oxygen supply and shear stress on nemadectin prodn. by Streptomyces cyaneogriseus ssp. noncyanogenus (S. cyaneogriseus) fermn. were investigated in shake flasks and 5-L bioreactors.  Results showed sufficient dissolved oxygen level was essential for cells growth and nemadectin biosynthesis, while strong shear stress had neg. impacts on both cell growth and nemadectin synthesis.  Furthermore, when a combined paddle type was applied in culturing S. cyaneogriseus, the nemadectin prodn. was increased by 23.6%.  The influence of different agitation rates and paddle types on volumetric oxygen transfers coeff. (KLa) and shear stress were quant. studied through computational fluid dynamics simulation (CFD).  The results of CFD revealed that high KLa as well as low shear stress co-existed under the combined impeller configuration at 650 rpm.  This study is expected to be helpful to the scale-up of nemadectin fermn. and other stress-sensitive but high-oxygen-consumption filamentous microorganism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK2RC-OLYBuLVg90H21EOLACvtfcHk0lirX01SU8pJWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKqtbfP&md5=3d7cd6a7ba3ddf49a5a671e5ab483cdf</span></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=10.1016%2Fj.biortech.2017.09.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biortech.2017.09.033%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DEnhancing%2520Nemadectin%2520Production%2520by%2520Streptomyces%2520Cyaneogriseus%2520Ssp.%2520Noncyanogenus%2520through%2520Quantitative%2520Evaluation%2520and%2520Optimization%2520of%2520Dissolved%2520Oxygen%2520and%2520Shear%2520Force%26jtitle%3DBioresour.%2520Technol.%26date%3D2018%26volume%3D255%26spage%3D180%26epage%3D188%26doi%3D10.1016%2Fj.biortech.2017.09.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Process for Eliminating Byproduct Dimethyl Sulfide from Production of Moxidectin</span>. <span class="NLM_patent">CN105294729A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Dai&author=H.+Li&author=R.+Wang&title=Process+for+Eliminating+Byproduct+Dimethyl+Sulfide+from+Production+of+Moxidectin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26atitle%3DProcess%2520for%2520Eliminating%2520Byproduct%2520Dimethyl%2520Sulfide%2520from%2520Production%2520of%2520Moxidectin%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit52b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Dai, Y.</span>; <span class="NLM_string-name">Wang, W.</span>; <span class="NLM_string-name">Zhao, D.</span>; <span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing High-Purity Moxidectin Using Membrane Separation</span>. <span class="NLM_patent">CN104356140A</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+Li&author=Y.+Dai&author=W.+Wang&author=D.+Zhao&author=R.+Wang&title=Method+for+Preparing+High-Purity+Moxidectin+Using+Membrane+Separation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26atitle%3DMethod%2520for%2520Preparing%2520High-Purity%2520Moxidectin%2520Using%2520Membrane%2520Separation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit52c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span>; <span class="NLM_string-name">Wen, J.</span>; <span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Moxidectin</span>. <span class="NLM_patent">CN104277050A</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+He&author=J.+Wen&author=H.+Zhang&title=Method+for+Preparing+Moxidectin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26atitle%3DMethod%2520for%2520Preparing%2520Moxidectin%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit52d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span>; <span class="NLM_string-name">Du, Z.</span>; <span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Preparation of Moxidectin</span>. <span class="NLM_patent">CN104017001B</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Dai&author=Z.+Du&author=R.+Wang&title=Preparation+of+Moxidectin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Moxidectin%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfitzner, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffatt, J. G.</span></span> <span> </span><span class="NLM_article-title">A New and Selective Oxidation of Alcohols</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">3027</span>– <span class="NLM_lpage">3028</span>, <span class="refDoi"> DOI: 10.1021/ja00902a036</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00902a036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaF3sXkvVantbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1963&pages=3027-3028&author=K.+E.+Pfitznerauthor=J.+G.+Moffatt&title=A+New+and+Selective+Oxidation+of+Alcohols&doi=10.1021%2Fja00902a036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The synthesis of nucleoside 5'-carboxaldehydes</span></div><div class="casAuthors">Pfitzner, K. E.; Moffatt, J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1963</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3027</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Addn. of dicyclohexylcarbodiimide (I) to an anhyd. soln. of pyridinium thymidine 5'-phosphate in Me2SO after 1 hr. at room temp. gave thymine (II) and inorg. phosphates.  A similar release of II resulted from P1,P2-dithymidine pyrophosphate, thymidine, and 5'-O-acetylthymidine, but not from 3'-O-acetylthymidine 5'phosphate, 3'-deoxythymidine 5'-phosphate, or the corresponding nucleosides in the presence of phosphate.  Treatment of 1 millimole 3'-O-acetylthymidine in 3 ml. anhyd. Me2SO contg. 0.5 millimole phosphoric acid with 3-5 millimoles I for several hrs. at room temp. gave no release of II, but rather 3'-O-acetyl thymidine 5'-carboxaldehyde (III), λ 267 mμ in H2O [2,4-di-nitrophenylhydrazone m. 233-34°,  (MeOH) 261 and 350 mμ (ε 19,300 and 21,650)], completely free of acidic nucleoside derivs. Redn. of III with NaBH4 gave II, while oxidn. of III with NaOI gave 3'-O-acetylthymidine 5'-carboxylic acid, which on alk. hydrolysis gave thymidine 5'-carboxylic acid. Similarly, the reaction of 2',3'-O-isopropylideneuridine and 2',3'-O-iso-propylideneadenosine with I and 0.5 mole-equiv. pyridinium trifluoroacetate or pyridinium phosphate in anhyd.  Me2SO, followed by treatment with 10% HOAc at 100° for 1 hr., gave uridine 5'carboxaldehyde and adenosine 5'-carboxaldehyde.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-8EJfx87wgbVg90H21EOLACvtfcHk0lgUDMcth8mJCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3sXkvVantbY%253D&md5=3f46daf90e60de38496a7379b113674e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fja00902a036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00902a036%26sid%3Dliteratum%253Aachs%26aulast%3DPfitzner%26aufirst%3DK.%2BE.%26aulast%3DMoffatt%26aufirst%3DJ.%2BG.%26atitle%3DA%2520New%2520and%2520Selective%2520Oxidation%2520of%2520Alcohols%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1963%26volume%3D85%26spage%3D3027%26epage%3D3028%26doi%3D10.1021%2Fja00902a036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razzak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kassas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, S.</span></span> <span> </span><span class="NLM_article-title">Analytical Profile of Moxidectin</span>. <i>Profiles Drug Subst., Excipients, Relat. Methodol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-407691-4.00007-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FB978-0-12-407691-4.00007-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=23668407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ChtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=315-366&author=A.+Awasthiauthor=M.+Razzakauthor=R.+Al-Kassasauthor=J.+Harveyauthor=S.+Garg&title=Analytical+Profile+of+Moxidectin&doi=10.1016%2FB978-0-12-407691-4.00007-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Analytical profile of moxidectin</span></div><div class="casAuthors">Awasthi, Atul; Razzak, Majid; Al-Kassas, Raida; Harvey, Joanne; Garg, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Profiles of Drug Substances, Excipients, and Related Methodology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-366</span>CODEN:
                <span class="NLM_cas:coden">PDSEBJ</span>;
        ISSN:<span class="NLM_cas:issn">1871-5125</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Moxidectin or F28249α is a potent endectocide and semisynthetic methoxime deriv. of naturally occurring nemadectin.  It is well known for the novel mode of action against a broad range of nematode and anthropod animal parasites.  In this work, physicochem. and pharmaceutical aspects of moxidectin are described including stability, semisynthesis, purifn. processes, formulation compns., impurities, and degrdn. pathways.  Addnl. expts. such as DSC, XRD, and CHN anal. were carried out to complete the profile of moxidectin.  The importance of safety and quality of drug substances was highlighted by chronol. developments involving moxidectin and its analogs.  The information gathered from the literature was used to trace the origins of moxidectin-related substances presented in the European Pharmacopeia (EP) compendial monograph.  During the review, it was noticed that majority of impurities presented in the EP does not have any potential to increase with time in drug substance or formulated products; therefore, they do not require monitoring during stability studies.  This also showed the requirement for further characterization of the impurities obsd. during long-term storage and development of stability indicating methods distinguishing between process impurities and the true degrdn. products.  Furthermore, the stability of moxidectin in formulations is also reviewed in conjunction with known degrdn. routes and innovative ways to formulate products that are stable and effective at intended shelf life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI7xKWihUrArVg90H21EOLACvtfcHk0lgUDMcth8mJCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ChtrrL&md5=0498df4db478ca73235464a0f702c3fa</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-407691-4.00007-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-407691-4.00007-1%26sid%3Dliteratum%253Aachs%26aulast%3DAwasthi%26aufirst%3DA.%26aulast%3DRazzak%26aufirst%3DM.%26aulast%3DAl-Kassas%26aufirst%3DR.%26aulast%3DHarvey%26aufirst%3DJ.%26aulast%3DGarg%26aufirst%3DS.%26atitle%3DAnalytical%2520Profile%2520of%2520Moxidectin%26jtitle%3DProfiles%2520Drug%2520Subst.%252C%2520Excipients%252C%2520Relat.%2520Methodol.%26date%3D2013%26volume%3D38%26spage%3D315%26epage%3D366%26doi%3D10.1016%2FB978-0-12-407691-4.00007-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Tafenoquine - a Radical Improvement?</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1056/NEJMe1816383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1056%2FNEJMe1816383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30650321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cjitFaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=285-286&author=N.+J.+White&title=Tafenoquine+-+a+Radical+Improvement%3F&doi=10.1056%2FNEJMe1816383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Tafenoquine - A Radical Improvement?</span></div><div class="casAuthors">White Nicholas J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-286</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvc9lL5gewfEcLvDNbOD4DfW6udTcc2eYtOi0_4B0flbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjitFaksA%253D%253D&md5=0866617ff05aeab14b4d4e12f9365c4a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1816383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1816383%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DTafenoquine%2520-%2520a%2520Radical%2520Improvement%253F%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D285%26epage%3D286%26doi%3D10.1056%2FNEJMe1816383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blumbergs, P.</span>; <span class="NLM_string-name">LaMontagne, M. P.</span></span> <span> </span><span class="NLM_article-title">4-Methyl-5-[(Un)Substituted Phenoxy]-2,6-dimethoxy-8-(aminoalkylamino)quinolines</span>. <span class="NLM_patent">US4617394A</span>, <span class="NLM_year">1986</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&author=P.+Blumbergs&author=M.+P.+LaMontagne&title=4-Methyl-5-%5B%28Un%29Substituted+Phenoxy%5D-2%2C6-dimethoxy-8-%28aminoalkylamino%29quinolines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlumbergs%26aufirst%3DP.%26atitle%3D4-Methyl-5-%255B%2528Un%2529Substituted%2520Phenoxy%255D-2%252C6-dimethoxy-8-%2528aminoalkylamino%2529quinolines%26date%3D1986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vennerstrom, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuzum, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dande, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhous, W. K.</span></span> <span> </span><span class="NLM_article-title">8-Aminoquinolines Active against Blood Stage Plasmodium Falciparum in Vitro Inhibit Hematin Polymerization</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1128/AAC.43.3.598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1128%2FAAC.43.3.598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10049273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK1MXhsF2htbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1999&pages=598-602&author=J.+L.+Vennerstromauthor=E.+O.+Nuzumauthor=R.+E.+Millerauthor=A.+Dornauthor=L.+Gerenaauthor=P.+A.+Dandeauthor=W.+Y.+Ellisauthor=R.+G.+Ridleyauthor=W.+K.+Milhous&title=8-Aminoquinolines+Active+against+Blood+Stage+Plasmodium+Falciparum+in+Vitro+Inhibit+Hematin+Polymerization&doi=10.1128%2FAAC.43.3.598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization</span></div><div class="casAuthors">Vennerstrom, Jonathan L.; Nuzum, Edwin O.; Miller, Robert E.; Dorn, Arnulf; Gerena, Lucia; Dande, Prasad A.; Ellis, William Y.; Ridley, Robert G.; Milhous, Wilbur K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">598-602</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">From the Walter Reed Army Institute of Research (WRAIR) inventory, thirteen 8-aminoquinoline analogs of primaquine were selected for screening against a panel of seven Plasmodium falciparum clones and isolates.  Six of the 13 8-aminoquinolines, including I, II, and III, had av. 50% inhibitory concns. between 50 and 100 nM against these P. falciparum clones and were thus an order of magnitude more potent than primaquine.  However, excluding chloroquine-resistant clones and isolates, these 8-aminoquinolines were all an order of magnitude less potent than chloroquine.  None of the 8-aminoquinolines was cross resistant with either chloroquine or mefloquine.  In contrast to the inactive primaquine prototype, 8 of the 13 8-aminoquinolines inhibited hematin polymn. more efficiently than did chloroquine.  Although alkoxy or aryloxy substituents at position 5 uniquely endowed these 13 8-aminoquinolines with impressive schizontocidal activity, the structural specificity of inhibition of both parasite growth and hematin polymn. was low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosjpI6rzAadrVg90H21EOLACvtfcHk0liLB60_Mm1Ehg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsF2htbc%253D&md5=15467291ff3d1a7553190a14997228c9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1128%2FAAC.43.3.598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.43.3.598%26sid%3Dliteratum%253Aachs%26aulast%3DVennerstrom%26aufirst%3DJ.%2BL.%26aulast%3DNuzum%26aufirst%3DE.%2BO.%26aulast%3DMiller%26aufirst%3DR.%2BE.%26aulast%3DDorn%26aufirst%3DA.%26aulast%3DGerena%26aufirst%3DL.%26aulast%3DDande%26aufirst%3DP.%2BA.%26aulast%3DEllis%26aufirst%3DW.%2BY.%26aulast%3DRidley%26aufirst%3DR.%2BG.%26aulast%3DMilhous%26aufirst%3DW.%2BK.%26atitle%3D8-Aminoquinolines%2520Active%2520against%2520Blood%2520Stage%2520Plasmodium%2520Falciparum%2520in%2520Vitro%2520Inhibit%2520Hematin%2520Polymerization%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1999%26volume%3D43%26spage%3D598%26epage%3D602%26doi%3D10.1128%2FAAC.43.3.598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque-Ortega, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzano, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanys, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamarro, F.</span></span> <span> </span><span class="NLM_article-title">Tafenoquine, an Antiplasmodial 8-Aminoquinoline, Targets Leishmania Respiratory Complex III and Induces Apoptosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5344</span>– <span class="NLM_lpage">5351</span>, <span class="refDoi"> DOI: 10.1128/AAC.00790-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1128%2FAAC.00790-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20837758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5344-5351&author=L.+Carvalhoauthor=J.+R.+Luque-Ortegaauthor=J.+I.+Manzanoauthor=S.+Castanysauthor=L.+Rivasauthor=F.+Gamarro&title=Tafenoquine%2C+an+Antiplasmodial+8-Aminoquinoline%2C+Targets+Leishmania+Respiratory+Complex+III+and+Induces+Apoptosis&doi=10.1128%2FAAC.00790-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58aR"><div class="casContent"><span class="casTitleNuber">58a</span><div class="casTitle"><span class="NLM_cas:atitle">Tafenoquine, an antiplasmodial 8-aminoquinoline, targets Leishmania respiratory complex III and induces apoptosis</span></div><div class="casAuthors">Carvalho, Luis; Luque-Ortega, Juan Roman; Manzano, Jose Ignacio; Castanys, Santiago; Rivas, Luis; Gamarro, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5344-5351</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tafenoquine (TFQ), an 8-aminoquinoline analog of primaquine, which is under clin. trial (phase IIb/III) for the treatment and prevention of malaria, may represent an alternative treatment for leishmaniasis.  Here, the authors have studied the mechanism of action of TFQ against Leishmania parasites.  TFQ impaired the overall bioenergetic metab. of Leishmania promastigotes, causing a rapid drop in intracellular ATP levels without affecting plasma membrane permeability.  TFQ induced mitochondrial dysfunction through the inhibition of cytochrome c reductase (respiratory complex III) with a decrease in the oxygen consumption rate and depolarization of mitochondrial membrane potential.  This was accompanied by ROS prodn., elevation of intracellular Ca2+ levels and concomitant nuclear DNA fragmentation.  It is concluded that TFQ targets Leishmania mitochondria, leading to an apoptosis-like death process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqub4UUn4WPo7Vg90H21EOLACvtfcHk0liLB60_Mm1Ehg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FO&md5=966bb6693b6e5cf4a16482a642b5e9e4</span></div><a href="/servlet/linkout?suffix=cit58a&amp;dbid=16384&amp;doi=10.1128%2FAAC.00790-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00790-10%26sid%3Dliteratum%253Aachs%26aulast%3DCarvalho%26aufirst%3DL.%26aulast%3DLuque-Ortega%26aufirst%3DJ.%2BR.%26aulast%3DManzano%26aufirst%3DJ.%2BI.%26aulast%3DCastanys%26aufirst%3DS.%26aulast%3DRivas%26aufirst%3DL.%26aulast%3DGamarro%26aufirst%3DF.%26atitle%3DTafenoquine%252C%2520an%2520Antiplasmodial%25208-Aminoquinoline%252C%2520Targets%2520Leishmania%2520Respiratory%2520Complex%2520III%2520and%2520Induces%2520Apoptosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5344%26epage%3D5351%26doi%3D10.1128%2FAAC.00790-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit58b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lanners, H. N.</span></span> <span> </span><span class="NLM_article-title">Effect of the 8-Aminoquinoline Primaquine on Culture-Derived Gametocytes of the Malaria Parasite Plasmodium Falciparum</span>. <i>Z. Parasitenkd.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">478</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1007/BF00928413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2FBF00928413" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1991&pages=478-481&author=H.+N.+Lanners&title=Effect+of+the+8-Aminoquinoline+Primaquine+on+Culture-Derived+Gametocytes+of+the+Malaria+Parasite+Plasmodium+Falciparum&doi=10.1007%2FBF00928413"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58b&amp;dbid=16384&amp;doi=10.1007%2FBF00928413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00928413%26sid%3Dliteratum%253Aachs%26aulast%3DLanners%26aufirst%3DH.%2BN.%26atitle%3DEffect%2520of%2520the%25208-Aminoquinoline%2520Primaquine%2520on%2520Culture-Derived%2520Gametocytes%2520of%2520the%2520Malaria%2520Parasite%2520Plasmodium%2520Falciparum%26jtitle%3DZ.%2520Parasitenkd.%26date%3D1991%26volume%3D77%26spage%3D478%26epage%3D481%26doi%3D10.1007%2FBF00928413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayes, M.</span></span> <span> </span><span class="NLM_article-title">Tafenoquine Succinate: Antimalarial</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1358/dof.2003.028.09.758545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdof.2003.028.09.758545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVKitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=859-869&author=J.+A.+McIntyreauthor=J.+Castanerauthor=M.+Bayes&title=Tafenoquine+Succinate%3A+Antimalarial&doi=10.1358%2Fdof.2003.028.09.758545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Tafenoquine succinate: Antimalarial</span></div><div class="casAuthors">McIntyre, J. A.; Castaner, J.; Bayes, M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">859-869</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Malaria is a significant public health problem in developing and third world countries.  Plasmodium falciparum and Plasmodium vivax parasites are responsible for the majority of cases of malaria infection.  Treatment focuses on both chemoprevention and treatment of acute infection, but the currently used drugs are threatened by drug-resistant species in many parts of the world.  Tatenoquine is a new 8-aminoquinoline with an improved therapeutic index and safety profile as compared to primaquine.  In pharmacol. studies, tafenoquine has been shown to be at least 10 times more potent than primaquine and has a much longer half-life, allowing less frequent dosing in chemoprophylactic regimens.  Its clin. efficacy has been demonstrated in a no. of studies, both as a chemoprophylactic agent for the prevention of P. falciparum infection and as an acute treatment against the liver stages of P. vivax.  Tafenoquine has the potential to become a widely used drug in the prevention and treatment of malaria infection and could replace some currently used drugs as resistant strains of Plasmodium species increase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIb_SpLEdDdrVg90H21EOLACvtfcHk0lgjeck-j2vJjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVKitb4%253D&md5=eced4bb3ff52010f67c6c82ad4afe4a0</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1358%2Fdof.2003.028.09.758545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2003.028.09.758545%26sid%3Dliteratum%253Aachs%26aulast%3DMcIntyre%26aufirst%3DJ.%2BA.%26aulast%3DCastaner%26aufirst%3DJ.%26aulast%3DBayes%26aufirst%3DM.%26atitle%3DTafenoquine%2520Succinate%253A%2520Antimalarial%26jtitle%3DDrugs%2520Future%26date%3D2003%26volume%3D28%26spage%3D859%26epage%3D869%26doi%3D10.1358%2Fdof.2003.028.09.758545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D.</span>; <span class="NLM_string-name">Davies, B. J.</span>; <span class="NLM_string-name">Kincey, P. M.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Quinoline Derivatives</span>. <span class="NLM_patent">WO2003093239A2</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=D.+Bell&author=B.+J.+Davies&author=P.+M.+Kincey&title=Process+for+the+Preparation+of+Quinoline+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DD.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Quinoline%2520Derivatives%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeds, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyavanagimatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, D. E.</span></span> <span> </span><span class="NLM_article-title">Development of ST-246 for Treatment of Poxvirus Infections</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2409</span>– <span class="NLM_lpage">2435</span>, <span class="refDoi"> DOI: 10.3390/v2112409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.3390%2Fv2112409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=21994624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVentbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=2409-2435&author=R.+Jordanauthor=J.+M.+Leedsauthor=S.+Tyavanagimattauthor=D.+E.+Hruby&title=Development+of+ST-246+for+Treatment+of+Poxvirus+Infections&doi=10.3390%2Fv2112409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Development of ST-246 for treatment of poxvirus infections</span></div><div class="casAuthors">Jordan, Robert; Leeds, Janet M.; Tyavanagimatt, Shanthakumar; Hruby, Dennis E.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2409-2435</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  ST-246 (Tecovirimat) is a small synthetic antiviral compd. being developed to treat pathogenic orthopoxvirus infections of humans.  The compd. was discovered as part of a high throughput screen designed to identify inhibitors of vaccinia virus-induced cytopathic effects.  The antiviral activity is specific for orthopoxviruses and the compd. does not inhibit the replication of other RNA- and DNA-contg. viruses or inhibit cell proliferation at concns. of compd. that are antiviral.  ST-246 targets vaccinia virus p37, a viral protein required for envelopment and secretion of extracellular forms of virus.  The compd. is orally bioavailable and protects multiple animal species from lethal orthopoxvirus challenge.  Preclin. safety pharmacol. studies in mice and non-human primates indicate that ST-246 is readily absorbed by the oral route and well tolerated with the no observable adverse effect level (NOAEL) in mice measured at 2000 mg/kg and the no observable effect level (NOEL) in non-human primates measured at 300 mg/kg.  Drug substance and drug product processes have been developed and com. scale batches have been produced using Good Manufg. Processes (GMP).  Human phase I clin. trials have shown that ST-246 is safe and well tolerated in healthy human volunteers.  Based on the results of the clin. evaluation, once a day dosing should provide plasma drug exposure in the range predicted to be antiviral based on data from efficacy studies in animal models of orthopoxvirus disease.  These data support the use of ST-246 as a therapeutic to treat pathogenic orthopoxvirus infections of humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmGadVchbhsbVg90H21EOLACvtfcHk0lgjeck-j2vJjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVentbjM&md5=35bd35088ffa95b6a8346adb5d46891c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3390%2Fv2112409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv2112409%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DLeeds%26aufirst%3DJ.%2BM.%26aulast%3DTyavanagimatt%26aufirst%3DS.%26aulast%3DHruby%26aufirst%3DD.%2BE.%26atitle%3DDevelopment%2520of%2520ST-246%2520for%2520Treatment%2520of%2520Poxvirus%2520Infections%26jtitle%3DViruses%26date%3D2010%26volume%3D2%26spage%3D2409%26epage%3D2435%26doi%3D10.3390%2Fv2112409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Tecovirimat: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1382</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0967-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0967-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30120738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFCku7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1377-1382&author=S.+M.+Hoy&title=Tecovirimat%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0967-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Tecovirimat: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1377-1382</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Tecovirimat (TPOXX) is an orthopoxvirus-specific antiviral drug developed by SIGA Technologies in conjunction with the US Department of Health and Human Services' Biomedical Advances Research and Development Authority.  It acts by inhibiting the activity of the orthopoxvirus VP37 envelope wrapping protein, thereby preventing the formation of egress-competent enveloped virions, which are essential for dissemination of the virus in the host.  In July 2018, oral tecovirimat was approved in the USA for the treatment of human smallpox disease caused by variola virus in adults and paediatric patients weighing ≥ 13 kg.  Tecovirimat was approved under the US FDA's Animal Rule, in which marketing approval is based on its efficacy in relevant animal models.  An i.v. formulation of tecovirimat is undergoing phase I development for the treatment of smallpox infection.  This article summarises the milestones in the development of tecovirimat leading to this first approval for the treatment of human smallpox disease in adults and paediatric patients weighing ≥ 13 kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsN9oWSErgorVg90H21EOLACvtfcHk0lgjeck-j2vJjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFCku7bF&md5=5824b1ec39cfd2be5d1915a25debae3a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0967-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0967-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DTecovirimat%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1377%26epage%3D1382%26doi%3D10.1007%2Fs40265-018-0967-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Merchlinsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albright, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiltz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkeley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challberg, M.</span></span> <span> </span><span class="NLM_article-title">The Development and Approval of Tecoviromat (TPOXX®), the First Antiviral against Smallpox</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.antiviral.2019.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=31181284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFOktLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=168-174&author=M.+Merchlinskyauthor=A.+Albrightauthor=V.+Olsonauthor=H.+Schiltzauthor=T.+Merkeleyauthor=C.+Hughesauthor=B.+Petersenauthor=M.+Challberg&title=The+Development+and+Approval+of+Tecoviromat+%28TPOXX%C2%AE%29%2C+the+First+Antiviral+against+Smallpox&doi=10.1016%2Fj.antiviral.2019.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63aR"><div class="casContent"><span class="casTitleNuber">63a</span><div class="casTitle"><span class="NLM_cas:atitle">The development and approval of tecoviromat (TPOXX), the first antiviral against smallpox</span></div><div class="casAuthors">Merchlinsky, Michael; Albright, Andrew; Olson, Victoria; Schiltz, Helen; Merkeley, Tyler; Hughes, Claiborne; Petersen, Brett; Challberg, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">168-174</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The classification of smallpox by the U.  S. Centers for Disease Control and Prevention (CDC) as a Category A Bioterrorism threat agent has resulted in the U.  S. Government investing significant funds to develop and stockpile a suite of medical countermeasures to ameliorate the consequences of a smallpox epidemic.  This stockpile includes both vaccines for prophylaxis and antivirals to treat symptomatic patients.  In this manuscript, we describe the path to approval for the first therapeutic against smallpox, identified during its development as ST-246, now known as tecovirimat and TPOXX, a small-mol. antiviral compd. sponsored by SIGA Technologies to treat symptomatic smallpox. Because the disease is no longer endemic, the development and approval of TPOXX was only possible under the U.  S. Food and Drug and Administration Animal Rule (FDA 2002).  In this article, we describe the combination of animal model studies and clin. trials that were used to satisfy the FDA requirements for the approval of TPOXX  under the Animal Rule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrraom8Rh5-irVg90H21EOLACvtfcHk0lg2-ErRPLCY1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFOktLfK&md5=a4ad1763632396c95698c9d0500e18fa</span></div><a href="/servlet/linkout?suffix=cit63a&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DMerchlinsky%26aufirst%3DM.%26aulast%3DAlbright%26aufirst%3DA.%26aulast%3DOlson%26aufirst%3DV.%26aulast%3DSchiltz%26aufirst%3DH.%26aulast%3DMerkeley%26aufirst%3DT.%26aulast%3DHughes%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DB.%26aulast%3DChallberg%26aufirst%3DM.%26atitle%3DThe%2520Development%2520and%2520Approval%2520of%2520Tecoviromat%2520%2528TPOXX%25C2%25AE%2529%252C%2520the%2520First%2520Antiviral%2520against%2520Smallpox%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D168%26spage%3D168%26epage%3D174%26doi%3D10.1016%2Fj.antiviral.2019.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit63b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Grosenbach, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honeychurch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinsangaram, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, D. E.</span></span> <span> </span><span class="NLM_article-title">Oral Tecovirimat for the Treatment of Smallpox</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1705688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1056%2FNEJMoa1705688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29972742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlert7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=44-53&author=D.+W.+Grosenbachauthor=K.+Honeychurchauthor=E.+A.+Roseauthor=J.+Chinsangaramauthor=A.+Frimmauthor=B.+Maitiauthor=C.+Lovejoyauthor=I.+Mearaauthor=P.+Longauthor=D.+E.+Hruby&title=Oral+Tecovirimat+for+the+Treatment+of+Smallpox&doi=10.1056%2FNEJMoa1705688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63bR"><div class="casContent"><span class="casTitleNuber">63b</span><div class="casTitle"><span class="NLM_cas:atitle">Oral tecovirimat for the treatment of smallpox</span></div><div class="casAuthors">Grosenbach, Douglas W.; Honeychurch, Kady; Rose, Eric A.; Chinsangaram, Jarasvech; Frimm, Annie; Maiti, Biswajit; Lovejoy, Candace; Meara, Ingrid; Long, Paul; Hruby, Dennis E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-53</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Smallpox was declared eradicated in 1980, but variola virus (VARV), which causes smallpox, still exists.  There is no known effective treatment for smallpox; therefore, tecovirimat is being developed as an oral smallpox therapy.  Because clin. trials in a context of natural disease are not possible, an alternative developmental path to evaluate efficacy and safety was needed. methods We investigated the efficacy of tecovirimat in nonhuman primate (monkeypox) and rabbit (rabbitpox) models in accordance with the Food and Drug Administration (FDA) Animal Efficacy Rule, which was interpreted for smallpox therapeutics by an expert advisory committee.  We also conducted a placebo-controlled pharmacokinetic and safety trial involving 449 adult volunteers. results The min. dose of tecovirimat required in order to achieve more than 90% survival in the monkeypox model was 10 mg per kg of body wt. for 14 days, and a dose of 40 mg per kg for 14 days was similarly efficacious in the rabbitpox model.  Although the ED per kg was higher in rabbits, exposure was lower, with a mean steady-state max., min., and av. (mean) concn. (Cmax, Cmin, and Cavg, resp.) of 374, 25, and 138 ng per mL, resp., in rabbits and 1444, 169, and 598 ng per mL in nonhuman primates, as well as an area under the concn.-time curve over 24 h (AUC0-24h) of 3318 ng × hours per mL in rabbits and 14,352 ng × hours per mL in nonhuman primates.  These findings suggested that the nonhuman primate was the more conservative model for the estn. of the required drug exposure in humans.  A dose of 600 mg twice daily for 14 days was selected for testing in humans and provided exposures in excess of those in nonhuman primates (mean steady-state Cmax, Cmin, and Cavg of 2209, 690, and 1270 ng per mL and AUC0-24h of 30,632 ng × hours per mL).  No pattern of troubling adverse events was obsd. conclusions On the basis of its efficacy in two animal models and pharmacokinetic and safety data in humans, tecovirimat is being advanced as a therapy for smallpox in accordance with the FDA Animal Rule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_dJtZ5rS5abVg90H21EOLACvtfcHk0lg2-ErRPLCY1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlert7rJ&md5=2ba24cfcf5191d7d74a843bb3ce81313</span></div><a href="/servlet/linkout?suffix=cit63b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1705688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1705688%26sid%3Dliteratum%253Aachs%26aulast%3DGrosenbach%26aufirst%3DD.%2BW.%26aulast%3DHoneychurch%26aufirst%3DK.%26aulast%3DRose%26aufirst%3DE.%2BA.%26aulast%3DChinsangaram%26aufirst%3DJ.%26aulast%3DFrimm%26aufirst%3DA.%26aulast%3DMaiti%26aufirst%3DB.%26aulast%3DLovejoy%26aufirst%3DC.%26aulast%3DMeara%26aufirst%3DI.%26aulast%3DLong%26aufirst%3DP.%26aulast%3DHruby%26aufirst%3DD.%2BE.%26atitle%3DOral%2520Tecovirimat%2520for%2520the%2520Treatment%2520of%2520Smallpox%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D44%26epage%3D53%26doi%3D10.1056%2FNEJMoa1705688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Review of the Patent Literature: Synthesis and Final Forms of Antiviral Drugs Tecovirimat and Baloxavir Marboxil</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1298</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ensrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=1298-1307&author=D.+L.+Hughes&title=Review+of+the+Patent+Literature%3A+Synthesis+and+Final+Forms+of+Antiviral+Drugs+Tecovirimat+and+Baloxavir+Marboxil&doi=10.1021%2Facs.oprd.9b00144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Review of the Patent Literature: Synthesis and Final Forms of Antiviral Drugs Tecovirimat and Baloxavir Marboxil</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1298-1307</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article reviews synthetic routes and final polymorphic forms of two recently approved antiviral drugs, TPOXX (tecovirimat) for the treatment of smallpox and Xofluza (baloxavir marboxil), a treatment for influenza.  The patent literature was the source of information for synthetic routes and final forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo__fk1JmXM4rVg90H21EOLACvtfcHk0lg2-ErRPLCY1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ensrrM&md5=1300a493cef08adecdd6009255967f71</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00144%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DReview%2520of%2520the%2520Patent%2520Literature%253A%2520Synthesis%2520and%2520Final%2520Forms%2520of%2520Antiviral%2520Drugs%2520Tecovirimat%2520and%2520Baloxavir%2520Marboxil%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26spage%3D1298%26epage%3D1307%26doi%3D10.1021%2Facs.oprd.9b00144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span>; <span class="NLM_string-name">Bailey, T. R.</span>; <span class="NLM_string-name">Rippin, S. R.</span>; <span class="NLM_string-name">Dai, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Isoindole Derivatives for Treatment and Prevention of Orthopoxvirus Infections</span>. <span class="NLM_patent">WO2008130348A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+Jordan&author=T.+R.+Bailey&author=S.+R.+Rippin&author=D.+Dai&title=Preparation+of+Isoindole+Derivatives+for+Treatment+and+Prevention+of+Orthopoxvirus+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DR.%26atitle%3DPreparation%2520of%2520Isoindole%2520Derivatives%2520for%2520Treatment%2520and%2520Prevention%2520of%2520Orthopoxvirus%2520Infections%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit65b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span>; <span class="NLM_string-name">Bailey, T. R.</span>; <span class="NLM_string-name">Rippin, S. R.</span>; <span class="NLM_string-name">Dai, D.</span></span> <span> </span><span class="NLM_article-title">Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases</span>. <span class="NLM_patent">US20120020922A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Jordan&author=T.+R.+Bailey&author=S.+R.+Rippin&author=D.+Dai&title=Compounds%2C+Compositions+and+Methods+for+Treatment+and+Prevention+of+Orthopoxvirus+Infections+and+Associated+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DR.%26atitle%3DCompounds%252C%2520Compositions%2520and%2520Methods%2520for%2520Treatment%2520and%2520Prevention%2520of%2520Orthopoxvirus%2520Infections%2520and%2520Associated%2520Diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyavanagimatt, S. R.</span>; <span class="NLM_string-name">Stone, M. A. C. L.</span>; <span class="NLM_string-name">Weimers, W. C.</span>; <span class="NLM_string-name">Nelson, D.</span>; <span class="NLM_string-name">Bolken, T. C.</span>; <span class="NLM_string-name">Hruby, D. E.</span>; <span class="NLM_string-name">O’Neill, M. H.</span>; <span class="NLM_string-name">Sweetapple, G.</span>; <span class="NLM_string-name">McCloughan, K. A.</span></span> <span> </span><span class="NLM_article-title">Polymorphic Forms ST-246</span>. <span class="NLM_patent">WO2011119698A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+R.+Tyavanagimatt&author=M.+A.+C.+L.+Stone&author=W.+C.+Weimers&author=D.+Nelson&author=T.+C.+Bolken&author=D.+E.+Hruby&author=M.+H.+O%E2%80%99Neill&author=G.+Sweetapple&author=K.+A.+McCloughan&title=Polymorphic+Forms+ST-246"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTyavanagimatt%26aufirst%3DS.%2BR.%26atitle%3DPolymorphic%2520Forms%2520ST-246%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avatrombopag-thrombocytopenia-adults-chronic-liver-disease" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avatrombopag-thrombocytopenia-adults-chronic-liver-disease</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-avatrombopag-thrombocytopenia-adults-chronic-liver-disease+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><a href="https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-doptelet_en.pdf" class="extLink">https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-doptelet_en.pdf</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.ema.europa.eu%2Fdocuments%2Fsmop-initial%2Fchmp-summary-positive-opinion-doptelet_en.pdf+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Avatrombopag: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1168</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0949-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0949-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29995177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlSjt7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1163-1168&author=M.+Shirley&title=Avatrombopag%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0949-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Avatrombopag: First Global Approval</span></div><div class="casAuthors">Shirley, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1163-1168</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Avatrombopag (Doptelet) is an orally bioavailable, small mol. thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.  In May 2018 avatrombopag received its first global approval, in the USA, for use in the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.  A Marketing Authorization Application for use of avatrombopag in this indication was submitted to the EMA in Apr. 2018.  Clin. development of avatrombopag in the treatment of other thrombocytopenic disorders, including immune thrombocytopenic purpura and chemotherapy-induced thrombocytopenia, is ongoing.  This article summarizes the milestones in the development of avatrombopag leading to this first approval for the treatment of thrombocytopenia in adult patients with CLD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJmYkB5ioYQbVg90H21EOLACvtfcHk0lgaS4ImBVeiog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlSjt7jL&md5=3759df7ee27fbb9f17a345115f755380</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0949-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0949-8%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DAvatrombopag%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1163%26epage%3D1168%26doi%3D10.1007%2Fs40265-018-0949-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugasawa, K.</span>; <span class="NLM_string-name">Watanuki, S.</span>; <span class="NLM_string-name">Koga, Y.</span>; <span class="NLM_string-name">Nagata, H.</span>; <span class="NLM_string-name">Obitsu, K.</span>; <span class="NLM_string-name">Wakayama, R.</span>; <span class="NLM_string-name">Hirayama, F.</span>; <span class="NLM_string-name">Suzuki, K.-I.</span></span> <span> </span><span class="NLM_article-title">2-Acylaminothiazole Derivative or Salt Thereof</span>. <span class="NLM_patent">WO2003062233A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=K.+Sugasawa&author=S.+Watanuki&author=Y.+Koga&author=H.+Nagata&author=K.+Obitsu&author=R.+Wakayama&author=F.+Hirayama&author=K.-I.+Suzuki&title=2-Acylaminothiazole+Derivative+or+Salt+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSugasawa%26aufirst%3DK.%26atitle%3D2-Acylaminothiazole%2520Derivative%2520or%2520Salt%2520Thereof%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit70b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugasawa, K.</span>; <span class="NLM_string-name">Koga, Y.</span>; <span class="NLM_string-name">Hirayama, F.</span>; <span class="NLM_string-name">Suzuki, K.-I.</span>; <span class="NLM_string-name">Awamura, Y.</span></span> <span> </span><span class="NLM_article-title">Novel Salt of 2-Acylaminothiazole Derivative</span>. <span class="NLM_patent">WO2004029049A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=K.+Sugasawa&author=Y.+Koga&author=F.+Hirayama&author=K.-I.+Suzuki&author=Y.+Awamura&title=Novel+Salt+of+2-Acylaminothiazole+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSugasawa%26aufirst%3DK.%26atitle%3DNovel%2520Salt%2520of%25202-Acylaminothiazole%2520Derivative%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit70c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugasawa, K.</span>; <span class="NLM_string-name">Miyafuji, A.</span>; <span class="NLM_string-name">Suzuki, K.</span>; <span class="NLM_string-name">Awamura, Y.</span></span> <span> </span><span class="NLM_article-title">2-Acylaminothiazole Compound Crystals</span>. <span class="NLM_patent">WO2013018362A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+Sugasawa&author=A.+Miyafuji&author=K.+Suzuki&author=Y.+Awamura&title=2-Acylaminothiazole+Compound+Crystals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSugasawa%26aufirst%3DK.%26atitle%3D2-Acylaminothiazole%2520Compound%2520Crystals%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span> <span> </span><span class="NLM_article-title">Revefenacin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1036-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1036-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30560478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=85-91&author=Y.-A.+Heo&title=Revefenacin%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1036-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Revefenacin: First Global Approval</span></div><div class="casAuthors">Heo, Young-A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-91</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Revefenacin (YUPELRI) inhalation soln., a long-acting muscarinic antagonist (i.e. an anticholinergic) developed by Theravance Biopharma and Mylan, is the first and currently the only once-daily, nebulized bronchodilator to be approved in the USA for the treatment of chronic obstructive pulmonary disease (COPD).  In Nov. 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD.  This article summarizes the milestones in the development of revefenacin leading to this first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreKt8JGiq2GLVg90H21EOLACvtfcHk0lgaS4ImBVeiog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F&md5=09384e244c9d6b3f9b4d39dd87705057</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1036-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1036-x%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26atitle%3DRevefenacin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D85%26epage%3D91%26doi%3D10.1007%2Fs40265-018-1036-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1080/17512433.2019.1587292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F17512433.2019.1587292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30803279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlslemtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=293-298&author=F.+Liauthor=J.+Yang&title=Revefenacin+for+the+Treatment+of+Chronic+Obstructive+Pulmonary+Disease&doi=10.1080%2F17512433.2019.1587292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Revefenacin for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Li, Fuyuan; Yang, Junyi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-298</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Acetylcholine is the predominant parasympathetic neurotransmitter in the airways, and plays a key role in the pathophysiol. of chronic obstructive pulmonary disease (COPD).  Muscarinic receptors are found in smooth muscle cells and submucosal glands.  Binding of acetylcholine to muscarinic receptors could trigger bronchoconstriction.  Muscarinic antagonists prevent acetylcholine from binding to its receptors and produce bronchodilation.  Revefenacin is the first once-daily dosed nebulized long-acting muscarinic antagonist indicated for the maintenance treatment of patients with COPD.  In this paper, the chem. properties, mechanism of action, pharmacokinetics, clin. efficacy and safety of Revefenacin was introduced, and the evolution of muscarinic antagonists is also briefly described.  Revefenacin is a new M3 muscarinic receptor antagonist, which could prevent acetylcholine from binding with the muscarinic receptor, making bronchodilation and relieving COPD symptoms.  Revefenacin has a rapid onset of action, and the curative effect is to maintain a long time.  Clin. trials showed that Revefenacin could significantly increase forced expiratory vol. in 1 s (FEV1) in patients with COPD and improve their quality of life.  The recommended dose of Revefenacin inhalation soln. is 175μg once daily.  Adverse reactions were mild and the drug was well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXCbQy8bWgVbVg90H21EOLACvtfcHk0lgWKD_ZfuKZqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlslemtbc%253D&md5=cf55198b6b6a62fb147722e4e0e753bb</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1080%2F17512433.2019.1587292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17512433.2019.1587292%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DRevefenacin%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2019%26volume%3D12%26spage%3D293%26epage%3D298%26doi%3D10.1080%2F17512433.2019.1587292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Axt, S.</span>; <span class="NLM_string-name">Church, T. J.</span>; <span class="NLM_string-name">Malathong, V.</span></span> <span> </span><span class="NLM_article-title">Crystalline Forms of a Biphenyl Compound</span>. <span class="NLM_patent">WO2006099165A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=S.+Axt&author=T.+J.+Church&author=V.+Malathong&title=Crystalline+Forms+of+a+Biphenyl+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAxt%26aufirst%3DS.%26atitle%3DCrystalline%2520Forms%2520of%2520a%2520Biphenyl%2520Compound%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit73b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Colson, P.-J.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing a Biphenyl-2-Ylcarbamic Acid</span>. <span class="NLM_patent">WO2012009166A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.-J.+Colson&title=Process+for+Preparing+a+Biphenyl-2-Ylcarbamic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DColson%26aufirst%3DP.-J.%26atitle%3DProcess%2520for%2520Preparing%2520a%2520Biphenyl-2-Ylcarbamic%2520Acid%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit73c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mammen, M.</span>; <span class="NLM_string-name">Ji, Y.-H.</span>; <span class="NLM_string-name">Mu, Y.</span>; <span class="NLM_string-name">Husfeld, C.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Biphenyl Compounds Useful as Muscarinic Receptor Antagonists</span>. <span class="NLM_patent">US20050203133A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Mammen&author=Y.-H.+Ji&author=Y.+Mu&author=C.+Husfeld&author=L.+Li&title=Biphenyl+Compounds+Useful+as+Muscarinic+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMammen%26aufirst%3DM.%26atitle%3DBiphenyl%2520Compounds%2520Useful%2520as%2520Muscarinic%2520Receptor%2520Antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Roxadustat: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01077-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-01077-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30805897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=563-572&author=S.+Dhillon&title=Roxadustat%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01077-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Roxadustat: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">563-572</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Roxadustat (Ai Rui Zhuo in China) is an orally administered, small mol. hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that is being developed by FibroGen, in collaboration with Astellas and AstraZeneca, for the treatment of anemia in patients with dialysis-dependent chronic kidney disease (CKD), non-dialysis-dependent CKD and in patients with myelodysplastic syndromes.  The drug reversibly binds to and inhibits HIF-prolyl hydroxylase enzymes that are responsible for the degrdn. of transcription factors in the HIF family under normal oxygen conditions.  Inhibition of these enzymes reduces HIF breakdown and promotes HIF activity, leading to an increase in endogenous erythropoietin prodn., thereby enhancing erythropoiesis.  It also reduces the expression of the peptide hormone hepcidin, improves iron availability and increases Hb levels.  HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metab.  Roxadustat is approved in China and is under regulatory review in Japan for the treatment of anemia in patients with dialysis-dependent CKD.  Studies are underway to investigate long-term cardiovascular outcomes with roxadustat vs. placebo (for non-dialysis-dependent CKD) or std. of care (for dialysis-dependent CKD).  This article summarizes the milestones in the development of roxadustat leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ_JyPI6KLs7Vg90H21EOLACvtfcHk0lgWKD_ZfuKZqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyit7k%253D&md5=039b607bef7f12a73d9727d89f3df8e4</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01077-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01077-1%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DRoxadustat%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D563%26epage%3D572%26doi%3D10.1007%2Fs40265-019-01077-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Provenzano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besarab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durham, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cangiano, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saikali, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmerich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczech, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neff, T. B.</span></span> <span> </span><span class="NLM_article-title">Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD</span>. <i>Clin. J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">991</span>, <span class="refDoi"> DOI: 10.2215/CJN.06890615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2215%2FCJN.06890615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27094610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVSks7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=982-991&author=R.+Provenzanoauthor=A.+Besarabauthor=C.+H.+Sunauthor=S.+A.+Diamondauthor=J.+H.+Durhamauthor=J.+L.+Cangianoauthor=J.+R.+Aielloauthor=J.+E.+Novakauthor=T.+Leeauthor=R.+Leongauthor=B.+K.+Robertsauthor=K.+G.+Saikaliauthor=S.+Hemmerichauthor=L.+A.+Szczechauthor=K.-H.+P.+Yuauthor=T.+B.+Neff&title=Oral+Hypoxia-Inducible+Factor+Prolyl+Hydroxylase+Inhibitor+Roxadustat+%28FG-4592%29+for+the+Treatment+of+Anemia+in+Patients+with+CKD&doi=10.2215%2FCJN.06890615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75aR"><div class="casContent"><span class="casTitleNuber">75a</span><div class="casTitle"><span class="NLM_cas:atitle">Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD</span></div><div class="casAuthors">Provenzano, Robert; Besarab, Anatole; Sun, Chao H.; Diamond, Susan A.; Durham, John H.; Cangiano, Jose L.; Aiello, Joseph R.; Novak, James E.; Lee, Tyson; Leong, Robert; Roberts, Brian K.; Saikali, Khalil G.; Hemmerich, Stefan; Szczech, Lynda A.; Yu, Kin-Hung Peony; Neff, Thomas B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">982-991</span>CODEN:
                <span class="NLM_cas:coden">CJASC7</span>;
        ISSN:<span class="NLM_cas:issn">1555-9041</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Background and objectives: Roxadustat (FG-4592), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metab., and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with nondialysis CKD.  Design, setting, participants, & measurements: The 145 patients with nondialysis CKD and Hb ≤10.5 g/dL were randomized into one of six cohorts of approx. 24 patients each with varying roxadustat starting doses (tiered wt. and fixed amts.) and frequencies (two and three times weekly) followed by Hb maintenance with roxadustat one to three times weekly.  Treatment duration was 16 or 24 wk.  I.v. iron was prohibited.  The primary end point was the proportion of patients achieving Hb increase of ≥1.0 g/dL from baseline and Hb of ≥11.0 g/dL by week 17 (16 wk of treatment).  Secondary analyses included mean Hb change from baseline, iron utilization, and serum lipids.  Safety was evaluated by frequency/severity of adverse events.  Results: Of the 145 patients enrolled, 143 were evaluable for efficacy.  Overall, 92% of patients achieved Hb response.  Higher compared with lower starting doses led to earlier achievement of Hb response.  Roxadustat-induced Hb increases were independent of baseline C-reactive protein levels and iron repletion status.  Overall, over the first 16 treatment weeks, hepcidin levels decreased by 16.9% (P = 0.004), reticulocyte Hb content was maintained, and Hb increased by a mean (±SD) of 1.83 (±0.09) g/dL (P<0.001).  Overall mean total cholesterol level was reduced by a mean (±SD) of 26 (±30) mg/dL (P<0.001) after 8 wk of therapy, independent of the use of statins or other lipid-lowering agents.  No drug-related serious adverse events were reported.  Conclusions: In patients with nondialysis CKD who were anemic, various starting dose regimens of roxadustat were well tolerated and achieved anemia correction with reduced serum hepcidin levels.  After anemia correction, Hb was maintained by roxadustat at various dose frequencies without i.v. iron supplementation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVZ7-oE2mfNrVg90H21EOLACvtfcHk0ljXXLuZwf1bzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVSks7bI&md5=710c58a01b4b7c6e2e610273ec82e26b</span></div><a href="/servlet/linkout?suffix=cit75a&amp;dbid=16384&amp;doi=10.2215%2FCJN.06890615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2215%252FCJN.06890615%26sid%3Dliteratum%253Aachs%26aulast%3DProvenzano%26aufirst%3DR.%26aulast%3DBesarab%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DC.%2BH.%26aulast%3DDiamond%26aufirst%3DS.%2BA.%26aulast%3DDurham%26aufirst%3DJ.%2BH.%26aulast%3DCangiano%26aufirst%3DJ.%2BL.%26aulast%3DAiello%26aufirst%3DJ.%2BR.%26aulast%3DNovak%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DLeong%26aufirst%3DR.%26aulast%3DRoberts%26aufirst%3DB.%2BK.%26aulast%3DSaikali%26aufirst%3DK.%2BG.%26aulast%3DHemmerich%26aufirst%3DS.%26aulast%3DSzczech%26aufirst%3DL.%2BA.%26aulast%3DYu%26aufirst%3DK.-H.%2BP.%26aulast%3DNeff%26aufirst%3DT.%2BB.%26atitle%3DOral%2520Hypoxia-Inducible%2520Factor%2520Prolyl%2520Hydroxylase%2520Inhibitor%2520Roxadustat%2520%2528FG-4592%2529%2520for%2520the%2520Treatment%2520of%2520Anemia%2520in%2520Patients%2520with%2520CKD%26jtitle%3DClin.%2520J.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2016%26volume%3D11%26spage%3D982%26epage%3D991%26doi%3D10.2215%2FCJN.06890615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit75b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) Protects against Cisplatin-Induced Acute Kidney Injury</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1042/CS20171625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1042%2FCS20171625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29581249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFamurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=825-838&author=Y.+Yangauthor=X.+Yuauthor=Y.+Zhangauthor=G.+Dingauthor=C.+Zhuauthor=S.+Huangauthor=Z.+Jiaauthor=A.+Zhang&title=Hypoxia-Inducible+Factor+Prolyl+Hydroxylase+Inhibitor+Roxadustat+%28FG-4592%29+Protects+against+Cisplatin-Induced+Acute+Kidney+Injury&doi=10.1042%2FCS20171625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75bR"><div class="casContent"><span class="casTitleNuber">75b</span><div class="casTitle"><span class="NLM_cas:atitle">Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury</span></div><div class="casAuthors">Yang, Yunwen; Yu, Xiaowen; Zhang, Yue; Ding, Guixia; Zhu, Chunhua; Huang, Songming; Jia, Zhanjun; Zhang, Aihua</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">825-838</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Renal hypoxia occurs in acute kidney injury (AKI) of various etiologies.  Activation of hypoxia-inducible transcription factor (HIF) has been identified as an important mechanism of cellular adaptation to low oxygen.  Preconditional HIF activation protects against AKI, suggesting a new approach in AKI treatment.  HIF is degraded under normoxic conditions mediated by oxygen-dependent hydroxylation of specific prolyl residues of the regulative α-subunits by HIF prolyl hydroxylases (PHD).  FG-4592 is a novel, orally active, small-mol. HIF PHD inhibitor for the treatment of anemia in patients with chronic kidney disease (CKD).  The current study aimed to evaluate the effect of FG-4592 (Roxadustat) on cis-diamminedichloroplatinum (cisplatin)-induced kidney injury.  In mice, pretreatment with FG-4592 markedly ameliorated cisplatin-induced kidney injury as shown by the improved renal function (blood urea nitrogen (BUN), serum creatinine (Scr), and cystatin C) and kidney morphol. (periodic acid-Schiff (PAS) staining) in line with a robust blockade of renal tubular injury markers of kidney injury mol. 1 (KIM-1) and neutrophil gelatinase-assocd. lipocalin (NGAL).  Meanwhile, the renal apoptosis and inflammation induced by cisplatin were also strikingly attenuated in FG-4592-treated mice.  Along with the protective effects shown above, FG-4592 pretreatment strongly enhanced HIF-1α in tubular cells, as well as the expressions of HIF target genes.  FG-4592 alone did not affect the renal function and morphol. in mice.  In vitro, FG-4592 treatment significantly up-regulated HIF-1α and protected the tubular cells against cisplatin-induced apoptosis.  In summary, FG-4592 treatment remarkably ameliorated the cisplatin-induced kidney injury possibly through the stabilization of HIF.  Thus, besides the role in treating CKD anemia, the clin. use of FG-4592 also could be extended to AKI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcKx-vnkcRmrVg90H21EOLACvtfcHk0ljXXLuZwf1bzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFamurvE&md5=7232accbdd48f1d0186ee96ff512d94a</span></div><a href="/servlet/linkout?suffix=cit75b&amp;dbid=16384&amp;doi=10.1042%2FCS20171625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20171625%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DHypoxia-Inducible%2520Factor%2520Prolyl%2520Hydroxylase%2520Inhibitor%2520Roxadustat%2520%2528FG-4592%2529%2520Protects%2520against%2520Cisplatin-Induced%2520Acute%2520Kidney%2520Injury%26jtitle%3DClin.%2520Sci.%26date%3D2018%26volume%3D132%26spage%3D825%26epage%3D838%26doi%3D10.1042%2FCS20171625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span>; <span class="NLM_string-name">Jin, H.</span>; <span class="NLM_string-name">Zheng, Y.</span>; <span class="NLM_string-name">Huang, M.</span>; <span class="NLM_string-name">Meng, X.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Roxadustat Intermediate 4-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate for Treating Chronic Anemia</span>. <span class="NLM_patent">CN106478504A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=F.+Zhou&author=H.+Jin&author=Y.+Zheng&author=M.+Huang&author=X.+Meng&title=Preparation+Method+of+Roxadustat+Intermediate+4-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate+for+Treating+Chronic+Anemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26atitle%3DPreparation%2520Method%2520of%2520Roxadustat%2520Intermediate%25204-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate%2520for%2520Treating%2520Chronic%2520Anemia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit76b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Roxadustat for Treatment of Chronic Nephrosis and Terminal Stage Nephrosis-Related Anaemia from 5-Nitrophenylethylamine</span>. <span class="NLM_patent">CN107602466A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=T.+Sun&title=Process+for+Preparation+of+Roxadustat+for+Treatment+of+Chronic+Nephrosis+and+Terminal+Stage+Nephrosis-Related+Anaemia+from+5-Nitrophenylethylamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DT.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Roxadustat%2520for%2520Treatment%2520of%2520Chronic%2520Nephrosis%2520and%2520Terminal%2520Stage%2520Nephrosis-Related%2520Anaemia%2520from%25205-Nitrophenylethylamine%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit76c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Roxadustat for Treating Chronic Kidney Disease and Anemia Associated with End-Stage Renal Disease</span>. <span class="NLM_patent">CN107698505A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=T.+Sun&title=Preparation+Method+of+Roxadustat+for+Treating+Chronic+Kidney+Disease+and+Anemia+Associated+with+End-Stage+Renal+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DT.%26atitle%3DPreparation%2520Method%2520of%2520Roxadustat%2520for%2520Treating%2520Chronic%2520Kidney%2520Disease%2520and%2520Anemia%2520Associated%2520with%2520End-Stage%2520Renal%2520Disease%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit76d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span>; <span class="NLM_string-name">Liu, W.</span>; <span class="NLM_string-name">Wei, X.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Song, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Roxadustat</span>. <span class="NLM_patent">WO2018072662A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Yang&author=W.+Liu&author=X.+Wei&author=Y.+Wang&author=Y.+Song&title=Preparation+Method+of+Roxadustat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DM.%26atitle%3DPreparation%2520Method%2520of%2520Roxadustat%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit76e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, R.</span>; <span class="NLM_string-name">Li, C.</span>; <span class="NLM_string-name">Qiao, D.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Roxadustat</span>. <span class="NLM_patent">CN108017583A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=R.+Han&author=C.+Li&author=D.+Qiao&title=Method+for+Preparing+Roxadustat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DR.%26atitle%3DMethod%2520for%2520Preparing%2520Roxadustat%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit76f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Roxadustat</span>. <span class="NLM_patent">CN108383787A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Z.+Wang&title=Method+for+Preparing+Roxadustat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DMethod%2520for%2520Preparing%2520Roxadustat%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit76g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span>; <span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Roxadustat (Fg-459) for Treating Chronic Anaemia</span>. <span class="NLM_patent">CN108424388A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=X.+Zheng&author=Y.+Zhang&title=Preparation+Method+of+Roxadustat+%28Fg-459%29+for+Treating+Chronic+Anaemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DPreparation%2520Method%2520of%2520Roxadustat%2520%2528Fg-459%2529%2520for%2520Treating%2520Chronic%2520Anaemia%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit76h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of Roxadustat, and Intermediate Compound Thereof</span>. <span class="NLM_patent">CN108794397A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Xu&title=Synthesis+Method+of+Roxadustat%2C+and+Intermediate+Compound+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26atitle%3DSynthesis%2520Method%2520of%2520Roxadustat%252C%2520and%2520Intermediate%2520Compound%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arend, M. P.</span>; <span class="NLM_string-name">Flippin, L. A.</span>; <span class="NLM_string-name">Guenzler-Pukall, V.</span>; <span class="NLM_string-name">Ho, W.-B.</span>; <span class="NLM_string-name">Turtle, E. D.</span>; <span class="NLM_string-name">Du, X.</span></span> <span> </span><span class="NLM_article-title">Preparation of Isoquinolinecarboxamides and Their Use in Mediating Hypoxia Inducible Factor and Increasing Endogenous Erythropoietin</span>. <span class="NLM_patent">WO2004108681A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=M.+P.+Arend&author=L.+A.+Flippin&author=V.+Guenzler-Pukall&author=W.-B.+Ho&author=E.+D.+Turtle&author=X.+Du&title=Preparation+of+Isoquinolinecarboxamides+and+Their+Use+in+Mediating+Hypoxia+Inducible+Factor+and+Increasing+Endogenous+Erythropoietin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DArend%26aufirst%3DM.%2BP.%26atitle%3DPreparation%2520of%2520Isoquinolinecarboxamides%2520and%2520Their%2520Use%2520in%2520Mediating%2520Hypoxia%2520Inducible%2520Factor%2520and%2520Increasing%2520Endogenous%2520Erythropoietin%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witschi, C.</span>; <span class="NLM_string-name">Park, J. M.</span>; <span class="NLM_string-name">Thompson, M. D.</span>; <span class="NLM_string-name">Martinelli, M. J.</span>; <span class="NLM_string-name">Yeowell, D. A.</span>; <span class="NLM_string-name">Arend, M. P.</span></span> <span> </span><span class="NLM_article-title">Crystalline Forms of a Isoquinolinecarbonylaminoacetic Acid Derivative as a Prolyl Hydroxylase Inhibitor</span>. <span class="NLM_patent">WO2014014835A2</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+Witschi&author=J.+M.+Park&author=M.+D.+Thompson&author=M.+J.+Martinelli&author=D.+A.+Yeowell&author=M.+P.+Arend&title=Crystalline+Forms+of+a+Isoquinolinecarbonylaminoacetic+Acid+Derivative+as+a+Prolyl+Hydroxylase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWitschi%26aufirst%3DC.%26atitle%3DCrystalline%2520Forms%2520of%2520a%2520Isoquinolinecarbonylaminoacetic%2520Acid%2520Derivative%2520as%2520a%2520Prolyl%2520Hydroxylase%2520Inhibitor%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chedid, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayvargiya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camilleri, M.</span></span> <span> </span><span class="NLM_article-title">Elobixibat for the Treatment of Constipation</span>. <i>Expert Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">951</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1080/17474124.2018.1522248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F17474124.2018.1522248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30204504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKjurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=951-960&author=V.+Chedidauthor=P.+Vijayvargiyaauthor=M.+Camilleri&title=Elobixibat+for+the+Treatment+of+Constipation&doi=10.1080%2F17474124.2018.1522248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Elobixibat for the treatment of constipation</span></div><div class="casAuthors">Chedid, Victor; Vijayvargiya, Priya; Camilleri, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">951-960</span>CODEN:
                <span class="NLM_cas:coden">ERGHBD</span>;
        ISSN:<span class="NLM_cas:issn">1747-4124</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic idiopathic constipation (CC) is highly prevalent worldwide.  A subset of patients with CC have reduced fecal (and by inference, intra-colonic) bile acids (BA).  Elobixibat, a locally-acting ileal bile acid transporter (IBAT) inhibitor, leads to increased BA delivery to the colon and represents a new class of treatment for CC.  BAs accelerate colonic transit and increase colonic secretion.  Therefore, IBAT inhibitors have potential to treat patients with CC. : Rationale for IBAT inhibitor in therapeutics, and preclin. and clin. pharmacol. of elobixibat: In vitro, elobixibat is a highly potent, selective IBAT inhibitor.  In humans, elobixibat accelerated colonic transit.  In phase 2A, 2B and 3 studies in CC, elobixibat was efficacious, well tolerated and safe.  An open-label, phase 3 trial (52 wk) confirmed the safety of elobixibat.  Elobixibat reduces LDL cholesterol, increases serum GLP-1, and has potential in metabolic syndrome.: Uniquely among current treatments of CC, elobixibat stimulates both motor and secretory functions in the colon.  These dual effects suggest that, when approved, elobixibat may be a first-line choice for constipation assocd. with colonic BA deficiency and a second-line treatment for all patients with CC and constipation-predominant irritable bowel syndrome.  Further studies are required to confirm efficacy for relief of CC.  Once approved, elobixibat will likely become a second-line choice for treatment of CC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3b2aP_4FRrVg90H21EOLACvtfcHk0liwC-KNwFY_yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKjurrM&md5=4a1ed28f27fc90216477dca9d62d6b35</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1080%2F17474124.2018.1522248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474124.2018.1522248%26sid%3Dliteratum%253Aachs%26aulast%3DChedid%26aufirst%3DV.%26aulast%3DVijayvargiya%26aufirst%3DP.%26aulast%3DCamilleri%26aufirst%3DM.%26atitle%3DElobixibat%2520for%2520the%2520Treatment%2520of%2520Constipation%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2018%26volume%3D12%26spage%3D951%26epage%3D960%26doi%3D10.1080%2F17474124.2018.1522248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camilleri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirapongsathorn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayvargiya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erwin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murad, M. H.</span></span> <span> </span><span class="NLM_article-title">Comparison of Efficacy of Pharmacological Treatments for Chronic Idiopathic Constipation: A Systematic Review and Network Meta-Analysis</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1611</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2016-311835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1136%2Fgutjnl-2016-311835" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27287486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVShurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1611&author=A.+D.+Nelsonauthor=M.+Camilleriauthor=S.+Chirapongsathornauthor=P.+Vijayvargiyaauthor=N.+Valentinauthor=A.+Shinauthor=P.+J.+Erwinauthor=Z.+Wangauthor=M.+H.+Murad&title=Comparison+of+Efficacy+of+Pharmacological+Treatments+for+Chronic+Idiopathic+Constipation%3A+A+Systematic+Review+and+Network+Meta-Analysis&doi=10.1136%2Fgutjnl-2016-311835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis</span></div><div class="casAuthors">Nelson, Alfred D.; Camilleri, Michael; Chirapongsathorn, Sakkarin; Vijayvargiya, Priya; Valentin, Nelson; Shin, Andrea; Erwin, Patricia J.; Wang, Zhen; Murad, M. Hassan</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1611-1623</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-anal.  Data sources We conducted searches (inception to May 2015) of MEDLINE, EMBASE, Scopus and Cochrane Central, as well as original data from authors or drug companies for the medications used for CIC.  Study selection Phase IIB and phase III randomised, placebo-controlled trials (RCT) of ≥4 wk' treatment for CIC in adults with Rome II or III criteria for functional constipation; trials included at least one of four end points.  Data extn. and synthesis Two investigators independently evaluated all full-text articles that met inclusion criteria and extd. data for primary and secondary end points, risk of bias and quality of evidence.  Outcomes Primary end points were ≥3 complete spontaneous bowel movements (CSBM)/wk and increase over baseline by ≥1 CSBM/wk.  Secondary end points were change from baseline (Δb) in the no. of SBM/wk and Δb CSBM/wk.  Results Twenty-one RCTs (9189 patients) met inclusion and end point criteria: 9 prucalopride, 3 lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium picosulfate (NaP).  All prespecified end points were unavailable in four polyethylene glycol studies.  Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥3 CSBM/wk end point.  No drug was superior at improving the primary end points on network metaanal.  Bisacodyl appeared superior to the other drugs for the secondary end point, Δb in no. of SBM/wk.  Conclusions Current drugs for CIC show similar efficacy.  Bisacodyl may be superior to prescription medications for Δb in the no. of SBM/wk in CIC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruhifelM1PN7Vg90H21EOLACvtfcHk0liwC-KNwFY_yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVShurvE&md5=e2ee393680fd4ffddd9e96417db85be5</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2016-311835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2016-311835%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DA.%2BD.%26aulast%3DCamilleri%26aufirst%3DM.%26aulast%3DChirapongsathorn%26aufirst%3DS.%26aulast%3DVijayvargiya%26aufirst%3DP.%26aulast%3DValentin%26aufirst%3DN.%26aulast%3DShin%26aufirst%3DA.%26aulast%3DErwin%26aufirst%3DP.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMurad%26aufirst%3DM.%2BH.%26atitle%3DComparison%2520of%2520Efficacy%2520of%2520Pharmacological%2520Treatments%2520for%2520Chronic%2520Idiopathic%2520Constipation%253A%2520A%2520Systematic%2520Review%2520and%2520Network%2520Meta-Analysis%26jtitle%3DGut%26date%3D2017%26volume%3D66%26spage%3D1611%26doi%3D10.1136%2Fgutjnl-2016-311835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miner, P. B.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Elobixibat, the First-in-Class Ileal Bile Acid Transporter Inhibitor, for the Treatment of Chronic Idiopathic Constipation</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1381</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1080/14656566.2018.1508450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F14656566.2018.1508450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30129377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1381-1388&author=P.+B.+Miner&title=Elobixibat%2C+the+First-in-Class+Ileal+Bile+Acid+Transporter+Inhibitor%2C+for+the+Treatment+of+Chronic+Idiopathic+Constipation&doi=10.1080%2F14656566.2018.1508450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation</span></div><div class="casAuthors">Miner, Philip B. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1381-1388</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Elobixibat is the first in class ileal bile acid transporter (IBAT) inhibitor.  IBAT inhibitors block ileal absorption of bile acids by: (1) interrupting the enterohepatic circulation of bile resulting in a fall in serum cholesterol and (2) increasing the delivery of bile acids into the colon.  Increasing colonic bile acids causes mucosal fluid secretion and enhances colonic motor activity.  Changes in colonic physiol. may be useful in treating constipation.  In this review, the author reviews the prevalence and medical cost of Chronic Idiopathic Constipation (CIC) and the heterogeneity of the CIC patient population as a complicating factor in drug development and clin. care.  And also reviews the history of Bile Acid cathartics and the complex pharmacophysiol. of bile therapy with fluid and electrolyte shifts, colonic motor function changes and mucosal immunol. activation.  Finally, the author reviews elobixabat development and the clin. trials that demonstrate improvement in constipation.  The early phases of elobixibat development provide confirmation of high IBAT binding affinity which translates into the expected inhibition of enterohepatic bile acid circulation and enhanced delivery of ileal bile acids to the colon assocd. with expected physiol. changes.  Elobixibat as a treatment of CIC appears promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6CcsditpIz7Vg90H21EOLACvtfcHk0lh-F66xAH4RiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLfF&md5=5ba00fab2446a3a735368df82bb5429a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1508450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1508450%26sid%3Dliteratum%253Aachs%26aulast%3DMiner%26aufirst%3DP.%2BB.%26atitle%3DElobixibat%252C%2520the%2520First-in-Class%2520Ileal%2520Bile%2520Acid%2520Transporter%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Idiopathic%2520Constipation%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26spage%3D1381%26epage%3D1388%26doi%3D10.1080%2F14656566.2018.1508450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Starke, I.</span>; <span class="NLM_string-name">Dahlstrom, M.</span>; <span class="NLM_string-name">Blomberg, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of N-[(8-Benzothiazepinyloxy)acetyl]phenylglycinates and Analogs as Ileal Bile Acid Transport Inhibitors</span>. <span class="NLM_patent">WO2002050051A1</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=I.+Starke&author=M.+Dahlstrom&author=D.+Blomberg&title=Preparation+of+N-%5B%288-Benzothiazepinyloxy%29acetyl%5Dphenylglycinates+and+Analogs+as+Ileal+Bile+Acid+Transport+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStarke%26aufirst%3DI.%26atitle%3DPreparation%2520of%2520N-%255B%25288-Benzothiazepinyloxy%2529acetyl%255Dphenylglycinates%2520and%2520Analogs%2520as%2520Ileal%2520Bile%2520Acid%2520Transport%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit82b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Starke, I.</span>; <span class="NLM_string-name">Dahlstrom, M.</span>; <span class="NLM_string-name">Blomberg, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1,5-Benzothiazepines for Use as Hypolipidemics</span>. <span class="NLM_patent">WO2001066533A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=I.+Starke&author=M.+Dahlstrom&author=D.+Blomberg&title=Preparation+of+1%2C5-Benzothiazepines+for+Use+as+Hypolipidemics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStarke%26aufirst%3DI.%26atitle%3DPreparation%2520of%25201%252C5-Benzothiazepines%2520for%2520Use%2520as%2520Hypolipidemics%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit82c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Starke, I.</span>; <span class="NLM_string-name">Dahlstrom, M. U. J.</span>; <span class="NLM_string-name">Blomberg, D.</span>; <span class="NLM_string-name">Alenfalk, S.</span>; <span class="NLM_string-name">Nordberg, P.</span>; <span class="NLM_string-name">Wallberg, A. C.</span>; <span class="NLM_string-name">Bostrom, S. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Benzothiazepine Derivatives for Potential Use as Ileal Bile Acid Transport Inhibitors for the Treatment of Hyperlipidemia</span>. <span class="NLM_patent">WO2003020710A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=I.+Starke&author=M.+U.+J.+Dahlstrom&author=D.+Blomberg&author=S.+Alenfalk&author=P.+Nordberg&author=A.+C.+Wallberg&author=S.+J.+Bostrom&title=Preparation+of+Benzothiazepine+Derivatives+for+Potential+Use+as+Ileal+Bile+Acid+Transport+Inhibitors+for+the+Treatment+of+Hyperlipidemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStarke%26aufirst%3DI.%26atitle%3DPreparation%2520of%2520Benzothiazepine%2520Derivatives%2520for%2520Potential%2520Use%2520as%2520Ileal%2520Bile%2520Acid%2520Transport%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Hyperlipidemia%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Take, Y.</span></span> <span> </span><span class="NLM_article-title">Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.244202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1124%2Fjpet.117.244202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29180359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2rtLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2018&pages=275-286&author=N.+Takahashiauthor=Y.+Take&title=Tegoprazan%2C+a+Novel+Potassium-Competitive+Acid+Blocker+to+Control+Gastric+Acid+Secretion+and+Motility&doi=10.1124%2Fjpet.117.244202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility</span></div><div class="casAuthors">Takahashi, Nobuyuki; Take, Yukinori</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-286</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Tegoprazan [(S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-carboxamide], a potassium-competitive acid blocker (P-CAB), is a novel potent and highly selective inhibitor of gastric H+/K+-ATPase.  Tegoprazan inhibited porcine, canine, and human H+/K+-ATPases in vitro with IC50 values ranging from 0.29 to 0.52μM, while that for canine kidney H+/K+-ATPase was more than 100μM.  A kinetic anal. revealed that tegoprazan inhibited H+/K+-ATPase in a potassium-competitive manner and the binding was reversible.  Oral single administrations of tegoprazan ranging from 0.3 to 30 mg/kg in dogs were well absorbed into the blood stream and distributed in gastric tissue/fluid higher than in plasma.  Tegoprazan potently inhibited histamine-induced gastric acid secretion in dogs, and a complete inhibition was obsd. at 1.0 mg/kg starting from 1 h after administration.  Moreover, an oral administration of tegoprazan at 1 and 3 mg/kg reversed the pentagastrin-induced acidified gastric pH to the neutral range.  Interestingly, 3 mg/kg tegoprazan immediately evoked a gastric phase III contraction of the migrating motor complex in pentagastrin-treated dogs and similar effects was obsd. with the other P-CAB, vonoprazan.  Tegoprazan is the novel P-CAB that may provide a new option for the therapy of gastric acid-related and motility-impaired diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8WdBeQ_mvpLVg90H21EOLACvtfcHk0lh-F66xAH4RiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2rtLbJ&md5=498d11b342041873399ec66ccfd5c5b3</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.244202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.244202%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DTake%26aufirst%3DY.%26atitle%3DTegoprazan%252C%2520a%2520Novel%2520Potassium-Competitive%2520Acid%2520Blocker%2520to%2520Control%2520Gastric%2520Acid%2520Secretion%2520and%2520Motility%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D364%26spage%3D275%26epage%3D286%26doi%3D10.1124%2Fjpet.117.244202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, I.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, I.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jee, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, P.-L.</span></span> <span> </span><span class="NLM_article-title">Randomised Phase 3 Trial: Tegoprazan, a Novel Potassium-Competitive Acid Blocker, Vs. Esomeprazole in Patients with Erosive Oesophagitis</span>. <i>Aliment. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1111/apt.15185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1111%2Fapt.15185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30843245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkslaitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=864-872&author=K.+J.+Leeauthor=B.+K.+Sonauthor=G.+H.+Kimauthor=H.-K.+Jungauthor=H.-Y.+Jungauthor=I.-K.+Chungauthor=I.-K.+Sungauthor=J.+I.+Kimauthor=J.+H.+Kimauthor=J.+S.+Leeauthor=J.+G.+Kwonauthor=J.+H.+Parkauthor=K.+C.+Huhauthor=K.+S.+Parkauthor=M.-I.+Parkauthor=N.+Kimauthor=O.+Y.+Leeauthor=S.+R.+Jeeauthor=S.+K.+Leeauthor=S.+J.+Younauthor=S.+K.+Kimauthor=S.+T.+Leeauthor=S.+J.+Hongauthor=S.+C.+Choiauthor=T.+N.+Kimauthor=Y.+H.+Younauthor=H.+J.+Parkauthor=M.+J.+Kangauthor=C.+H.+Parkauthor=B.+T.+Kimauthor=S.+Younauthor=G.+S.+Songauthor=P.-L.+Rhee&title=Randomised+Phase+3+Trial%3A+Tegoprazan%2C+a+Novel+Potassium-Competitive+Acid+Blocker%2C+Vs.+Esomeprazole+in+Patients+with+Erosive+Oesophagitis&doi=10.1111%2Fapt.15185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis</span></div><div class="casAuthors">Lee, Kwang Jae; Son, Byoung Kwan; Kim, Gwang Ha; Jung, Hye-Kyung; Jung, Hwoon-Yong; Chung, Il-Kwun; Sung, In-Kyung; Kim, Jin Il; Kim, Jong Hyeok; Lee, Joon Seong; Kwon, Joong Goo; Park, Jung Ho; Huh, Kyu Chan; Park, Kyung Sik; Park, Moo-In; Kim, Nayoung; Lee, Oh Young; Jee, Sam Ryong; Lee, Sang Kil; Youn, Sei Jin; Kim, Sung Kook; Lee, Soo Teik; Hong, Su Jin; Choi, Suck Chei; Kim, Tae Nyeun; Youn, Young Hoon; Park, Hyo Ju; Kang, Min Ja; Park, Chi Hye; Kim, Bong Tae; Youn, Sangjun; Song, Geun Seog; Rhee, Poong-Lyul</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">864-872</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clin. benefit in acid-related disorders.  Aim : To confirm the non-inferiority of tegoprazan to esomeprazole in patients with erosive oesophagitis (EE).  Methods : In this multicentre, randomised, double-blind, parallel-group comparison study, 302 Korean patients with endoscopically confirmed EE (Los Angeles Classification Grades A-D) were randomly allocated to either tegoprazan (50 or 100 mg) or esomeprazole (40 mg) treatment groups for 4 or 8 wk.  The primary endpoint was the cumulative proportion of patients with healed EE confirmed by endoscopy up to 8 wk from treatment initiation.  Symptoms, safety and tolerability were also assessed.  Results : The cumulative healing rates at week 8 were 98.9% (91/92), 98.9% (90/91) and 98.9% (87/88) for tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg, resp.  Both doses of tegoprazan were non-inferior to esomeprazole 40 mg.  The incidence of adverse events was comparable among the groups, and tegoprazan was well-tolerated.  Conclusion : Once daily administration of tegoprazan 50 or 100 mg showed non-inferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZeNan9K-TibVg90H21EOLACvtfcHk0ljm2LutYVCoWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkslaitbc%253D&md5=889642f934ab5feac86f8812c8380062</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1111%2Fapt.15185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fapt.15185%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DSon%26aufirst%3DB.%2BK.%26aulast%3DKim%26aufirst%3DG.%2BH.%26aulast%3DJung%26aufirst%3DH.-K.%26aulast%3DJung%26aufirst%3DH.-Y.%26aulast%3DChung%26aufirst%3DI.-K.%26aulast%3DSung%26aufirst%3DI.-K.%26aulast%3DKim%26aufirst%3DJ.%2BI.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DKwon%26aufirst%3DJ.%2BG.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DHuh%26aufirst%3DK.%2BC.%26aulast%3DPark%26aufirst%3DK.%2BS.%26aulast%3DPark%26aufirst%3DM.-I.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DO.%2BY.%26aulast%3DJee%26aufirst%3DS.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DYoun%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DS.%2BT.%26aulast%3DHong%26aufirst%3DS.%2BJ.%26aulast%3DChoi%26aufirst%3DS.%2BC.%26aulast%3DKim%26aufirst%3DT.%2BN.%26aulast%3DYoun%26aufirst%3DY.%2BH.%26aulast%3DPark%26aufirst%3DH.%2BJ.%26aulast%3DKang%26aufirst%3DM.%2BJ.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DKim%26aufirst%3DB.%2BT.%26aulast%3DYoun%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DG.%2BS.%26aulast%3DRhee%26aufirst%3DP.-L.%26atitle%3DRandomised%2520Phase%25203%2520Trial%253A%2520Tegoprazan%252C%2520a%2520Novel%2520Potassium-Competitive%2520Acid%2520Blocker%252C%2520Vs.%2520Esomeprazole%2520in%2520Patients%2520with%2520Erosive%2520Oesophagitis%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D49%26spage%3D864%26epage%3D872%26doi%3D10.1111%2Fapt.15185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanazawa, T.</span>; <span class="NLM_string-name">Koike, H.</span></span> <span> </span><span class="NLM_article-title">Chromane Substituted Benzimidazole Derivatives</span>. <span class="NLM_patent">US20070142448A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Hanazawa&author=H.+Koike&title=Chromane+Substituted+Benzimidazole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHanazawa%26aufirst%3DT.%26atitle%3DChromane%2520Substituted%2520Benzimidazole%2520Derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiaolong, Q.</span>; <span class="NLM_string-name">Lin, H.</span>; <span class="NLM_string-name">Wenbo, L.</span>; <span class="NLM_string-name">Ping, Z.</span>; <span class="NLM_string-name">Lingling, C.</span>; <span class="NLM_string-name">Xingang, Z.</span>; <span class="NLM_string-name">Ping, W.</span>; <span class="NLM_string-name">Donghui, W.</span>; <span class="NLM_string-name">Lei, C.</span>; <span class="NLM_string-name">Jun, C.</span></span> <span> </span><span class="NLM_article-title">Method for Synthetizing Tegoprazan Chiral Alcohol</span>. <span class="NLM_patent">CN109320485</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Q.+Xiaolong&author=H.+Lin&author=L.+Wenbo&author=Z.+Ping&author=C.+Lingling&author=Z.+Xingang&author=W.+Ping&author=W.+Donghui&author=C.+Lei&author=C.+Jun&title=Method+for+Synthetizing+Tegoprazan+Chiral+Alcohol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXiaolong%26aufirst%3DQ.%26atitle%3DMethod%2520for%2520Synthetizing%2520Tegoprazan%2520Chiral%2520Alcohol%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Elagolix: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1501</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0977-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0977-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30194661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ylsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1501-1508&author=Y.+N.+Lamb&title=Elagolix%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0977-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Elagolix: First Global Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1501-1508</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Elagolix (ORILISSA), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the treatment of reproductive hormone-dependent disorders in women.  In July 2018, the US FDA approved elagolix tablets for the management of moderate to severe pain assocd. with endometriosis.  This approval was based on pos. results in two replicate phase III trials; addnl. phase III trials in the USA, Canada and Puerto Rico are currently evaluating elagolix as both monotherapy and in combination with low-dose hormone add-back therapy in the same indication.  Elagolix with and without low-dose hormone add-back therapy is also undergoing phase III clin. development for heavy menstrual bleeding assocd. with uterine fibroids in the aforementioned locations.  This article summarizes the milestones in the development of elagolix leading to its first approval for the management of moderate to severe pain assocd. with endometriosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozwY9v1KHNcLVg90H21EOLACvtfcHk0ljm2LutYVCoWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ylsLzE&md5=984d0fcdfc38444ac282e0d6f519c1b7</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0977-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0977-4%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DElagolix%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1501%26epage%3D1508%26doi%3D10.1007%2Fs40265-018-0977-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barra, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, S.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive Review of Hormonal and Biological Therapies for Endometriosis: Latest Developments</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1080/14712598.2019.1581761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F14712598.2019.1581761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30763525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFSku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=343-360&author=F.+Barraauthor=G.+Grandiauthor=M.+Tantariauthor=C.+Scalaauthor=F.+Facchinettiauthor=S.+Ferrero&title=A+Comprehensive+Review+of+Hormonal+and+Biological+Therapies+for+Endometriosis%3A+Latest+Developments&doi=10.1080%2F14712598.2019.1581761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of hormonal and biological therapies for endometriosis: latest developments</span></div><div class="casAuthors">Barra, Fabio; Grandi, Giovanni; Tantari, Matteo; Scala, Carolina; Facchinetti, Fabio; Ferrero, Simone</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">343-360</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Endometriosis is a chronic benign estrogen-dependent disease characterized by the presence of endometriotic glands and stroma outside the uterine cavity.  Although combined hormonal contraceptives and progestins, currently available first-line treatments for endometriosis, are efficacious and well tolerated for treating disease-related pain, some women experience partial or no improvement of pain or its recurrence is frequent after discontinuation of the therapies.  For these reasons, new drugs are under investigation for the treatment of endometriosis.: This review aims to give to the reader a complete and updated overview of hormonal and biol. therapies for the treatment of endometriosis, underlining the latest developments in this field of research.: Among the new drugs investigated, late clin. trials on gonadotropin-releasing hormone (GnRH) antagonists and aromatase inhibitors (AIs) have demonstrated the most promising results.  For this reason, elagolix, a new GnRH-antagonist, recently received the approval by the Food and Drug Administration (FDA) for treating pain assocd. to endometriosis.  Other drugs with innovative targets have been identified, but the majority of these compds. have only been evaluated in pre-clin. studies or early clin. trials.  Thus, a further extensive clin. research is necessary to better elucidate their pharmacol. characteristics, their efficacy, and safety for the treatment of this benign chronic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp27SZ7oHUK1LVg90H21EOLACvtfcHk0ljm2LutYVCoWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFSku7g%253D&md5=7fc04c9ff607504a28bdd191dce41ed0</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1080%2F14712598.2019.1581761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14712598.2019.1581761%26sid%3Dliteratum%253Aachs%26aulast%3DBarra%26aufirst%3DF.%26aulast%3DGrandi%26aufirst%3DG.%26aulast%3DTantari%26aufirst%3DM.%26aulast%3DScala%26aufirst%3DC.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DFerrero%26aufirst%3DS.%26atitle%3DA%2520Comprehensive%2520Review%2520of%2520Hormonal%2520and%2520Biological%2520Therapies%2520for%2520Endometriosis%253A%2520Latest%2520Developments%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2019%26volume%3D19%26spage%3D343%26epage%3D360%26doi%3D10.1080%2F14712598.2019.1581761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pokrzywinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snabes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surrey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, K. S.</span></span> <span> </span><span class="NLM_article-title">Impact of Elagolix on Work Loss Due to Endometriosis-Associated Pain: Estimates Based on the Results of Two Phase III Clinical Trials</span>. <i>Fertil. Steril.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1016/j.fertnstert.2019.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.fertnstert.2019.04.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=31227284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2kur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2019&pages=545-551&author=R.+M.+Pokrzywinskiauthor=A.+M.+Solimanauthor=J.+Chenauthor=M.+Snabesauthor=M.+P.+Diamondauthor=E.+Surreyauthor=K.+S.+Coyne&title=Impact+of+Elagolix+on+Work+Loss+Due+to+Endometriosis-Associated+Pain%3A+Estimates+Based+on+the+Results+of+Two+Phase+III+Clinical+Trials&doi=10.1016%2Fj.fertnstert.2019.04.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89aR"><div class="casContent"><span class="casTitleNuber">89a</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials</span></div><div class="casAuthors">Pokrzywinski, Robin M.; Soliman, Ahmed M.; Chen, Jun; Snabes, Michael; Diamond, Michael P.; Surrey, Eric; Coyne, Karin S.</div><div class="citationInfo"><span class="NLM_cas:title">Fertility and Sterility</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">545-551</span>CODEN:
                <span class="NLM_cas:coden">FESTAS</span>;
        ISSN:<span class="NLM_cas:issn">0015-0282</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">To est. the impact of elagolix on work loss due to endometriosis-assocd. pain.  Post hoc anal. of data from the Elaris I and II clin. trials.Not applicable.  Employed women ages 18-49 years with moderate-to-severe endometriosis-assocd. pain.  In the two trials, participants were randomized to 6 mo of treatment with placebo, elagolix 150 mg once a day, or elagolix 200 mg twice a day.  Data on planned work hours, presenteeism, absenteeism, and total work loss (absenteeism + presenteeism) at baseline and month 3 were collected using the Health-Related Productivity Questionnaire.  This anal. included employed participants from EM-I (n = 672) and EM-II (n = 626).  Between baseline and month 3, compared with participants treated with placebo, participants treated with elagolix 150 mg once a day gained > 2 h total work/wk (EM-I, 2.20 ± 1.03; EM-II, 2.65 ± 1.14).  Participants treated with 200 mg twice a day gained > 4 h total work/wk (EM-I, 4.91 ± 1.04; EM-II, 4.64 ± 1.14).  Both absenteeism and presenteeism were reduced, although most of the gain was due to reduced presenteeism.  Estd. cost savings after 6 mo of treatment with elagolix were > $1,500 U.  S. at 150 mg once a day and > $3,300 U.  S. at 200 mg twice a day.  Compared with placebo, treating moderate-to-severe endometriosis-assocd. pain with elagolix reduced absenteeism and improved productivity in employed women, which should result in cost savings.  NCT01620528 (EM-I) and NCT01931670 (EM-II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTDy7myDsC3LVg90H21EOLACvtfcHk0ljZCLcdrnzqsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2kur%252FJ&md5=9279bdbdaf942c635f245a9fb4b31574</span></div><a href="/servlet/linkout?suffix=cit89a&amp;dbid=16384&amp;doi=10.1016%2Fj.fertnstert.2019.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fertnstert.2019.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DPokrzywinski%26aufirst%3DR.%2BM.%26aulast%3DSoliman%26aufirst%3DA.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSnabes%26aufirst%3DM.%26aulast%3DDiamond%26aufirst%3DM.%2BP.%26aulast%3DSurrey%26aufirst%3DE.%26aulast%3DCoyne%26aufirst%3DK.%2BS.%26atitle%3DImpact%2520of%2520Elagolix%2520on%2520Work%2520Loss%2520Due%2520to%2520Endometriosis-Associated%2520Pain%253A%2520Estimates%2520Based%2520on%2520the%2520Results%2520of%2520Two%2520Phase%2520III%2520Clinical%2520Trials%26jtitle%3DFertil.%2520Steril.%26date%3D2019%26volume%3D112%26spage%3D545%26epage%3D551%26doi%3D10.1016%2Fj.fertnstert.2019.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit89b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sidduri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping Lou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huby, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwinge, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renzetti, L. M.</span></span> <span> </span><span class="NLM_article-title">N-Cycloalkanoyl-L-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2475</span>– <span class="NLM_lpage">2478</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00386-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0960-894X%2802%2900386-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=12161161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvVGjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=2475-2478&author=A.+Sidduriauthor=J.+W.+Tilleyauthor=K.+Hullauthor=J.+Ping+Louauthor=G.+Kaplanauthor=A.+Sheffronauthor=L.+Chenauthor=R.+Campbellauthor=R.+Guthrieauthor=T.-N.+Huangauthor=N.+Hubyauthor=K.+Rowanauthor=V.+Schwingeauthor=L.+M.+Renzetti&title=N-Cycloalkanoyl-L-Phenylalanine+Derivatives+as+VCAM%2FVLA-4+Antagonists&doi=10.1016%2FS0960-894X%2802%2900386-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89bR"><div class="casContent"><span class="casTitleNuber">89b</span><div class="casTitle"><span class="NLM_cas:atitle">N-Cycloalkanoyl-l-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists</span></div><div class="casAuthors">Sidduri, Achyutharao; Tilley, Jefferson W.; Hull, Kenneth; Lou, Jian Ping; Kaplan, Gerry; Sheffron, Allen; Chen, Li; Campbell, Robert; Guthrie, Robert; Huang, Tai-Nan; Huby, Nicholas; Rowan, Karen; Schwinge, Virginia; Renzetti, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2475-2478</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A systematic structure-activity relationship investigation of the lead compd., cycloalkanoyl phenylalanine deriv. resulted the identification of several N-[(substituted alkyl)cycloalkanoyl]-4-[((2,6-dichlorophenyl)carbonyl)amino]-l-phenylalanine derivs. as potent VCAM/VLA-4 antagonists.  The data are consistent with a model of these compds. in which these alkanoylphenylalanines reside in a compact gauche (-) bioactive conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOxvGLJqVLP7Vg90H21EOLACvtfcHk0ljZCLcdrnzqsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvVGjt7s%253D&md5=d94ec7757550db2569845abcf3dec5d3</span></div><a href="/servlet/linkout?suffix=cit89b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900386-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900386-4%26sid%3Dliteratum%253Aachs%26aulast%3DSidduri%26aufirst%3DA.%26aulast%3DTilley%26aufirst%3DJ.%2BW.%26aulast%3DHull%26aufirst%3DK.%26aulast%3DPing%2BLou%26aufirst%3DJ.%26aulast%3DKaplan%26aufirst%3DG.%26aulast%3DSheffron%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DGuthrie%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DT.-N.%26aulast%3DHuby%26aufirst%3DN.%26aulast%3DRowan%26aufirst%3DK.%26aulast%3DSchwinge%26aufirst%3DV.%26aulast%3DRenzetti%26aufirst%3DL.%2BM.%26atitle%3DN-Cycloalkanoyl-L-Phenylalanine%2520Derivatives%2520as%2520VCAM%252FVLA-4%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D2475%26epage%3D2478%26doi%3D10.1016%2FS0960-894X%2802%2900386-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucci, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pontillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozigian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struthers, R. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-Methoxyphenyl)-3-(2-Fluoro-6-[Trifluoromethyl]Benzyl)-4-Methyl-2,6-Dioxo-3,6-Dihydro-2h-Pyrimidin-1-Yl]-1-Phenylethylamino}Butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7478</span>– <span class="NLM_lpage">7485</span>, <span class="refDoi"> DOI: 10.1021/jm8006454</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8006454" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOrs73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7478-7485&author=C.+Chenauthor=D.+Wuauthor=Z.+Guoauthor=Q.+Xieauthor=G.+J.+Reinhartauthor=A.+Madanauthor=J.+Wenauthor=T.+Chenauthor=C.+Q.+Huangauthor=M.+Chenauthor=Y.+Chenauthor=F.+C.+Tucciauthor=M.+Rowbottomauthor=J.+Pontilloauthor=Y.-F.+Zhuauthor=W.+Wadeauthor=J.+Saundersauthor=H.+Bozigianauthor=R.+S.+Struthers&title=Discovery+of+Sodium+R-%28%2B%29-4-%7B2-%5B5-%282-Fluoro-3-Methoxyphenyl%29-3-%282-Fluoro-6-%5BTrifluoromethyl%5DBenzyl%29-4-Methyl-2%2C6-Dioxo-3%2C6-Dihydro-2h-Pyrimidin-1-Yl%5D-1-Phenylethylamino%7DButyrate+%28Elagolix%29%2C+a+Potent+and+Orally+Available+Nonpeptide+Antagonist+of+the+Human+Gonadotropin-Releasing+Hormone+Receptor&doi=10.1021%2Fjm8006454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90aR"><div class="casContent"><span class="casTitleNuber">90a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor</span></div><div class="casAuthors">Chen, Chen; Wu, Dongpei; Guo, Zhiqiang; Xie, Qiu; Reinhart, Greg J.; Madan, Ajay; Wen, Jenny; Chen, Takung; Huang, Charles Q.; Chen, Mi; Chen, Yongsheng; Tucci, Fabio C.; Rowbottom, Martin; Pontillo, Joseph; Zhu, Yun-Fei; Wade, Warren; Saunders, John; Bozigian, Haig; Struthers, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7478-7485</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of novel uracil phenylethylamines bearing a butyric acid as potent human gonadotropin-releasing hormone receptor (hGnRH-R) antagonists is described.  A major focus of this optimization was to improve the CYP3A4 inhibition liability of these uracils while maintaining their GnRH-R potency. R-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyric acid sodium salt, 10b (elagolix), was identified as a potent and selective hGnRH-R antagonist.  Oral administration of 10b suppressed LH in castrated macaques.  These efforts led to the identification of 10b as a clin. compd. for the treatment of endometriosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmNakYnE-bL7Vg90H21EOLACvtfcHk0ljZCLcdrnzqsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOrs73M&md5=d46a3b0801c6026cb9137cf6fffd9f54</span></div><a href="/servlet/linkout?suffix=cit90a&amp;dbid=16384&amp;doi=10.1021%2Fjm8006454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8006454%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DReinhart%26aufirst%3DG.%2BJ.%26aulast%3DMadan%26aufirst%3DA.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DC.%2BQ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTucci%26aufirst%3DF.%2BC.%26aulast%3DRowbottom%26aufirst%3DM.%26aulast%3DPontillo%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DY.-F.%26aulast%3DWade%26aufirst%3DW.%26aulast%3DSaunders%26aufirst%3DJ.%26aulast%3DBozigian%26aufirst%3DH.%26aulast%3DStruthers%26aufirst%3DR.%2BS.%26atitle%3DDiscovery%2520of%2520Sodium%2520R-%2528%252B%2529-4-%257B2-%255B5-%25282-Fluoro-3-Methoxyphenyl%2529-3-%25282-Fluoro-6-%255BTrifluoromethyl%255DBenzyl%2529-4-Methyl-2%252C6-Dioxo-3%252C6-Dihydro-2h-Pyrimidin-1-Yl%255D-1-Phenylethylamino%257DButyrate%2520%2528Elagolix%2529%252C%2520a%2520Potent%2520and%2520Orally%2520Available%2520Nonpeptide%2520Antagonist%2520of%2520the%2520Human%2520Gonadotropin-Releasing%2520Hormone%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7478%26epage%3D7485%26doi%3D10.1021%2Fjm8006454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit90b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, D. J.</span>; <span class="NLM_string-name">Treiber, L. R.</span>; <span class="NLM_string-name">Hughes, R. M.</span>; <span class="NLM_string-name">Campopiano, O.</span>; <span class="NLM_string-name">Wang, P.</span>; <span class="NLM_string-name">Zhao, Y.</span>; <span class="NLM_string-name">Chou, S. K.</span>; <span class="NLM_string-name">Ouellette, M. A.</span>; <span class="NLM_string-name">Hettinger, D. N.</span></span> <span> </span><span class="NLM_article-title">Processes for the Preparation of Uracil Derivatives</span>. <span class="NLM_patent">US8765948B2</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+J.+Gallagher&author=L.+R.+Treiber&author=R.+M.+Hughes&author=O.+Campopiano&author=P.+Wang&author=Y.+Zhao&author=S.+K.+Chou&author=M.+A.+Ouellette&author=D.+N.+Hettinger&title=Processes+for+the+Preparation+of+Uracil+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGallagher%26aufirst%3DD.%2BJ.%26atitle%3DProcesses%2520for%2520the%2520Preparation%2520of%2520Uracil%2520Derivatives%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman-Kien, A. E.</span></span> <span> </span><span class="NLM_article-title">Disseminated Kaposi’s Sarcoma Syndrome in Young Homosexual Men</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">468</span>, <span class="refDoi"> DOI: 10.1016/S0190-9622(81)80010-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0190-9622%2881%2980010-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=7287964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADyaL38%252FjtFCjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1981&pages=468&author=A.+E.+Friedman-Kien&title=Disseminated+Kaposi%E2%80%99s+Sarcoma+Syndrome+in+Young+Homosexual+Men&doi=10.1016%2FS0190-9622%2881%2980010-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91aR"><div class="casContent"><span class="casTitleNuber">91a</span><div class="casTitle"><span class="NLM_cas:atitle">Disseminated Kaposi's sarcoma syndrome in young homosexual men</span></div><div class="casAuthors">Friedman-Kien A E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">468-71</span>
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8T9XkCStdIgqdek-gHSrIfW6udTcc2eZra3fr8guUcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL38%252FjtFCjsg%253D%253D&md5=0146de8d279b8cc66574d1fcc6485dfe</span></div><a href="/servlet/linkout?suffix=cit91a&amp;dbid=16384&amp;doi=10.1016%2FS0190-9622%2881%2980010-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0190-9622%252881%252980010-2%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman-Kien%26aufirst%3DA.%2BE.%26atitle%3DDisseminated%2520Kaposi%25E2%2580%2599s%2520Sarcoma%2520Syndrome%2520in%2520Young%2520Homosexual%2520Men%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D1981%26volume%3D5%26spage%3D468%26doi%3D10.1016%2FS0190-9622%2881%2980010-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit91b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0927-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0927-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29869203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=959-963&author=A.+Markham&title=Fostamatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0927-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91bR"><div class="casContent"><span class="casTitleNuber">91b</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">959-963</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Rigel Pharmaceuticals are developing the spleen tyrosine kinase (SYK) inhibitor fostamatinib (TAVALISSE) as a treatment for immune thrombocytopenia (ITP), autoimmune haemolytic anemia and IgA nephropathy.  Based on pos. results in the phase III FIT clin. trial program, the drug was recently approved in the US as a treatment for thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment.  This article summarizes the milestones in the development of fostamatinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgnmCw2LTVXrVg90H21EOLACvtfcHk0ljjvRlN0aJEHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsb7M&md5=e58fd226c946b7e2087a74d31eeba972</span></div><a href="/servlet/linkout?suffix=cit91b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0927-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0927-1%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DFostamatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D959%26epage%3D963%26doi%3D10.1007%2Fs40265-018-0927-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hymes, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prose, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubenstein, L. J.</span></span> <span> </span><span class="NLM_article-title">Kaposi’s Sarcoma in Homosexual Men-a Report of Eight Cases</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>318</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(81)92740-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0140-6736%2881%2992740-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=1981&pages=598-600&author=K.+B.+Hymesauthor=J.+B.+Greeneauthor=A.+Marcusauthor=D.+C.+Williamauthor=T.+Cheungauthor=N.+S.+Proseauthor=H.+Ballardauthor=L.+J.+Laubenstein&title=Kaposi%E2%80%99s+Sarcoma+in+Homosexual+Men-a+Report+of+Eight+Cases&doi=10.1016%2FS0140-6736%2881%2992740-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2881%2992740-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252881%252992740-9%26sid%3Dliteratum%253Aachs%26aulast%3DHymes%26aufirst%3DK.%2BB.%26aulast%3DGreene%26aufirst%3DJ.%2BB.%26aulast%3DMarcus%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DD.%2BC.%26aulast%3DCheung%26aufirst%3DT.%26aulast%3DProse%26aufirst%3DN.%2BS.%26aulast%3DBallard%26aufirst%3DH.%26aulast%3DLaubenstein%26aufirst%3DL.%2BJ.%26atitle%3DKaposi%25E2%2580%2599s%2520Sarcoma%2520in%2520Homosexual%2520Men-a%2520Report%2520of%2520Eight%2520Cases%26jtitle%3DLancet%26date%3D1981%26volume%3D318%26spage%3D598%26epage%3D600%26doi%3D10.1016%2FS0140-6736%2881%2992740-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit92b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmann, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert-Guroff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zolla-Pazner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibowitch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, M.</span></span> <span> </span><span class="NLM_article-title">Isolation of Human T-Cell Leukemia Virus in Acquired Immune Deficiency Syndrome (AIDS)</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>220</i></span>,  <span class="NLM_fpage">865</span>, <span class="refDoi"> DOI: 10.1126/science.6601823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1126%2Fscience.6601823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=6601823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADyaL3s7psleltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=220&publication_year=1983&pages=865&author=R.+C.+Galloauthor=P.+S.+Sarinauthor=E.+P.+Gelmannauthor=M.+Robert-Guroffauthor=E.+Richardsonauthor=V.+S.+Kalyanaramanauthor=D.+Mannauthor=G.+D.+Sidhuauthor=R.+E.+Stahlauthor=S.+Zolla-Paznerauthor=J.+Leibowitchauthor=M.+Popovic&title=Isolation+of+Human+T-Cell+Leukemia+Virus+in+Acquired+Immune+Deficiency+Syndrome+%28AIDS%29&doi=10.1126%2Fscience.6601823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92bR"><div class="casContent"><span class="casTitleNuber">92b</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)</span></div><div class="casAuthors">Gallo R C; Sarin P S; Gelmann E P; Robert-Guroff M; Richardson E; Kalyanaraman V S; Mann D; Sidhu G D; Stahl R E; Zolla-Pazner S; Leibowitch J; Popovic M</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">220</span>
        (<span class="NLM_cas:issue">4599</span>),
    <span class="NLM_cas:pages">865-7</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Several isolates of a human type-C retrovirus belonging to one group, known as human T-cell leukemia virus (HTLV), have previously been obtained from patients with adult T-cell leukemia or lymphoma.  The T-cell tropism of HTLV and its prevalence in the Caribbean basin prompted a search for it in patients with the epidemic T-cell immune deficiency disorder known as AIDS.  Peripheral blood lymphocytes from one patient in the United States and two in France were cultured with T-cell growth factor (TCGF) an shown to express HTLV antigens.  Virus from the U.S. patient was isolated and characterized and shown to be related to HTLV subgroup I.  The virus was also transmitted into normal human T cells from umbilical cord blood of a newborn.  Whether or not HTLV-I or other retroviruses of this family with T-cell tropism cause AIDS, it is possible that patients from whom the virus can be isolated can also transmit it to others.  If the target cell of AIDS is the mature T cell as suspected, the methods used in these studies may prove useful for the long-term growth of these cells and for the identification of antigens specific for the etiological agent of AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtPEhazvKyxty3lHz94U-GfW6udTcc2ebJVdeS0COrHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s7psleltQ%253D%253D&md5=fd07e27fb89195143ef9aa8db269c871</span></div><a href="/servlet/linkout?suffix=cit92b&amp;dbid=16384&amp;doi=10.1126%2Fscience.6601823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6601823%26sid%3Dliteratum%253Aachs%26aulast%3DGallo%26aufirst%3DR.%2BC.%26aulast%3DSarin%26aufirst%3DP.%2BS.%26aulast%3DGelmann%26aufirst%3DE.%2BP.%26aulast%3DRobert-Guroff%26aufirst%3DM.%26aulast%3DRichardson%26aufirst%3DE.%26aulast%3DKalyanaraman%26aufirst%3DV.%2BS.%26aulast%3DMann%26aufirst%3DD.%26aulast%3DSidhu%26aufirst%3DG.%2BD.%26aulast%3DStahl%26aufirst%3DR.%2BE.%26aulast%3DZolla-Pazner%26aufirst%3DS.%26aulast%3DLeibowitch%26aufirst%3DJ.%26aulast%3DPopovic%26aufirst%3DM.%26atitle%3DIsolation%2520of%2520Human%2520T-Cell%2520Leukemia%2520Virus%2520in%2520Acquired%2520Immune%2520Deficiency%2520Syndrome%2520%2528AIDS%2529%26jtitle%3DScience%26date%3D1983%26volume%3D220%26spage%3D865%26doi%3D10.1126%2Fscience.6601823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bussel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trelinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homenda, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windyga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivcheva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalafallah, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaja, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovtsov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zayed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duliege, A.-M.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase 3, Randomized, Placebo-Controlled Trials</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1002/ajh.25125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fajh.25125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29696684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ylur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2018&pages=921-930&author=J.+Busselauthor=D.+M.+Arnoldauthor=E.+Grossbardauthor=J.+Mayerauthor=J.+Trelinskiauthor=W.+Homendaauthor=A.+Hellmannauthor=J.+Windygaauthor=L.+Sivchevaauthor=A.+A.+Khalafallahauthor=F.+Zajaauthor=N.+Cooperauthor=V.+Markovtsovauthor=H.+Zayedauthor=A.-M.+Duliege&title=Fostamatinib+for+the+Treatment+of+Adult+Persistent+and+Chronic+Immune+Thrombocytopenia%3A+Results+of+Two+Phase+3%2C+Randomized%2C+Placebo-Controlled+Trials&doi=10.1002%2Fajh.25125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials</span></div><div class="casAuthors">Bussel, James; Arnold, Donald M.; Grossbard, Elliot; Mayer, Jiri; Trelinski, Jacek; Homenda, Wojciech; Hellmann, Andrzej; Windyga, Jerzy; Sivcheva, Liliya; Khalafallah, Alhossain A.; Zaja, Francesco; Cooper, Nichola; Markovtsov, Vadim; Zayed, Hany; Duliege, Anne-Marie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">921-930</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk) signaling is central to phagocytosis-based, antibody-mediated platelet destruction in adults with immune thrombocytopenia (ITP).  Fostamatinib, an oral Syk inhibitor, produced sustained on-treatment responses in a phase 2 ITP study.  In two parallel, phase 3, multicenter, randomized, double-blind, placebo-controlled trials (FIT1 and FIT2), patients with persistent/chronic ITP were randomized 2:1 to fostamatinib (n = 101) or placebo (n = 49) at 100 mg BID for 24 wk with a dose increase in nonresponders to 150 mg BID after 4 wk.  The primary endpoint was stable response (platelets ≥50 000/μL at ≥4 of 6 biweekly visits, weeks 14-24, without rescue therapy).  Baseline median platelet count was 16 000/μL; median duration of ITP was 8.5 years.  Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P = .0003).  Overall responses (defined retrospectively as ≥1 platelet count ≥50 000/μL within the first 12 wk on treatment) occurred in 43% of patients on fostamatinib vs. 14% on placebo (P = .0006).  Median time to response was 15 days (on 100 mg bid), and 83% responded within 8 wk.  The most common adverse events were diarrhea (31% on fostamatinib vs. 15% on placebo), hypertension (28% vs. 13%), nausea (19% vs. 8%), dizziness (11% vs. 8%), and ALT increase (11% vs. 0%).  Most events were mild or moderate and resolved spontaneously or with medical management (antihypertensive, anti-motility agents).  Fostamatinib produced clin.-meaningful responses in ITP patients including those who failed splenectomy, thrombopoietic agents, and/or rituximab.  Fostamatinib is a novel ITP treatment option that targets an important mechanism of ITP pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXWLFmFwBPrLVg90H21EOLACvtfcHk0lipIj4-5v5AqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ylur%252FF&md5=06dff53ac5d8e7752b760844f9f22384</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fajh.25125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.25125%26sid%3Dliteratum%253Aachs%26aulast%3DBussel%26aufirst%3DJ.%26aulast%3DArnold%26aufirst%3DD.%2BM.%26aulast%3DGrossbard%26aufirst%3DE.%26aulast%3DMayer%26aufirst%3DJ.%26aulast%3DTrelinski%26aufirst%3DJ.%26aulast%3DHomenda%26aufirst%3DW.%26aulast%3DHellmann%26aufirst%3DA.%26aulast%3DWindyga%26aufirst%3DJ.%26aulast%3DSivcheva%26aufirst%3DL.%26aulast%3DKhalafallah%26aufirst%3DA.%2BA.%26aulast%3DZaja%26aufirst%3DF.%26aulast%3DCooper%26aufirst%3DN.%26aulast%3DMarkovtsov%26aufirst%3DV.%26aulast%3DZayed%26aufirst%3DH.%26aulast%3DDuliege%26aufirst%3DA.-M.%26atitle%3DFostamatinib%2520for%2520the%2520Treatment%2520of%2520Adult%2520Persistent%2520and%2520Chronic%2520Immune%2520Thrombocytopenia%253A%2520Results%2520of%2520Two%2520Phase%25203%252C%2520Randomized%252C%2520Placebo-Controlled%2520Trials%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2018%26volume%3D93%26spage%3D921%26epage%3D930%26doi%3D10.1002%2Fajh.25125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3614</span>– <span class="NLM_lpage">3643</span>, <span class="refDoi"> DOI: 10.1021/jm201271b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201271b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3614-3643&author=R.+Singhauthor=E.+S.+Masudaauthor=D.+G.+Payan&title=Discovery+and+Development+of+Spleen+Tyrosine+Kinase+%28SYK%29+Inhibitors&doi=10.1021%2Fjm201271b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94aR"><div class="casContent"><span class="casTitleNuber">94a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors</span></div><div class="casAuthors">Singh, Rajinder; Masuda, Esteban S.; Payan, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3614-3643</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (SYK) is a member of the cytoplasmic protein tyrosine kinase (PTK) family and has been identified as an important target for the development of therapeutics for the treatment of allergic and autoimmune diseases.  Maladies resulting from chronic inflammation and autoimmune dysfunction include, asthma, rheumatoid arthritis (RA), Crohn's disease, systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia purpura (ITP).  SYK has garnered substantial attention because of its importance as a key signal transduction regulator through antigen and Fc receptors in hematopoietic cells.  Recently SYK has entered the mainstream of potential pharmaceutical targets with a no. of inhibitor classes being reported in the literature.  The true potential as a validated target for inhibition by small mols. has been investigated in the last few years, with the emergence of advanced clin. trial data.  Structurally SYK possesses a tandem N-terminal Src homol. 2 domains (SH2), referred to as N-SH2 and C-SH2 domains, followed by a C-terminal kinase domain and most closely related to ZAP-70.  The multiple phosphorylation sites on SYK are fundamental structural prerequisites for its diverse functional activity.  Overall, these phosphorylation sites contribute to maintaining the kinase in an inactivated state.  In addn., they are implicated in events leading to primary activation of the kinase catalytic domain, amplification of this activity, and the orchestrated phosphorylation of multiple substrates.  Utilization of the numerous sites of phosphorylation on SYK leads to the activation of a multitude of signaling networks relevant to immune and autoimmune maladies.  SYK serves as a master regulator of inflammatory responses in a multitude of immune cells and as a result, inhibiting SYK activity dampens inflammation broadly and comprehensively.  The validation of SYK as an effective target for therapeutic intervention in autoimmune and inflammatory disorders has picked up pace over the last decade.  In particular, this has been attributable to the recognition of key biol. findings, coupled with successful small mol. inhibitors of SYK that have shown early indications of clin. efficacy in diverse autoimmune and inflammatory diseases.  SYK as a target has gained reinforcement with the successful completion of several Phase 2 clin. studies in RA, ITP and B-cell lymphoma.  Addnl. clin. studies are under way that may further emphasize the position of SYK as a therapeutically relevant target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp363qA4V4g-rVg90H21EOLACvtfcHk0lipIj4-5v5AqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D&md5=1b51e1b658842f2b562d533edb05e685</span></div><a href="/servlet/linkout?suffix=cit94a&amp;dbid=16384&amp;doi=10.1021%2Fjm201271b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201271b%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DMasuda%26aufirst%3DE.%2BS.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Spleen%2520Tyrosine%2520Kinase%2520%2528SYK%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3614%26epage%3D3643%26doi%3D10.1021%2Fjm201271b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit94b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mocsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V. L. J.</span></span> <span> </span><span class="NLM_article-title">The SYK Tyrosine Kinase: A Crucial Player in Diverse Biological Functions</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1038/nri2765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fnri2765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20467426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=387-402&author=A.+Mocsaiauthor=J.+Rulandauthor=V.+L.+J.+Tybulewicz&title=The+SYK+Tyrosine+Kinase%3A+A+Crucial+Player+in+Diverse+Biological+Functions&doi=10.1038%2Fnri2765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94bR"><div class="casContent"><span class="casTitleNuber">94b</span><div class="casTitle"><span class="NLM_cas:atitle">The SYK tyrosine kinase: a crucial player in diverse biological functions</span></div><div class="casAuthors">Mocsai, Attila; Ruland, Jurgen; Tybulewicz, Victor L. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-402</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Spleen tyrosine kinase (SYK) is known to have a crucial role in adaptive immune receptor signalling.  However, recent reports indicate that SYK also mediates other, unexpectedly diverse biol. functions, including cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development.  SYK is activated by C-type lectins and integrins, and activates new targets, including the CARD9-BCL-10-MALT1 pathway and the NLRP3 inflammasome.  Studies using Drosophila melanogaster suggest that there is an evolutionarily ancient origin of SYK-mediated signalling.  Moreover, SYK has a crucial role in autoimmune diseases and haematol. malignancies.  This Review summarizes our current understanding of the diverse functions of SYK and how this is being translated for therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3YO5BcMqrf7Vg90H21EOLACvtfcHk0ljS9TwPHKjrAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D&md5=85857a2b9beb84e0fe74263a90fa8a53</span></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=10.1038%2Fnri2765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2765%26sid%3Dliteratum%253Aachs%26aulast%3DMocsai%26aufirst%3DA.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DTybulewicz%26aufirst%3DV.%2BL.%2BJ.%26atitle%3DThe%2520SYK%2520Tyrosine%2520Kinase%253A%2520A%2520Crucial%2520Player%2520in%2520Diverse%2520Biological%2520Functions%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D10%26spage%3D387%26epage%3D402%26doi%3D10.1038%2Fnri2765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussel, J. B.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib for Persistent/Chronic Adult Immune Thrombocytopenia</span>. <i>Immunotherapy</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.2217/imt-2017-0097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2217%2Fimt-2017-0097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28967793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=9-25&author=A.+Newlandauthor=E.-J.+Leeauthor=V.+McDonaldauthor=J.+B.+Bussel&title=Fostamatinib+for+Persistent%2FChronic+Adult+Immune+Thrombocytopenia&doi=10.2217%2Fimt-2017-0097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib for persistent/chronic adult immune thrombocytopenia</span></div><div class="casAuthors">Newland, Adrian; Lee, Eun-Ju; McDonald, Vickie; Bussel, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Immunotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-25</span>CODEN:
                <span class="NLM_cas:coden">IMMUCO</span>;
        ISSN:<span class="NLM_cas:issn">1750-7448</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by phagocytosis and destruction of autoantibody-coated platelets via spleen tyrosine kinase (Syk)-mediated signal transduction in macrophages.  Effectiveness of existing therapies varies, and even leading treatments (e.g., IVIg, splenectomy, rituximab, thrombopoietic agents) do not provide optimal management for a substantial no. of patients with chronic ITP.  Fostamatinib disodium is an orally-bioavailable investigational agent being developed for treatment of primary persistent/chronic adult ITP.  Fostamatinib inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis.  Promising findings have been described in several autoimmune diseases, including rheumatoid arthritis, and sustained responses with manageable adverse events obsd. with ongoing treatment in patients with heavily treated chronic ITP.  Fostamatinib represents an active therapy targeting a previously unexplored mechanism of ITP pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8Xq2q4K3g_rVg90H21EOLACvtfcHk0ljS9TwPHKjrAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbnM&md5=586a0d541c4bd2ea226ea9e7667d61b3</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.2217%2Fimt-2017-0097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fimt-2017-0097%26sid%3Dliteratum%253Aachs%26aulast%3DNewland%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DE.-J.%26aulast%3DMcDonald%26aufirst%3DV.%26aulast%3DBussel%26aufirst%3DJ.%2BB.%26atitle%3DFostamatinib%2520for%2520Persistent%252FChronic%2520Adult%2520Immune%2520Thrombocytopenia%26jtitle%3DImmunotherapy%26date%3D2018%26volume%3D10%26spage%3D9%26epage%3D25%26doi%3D10.2217%2Fimt-2017-0097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweeny, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamidipati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, D. T. W.</span></span> <span> </span><span class="NLM_article-title">Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1166</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.032151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1124%2Fdmd.110.032151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20371637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Klsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1166-1176&author=D.+J.+Sweenyauthor=W.+Liauthor=J.+Cloughauthor=S.+Bhamidipatiauthor=R.+Singhauthor=G.+Parkauthor=M.+Baluomauthor=E.+Grossbardauthor=D.+T.+W.+Lau&title=Metabolism+of+Fostamatinib%2C+the+Oral+Methylene+Phosphate+Prodrug+of+the+Spleen+Tyrosine+Kinase+Inhibitor+R406+in+Humans%3A+Contribution+of+Hepatic+and+Gut+Bacterial+Processes+to+the+Overall+Biotransformation&doi=10.1124%2Fdmd.110.032151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation</span></div><div class="casAuthors">Sweeny, David J.; Li, Weiqun; Clough, Jeffrey; Bhamidipati, Somasekhar; Singh, Rajinder; Park, Gary; Baluom, Muhammad; Grossbard, Elliott; Lau, David T.-W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1166-1176</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The metab. of the spleen tyrosine kinase inhibitor N4-(2,2-dimethyl-3-oxo-4-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethyoxyphenyl)-2,4-pyrimidinediamine (R406) and its oral prodrug N4-(2,2-dimethyl-4-[(dihydrogenphosphonoxy)methyl]-3-oxo-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethyoxyphenyl)-2,4-pyrimidinediamine disodium hexahydrate (R788, fostamatinib) was detd. in vitro and in humans.  R788 was rapidly converted to R406 by human intestinal microsomes, and only low levels of R788 were obsd. in plasma of human subjects after oral administration of 14C-R788.  R406 was the major drug-related compd. in plasma from human subjects, and only low levels of metabolites were obsd. in plasma.  The plasma metabolites of R406 were identified as a sulfate conjugate and glucuronide conjugate of the para-O-demethylated metabolite of R406 (R529) and a direct N-glucuronide conjugate of R406.  Elimination of drug-related material into the urine accounted for 19% of the administered dose, and the major metabolite in urine from all the human subjects was the lactam N-glucuronide of R406.  On av., 80% of the total drug was recovered in feces.  Two drug-related peaks were obsd.; one peak was identified as R406, and the other peak was identified as a unique 3,5-benzene diol metabolite of R406.  The 3,5-benzene diol metabolite appeared to result from the subsequent O-demethylations and dehydroxylation of R529 by anaerobic gut bacteria because only R529 was converted to this metabolite after the in vitro incubation with human fecal samples.  These data indicate that the major fecal metabolite of R406 obsd. in humans is a product of a hepatic cytochrome P 450-mediated O-demethylation and subsequent O-demethylations and dehydroxylation by gut bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjYey4HpvXGbVg90H21EOLACvtfcHk0ljS9TwPHKjrAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Klsb0%253D&md5=391fda31851968948d538f70319979e1</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.032151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.032151%26sid%3Dliteratum%253Aachs%26aulast%3DSweeny%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DClough%26aufirst%3DJ.%26aulast%3DBhamidipati%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DG.%26aulast%3DBaluom%26aufirst%3DM.%26aulast%3DGrossbard%26aufirst%3DE.%26aulast%3DLau%26aufirst%3DD.%2BT.%2BW.%26atitle%3DMetabolism%2520of%2520Fostamatinib%252C%2520the%2520Oral%2520Methylene%2520Phosphate%2520Prodrug%2520of%2520the%2520Spleen%2520Tyrosine%2520Kinase%2520Inhibitor%2520R406%2520in%2520Humans%253A%2520Contribution%2520of%2520Hepatic%2520and%2520Gut%2520Bacterial%2520Processes%2520to%2520the%2520Overall%2520Biotransformation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1166%26epage%3D1176%26doi%3D10.1124%2Fdmd.110.032151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKeever, B.</span>; <span class="NLM_string-name">Diorazio, L. J.</span>; <span class="NLM_string-name">Jones, M. F.</span>; <span class="NLM_string-name">Ferris, L.</span>; <span class="NLM_string-name">Janbon, S. L. M.</span>; <span class="NLM_string-name">Siedlecki, P. S.</span>; <span class="NLM_string-name">Churchill, G. H.</span>; <span class="NLM_string-name">Crafts, P. A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pharmaceutical 2,4-Pyrimidinediamines in Large Scale</span>. <span class="NLM_patent">WO2015095765A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=B.+McKeever&author=L.+J.+Diorazio&author=M.+F.+Jones&author=L.+Ferris&author=S.+L.+M.+Janbon&author=P.+S.+Siedlecki&author=G.+H.+Churchill&author=P.+A.+Crafts&title=Preparation+of+Pharmaceutical+2%2C4-Pyrimidinediamines+in+Large+Scale"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeever%26aufirst%3DB.%26atitle%3DPreparation%2520of%2520Pharmaceutical%25202%252C4-Pyrimidinediamines%2520in%2520Large%2520Scale%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever-Abbas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R.</span></span> <span> </span><span class="NLM_article-title">Real-Time Monitoring and Control of Critical Process Impurities During the Manufacture of Fostamatinib Disodium</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.5b00008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFKlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=537-542&author=R.+Hartauthor=A.+Herringauthor=G.+P.+Howellauthor=B.+McKeever-Abbasauthor=N.+Pedgeauthor=R.+Woodward&title=Real-Time+Monitoring+and+Control+of+Critical+Process+Impurities+During+the+Manufacture+of+Fostamatinib+Disodium&doi=10.1021%2Facs.oprd.5b00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Real-Time Monitoring and Control of Critical Process Impurities during the Manufacture of Fostamatinib Disodium</span></div><div class="casAuthors">Hart, Richard; Herring, Adam; Howell, Gareth P.; McKeever-Abbas, Ben; Pedge, Nicholas; Woodward, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">537-542</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Process anal. technol. (PAT) was used to probe, monitor, and control the formation of process impurities during the synthesis of a pharmaceutical intermediate at 600 kg input scale.  An accurate detn. of end of reaction (EoR) was vital in limiting side-products, and a novel inline UV/vis-based approach was used where more traditional EoR techniques had failed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_IN2TK848BLVg90H21EOLACvtfcHk0lhA2_OcvScuAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFKlsLg%253D&md5=b31da49d6176f9a4e2ae81da5319b124</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00008%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DR.%26aulast%3DHerring%26aufirst%3DA.%26aulast%3DHowell%26aufirst%3DG.%2BP.%26aulast%3DMcKeever-Abbas%26aufirst%3DB.%26aulast%3DPedge%26aufirst%3DN.%26aulast%3DWoodward%26aufirst%3DR.%26atitle%3DReal-Time%2520Monitoring%2520and%2520Control%2520of%2520Critical%2520Process%2520Impurities%2520During%2520the%2520Manufacture%2520of%2520Fostamatinib%2520Disodium%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D537%26epage%3D542%26doi%3D10.1021%2Facs.oprd.5b00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukumo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kifuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakairi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritani, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Evocalcet, a Next-Generation Calcium-Sensing Receptor Agonist for the Treatment of Hyperparathyroidism</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2055</span>– <span class="NLM_lpage">2060</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.04.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmcl.2018.04.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29724589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVCnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2055-2060&author=H.+Miyazakiauthor=Y.+Ikedaauthor=O.+Sakuraiauthor=T.+Miyakeauthor=R.+Tsubotaauthor=J.+Okabeauthor=M.+Kurodaauthor=Y.+Hisadaauthor=T.+Yanagidaauthor=H.+Yonedaauthor=Y.+Tsukumoauthor=S.+Tokunagaauthor=T.+Kawataauthor=R.+Ohashiauthor=H.+Fukudaauthor=K.+Kojimaauthor=A.+Kannamiauthor=T.+Kifujiauthor=N.+Satoauthor=A.+Ideiauthor=T.+Iguchiauthor=T.+Sakairiauthor=Y.+Moritani&title=Discovery+of+Evocalcet%2C+a+Next-Generation+Calcium-Sensing+Receptor+Agonist+for+the+Treatment+of+Hyperparathyroidism&doi=10.1016%2Fj.bmcl.2018.04.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism</span></div><div class="casAuthors">Miyazaki, Hiroshi; Ikeda, Yousuke; Sakurai, Osamu; Miyake, Tsutomu; Tsubota, Rie; Okabe, Jyunko; Kuroda, Masataka; Hisada, Yutaka; Yanagida, Tetsuya; Yoneda, Hikaru; Tsukumo, Yukihito; Tokunaga, Shin; Kawata, Takehisa; Ohashi, Rikiya; Fukuda, Hajime; Kojima, Koki; Kannami, Ayako; Kifuji, Takayuki; Sato, Naoya; Idei, Akiko; Iguchi, Taku; Sakairi, Tetsuya; Moritani, Yasunori</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2055-2060</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The calcium-sensing receptor (CaSR) plays an important role in sensing extracellular calcium ions and regulating parathyroid hormone secretion by parathyroid gland cells, and the receptor is a suitable target for the treatment of hyperparathyroidism.  Cinacalcet hydrochloride is a representative CaSR agonist which widely used for the hyperparathyroidism.  However, it has several issues to clin. use, such as nausea/vomiting and strong inhibition of CYP2D6.  We tried to improve these issues of cinacalcet for a new pharmaceutical agent as a preferable CaSR agonist.  Optimization from cinacalcet resulted in the identification of pyrrolidine compds. and successfully led to the discovery of evocalcet as an oral allosteric CaSR agonist.  Evocalcet, which exhibited highly favorable profiles such as CaSR agonistic activity and good DMPK profiles, will provide a novel therapeutic option for secondary hyperparathyroidism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3j0sLMaFRA7Vg90H21EOLACvtfcHk0lhA2_OcvScuAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVCnsbk%253D&md5=4181ddd3deff7a144478d71e2d7d0899</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.04.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.04.055%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DH.%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DSakurai%26aufirst%3DO.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DTsubota%26aufirst%3DR.%26aulast%3DOkabe%26aufirst%3DJ.%26aulast%3DKuroda%26aufirst%3DM.%26aulast%3DHisada%26aufirst%3DY.%26aulast%3DYanagida%26aufirst%3DT.%26aulast%3DYoneda%26aufirst%3DH.%26aulast%3DTsukumo%26aufirst%3DY.%26aulast%3DTokunaga%26aufirst%3DS.%26aulast%3DKawata%26aufirst%3DT.%26aulast%3DOhashi%26aufirst%3DR.%26aulast%3DFukuda%26aufirst%3DH.%26aulast%3DKojima%26aufirst%3DK.%26aulast%3DKannami%26aufirst%3DA.%26aulast%3DKifuji%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DN.%26aulast%3DIdei%26aufirst%3DA.%26aulast%3DIguchi%26aufirst%3DT.%26aulast%3DSakairi%26aufirst%3DT.%26aulast%3DMoritani%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Evocalcet%252C%2520a%2520Next-Generation%2520Calcium-Sensing%2520Receptor%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Hyperparathyroidism%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2055%26epage%3D2060%26doi%3D10.1016%2Fj.bmcl.2018.04.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekercioglu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busse, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guyatt, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thabane, L.</span></span> <span> </span><span class="NLM_article-title">Cinacalcet Versus Standard Treatment for Chronic Kidney Disease: A Protocol for a Systematic Review and Meta-Analysis</span>. <i>Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2</span>, <span class="refDoi"> DOI: 10.1186/s13643-015-0177-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1186%2Fs13643-015-0177-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=26729302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BC28rntFOqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=2&author=N.+Sekerciogluauthor=J.+W.+Busseauthor=R.+A.+Mustafaauthor=G.+H.+Guyattauthor=L.+Thabane&title=Cinacalcet+Versus+Standard+Treatment+for+Chronic+Kidney+Disease%3A+A+Protocol+for+a+Systematic+Review+and+Meta-Analysis&doi=10.1186%2Fs13643-015-0177-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis</span></div><div class="casAuthors">Sekercioglu Nigar; Busse Jason W; Mustafa Reem A; Guyatt Gordon H; Thabane Lehana; Busse Jason W; Busse Jason W; Mustafa Reem A; Guyatt Gordon H; Thabane Lehana; Thabane Lehana; Thabane Lehana; Thabane Lehana</div><div class="citationInfo"><span class="NLM_cas:title">Systematic reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic kidney disease-mineral and bone disorders (CKD-MBD) have been associated with poor health outcomes, including diminished quality and length of life.  Standard management for CKD-MBD includes phosphate-restricted diet, active vitamin D, vitamin D analogs, and phosphate binders.  Persistently elevated parathyroid hormone (PTH) levels may require the addition of Cinacalcet hydrochloride (cinacalcet) which sensitizes calcium receptors on the parathyroid glands.  The objective of this systematic review is to compare the effect of cinacalcet versus standard treatment in patients with CKD-MBD.  METHODS/DESIGN:  Data sources will include MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, and Web of Science from 1996 to June 2015.  Teams of two reviewers will, independently and in duplicate, screen titles and abstracts and potentially eligible full text reports to determine eligibility, and subsequently abstract data and assess risk of bias in eligible trials.  We will calculate the effect estimates (risk ratios or mean differences) and 95 % confidence intervals, as well as statistical measures of variability in results across studies using random effect models for patient-important and intermediate outcomes.  We will use the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to rate the quality of evidence about estimates of effect on an outcome-by-outcome basis.  We will present our results with a GRADE summary table.  DISCUSSION:  Our review will explore the effect of cinacalcet versus standard treatment in patients with CKD-MBD.  The results of this systematic review will help guide management of this patient population, and identify targets for future research.  SYSTEMATIC REVIEW REGISTRATION:  PROSPERO CRD42015020318 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015020318.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHG2tAb9KNlvEeosoOnpOLfW6udTcc2ebESuAK66zJZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rntFOqsw%253D%253D&md5=775fa94550341d5c71af4ea8166f7311</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1186%2Fs13643-015-0177-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13643-015-0177-1%26sid%3Dliteratum%253Aachs%26aulast%3DSekercioglu%26aufirst%3DN.%26aulast%3DBusse%26aufirst%3DJ.%2BW.%26aulast%3DMustafa%26aufirst%3DR.%2BA.%26aulast%3DGuyatt%26aufirst%3DG.%2BH.%26aulast%3DThabane%26aufirst%3DL.%26atitle%3DCinacalcet%2520Versus%2520Standard%2520Treatment%2520for%2520Chronic%2520Kidney%2520Disease%253A%2520A%2520Protocol%2520for%2520a%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DSyst.%2520Rev.%26date%3D2016%26volume%3D5%26spage%3D2%26doi%3D10.1186%2Fs13643-015-0177-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fukagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimazaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akizawa, T.</span></span> <span> </span><span class="NLM_article-title">Evocalcet study, g. Head-to-Head Comparison of the New Calcimimetic Agent Evocalcet with Cinacalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">818</span>– <span class="NLM_lpage">825</span>, <span class="refDoi"> DOI: 10.1016/j.kint.2018.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.kint.2018.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30049473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2018&pages=818-825&author=M.+Fukagawaauthor=R.+Shimazakiauthor=T.+Akizawa&title=Evocalcet+study%2C+g.+Head-to-Head+Comparison+of+the+New+Calcimimetic+Agent+Evocalcet+with+Cinacalcet+in+Japanese+Hemodialysis+Patients+with+Secondary+Hyperparathyroidism&doi=10.1016%2Fj.kint.2018.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101aR"><div class="casContent"><span class="casTitleNuber">101a</span><div class="casTitle"><span class="NLM_cas:atitle">Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism</span></div><div class="casAuthors">Fukagawa, Masafumi; Shimazaki, Ryutaro; Akizawa, Tadao</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">818-825</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Secondary hyperparathyroidism (SHPT) leads to cardiovascular calcification, which affects survival and quality of life in patients with chronic kidney disease.  Cinacalcet is used to control SHPT, but it may induce gastrointestinal symptoms, resulting in lower adherence and insufficient dosages.  Therefore, a need exists to develop new calcimimetics that cause fewer gastrointestinal symptoms.  Here we conducted a phase 3, randomized, double-blind, double-dummy trial for a head-to-head comparison of the efficacy and safety of evocalcet, a new oral calcimimetic, to the established cinacalcet.  Japanese patients with SHPT on hemodialysis were randomized to receive evocalcet or cinacalcet (317 patients each) for 30 wk.  The primary efficacy endpoint was non-inferiority of evocalcet to cinacalcet in the proportion of patients achieving a mean intact parathyroid hormone level of 60 to 240 pg/mL from week 28 to 30 (non-inferiority margin, -15%, per protocol set analyses).  In the evocalcet and cinacalcet groups, 72.7% and 76.7%, resp., achieved the target intact parathyroid hormone level (between-group difference: -4.0% [95% confidence interval -11.4%, 3.5%], for non-inferiority).  The incidence of gastrointestinal-related adverse events was 18.6% and 32.8%, resp. (between-group difference: -14.2% [-20.9%, -7.5%], significant for superiority).  Thus, the non-inferiority of evocalcet to cinacalcet in suppressing intact parathyroid hormone with fewer gastrointestinal-related adverse events was demonstrated.  Hence, evocalcet may be a favorable alternative to existing calcimimetics for management of SHPT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Ydg7wWev1bVg90H21EOLACvtfcHk0liY8k1gfLzNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsrnF&md5=210c079361a6727058a399dbd6af385b</span></div><a href="/servlet/linkout?suffix=cit101a&amp;dbid=16384&amp;doi=10.1016%2Fj.kint.2018.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.kint.2018.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DFukagawa%26aufirst%3DM.%26aulast%3DShimazaki%26aufirst%3DR.%26aulast%3DAkizawa%26aufirst%3DT.%26atitle%3DEvocalcet%2520study%252C%2520g.%2520Head-to-Head%2520Comparison%2520of%2520the%2520New%2520Calcimimetic%2520Agent%2520Evocalcet%2520with%2520Cinacalcet%2520in%2520Japanese%2520Hemodialysis%2520Patients%2520with%2520Secondary%2520Hyperparathyroidism%26jtitle%3DKidney%2520Int.%26date%3D2018%26volume%3D94%26spage%3D818%26epage%3D825%26doi%3D10.1016%2Fj.kint.2018.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit101b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Wagenen, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balandrin, M. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Calcimimetic and Calcilytic Compounds</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/bs.pmch.2017.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fbs.pmch.2017.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29680147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BC1MjltFOgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1-86&author=E.+F.+Nemethauthor=B.+C.+Van+Wagenenauthor=M.+F.+Balandrin&title=Discovery+and+Development+of+Calcimimetic+and+Calcilytic+Compounds&doi=10.1016%2Fbs.pmch.2017.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101bR"><div class="casContent"><span class="casTitleNuber">101b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Calcimimetic and Calcilytic Compounds</span></div><div class="casAuthors">Nemeth Edward F; Van Wagenen Bradford C; Balandrin Manuel F</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-86</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">The extracellular calcium receptor (CaR) is a G protein-coupled receptor (GPCR) and the pivotal molecule regulating systemic Ca(2+) homeostasis.  The CaR was a challenging target for drug discovery because its physiological ligand is an inorganic ion (Ca(2+)) rather than a molecule so there was no structural template to guide medicinal chemistry.  Nonetheless, small molecules targeting this receptor were discovered.  Calcimimetics are agonists or positive allosteric modulators of the CaR, while calcilytics are antagonists and all to date are negative allosteric modulators.  The calcimimetic cinacalcet was the first allosteric modulator of a GPCR to achieve regulatory approval and is a first-in-class treatment for secondary hyperparathyroidism in patients on dialysis, and for hypercalcemia in some forms of primary hyperparathyroidism.  It is also useful in treating some rare genetic diseases that cause hypercalcemia.  Two other calcimimetics are now on the market (etelcalcetide) or under regulatory review (evocalcet).  Calcilytics stimulate the secretion of parathyroid hormone and were initially developed as treatments for osteoporosis.  Three different calcilytics of two different chemotypes failed in clinical trials due to lack of efficacy.  Calcilytics are now being repurposed and might be useful in treating hypoparathyroidism and several rare genetic diseases causing hypocalcemia.  The challenges ahead for medicinal chemists are to design compounds that select conformations of the CaR that preferentially target a particular signalling pathway and/or that affect the CaR in a tissue-selective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZ9pfcWWVZ5mPgL4LrC-0VfW6udTcc2ebCvk4RSYGYGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjltFOgsw%253D%253D&md5=a36b9f668aca3890332d63d0e628bcbc</span></div><a href="/servlet/linkout?suffix=cit101b&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2017.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2017.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DNemeth%26aufirst%3DE.%2BF.%26aulast%3DVan%2BWagenen%26aufirst%3DB.%2BC.%26aulast%3DBalandrin%26aufirst%3DM.%2BF.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Calcimimetic%2520and%2520Calcilytic%2520Compounds%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D57%26spage%3D1%26epage%3D86%26doi%3D10.1016%2Fbs.pmch.2017.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomoyuki, N.</span>; <span class="NLM_string-name">Yuusuke, M.</span>; <span class="NLM_string-name">Michihiro, M.</span>; <span class="NLM_string-name">Atsushi, H.</span></span> <span> </span><span class="NLM_article-title">Polyethylene Glycol Derivative</span>. <span class="NLM_patent">WO2018174283A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=N.+Tomoyuki&author=M.+Yuusuke&author=M.+Michihiro&author=H.+Atsushi&title=Polyethylene+Glycol+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTomoyuki%26aufirst%3DN.%26atitle%3DPolyethylene%2520Glycol%2520Derivative%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Anlotinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1057</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0939-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0939-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29943374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1aksL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1057-1062&author=Y.+Y.+Syed&title=Anlotinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0939-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Anlotinib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1057-1062</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Labs. are co-developing anlotinib (Focus V) for the treatment of advanced cancer.  Anlotinib is an oral small mol. inhibitor of multiple receptor tyrosine kinases, with a broad spectrum of inhibitory effects on tumor angiogenesis and growth.  Anlotinib is approved in China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have undergone progression or recurrence after ≥ 2 lines of systemic chemotherapy.  Anlotinib is also undergoing phase II and/or III clin. development for various sarcomas and carcinomas in China, USA and Italy.  This article summarizes the milestones in the development of anlotinib leading to this first approval for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqABdQcz5d4A7Vg90H21EOLACvtfcHk0lg2stIKPPYgEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1aksL%252FL&md5=3d2f6b7b389292c75b6e5e1f95b3475a</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0939-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0939-x%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DAnlotinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1057%26epage%3D1062%26doi%3D10.1007%2Fs40265-018-0939-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span> <span> </span><span class="NLM_article-title">Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">120</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0664-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1186%2Fs13045-018-0664-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30231931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=120&author=G.+Shenauthor=F.+Zhengauthor=D.+Renauthor=F.+Duauthor=Q.+Dongauthor=Z.+Wangauthor=F.+Zhaoauthor=R.+Ahmadauthor=J.+Zhao&title=Anlotinib%3A+A+Novel+Multi-Targeting+Tyrosine+Kinase+Inhibitor+in+Clinical+Development&doi=10.1186%2Fs13045-018-0664-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development</span></div><div class="casAuthors">Shen, Guoshuang; Zheng, Fangchao; Ren, Dengfeng; Du, Feng; Dong, Qiuxia; Wang, Ziyi; Zhao, Fuxing; Ahmad, Raees; Zhao, Jiuda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120/1-120/11</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.  Compared to the effect of placebo, it improved both progression-free survival (PFS) and overall survival (OS) in a phase III trial in patients with advanced non-small-cell lung cancer (NSCLC), despite progression of the cancer after two lines of prior treatments.  Recently, the China Food and Drug Administration (CFDA) approved single agent anlotinib as a third-line treatment for patients with advanced NSCLC.  Moreover, a randomized phase IIB trial demonstrated that anlotinib significantly prolonged the median PFS in patients with advanced soft tissue sarcoma (STS).  Anlotinib also showed promising efficacy in patients with advanced medullary thyroid carcinoma and metastatic renal cell carcinoma (mRCC).  The tolerability profile of anlotinib is similar to that of other tyrosine kinase inhibitors that target VEGFR and other tyrosine kinase-mediated pathways; however, anlotinib has a significantly lower incidence of grade 3 or higher side effects compared to that of sunitinib.  We review the rationale, clin. evidence, and future perspectives of anlotinib for the treatment of multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCMhzvg4Az7bVg90H21EOLACvtfcHk0lg2stIKPPYgEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsLo%253D&md5=31c4d8e23723484492a88b3272b5cb80</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0664-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0664-7%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DF.%26aulast%3DRen%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26atitle%3DAnlotinib%253A%2520A%2520Novel%2520Multi-Targeting%2520Tyrosine%2520Kinase%2520Inhibitor%2520in%2520Clinical%2520Development%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D120%26doi%3D10.1186%2Fs13045-018-0664-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, L.</span></span> <span> </span><span class="NLM_article-title">Preclinical Characterization of Anlotinib, a Highly Potent and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1207</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.1111/cas.13536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1111%2Fcas.13536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29446853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlSqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=1207-1219&author=C.+Xieauthor=X.+Wanauthor=H.+Quanauthor=M.+Zhengauthor=L.+Fuauthor=Y.+Liauthor=L.+Lou&title=Preclinical+Characterization+of+Anlotinib%2C+a+Highly+Potent+and+Selective+Vascular+Endothelial+Growth+Factor+Receptor-2+Inhibitor&doi=10.1111%2Fcas.13536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105aR"><div class="casContent"><span class="casTitleNuber">105a</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor</span></div><div class="casAuthors">Xie, Chengying; Wan, Xiaozhe; Quan, Haitian; Zheng, Mingyue; Fu, Li; Li, Yun; Lou, Liguang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1207-1219</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Abrogating tumor angiogenesis by inhibiting vascular endothelial growth factor receptor-2 (VEGFR2) has been established as a therapeutic strategy for treating cancer.  However, because of their low selectivity, most small mol. inhibitors of VEGFR2 tyrosine kinase show unexpected adverse effects and limited anticancer efficacy.  In the present study, we detailed the pharmacol. properties of anlotinib, a highly potent and selective VEGFR2 inhibitor, in preclin. models.  Anlotinib occupied the ATP-binding pocket of VEGFR2 tyrosine kinase and showed high selectivity and inhibitory potency (IC50 <1 nmol/L) for VEGFR2 relative to other tyrosine kinases.  Concordant with this activity, anlotinib inhibited VEGF-induced signaling and cell proliferation in HUVEC with picomolar IC50 values.  However, micromolar concns. of anlotinib were required to inhibit tumor cell proliferation directly in vitro.  Anlotinib significantly inhibited HUVEC migration and tube formation; it also inhibited microvessel growth from explants of rat aorta in vitro and decreased vascular d. in tumor tissue in vivo.  Compared with the well-known tyrosine kinase inhibitor sunitinib, once-daily oral dose of anlotinib showed broader and stronger in vivo antitumor efficacy and, in some models, caused tumor regression in nude mice.  Collectively, these results indicate that anlotinib is a well-tolerated, orally active VEGFR2 inhibitor that targets angiogenesis in tumor growth, and support ongoing clin. evaluation of anlotinib for a variety of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNPRNZFdMmpLVg90H21EOLACvtfcHk0lg2stIKPPYgEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlSqt70%253D&md5=e07c97d47bf00e0a7ca97e05d4d65b01</span></div><a href="/servlet/linkout?suffix=cit105a&amp;dbid=16384&amp;doi=10.1111%2Fcas.13536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13536%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DC.%26aulast%3DWan%26aufirst%3DX.%26aulast%3DQuan%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLou%26aufirst%3DL.%26atitle%3DPreclinical%2520Characterization%2520of%2520Anlotinib%252C%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor-2%2520Inhibitor%26jtitle%3DCancer%2520Sci.%26date%3D2018%26volume%3D109%26spage%3D1207%26epage%3D1219%26doi%3D10.1111%2Fcas.13536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit105b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, Y.</span></span> <span> </span><span class="NLM_article-title">Safety, Pharmacokinetics, and Antitumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Patients with Advanced Refractory Solid Tumors</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0332-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1186%2Fs13045-016-0332-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27716285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=105&author=Y.+Sunauthor=W.+Niuauthor=F.+Duauthor=C.+Duauthor=S.+Liauthor=J.+Wangauthor=L.+Liauthor=F.+Wangauthor=Y.+Haoauthor=C.+Liauthor=Y.+Chi&title=Safety%2C+Pharmacokinetics%2C+and+Antitumor+Properties+of+Anlotinib%2C+an+Oral+Multi-Target+Tyrosine+Kinase+Inhibitor%2C+in+Patients+with+Advanced+Refractory+Solid+Tumors&doi=10.1186%2Fs13045-016-0332-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105bR"><div class="casContent"><span class="casTitleNuber">105b</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors</span></div><div class="casAuthors">Sun, Yongkun; Niu, Wei; Du, Feng; Du, Chunxia; Li, Shuting; Wang, Jinwan; Li, Li; Wang, Fengqing; Hao, Yu; Li, Chuan; Chi, Yihebali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105/1-105/9</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Anlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.  We aimed to evaluate the safety, pharmacokinetics, and antitumor activity of anlotinib in patients with advanced refractory solid tumors.  Methods: Anlotinib (5-16 mg) was orally administered in patients with solid tumor once a day on two schedules: (1) four consecutive weeks (4/0) or (2) 2-wk on/1-wk off (2/1).  Pharmacokinetic sampling was performed in all patients.  Twenty-one patients were further enrolled in an expanded cohort study on the recommended dose and schedule.  Preliminary tumor response was also assessed.  Results: On the 4/0 schedule, dose-limiting toxicity (DLT) was grade 3 hypertension at 10 mg.  On the 2/1 schedule, DLT was grade 3 hypertension and grade 3 fatigue at 16 mg.  Pharmacokinetic assessment indicated that anlotinib had long elimination half-lives and significant accumulation during multiple oral doses.  The 2/1 schedule was selected, with 12 mg once daily as the max. tolerated dose for the expanding study.  Twenty of the 21 patients (with colon adenocarcinoma, non-small cell lung cancer, renal clear cell cancer, medullary thyroid carcinoma, and soft tissue sarcoma) were assessable for antitumor activity of anlotinib: 3 patients had partial response, 14 patients had stable disease including 12 tumor burden shrinkage, and 3 had disease progression.  The main serious adverse effects were hypertension, triglyceride elevation, hand-foot skin reaction, and lipase elevation.  Conclusions: At the dose of 12 mg once daily at the 2/1 schedule, anlotinib displayed manageable toxicity, long circulation, and broad-spectrum antitumor potential, justifying the conduct of further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDNQUtYXwHILVg90H21EOLACvtfcHk0lg2stIKPPYgEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajsbjN&md5=38e37bd976e43f78f9d2ddae6fe61c97</span></div><a href="/servlet/linkout?suffix=cit105b&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0332-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0332-8%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChi%26aufirst%3DY.%26atitle%3DSafety%252C%2520Pharmacokinetics%252C%2520and%2520Antitumor%2520Properties%2520of%2520Anlotinib%252C%2520an%2520Oral%2520Multi-Target%2520Tyrosine%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Refractory%2520Solid%2520Tumors%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D105%26doi%3D10.1186%2Fs13045-016-0332-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syrigos, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saif, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karapanagiotou, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikonomopoulos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marinis, F.</span></span> <span> </span><span class="NLM_article-title">The Need for Third-Line Treatment in Non-Small Cell Lung Cancer: An Overview of New Options</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=21378351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BC3M3ktlOgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=649-659&author=K.+N.+Syrigosauthor=M.+W.+Saifauthor=E.+M.+Karapanagiotouauthor=G.+Oikonomopoulosauthor=F.+De+Marinis&title=The+Need+for+Third-Line+Treatment+in+Non-Small+Cell+Lung+Cancer%3A+An+Overview+of+New+Options"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The need for third-line treatment in non-small cell lung cancer: an overview of new options</span></div><div class="casAuthors">Syrigos Kostas N; Saif Muhammad W; Karapanagiotou Eleni M; Oikonomopoulos George; De Marinis Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">649-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As a result of improved effectiveness of first-, second-line and maintenance therapeutic regimens in non-small cell lung cancer, there is need for new options as third-line treatment.  Erlotinib and gefitinib are currently the only drugs of proven efficacy in the third-line setting.  Chemotherapy drugs, such as pemetrexed, are being investigated, as are many new agents, such as cetuximab, sunitinib, sorafenib, everolimus, enzastaurin, afilbercept.  These novel targeted therapies seem to improve response rates and progression-free survival and their toxicity is tolerable.  In an effort to prolong survival while maintaining quality of life, large prospective studies are needed to examine the effectiveness and safety of third-line regimens in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShxxgwn_cICo3yKPtYViAGfW6udTcc2eZtXDghU-ztSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3ktlOgtQ%253D%253D&md5=1dd65e85411730c21951f8baab1efb07</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSyrigos%26aufirst%3DK.%2BN.%26aulast%3DSaif%26aufirst%3DM.%2BW.%26aulast%3DKarapanagiotou%26aufirst%3DE.%2BM.%26aulast%3DOikonomopoulos%26aufirst%3DG.%26aulast%3DDe%2BMarinis%26aufirst%3DF.%26atitle%3DThe%2520Need%2520for%2520Third-Line%2520Treatment%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520An%2520Overview%2520of%2520New%2520Options%26jtitle%3DAnticancer%2520Res.%26date%3D2011%26volume%3D31%26spage%3D649%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span> <span> </span><span class="NLM_article-title">Anlotinib Inhibits Angiogenesis Via Suppressing the Activation of VEGFR2, PDGFRβ and FGFR1</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>654</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.gene.2018.02.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.gene.2018.02.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29454091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=654&publication_year=2018&pages=77-86&author=B.+Linauthor=X.+Songauthor=D.+Yangauthor=D.+Baiauthor=Y.+Yaoauthor=N.+Lu&title=Anlotinib+Inhibits+Angiogenesis+Via+Suppressing+the+Activation+of+VEGFR2%2C+PDGFR%CE%B2+and+FGFR1&doi=10.1016%2Fj.gene.2018.02.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1</span></div><div class="casAuthors">Lin, Binyan; Song, Xiuming; Yang, Dawei; Bai, Dongsheng; Yao, Yuyuan; Lu, Na</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">654</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tumor cells recruit vascular endothelial cells and circulating endothelial progenitor cells to form new vessels to support their own growth and metastasis.  VEGF, PDGF-BB and FGF-2 are three major pro-angiogenic factors and applied to promote angiogenesis.  In this research, we demonstrated that anlotinib, a potent multi-tyrosine kinases inhibitor (TKI), showed a significant inhibitory effect on VEGF/PDGF-BB/FGF-2-induced angiogenesis in vitro and in vivo.  Wound healing assay, chamber directional migration assay and tube formation assay indicated that anlotinib inhibited VEGF/PDGF-BB/FGF-2-induced cell migration and formation of capillary-like tubes in endothelial cells.  Furthermore, anlotinib suppressed blood vessels sprout and microvessel d. in rat aortic ring assay and chicken chorioallantoic membrane (CAM) assay.  Importantly, according to our study, the anti-angiogenic effect of anlotinib is superior to sunitinib, sorafenib and nintedanib, which are three main anti-angiogenesis drugs in clinic.  Mechanistically, anlotinib inhibits the activation of VEGFR2, PDGFRβ and FGFR1 as well their common downstream ERK signaling.  Therefore, anlotinib is a potential agent to inhibit angiogenesis and be applied to tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ1_1sUZdru7Vg90H21EOLACvtfcHk0lgvA1HMhQxenQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFeitrw%253D&md5=57b3bebdd38f455cd470a812a78b479f</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2018.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2018.02.026%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DB.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DBai%26aufirst%3DD.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DN.%26atitle%3DAnlotinib%2520Inhibits%2520Angiogenesis%2520Via%2520Suppressing%2520the%2520Activation%2520of%2520VEGFR2%252C%2520PDGFR%25CE%25B2%2520and%2520FGFR1%26jtitle%3DGene%26date%3D2018%26volume%3D654%26spage%3D77%26epage%3D86%26doi%3D10.1016%2Fj.gene.2018.02.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span> <span> </span><span class="NLM_article-title">Anlotinib as a Third-Line Therapy in Patients with Refractory Advanced Non-Small-Cell Lung Cancer: A Multicentre, Randomised Phase II Trial (ALTER0302)</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1038/bjc.2017.478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fbjc.2017.478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29438373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=654-661&author=B.+Hanauthor=K.+Liauthor=Y.+Zhaoauthor=B.+Liauthor=Y.+Chengauthor=J.+Zhouauthor=Y.+Luauthor=Y.+Shiauthor=Z.+Wangauthor=L.+Jiangauthor=Y.+Luoauthor=Y.+Zhangauthor=C.+Huangauthor=Q.+Liauthor=G.+Wu&title=Anlotinib+as+a+Third-Line+Therapy+in+Patients+with+Refractory+Advanced+Non-Small-Cell+Lung+Cancer%3A+A+Multicentre%2C+Randomised+Phase+II+Trial+%28ALTER0302%29&doi=10.1038%2Fbjc.2017.478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)</span></div><div class="casAuthors">Han, Baohui; Li, Kai; Zhao, Yizhuo; Li, Baolan; Cheng, Ying; Zhou, Jianying; Lu, You; Shi, Yuankai; Wang, Zhehai; Jiang, Liyan; Luo, Yi; Zhang, Yiping; Huang, Cheng; Li, Qiang; Wu, Guoming</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">654-661</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumor angiogenesis and proliferative signalling.  The objective of this study was to assess the safety and efficacy of third-line anlotinib for patients with refractory advanced non-small-cell lung cancer (RA-NSCLC).  Methods: Eligible patients were randomized 1 : 1 to receive anlotinib (12 mg per day, per os; days 1-14; 21 days per cycle) or a placebo.  The primary end point was progression-free survival (PFS).  Results: A total of 117 eligible patients enrolled from 13 clin. centers in China were analyzed in the full anal. set.  No patients received immune check-point inhibitors and epidermal growth factor receptor status was unknown in 60.7% of the population.  PFS was better with anlotinib compared with the placebo (4.8 vs 1.2 mo; hazard ratio (HR)=0.32; 95% confidence interval (CI), 0.20-0.51; P<0.0001), as well as overall response rate (ORR) (10.0%; 95% CI, 2.4-17.6% vs 0%; 95% CI, 0-6.27%; P=0.028).  The median overall survival (OS) was 9.3 mo (95% CI, 6.8-15.1) for the anlotinib group and 6.3 mo (95% CI, 4.3-10.5) for the placebo group (HR=0.78; 95% CI, 0.51-1.18; P=0.2316).  Adverse events were more frequent in the anlotinib than the placebo group.  The percentage of grade 3-4 treatment-related adverse events was 21.67% in the anlotinib group.  Conclusions: Anlotinib as a third-line treatment provided significant PFS benefits to patients with RA-NSCLC when compared with the placebo, and the toxicity profiles showed good tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri6DYDQBnPr7Vg90H21EOLACvtfcHk0lgvA1HMhQxenQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSgsbk%253D&md5=6fee39699543db9ae2aafe82da90c188</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.478%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DG.%26atitle%3DAnlotinib%2520as%2520a%2520Third-Line%2520Therapy%2520in%2520Patients%2520with%2520Refractory%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%253A%2520A%2520Multicentre%252C%2520Randomised%2520Phase%2520II%2520Trial%2520%2528ALTER0302%2529%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D654%26epage%3D661%26doi%3D10.1038%2Fbjc.2017.478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. P.</span></span> <span> </span><span class="NLM_article-title">Substituted Quinoline Compounds as Angiogenesis Inhibitors and Their Preparation and Use in the Treatment of Angiogenesis and Cancer</span>. <span class="NLM_patent">WO2008112407A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=G.+P.+Chen&title=Substituted+Quinoline+Compounds+as+Angiogenesis+Inhibitors+and+Their+Preparation+and+Use+in+the+Treatment+of+Angiogenesis+and+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%2BP.%26atitle%3DSubstituted%2520Quinoline%2520Compounds%2520as%2520Angiogenesis%2520Inhibitors%2520and%2520Their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Angiogenesis%2520and%2520Cancer%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit109b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. P. C.</span></span> <span> </span><span class="NLM_article-title">Kinase Inhibitors for the Treatment of Disease Associated with Angiogenesis</span>. <span class="NLM_patent">WO2010021918A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=G.+P.+C.+Chen&title=Kinase+Inhibitors+for+the+Treatment+of+Disease+Associated+with+Angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%2BP.%2BC.%26atitle%3DKinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Disease%2520Associated%2520with%2520Angiogenesis%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit109c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. P.</span>; <span class="NLM_string-name">Yan, C.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing an Anti-Cancer Agent, 1-{[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy]methyl}cyclopropanamine, Its Crystalline Form and Its Salts</span>. <span class="NLM_patent">WO2016179123A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=G.+P.+Chen&author=C.+Yan&title=Process+for+Preparing+an+Anti-Cancer+Agent%2C+1-%7B%5B4-%284-Fluoro-2-methyl-1H-indol-5-yloxy%29-6-methoxyquinolin-7-yloxy%5Dmethyl%7Dcyclopropanamine%2C+Its+Crystalline+Form+and+Its+Salts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%2BP.%26atitle%3DProcess%2520for%2520Preparing%2520an%2520Anti-Cancer%2520Agent%252C%25201-%257B%255B4-%25284-Fluoro-2-methyl-1H-indol-5-yloxy%2529-6-methoxyquinolin-7-yloxy%255Dmethyl%257Dcyclopropanamine%252C%2520Its%2520Crystalline%2520Form%2520and%2520Its%2520Salts%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span>; <span class="NLM_string-name">Zhang, X.</span>; <span class="NLM_string-name">Gao, Y.</span>; <span class="NLM_string-name">Chen, G.</span>; <span class="NLM_string-name">Wang, Q.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dong, P.</span>; <span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Crystal of Quinoline Derivative and Preparation Method Thereof</span>. <span class="NLM_patent">CN102344438A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Zhao&author=X.+Zhang&author=Y.+Gao&author=G.+Chen&author=Q.+Wang&author=Z.+Chen&author=P.+Dong&author=J.+Jin&title=Crystal+of+Quinoline+Derivative+and+Preparation+Method+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DR.%26atitle%3DCrystal%2520of%2520Quinoline%2520Derivative%2520and%2520Preparation%2520Method%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit110b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Jiang, H.</span>; <span class="NLM_string-name">Tian, X.</span>; <span class="NLM_string-name">Yang, L.</span></span> <span> </span><span class="NLM_article-title">Quinoline Derivative for Treatment of Neuroendocrine Tumors</span>. <span class="NLM_patent">WO2019052520A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=X.+Zhang&author=X.+Wang&author=H.+Jiang&author=X.+Tian&author=L.+Yang&title=Quinoline+Derivative+for+Treatment+of+Neuroendocrine+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DQuinoline%2520Derivative%2520for%2520Treatment%2520of%2520Neuroendocrine%2520Tumors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinhold, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Claire, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehrman, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span> <span> </span><span class="NLM_article-title">3′-Azido-3′-Deoxythymidine (BW A509U): An Antiviral Agent That Inhibits the Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus in Vitro</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">7096</span>, <span class="refDoi"> DOI: 10.1073/pnas.82.20.7096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1073%2Fpnas.82.20.7096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=2413459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaL2MXlvV2htbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1985&pages=7096&author=H.+Mitsuyaauthor=K.+J.+Weinholdauthor=P.+A.+Furmanauthor=M.+H.+St.+Claireauthor=S.+N.+Lehrmanauthor=R.+C.+Galloauthor=D.+Bolognesiauthor=D.+W.+Barryauthor=S.+Broder&title=3%E2%80%B2-Azido-3%E2%80%B2-Deoxythymidine+%28BW+A509U%29%3A+An+Antiviral+Agent+That+Inhibits+the+Infectivity+and+Cytopathic+Effect+of+Human+T-Lymphotropic+Virus+Type+III%2FLymphadenopathy-Associated+Virus+in+Vitro&doi=10.1073%2Fpnas.82.20.7096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">3'-Azido-3'-deoxythymidine (BW A509U):  an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro</span></div><div class="casAuthors">Mitsuya, Hiroaki; Weinhold, Kent J.; Furman, Phillip A.; St. Clair, Marty H.; Lehrman, Sandra Nusinoff; Gallo, Robert C.; Bolognesi, Dani; Barry, David W.; Broder, Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7096-100</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The antiviral effects of a thymidine analog, 3'-azido-3'-deoxythymidine (BW A509U)(I)  [30516-87-1], which, as a triphosphate, inhibits the reverse transcriptase of human T-lymphotropic virus type III (HTLV-III)/lymphadenopathy-assocd. virus (LAV) was detd.  This agent blocked the expression of the p24 gag protein of HTLV-III/LAV in H9 cells following exposure to virus.  The drug also inhibited the cytopathic effect of HTLV-IIIB (a virus derived from a pool of American patients) and HTLV-III/RF-II (an isolate obtained from a Haitian patient that differs by about 20% in the amino acid sequence of the envelope gene from several isolates of HTLV-III/LAV, including HTLV-IIIB, analyzed so far).  3'-Azido-3'-deoxythymidine also completely blocked viral replication as assessed by reverse transcriptase prodn. in normal human peripheral blood mononuclear cells exposed to HTLV-III.  Finally, at concns. of 3'-azido-3'-deoxythymidine that block the in vitro infectively and cytopathic effect of HTLV-IIIB, the in vitro immune functions of normal T cells remain basically intact.  These results are relevant to the treatment of AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6ef2jfFgGQbVg90H21EOLACvtfcHk0lghLxUcVmZV4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlvV2htbk%253D&md5=f56aaaed3c081c9a393e5fa8893f769c</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1073%2Fpnas.82.20.7096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.82.20.7096%26sid%3Dliteratum%253Aachs%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DWeinhold%26aufirst%3DK.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DSt.%2BClaire%26aufirst%3DM.%2BH.%26aulast%3DLehrman%26aufirst%3DS.%2BN.%26aulast%3DGallo%26aufirst%3DR.%2BC.%26aulast%3DBolognesi%26aufirst%3DD.%26aulast%3DBarry%26aufirst%3DD.%2BW.%26aulast%3DBroder%26aufirst%3DS.%26atitle%3D3%25E2%2580%25B2-Azido-3%25E2%2580%25B2-Deoxythymidine%2520%2528BW%2520A509U%2529%253A%2520An%2520Antiviral%2520Agent%2520That%2520Inhibits%2520the%2520Infectivity%2520and%2520Cytopathic%2520Effect%2520of%2520Human%2520T-Lymphotropic%2520Virus%2520Type%2520III%252FLymphadenopathy-Associated%2520Virus%2520in%2520Vitro%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1985%26volume%3D82%26spage%3D7096%26doi%3D10.1073%2Fpnas.82.20.7096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span> <span> </span><span class="NLM_article-title">Apalutamide: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0900-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0900-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29626324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVaqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=699-705&author=Z.+T.+Al-Salama&title=Apalutamide%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0900-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Apalutamide: First Global Approval</span></div><div class="casAuthors">Al-Salama, Zaina T.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">699-705</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Apalutamide (ErleadaTM) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC).  It binds directly to the ligand-binding domain of the AR and blocks the effects of androgens.  In Feb. 2018, apalutamide received its first global approval in the USA for the treatment of non-metastatic castration-resistant PC (nmCRPC).  Apalutamide is undergoing phase III investigation in chemotherapy-naive patients with metastatic CRPC (in combination with abiraterone acetate plus prednisone), patients with high-risk localized or locally advanced PC receiving primary radiation therapy, and in patients with metastatic hormone-sensitive PC and biochem.-relapsed PC.  This article summarizes the milestones in the development of apalutamide leading to this first approval in nmCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfajxysBf-c7Vg90H21EOLACvtfcHk0lhJbc9MT8dthw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVaqtr8%253D&md5=b6a8295485956422287476b4192ee789</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0900-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0900-z%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26atitle%3DApalutamide%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D699%26epage%3D705%26doi%3D10.1007%2Fs40265-018-0900-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span>; <span class="NLM_string-name">Yoo, D.</span>; <span class="NLM_string-name">Sawyers, C. L.</span>; <span class="NLM_string-name">Tran, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of Diarylthiohydantoins as Androgen Receptor Antagonists for the Treatment of Hormone Refractory Prostate Cancer</span>. <span class="NLM_patent">US20070254933A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Jung&author=D.+Yoo&author=C.+L.+Sawyers&author=C.+Tran&title=Preparation+of+Diarylthiohydantoins+as+Androgen+Receptor+Antagonists+for+the+Treatment+of+Hormone+Refractory+Prostate+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Diarylthiohydantoins%2520as%2520Androgen%2520Receptor%2520Antagonists%2520for%2520the%2520Treatment%2520of%2520Hormone%2520Refractory%2520Prostate%2520Cancer%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebenek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, T. A.</span></span> <span> </span><span class="NLM_article-title">The Accuracy of Reverse Transcriptase from HIV-1</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>242</i></span>,  <span class="NLM_fpage">1171</span>, <span class="refDoi"> DOI: 10.1126/science.2460925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1126%2Fscience.2460925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=2460925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaL1MXjs1SmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=242&publication_year=1988&pages=1171&author=J.+D.+Robertsauthor=K.+Bebenekauthor=T.+A.+Kunkel&title=The+Accuracy+of+Reverse+Transcriptase+from+HIV-1&doi=10.1126%2Fscience.2460925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The accuracy of reverse transcriptase from HIV-1</span></div><div class="casAuthors">Roberts, John D.; Bebenek, Katarzyna; Kunkel, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">242</span>
        (<span class="NLM_cas:issue">4882</span>),
    <span class="NLM_cas:pages">1171-3</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A study was conducted to det. the fidelity of DNA synthesis catalyzed in vitro by the reverse transcriptase from a human immunodeficiency virus type 1 (HIV-1).  Like other retroviral reverse transcriptases, the HIV-1 enzyme does not correct errors by exonucleolytic proofreading.  Measurements with M13mp2-based fidelity assays indicated that the HIV-1 enzyme, isolated either from virus particles or from Escherichia coli cells infected with a plasmid expressing the cloned gene, was exceptionally inaccurate, having an av. error rate per detectable nucleotide incorporated of 1/1700.  It was, in fact, the least accurate reverse transcriptase described to date, one-tenth as accurate as the polymerases isolated from avian myeloblastosis or murine leukemia viruses, which have av. error rates of ∼1/17,000 and ∼1/30,000, resp.  DNA sequence analyses of mutations generated by HIV-1 polymerase showed that base substitution, addn., and deletion errors were all produced.  Certain template positions were mutational hotspots where the error rate could be as high as 1 per 70 polymd. nucleotides.  The data are consistent with the notion that the exceptional diversity of the HIV-1 genome results from error-prone reverse transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraUU7LzeJgzrVg90H21EOLACvtfcHk0lhJbc9MT8dthw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXjs1SmsQ%253D%253D&md5=c8c40b64b883d6ae14d445f07a243e59</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1126%2Fscience.2460925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2460925%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DJ.%2BD.%26aulast%3DBebenek%26aufirst%3DK.%26aulast%3DKunkel%26aufirst%3DT.%2BA.%26atitle%3DThe%2520Accuracy%2520of%2520Reverse%2520Transcriptase%2520from%2520HIV-1%26jtitle%3DScience%26date%3D1988%26volume%3D242%26spage%3D1171%26doi%3D10.1126%2Fscience.2460925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isaacsson Velho, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carducci, M. A.</span></span> <span> </span><span class="NLM_article-title">Investigational Therapies Targeting the Androgen Signaling Axis and the Androgen Receptor and in Prostate Cancer - Recent Developments and Future Directions</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1080/13543784.2018.1513490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F13543784.2018.1513490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30118330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GktL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=811-822&author=P.+Isaacsson+Velhoauthor=M.+A.+Carducci&title=Investigational+Therapies+Targeting+the+Androgen+Signaling+Axis+and+the+Androgen+Receptor+and+in+Prostate+Cancer+-+Recent+Developments+and+Future+Directions&doi=10.1080%2F13543784.2018.1513490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions</span></div><div class="casAuthors">Isaacsson Velho, Pedro; Carducci, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">811-822</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Despite the heterogeneity of prostate cancer (PCa), androgen stimulation is fundamental to its development, growth, and lethality.  Therefore, the blockade of androgen receptor (AR) signaling is crit. to controlling the disease, even after progression with castrate levels of androgens.  We review the current understanding of new ways to block the AR, using novel antiandrogen inhibitors, which act on different parts of the AR signaling pathway in PCa.  We also review new approaches, such as the use of poly(ADP-ribose) polymerase (PARP) inhibitors, targeting both the AR and the DNA repair pathway, potentially adding synergy and improving efficacy and the combination of AR inhibitors and immunotherapy.  Bipolar androgen therapy (BAT), an innovative strategy to target the AR, has shown early evidence of efficacy in PCa is also discussed in detail.  We highlight some of the key ongoing studies of greatest relevance to this topic.: Clin. trials investigating new AR-targeted therapies should be encouraged in patients with PCa.  While it is unlikely that one AR inhibitor will produce long-lasting responses in a substantial proportion of patients, there is evidence that some strategies, such as the BAT could resensitize the AR to antiandrogens, alternating therapies and delaying time to progression, maximizing benefit to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod_gi-9BnoLLVg90H21EOLACvtfcHk0lhJbc9MT8dthw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GktL7E&md5=2659edaa5397a0ee6fe46e6651e2ce6a</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1080%2F13543784.2018.1513490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2018.1513490%26sid%3Dliteratum%253Aachs%26aulast%3DIsaacsson%2BVelho%26aufirst%3DP.%26aulast%3DCarducci%26aufirst%3DM.%2BA.%26atitle%3DInvestigational%2520Therapies%2520Targeting%2520the%2520Androgen%2520Signaling%2520Axis%2520and%2520the%2520Androgen%2520Receptor%2520and%2520in%2520Prostate%2520Cancer%2520-%2520Recent%2520Developments%2520and%2520Future%2520Directions%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2018%26volume%3D27%26spage%3D811%26epage%3D822%26doi%3D10.1080%2F13543784.2018.1513490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bambury, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathkopf, D. E.</span></span> <span> </span><span class="NLM_article-title">Novel and Next-Generation Androgen Receptor-Directed Therapies for Prostate Cancer: Beyond Abiraterone and Enzalutamide</span>. <i>Urol. Oncol.: Semin. Orig. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1016/j.urolonc.2015.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.urolonc.2015.05.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=26162486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=348-355&author=R.+M.+Bamburyauthor=D.+E.+Rathkopf&title=Novel+and+Next-Generation+Androgen+Receptor-Directed+Therapies+for+Prostate+Cancer%3A+Beyond+Abiraterone+and+Enzalutamide&doi=10.1016%2Fj.urolonc.2015.05.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide</span></div><div class="casAuthors">Bambury, Richard M.; Rathkopf, Dana E.</div><div class="citationInfo"><span class="NLM_cas:title">Urologic Oncology: Seminars and Original Investigations</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">348-355</span>CODEN:
                <span class="NLM_cas:coden">UOSOAA</span>;
        ISSN:<span class="NLM_cas:issn">1078-1439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The approval of abiraterone and enzalutamide for the treatment of advanced castration-resistant prostate cancer heralded a paradigm shift in the management of this disease.  Nevertheless, new and improved treatments are needed since the disease remains incurable for the majority of these patients.  In this article, we review the biol. of castration-resistant disease as well as emerging therapeutic compds. directed at the androgen receptor, including galeterone, VT-464, ARN-509, and ODM-201.  Mechanisms of action, early clin. data, and ongoing clin. studies for these compds. are all reviewed.  The need to find optimal sequencing and combination strategies as well as the need for predictive biomarkers of response to these agents is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq18y5Xt5wFGrVg90H21EOLACvtfcHk0ljIgvBLWpg-jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygsrbL&md5=f16bb4806d79d9030f52f2e4c170e448</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2015.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2015.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DBambury%26aufirst%3DR.%2BM.%26aulast%3DRathkopf%26aufirst%3DD.%2BE.%26atitle%3DNovel%2520and%2520Next-Generation%2520Androgen%2520Receptor-Directed%2520Therapies%2520for%2520Prostate%2520Cancer%253A%2520Beyond%2520Abiraterone%2520and%2520Enzalutamide%26jtitle%3DUrol.%2520Oncol.%253A%2520Semin.%2520Orig.%2520Invest.%26date%3D2016%26volume%3D34%26spage%3D348%26epage%3D355%26doi%3D10.1016%2Fj.urolonc.2015.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadaschik, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainwaring, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Gitlitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espina, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rackoff, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, E. J.</span></span> <span> </span><span class="NLM_article-title">Apalutamide Treatment and Metastasis-Free Survival in Prostate Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1408</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1715546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1056%2FNEJMoa1715546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29420164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVCmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1408-1418&author=M.+R.+Smithauthor=F.+Saadauthor=S.+Chowdhuryauthor=S.+Oudardauthor=B.+A.+Hadaschikauthor=J.+N.+Graffauthor=D.+Olmosauthor=P.+N.+Mainwaringauthor=J.+Y.+Leeauthor=H.+Uemuraauthor=A.+Lopez-Gitlitzauthor=G.+C.+Trudelauthor=B.+M.+Espinaauthor=Y.+Shuauthor=Y.+C.+Parkauthor=W.+R.+Rackoffauthor=M.+K.+Yuauthor=E.+J.+Small&title=Apalutamide+Treatment+and+Metastasis-Free+Survival+in+Prostate+Cancer&doi=10.1056%2FNEJMoa1715546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Apalutamide treatment and metastasis-free survival in prostate cancer</span></div><div class="casAuthors">Smith, Matthew R.; Saad, Fred; Chowdhury, Simon; Oudard, Stephane; Hadaschik, Boris A.; Graff, Julie N.; Olmos, David; Mainwaring, Paul N.; Lee, Ji Youl; Uemura, Hiroji; Lopez-Gitlitz, Angela; Trudel, Geralyn C.; Espina, Byron M.; Shu, Youyi; Park, Youn C.; Rackoff, Wayne R.; Yu, Margaret K.; Small, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1408-1418</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer.  We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis. methods We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 mo or less.  Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo.  All the patients continued to receive androgen-deprivation therapy.  The primary end point was metastasis-free survival, which was defined as the time from randomization to the first detection of distant metastasis on imaging or death. results A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo group).  In the planned primary anal., which was performed after 378 events had occurred, median metastasis-free survival was 40.5 mo in the apalutamide group as compared with 16.2 mo in the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 0.35; P<0.001).  Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001).  The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group.  The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%). conclusions Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0nCARi0YWC7Vg90H21EOLACvtfcHk0ljIgvBLWpg-jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVCmurk%253D&md5=ef5fead8f1f12720031f124b412c937a</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1715546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1715546%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BR.%26aulast%3DSaad%26aufirst%3DF.%26aulast%3DChowdhury%26aufirst%3DS.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DHadaschik%26aufirst%3DB.%2BA.%26aulast%3DGraff%26aufirst%3DJ.%2BN.%26aulast%3DOlmos%26aufirst%3DD.%26aulast%3DMainwaring%26aufirst%3DP.%2BN.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DUemura%26aufirst%3DH.%26aulast%3DLopez-Gitlitz%26aufirst%3DA.%26aulast%3DTrudel%26aufirst%3DG.%2BC.%26aulast%3DEspina%26aufirst%3DB.%2BM.%26aulast%3DShu%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DY.%2BC.%26aulast%3DRackoff%26aufirst%3DW.%2BR.%26aulast%3DYu%26aufirst%3DM.%2BK.%26aulast%3DSmall%26aufirst%3DE.%2BJ.%26atitle%3DApalutamide%2520Treatment%2520and%2520Metastasis-Free%2520Survival%2520in%2520Prostate%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D1408%26epage%3D1418%26doi%3D10.1056%2FNEJMoa1715546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Bian, J.</span>; <span class="NLM_string-name">Yu, J.</span>; <span class="NLM_string-name">Wang, M.</span>; <span class="NLM_string-name">Dai, X.</span></span> <span> </span><span class="NLM_article-title">Preparation of Apalutamide</span>. <span class="NLM_patent">CN107501237A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Qin&author=Y.+Chen&author=J.+Bian&author=J.+Yu&author=M.+Wang&author=X.+Dai&title=Preparation+of+Apalutamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Apalutamide%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit118b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span>; <span class="NLM_string-name">Yang, J.</span>; <span class="NLM_string-name">Nie, F.</span>; <span class="NLM_string-name">Yang, Y.</span>; <span class="NLM_string-name">Jiang, X.</span></span> <span> </span><span class="NLM_article-title">Preparation of Diaryl Thiohydantoin Compound Apalutamide</span>. <span class="NLM_patent">CN108047200A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=H.+Bian&author=J.+Yang&author=F.+Nie&author=Y.+Yang&author=X.+Jiang&title=Preparation+of+Diaryl+Thiohydantoin+Compound+Apalutamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBian%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520Diaryl%2520Thiohydantoin%2520Compound%2520Apalutamide%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit118c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span>; <span class="NLM_string-name">Wei, D.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Preparing Method of Apalutamide and Intermediates</span>. <span class="NLM_patent">CN108069869A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Z.+Hu&author=D.+Wei&author=X.+Zhu&author=S.+Wang&title=Preparing+Method+of+Apalutamide+and+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DZ.%26atitle%3DPreparing%2520Method%2520of%2520Apalutamide%2520and%2520Intermediates%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit118d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, A. R.</span>; <span class="NLM_string-name">Kanniah, S. L.</span>; <span class="NLM_string-name">Arote, N. D.</span>; <span class="NLM_string-name">Bhagwat, O. V.</span>; <span class="NLM_string-name">Sonar, J. K.</span>; <span class="NLM_string-name">Poundkar, V. B.</span>; <span class="NLM_string-name">Wagh, Y. D.</span></span> <span> </span><span class="NLM_article-title">Solid State Forms of Apalutamide</span>. <span class="NLM_patent">WO2018112001A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+R.+Muthusamy&author=S.+L.+Kanniah&author=N.+D.+Arote&author=O.+V.+Bhagwat&author=J.+K.+Sonar&author=V.+B.+Poundkar&author=Y.+D.+Wagh&title=Solid+State+Forms+of+Apalutamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMuthusamy%26aufirst%3DA.%2BR.%26atitle%3DSolid%2520State%2520Forms%2520of%2520Apalutamide%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit118e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-H.</span>; <span class="NLM_string-name">Guo, J.-C.</span>; <span class="NLM_string-name">Shih, W.-L.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Apalutamide</span>. <span class="NLM_patent">US20180201601A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.-H.+Chen&author=J.-C.+Guo&author=W.-L.+Shih&title=Process+for+Preparing+Apalutamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.-H.%26atitle%3DProcess%2520for%2520Preparing%2520Apalutamide%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit118f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Pawar, A. A.</span>; <span class="NLM_string-name">Subba Reddy, P. R.</span>; <span class="NLM_string-name">Mudapaka, V. K.</span>; <span class="NLM_string-name">Gopi, S. P.</span>; <span class="NLM_string-name">Reddy, K. R. S.</span>; <span class="NLM_string-name">Verma, H.</span></span> <span> </span><span class="NLM_article-title">Amorphous Solid Dispersions of Apalutamide and Process for the Preparation Thereof</span>. <span class="NLM_patent">WO2019016747A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+A.+Pawar&author=P.+R.+Subba+Reddy&author=V.+K.+Mudapaka&author=S.+P.+Gopi&author=K.+R.+S.+Reddy&author=H.+Verma&title=Amorphous+Solid+Dispersions+of+Apalutamide+and+Process+for+the+Preparation+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPawar%26aufirst%3DA.%2BA.%26atitle%3DAmorphous%2520Solid%2520Dispersions%2520of%2520Apalutamide%2520and%2520Process%2520for%2520the%2520Preparation%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span>; <span class="NLM_string-name">Bonnefous, C.</span>; <span class="NLM_string-name">Julien, J. D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Spiro Thiohydantoin Compounds as Androgen Receptor Modulators</span>. <span class="NLM_patent">WO2011103202A2</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+D.+Smith&author=C.+Bonnefous&author=J.+D.+Julien&title=Preparation+of+Spiro+Thiohydantoin+Compounds+as+Androgen+Receptor+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DPreparation%2520of%2520Spiro%2520Thiohydantoin%2520Compounds%2520as%2520Androgen%2520Receptor%2520Modulators%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit119b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Haim, C. B.</span>; <span class="NLM_string-name">Horvath, A.</span>; <span class="NLM_string-name">Weerts, J. E. E.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Apalutamide</span>. <span class="NLM_patent">WO2016100652A2</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=C.+B.+Haim&author=A.+Horvath&author=J.+E.+E.+Weerts&title=Process+for+the+Preparation+of+Apalutamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHaim%26aufirst%3DC.%2BB.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Apalutamide%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit119c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Haim, C. B.</span>; <span class="NLM_string-name">Horvath, A.</span>; <span class="NLM_string-name">Weerts, J. E. E.</span>; <span class="NLM_string-name">Albaneze-Walker, J.</span></span> <span> </span><span class="NLM_article-title">Processes for the Preparation of a Diarylthiohydantoin Compound</span>. <span class="NLM_patent">WO2016100645A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=C.+B.+Haim&author=A.+Horvath&author=J.+E.+E.+Weerts&author=J.+Albaneze-Walker&title=Processes+for+the+Preparation+of+a+Diarylthiohydantoin+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHaim%26aufirst%3DC.%2BB.%26atitle%3DProcesses%2520for%2520the%2520Preparation%2520of%2520a%2520Diarylthiohydantoin%2520Compound%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit119d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bignan, G.</span>; <span class="NLM_string-name">Connolly, P. J.</span>; <span class="NLM_string-name">Hickson, I.</span>; <span class="NLM_string-name">Meerpoel, L.</span>; <span class="NLM_string-name">Pande, V.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Branch, J.</span>; <span class="NLM_string-name">Rocaboy, C.</span>; <span class="NLM_string-name">Trabalon Escolar, L. B.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Thiohydantoin Derivatives as Androgen Receptor Antagonists</span>. <span class="NLM_patent">WO2017123542A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Bignan&author=P.+J.+Connolly&author=I.+Hickson&author=L.+Meerpoel&author=V.+Pande&author=Z.+Zhang&author=J.+Branch&author=C.+Rocaboy&author=L.+B.+Trabalon+Escolar&title=Preparation+of+Substituted+Thiohydantoin+Derivatives+as+Androgen+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBignan%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Substituted%2520Thiohydantoin%2520Derivatives%2520as%2520Androgen%2520Receptor%2520Antagonists%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, M.</span></span> <span> </span><span class="NLM_article-title">Selective Catalytic Hydrogenation of Functionalized Nitroarenes: An Update</span>. <i>ChemCatChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1002/cctc.200900129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fcctc.200900129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1amt7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=210-221&author=H.-U.+Blaserauthor=H.+Steinerauthor=M.+Studer&title=Selective+Catalytic+Hydrogenation+of+Functionalized+Nitroarenes%3A+An+Update&doi=10.1002%2Fcctc.200900129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Catalytic Hydrogenation of Functionalized Nitroarenes: An Update</span></div><div class="casAuthors">Blaser, Hans-Ulrich; Steiner, Heinz; Studer, Martin</div><div class="citationInfo"><span class="NLM_cas:title">ChemCatChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-221</span>CODEN:
                <span class="NLM_cas:coden">CHEMK3</span>;
        ISSN:<span class="NLM_cas:issn">1867-3880</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Progress made in the last decade for the selective catalytic hydrogenation of nitroarenes in the presence of other reducible functions is reviewed.  The main focus is on catalytic systems capable of reducing nitro groups with very high chemoselectivity in substrates contg. carbon-carbon or carbon-nitrogen double or triple bonds, carbonyl or benzyl groups, and multiple Cl, Br, or I substituents.  The performance of new catalyst types is described, most notably of gold-based catalysts, but also of modified classical Pt, Pd, and Ni catalysts, as well as homogeneous catalysts.  The best results for the various chemoselectivity problems are compiled and assessed with regard to their versatility and synthetic viability.  In addn., progress in understanding mechanistic aspects are briefly described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZbqcwraSCLbVg90H21EOLACvtfcHk0lh-jVws67i8sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1amt7nM&md5=1044185cf70d0c5bd48031a26a62c437</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1002%2Fcctc.200900129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcctc.200900129%26sid%3Dliteratum%253Aachs%26aulast%3DBlaser%26aufirst%3DH.-U.%26aulast%3DSteiner%26aufirst%3DH.%26aulast%3DStuder%26aufirst%3DM.%26atitle%3DSelective%2520Catalytic%2520Hydrogenation%2520of%2520Functionalized%2520Nitroarenes%253A%2520An%2520Update%26jtitle%3DChemCatChem%26date%3D2009%26volume%3D1%26spage%3D210%26epage%3D221%26doi%3D10.1002%2Fcctc.200900129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rose, A. A. N.</span></span> <span> </span><span class="NLM_article-title">Encorafenib and Binimetinib for the Treatment of BRAF V600E/K-Mutated Melanoma</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1358/dot.2019.55.4.2958476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdot.2019.55.4.2958476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3M7hvFOqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=247-264&author=A.+A.+N.+Rose&title=Encorafenib+and+Binimetinib+for+the+Treatment+of+BRAF+V600E%2FK-Mutated+Melanoma&doi=10.1358%2Fdot.2019.55.4.2958476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma</span></div><div class="casAuthors">Rose A A N</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">247-264</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">BRAF is a constituent of the mitogen-activated protein kinase (MAPK) signaling pathway, which serves to activate downstream MEK, and is one of the most commonly mutated oncogenes in human tumors.  Indeed, BRAF V600 mutations are present in approximately 40% of metastatic melanoma tumors.  Encorafenib (LGX-818, Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK, respectively.  BRAF and MEK inhibitors have been shown to improve overall and progression-free survival among patients with metastatic melanoma.  Of these inhibitors, encorafenib and binimetinib are the newest combination, which received approval by the Food and Drug Administration (FDA) for the treatment of BRAF V600E/K-mutated melanoma in June 2018.  This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF V600-mutated melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzgEWjSIiY6SM8MEzWGjS9fW6udTcc2eY_2sAnhNlqbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7hvFOqug%253D%253D&md5=0a6adb92ca9611aa52a5ca5c5bf9240e</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1358%2Fdot.2019.55.4.2958476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2019.55.4.2958476%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DA.%2BA.%2BN.%26atitle%3DEncorafenib%2520and%2520Binimetinib%2520for%2520the%2520Treatment%2520of%2520BRAF%2520V600E%252FK-Mutated%2520Melanoma%26jtitle%3DDrugs%2520Today%26date%3D2019%26volume%3D55%26spage%3D247%26epage%3D264%26doi%3D10.1358%2Fdot.2019.55.4.2958476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Liberal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span> <span> </span><span class="NLM_article-title">BRAF and MEK Inhibition for the Treatment of Advanced BRAF Mutant Melanoma</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1297</span>, <span class="refDoi"> DOI: 10.1517/14656566.2015.1044971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1517%2F14656566.2015.1044971" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=26001180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFait78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1285-1297&author=J.+Richmanauthor=J.+Martin-Liberalauthor=S.+Diemauthor=J.+Larkin&title=BRAF+and+MEK+Inhibition+for+the+Treatment+of+Advanced+BRAF+Mutant+Melanoma&doi=10.1517%2F14656566.2015.1044971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma</span></div><div class="casAuthors">Richman, Juliet; Martin-Liberal, Juan; Diem, Stefan; Larkin, James</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1285-1297</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: BRAF inhibition alone has achieved unprecedented efficacy results in patients affected by BRAF-mutated advanced melanoma.  Since these findings, it was postulated that dual inhibition of BRAF and other components of the RAS/RAF/MEK/ERK MAPK pathway (such as MEK) would be superior to BRAF inhibition as monotherapy.  A series of recent clin. trials have confirmed this hypothesis.  Areas covered: In this article, the biol. rationale for both single and concomitant inhibitions of the MAPK pathway in BRAF mutant melanoma is provided.  Moreover, available clin. data on the efficacy and toxicity of BRAF and MEK inhibition as single agents and in combination are extensively reviewed.  Expert opinion: Dual BRAF and MEK inhibition in advanced BRAF-mutated melanoma is superior to single inhibition in terms of efficacy without significant increase in toxicity.  Therefore, BRAF plus MEK inhibition is expected to supersede single-agent BRAF inhibition in these patients in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1FrIWkBI77bVg90H21EOLACvtfcHk0lh-jVws67i8sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFait78%253D&md5=ead554efadd66f2c617dbfd9baa4e2d3</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1044971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1044971%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DJ.%26aulast%3DMartin-Liberal%26aufirst%3DJ.%26aulast%3DDiem%26aufirst%3DS.%26aulast%3DLarkin%26aufirst%3DJ.%26atitle%3DBRAF%2520and%2520MEK%2520Inhibition%2520for%2520the%2520Treatment%2520of%2520Advanced%2520BRAF%2520Mutant%2520Melanoma%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D1285%26epage%3D1297%26doi%3D10.1517%2F14656566.2015.1044971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krajsova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loquai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moutouh-de Parseval, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickard, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma (COLUMBUS): A Multicentre, Open-Label, Randomised Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30142-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS1470-2045%2818%2930142-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29573941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlslKltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=603-615&author=R.+Dummerauthor=P.+A.+Asciertoauthor=H.+J.+Gogasauthor=A.+Aranceauthor=M.+Mandalaauthor=G.+Liszkayauthor=C.+Garbeauthor=D.+Schadendorfauthor=I.+Krajsovaauthor=R.+Gutzmerauthor=V.+Chiarion-Sileniauthor=C.+Dutriauxauthor=J.+W.+B.+de+Grootauthor=N.+Yamazakiauthor=C.+Loquaiauthor=L.+A.+Moutouh-de+Parsevalauthor=M.+D.+Pickardauthor=V.+Sandorauthor=C.+Robertauthor=K.+T.+Flaherty&title=Encorafenib+Plus+Binimetinib+Versus+Vemurafenib+or+Encorafenib+in+Patients+with+BRAF-Mutant+Melanoma+%28COLUMBUS%29%3A+A+Multicentre%2C+Open-Label%2C+Randomised+Phase+3+Trial&doi=10.1016%2FS1470-2045%2818%2930142-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial</span></div><div class="casAuthors">Dummer, Reinhard; Ascierto, Paolo A.; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A.; Pickard, Michael D.; Sandor, Victor; Robert, Caroline; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">603-615</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Combined BRAF-MEK inhibitor therapy is the std. of care for BRAFV600-mutant advanced melanoma.  We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, vs. vemurafenib in patients with advanced BRAFV600-mutant melanoma.  COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries.  Eligible patients were aged 18 years or older and had histol. confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a BRAFV600E or BRAFV600K mutation; an Eastern Cooperative Oncol. Group (ECOG) performance status of 0 or 1; and were treatment naive or had progressed on or after previous first-line immunotherapy.  In part 1 of the study, patients were randomly assigned (1:1:1) via interactive response technol. to receive either oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group).  The primary endpoint was progression-free survival by blinded independent central review for encorafenib plus binimetinib vs. vemurafenib.  Efficacy analyses were by intention-to-treat.  Safety was analyzed in patients who received at least one dose of study drug and one postbaseline safety assessment.  The results of part 2 will be published sep.  This study is registered with ClinicalTrials.gov, no. NCT01909453, and EudraCT, no. 2013-001176-38.  Between Dec 30, 2013, and Apr. 10, 2015, 577 of 1345 screened patients were randomly assigned to either the encorafenib plus binimetinib group (n=192), the encorafenib group (n=194), or the vemurafenib group (n=191).  With a median follow-up of 16·6 mo (95% CI 14·8-16·9), median progression-free survival was 14·9 mo (95% CI 11·0-18·5) in the encorafenib plus binimetinib group and 7·3 mo (5·6-8·2) in the vemurafenib group (hazard ratio [HR] 0·54, 95% CI 0·41-0·71; two-sided p<0·0001).  The most common grade 3-4 adverse events seen in more than 5% of patients in the encorafenib plus binimetinib group were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased creatine phosphokinase (13 [7%]), and hypertension (11 [6%]); in the encorafenib group they were palmoplantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and in the vemurafenib group it was arthralgia (11 [6%] of 186 patients).  There were no treatment-related deaths except for one death in the combination group, which was considered possibly related to treatment by the investigator.  Encorafenib plus binimetinib and encorafenib monotherapy showed favorable efficacy compared with vemurafenib.  Overall, encorafenib plus binimetinib appears to have an improved tolerability profile compared with encorafenib or vemurafenib.  Encorafenib plus binimetinib could represent a new treatment option for patients with BRAF-mutant melanoma.Array BioPharma, Novartis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjPYLzOZ57s7Vg90H21EOLACvtfcHk0ljt78t5vG7QrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlslKltr4%253D&md5=4570e5b6091c5683a5f8a2d09110d541</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930142-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930142-6%26sid%3Dliteratum%253Aachs%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DGogas%26aufirst%3DH.%2BJ.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DKrajsova%26aufirst%3DI.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BW.%2BB.%26aulast%3DYamazaki%26aufirst%3DN.%26aulast%3DLoquai%26aufirst%3DC.%26aulast%3DMoutouh-de%2BParseval%26aufirst%3DL.%2BA.%26aulast%3DPickard%26aufirst%3DM.%2BD.%26aulast%3DSandor%26aufirst%3DV.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DEncorafenib%2520Plus%2520Binimetinib%2520Versus%2520Vemurafenib%2520or%2520Encorafenib%2520in%2520Patients%2520with%2520BRAF-Mutant%2520Melanoma%2520%2528COLUMBUS%2529%253A%2520A%2520Multicentre%252C%2520Open-Label%252C%2520Randomised%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D603%26epage%3D615%26doi%3D10.1016%2FS1470-2045%2818%2930142-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Synthesizing Method for Binimetinib</span>. <span class="NLM_patent">CN105820124A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Chen&title=Synthesizing+Method+for+Binimetinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DSynthesizing%2520Method%2520for%2520Binimetinib%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krell, C. M.</span>; <span class="NLM_string-name">Misun, M.</span>; <span class="NLM_string-name">Niederer, D. A.</span>; <span class="NLM_string-name">Pachinger, W. H.</span>; <span class="NLM_string-name">Wolf, M.-C.</span>; <span class="NLM_string-name">Zimmermann, D.</span>; <span class="NLM_string-name">Liu, W.</span>; <span class="NLM_string-name">Stengel, P. J.</span>; <span class="NLM_string-name">Nichols, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of and Formulation Comprising a Mek Inhibitor</span>. <span class="NLM_patent">WO2014063024A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+M.+Krell&author=M.+Misun&author=D.+A.+Niederer&author=W.+H.+Pachinger&author=M.-C.+Wolf&author=D.+Zimmermann&author=W.+Liu&author=P.+J.+Stengel&author=P.+Nichols&title=Preparation+of+and+Formulation+Comprising+a+Mek+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKrell%26aufirst%3DC.%2BM.%26atitle%3DPreparation%2520of%2520and%2520Formulation%2520Comprising%2520a%2520Mek%2520Inhibitor%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1947</span>– <span class="NLM_lpage">1953</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1028-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1028-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30506139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3crnslGgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1947-1953&author=M.+Shirley&title=Dacomitinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1028-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib: First Global Approval</span></div><div class="casAuthors">Shirley Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1947-1953</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dacomitinib (Vizimpro(®)) is an orally administered, small-molecule irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid tumours.  In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.  Registration applications for the use of dacomitinib as first-line treatment for patients with EGFR-mutation-positive metastatic NSCLC have also been submitted in the EU and Japan.  This article summarizes the milestones in the development of dacomitinib leading to this first approval for the first-line treatment of patients with EGFR-mutated metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA4VT-ypttQfSAs_PE1QvifW6udTcc2ebabqC9YtP8RLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnslGgsw%253D%253D&md5=0e035cd4b47b60f40c2af1d3c1fb5add</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1028-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1028-x%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DDacomitinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1947%26epage%3D1953%26doi%3D10.1007%2Fs40265-018-1028-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Díaz-Serrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugazagoitia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, L. P.-A.</span></span> <span> </span><span class="NLM_article-title">Targeting EGFR in Lung Cancer: Current Standards and Developments</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0916-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0916-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29915896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1aksr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=893-911&author=A.+D%C3%ADaz-Serranoauthor=P.+Gellaauthor=E.+Jim%C3%A9nezauthor=J.+Zugazagoitiaauthor=L.+P.-A.+Rodr%C3%ADguez&title=Targeting+EGFR+in+Lung+Cancer%3A+Current+Standards+and+Developments&doi=10.1007%2Fs40265-018-0916-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting EGFR in Lung Cancer: Current Standards and Developments</span></div><div class="casAuthors">Diaz-Serrano, Asuncion; Gella, Pablo; Jimenez, Elisabeth; Zugazagoitia, Jon; Paz-Ares Rodriguez, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">893-911</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Lung cancer is the second most common malignant tumor and the leading cause of cancer death.  Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a distinct subtype of lung cancer comprising approx. 15-40% of non-squamous tumors.  The development of first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) has been a significant step forward in the treatment of patients with EGFR-mutant tumors, and over the last few years has been the therapy of choice in the initial management of patients with activating mutations in EGFR, with some differences in efficacy and toxicity profile.  Up to 50% of patients treated with first- and second-generation TKIs develop an EGFR exon 20 T790M mutation at the time of progression.  In this context, osimertinib has shown a great benefit in terms of progression-free survival (PFS) in the second-line setting, including central nervous system metastasis control.  The FLAURA trial, which compared osimertinib to first-generation inhibitors as first-line therapy, showed a clear PFS advantage for osimertinib and a trend towards an increased overall survival (OS) assessed by investigator review.  Although T790M mutation is the most common mechanism of resistance to first- and second-generation EGFR TKIs, other EGFR-dependent and -independent mechanisms have been described, such as HER2 and MET amplifications or BRAF and MEK mutations.  Some mechanisms of resistance to osimertinib and other third-generation TKIs have also been described.  Several fourth-generation TKIs, targeted drug combinations and immunotherapy strategies are under investigation to overcome resistance to EGFR TKIs in order to improve EGFR-mutant NSCLC patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJpVCr1NbkELVg90H21EOLACvtfcHk0lj8z5WpZLW12Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1aksr3J&md5=e5223d828d256d44256bd5db029306b5</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0916-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0916-4%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25ADaz-Serrano%26aufirst%3DA.%26aulast%3DGella%26aufirst%3DP.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DE.%26aulast%3DZugazagoitia%26aufirst%3DJ.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DL.%2BP.-A.%26atitle%3DTargeting%2520EGFR%2520in%2520Lung%2520Cancer%253A%2520Current%2520Standards%2520and%2520Developments%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D893%26epage%3D911%26doi%3D10.1007%2Fs40265-018-0916-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbar, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR-Mutation-Positive Non-Small-Cell Lung Cancer (ARCHER 1050): A Randomised, Open-Label, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30608-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS1470-2045%2817%2930608-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28958502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1454-1466&author=Y.-L.+Wuauthor=Y.+Chengauthor=X.+Zhouauthor=K.+H.+Leeauthor=K.+Nakagawaauthor=S.+Nihoauthor=F.+Tsujiauthor=R.+Linkeauthor=R.+Rosellauthor=J.+Corralauthor=M.+R.+Migliorinoauthor=A.+Pluzanskiauthor=E.+I.+Sbarauthor=T.+Wangauthor=J.+L.+Whiteauthor=S.+Nadanacivaauthor=R.+Sandinauthor=T.+S.+Mok&title=Dacomitinib+Versus+Gefitinib+as+First-Line+Treatment+for+Patients+with+EGFR-Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28ARCHER+1050%29%3A+A+Randomised%2C+Open-Label%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2817%2930608-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; Sbar, Eric I.; Wang, Tao; White, Jane Liang; Nadanaciva, Sashi; Sandin, Rickard; Mok, Tony S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1466</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.  We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-pos. non-small-cell lung cancer (NSCLC).  In this international, multicenter, randomized, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centers and university hospitals in seven countries or special administrative regions.  We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met.  Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system.  The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population.  Safety was assessed in all patients who received at least one dose of study treatment.  This study is registered with ClinicalTrials.gov, no. NCT01774721, and is ongoing but no longer recruiting patients.  Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225).  Median duration of follow-up for progression-free survival was 22·1 mo (95% CI 20·3-23·9).  Median progression-free survival according to masked independent review was 14·7 mo (95% CI 11·1-16·6) in the dacomitinib group and 9·2 mo (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001).  The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).  Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib.  Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).  Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-pos. NSCLC and should be considered as a new treatment option for this population.  SFJ Pharmaceuticals Group and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqZ8AKr7cDZLVg90H21EOLACvtfcHk0lj8z5WpZLW12Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI&md5=89eb8749060bfa3dfe79a84537b2b27b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930608-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930608-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DTsuji%26aufirst%3DF.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DMigliorino%26aufirst%3DM.%2BR.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DJ.%2BL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSandin%26aufirst%3DR.%26aulast%3DMok%26aufirst%3DT.%2BS.%26atitle%3DDacomitinib%2520Versus%2520Gefitinib%2520as%2520First-Line%2520Treatment%2520for%2520Patients%2520with%2520EGFR-Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528ARCHER%25201050%2529%253A%2520A%2520Randomised%252C%2520Open-Label%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D1454%26epage%3D1466%26doi%3D10.1016%2FS1470-2045%2817%2930608-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakhoury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, F. O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivault, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-D]Pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8103</span>– <span class="NLM_lpage">8124</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8103-8124&author=J.+B.+Smaillauthor=A.+J.+Gonzalesauthor=J.+A.+Spicerauthor=H.+Leeauthor=J.+E.+Reedauthor=K.+Sextonauthor=I.+W.+Althausauthor=T.+Zhuauthor=S.+L.+Blackauthor=A.+Blaserauthor=W.+A.+Dennyauthor=P.+A.+Ellisauthor=S.+Fakhouryauthor=P.+J.+Harveyauthor=K.+Hookauthor=F.+O.+J.+McCarthyauthor=B.+D.+Palmerauthor=F.+Rivaultauthor=K.+Schlosserauthor=T.+Ellisauthor=A.+M.+Thompsonauthor=E.+Trachetauthor=R.+T.+Wintersauthor=H.+Tecleauthor=A.+Bridges&title=Tyrosine+Kinase+Inhibitors.+20.+Optimization+of+Substituted+Quinazoline+and+Pyrido%5B3%2C4-D%5DPyrimidine+Derivatives+as+Orally+Active%2C+Irreversible+Inhibitors+of+the+Epidermal+Growth+Factor+Receptor+Family&doi=10.1021%2Facs.jmedchem.6b00883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129aR"><div class="casContent"><span class="casTitleNuber">129a</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family</span></div><div class="casAuthors">Smaill, Jeff B.; Gonzales, Andrea J.; Spicer, Julie A.; Lee, Helen; Reed, Jessica E.; Sexton, Karen; Althaus, Irene W.; Zhu, Tong; Black, Shannon L.; Blaser, Adrian; Denny, William A.; Ellis, Paul A.; Fakhoury, Stephen; Harvey, Patricia J.; Hook, Ken; McCarthy, Florence O. J.; Palmer, Brian D.; Rivault, Freddy; Schlosser, Kevin; Ellis, Teresa; Thompson, Andrew M.; Trachet, Erin; Winters, R. Thomas; Tecle, Haile; Bridges, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8103-8124</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationships for inhibition of erbB1, erbB2 and erbB4 were detd. for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogs of the irreversible pan-erbB inhibitor, canertinib.  Cyclic amine bearing crotonamides were detd. to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays.  The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated.  Several anilines were identified as providing potent, reversible pan-erbB inhibition.  Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo.  Quinazoline I and pyrido[3,4-d]pyrimidine II were identified as clearly superior to canertinib.  Both compds. possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents resp.  Pharmacokinetic comparison of compds. I and II across three species selected compd. I as the preferred candidate.  Compd. I (PF-00299804) has been assigned the nomenclature of dacomitinib and is currently under clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0-NpOmVq10bVg90H21EOLACvtfcHk0lg_SJaASQ2eBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM&md5=442afda669a5c1b7a190cd82b77bee33</span></div><a href="/servlet/linkout?suffix=cit129a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DSpicer%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DSexton%26aufirst%3DK.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBlack%26aufirst%3DS.%2BL.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DFakhoury%26aufirst%3DS.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DHook%26aufirst%3DK.%26aulast%3DMcCarthy%26aufirst%3DF.%2BO.%2BJ.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRivault%26aufirst%3DF.%26aulast%3DSchlosser%26aufirst%3DK.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%26atitle%3DTyrosine%2520Kinase%2520Inhibitors.%252020.%2520Optimization%2520of%2520Substituted%2520Quinazoline%2520and%2520Pyrido%255B3%252C4-D%255DPyrimidine%2520Derivatives%2520as%2520Orally%2520Active%252C%2520Irreversible%2520Inhibitors%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8103%26epage%3D8124%26doi%3D10.1021%2Facs.jmedchem.6b00883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit129b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. E.</span>; <span class="NLM_string-name">Smaill, J. B.</span></span> <span> </span><span class="NLM_article-title">The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor</span>. In  <i>Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Magid, A. F.</span>, <span class="NLM_string-name">Pesti, J. A.</span>, <span class="NLM_string-name">Vaidyanathan, R.</span></span>, Eds.; <span class="NLM_publisher-name">ACS Publications</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">233</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1239.ch008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=207-233&author=J.+E.+Reed&author=J.+B.+Smaillauthor=A.+F.+Abdel-Magid&author=J.+A.+Pesti&author=R.+Vaidyanathan&title=Comprehensive+Accounts+of+Pharmaceutical+Research+and+Development%3A+From+Discovery+to+Late-Stage+Process+Development+Volume+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129b&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1239.ch008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Fbk-2016-1239.ch008%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520Discovery%2520of%2520Dacomitinib%252C%2520a%2520Potent%2520Irreversible%2520EGFR%2520Inhibitor%26btitle%3DComprehensive%2520Accounts%2520of%2520Pharmaceutical%2520Research%2520and%2520Development%253A%2520From%2520Discovery%2520to%2520Late-Stage%2520Process%2520Development%2520Volume%25201%26aulast%3DAbdel-Magid%26aufirst%3DA.%2BF.%26pub%3DACS%2520Publications%26date%3D2016%26spage%3D207%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span>; <span class="NLM_string-name">Dirat, O.</span></span> <span> </span><span class="NLM_article-title">Early and Late Stage Process Development for the Manufacture of Dacomitinib</span>. In  <i>Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Magid, A. F.</span>, <span class="NLM_string-name">Pesti, J. A.</span>, <span class="NLM_string-name">Vaidyanathan, R.</span></span>, Eds.; <span class="NLM_publisher-name">ACS Publications</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">252</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1239.ch009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=235-252&author=S.+Yu&author=O.+Diratauthor=A.+F.+Abdel-Magid&author=J.+A.+Pesti&author=R.+Vaidyanathan&title=Comprehensive+Accounts+of+Pharmaceutical+Research+and+Development%3A+From+Discovery+to+Late-Stage+Process+Development+Volume+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1239.ch009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Fbk-2016-1239.ch009%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DS.%26atitle%3DEarly%2520and%2520Late%2520Stage%2520Process%2520Development%2520for%2520the%2520Manufacture%2520of%2520Dacomitinib%26btitle%3DComprehensive%2520Accounts%2520of%2520Pharmaceutical%2520Research%2520and%2520Development%253A%2520From%2520Discovery%2520to%2520Late-Stage%2520Process%2520Development%2520Volume%25201%26aulast%3DAbdel-Magid%26aufirst%3DA.%2BF.%26pub%3DACS%2520Publications%26date%3D2016%26spage%3D235%26epage%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span>; <span class="NLM_string-name">Mo, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of EGFR (Epidermal Growth Factor Receptor) Inhibitor Dacomitinib</span>. <span class="NLM_patent">CN103304492A</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+Lin&author=G.+Mo&title=Synthesis+Method+of+EGFR+%28Epidermal+Growth+Factor+Receptor%29+Inhibitor+Dacomitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DK.%26atitle%3DSynthesis%2520Method%2520of%2520EGFR%2520%2528Epidermal%2520Growth%2520Factor%2520Receptor%2529%2520Inhibitor%2520Dacomitinib%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Krajczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boryski, J.</span></span> <span> </span><span class="NLM_article-title">Dimroth Rearrangement-Old but Not Outdated</span>. <i>Curr. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2515</span>– <span class="NLM_lpage">2529</span>, <span class="refDoi"> DOI: 10.2174/1385272821666170427125720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F1385272821666170427125720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=2515-2529&author=A.+Krajczykauthor=J.+Boryski&title=Dimroth+Rearrangement-Old+but+Not+Outdated&doi=10.2174%2F1385272821666170427125720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132aR"><div class="casContent"><span class="casTitleNuber">132a</span><div class="casTitle"><span class="NLM_cas:atitle">Dimroth Rearrangement-Old but not Outdated</span></div><div class="casAuthors">Krajczyk, Anna; Boryski, Jerzy</div><div class="citationInfo"><span class="NLM_cas:title">Current Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2515-2529</span>CODEN:
                <span class="NLM_cas:coden">CORCFE</span>;
        ISSN:<span class="NLM_cas:issn">1385-2728</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The aim of this review is to present a general outlook on the Dimroth rearrangement along with the situations in which it may occur, and to briefly describe its potential applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_ENWP1DHSFrVg90H21EOLACvtfcHk0lg_SJaASQ2eBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOgtr8%253D&md5=6089af4dae3823a833ac73f3f6761f9c</span></div><a href="/servlet/linkout?suffix=cit132a&amp;dbid=16384&amp;doi=10.2174%2F1385272821666170427125720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1385272821666170427125720%26sid%3Dliteratum%253Aachs%26aulast%3DKrajczyk%26aufirst%3DA.%26aulast%3DBoryski%26aufirst%3DJ.%26atitle%3DDimroth%2520Rearrangement-Old%2520but%2520Not%2520Outdated%26jtitle%3DCurr.%2520Org.%2520Chem.%26date%3D2017%26volume%3D21%26spage%3D2515%26epage%3D2529%26doi%3D10.2174%2F1385272821666170427125720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit132b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">El Ashry, E. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadeem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Kilany, Y.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Dimroth Rearrangement: A Valuable Tool for the Synthesis of Heterocycles</span>. <i>Adv. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/S0065-2725(10)01005-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0065-2725%2810%2901005-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSksLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2010&pages=161-228&author=E.+S.+H.+El+Ashryauthor=S.+Nadeemauthor=M.+R.+Shahauthor=Y.+El+Kilany&title=Recent+Advances+in+the+Dimroth+Rearrangement%3A+A+Valuable+Tool+for+the+Synthesis+of+Heterocycles&doi=10.1016%2FS0065-2725%2810%2901005-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132bR"><div class="casContent"><span class="casTitleNuber">132b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the Dimroth rearrangement: a valuable tool for the synthesis of heterocycles</span></div><div class="casAuthors">El Ashry, El Sayed H.; Nadeem, Said; Shah, Muhammad Raza; El Kilany, Yeldez</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-228</span>CODEN:
                <span class="NLM_cas:coden">AHTCAG</span>;
        ISSN:<span class="NLM_cas:issn">0065-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review was given covering recent advances in Dimroth rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc9ADjRpXbf7Vg90H21EOLACvtfcHk0liJy-Aez-l_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSksLvI&md5=516baf2204fea17ef557004202be72fd</span></div><a href="/servlet/linkout?suffix=cit132b&amp;dbid=16384&amp;doi=10.1016%2FS0065-2725%2810%2901005-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2725%252810%252901005-6%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BAshry%26aufirst%3DE.%2BS.%2BH.%26aulast%3DNadeem%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DM.%2BR.%26aulast%3DEl%2BKilany%26aufirst%3DY.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Dimroth%2520Rearrangement%253A%2520A%2520Valuable%2520Tool%2520for%2520the%2520Synthesis%2520of%2520Heterocycles%26jtitle%3DAdv.%2520Heterocycl.%2520Chem.%26date%3D2010%26volume%3D101%26spage%3D161%26epage%3D228%26doi%3D10.1016%2FS0065-2725%2810%2901005-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit132c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">El Ashry, E. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Kilany, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assafir, H.</span></span> <span> </span><span class="NLM_article-title">Dimroth Rearrangement: Translocation of Heteroatoms in Heterocyclic Rings and Its Role in Ring Transformations of Heterocycles</span>. <i>Adv. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/S0065-2725(08)60984-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0065-2725%2808%2960984-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVKntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1999&pages=79-165&author=E.+S.+H.+El+Ashryauthor=Y.+El+Kilanyauthor=N.+Rashedauthor=H.+Assafir&title=Dimroth+Rearrangement%3A+Translocation+of+Heteroatoms+in+Heterocyclic+Rings+and+Its+Role+in+Ring+Transformations+of+Heterocycles&doi=10.1016%2FS0065-2725%2808%2960984-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132cR"><div class="casContent"><span class="casTitleNuber">132c</span><div class="casTitle"><span class="NLM_cas:atitle">Dimroth rearrangement: Translocation of heteroatoms in heterocyclic rings and its role in ring transformations of heterocycles</span></div><div class="casAuthors">El Ashry, E. S. H.; El Kilany, Y.; Rashed, N.; Assafir, H.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">79-167</span>CODEN:
                <span class="NLM_cas:coden">AHTCAG</span>;
        ISSN:<span class="NLM_cas:issn">0065-2725</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with many refs. covering rearrangements in rings of fused systems and translocations of exo- and endocyclic heteroatoms in heterocyclic rings.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM45QBxKFI0bVg90H21EOLACvtfcHk0liJy-Aez-l_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVKntQ%253D%253D&md5=1099d48f4dc9bf6fdc5724f9e2e1ccc6</span></div><a href="/servlet/linkout?suffix=cit132c&amp;dbid=16384&amp;doi=10.1016%2FS0065-2725%2808%2960984-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2725%252808%252960984-8%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BAshry%26aufirst%3DE.%2BS.%2BH.%26aulast%3DEl%2BKilany%26aufirst%3DY.%26aulast%3DRashed%26aufirst%3DN.%26aulast%3DAssafir%26aufirst%3DH.%26atitle%3DDimroth%2520Rearrangement%253A%2520Translocation%2520of%2520Heteroatoms%2520in%2520Heterocyclic%2520Rings%2520and%2520Its%2520Role%2520in%2520Ring%2520Transformations%2520of%2520Heterocycles%26jtitle%3DAdv.%2520Heterocycl.%2520Chem.%26date%3D1999%26volume%3D75%26spage%3D79%26epage%3D165%26doi%3D10.1016%2FS0065-2725%2808%2960984-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span>; <span class="NLM_string-name">Wang, Q.</span>; <span class="NLM_string-name">Su, R.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Huo, X.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib Solvate, Novel Crystalline Form of Dacomitinib and Preparation Method and Use of Dacomitinib in Novel Crystalline Form</span>. <span class="NLM_patent">CN107793368A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Q.+Wang&author=Q.+Wang&author=R.+Su&author=H.+Li&author=X.+Huo&author=L.+Wang&author=J.+Wang&title=Dacomitinib+Solvate%2C+Novel+Crystalline+Form+of+Dacomitinib+and+Preparation+Method+and+Use+of+Dacomitinib+in+Novel+Crystalline+Form"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26atitle%3DDacomitinib%2520Solvate%252C%2520Novel%2520Crystalline%2520Form%2520of%2520Dacomitinib%2520and%2520Preparation%2520Method%2520and%2520Use%2520of%2520Dacomitinib%2520in%2520Novel%2520Crystalline%2520Form%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagrillo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, C. A. M.</span></span> <span> </span><span class="NLM_article-title">Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">69</span>, <span class="refDoi"> DOI: 10.3390/ph12020069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.3390%2Fph12020069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKksLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=69&author=D.+A.+Rodriguesauthor=F.+S.+Sagrilloauthor=C.+A.+M.+Fraga&title=Duvelisib%3A+A+2018+Novel+FDA-Approved+Small+Molecule+Inhibiting+Phosphoinositide+3-Kinases&doi=10.3390%2Fph12020069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134aR"><div class="casContent"><span class="casTitleNuber">134a</span><div class="casTitle"><span class="NLM_cas:atitle">Duvelisib: a 2018 novel FDA-approved small molecule inhibiting phosphoinositide 3-kinases</span></div><div class="casAuthors">Rodrigues, Daniel A.; Sagrillo, Fernanda S.; Fraga, Carlos A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Duvelisib (Copiktra) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ).  In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) after at least two prior therapies.  Duvelisib has also been approved under accelerated track for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.  In this review, we provide a series of information about duvelisib, such as the development of clin. trials for LLC/SLL and FL and the steps used for its synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKfwFmy1g2D7Vg90H21EOLACvtfcHk0liJy-Aez-l_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKksLvO&md5=2eed3f6f628369e9551d7c0d1a4476b5</span></div><a href="/servlet/linkout?suffix=cit134a&amp;dbid=16384&amp;doi=10.3390%2Fph12020069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph12020069%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DD.%2BA.%26aulast%3DSagrillo%26aufirst%3DF.%2BS.%26aulast%3DFraga%26aufirst%3DC.%2BA.%2BM.%26atitle%3DDuvelisib%253A%2520A%25202018%2520Novel%2520FDA-Approved%2520Small%2520Molecule%2520Inhibiting%2520Phosphoinositide%25203-Kinases%26jtitle%3DPharmaceuticals%26date%3D2019%26volume%3D12%26spage%3D69%26doi%3D10.3390%2Fph12020069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit134b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vangapandu, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V.</span></span> <span> </span><span class="NLM_article-title">Duvelisib: A Phosphoinositide-3 Kinase Delta/Gamma Inhibitor for Chronic Lymphocytic Leukemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1312338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F13543784.2017.1312338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28388280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVeqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=625-632&author=H.+V.+Vangapanduauthor=N.+Jainauthor=V.+Gandhi&title=Duvelisib%3A+A+Phosphoinositide-3+Kinase+Delta%2FGamma+Inhibitor+for+Chronic+Lymphocytic+Leukemia&doi=10.1080%2F13543784.2017.1312338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134bR"><div class="casContent"><span class="casTitleNuber">134b</span><div class="casTitle"><span class="NLM_cas:atitle">Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia</span></div><div class="casAuthors">Vangapandu, Hima V.; Jain, Nitin; Gandhi, Varsha</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">625-632</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity.  Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse.  Therefore, for the past few years, development of targeted therapies is on the rise.  PI3K is a major player in the B-cell receptor (BCR) signaling axis, which is crit. for the survival and maintenance of B cells.  Duvelisib, a PI3K δ/γ dual isoform specific inhibitor that induces apoptosis and reduces cytokine and chemokine levels in vitro, holds promise for CLL.  Herein, we review PI3K isoforms and their inhibitors in general, and duvelisib in particular; examine literature on preclin. investigations, pharmacokinetics and clin. studies of duvelisib either as single agent or in combination, for patients with CLL and other lymphoid malignancies.  Duvelisib targets the PI3K δ isoform, which is necessary for cell proliferation and survival, and γ isoform, which is crit. for cytokine signaling and pro-inflammatory responses from the microenvironment.  In phase I clin. trials, duvelisib as a single agent showed promise for CLL and other lymphoid malignancies.  Phase II and III trials of duvelisib alone or in combination with other agents are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6_pe9x-0X77Vg90H21EOLACvtfcHk0liJy-Aez-l_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVeqsLg%253D&md5=acb74fe8a63bb3941b7e1b565a509d77</span></div><a href="/servlet/linkout?suffix=cit134b&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1312338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1312338%26sid%3Dliteratum%253Aachs%26aulast%3DVangapandu%26aufirst%3DH.%2BV.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DGandhi%26aufirst%3DV.%26atitle%3DDuvelisib%253A%2520A%2520Phosphoinositide-3%2520Kinase%2520Delta%252FGamma%2520Inhibitor%2520for%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D625%26epage%3D632%26doi%3D10.1080%2F13543784.2017.1312338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaneda, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messer, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralainirina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leem, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorjestani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueiredo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foubert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rausch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazer, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varner, J. A.</span></span> <span> </span><span class="NLM_article-title">PI3Kgamma Is a Molecular Switch That Controls Immune Suppression</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>539</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1038/nature19834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fnature19834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27642729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvV2it7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=539&publication_year=2016&pages=437-442&author=M.+M.+Kanedaauthor=K.+S.+Messerauthor=N.+Ralainirinaauthor=H.+Liauthor=C.+J.+Leemauthor=S.+Gorjestaniauthor=G.+Wooauthor=A.+V.+Nguyenauthor=C.+C.+Figueiredoauthor=P.+Foubertauthor=M.+C.+Schmidauthor=M.+Pinkauthor=D.+G.+Winklerauthor=M.+Rauschauthor=V.+J.+Palombellaauthor=J.+Kutokauthor=K.+McGovernauthor=K.+A.+Frazerauthor=X.+Wuauthor=M.+Karinauthor=R.+Sasikauthor=E.+E.+Cohenauthor=J.+A.+Varner&title=PI3Kgamma+Is+a+Molecular+Switch+That+Controls+Immune+Suppression&doi=10.1038%2Fnature19834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kγ is a molecular switch that controls immune suppression</span></div><div class="casAuthors">Kaneda, Megan M.; Messer, Karen S.; Ralainirina, Natacha; Li, Hongying; Leem, Christopher J.; Gorjestani, Sara; Woo, Gyunghwi; Nguyen, Abraham V.; Figueiredo, Camila C.; Foubert, Philippe; Schmid, Michael C.; Pink, Melissa; Winkler, David G.; Rausch, Matthew; Palombella, Vito J.; Kutok, Jeffery; McGovern, Karen; Frazer, Kelly A.; Wu, Xuefeng; Karin, Michael; Sasik, Roman; Cohen, Ezra E. W.; Varner, Judith A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">539</span>
        (<span class="NLM_cas:issue">7629</span>),
    <span class="NLM_cas:pages">437-442</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Macrophages play crit., but opposite, roles in acute and chronic inflammation and cancer.  In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T cells, whereas macrophages in neoplastic and parasitic diseases express anti-inflammatory cytokines that induce immune suppression and may promote resistance to T cell checkpoint inhibitors.  Here we show that macrophage PI 3-kinase γ controls a crit. switch between immune stimulation and suppression during inflammation and cancer.  PI3Kγ signalling through Akt and mTor inhibits NFκB activation while stimulating C/EBPβ activation, thereby inducing a transcriptional program that promotes immune suppression during inflammation and tumor growth.  By contrast, selective inactivation of macrophage PI3Kγ stimulates and prolongs NFκB activation and inhibits C/EBPβ activation, thus promoting an immunostimulatory transcriptional program that restores CD8+ T cell activation and cytotoxicity.  PI3Kγ synergizes with checkpoint inhibitor therapy to promote tumor regression and increased survival in mouse models of cancer.  In addn., PI3Kγ-directed, anti-inflammatory gene expression can predict survival probability in cancer patients.  Our work thus demonstrates that therapeutic targeting of intracellular signalling pathways that regulate the switch between macrophage polarization states can control immune suppression in cancer and other disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMN1E8I633erVg90H21EOLACvtfcHk0lgFul1Mk1oItw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvV2it7fL&md5=89edbf1f65665684c8360de9350f9195</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fnature19834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19834%26sid%3Dliteratum%253Aachs%26aulast%3DKaneda%26aufirst%3DM.%2BM.%26aulast%3DMesser%26aufirst%3DK.%2BS.%26aulast%3DRalainirina%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLeem%26aufirst%3DC.%2BJ.%26aulast%3DGorjestani%26aufirst%3DS.%26aulast%3DWoo%26aufirst%3DG.%26aulast%3DNguyen%26aufirst%3DA.%2BV.%26aulast%3DFigueiredo%26aufirst%3DC.%2BC.%26aulast%3DFoubert%26aufirst%3DP.%26aulast%3DSchmid%26aufirst%3DM.%2BC.%26aulast%3DPink%26aufirst%3DM.%26aulast%3DWinkler%26aufirst%3DD.%2BG.%26aulast%3DRausch%26aufirst%3DM.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DKutok%26aufirst%3DJ.%26aulast%3DMcGovern%26aufirst%3DK.%26aulast%3DFrazer%26aufirst%3DK.%2BA.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DSasik%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DVarner%26aufirst%3DJ.%2BA.%26atitle%3DPI3Kgamma%2520Is%2520a%2520Molecular%2520Switch%2520That%2520Controls%2520Immune%2520Suppression%26jtitle%3DNature%26date%3D2016%26volume%3D539%26spage%3D437%26epage%3D442%26doi%3D10.1038%2Fnature19834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ram, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span> <span> </span><span class="NLM_article-title">Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">988</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1038/nrd1902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fnrd1902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=16341064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=988-1004&author=B.+T.+Hennessyauthor=D.+L.+Smithauthor=P.+T.+Ramauthor=Y.+Luauthor=G.+B.+Mills&title=Exploiting+the+PI3K%2FAKT+Pathway+for+Cancer+Drug+Discovery&doi=10.1038%2Fnrd1902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136aR"><div class="casContent"><span class="casTitleNuber">136a</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery</span></div><div class="casAuthors">Hennessy, Bryan T.; Smith, Debra L.; Ram, Prahlad T.; Lu, Yiling; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">988-1004</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy.  Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway.  This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq40Fg-hLrrMbVg90H21EOLACvtfcHk0lgFul1Mk1oItw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI&md5=faecabc3a6799137d133afb37d139ceb</span></div><a href="/servlet/linkout?suffix=cit136a&amp;dbid=16384&amp;doi=10.1038%2Fnrd1902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1902%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DRam%26aufirst%3DP.%2BT.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DExploiting%2520the%2520PI3K%252FAKT%2520Pathway%2520for%2520Cancer%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D988%26epage%3D1004%26doi%3D10.1038%2Fnrd1902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit136b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Phosphoinositide 3-Kinase Pathway in Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+Phosphoinositide+3-Kinase+Pathway+in+Cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136bR"><div class="casContent"><span class="casTitleNuber">136b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0lgFul1Mk1oItw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit136b&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520Phosphoinositide%25203-Kinase%2520Pathway%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, G.</span></span> <span> </span><span class="NLM_article-title">Novel Drugs in Follicular Lymphoma</span>. <i>Mediterr. J. Hematol. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e2016061</span>, <span class="refDoi"> DOI: 10.4084/mjhid.2016.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.4084%2Fmjhid.2016.061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=e2016061&author=A.+Anastasiaauthor=G.+Rossi&title=Novel+Drugs+in+Follicular+Lymphoma&doi=10.4084%2Fmjhid.2016.061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.4084%2Fmjhid.2016.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4084%252Fmjhid.2016.061%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasia%26aufirst%3DA.%26aulast%3DRossi%26aufirst%3DG.%26atitle%3DNovel%2520Drugs%2520in%2520Follicular%2520Lymphoma%26jtitle%3DMediterr.%2520J.%2520Hematol.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D8%26spage%3De2016061%26doi%3D10.4084%2Fmjhid.2016.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span>; <span class="NLM_string-name">Martin, M.</span>; <span class="NLM_string-name">Isbester, P.</span>; <span class="NLM_string-name">Lane, B.</span>; <span class="NLM_string-name">Kropp, J.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Isoquinolines and Solid Forms of Isoquinolines</span>. <span class="NLM_patent">WO2012097000A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+Ren&author=M.+Martin&author=P.+Isbester&author=B.+Lane&author=J.+Kropp&title=Process+for+Preparing+Isoquinolines+and+Solid+Forms+of+Isoquinolines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DP.%26atitle%3DProcess%2520for%2520Preparing%2520Isoquinolines%2520and%2520Solid%2520Forms%2520of%2520Isoquinolines%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Encorafenib and Binimetinib: First Global Approvals</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1277</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0963-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0963-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30117021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFehsrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1277-1284&author=M.+Shirley&title=Encorafenib+and+Binimetinib%3A+First+Global+Approvals&doi=10.1007%2Fs40265-018-0963-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Encorafenib and Binimetinib: First Global Approvals</span></div><div class="casAuthors">Shirley, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1277-1284</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Encorafenib (Braftovi), a BRAF inhibitor, and binimetinib (Mektovi), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPharma.  In June 2018 they each received their first global approval, in the USA, for use in combination, for patients with unresectable or metastatic melanoma with a BRAFV600E or -V600K mutation as detected by an FDA-approved test.  Registration applications for encorafenib and binimetinib for use in combination in the treatment of BRAF-mutation-pos. advanced melanoma have also been submitted in the EU, Australia, Switzerland and Japan, with the EMA Committee for Medicinal Products for Human Use adopting a pos. opinion in July 2018 towards granting the drugs marketing authorizations in the EU.  Encorafenib plus binimetinib combination therapy is also in ongoing phase III clin. development in the treatment of metastatic colorectal cancer.  This article summarizes the milestones in the development of encorafenib and binimetinib leading to these first approvals for the treatment of BRAFV600E or -V600K-mutation-pos. unresectable or metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2LM_GzUpVoLVg90H21EOLACvtfcHk0ljLzngKF6ewwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFehsrnK&md5=13c3b196d9db53a4b7a6e870d2f69e32</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0963-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0963-x%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DEncorafenib%2520and%2520Binimetinib%253A%2520First%2520Global%2520Approvals%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1277%26epage%3D1284%26doi%3D10.1007%2Fs40265-018-0963-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Cancer Genome Atlas Network.</span> <span> </span><span class="NLM_article-title">Genomic Classification of Cutaneous
Melanoma</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">1681</span>– <span class="NLM_lpage">1696</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2015.05.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.cell.2015.05.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=26091043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2015&pages=1681-1696&author=Cancer+Genome+Atlas+Network.&title=Genomic+Classification+of+Cutaneous%0AMelanoma&doi=10.1016%2Fj.cell.2015.05.044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.05.044%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGenomic%2520Classification%2520of%2520Cutaneous%250AMelanoma%26jtitle%3DCell%26date%3D2015%26volume%3D161%26spage%3D1681%26epage%3D1696%26doi%3D10.1016%2Fj.cell.2015.05.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span> <span> </span><span class="NLM_article-title">BRAF and MEK Inhibitors in the Era of Immunotherapy in Melanoma Patients</span>. <i>Wspolczesna Onkol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.5114/wo.2018.73890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.5114%2Fwo.2018.73890" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=68-72&author=J.+Mackiewiczauthor=A.+Mackiewicz&title=BRAF+and+MEK+Inhibitors+in+the+Era+of+Immunotherapy+in+Melanoma+Patients&doi=10.5114%2Fwo.2018.73890"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.5114%2Fwo.2018.73890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Fwo.2018.73890%26sid%3Dliteratum%253Aachs%26aulast%3DMackiewicz%26aufirst%3DJ.%26aulast%3DMackiewicz%26aufirst%3DA.%26atitle%3DBRAF%2520and%2520MEK%2520Inhibitors%2520in%2520the%2520Era%2520of%2520Immunotherapy%2520in%2520Melanoma%2520Patients%26jtitle%3DWspolczesna%2520Onkol.%26date%3D2018%26volume%3D22%26spage%3D68%26epage%3D72%26doi%3D10.5114%2Fwo.2018.73890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span>; <span class="NLM_string-name">Jin, X.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Poon, D.</span>; <span class="NLM_string-name">Tellew, J.</span>; <span class="NLM_string-name">Wan, Y.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Xie, Y.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions as Protein Kinase Inhibitors</span>. <span class="NLM_patent">WO2011025927A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Huang&author=X.+Jin&author=Z.+Liu&author=D.+Poon&author=J.+Tellew&author=Y.+Wan&author=X.+Wang&author=Y.+Xie&title=Compounds+and+Compositions+as+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DS.%26atitle%3DCompounds%2520and%2520Compositions%2520as%2520Protein%2520Kinase%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Fruquintinib, a Potent and Highly Selective Small Molecule Inhibitor of Vegfr 1, 2, 3 Tyrosine Kinases for Cancer Therapy</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1635</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.4161/15384047.2014.964087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.4161%2F15384047.2014.964087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=25482937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1635-1645&author=Q.+Sunauthor=J.+Zhouauthor=Z.+Zhangauthor=M.+Guoauthor=J.+Liangauthor=F.+Zhouauthor=J.+Longauthor=W.+Zhangauthor=F.+Yinauthor=H.+Caiauthor=H.+Yangauthor=W.+Zhangauthor=Y.+Guauthor=L.+Niauthor=Y.+Saiauthor=Y.+Cuiauthor=M.+Zhangauthor=M.+Hongauthor=J.+Sunauthor=Z.+Yangauthor=W.+Qingauthor=W.+Suauthor=Y.+Ren&title=Discovery+of+Fruquintinib%2C+a+Potent+and+Highly+Selective+Small+Molecule+Inhibitor+of+Vegfr+1%2C+2%2C+3+Tyrosine+Kinases+for+Cancer+Therapy&doi=10.4161%2F15384047.2014.964087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy</span></div><div class="casAuthors">Sun, Qiaoling; Zhou, Jinghong; Zhang, Zheng; Guo, Mingchuan; Liang, Junqing; Zhou, Feng; Long, Jingwen; Zhang, Wei; Yin, Fang; Cai, Huaqing; Yang, Haibin; Zhang, Weihan; Gu, Yi; Ni, Liang; Sai, Yang; Cui, Yumin; Zhang, Meifang; Hong, Minhua; Sun, Junen; Yang, Zheng; Qing, Weiguo; Su, Weiguo; Ren, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1635-1645</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">VEGF/VEGFR signal axis has been proven to be an important target for development of novel cancer therapies.  One challenging aspect in small mol. VEGFR inhibitors is to achieve sustained target inhibition at tolerable doses previously seen only with the long-acting biologics.  It would require high potency (low effective drug concns.) and sufficient drug exposures at tolerated doses so that the drug concn. can be maintained above effective drug concn. for target inhibition within the dosing period.  Fruquintinib (HMPL-013) is a small mol. inhibitor with strong potency and high selectivity against VEGFR family currently in Phase II clin. studies.  Anal. of Phase I pharmacokinetic data revealed that at the max. tolerated dose of once daily oral administration fruquintinib achieved complete VEGFR2 suppression (drug concns. were maintained above that required to produce >85% inhibition of VEGFR2 phosphorylation in mouse) for 24 h/day.  In this article, the preclin. data for fruquintinib will be described, including kinase enzyme activity and selectivity, cellular VEGFR inhibition and VEGFR-driven functional activity, in vivo VEGFR phosphorylation inhibition in the lung tissue in mouse and tumor growth inhibition in a panel of tumor xenograft and patient derive xenograft models in mouse.  Pharmacokinetic and target inhibition data are also presented to provide a correlation between target inhibition and tumor growth inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj6Wfr9ByAXrVg90H21EOLACvtfcHk0ljLzngKF6ewwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslertLc%253D&md5=6007c07007eba7cffd680b48db6e7fae</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.4161%2F15384047.2014.964087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F15384047.2014.964087%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DSai%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DQing%26aufirst%3DW.%26aulast%3DSu%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Fruquintinib%252C%2520a%2520Potent%2520and%2520Highly%2520Selective%2520Small%2520Molecule%2520Inhibitor%2520of%2520Vegfr%25201%252C%25202%252C%25203%2520Tyrosine%2520Kinases%2520for%2520Cancer%2520Therapy%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2014%26volume%3D15%26spage%3D1635%26epage%3D1645%26doi%3D10.4161%2F15384047.2014.964087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Fruquintinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1761</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0998-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0998-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30357594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cvivFKgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1757-1761&author=M.+Shirley&title=Fruquintinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0998-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Fruquintinib: First Global Approval</span></div><div class="casAuthors">Shirley Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1757-1761</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fruquintinib (Elunate(®)) is an orally available, potent and highly selective small molecule inhibitor of VEGFR-1, -2 and -3 that was discovered and developed by Hutchison MediPharma for the treatment of solid tumours.  In September 2018, fruquintinib received its first global approval, in China, for use in the treatment of metastatic colorectal cancer (CRC) in patients who have failed at least two prior systemic anti-neoplastic therapies.  Fruquintinib is in ongoing phase III clinical development for use in the treatment of advanced NSCLC and advanced gastric cancer.  This article summarizes the milestones in the development of fruquintinib leading to this first approval for the treatment of metastatic CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgv6IkRgnDqbmQt-ICR3qNfW6udTcc2ebTOHWYk9MUlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvivFKgsQ%253D%253D&md5=d3a7bc508dbcd87aacfc547ba27284e0</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0998-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0998-z%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DFruquintinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1757%26epage%3D1761%26doi%3D10.1007%2Fs40265-018-0998-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span>; <span class="NLM_string-name">Li, W.</span>; <span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide</span>. <span class="NLM_patent">WO2016037550A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Z.+Wu&author=W.+Li&author=Y.+Chu&title=Crystalline+Forms+of+6-%28%286%2C7-Dimethoxyquinazolin-4-yl%29oxy%29-N%2C2-dimethylbenzofuran-3-carboxamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DCrystalline%2520Forms%2520of%25206-%2528%25286%252C7-Dimethoxyquinazolin-4-yl%2529oxy%2529-N%252C2-dimethylbenzofuran-3-carboxamide%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span>; <span class="NLM_string-name">Li, W.</span>; <span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">6-(6,7-Dimethoxyquinazoline-4-yloxy)-N, 2-Dimethyl Benzofuran-3-Methane Amide Crystal Form</span>. <span class="NLM_patent">CN105461702A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Z.+Wu&author=W.+Li&author=Y.+Chu&title=6-%286%2C7-Dimethoxyquinazoline-4-yloxy%29-N%2C+2-Dimethyl+Benzofuran-3-Methane+Amide+Crystal+Form"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26atitle%3D6-%25286%252C7-Dimethoxyquinazoline-4-yloxy%2529-N%252C%25202-Dimethyl%2520Benzofuran-3-Methane%2520Amide%2520Crystal%2520Form%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit146b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Yi, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Quinazoline Derivative Crystal Form B</span>. <span class="NLM_patent">CN105777723A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Yu&author=J.+Chen&author=D.+Yi&title=Preparation+of+Quinazoline+Derivative+Crystal+Form+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Quinazoline%2520Derivative%2520Crystal%2520Form%2520B%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit146c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Yi, D.</span></span> <span> </span><span class="NLM_article-title">Preparation and Application of Fruquintinib Crystal Form C</span>. <span class="NLM_patent">CN105777722A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Yu&author=J.+Chen&author=D.+Yi&title=Preparation+and+Application+of+Fruquintinib+Crystal+Form+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26atitle%3DPreparation%2520and%2520Application%2520of%2520Fruquintinib%2520Crystal%2520Form%2520C%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit146d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Yi, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Crystal Form a of 6-[(6,7-Dimethoxy-4-quinazolinyl)oxy]-N,2-Dimethyl-3-benzofurancarboxamide</span>. <span class="NLM_patent">CN105777721A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Yu&author=J.+Chen&author=D.+Yi&title=Preparation+of+Crystal+Form+a+of+6-%5B%286%2C7-Dimethoxy-4-quinazolinyl%29oxy%5D-N%2C2-Dimethyl-3-benzofurancarboxamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Crystal%2520Form%2520a%2520of%25206-%255B%25286%252C7-Dimethoxy-4-quinazolinyl%2529oxy%255D-N%252C2-Dimethyl-3-benzofurancarboxamide%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-G.</span>; <span class="NLM_string-name">Zhang, W.</span>; <span class="NLM_string-name">Yan, X.</span>; <span class="NLM_string-name">Cui, Y.</span>; <span class="NLM_string-name">Ren, Y.</span>; <span class="NLM_string-name">Duan, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Quinazoline Derivatives as KDR Inhibitors</span>. <span class="NLM_patent">WO2009137797A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=W.-G.+Su&author=W.+Zhang&author=X.+Yan&author=Y.+Cui&author=Y.+Ren&author=J.+Duan&title=Preparation+of+Quinazoline+Derivatives+as+KDR+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DW.-G.%26atitle%3DPreparation%2520of%2520Quinazoline%2520Derivatives%2520as%2520KDR%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit147b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.</span>; <span class="NLM_string-name">Zhang, W.</span>; <span class="NLM_string-name">Yan, X.</span>; <span class="NLM_string-name">Cui, Y.</span>; <span class="NLM_string-name">Ren, Y.</span>; <span class="NLM_string-name">Duan, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Quinazoline Derivatives as Angiogenesis Inhibitors</span>. <span class="NLM_patent">CN101575333A</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=W.+Su&author=W.+Zhang&author=X.+Yan&author=Y.+Cui&author=Y.+Ren&author=J.+Duan&title=Preparation+of+Quinazoline+Derivatives+as+Angiogenesis+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DW.%26atitle%3DPreparation%2520of%2520Quinazoline%2520Derivatives%2520as%2520Angiogenesis%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-1062-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-1062-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30721452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=331-339&author=S.+Dhillon&title=Gilteritinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-1062-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-339</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Gilteritinib (Xospata) is an orally available small mol. receptor tyrosine kinase inhibitor developed by Astellas Pharma in collaboration with Kotobuki Pharmaceutical for the treatment of acute myeloid leukemia (AML) harbouring FMS-like tyrosine kinase 3 (FLT3) mutations.  Gilteritinib inhibits FLT3 (STK1 or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246).  Gilteritinib inhibits FLT3 signalling in cells expressing FLT3 internal tandem duplication (ITD), tyrosine kinase domain mutation FLT3-D835Y and the double mutant FLT3-ITD-D835Y, thereby inducing apoptosis.  Gilteritinib also binds to and inhibits the wild-type and mutated forms of ALK, resulting in reduced tumor cell proliferation in cancer cell types that overexpress the mutation.  Gilteritinib is approved in Japan for the treatment of relapsed or refractory AML with FLT3 mutation.  Recently, it was also approved in the USA for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation, as detected by an FDA-approved test.  Clin. development of gilteritinib is underway in several countries worldwide.  Development for non-small cell lung cancer and solid tumors has been discontinued.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4eM9A80qh7Vg90H21EOLACvtfcHk0ljk0y6-hxH7Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyis78%253D&md5=54765ef94cdc6b66d133f2728755dd6b</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-1062-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-1062-3%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DGilteritinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D331%26epage%3D339%26doi%3D10.1007%2Fs40265-019-1062-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib, a FLT3/Axl Inhibitor, Shows Antileukemic Activity in Mouse Models of FLT3 Mutated Acute Myeloid Leukemia</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1007/s10637-017-0470-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs10637-017-0470-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28516360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=556-565&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=M.+Yamadaauthor=R.+Tanakaauthor=R.+Saitoauthor=I.+Shimadaauthor=K.+Moriauthor=S.+Kuromitsu&title=Gilteritinib%2C+a+FLT3%2FAxl+Inhibitor%2C+Shows+Antileukemic+Activity+in+Mouse+Models+of+FLT3+Mutated+Acute+Myeloid+Leukemia&doi=10.1007%2Fs10637-017-0470-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149aR"><div class="casContent"><span class="casTitleNuber">149a</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span></div><div class="casAuthors">Mori, Masamichi; Kaneko, Naoki; Ueno, Yoko; Yamada, Masaki; Tanaka, Ruriko; Saito, Rika; Shimada, Itsuro; Mori, Kenichi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Advances in the understanding of the mol. basis for acute myeloid leukemia (AML) have generated new potential targets for treatment.  Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are assocd. with poor overall survival.  AXL plays a role in the activation of FLT3 and has been implicated in the pathogenesis of AML.  The studies reported here evaluated the ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and animal models of AML.  Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity against c-KIT.  Gilteritinib demonstrated potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3.  Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these assays.  Furthermore, gilteritinib decreased the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models.  In vivo, gilteritinib was distributed at high levels in xenografted tumors after oral administration.  The decreased FLT3 activity and high intratumor distribution of gilteritinib translated to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML.  No overt toxicity was seen in mouse models treated with gilteritinib.  These results indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in the treatment of FLT3 mutation-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMaOcOB0-DOrVg90H21EOLACvtfcHk0ljk0y6-hxH7Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D&md5=ffdf8ee1887cd2c6623dda70bb98a464</span></div><a href="/servlet/linkout?suffix=cit149a&amp;dbid=16384&amp;doi=10.1007%2Fs10637-017-0470-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-017-0470-z%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DGilteritinib%252C%2520a%2520FLT3%252FAxl%2520Inhibitor%252C%2520Shows%2520Antileukemic%2520Activity%2520in%2520Mouse%2520Models%2520of%2520FLT3%2520Mutated%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26spage%3D556%26epage%3D565%26doi%3D10.1007%2Fs10637-017-0470-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit149b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib for the Treatment of Patients with FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia</span>. <i>Expert Rev. Precis. Med. Drug. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1080/23808993.2019.1612709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F23808993.2019.1612709" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=105-112&author=E.+S.+Wang&title=Gilteritinib+for+the+Treatment+of+Patients+with+FLT3+Mutated+Relapsed+or+Refractory+Acute+Myeloid+Leukemia&doi=10.1080%2F23808993.2019.1612709"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149b&amp;dbid=16384&amp;doi=10.1080%2F23808993.2019.1612709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F23808993.2019.1612709%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DE.%2BS.%26atitle%3DGilteritinib%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520FLT3%2520Mutated%2520Relapsed%2520or%2520Refractory%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DExpert%2520Rev.%2520Precis.%2520Med.%2520Drug.%2520Dev.%26date%3D2019%26volume%3D4%26spage%3D105%26epage%3D112%26doi%3D10.1080%2F23808993.2019.1612709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span>; <span class="NLM_string-name">Kurosawa, K.</span>; <span class="NLM_string-name">Matsuya, T.</span>; <span class="NLM_string-name">Iikubo, K.</span>; <span class="NLM_string-name">Kondoh, Y.</span>; <span class="NLM_string-name">Kamikawa, A.</span>; <span class="NLM_string-name">Tomiyama, H.</span>; <span class="NLM_string-name">Iwai, Y.</span></span> <span> </span><span class="NLM_article-title">Diamino Heterocyclic Carboxamide Compound</span>. <span class="NLM_patent">US8969336</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=I.+Shimada&author=K.+Kurosawa&author=T.+Matsuya&author=K.+Iikubo&author=Y.+Kondoh&author=A.+Kamikawa&author=H.+Tomiyama&author=Y.+Iwai&title=Diamino+Heterocyclic+Carboxamide+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DI.%26atitle%3DDiamino%2520Heterocyclic%2520Carboxamide%2520Compound%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Q.</span>; <span class="NLM_string-name">Zhou, Z.</span>; <span class="NLM_string-name">Gao, Q.</span>; <span class="NLM_string-name">Zheng, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of 3,5-Disubstituted-Pyrazine-2-formamide Compound</span>. <span class="NLM_patent">CN106083821A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Q.+Yue&author=Z.+Zhou&author=Q.+Gao&author=B.+Zheng&title=Synthesis+Method+of+3%2C5-Disubstituted-Pyrazine-2-formamide+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DQ.%26atitle%3DSynthesis%2520Method%2520of%25203%252C5-Disubstituted-Pyrazine-2-formamide%2520Compound%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28AP26113%29%2C+a+Phosphine+Oxide-Containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0ljnHH2MPoMrDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528AP26113%2529%252C%2520a%2520Phosphine%2520Oxide-Containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Glasdegib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1047-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1047-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30666593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=207-213&author=S.+M.+Hoy&title=Glasdegib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1047-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153aR"><div class="casContent"><span class="casTitleNuber">153a</span><div class="casTitle"><span class="NLM_cas:atitle">Glasdegib: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-213</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Glasdegib (DAURISMO) is an oral inhibitor of the Hedgehog signalling pathway, the activation of which is assocd. with a no. of malignancies.  It has been developed by Pfizer and was approved in Nov. 2018 in the USA for use in combination with low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in patients aged = 75 years or those who have comorbidities that preclude use of intensive induction chemotherapy.  Glasdegib is the first Hedgehog pathway inhibitor to be approved for AML in the USA.  It received orphan designation for the treatment of AML in the USA in June 2017 and in the EU in Oct. 2017, and for the treatment of myelodysplastic syndrome (MDS) in the USA in Oct. 2017.  It is also undergoing clin. development for use in select haematol. and other malignancies, including MDS, in various countries worldwide.  This article summarizes the milestones in the development of glasdegib leading to its use in combination with low-dose cytarabine for the treatment of newly-diagnosed AML in patients aged = 75 years or those who have comorbidities that preclude use of intensive induction chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeH-czMi5FQrVg90H21EOLACvtfcHk0ljnHH2MPoMrDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqtLs%253D&md5=8ca00a70ef07e03b24e52fa57638867e</span></div><a href="/servlet/linkout?suffix=cit153a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1047-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1047-7%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DGlasdegib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D207%26epage%3D213%26doi%3D10.1007%2Fs40265-018-1047-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit153b"><span><span class="NLM_label">(b) </span><a href="https://www.fda.gov/Drugs/Fda-Approves-Glasdegib-Aml-Adults-Age-75-or-Older-or-Who-Have-Comorbidities" class="extLink">https://www.fda.gov/Drugs/Fda-Approves-Glasdegib-Aml-Adults-Age-75-or-Older-or-Who-Have-Comorbidities</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2FDrugs%2FFda-Approves-Glasdegib-Aml-Adults-Age-75-or-Older-or-Who-Have-Comorbidities+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesinos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DesJardins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeremski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span> <span> </span><span class="NLM_article-title">Randomized Comparison of Low Dose Cytarabine with or without Glasdegib in Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0312-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fs41375-018-0312-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30555165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=379-389&author=J.+E.+Cortesauthor=F.+H.+Heidelauthor=A.+Hellmannauthor=W.+Fiedlerauthor=B.+D.+Smithauthor=T.+Robakauthor=P.+Montesinosauthor=D.+A.+Pollyeaauthor=P.+DesJardinsauthor=O.+Ottmannauthor=W.+W.+Maauthor=M.+N.+Shaikauthor=A.+D.+Lairdauthor=M.+Zeremskiauthor=A.+O%E2%80%99Connellauthor=G.+Chanauthor=M.+Heuser&title=Randomized+Comparison+of+Low+Dose+Cytarabine+with+or+without+Glasdegib+in+Patients+with+Newly+Diagnosed+Acute+Myeloid+Leukemia+or+High-Risk+Myelodysplastic+Syndrome&doi=10.1038%2Fs41375-018-0312-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome</span></div><div class="casAuthors">Cortes, Jorge E.; Heidel, Florian H.; Hellmann, Andrzej; Fiedler, Walter; Smith, B. Douglas; Robak, Tadeusz; Montesinos, Pau; Pollyea, Daniel A.; DesJardins, Pierre; Ottmann, Oliver; Ma, Weidong Wendy; Shaik, M. Naveed; Laird, A. Douglas; Zeremski, Mirjana; O'Connell, Ashleigh; Chan, Geoffrey; Heuser, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">379-389</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Glasdegib is a Hedgehog pathway inhibitor.  This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy.  Glasdegib 100 mg (oral, QD) was administered continuously in 28-day cycles; LDAC 20 mg (s.c., BID) was administered for 10 per 28 days.  Patients (stratified by cytogenetic risk) were randomized (2:1) to receive glasdegib/LDAC or LDAC.  The primary endpoint was overall survival.  Eighty-eight and 44 patients were randomized to glasdegib/LDAC and LDAC, resp.  Median (80% confidence interval [CI]) overall survival was 8.8 (6.9-9.9) months with glasdegib/LDAC and 4.9 (3.5-6.0) months with LDAC (hazard ratio, 0.51; 80% CI, 0.39-0.67, P = 0.0004).  Fifteen (17.0%) and 1 (2.3%) patients in the glasdegib/LDAC and LDAC arms, resp., achieved complete remission (P < 0.05).  Nonhematol. grade 3/4 all-causality adverse events included pneumonia (16.7%) and fatigue (14.3%) with glasdegib/LDAC and pneumonia (14.6%) with LDAC.  Clin. efficacy was evident across patients with diverse mutational profiles.  Glasdegib plus LDAC has a favorable benefit-risk profile and may be a promising option for AML patients unsuitable for intensive chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokx5onjXmKwLVg90H21EOLACvtfcHk0ljnHH2MPoMrDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitLjL&md5=8f40182c7f9b69a2fdc6d2ab558d9723</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0312-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0312-9%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26aulast%3DHellmann%26aufirst%3DA.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DMontesinos%26aufirst%3DP.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DDesJardins%26aufirst%3DP.%26aulast%3DOttmann%26aufirst%3DO.%26aulast%3DMa%26aufirst%3DW.%2BW.%26aulast%3DShaik%26aufirst%3DM.%2BN.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DZeremski%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DHeuser%26aufirst%3DM.%26atitle%3DRandomized%2520Comparison%2520of%2520Low%2520Dose%2520Cytarabine%2520with%2520or%2520without%2520Glasdegib%2520in%2520Patients%2520with%2520Newly%2520Diagnosed%2520Acute%2520Myeloid%2520Leukemia%2520or%2520High-Risk%2520Myelodysplastic%2520Syndrome%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26spage%3D379%26epage%3D389%26doi%3D10.1038%2Fs41375-018-0312-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shavnya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzillo, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyden, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaGreca, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alsina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkalcevic, G. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">106</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1021/ml2002423</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml2002423" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=106-111&author=M.+J.+Munchhofauthor=Q.+Liauthor=A.+Shavnyaauthor=G.+V.+Borzilloauthor=T.+L.+Boydenauthor=C.+S.+Jonesauthor=S.+D.+LaGrecaauthor=L.+Martinez-Alsinaauthor=N.+Patelauthor=K.+Pelletierauthor=L.+A.+Reiterauthor=M.+D.+Robbinsauthor=G.+T.+Tkalcevic&title=Discovery+of+PF-04449913%2C+a+Potent+and+Orally+Bioavailable+Inhibitor+of+Smoothened&doi=10.1021%2Fml2002423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened</span></div><div class="casAuthors">Munchhof, Michael J.; Li, Qifang; Shavnya, Andrei; Borzillo, Gary V.; Boyden, Tracey L.; Jones, Christopher S.; LaGreca, Susan D.; Martinez-Alsina, Luis; Patel, Nandini; Pelletier, Kathleen; Reiter, Larry A.; Robbins, Michael D.; Tkalcevic, George T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">106-111</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hedgehog signaling pathway have generated a great deal of interest in the oncol. area due to the mounting evidence of their potential to provide promising therapeutic options for patients.  Herein, we describe the discovery strategy to overcome the issues inherent in lead structure 1 that resulted in the identification of Smoothened inhibitor 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea (PF-04449913, 26), which has been advanced to human clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCSrORZG_pxbVg90H21EOLACvtfcHk0lhTI3NSC1FDaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsLnO&md5=298ea79230c119359512b1ad07900557</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Fml2002423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml2002423%26sid%3Dliteratum%253Aachs%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DShavnya%26aufirst%3DA.%26aulast%3DBorzillo%26aufirst%3DG.%2BV.%26aulast%3DBoyden%26aufirst%3DT.%2BL.%26aulast%3DJones%26aufirst%3DC.%2BS.%26aulast%3DLaGreca%26aufirst%3DS.%2BD.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DPelletier%26aufirst%3DK.%26aulast%3DReiter%26aufirst%3DL.%2BA.%26aulast%3DRobbins%26aufirst%3DM.%2BD.%26aulast%3DTkalcevic%26aufirst%3DG.%2BT.%26atitle%3DDiscovery%2520of%2520PF-04449913%252C%2520a%2520Potent%2520and%2520Orally%2520Bioavailable%2520Inhibitor%2520of%2520Smoothened%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D106%26epage%3D111%26doi%3D10.1021%2Fml2002423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triche, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, A. A.</span></span> <span> </span><span class="NLM_article-title">GLI3 Repressor Determines Hedgehog Pathway Activation and Is Required for Response to SMO Antagonist Glasdegib in AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">3465</span>– <span class="NLM_lpage">3475</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-05-718585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1182%2Fblood-2016-05-718585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28487292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFamt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=3465-3475&author=P.+Chaudhryauthor=M.+Singhauthor=T.+J.+Tricheauthor=M.+Guzmanauthor=A.+A.+Merchant&title=GLI3+Repressor+Determines+Hedgehog+Pathway+Activation+and+Is+Required+for+Response+to+SMO+Antagonist+Glasdegib+in+AML&doi=10.1182%2Fblood-2016-05-718585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156aR"><div class="casContent"><span class="casTitleNuber">156a</span><div class="casTitle"><span class="NLM_cas:atitle">GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML</span></div><div class="casAuthors">Chaudhry, Parvesh; Singh, Mohan; Triche, Timothy J.; Guzman, Monica; Merchant, Akil A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3465-3475</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Hedgehog (Hh) signaling pathway is activated in many cancers and is a promising target for therapeutic development.  Deletions in the receptor Patched (PTCH) or activating mutations in Smoothened (SMO) have been reported in basal cell carcinoma and medulloblastoma, but are largely absent in most tumor types.  Therefore, the mechanism of pathway activation in most cancers, including hematol. malignancies, remains unknown.  In normal tissues, Hh pathway activation via PTCH/SMO causes an increase in the downstream transcriptional activator GLI1 and a decrease in the GLI3 transcriptional repressor (GLI3R).  In this article,weconfirm that theHhpathway is active in acute myeloid leukemia (AML), however, this activity is largely independent of SMO.  Epigenetic and gene expression anal. of The Cancer Genome Atlas AML data set reveals that GLI3 expression is silenced in mostAMLpatient samples, and the GLI3 locus is abnormally methylated.Weshow that GLI3R is required for the therapeutic effect of SMO antagonists in AML samples and restoration of GLI3R suppresses the growth of AML.  We addnl. demonstrate that GLI3R repressesAMLgrowth by downregulatingAKTexpression.  In summary,this study provides the first evidence that GLI3R plays an essential role in SMO-independent Hh signaling in AML, and suggests that GLI3R could serve as a potential biomarker for patient selection in SMO antagonist clin. trials.  Furthermore, these data support rational combinations of hypomethylating agents with SMO antagonists in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwpV6MABYMMLVg90H21EOLACvtfcHk0lhTI3NSC1FDaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFamt7rK&md5=32db4f56b56b90e8a32b675018a4610f</span></div><a href="/servlet/linkout?suffix=cit156a&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-05-718585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-05-718585%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhry%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DTriche%26aufirst%3DT.%2BJ.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DMerchant%26aufirst%3DA.%2BA.%26atitle%3DGLI3%2520Repressor%2520Determines%2520Hedgehog%2520Pathway%2520Activation%2520and%2520Is%2520Required%2520for%2520Response%2520to%2520SMO%2520Antagonist%2520Glasdegib%2520in%2520AML%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D3465%26epage%3D3475%26doi%3D10.1182%2Fblood-2016-05-718585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit156b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W.</span></span> <span> </span><span class="NLM_article-title">Activation of the Hedgehog Pathway in Chronic Myelogeneous Leukemia Patients</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1186/1756-9966-30-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1186%2F1756-9966-30-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=21235817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Klu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=8&author=B.+Longauthor=H.+Zhuauthor=C.+Zhuauthor=T.+Liuauthor=W.+Meng&title=Activation+of+the+Hedgehog+Pathway+in+Chronic+Myelogeneous+Leukemia+Patients&doi=10.1186%2F1756-9966-30-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156bR"><div class="casContent"><span class="casTitleNuber">156b</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the hedgehog pathway in chronic myelogeneous leukemia patients</span></div><div class="casAuthors">Long, Bing; Zhu, Huanling; Zhu, Cuixia; Liu, Ting; Meng, Wentong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Hedgehog (Hh) signaling pathway is involved in regulation of many tissues development and oncogenesis.  Recently, Hh signaling has been identified as a required functional pathway for leukemia stem cells(LSCs), and loss of this pathway impairs leukemia progression.  Objectives: The aim of this study was to det. the expression of Hedgehog signaling mols. in Chronic Myelogeneous Leukemia (CML) patients and normal people by semiquant. polymerase chain reaction (PCR) and to correlate mRNA expression to patients' clin. data.  Results: Here, we showed that Sonic hedgehog (Shh), Smoothened (Smo), and Gli1 genes of Hh signaling were significantly upregulated in CML patients when compared with normal people (P<0.001).  The levels of Shh, Smo mRNA in chronic phase of CML patients were obviously lower than that in blast crisis (p<0.05).  There were no significant differences of Shh, Ptch1, Smo, Gli1 mRNA expression found when comparing CML patients of chronic phase(CP) with imatinib(IM) treated or not(p>0.05).  Conclusions: These findings suggested that activation of the Hh pathway maybe assocd. with CML progression.  Treatment of CML with imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase inhibitor, has no significant influence on the inhibition of Hh pathway of CML-CP patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgyBC327KiFrVg90H21EOLACvtfcHk0lhTI3NSC1FDaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Klu7s%253D&md5=bcd89f1907b8535ee3d151fda6cb51c6</span></div><a href="/servlet/linkout?suffix=cit156b&amp;dbid=16384&amp;doi=10.1186%2F1756-9966-30-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-9966-30-8%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DMeng%26aufirst%3DW.%26atitle%3DActivation%2520of%2520the%2520Hedgehog%2520Pathway%2520in%2520Chronic%2520Myelogeneous%2520Leukemia%2520Patients%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D30%26spage%3D8%26doi%3D10.1186%2F1756-9966-30-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heretsch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzagkaroulaki, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannis, A.</span></span> <span> </span><span class="NLM_article-title">Modulators of the Hedgehog Signaling Pathway</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6613</span>– <span class="NLM_lpage">6624</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2010.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20708941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFamtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=6613-6624&author=P.+Heretschauthor=L.+Tzagkaroulakiauthor=A.+Giannis&title=Modulators+of+the+Hedgehog+Signaling+Pathway&doi=10.1016%2Fj.bmc.2010.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Modulators of the hedgehog signaling pathway</span></div><div class="casAuthors">Heretsch, Philipp; Tzagkaroulaki, Lito; Giannis, Athanassios</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6613-6624</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since its discovery by C. Nuesslein-Volhard and E. F. Wieschaus, hedgehog (hh) signaling has come a long way.  Today it is regarded as a key regulator in embryogenesis where it governs processes like cell proliferation, differentiation, and tissue patterning.  Furthermore, in adults it is involved in the maintenance of stem cells, and in tissue repair and regeneration.  But hh signaling has a second-much darker-face: it plays an important role in several types of human cancers where it promotes growth and enables proliferation of tumor stem cells.  The etiol. of medulloblastoma and basal cell carcinoma is tightly linked to aberrant hh activity, but also cancers of the prostate, the pancreas, the colon, the breasts, rhabdomyosarcoma, and leukemia, are dependent on irregular hh activity.  Recent clin. studies have shown that hh signaling can be the basis of an important new class of therapeutic agents with far-reaching implications in oncol.  Thus, modulation of hh signaling by means of small mols. has emerged as a valuable tool in combating these hh-dependent cancers.  Cyclopamine, a unique natural product with a fascinating history, was the first identified inhibitor of hh signaling and its story is closely linked to the progress in the whole field.  In this review we will trace the story of cyclopamine, give an overview on the biol. modes of hh signaling both in untransformed and malignant cells, and finally present potent modulators of the hh pathway-many of them already in clin. studies.  For more than 30 years now the knowledge on hh signaling has grown steadily-an end to this development is far from being conceivable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphJz_mK5dDvbVg90H21EOLACvtfcHk0ljbe1BX6ImOOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFamtrfO&md5=3187f3b583e2094cd0cfd1690ffe3071</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DHeretsch%26aufirst%3DP.%26aulast%3DTzagkaroulaki%26aufirst%3DL.%26aulast%3DGiannis%26aufirst%3DA.%26atitle%3DModulators%2520of%2520the%2520Hedgehog%2520Signaling%2520Pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D6613%26epage%3D6624%26doi%3D10.1016%2Fj.bmc.2010.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiesslich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neureiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neureiter, D.</span></span> <span> </span><span class="NLM_article-title">Thoughts on Investigational Hedgehog Pathway Inhibitors for the Treatment of Cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1274392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F13543784.2017.1274392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28004600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=133-136&author=T.+Jagerauthor=M.+Ockerauthor=T.+Kiesslichauthor=E.+Neureiterauthor=D.+Neureiter&title=Thoughts+on+Investigational+Hedgehog+Pathway+Inhibitors+for+the+Treatment+of+Cancer&doi=10.1080%2F13543784.2017.1274392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158aR"><div class="casContent"><span class="casTitleNuber">158a</span><div class="casTitle"><span class="NLM_cas:atitle">Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer</span></div><div class="casAuthors">Jager Tarkan; Ocker Matthias; Ocker Matthias; Kiesslich Tobias; Kiesslich Tobias; Neureiter Elen; Neureiter Daniel; Neureiter Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on investigational drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-136</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5cBz8zkyS2JPlX7E30qdzfW6udTcc2eaF8_Ds5Juj-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKntQ%253D%253D&md5=a1fbfd34b2de5e49f4a1828c7d7e3943</span></div><a href="/servlet/linkout?suffix=cit158a&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1274392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1274392%26sid%3Dliteratum%253Aachs%26aulast%3DJager%26aufirst%3DT.%26aulast%3DOcker%26aufirst%3DM.%26aulast%3DKiesslich%26aufirst%3DT.%26aulast%3DNeureiter%26aufirst%3DE.%26aulast%3DNeureiter%26aufirst%3DD.%26atitle%3DThoughts%2520on%2520Investigational%2520Hedgehog%2520Pathway%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D133%26epage%3D136%26doi%3D10.1080%2F13543784.2017.1274392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit158b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller-Moslin, K.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">500</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201000011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fcmdc.201000011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20229564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFyqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=500-512&author=S.+Peukertauthor=K.+Miller-Moslin&title=Small-Molecule+Inhibitors+of+the+Hedgehog+Signaling+Pathway+as+Cancer+Therapeutics&doi=10.1002%2Fcmdc.201000011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158bR"><div class="casContent"><span class="casTitleNuber">158b</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics</span></div><div class="casAuthors">Peukert, Stefan; Miller-Moslin, Karen</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">500-512</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Inhibitors of the Hedgehog (Hh) mol. signaling pathway have emerged in recent years as a promising new class of potential therapeutics for cancer treatment.  Numerous drug discovery efforts have resulted in the identification of a wide variety of small mols. that target different members of this pathway, including Smoothened (Smo), Sonic hedgehog protein (Shh), and Gli1.  Several Smo inhibitors have now entered human clin. trials, and successful proof-of-concept studies have been carried out in patients with defined genetic mutations in the Hh pathway.  This review provides a general overview of three main topics in this rapidly expanding area: (1) the various types of biol. assays and in vivo models that have been employed for the identification and optimization of Hh pathway inhibitors; (2) Smo inhibitors reported to date, including recent clin. results where available; and (3) efforts toward the identification and characterization of inhibitors of other members of the Hh pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwPNA0A-NVA7Vg90H21EOLACvtfcHk0ljbe1BX6ImOOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFyqt7o%253D&md5=429705c283818ba2af09f66aceea2ff3</span></div><a href="/servlet/linkout?suffix=cit158b&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000011%26sid%3Dliteratum%253Aachs%26aulast%3DPeukert%26aufirst%3DS.%26aulast%3DMiller-Moslin%26aufirst%3DK.%26atitle%3DSmall-Molecule%2520Inhibitors%2520of%2520the%2520Hedgehog%2520Signaling%2520Pathway%2520as%2520Cancer%2520Therapeutics%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D500%26epage%3D512%26doi%3D10.1002%2Fcmdc.201000011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puchlopek-Dermenci, A. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, H. J.</span></span> <span> </span><span class="NLM_article-title">Development of a Concise, Asymmetric Synthesis of a Smoothened Receptor (SMO) Inhibitor: Enzymatic Transamination of a 4-Piperidinone with Dynamic Kinetic Resolution</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">860</span>– <span class="NLM_lpage">863</span>, <span class="refDoi"> DOI: 10.1021/ol403630g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol403630g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=860-863&author=Z.+Pengauthor=J.+W.+Wongauthor=E.+C.+Hansenauthor=A.+L.+A.+Puchlopek-Dermenciauthor=H.+J.+Clarke&title=Development+of+a+Concise%2C+Asymmetric+Synthesis+of+a+Smoothened+Receptor+%28SMO%29+Inhibitor%3A+Enzymatic+Transamination+of+a+4-Piperidinone+with+Dynamic+Kinetic+Resolution&doi=10.1021%2Fol403630g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Concise, Asymmetric Synthesis of a Smoothened Receptor (SMO) Inhibitor: Enzymatic Transamination of a 4-Piperidinone with Dynamic Kinetic Resolution</span></div><div class="casAuthors">Peng, Zhihui; Wong, John W.; Hansen, Eric C.; Puchlopek-Dermenci, Angela L. A.; Clarke, Hugh J.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">860-863</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A concise, asym. synthesis of a smoothened receptor inhibitor I is described.  The synthesis features an enzymic transamination with concurrent dynamic kinetic resoln. (DKR) of a 4-piperidone II to establish the two stereogenic centers required in a single step.  This efficient reaction affords the desired anti amine III in >10:1 dr and >99% ee.  The title compd. is prepd. in only five steps with 40% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqszZmrhpvptrVg90H21EOLACvtfcHk0ljbe1BX6ImOOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKktrk%253D&md5=4cb54842346c8cb6f16460612599f6ee</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fol403630g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol403630g%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DJ.%2BW.%26aulast%3DHansen%26aufirst%3DE.%2BC.%26aulast%3DPuchlopek-Dermenci%26aufirst%3DA.%2BL.%2BA.%26aulast%3DClarke%26aufirst%3DH.%2BJ.%26atitle%3DDevelopment%2520of%2520a%2520Concise%252C%2520Asymmetric%2520Synthesis%2520of%2520a%2520Smoothened%2520Receptor%2520%2528SMO%2529%2520Inhibitor%253A%2520Enzymatic%2520Transamination%2520of%2520a%25204-Piperidinone%2520with%2520Dynamic%2520Kinetic%2520Resolution%26jtitle%3DOrg.%2520Lett.%26date%3D2014%26volume%3D16%26spage%3D860%26epage%3D863%26doi%3D10.1021%2Fol403630g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, E. C.</span>; <span class="NLM_string-name">Seadeek, C. S.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Crystalline Forms of 1-((2r,4r)-2-(1h-Benzo[D]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea Maleate</span>. <span class="NLM_patent">WO2016170451A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.+C.+Hansen&author=C.+S.+Seadeek&title=Process+for+Preparing+Crystalline+Forms+of+1-%28%282r%2C4r%29-2-%281h-Benzo%5BD%5Dimidazol-2-yl%29-1-methylpiperidin-4-yl%29-3-%284-cyanophenyl%29urea+Maleate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DE.%2BC.%26atitle%3DProcess%2520for%2520Preparing%2520Crystalline%2520Forms%2520of%25201-%2528%25282r%252C4r%2529-2-%25281h-Benzo%255BD%255Dimidazol-2-yl%2529-1-methylpiperidin-4-yl%2529-3-%25284-cyanophenyl%2529urea%2520Maleate%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Ivosidenib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1509</span>– <span class="NLM_lpage">1516</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0978-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0978-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30209701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSnu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1509-1516&author=S.+Dhillon&title=Ivosidenib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0978-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Ivosidenib: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1509-1516</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ivosidenib (Tibsovo) is a small mol., orally available inhibitor of mutated cytosolic isocitrate dehydrogenase 1 (IDH1) that is being developed by Agios Pharmaceuticals for the treatment of cancer in patients with IDH1 mutations.  The mutated form of the IDH1 enzyme produces a metabolite, 2-hydroxyglutarate (2-HG), which is thought to play a role in the formation and progression of acute myeloid leukemia (AML), gliomas and other cancers.  Elevated 2-HG levels interfere with cellular metab. and epigenetic regulation, thereby contributing to oncogenesis.  Ivosidenib targets the IDH1 metabolic pathway to prevent a build-up of the oncometabolite 2-HG.  This article summarizes the milestones in the development of ivosidenib leading to this first approval in the USA for the treatment of patients with relapsed or refractory AML with a susceptible IDH1 mutation.  Clin. development for AML, cholangiocarcinoma, glioma, myelodysplastic syndromes and solid tumors is ongoing worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr2rLroCG57LVg90H21EOLACvtfcHk0liRof9PZQ5Rkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSnu7rJ&md5=e18b0f17ef1376e1730ced8864dd5f1c</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0978-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0978-3%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DIvosidenib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1509%26epage%3D1516%26doi%3D10.1007%2Fs40265-018-0978-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Boddu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of Isocitrate Dehydrogenase Mutant AML</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1317745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F13543784.2017.1317745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28388242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlSmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=525-530&author=P.+Bodduauthor=G.+Borthakur&title=Therapeutic+Targeting+of+Isocitrate+Dehydrogenase+Mutant+AML&doi=10.1080%2F13543784.2017.1317745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162aR"><div class="casContent"><span class="casTitleNuber">162a</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of isocitrate dehydrogenase mutant AML</span></div><div class="casAuthors">Boddu, Prajwal; Borthakur, Gautam</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525-530</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The present article relates to mIDH inhibitors currently undergoing active development in clin. trials and also incorporate a section outlining agents targeting other simultaneously dysregulated pathways uniquely operational in IDH-mutated acute myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4-tiAS8V0ObVg90H21EOLACvtfcHk0liRof9PZQ5Rkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlSmu70%253D&md5=56f64f762e556aafeaecf6cc2af2da03</span></div><a href="/servlet/linkout?suffix=cit162a&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1317745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1317745%26sid%3Dliteratum%253Aachs%26aulast%3DBoddu%26aufirst%3DP.%26aulast%3DBorthakur%26aufirst%3DG.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Isocitrate%2520Dehydrogenase%2520Mutant%2520AML%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D525%26epage%3D530%26doi%3D10.1080%2F13543784.2017.1317745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit162b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nassereddine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lap, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haroun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabbara, I.</span></span> <span> </span><span class="NLM_article-title">The Role of Mutant IDH1 and IDH2 Inhibitors in the Treatment of Acute Myeloid Leukemia</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1983</span>– <span class="NLM_lpage">1991</span>, <span class="refDoi"> DOI: 10.1007/s00277-017-3161-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs00277-017-3161-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29090344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslCmtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=1983-1991&author=S.+Nassereddineauthor=C.+J.+Lapauthor=F.+Harounauthor=I.+Tabbara&title=The+Role+of+Mutant+IDH1+and+IDH2+Inhibitors+in+the+Treatment+of+Acute+Myeloid+Leukemia&doi=10.1007%2Fs00277-017-3161-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162bR"><div class="casContent"><span class="casTitleNuber">162b</span><div class="casTitle"><span class="NLM_cas:atitle">The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Nassereddine, Samah; Lap, Coen J.; Haroun, Faysal; Tabbara, Imad</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1983-1991</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">For decades, researchers have looked into the pathophysiol. of acute myeloid leukemia (AML).  With the advances in mol. techniques, the two-hit hypothesis was replaced by a multi-hit model, which also emphasizes the importance of aberrant epigenetic regulation in the pathogenesis of AML.  IDH1 and IDH2 are two isoforms of isocitrate dehydrogenase that perform crucial roles in cellular metab.  Somatic mutations in either of these two genes impart a neomorphic enzymic activity upon the encoded enzymes resulting in the ability to convert α-ketoglutarate (αKG) into the oncometabolite R2-hydroxyglutarate (R2-HG), which can competitively inhibit multiple αKG-dependent dioxygenases.  Inhibition of various classes of αKG-dependent dioxygenases results in dramatic epigenetic changes in hematopoietic cells, which has been found to directly impair differentiation.  In addn. to a global dysregulation of gene expression, other mechanisms have been described through which R2-HG promotes leukemic transformation including the induction of B cell lymphoma 2 dependency and stimulation of the EglN family of prolyl 4-hydroxylases (EglN).  Due to the fact that mutations in IDH1 and IDH2 are acquired early during AML clonal evolution as well as because these mutations tend to remain stable during AML progression, the pharmaceutical industry has prompted the development of specific mutant IDH enzyme inhibitors.  More recently, the FDA approved the first mutant IDH2 inhibitor, enasidenib (AG-221), for patients with relapsed or refractory IDH2-mutated AML (RR-AML).  This has brought a lot of excitement to researchers, clinicians, and patients, esp. because the treatment of AML remains challenging and is still assocd. with a high mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0MoaTYhzKz7Vg90H21EOLACvtfcHk0liRof9PZQ5Rkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslCmtrrL&md5=8b84f1581f0beef64cf14e6bf9f1a7c0</span></div><a href="/servlet/linkout?suffix=cit162b&amp;dbid=16384&amp;doi=10.1007%2Fs00277-017-3161-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-017-3161-0%26sid%3Dliteratum%253Aachs%26aulast%3DNassereddine%26aufirst%3DS.%26aulast%3DLap%26aufirst%3DC.%2BJ.%26aulast%3DHaroun%26aufirst%3DF.%26aulast%3DTabbara%26aufirst%3DI.%26atitle%3DThe%2520Role%2520of%2520Mutant%2520IDH1%2520and%2520IDH2%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DAnn.%2520Hematol.%26date%3D2017%26volume%3D96%26spage%3D1983%26epage%3D1991%26doi%3D10.1007%2Fs00277-017-3161-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quivoron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadrzadeh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gliser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saada, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agresta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penard-Lacronique, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K.</span></span> <span> </span><span class="NLM_article-title">AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3734</span>, <span class="refDoi"> DOI: 10.1182/blood.V124.21.3734.3734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1182%2Fblood.V124.21.3734.3734" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3734&author=E.+Hansenauthor=C.+Quivoronauthor=K.+Straleyauthor=R.+M.+Lemieuxauthor=J.+Popovici-Mullerauthor=H.+Sadrzadehauthor=A.+T.+Fathiauthor=C.+Gliserauthor=M.+Davidauthor=V.+Saadaauthor=J.+Micolauthor=O.+Bernardauthor=M.+Dorschauthor=H.+Yangauthor=M.+Suauthor=S.+Agrestaauthor=S.+de+Bottonauthor=V.+Penard-Lacroniqueauthor=K.+Yen&title=AG-120%2C+an+Oral%2C+Selective%2C+First-in-Class%2C+Potent+Inhibitor+of+Mutant+IDH1%2C+Reduces+Intracellular+2HG+and+Induces+Cellular+Differentiation+in+TF-1+R132H+Cells+and+Primary+Human+IDH1+Mutant+AML+Patient+Samples+Treated+Ex+Vivo&doi=10.1182%2Fblood.V124.21.3734.3734"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163a&amp;dbid=16384&amp;doi=10.1182%2Fblood.V124.21.3734.3734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V124.21.3734.3734%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DE.%26aulast%3DQuivoron%26aufirst%3DC.%26aulast%3DStraley%26aufirst%3DK.%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DSadrzadeh%26aufirst%3DH.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DGliser%26aufirst%3DC.%26aulast%3DDavid%26aufirst%3DM.%26aulast%3DSaada%26aufirst%3DV.%26aulast%3DMicol%26aufirst%3DJ.%26aulast%3DBernard%26aufirst%3DO.%26aulast%3DDorsch%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DAgresta%26aufirst%3DS.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DPenard-Lacronique%26aufirst%3DV.%26aulast%3DYen%26aufirst%3DK.%26atitle%3DAG-120%252C%2520an%2520Oral%252C%2520Selective%252C%2520First-in-Class%252C%2520Potent%2520Inhibitor%2520of%2520Mutant%2520IDH1%252C%2520Reduces%2520Intracellular%25202HG%2520and%2520Induces%2520Cellular%2520Differentiation%2520in%2520TF-1%2520R132H%2520Cells%2520and%2520Primary%2520Human%2520IDH1%2520Mutant%2520AML%2520Patient%2520Samples%2520Treated%2520Ex%2520Vivo%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D3734%26doi%3D10.1182%2Fblood.V124.21.3734.3734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit163b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">DiNardo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roboz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mims, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannis, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnellan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigneux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prince, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foran, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arellano, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekeres, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willekens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapsalis, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldwasser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agresta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">2386</span>– <span class="NLM_lpage">2398</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1716984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1056%2FNEJMoa1716984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29860938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1WjsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=2386-2398&author=C.+D.+DiNardoauthor=E.+M.+Steinauthor=S.+de+Bottonauthor=G.+J.+Robozauthor=J.+K.+Altmanauthor=A.+S.+Mimsauthor=R.+Swordsauthor=R.+H.+Collinsauthor=G.+N.+Mannisauthor=D.+A.+Pollyeaauthor=W.+Donnellanauthor=A.+T.+Fathiauthor=A.+Pigneuxauthor=H.+P.+Erbaauthor=G.+T.+Princeauthor=A.+S.+Steinauthor=G.+L.+Uyauthor=J.+M.+Foranauthor=E.+Traerauthor=R.+K.+Stuartauthor=M.+L.+Arellanoauthor=J.+L.+Slackauthor=M.+A.+Sekeresauthor=C.+Willekensauthor=S.+Choeauthor=H.+Wangauthor=V.+Zhangauthor=K.+E.+Yenauthor=S.+M.+Kapsalisauthor=H.+Yangauthor=D.+Daiauthor=B.+Fanauthor=M.+Goldwasserauthor=H.+Liuauthor=S.+Agrestaauthor=B.+Wuauthor=E.+C.+Attarauthor=M.+S.+Tallmanauthor=R.+M.+Stoneauthor=H.+M.+Kantarjian&title=Durable+Remissions+with+Ivosidenib+in+IDH1-Mutated+Relapsed+or+Refractory+AML&doi=10.1056%2FNEJMoa1716984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163bR"><div class="casContent"><span class="casTitleNuber">163b</span><div class="casTitle"><span class="NLM_cas:atitle">Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML</span></div><div class="casAuthors">DiNardo, C. D.; Stein, E. M.; de Botton, S.; Roboz, G. J.; Altman, J. K.; Mims, A. S.; Swords, R.; Collins, R. H.; Mannis, G. N.; Pollyea, D. A.; Donnellan, W.; Fathi, A. T.; Pigneux, A.; Erba, H. P.; Prince, G. T.; Stein, A. S.; Uy, G. L.; Foran, J. M.; Traer, E.; Stuart, R. K.; Arellano, M. L.; Slack, J. L.; Sekeres, M. A.; Willekens, C.; Choe, S.; Wang, H.; Zhang, V.; Yen, K. E.; Kapsalis, S. M.; Yang, H.; Dai, D.; Fan, B.; Goldwasser, M.; Liu, H.; Agresta, S.; Wu, B.; Attar, E. C.; Tallman, M. S.; Stone, R. M.; Kantarjian, H. M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2386-2398</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in 6 to 10% of patients with acute myeloid leukemia (AML).  Ivosidenib (AG-120) is an oral, targeted, small-mol. inhibitor of mutant IDH1.  We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1-mutated AML.  Safety and efficacy were assessed in all treated patients.  The primary efficacy population included patients with relapsed or refractory AML receiving 500 mg of ivosidenib daily with at least 6 mo of follow-up.  Overall, 258 patients received ivosidenib and had safety outcomes assessed.  Among patients with relapsed or refractory AML (179 patients), treatment-related adverse events of grade 3 or higher that occurred in at least 3 patients were prolongation of the QT interval (in 7.8% of the patients), the IDH differentiation syndrome (in 3.9%), anemia (in 2.2%), thrombocytopenia or a decrease in the platelet count (in 3.4%), and leukocytosis (in 1.7%).  In the primary efficacy population (125 patients), the rate of complete remission or complete remission with partial hematol. recovery was 30.4% (95% confidence interval [CI], 22.5 to 39.3), the rate of complete remission was 21.6% (95% CI, 14.7 to 29.8), and the overall response rate was 41.6% (95% CI, 32.9 to 50.8).  The median durations of these responses were 8.2 mo (95% CI, 5.5 to 12.0), 9.3 mo (95% CI, 5.6 to 18.3), and 6.5 mo (95% CI, 4.6 to 9.3), resp.  Transfusion independence was attained in 29 of 84 patients (35%), and patients who had a response had fewer infections and febrile neutropenia episodes than those who did not have a response.  Among 34 patients who had a complete remission or complete remission with partial hematol. recovery, 7 (21%) had no residual detectable IDH1 mutations on digital polymerase-chain-reaction assay.  No preexisting co-occurring single gene mutation predicted clin. response or resistance to treatment.  In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was assocd. with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and mol. remissions in some patients with complete remission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAH6OFnOLWHbVg90H21EOLACvtfcHk0lhbVDSB8cLo1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1WjsrnO&md5=d60a1161c02f7d4aa39c8fbf6ed2dea1</span></div><a href="/servlet/linkout?suffix=cit163b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1716984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1716984%26sid%3Dliteratum%253Aachs%26aulast%3DDiNardo%26aufirst%3DC.%2BD.%26aulast%3DStein%26aufirst%3DE.%2BM.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DMims%26aufirst%3DA.%2BS.%26aulast%3DSwords%26aufirst%3DR.%26aulast%3DCollins%26aufirst%3DR.%2BH.%26aulast%3DMannis%26aufirst%3DG.%2BN.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DDonnellan%26aufirst%3DW.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DPrince%26aufirst%3DG.%2BT.%26aulast%3DStein%26aufirst%3DA.%2BS.%26aulast%3DUy%26aufirst%3DG.%2BL.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DTraer%26aufirst%3DE.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DArellano%26aufirst%3DM.%2BL.%26aulast%3DSlack%26aufirst%3DJ.%2BL.%26aulast%3DSekeres%26aufirst%3DM.%2BA.%26aulast%3DWillekens%26aufirst%3DC.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DV.%26aulast%3DYen%26aufirst%3DK.%2BE.%26aulast%3DKapsalis%26aufirst%3DS.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DB.%26aulast%3DGoldwasser%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DAgresta%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DAttar%26aufirst%3DE.%2BC.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26atitle%3DDurable%2520Remissions%2520with%2520Ivosidenib%2520in%2520IDH1-Mutated%2520Relapsed%2520or%2520Refractory%2520AML%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D2386%26epage%3D2398%26doi%3D10.1056%2FNEJMoa1716984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span>; <span class="NLM_string-name">Popovici-Muller, J.</span>; <span class="NLM_string-name">Travins, J.</span>; <span class="NLM_string-name">Cai, Z.</span>; <span class="NLM_string-name">Cui, D.</span>; <span class="NLM_string-name">Ding, Z.</span></span> <span> </span><span class="NLM_article-title">Therapeutically Active Compounds and Their Methods of Use</span>. <span class="NLM_patent">WO2013107291A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+M.+Lemieux&author=J.+Popovici-Muller&author=J.+Travins&author=Z.+Cai&author=D.+Cui&author=Z.+Ding&title=Therapeutically+Active+Compounds+and+Their+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26atitle%3DTherapeutically%2520Active%2520Compounds%2520and%2520Their%2520Methods%2520of%2520Use%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit164b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span>; <span class="NLM_string-name">Popovici-Muller, J.</span>; <span class="NLM_string-name">Travins, J.</span>; <span class="NLM_string-name">Cai, Z.</span>; <span class="NLM_string-name">Cui, D.</span>; <span class="NLM_string-name">Ding, Z.</span></span> <span> </span><span class="NLM_article-title">Therapeutically Active Compounds and Their Methods of Use</span>. <span class="NLM_patent">WO2015010297A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=R.+M.+Lemieux&author=J.+Popovici-Muller&author=J.+Travins&author=Z.+Cai&author=D.+Cui&author=Z.+Ding&title=Therapeutically+Active+Compounds+and+Their+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26atitle%3DTherapeutically%2520Active%2520Compounds%2520and%2520Their%2520Methods%2520of%2520Use%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit164c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penard-Lacronique, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quivoron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saada, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaharski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.-S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00421</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00421" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=300-305&author=J.+Popovici-Mullerauthor=R.+M.+Lemieuxauthor=E.+Artinauthor=J.+O.+Saundersauthor=F.+G.+Salituroauthor=J.+Travinsauthor=G.+Cianchettaauthor=Z.+Caiauthor=D.+Zhouauthor=D.+Cuiauthor=P.+Chenauthor=K.+Straleyauthor=E.+Tobinauthor=F.+Wangauthor=M.+D.+Davidauthor=V.+Penard-Lacroniqueauthor=C.+Quivoronauthor=V.+Saadaauthor=S.+de+Bottonauthor=S.+Grossauthor=L.+Dangauthor=H.+Yangauthor=L.+Utleyauthor=Y.+Chenauthor=H.+Kimauthor=S.+Jinauthor=Z.+Guauthor=G.+Yaoauthor=Z.+Luoauthor=X.+Lvauthor=C.+Fangauthor=L.+Yanauthor=A.+Olaharskiauthor=L.+Silvermanauthor=S.+Billerauthor=S.-S.+M.+Suauthor=K.+Yen&title=Discovery+of+AG-120+%28Ivosidenib%29%3A+A+First-in-Class+Mutant+IDH1+Inhibitor+for+the+Treatment+of+IDH1+Mutant+Cancers&doi=10.1021%2Facsmedchemlett.7b00421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164cR"><div class="casContent"><span class="casTitleNuber">164c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers</span></div><div class="casAuthors">Popovici-Muller, Janeta; Lemieux, Rene M.; Artin, Erin; Saunders, Jeffrey O.; Salituro, Francesco G.; Travins, Jeremy; Cianchetta, Giovanni; Cai, Zhenwei; Zhou, Ding; Cui, Dawei; Chen, Ping; Straley, Kimberly; Tobin, Erica; Wang, Fang; David, Muriel D.; Penard-Lacronique, Virginie; Quivoron, Cyril; Saada, Veronique; de Botton, Stephane; Gross, Stefan; Dang, Lenny; Yang, Hua; Utley, Luke; Chen, Yue; Kim, Hyeryun; Jin, Shengfang; Gu, Zhiwei; Yao, Gui; Luo, Zhiyong; Lv, Xiaobing; Fang, Cheng; Yan, Liping; Olaharski, Andrew; Silverman, Lee; Biller, Scott; Su, Shin-San M.; Yen, Katharine</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">300-305</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the prodn. of D-2-hydroxyglutarate (2-HG), an oncometabolite.  Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation.  IDH1 mutations have been described in an array of hematol. malignancies and solid tumors.  Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo.  Preliminary data from phase 1 clin. trials enrolling patients with cancers harboring an IDH1 mutation indicate that AG-120 has an acceptable safety profile and clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmTLcR37BiPrVg90H21EOLACvtfcHk0lh9rX3wV4BhSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D&md5=730ac2faa6844e4abe3fd9a360d74d29</span></div><a href="/servlet/linkout?suffix=cit164c&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00421%26sid%3Dliteratum%253Aachs%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26aulast%3DArtin%26aufirst%3DE.%26aulast%3DSaunders%26aufirst%3DJ.%2BO.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DTravins%26aufirst%3DJ.%26aulast%3DCianchetta%26aufirst%3DG.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DStraley%26aufirst%3DK.%26aulast%3DTobin%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DDavid%26aufirst%3DM.%2BD.%26aulast%3DPenard-Lacronique%26aufirst%3DV.%26aulast%3DQuivoron%26aufirst%3DC.%26aulast%3DSaada%26aufirst%3DV.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DUtley%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DOlaharski%26aufirst%3DA.%26aulast%3DSilverman%26aufirst%3DL.%26aulast%3DBiller%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DS.-S.%2BM.%26aulast%3DYen%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520AG-120%2520%2528Ivosidenib%2529%253A%2520A%2520First-in-Class%2520Mutant%2520IDH1%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520IDH1%2520Mutant%2520Cancers%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D300%26epage%3D305%26doi%3D10.1021%2Facsmedchemlett.7b00421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, A. R.</span>; <span class="NLM_string-name">Singh, A.</span>; <span class="NLM_string-name">Yazali, V. S.</span>; <span class="NLM_string-name">Luthra, P. K.</span>; <span class="NLM_string-name">Vasoya, S. L.</span>; <span class="NLM_string-name">Patil, B. T.</span>; <span class="NLM_string-name">Taneja, A. K.</span>; <span class="NLM_string-name">Srivastav, N. C.</span>; <span class="NLM_string-name">Singh, R.</span>; <span class="NLM_string-name">Rengasamy, V.</span>; <span class="NLM_string-name">Tyagi, A.</span></span> <span> </span><span class="NLM_article-title">Solid State Forms of Ivosidenib</span>. <span class="NLM_patent">WO2019104318A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+R.+Muthusamy&author=A.+Singh&author=V.+S.+Yazali&author=P.+K.+Luthra&author=S.+L.+Vasoya&author=B.+T.+Patil&author=A.+K.+Taneja&author=N.+C.+Srivastav&author=R.+Singh&author=V.+Rengasamy&author=A.+Tyagi&title=Solid+State+Forms+of+Ivosidenib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMuthusamy%26aufirst%3DA.%2BR.%26atitle%3DSolid%2520State%2520Forms%2520of%2520Ivosidenib%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Larotrectinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1044-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1044-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30635837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=201-206&author=L.+J.+Scott&title=Larotrectinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1044-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib: First Global Approval</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-206</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Larotrectinib (Vitrakvi) is an orally administered, small mol., highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncol. in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbor neurotrophic receptor tyrosine kinase (NTRK) gene fusions.  In Nov. 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.  A registration application for the use of larotrectinib in pediatric and adult patients with locally advanced or metastatic solid tumors with NTRK gene fusion proteins has been submitted in the EU.  This article summarizes the milestones in the development of larotrectinib leading to its first approval for the treatment of adult and pediatric patients with solid tumors that have NTRK gene fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMpwdBG0H7ELVg90H21EOLACvtfcHk0lh9rX3wV4BhSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsb8%253D&md5=8c3d442665ece609cc09422052903696</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1044-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1044-x%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DLarotrectinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D201%26epage%3D206%26doi%3D10.1007%2Fs40265-018-1044-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span> <span> </span><span class="NLM_article-title">NTRK Fusion-Positive Cancers and TRK Inhibitor Therapy</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/s41571-018-0113-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fs41571-018-0113-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30333516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCrsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=731-747&author=E.+Coccoauthor=M.+Scaltritiauthor=A.+Drilon&title=NTRK+Fusion-Positive+Cancers+and+TRK+Inhibitor+Therapy&doi=10.1038%2Fs41571-018-0113-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">NTRK fusion-positive cancers and TRK inhibitor therapy</span></div><div class="casAuthors">Cocco, Emiliano; Scaltriti, Maurizio; Drilon, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, resp.) are oncogenic drivers of various adult and paediatric tumor types.  These fusions can be detected in the clinic using a variety of methods, including tumor DNA and RNA sequencing and plasma cell-free DNA profiling.  The treatment of patients with NTRK fusion-pos. cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is assocd. with high response rates (>75%), regardless of tumor histol.  First-generation TRK inhibitors are well tolerated by most patients, with toxicity profiles characterized by occasional off-tumor, on-target adverse events (attributable to TRK inhibition in non-malignant tissues).  Despite durable disease control in many patients, advanced-stage NTRK fusion-pos. cancers eventually become refractory to TRK inhibition; resistance can be mediated by the acquisition of NTRK kinase domain mutations.  Fortunately, certain resistance mutations can be overcome by second-generation TRK inhibitors, including LOXO-195 and TPX-0005 that are being explored in clin. trials.  In this Review, we discuss the biol. of NTRK fusions, strategies to target these drivers in the treatment-naive and acquired-resistance disease settings, and the unique safety profile of TRK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2tGShkjX-5LVg90H21EOLACvtfcHk0lhAJr8OEHKnvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCrsLnO&md5=fbc1f5b0de3614008f1b1f1e2e6167ce</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fs41571-018-0113-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41571-018-0113-0%26sid%3Dliteratum%253Aachs%26aulast%3DCocco%26aufirst%3DE.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DDrilon%26aufirst%3DA.%26atitle%3DNTRK%2520Fusion-Positive%2520Cancers%2520and%2520TRK%2520Inhibitor%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26spage%3D731%26epage%3D747%26doi%3D10.1038%2Fs41571-018-0113-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span> <span> </span><span class="NLM_article-title">Larotrectinib in NTRK-Rearranged Solid Tumors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1557</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00126</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00126" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks1Chsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=1555-1557&author=F.+H.+Wilsonauthor=R.+S.+Herbst&title=Larotrectinib+in+NTRK-Rearranged+Solid+Tumors&doi=10.1021%2Facs.biochem.9b00126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib in NTRK-Rearranged Solid Tumors</span></div><div class="casAuthors">Wilson, Frederick H.; Herbst, Roy S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1555-1557</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Larotrectinib (LOXO-101 and ARRY470) is an orally available, potent, and selective ATP-competitive pan-tropomyosin receptor tyrosine kinase (TRK) inhibitor with low nanomolar 50% inhibitory concns.  Early phase clin. trials for safety and efficacy of larotrectinib in adult and pediatric patients with diverse TRK fusion-pos. malignancies were recently reported.  Responses were obsd. in 75% of patients regardless of patient age, tumor type, TRK family member, or identity of the TRK fusion partner.  On the basis of these findings, the Food and Drug Administration granted accelerated approval to larotrectinib in Nov. 2018 for the treatment of adult and pediatric patients with advanced solid tumors harboring an NTRK gene fusion.  Using structural insights derived from X-ray crystallog. of TRK proteins and in silico modeling of addnl. structurally distinct TRK inhibitors, a second TRK inhibitor called LOXO195 was identified as a candidate compd. with potential activity against secondary mutations conferring resistance to larotrectinib.  On the basis of prior experience with acquired resistance to other kinase-directed therapies, LOXO-195 was developed nearly in parallel with larotrectinib in anticipation of acquired resistance to larotrectinib in treated patients.  A phase 1/2 clin. trial evaluating the safety and preliminary efficacy of LOXO-195 in adults and children with TRK-driven solid tumors refractory to a prior TRK inhibitor is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7SElFd-Ty17Vg90H21EOLACvtfcHk0lhAJr8OEHKnvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks1Chsb0%253D&md5=d92f8170ae3bd22f4c5e76bf058d8edc</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00126%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DF.%2BH.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26atitle%3DLarotrectinib%2520in%2520NTRK-Rearranged%2520Solid%2520Tumors%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D1555%26epage%3D1557%26doi%3D10.1021%2Facs.biochem.9b00126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F. Y.</span></span> <span> </span><span class="NLM_article-title">A Tumor-Agnostic NTRK (TRK) Inhibitor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.02.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.cell.2019.02.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30901551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVWgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2019&pages=8&author=F.+W.+Huangauthor=F.+Y.+Feng&title=A+Tumor-Agnostic+NTRK+%28TRK%29+Inhibitor&doi=10.1016%2Fj.cell.2019.02.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">A Tumor-Agnostic NTRK (TRK) Inhibitor</span></div><div class="casAuthors">Huang, Franklin W.; Feng, Felix Y.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Larotrectinib is a small-mol. kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer.  Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights.  To view this Bench to Bedside, open or download the PDF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOCr1TgE8Pl7Vg90H21EOLACvtfcHk0lhAJr8OEHKnvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVWgtLg%253D&md5=339c53baa9365f3eefc6948b4fc2cfaf</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.02.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.02.049%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DF.%2BW.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26atitle%3DA%2520Tumor-Agnostic%2520NTRK%2520%2528TRK%2529%2520Inhibitor%26jtitle%3DCell%26date%3D2019%26volume%3D177%26spage%3D8%26doi%3D10.1016%2Fj.cell.2019.02.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, M.</span>; <span class="NLM_string-name">Eary, C. T.</span>; <span class="NLM_string-name">Spencer, S.</span>; <span class="NLM_string-name">Juengst, D.</span>; <span class="NLM_string-name">Hache, B.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Haas, J.</span>; <span class="NLM_string-name">Andrews, S. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide</span>. <span class="NLM_patent">WO2017201241A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+Reynolds&author=C.+T.+Eary&author=S.+Spencer&author=D.+Juengst&author=B.+Hache&author=Y.+Jiang&author=J.+Haas&author=S.+W.+Andrews&title=Preparation+of+%28S%29-N-%285-%28%28R%29-2-%282%2C5-Difluorophenyl%29pyrrolidin-1-yl%29pyrazolo%5B1%2C5-a%5Dpyrimidin-3-yl%29-3-hydroxypyrrolidine-1-carboxamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520%2528S%2529-N-%25285-%2528%2528R%2529-2-%25282%252C5-Difluorophenyl%2529pyrrolidin-1-yl%2529pyrazolo%255B1%252C5-a%255Dpyrimidin-3-yl%2529-3-hydroxypyrrolidine-1-carboxamide%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryser, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diebold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautschi, O.</span></span> <span> </span><span class="NLM_article-title">Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Update and Perspectives</span>. <i>Curr. Opin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1097/CCO.0000000000000494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1097%2FCCO.0000000000000494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30394941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlCmtrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2019&pages=8-12&author=C.+O.+Ryserauthor=J.+Dieboldauthor=O.+Gautschi&title=Treatment+of+Anaplastic+Lymphoma+Kinase-Positive+Non-Small+Cell+Lung+Cancer%3A+Update+and+Perspectives&doi=10.1097%2FCCO.0000000000000494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives</span></div><div class="casAuthors">Ryser, Christoph Oliver; Diebold, Joachim; Gautschi, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-12</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: We describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.  Recent findings: Five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.  This review summarizes published data, together with drug-specific information on dosing and toxicity.  Moreover, we discuss different clin. scenarios and potential treatment options in patients with tumor progression, based on current literature and our own experience.  Summary: Patients with metastatic, anaplastic lymphoma kinase-rearranged nonsmall cell lung cancer should be managed by interdisciplinary expert teams.  New drugs with enhanced brain activity are available, and some patients may benefit from local therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMSqOqWnTEdrVg90H21EOLACvtfcHk0lgWdq519qquDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlCmtrrK&md5=fe23a33e86c430f7eb71be1dd441812d</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1097%2FCCO.0000000000000494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0000000000000494%26sid%3Dliteratum%253Aachs%26aulast%3DRyser%26aufirst%3DC.%2BO.%26aulast%3DDiebold%26aufirst%3DJ.%26aulast%3DGautschi%26aufirst%3DO.%26atitle%3DTreatment%2520of%2520Anaplastic%2520Lymphoma%2520Kinase-Positive%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Update%2520and%2520Perspectives%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2019%26volume%3D31%26spage%3D8%26epage%3D12%26doi%3D10.1097%2FCCO.0000000000000494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Lorlatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1041-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1041-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30604291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=93-98&author=Y.+Y.+Syed&title=Lorlatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1041-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-98</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Lorlatinib is an oral small mol. inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-pos. non-small cell lung cancer (NSCLC).  Based on results from a phase I/II trial, lorlatinib received approval in Japan in Sept. 2018 and in the USA in Nov. 2018 for the treatment of ALK-pos. NSCLC.  This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU4Wwiia48VbVg90H21EOLACvtfcHk0lgWdq519qquDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D&md5=f041ba0200e2d607bb2a014884455990</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1041-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1041-0%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DLorlatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D93%26epage%3D98%26doi%3D10.1007%2Fs40265-018-1041-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10r)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2h-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]-Benzoxadiazacyclotetradecine-3-Carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Ros Oncogene 1 (Ros1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810r%29-7-Amino-12-Fluoro-2%2C10%2C16-Trimethyl-15-Oxo-10%2C15%2C16%2C17-Tetrahydro-2h-8%2C4-%28Metheno%29Pyrazolo%5B4%2C3-H%5D%5B2%2C5%2C11%5D-Benzoxadiazacyclotetradecine-3-Carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+C-Ros+Oncogene+1+%28Ros1%29+with+Preclinical+Brain+Exposure+and+Broad-Spectrum+Potency+against+ALK-Resistant+Mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lgWdq519qquDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810r%2529-7-Amino-12-Fluoro-2%252C10%252C16-Trimethyl-15-Oxo-10%252C15%252C16%252C17-Tetrahydro-2h-8%252C4-%2528Metheno%2529Pyrazolo%255B4%252C3-H%255D%255B2%252C5%252C11%255D-Benzoxadiazacyclotetradecine-3-Carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520C-Ros%2520Oncogene%25201%2520%2528Ros1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-Spectrum%2520Potency%2520against%2520ALK-Resistant%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satouchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.-F.</span></span> <span> </span><span class="NLM_article-title">ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1370</span>– <span class="NLM_lpage">1379</span>, <span class="refDoi"> DOI: 10.1200/JCO.18.02236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1200%2FJCO.18.02236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30892989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cbmt1yntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=1370-1379&author=A.+T.+Shawauthor=B.+J.+Solomonauthor=B.+Besseauthor=T.+M.+Bauerauthor=C.-C.+Linauthor=R.+A.+Sooauthor=G.+J.+Rielyauthor=S.-H.+I.+Ouauthor=J.+S.+Clancyauthor=S.+Liauthor=A.+Abbattistaauthor=H.+Thurmauthor=M.+Satouchiauthor=D.+R.+Camidgeauthor=S.+Kaoauthor=R.+Chiariauthor=S.+M.+Gadgeelauthor=E.+Felipauthor=J.-F.+Martini&title=ALK+Resistance+Mutations+and+Efficacy+of+Lorlatinib+in+Advanced+Anaplastic+Lymphoma+Kinase-Positive+Non-Small-Cell+Lung+Cancer&doi=10.1200%2FJCO.18.02236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Shaw Alice T; Solomon Benjamin J; Besse Benjamin; Bauer Todd M; Lin Chia-Chi; Soo Ross A; Riely Gregory J; Ou Sai-Hong Ignatius; Clancy Jill S; Li Sherry; Thurm Holger; Martini Jean-Francois; Abbattista Antonello; Satouchi Miyako; Camidge D Ross; Kao Steven; Chiari Rita; Gadgeel Shirish M; Felip Enriqueta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1370-1379</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non-small-cell lung cancer, including in patients who have failed prior ALK TKIs.  Molecular determinants of response to lorlatinib have not been established, but preclinical data suggest that ALK resistance mutations may represent a biomarker of response in previously treated patients.  PATIENTS AND METHODS:  Baseline plasma and tumor tissue samples were collected from 198 patients with ALK-positive non-small-cell lung cancer from the registrational phase II study of lorlatinib.  We analyzed plasma DNA for ALK mutations using Guardant360.  Tumor tissue DNA was analyzed using an ALK mutation-focused next-generation sequencing assay.  Objective response rate, duration of response, and progression-free survival were evaluated according to ALK mutation status.  RESULTS:  Approximately one quarter of patients had ALK mutations detected by plasma or tissue genotyping.  In patients with crizotinib-resistant disease, the efficacy of lorlatinib was comparable among patients with and without ALK mutations using plasma or tissue genotyping.  In contrast, in patients who had failed 1 or more second-generation ALK TKIs, objective response rate was higher among patients with ALK mutations (62% v 32% [plasma]; 69% v 27% [tissue]).  Progression-free survival was similar in patients with and without ALK mutations on the basis of plasma genotyping (median, 7.3 months v 5.5 months; hazard ratio, 0.81) but significantly longer in patients with ALK mutations identified by tissue genotyping (median, 11.0 months v 5.4 months; hazard ratio, 0.47).  CONCLUSION:  In patients who have failed 1 or more second-generation ALK TKIs, lorlatinib shows greater efficacy in patients with ALK mutations compared with patients without ALK mutations.  Tumor genotyping for ALK mutations after failure of a second-generation TKI may identify patients who are more likely to derive clinical benefit from lorlatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSncho2_xqX8ULxIEhxUjPfW6udTcc2eZ5m0HCYN-zeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbmt1yntg%253D%253D&md5=66ac31b67ead0ec2ab21309b875a081f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1200%2FJCO.18.02236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.18.02236%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DClancy%26aufirst%3DJ.%2BS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DSatouchi%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DKao%26aufirst%3DS.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DMartini%26aufirst%3DJ.-F.%26atitle%3DALK%2520Resistance%2520Mutations%2520and%2520Efficacy%2520of%2520Lorlatinib%2520in%2520Advanced%2520Anaplastic%2520Lymphoma%2520Kinase-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D1370%26epage%3D1379%26doi%3D10.1200%2FJCO.18.02236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Lorlatinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer: Results from a Global Phase 2 Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1654</span>– <span class="NLM_lpage">1667</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30649-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS1470-2045%2818%2930649-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30413378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFamt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1654-1667&author=B.+J.+Solomonauthor=B.+Besseauthor=T.+M.+Bauerauthor=E.+Felipauthor=R.+A.+Sooauthor=D.+R.+Camidgeauthor=R.+Chiariauthor=A.+Bearzauthor=C.-C.+Linauthor=S.+M.+Gadgeelauthor=G.+J.+Rielyauthor=E.+H.+Tanauthor=T.+Setoauthor=L.+P.+Jamesauthor=J.+S.+Clancyauthor=A.+Abbattistaauthor=J.-F.+Martiniauthor=J.+Chenauthor=G.+Peltzauthor=H.+Thurmauthor=S.-H.+I.+Ouauthor=A.+T.+Shaw&title=Lorlatinib+in+Patients+with+ALK-Positive+Non-Small-Cell+Lung+Cancer%3A+Results+from+a+Global+Phase+2+Study&doi=10.1016%2FS1470-2045%2818%2930649-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study</span></div><div class="casAuthors">Solomon, Benjamin J.; Besse, Benjamin; Bauer, Todd M.; Felip, Enriqueta; Soo, Ross A.; Camidge, D. Ross; Chiari, Rita; Bearz, Alessandra; Lin, Chia-Chi; Gadgeel, Shirish M.; Riely, Gregory J.; Tan, Eng Huat; Seto, Takashi; James, Leonard P.; Clancy, Jill S.; Abbattista, Antonello; Martini, Jean-Francois; Chen, Joseph; Peltz, Gerson; Thurm, Holger; Ignatius Ou, Sai-Hong; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1654-1667</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations.  In a phase 1 study, activity was seen in patients with ALK-pos. non-small-cell lung cancer, most of whom had CNS metastases and progression after ALK-directed therapy.  We aimed to analyze the overall and intracranial antitumor activity of lorlatinib in patients with ALK-pos., advanced non-small-cell lung cancer.  In this phase 2 study, patients with histol. or cytol. ALK-pos. or ROS1-pos., advanced, non-small-cell lung cancer, with or without CNS metastases, with an Eastern Cooperative Oncol. Group performance status of 0, 1, or 2, and adequate end-organ function were eligible.  Patients were enrolled into six different expansion cohorts (EXP1-6) on the basis of ALK and ROS1 status and previous therapy, and were given lorlatinib 100 mg orally once daily continuously in 21-day cycles.  The primary endpoint was overall and intracranial tumor response by independent central review, assessed in pooled subgroups of ALK-pos. patients.  Analyses of activity and safety were based on the safety anal. set (ie, all patients who received at least one dose of lorlatinib) as assessed by independent central review.  Patients with measurable CNS metastases at baseline by independent central review were included in the intracranial activity analyses.  In this report, we present lorlatinib activity data for the ALK-pos. patients (EXP1-5 only), and safety data for all treated patients (EXP1-6).  This study is ongoing and is registered with ClinicalTrials.gov, no. NCT01970865.  Between Sept 15, 2015, and Oct 3, 2016, 276 patients were enrolled: 30 who were ALK pos. and treatment naive (EXP1); 59 who were ALK pos. and received previous crizotinib without (n=27; EXP2) or with (n=32; EXP3A) previous chemotherapy; 28 who were ALK pos. and received one previous non-crizotinib ALK tyrosine kinase inhibitor, with or without chemotherapy (EXP3B); 112 who were ALK pos. with two (n=66; EXP4) or three (n=46; EXP5) previous ALK tyrosine kinase inhibitors with or without chemotherapy; and 47 who were ROS1 pos. with any previous treatment (EXP6).  One patient in EXP4 died before receiving lorlatinib and was excluded from the safety anal. set.  In treatment-naive patients (EXP1), an objective response was achieved in 27 (90·0%; 95% CI 73·5-97·9) of 30 patients.  Three patients in EXP1 had measurable baseline CNS lesions per independent central review, and objective intracranial responses were obsd. in two (66·7%; 95% CI 9·4-99·2).  In ALK-pos. patients with at least one previous ALK tyrosine kinase inhibitor (EXP2-5), objective responses were achieved in 93 (47·0%; 39·9-54·2) of 198 patients and objective intracranial response in those with measurable baseline CNS lesions in 51 (63·0%; 51·5-73·4) of 81 patients.  Objective response was achieved in 41 (69·5%; 95% CI 56·1-80·8) of 59 patients who had only received previous crizotinib (EXP2-3A), nine (32·1%; 15·9-52·4) of 28 patients with one previous non-crizotinib ALK tyrosine kinase inhibitor (EXP3B), and 43 (38·7%; 29·6-48·5) of 111 patients with two or more previous ALK tyrosine kinase inhibitors (EXP4-5).  Objective intracranial response was achieved in 20 (87·0%; 95% CI 66·4-97·2) of 23 patients with measurable baseline CNS lesions in EXP2-3A, five (55·6%; 21·2-86·3) of nine patients in EXP3B, and 26 (53·1%; 38·3-67·5) of 49 patients in EXP4-5.  The most common treatment-related adverse events across all patients were hypercholesterolemia (224 [81%] of 275 patients overall and 43 [16%] grade 3-4) and hypertriglyceridemia (166 [60%] overall and 43 [16%] grade 3-4).  Serious treatment-related adverse events occurred in 19 (7%) of 275 patients and seven patients (3%) permanently discontinued treatment because of treatment-related adverse events.  No treatment-related deaths were reported.  Consistent with its broad ALK mutational coverage and CNS penetration, lorlatinib showed substantial overall and intracranial activity both in treatment-naive patients with ALK-pos. non-small-cell lung cancer, and in those who had progressed on crizotinib, second-generation ALK tyrosine kinase inhibitors, or after up to three previous ALK tyrosine kinase inhibitors.  Thus, lorlatinib could represent an effective treatment option for patients with ALK-pos. non-small-cell lung cancer in first-line or subsequent therapy.Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13AyVlJJCKrVg90H21EOLACvtfcHk0ljM5-xzvIGw_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFamt7zF&md5=0d47716d988ee784448e5cfc599cdef9</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930649-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930649-1%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DClancy%26aufirst%3DJ.%2BS.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DLorlatinib%2520in%2520Patients%2520with%2520ALK-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%253A%2520Results%2520from%2520a%2520Global%2520Phase%25202%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D1654%26epage%3D1667%26doi%3D10.1016%2FS1470-2045%2818%2930649-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makowski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colon-Cruz, R.</span></span> <span> </span><span class="NLM_article-title">Developing an Asymmetric Transfer Hydrogenation Process for (S)-5-Fluoro-3-Methylisobenzofuran-1(3h)-One, a Key Intermediate to Lorlatinib</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1340</span>– <span class="NLM_lpage">1348</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00187</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00187" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1340-1348&author=S.+Duanauthor=B.+Liauthor=R.+W.+Duggerauthor=B.+Conwayauthor=R.+Kumarauthor=C.+Martinezauthor=T.+Makowskiauthor=R.+Pearsonauthor=M.+Olivierauthor=R.+Colon-Cruz&title=Developing+an+Asymmetric+Transfer+Hydrogenation+Process+for+%28S%29-5-Fluoro-3-Methylisobenzofuran-1%283h%29-One%2C+a+Key+Intermediate+to+Lorlatinib&doi=10.1021%2Facs.oprd.7b00187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Developing an Asymmetric Transfer Hydrogenation Process for (S)-5-Fluoro-3-methylisobenzofuran-1(3H)-one, a Key Intermediate to Lorlatinib</span></div><div class="casAuthors">Duan, Shengquan; Li, Bryan; Dugger, Robert W.; Conway, Brian; Kumar, Rajesh; Martinez, Carlos; Makowski, Teresa; Pearson, Robert; Olivier, Mark; Colon-Cruz, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1340-1348</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthesis of (S)-5-fluoro-3-methylisobenzofuran-1(3H)-one (I), a key intermediate to lorlatinib, is described.  A few synthetic methodologies, i.e., boron redn., enzymic redn., asym. hydrogenation, and asym. transfer hydrogenation, were evaluated for the chiral redn. of the substituted acetophenone intermediate.  A manufg. process, on the basis of the asym. transfer hydrogenation, was developed.  This process was successfully scaled up to prep. 400 kg of I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUZVVRYmmYYrVg90H21EOLACvtfcHk0lh3IWg-a-CsqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurrF&md5=ffd07ec1715c2f1ede2708c2c67d2f0f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00187%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DDugger%26aufirst%3DR.%2BW.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DMartinez%26aufirst%3DC.%26aulast%3DMakowski%26aufirst%3DT.%26aulast%3DPearson%26aufirst%3DR.%26aulast%3DOlivier%26aufirst%3DM.%26aulast%3DColon-Cruz%26aufirst%3DR.%26atitle%3DDeveloping%2520an%2520Asymmetric%2520Transfer%2520Hydrogenation%2520Process%2520for%2520%2528S%2529-5-Fluoro-3-Methylisobenzofuran-1%25283h%2529-One%252C%2520a%2520Key%2520Intermediate%2520to%2520Lorlatinib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D1340%26epage%3D1348%26doi%3D10.1021%2Facs.oprd.7b00187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nematalla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raggon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, J.</span></span> <span> </span><span class="NLM_article-title">Exploratory Process Development of Lorlatinib</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.8b00210</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.8b00210" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=1289-1293&author=B.+Liauthor=R.+W.+Barnhartauthor=J.+E.+Hoffmanauthor=A.+Nematallaauthor=J.+Raggonauthor=P.+Richardsonauthor=N.+Sachauthor=J.+Weaver&title=Exploratory+Process+Development+of+Lorlatinib&doi=10.1021%2Facs.oprd.8b00210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Exploratory Process Development of Lorlatinib</span></div><div class="casAuthors">Li, Bryan; Barnhart, Richard W.; Hoffman, Jacqui E.; Nematalla, Asaad; Raggon, Jeffrey; Richardson, Paul; Sach, Neal; Weaver, John</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1289-1293</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The original synthesis of lorlatinib (I) was applied and improved in the first GMP campaign.  In this approach, a slow addn. of the boronate ester was crit. in suppressing the formation of a homocoupled impurity in the Suzuki-Miyaura coupling, and the chemoselective hydrolysis of Me ester was accomplished by potassium trimethylsilanoate.  The synthesis was completed with macrocyclic amidation followed by deprotection of the Boc groups.  A thorough process safety evaluation of HATU enabled its use as the coupling reagent for the macrocyclic amidation, which improved the yield and eliminated the only chromatog. operation in the synthetic sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRVJZSwiHBgrVg90H21EOLACvtfcHk0lh3IWg-a-CsqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsLfI&md5=4bb70a5071d2a8cb45661a3d223fb96f</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.8b00210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.8b00210%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DBarnhart%26aufirst%3DR.%2BW.%26aulast%3DHoffman%26aufirst%3DJ.%2BE.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DRaggon%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DWeaver%26aufirst%3DJ.%26atitle%3DExploratory%2520Process%2520Development%2520of%2520Lorlatinib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2018%26volume%3D22%26spage%3D1289%26epage%3D1293%26doi%3D10.1021%2Facs.oprd.8b00210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, R. A.</span></span> <span> </span><span class="NLM_article-title">Kinase Inhibitors of Marine Origin</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">6761</span>– <span class="NLM_lpage">6815</span>, <span class="refDoi"> DOI: 10.1021/cr300410v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr300410v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVGiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2013&pages=6761-6815&author=S.+B.+Bharateauthor=S.+D.+Sawantauthor=P.+P.+Singhauthor=R.+A.+Vishwakarma&title=Kinase+Inhibitors+of+Marine+Origin&doi=10.1021%2Fcr300410v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178aR"><div class="casContent"><span class="casTitleNuber">178a</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitors of Marine Origin</span></div><div class="casAuthors">Bharate, Sandip B.; Sawant, Sanghapal D.; Singh, Parvinder Pal; Vishwakarma, Ram A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6761-6815</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The primary aim of this review is to discuss and critically analyze marine-derived small-mol. inhibitors of protein and lipid kinases, with an emphasis on medicinal chem., lead optimization, patent literature, preclin. profiling and clin. development (354 compds. are described and 717 refs. are provided).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraZAF-t78hZrVg90H21EOLACvtfcHk0lh3IWg-a-CsqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVGiur8%253D&md5=9ab17c0a26a7144ec729aab8383a7436</span></div><a href="/servlet/linkout?suffix=cit178a&amp;dbid=16384&amp;doi=10.1021%2Fcr300410v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr300410v%26sid%3Dliteratum%253Aachs%26aulast%3DBharate%26aufirst%3DS.%2BB.%26aulast%3DSawant%26aufirst%3DS.%2BD.%26aulast%3DSingh%26aufirst%3DP.%2BP.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DKinase%2520Inhibitors%2520of%2520Marine%2520Origin%26jtitle%3DChem.%2520Rev.%26date%3D2013%26volume%3D113%26spage%3D6761%26epage%3D6815%26doi%3D10.1021%2Fcr300410v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit178b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Rinehart, K. L.</span>; <span class="NLM_string-name">Lithgow-Bertelloni, A. M.</span></span> <span> </span><span class="NLM_article-title">Dehydrodidemnin B</span>. <span class="NLM_patent">WO9104985A1</span>, <span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=K.+L.+Rinehart&author=A.+M.+Lithgow-Bertelloni&title=Dehydrodidemnin+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRinehart%26aufirst%3DK.%2BL.%26atitle%3DDehydrodidemnin%2520B%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urdiales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morata, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Castro, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Jiménez, F.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative Effect of Dehydrodidemnin B (DDB), a Depsipeptide Isolated from Mediterranean Tunicates</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/0304-3835(96)04151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2F0304-3835%2896%2904151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=8603376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK28Xhslejurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1996&pages=31-37&author=J.+Urdialesauthor=P.+Morataauthor=I.+N.+De+Castroauthor=F.+S%C3%A1nchez-Jim%C3%A9nez&title=Antiproliferative+Effect+of+Dehydrodidemnin+B+%28DDB%29%2C+a+Depsipeptide+Isolated+from+Mediterranean+Tunicates&doi=10.1016%2F0304-3835%2896%2904151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates</span></div><div class="casAuthors">Urdiales, Jose L.; Morata, Pilar; Nunez De Castro, Ignacio; Sanchez-Jimenez, Francisca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">31-7</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The biol. effects of dehydrodidemnin B (DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB).  Daily administration of DB or DDB (2.5 μg/mouse) almost duplicated the animal life-span and total no. of tumor cells decreased by 70-90%.  Results suggest a major effect of DDB when administered in the lag phase of growth.  DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by the DDB-treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfkvs5GBkoS7Vg90H21EOLACvtfcHk0lh3IWg-a-CsqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xhslejurc%253D&md5=e8b33a94cc19d5036368d2ead4ff8556</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2F0304-3835%2896%2904151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3835%252896%252904151-1%26sid%3Dliteratum%253Aachs%26aulast%3DUrdiales%26aufirst%3DJ.%26aulast%3DMorata%26aufirst%3DP.%26aulast%3DDe%2BCastro%26aufirst%3DI.%2BN.%26aulast%3DS%25C3%25A1nchez-Jim%25C3%25A9nez%26aufirst%3DF.%26atitle%3DAntiproliferative%2520Effect%2520of%2520Dehydrodidemnin%2520B%2520%2528DDB%2529%252C%2520a%2520Depsipeptide%2520Isolated%2520from%2520Mediterranean%2520Tunicates%26jtitle%3DCancer%2520Lett.%26date%3D1996%26volume%3D102%26spage%3D31%26epage%3D37%26doi%3D10.1016%2F0304-3835%2896%2904151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Losada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Alonso, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Murcia, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Leal, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domínguez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gago, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galmarini, C. M.</span></span> <span> </span><span class="NLM_article-title">Translation Elongation Factor eEF1A2 Is a Novel Anticancer Target for the Marine Natural Product Plitidepsin</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">35100</span>, <span class="refDoi"> DOI: 10.1038/srep35100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fsrep35100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27713531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Cgtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=35100&author=A.+Losadaauthor=M.+J.+Mu%C3%B1oz-Alonsoauthor=C.+Garc%C3%ADaauthor=P.+A.+S%C3%A1nchez-Murciaauthor=J.+F.+Mart%C3%ADnez-Lealauthor=J.+M.+Dom%C3%ADnguezauthor=M.+P.+Lilloauthor=F.+Gagoauthor=C.+M.+Galmarini&title=Translation+Elongation+Factor+eEF1A2+Is+a+Novel+Anticancer+Target+for+the+Marine+Natural+Product+Plitidepsin&doi=10.1038%2Fsrep35100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin</span></div><div class="casAuthors">Losada, Alejandro; Munoz-Alonso, Maria Jose; Garcia, Carolina; Sanchez-Murcia, Pedro A.; Martinez-Leal, Juan Fernando; Dominguez, Juan Manuel; Lillo, M. Pilar; Gago, Federico; Galmarini, Carlos M.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35100</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">EEF1A2 is one of the isoforms of the alpha subunit of the eukaryotic Elongation Factor 1.  It is overexpressed in human tumors and is endowed with oncogenic properties, favoring tumor cell proliferation while inhibiting apoptosis.  We demonstrate that plitidepsin, an antitumor agent of marine origin that has successfully completed a phase-III clin. trial for multiple myeloma, exerts its antitumor activity by targeting eEF1A2.  The drug interacts with eEF1A2 with a KD of 80 nM and a target residence time of circa 9 min.  This protein was also identified as capable of binding [14C]-plitidepsin in a cell lysate from K-562 tumor cells.  A mol. modeling approach was used to identify a favorable binding site for plitidepsin at the interface between domains 1 and 2 of eEF1A2 in the GTP conformation.  Three tumor cell lines selected for at least 100-fold more resistance to plitidepsin than their resp. parental cells showed reduced levels of eEF1A2 protein.  Ectopic expression of eEF1A2 in resistant cells restored the sensitivity to plitidepsin.  FLIM-phasor FRET expts. demonstrated that plitidepsin localizes in tumor cells sufficiently close to eEF1A2 as to suggest the formation of drug-protein complexes in living cells.  Altogether, our results strongly suggest that eEF1A2 is the primary target of plitidepsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodS9RXtf_pNLVg90H21EOLACvtfcHk0ljkLk5rRKreAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Cgtb7M&md5=ed7bdf2fb20ed615dd71fab64bdce05c</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fsrep35100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep35100%26sid%3Dliteratum%253Aachs%26aulast%3DLosada%26aufirst%3DA.%26aulast%3DMu%25C3%25B1oz-Alonso%26aufirst%3DM.%2BJ.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DC.%26aulast%3DS%25C3%25A1nchez-Murcia%26aufirst%3DP.%2BA.%26aulast%3DMart%25C3%25ADnez-Leal%26aufirst%3DJ.%2BF.%26aulast%3DDom%25C3%25ADnguez%26aufirst%3DJ.%2BM.%26aulast%3DLillo%26aufirst%3DM.%2BP.%26aulast%3DGago%26aufirst%3DF.%26aulast%3DGalmarini%26aufirst%3DC.%2BM.%26atitle%3DTranslation%2520Elongation%2520Factor%2520eEF1A2%2520Is%2520a%2520Novel%2520Anticancer%2520Target%2520for%2520the%2520Marine%2520Natural%2520Product%2520Plitidepsin%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D35100%26doi%3D10.1038%2Fsrep35100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Plitidepsin: A Potential New Treatment for Relapsed/Refractory Multiple Myeloma</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.2217/fon-2018-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2217%2Ffon-2018-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30111169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=109-120&author=M.+Leischauthor=A.+Egleauthor=R.+Greil&title=Plitidepsin%3A+A+Potential+New+Treatment+for+Relapsed%2FRefractory+Multiple+Myeloma&doi=10.2217%2Ffon-2018-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma</span></div><div class="casAuthors">Leisch, Michael; Egle, Alexander; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-120</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Plitidepsin is a marine-derived anticancer compd. isolated from the Mediterranean tunicate Applidium albicans.  It exerts pleiotropic effects on cancer cells, most likely by binding to the eukaryotic translation eEF1A2.  This ultimately leads to cell-cycle arrest, growth inhibition and induction of apoptosis via multiple pathway alterations.  Recently, a Phase III randomized trial in patients with relapsed/refractory multiple myeloma reported outcomes for plitidepsin plus dexamethasone compared with dexamethasone.  Median progression-free survival was 3.8 mo in the plitidepsin arm and 1.9 mo in the dexamethasone arm (HR: 0.611; p = 0.0048).  Here, we review preclin. data regarding plitidepsins mechanism of action, give an overview of clin. trial results across different tumor types as well as the latest results in multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreQ2wJUJXILbVg90H21EOLACvtfcHk0ljkLk5rRKreAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGis7k%253D&md5=011f4da81faa52d1a59279093753f05d</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.2217%2Ffon-2018-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2018-0492%26sid%3Dliteratum%253Aachs%26aulast%3DLeisch%26aufirst%3DM.%26aulast%3DEgle%26aufirst%3DA.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DPlitidepsin%253A%2520A%2520Potential%2520New%2520Treatment%2520for%2520Relapsed%252FRefractory%2520Multiple%2520Myeloma%26jtitle%3DFuture%2520Oncol.%26date%3D2019%26volume%3D15%26spage%3D109%26epage%3D120%26doi%3D10.2217%2Ffon-2018-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, I.</span>; <span class="NLM_string-name">Polanco, C.</span>; <span class="NLM_string-name">Cuevas, F.</span>; <span class="NLM_string-name">Mandez, P.</span>; <span class="NLM_string-name">Cuevas, C.</span>; <span class="NLM_string-name">Gallego, P.</span>; <span class="NLM_string-name">Munt, S.</span>; <span class="NLM_string-name">Manzanares, I.</span></span> <span> </span><span class="NLM_article-title">Synthetic Methods for Aplidine and New Antitumoral Derivatives, Methods of Making and Using Them</span>. <span class="NLM_patent">WO2002002596A2</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=I.+Rodriguez&author=C.+Polanco&author=F.+Cuevas&author=P.+Mandez&author=C.+Cuevas&author=P.+Gallego&author=S.+Munt&author=I.+Manzanares&title=Synthetic+Methods+for+Aplidine+and+New+Antitumoral+Derivatives%2C+Methods+of+Making+and+Using+Them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DI.%26atitle%3DSynthetic%2520Methods%2520for%2520Aplidine%2520and%2520New%2520Antitumoral%2520Derivatives%252C%2520Methods%2520of%2520Making%2520and%2520Using%2520Them%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Pyrotinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1755</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0997-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0997-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30341682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cvhtlyjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1751-1755&author=H.+A.+Blair&title=Pyrotinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0997-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrotinib: First Global Approval</span></div><div class="casAuthors">Blair Hannah A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1751-1755</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours.  Based on positive results in a phase II trial, the drug recently received conditional approval in China for use in combination with capecitabine for the treatment of HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy.  This article summarizes the milestones in the development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSojcxi5hdr-Zw7prLlxLOzfW6udTcc2eYz2aANCtn5qbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvhtlyjtQ%253D%253D&md5=89ed6376fc6a528100a00d18737d37ec</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0997-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0997-0%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DPyrotinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1751%26epage%3D1755%26doi%3D10.1007%2Fs40265-018-0997-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Pyrotinib: A Novel Irreversible EGFR/HER2 Dual Tyrosine Kinase Inhibitor with Favorable Safety Profiles for the Treatment of Breast Cancer</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.01.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.ejps.2017.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28115222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1Wqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2017&pages=51-61&author=X.+Liauthor=C.+Yangauthor=H.+Wanauthor=G.+Zhangauthor=J.+Fengauthor=L.+Zhangauthor=X.+Chenauthor=D.+Zhongauthor=L.+Louauthor=W.+Taoauthor=L.+Zhang&title=Discovery+and+Development+of+Pyrotinib%3A+A+Novel+Irreversible+EGFR%2FHER2+Dual+Tyrosine+Kinase+Inhibitor+with+Favorable+Safety+Profiles+for+the+Treatment+of+Breast+Cancer&doi=10.1016%2Fj.ejps.2017.01.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer</span></div><div class="casAuthors">Li, Xin; Yang, Changyong; Wan, Hong; Zhang, Ge; Feng, Jun; Zhang, Lei; Chen, Xiaoyan; Zhong, Dafang; Lou, Liguang; Tao, Weikang; Zhang, Lianshan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-61</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery and development of a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor SHR1258 (pyrotinib) for the treatment of HER2-postive breast cancer is presented.  The structure-activity relationship of lead series and their pharmacokinetic properties were evaluated to identify the potential candidates for further in vivo efficacy studies and preclin. safety assessments.  Metabolic pathway and drug-drug interaction were also investigated in preclin. settings.  In particular, major metabolites in human and animal species were assessed with regard to potential toxicity or off-target side effects.  Overall, the potent and selective EGFR/HER2 dual inhibitor, pyrotinib, displayed robust anti-tumor effects on HER2-overexpressing xenograft models and sufficiently safety windows in animals as well as favorable pharmacokinetic properties in human, which substantially ensures current clin. development.  Finally, recent advances of pyrotinib in clin. studies are highlighted with very encouraging outcomes in patients with HER2-postive advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdbJnY0jwOjLVg90H21EOLACvtfcHk0lgOwLhnySpNYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1Wqsrw%253D&md5=12f13882a32cfb56959f58deaadadce8</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DD.%26aulast%3DLou%26aufirst%3DL.%26aulast%3DTao%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Pyrotinib%253A%2520A%2520Novel%2520Irreversible%2520EGFR%252FHER2%2520Dual%2520Tyrosine%2520Kinase%2520Inhibitor%2520with%2520Favorable%2520Safety%2520Profiles%2520for%2520the%2520Treatment%2520of%2520Breast%2520Cancer%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D110%26spage%3D51%26epage%3D61%26doi%3D10.1016%2Fj.ejps.2017.01.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chew, W.</span>; <span class="NLM_string-name">Cheal, G. K.</span>; <span class="NLM_string-name">Lunetta, J. F.</span></span> <span> </span><span class="NLM_article-title">Methods of Synthesizing Substituted 3-Cyanoquinolines and Intermediates Thereof</span>. <span class="NLM_patent">WO2006127207A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=W.+Chew&author=G.+K.+Cheal&author=J.+F.+Lunetta&title=Methods+of+Synthesizing+Substituted+3-Cyanoquinolines+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChew%26aufirst%3DW.%26atitle%3DMethods%2520of%2520Synthesizing%2520Substituted%25203-Cyanoquinolines%2520and%2520Intermediates%2520Thereof%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit185b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chew, W.</span>; <span class="NLM_string-name">Papamichelakis, M.</span></span> <span> </span><span class="NLM_article-title">Methods of Preparing 3-Cyano-Quinolines and Intermediates Made Thereby</span>. <span class="NLM_patent">WO2006127205A2</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=W.+Chew&author=M.+Papamichelakis&title=Methods+of+Preparing+3-Cyano-Quinolines+and+Intermediates+Made+Thereby"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChew%26aufirst%3DW.%26atitle%3DMethods%2520of%2520Preparing%25203-Cyano-Quinolines%2520and%2520Intermediates%2520Made%2520Thereby%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span>; <span class="NLM_string-name">Zhang, Q.</span>; <span class="NLM_string-name">Cao, Y.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Tyrosine Kinase Inhibitor and Derivative Thereof</span>. <span class="NLM_patent">WO2017186140A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Wu&author=Q.+Zhang&author=Y.+Cao&title=Method+for+Preparing+Tyrosine+Kinase+Inhibitor+and+Derivative+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26atitle%3DMethod%2520for%2520Preparing%2520Tyrosine%2520Kinase%2520Inhibitor%2520and%2520Derivative%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutically Acceptable Salt of (E)-N-[4-[[3-Chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide, Preparation Method Therefor, and Medical Use Thereof</span>. <span class="NLM_patent">WO2012122865A2</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=X.+Li&author=B.+Wang&title=Pharmaceutically+Acceptable+Salt+of+%28E%29-N-%5B4-%5B%5B3-Chloro-4-%282-pyridylmethoxy%29phenyl%5Damino%5D-3-cyano-7-ethoxy-6-quinolyl%5D-3-%5B%282r%29-1-methylpyrrolidin-2-yl%5Dprop-2-enamide%2C+Preparation+Method+Therefor%2C+and+Medical+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26atitle%3DPharmaceutically%2520Acceptable%2520Salt%2520of%2520%2528E%2529-N-%255B4-%255B%255B3-Chloro-4-%25282-pyridylmethoxy%2529phenyl%255Damino%255D-3-cyano-7-ethoxy-6-quinolyl%255D-3-%255B%25282r%2529-1-methylpyrrolidin-2-yl%255Dprop-2-enamide%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Medical%2520Use%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Talazoparib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1939</span>– <span class="NLM_lpage">1946</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1026-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1026-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30506138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3crnslGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1939-1946&author=S.+M.+Hoy&title=Talazoparib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1026-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Talazoparib: First Global Approval</span></div><div class="casAuthors">Hoy Sheridan M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1939-1946</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Talazoparib (TALZENNA®) is an oral inhibitor of the polyadenosine 5'-diphosphoribose polymerase (PARP) enzymes, which play a critical role in repairing DNA single-strand breaks.  It has been developed by Pfizer and was recently approved in the USA for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer (as detected by a US FDA-approved assay).  A regulatory assessment for talazoparib in this patient population is underway in the EU, with talazoparib also undergoing development for use in metastatic castration-resistant prostate cancer and various solid tumours, and as neoadjuvant therapy in early triple negative breast cancer.  This article summarizes the milestones in the development of talazoparib leading to its first approval for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative, locally advanced or metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA4VT-ypttQZNiNltV31zlfW6udTcc2ean3nGjFlfCpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnslGgsg%253D%253D&md5=e5799d67f592d4e449e18f09fc727a4b</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1026-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1026-z%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DTalazoparib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1939%26epage%3D1946%26doi%3D10.1007%2Fs40265-018-1026-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulai, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. R.</span></span> <span> </span><span class="NLM_article-title">Development of Poly(ADP-ribose) Polymerase Inhibitors in the Treatment of BRCA-Mutated Breast Cancer</span>. <i>Clin. Adv. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30067621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ktFSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=491-501&author=N.+H.+Sulaiauthor=A.+R.+Tan&title=Development+of+Poly%28ADP-ribose%29+Polymerase+Inhibitors+in+the+Treatment+of+BRCA-Mutated+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer</span></div><div class="casAuthors">Sulai Nanna H; Tan Antoinette R</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">491-501</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">The poly(ADP-ribose) polymerases (PARPs) 1 and 2 are DNA-binding enzymes that play a critical role in the repair of DNA.  The use of PARP inhibitors is a rational therapeutic approach to selectively killing a subset of cancer cells with deficiencies in DNA repair pathways.  PARP inhibitors that have undergone clinical investigation in the treatment of breast cancer include olaparib, talazoparib, veliparib, niraparib, and rucaparib.  The antitumor activity of PARP inhibitors as single agents has been demonstrated in BRCA-associated metastatic breast cancer.  In 2018, olaparib became the first oral PARP inhibitor to receive approval in the United States for the treatment of advanced BRCA-mutated breast cancer, an approval that represents a major change in the treatment paradigm for this subtype of breast cancer.  PARP inhibition plus chemotherapy and PARP inhibition plus immunotherapy are novel approaches undergoing extensive study in breast cancer.  This review focuses on the clinical development of PARP inhibitors administered singly or in combination with other agents for early-stage and metastatic BRCA-mutated breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRNVLPSo_8ek0EgZCMqtRBifW6udTcc2ebTyIiQei-LdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ktFSquw%253D%253D&md5=93140138e625e5aba394ab0e9b2b24ad</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSulai%26aufirst%3DN.%2BH.%26aulast%3DTan%26aufirst%3DA.%2BR.%26atitle%3DDevelopment%2520of%2520Poly%2528ADP-ribose%2529%2520Polymerase%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520BRCA-Mutated%2520Breast%2520Cancer%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D16%26spage%3D491%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">5588</span>– <span class="NLM_lpage">5599</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-2753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1158%2F0008-5472.CAN-12-2753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=23118055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=5588-5599&author=J.+Muraiauthor=S.-y.+N.+Huangauthor=B.+B.+Dasauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+H.+Doroshowauthor=J.+Jiauthor=S.+Takedaauthor=Y.+Pommier&title=Trapping+of+PARP1+and+PARP2+by+Clinical+PARP+Inhibitors&doi=10.1158%2F0008-5472.CAN-12-2753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190aR"><div class="casContent"><span class="casTitleNuber">190a</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-yin N.; Das, Benu Brata; Renaud, Amelie; Zhang, Yiping; Doroshow, James H.; Ji, Jiuping; Takeda, Shunichi; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5588-5599</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These findings indicate that PARP inhibitors in clin. trials not only block catalytic function but also trap PARP enzymes on DNA, illuminating the mechanistic basis for their cytotoxic activity in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW3m55HXn9ObVg90H21EOLACvtfcHk0lg1CWrlJzrVWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE&md5=81c590b6a4fbb9efc9c64f7de5e89524</span></div><a href="/servlet/linkout?suffix=cit190a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-2753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-2753%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.-y.%2BN.%26aulast%3DDas%26aufirst%3DB.%2BB.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DTrapping%2520of%2520PARP1%2520and%2520PARP2%2520by%2520Clinical%2520PARP%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D5588%26epage%3D5599%26doi%3D10.1158%2F0008-5472.CAN-12-2753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit190b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1158%2F1535-7163.MCT-13-0803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=24356813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=433-443&author=J.+Muraiauthor=S.-Y.+N.+Huangauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+Jiauthor=S.+Takedaauthor=J.+Morrisauthor=B.+A.+Teicherauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Stereospecific+PARP+Trapping+by+BMN+673+and+Comparison+with+Olaparib+and+Rucaparib&doi=10.1158%2F1535-7163.MCT-13-0803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190bR"><div class="casContent"><span class="casTitleNuber">190b</span><div class="casTitle"><span class="NLM_cas:atitle">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-Yin N.; Renaud, Amelie; Zhang, Yiping; Ji, Jiuping; Takeda, Shunichi; Morris, Joel; Teicher, Beverly; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks.  We recently reported that several PARP inhibitors have an addnl. cytotoxic mechanism by trapping PARP-DNA complexes, and that both olaparib and niraparib act as PARP poisons at pharmacol. concns.  Therefore, we have proposed that PARP inhibitors should be evaluated based both on catalytic PARP inhibition and PARP-DNA trapping.  Here, we evaluated the novel PARP inhibitor, BMN 673, and compared its effects on PARP1 and PARP2 with two other clin. PARP inhibitors, olaparib and rucaparib, using biochem. and cellular assays in genetically modified chicken DT40 and human cancer cell lines.  Although BMN 673, olaparib, and rucaparib are comparable at inhibiting PARP catalytic activity, BMN 673 is ∼100-fold more potent at trapping PARP-DNA complexes and more cytotoxic as single agent than olaparib, whereas olaparib and rucaparib show similar potencies in trapping PARP-DNA complexes.  The high level of resistance of PARP1/2 knockout cells to BMN 673 demonstrates the selectivity of BMN 673 for PARP1/2.  Moreover, we show that BMN 673 acts by stereospecific binding to PARP1 as its enantiomer, LT674, is several orders of magnitude less efficient.  BMN 673 is also approx. 100-fold more cytotoxic than olaparib and rucaparib in combination with the DNA alkylating agents Me methane sulfonate (MMS) and temozolomide.  Our study demonstrates that BMN 673 is the most potent clin. PARP inhibitor tested to date with the highest efficiency at trapping PARP-DNA complexes.  Mol Cancer Ther; 13(2); 433-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8p5YTwAneh7Vg90H21EOLACvtfcHk0lg1CWrlJzrVWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D&md5=513c544d1cb5c2203e7696af76201afd</span></div><a href="/servlet/linkout?suffix=cit190b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0803%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.-Y.%2BN.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DStereospecific%2520PARP%2520Trapping%2520by%2520BMN%2520673%2520and%2520Comparison%2520with%2520Olaparib%2520and%2520Rucaparib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D433%26epage%3D443%26doi%3D10.1158%2F1535-7163.MCT-13-0803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi-Scharber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, L. E.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of (8s, 9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1 H-1, 2, 4-Triazol-5-Yl)-2, 7, 8, 9-Tetrahydro-3 H-Pyrido [4, 3, 2-De] Phthalazin-3-One (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly (ADP-Ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01498</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01498" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=335-357&author=B.+Wangauthor=D.+Chuauthor=Y.+Fengauthor=Y.+Shenauthor=M.+Aoyagi-Scharberauthor=L.+E.+Post&title=Discovery+and+Characterization+of+%288s%2C+9r%29-5-Fluoro-8-%284-Fluorophenyl%29-9-%281-Methyl-1+H-1%2C+2%2C+4-Triazol-5-Yl%29-2%2C+7%2C+8%2C+9-Tetrahydro-3+H-Pyrido+%5B4%2C+3%2C+2-De%5D+Phthalazin-3-One+%28BMN+673%2C+Talazoparib%29%2C+a+Novel%2C+Highly+Potent%2C+and+Orally+Efficacious+Poly+%28ADP-Ribose%29+Polymerase-1%2F2+Inhibitor%2C+as+an+Anticancer+Agent&doi=10.1021%2Facs.jmedchem.5b01498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent</span></div><div class="casAuthors">Wang, Bing; Chu, Daniel; Feng, Ying; Shen, Yuqiao; Aoyagi-Scharber, Mika; Post, Leonard E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">335-357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors.  Lead optimization led to the identification of (I) (talazoparib; BMN 673; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one).  The novel stereospecific dual chiral-center-embedded structure of this compd. has enabled extensive and unique binding interactions with PARP1/2 proteins. I demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity with Ki = 1.2 and 0.87 nM, resp.  It inhibits PARP-mediated PARylation in a whole-cell assay with an EC50 of 2.51 nM and prevents proliferation of cancer cells carrying mutant BRCA1/2, with EC50 = 0.3 nM (MX-1) and 5 nM (Capan-1), resp. I is orally available, displaying favorable pharmacokinetic (PK) properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as a single-agent or in combination with chemotherapy agents such as temozolomide and cisplatin. I has completed phase 1 clin. trial and is currently being studied in phase 2 and 3 clin. trials for the treatment of locally advanced and/or metastatic breast cancer with germline BRCA1/2 deleterious mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBpTb90_rQhLVg90H21EOLACvtfcHk0lgfaF8uqPSbng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN&md5=443bfeb7aeda6c6522d41ab52793931a</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01498%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DPost%26aufirst%3DL.%2BE.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520%25288s%252C%25209r%2529-5-Fluoro-8-%25284-Fluorophenyl%2529-9-%25281-Methyl-1%2520H-1%252C%25202%252C%25204-Triazol-5-Yl%2529-2%252C%25207%252C%25208%252C%25209-Tetrahydro-3%2520H-Pyrido%2520%255B4%252C%25203%252C%25202-De%255D%2520Phthalazin-3-One%2520%2528BMN%2520673%252C%2520Talazoparib%2529%252C%2520a%2520Novel%252C%2520Highly%2520Potent%252C%2520and%2520Orally%2520Efficacious%2520Poly%2520%2528ADP-Ribose%2529%2520Polymerase-1%252F2%2520Inhibitor%252C%2520as%2520an%2520Anticancer%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D335%26epage%3D357%26doi%3D10.1021%2Facs.jmedchem.5b01498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span>; <span class="NLM_string-name">Chu, D.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Jiang, Q.</span>; <span class="NLM_string-name">Lu, L.</span></span> <span> </span><span class="NLM_article-title">Processes of Synthesizing Dihydropyridophthalazinone Derivatives</span>. <span class="NLM_patent">WO2011097602A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=B.+Wang&author=D.+Chu&author=Y.+Liu&author=Q.+Jiang&author=L.+Lu&title=Processes+of+Synthesizing+Dihydropyridophthalazinone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26atitle%3DProcesses%2520of%2520Synthesizing%2520Dihydropyridophthalazinone%2520Derivatives%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit192b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span>; <span class="NLM_string-name">Chu, D.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Peng, S.</span></span> <span> </span><span class="NLM_article-title">Crystalline (8s,9r)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one Tosylate Salt</span>. <span class="NLM_patent">WO2012054698A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=B.+Wang&author=D.+Chu&author=Y.+Liu&author=S.+Peng&title=Crystalline+%288s%2C9r%29-5-Fluoro-8-%284-fluorophenyl%29-9-%281-methyl-1h-1%2C2%2C4-triazol-5-yl%29-8%2C9-dihydro-2h-pyrido%5B4%2C3%2C2-de%5Dphthalazin-3%287h%29-one+Tosylate+Salt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26atitle%3DCrystalline%2520%25288s%252C9r%2529-5-Fluoro-8-%25284-fluorophenyl%2529-9-%25281-methyl-1h-1%252C2%252C4-triazol-5-yl%2529-8%252C9-dihydro-2h-pyrido%255B4%252C3%252C2-de%255Dphthalazin-3%25287h%2529-one%2520Tosylate%2520Salt%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit192c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span>; <span class="NLM_string-name">Gutierrez, A. A.</span>; <span class="NLM_string-name">Shen, Y.</span>; <span class="NLM_string-name">Wang, E. W.</span>; <span class="NLM_string-name">Okhamafe, A. O.</span>; <span class="NLM_string-name">Price, C. P.</span>; <span class="NLM_string-name">Chou, T.</span></span> <span> </span><span class="NLM_article-title">Dihydropyridophthalazinone Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) for the Treatment of Multiple Myeloma</span>. <span class="NLM_patent">WO2013028495A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Feng&author=A.+A.+Gutierrez&author=Y.+Shen&author=E.+W.+Wang&author=A.+O.+Okhamafe&author=C.+P.+Price&author=T.+Chou&title=Dihydropyridophthalazinone+Inhibitors+of+Poly+%28Adp-Ribose%29+Polymerase+%28Parp%29+for+the+Treatment+of+Multiple+Myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%26atitle%3DDihydropyridophthalazinone%2520Inhibitors%2520of%2520Poly%2520%2528Adp-Ribose%2529%2520Polymerase%2520%2528Parp%2529%2520for%2520the%2520Treatment%2520of%2520Multiple%2520Myeloma%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit192d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M.</span></span> <span> </span><span class="NLM_article-title">Triazole Intermediates Useful in the Synthesis of Protected N-Alkyltriazolecarbaldehydes</span>. <span class="NLM_patent">WO2015069851A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+Henderson&title=Triazole+Intermediates+Useful+in+the+Synthesis+of+Protected+N-Alkyltriazolecarbaldehydes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DM.%26atitle%3DTriazole%2520Intermediates%2520Useful%2520in%2520the%2520Synthesis%2520of%2520Protected%2520N-Alkyltriazolecarbaldehydes%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span>; <span class="NLM_string-name">Yohi, P. W.</span>; <span class="NLM_string-name">Xu, M.</span>; <span class="NLM_string-name">Cruise, D.</span>; <span class="NLM_string-name">Huang, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Parpinhibitor Talazoparib</span>. <span class="NLM_patent">WO2017215166A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Xu&author=P.+W.+Yohi&author=M.+Xu&author=D.+Cruise&author=L.+Huang&title=Synthesis+of+Parpinhibitor+Talazoparib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520Parpinhibitor%2520Talazoparib%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><a href="https://www.prnewswire.com/news-releases/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension-300735092.html" class="extLink">https://www.prnewswire.com/news-releases/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension-300735092.html</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fsanten-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension-300735092.html+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okanari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odani-Kawabata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shams, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, K.</span></span> <span> </span><span class="NLM_article-title">Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and Its Prodrug Omidenepag Isopropyl</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6869</span>– <span class="NLM_lpage">6891</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlSmu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6869-6891&author=R.+Iwamuraauthor=M.+Tanakaauthor=E.+Okanariauthor=T.+Kiriharaauthor=N.+Odani-Kawabataauthor=N.+Shamsauthor=K.+Yoneda&title=Identification+of+a+Selective%2C+Non-Prostanoid+EP2+Receptor+Agonist+for+the+Treatment+of+Glaucoma%3A+Omidenepag+and+Its+Prodrug+Omidenepag+Isopropyl&doi=10.1021%2Facs.jmedchem.8b00808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl</span></div><div class="casAuthors">Iwamura, Ryo; Tanaka, Masayuki; Okanari, Eiji; Kirihara, Tomoko; Odani-Kawabata, Noriko; Shams, Naveed; Yoneda, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6869-6891</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EP2 receptor agonists are expected to be effective ocular hypotensive agents; however, it has been suggested that agonism to other EP receptor subtypes may lead to undesirable effects.  Through medicinal chem. efforts, we identified a scaffold bearing a (pyridin-2-ylamino)acetic acid moiety as a promising EP2-selective receptor agonist. (6-((4-(Pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-ylamino)acetic acid 13ax (omidenepag, OMD) exerted potent and selective activity toward the human EP2 receptor (h-EP2).  Low doses of omidenepag iso-Pr (OMDI), a prodrug of 13ax, lowered intraocular pressure (IOP) in ocular normotensive monkeys.  OMDI was selected as a clin. candidate for the treatment of glaucoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlk0pJferBArVg90H21EOLACvtfcHk0lgfaF8uqPSbng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlSmu7zI&md5=d7fc57da815da074427a656c40fb65e3</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00808%26sid%3Dliteratum%253Aachs%26aulast%3DIwamura%26aufirst%3DR.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DOkanari%26aufirst%3DE.%26aulast%3DKirihara%26aufirst%3DT.%26aulast%3DOdani-Kawabata%26aufirst%3DN.%26aulast%3DShams%26aufirst%3DN.%26aulast%3DYoneda%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520a%2520Selective%252C%2520Non-Prostanoid%2520EP2%2520Receptor%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Glaucoma%253A%2520Omidenepag%2520and%2520Its%2520Prodrug%2520Omidenepag%2520Isopropyl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6869%26epage%3D6891%26doi%3D10.1021%2Facs.jmedchem.8b00808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. D.</span></span> <span> </span><span class="NLM_article-title">A Novel, Non-Prostanoid EP2 Receptor-Selective Prostaglandin E2 Agonist Stimulates Local Bone Formation and Enhances Fracture Healing</span>. <i>J. Bone Miner. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2033</span>– <span class="NLM_lpage">2042</span>, <span class="refDoi"> DOI: 10.1359/jbmr.2003.18.11.2033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1359%2Fjbmr.2003.18.11.2033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=14606517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVyiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=2033-2042&author=M.+Liauthor=H.+Z.+Keauthor=H.+Qiauthor=D.+R.+Healyauthor=Y.+Liauthor=D.+T.+Crawfordauthor=V.+M.+Paralkarauthor=T.+A.+Owenauthor=K.+O.+Cameronauthor=B.+A.+Lefkerauthor=T.+A.+Brownauthor=D.+D.+Thompson&title=A+Novel%2C+Non-Prostanoid+EP2+Receptor-Selective+Prostaglandin+E2+Agonist+Stimulates+Local+Bone+Formation+and+Enhances+Fracture+Healing&doi=10.1359%2Fjbmr.2003.18.11.2033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196aR"><div class="casContent"><span class="casTitleNuber">196a</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing</span></div><div class="casAuthors">Li, Mei; Ke, Hua Zhu; Qi, Hong; Healy, David R.; Li, Yan; Crawford, D. Todd; Paralkar, Vishwas M.; Owen, Thomas A.; Cameron, Kimberly O.; Lefker, Bruce A.; Brown, Thomas A.; Thompson, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2033-2042</span>CODEN:
                <span class="NLM_cas:coden">JBMREJ</span>;
        ISSN:<span class="NLM_cas:issn">0884-0431</span>.
    
            (<span class="NLM_cas:orgname">American Society for Bone and Mineral Research</span>)
        </div><div class="casAbstract">CP-533,536, a newly discovered, non-prostanoid EP2 receptor-selective PGE2 agonist, stimulates local bone formation and enhances fracture healing in rat models.  There is a significant medical need for agents that can stimulate local bone formation and enhance fracture healing.  The authors tested the effects of CP-533,536, a newly discovered, non-prostanoid EP2 receptor-selective PGE2 agonist, in stimulating local bone formation and enhancing fracture healing in rat models.  In the first model, a single injection of CP-533,536 at doses of 0.3, 1, or 3 mg/kg to the proximal tibial metaphysis of 6-wk-old male rats was given on day 1, and the local bone anabolic effect was detd. on day 7.  The authors then tested the effects of this compd. in inducing bone formation on rat periosteum of the femur.  A single dose of 0.3 mg of CP-533,536 incorporated in a poly-(DL-lactide-co-glycolide) (PLGH) matrix was injected onto the periosteum of the femur in 3-wk-old male rats, and local bone formation was detd. on day 14.  Finally, the ability of CP-533,536 in PLGH matrix in enhancing fracture healing was tested using the rat femoral fracture model.  CP-533,536 in PLGH matrix at doses of 0.05, 0.5, or 5 mg was delivered to the local fracture site on the same day of fracture, and its efficacy was evaluated on day 21.  A single injection of CP-533,536 at doses of 0.3, 1, or 3 mg/kg to the proximal tibial metaphysis dose-dependently stimulated local lamellar bone formation on trabecular, endocortical, and periosteal surfaces, and thus increased bone mineral content and bone strength at the injected site.  Similarly, a single injection of 0.3 mg of CP-533,536 incorporated in PLGH matrix onto the periosteum of the femur induced significantly local bone formation.  In the rat femoral fracture model, CP-533,536 in PLGH matrix at doses of 0.05, 0.5, and 5 mg dose-dependently increased callus size, d., and strength compared with PLGH matrix alone.  These results show that CP-533,536 stimulates new bone formation on trabecular, endocortical, and periosteal surfaces and enhances fracture healing.  These data reveal that EP2 receptor-selective agonists provide therapeutic potential for local bone augmentation, bone repair, and bone healing in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-eB8GOoJsErVg90H21EOLACvtfcHk0lgO7oq-lFvrKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVyiu7o%253D&md5=96d5d5fca5c87a121edda85af9cdbb9b</span></div><a href="/servlet/linkout?suffix=cit196a&amp;dbid=16384&amp;doi=10.1359%2Fjbmr.2003.18.11.2033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1359%252Fjbmr.2003.18.11.2033%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DKe%26aufirst%3DH.%2BZ.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DHealy%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCrawford%26aufirst%3DD.%2BT.%26aulast%3DParalkar%26aufirst%3DV.%2BM.%26aulast%3DOwen%26aufirst%3DT.%2BA.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26aulast%3DLefker%26aufirst%3DB.%2BA.%26aulast%3DBrown%26aufirst%3DT.%2BA.%26aulast%3DThompson%26aufirst%3DD.%2BD.%26atitle%3DA%2520Novel%252C%2520Non-Prostanoid%2520EP2%2520Receptor-Selective%2520Prostaglandin%2520E2%2520Agonist%2520Stimulates%2520Local%2520Bone%2520Formation%2520and%2520Enhances%2520Fracture%2520Healing%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2003%26volume%3D18%26spage%3D2033%26epage%3D2042%26doi%3D10.1359%2Fjbmr.2003.18.11.2033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit196b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borovecki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasser, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva-Jardine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korsmeyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowchalk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukicevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. D.</span></span> <span> </span><span class="NLM_article-title">An EP2 Receptor-Selective Prostaglandin E2 Agonist Induces Bone Healing</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">6736</span>– <span class="NLM_lpage">6740</span>, <span class="refDoi"> DOI: 10.1073/pnas.1037343100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1073%2Fpnas.1037343100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=12748385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktlygsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=6736-6740&author=V.+M.+Paralkarauthor=F.+Boroveckiauthor=H.+Z.+Keauthor=K.+O.+Cameronauthor=B.+Lefkerauthor=W.+A.+Grasserauthor=T.+A.+Owenauthor=M.+Liauthor=P.+DaSilva-Jardineauthor=M.+Zhouauthor=R.+L.+Dunnauthor=F.+Dumontauthor=R.+Korsmeyerauthor=P.+Krasneyauthor=T.+A.+Brownauthor=D.+Plowchalkauthor=S.+Vukicevicauthor=D.+D.+Thompson&title=An+EP2+Receptor-Selective+Prostaglandin+E2+Agonist+Induces+Bone+Healing&doi=10.1073%2Fpnas.1037343100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196bR"><div class="casContent"><span class="casTitleNuber">196b</span><div class="casTitle"><span class="NLM_cas:atitle">An EP2 receptor-selective prostaglandin E2 agonist induces bone healing</span></div><div class="casAuthors">Paralkar, V. M.; Borovecki, F.; Ke, H. Z.; Cameron, K. O.; Lefker, B.; Grasser, W. A.; Owen, T. A.; Li, M.; Da Silva-Jardine, P.; Zhou, M.; Dunn, R. L.; Dumont, F.; Korsmeyer, R.; Krasney, P.; Brown, T. A.; Plowchalk, D.; Vukicevic, S.; Thompson, D. D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6736-6740</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The morbidity and mortality assocd. with impaired/delayed fracture healing remain high.  Our objective was to identify a small nonpeptidyl mol. with the ability to promote fracture healing and prevent malunions.  Prostaglandin E2 (PGE2) causes significant increases in bone mass and bone strength when administered systemically or locally to the skeleton.  However, due to side effects, PGE2 is an unacceptable therapeutic option for fracture healing.  PGE2 mediates its tissue-specific pharmacol. activity via four different G protein-coupled receptor subtypes, EP1, -2, -3, and -4.  The anabolic action of PGE2 in bone has been linked to an elevated level of cAMP, thereby implicating the EP2 and/or EP4 receptor subtypes in bone formation.  We identified an EP2 selective agonist, CP-533,536, which has the ability to heal canine long bone segmental and fracture model defects without the objectionable side effects of PGE2, suggesting that the EP2 receptor subtype is a major contributor to PGE2's local bone anabolic activity.  The potent bone anabolic activity of CP-533,536 offers a therapeutic alternative for the treatment of fractures and bone defects in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDrg8xp8EmpbVg90H21EOLACvtfcHk0lgO7oq-lFvrKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktlygsLk%253D&md5=22efaca07d0dbad4a3da8b52ef37b21e</span></div><a href="/servlet/linkout?suffix=cit196b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1037343100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1037343100%26sid%3Dliteratum%253Aachs%26aulast%3DParalkar%26aufirst%3DV.%2BM.%26aulast%3DBorovecki%26aufirst%3DF.%26aulast%3DKe%26aufirst%3DH.%2BZ.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26aulast%3DLefker%26aufirst%3DB.%26aulast%3DGrasser%26aufirst%3DW.%2BA.%26aulast%3DOwen%26aufirst%3DT.%2BA.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DDaSilva-Jardine%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DDunn%26aufirst%3DR.%2BL.%26aulast%3DDumont%26aufirst%3DF.%26aulast%3DKorsmeyer%26aufirst%3DR.%26aulast%3DKrasney%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DT.%2BA.%26aulast%3DPlowchalk%26aufirst%3DD.%26aulast%3DVukicevic%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DD.%2BD.%26atitle%3DAn%2520EP2%2520Receptor-Selective%2520Prostaglandin%2520E2%2520Agonist%2520Induces%2520Bone%2520Healing%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D6736%26epage%3D6740%26doi%3D10.1073%2Fpnas.1037343100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamura, R.</span>; <span class="NLM_string-name">Tanaka, M.</span>; <span class="NLM_string-name">Katsube, T.</span>; <span class="NLM_string-name">Shigetomi, M.</span>; <span class="NLM_string-name">Okanari, E.</span>; <span class="NLM_string-name">Tokunaga, Y.</span>; <span class="NLM_string-name">Fujiwara, H.</span></span> <span> </span><span class="NLM_article-title">Pyridylaminoacetic Acid Compound</span>. <span class="NLM_patent">WO2009113600A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Iwamura&author=M.+Tanaka&author=T.+Katsube&author=M.+Shigetomi&author=E.+Okanari&author=Y.+Tokunaga&author=H.+Fujiwara&title=Pyridylaminoacetic+Acid+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIwamura%26aufirst%3DR.%26atitle%3DPyridylaminoacetic%2520Acid%2520Compound%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit197b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span>; <span class="NLM_string-name">Oue, M.</span>; <span class="NLM_string-name">Wada, Y.</span></span> <span> </span><span class="NLM_article-title">N-Substituted Sulfonamide Compound and Method for Producing Same</span>. <span class="NLM_patent">WO2015190507A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Yamamoto&author=M.+Oue&author=Y.+Wada&title=N-Substituted+Sulfonamide+Compound+and+Method+for+Producing+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DN-Substituted%2520Sulfonamide%2520Compound%2520and%2520Method%2520for%2520Producing%2520Same%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><a href="https://www.drugbank.ca/drugs/DB08820" class="extLink">https://www.drugbank.ca/drugs/DB08820</a> (accessed Jul 28, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB08820+%28accessed+Jul+28%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><a href="https://www.drugs.com/newdrugs/fda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-cystic-fibrosis-ages-12-older-certain-mutations-4693.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-cystic-fibrosis-ages-12-older-certain-mutations-4693.html</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-cystic-fibrosis-ages-12-older-certain-mutations-4693.html+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilewski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanathan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tullis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekstrom-Himes, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. T.</span></span> <span> </span><span class="NLM_article-title">Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1164/rccm.201704-0717OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1164%2Frccm.201704-0717OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28930490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFClt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2018&pages=214-224&author=S.+H.+Donaldsonauthor=J.+M.+Pilewskiauthor=M.+Grieseauthor=J.+Cookeauthor=L.+Viswanathanauthor=E.+Tullisauthor=J.+C.+Daviesauthor=J.+A.+Lekstrom-Himesauthor=L.+T.+Wang&title=Tezacaftor%2FIvacaftor+in+Subjects+with+Cystic+Fibrosis+and+F508del%2FF508del-CFTR+or+F508del%2FG551D-CFTR&doi=10.1164%2Frccm.201704-0717OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200aR"><div class="casContent"><span class="casTitleNuber">200a</span><div class="casTitle"><span class="NLM_cas:atitle">Tezacaftor/ivacaftor in subjects with cystic fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR</span></div><div class="casAuthors">Donaldson, Scott H.; Pilewski, Joseph M.; Griese, Matthias; Cooke, Jon; Viswanathan, Lakshmi; Tullis, Elizabeth; Davies, Jane C.; Lekstrom-Himes, Julie A.; Wang, Linda T.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-224</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Tezacaftor (formerly VX-661) is an investigational small mol. that improves processing and trafficking of the cystic fibrosis transmembrane conductance regulator (CFTR) in vitro, and improves CFTR function alone and in combination with ivacaftor.  To evaluate the safety and efficacy of tezacaftor monotherapy and of tezacaftor/ivacaftor combination therapy in subjects with cystic fibrosis homozygous for F508del or compd. heterozygous for F508del and G551D.  This was a randomized, placebo-controlled, double-blind, multicenter, phase 2 study (NCT01531673).  Subjects homozygous for F508del received tezacaftor (10 to 150 mg) every day alone or in combination with ivacaftor (150 mg every 12 h) in a dose escalation phase, as well as in a dosage regimen testing phase.  Subjects compd. heterozygous for F508del and G551D, taking physician-prescribed ivacaftor, received tezacaftor (100 mg every day).  Primary endpoints were safety through Day 56 and change in sweat chloride from baseline through Day 28.  Secondary endpoints included change in percent predicted FEV1 (ppFEV1) from baseline through Day 28 and pharmacokinetics.  The incidence of adverse events was similar across treatment arms.  Tezacaftor (100 mg every day)/ivacaftor (150 mg every 12 h) resulted in a 6.04 mmol/L decrease in sweat chloride and 3.75 percentage point increase in ppFEV1 in subjects homozygous for F508del, and a 7.02 mmol/L decrease in sweat chloride and 4.60 percentage point increase in ppFEV1 in subjects compd. heterozygous for F508del and G551D from baseline through Day 28 (P<0.05 for all).  These results support continued clin. development of tezacaftor (100 mg every day) in combination with ivacaftor (150 mg every 12 h) in subjects with cystic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTXp3OwI7Y2bVg90H21EOLACvtfcHk0ljLi8zMnEKTyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFClt7%252FI&md5=b04a30024a61f63458b3aaea8bd51b18</span></div><a href="/servlet/linkout?suffix=cit200a&amp;dbid=16384&amp;doi=10.1164%2Frccm.201704-0717OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201704-0717OC%26sid%3Dliteratum%253Aachs%26aulast%3DDonaldson%26aufirst%3DS.%2BH.%26aulast%3DPilewski%26aufirst%3DJ.%2BM.%26aulast%3DGriese%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DJ.%26aulast%3DViswanathan%26aufirst%3DL.%26aulast%3DTullis%26aufirst%3DE.%26aulast%3DDavies%26aufirst%3DJ.%2BC.%26aulast%3DLekstrom-Himes%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DL.%2BT.%26atitle%3DTezacaftor%252FIvacaftor%2520in%2520Subjects%2520with%2520Cystic%2520Fibrosis%2520and%2520F508del%252FF508del-CFTR%2520or%2520F508del%252FG551D-CFTR%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2018%26volume%3D197%26spage%3D214%26epage%3D224%26doi%3D10.1164%2Frccm.201704-0717OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit200b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor-Cousar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKone, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Ent, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingenito, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekstrom-Himes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span> <span> </span><span class="NLM_article-title">Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1709846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1056%2FNEJMoa1709846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29099344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFyr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=2013-2023&author=J.+L.+Taylor-Cousarauthor=A.+Munckauthor=E.+F.+McKoneauthor=C.+K.+van+der+Entauthor=A.+Moellerauthor=C.+Simardauthor=L.+T.+Wangauthor=E.+P.+Ingenitoauthor=C.+McKeeauthor=Y.+Luauthor=J.+Lekstrom-Himesauthor=J.+S.+Elborn&title=Tezacaftor-Ivacaftor+in+Patients+with+Cystic+Fibrosis+Homozygous+for+Phe508del&doi=10.1056%2FNEJMoa1709846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200bR"><div class="casContent"><span class="casTitleNuber">200b</span><div class="casTitle"><span class="NLM_cas:atitle">Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del</span></div><div class="casAuthors">Taylor-Cousar, Jennifer L.; Munck, Anne; McKone, Edward F.; van der Ent, Cornelis K.; Moeller, Alexander; Simard, Christopher; Wang, Linda T.; Ingenito, Edward P.; McKee, Charlotte; Lu, Yimeng; Lekstrom-Himes, Julie; Elborn, J. Stuart</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2013-2023</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Combination treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators tezacaftor (VX-661) and ivacaftor (VX-770) was designed to target the underlying cause of disease in patients with cystic fibrosis.  In this phase 3, randomized, double-blind, multicenter, placebo-controlled, parallel-group trial, we evaluated combination therapy with tezacaftor and ivacaftor in patients 12 years of age or older who had cystic fibrosis and were homozygous for the CFTR Phe508del mutation.  Patients were randomly assigned in a 1:1 ratio to receive either 100 mg of tezacaftor once daily and 150 mg of ivacaftor twice daily or matched placebo for 24 wk.  The primary end point was the abs. change in the percentage of the predicted forced expiratory vol. in 1 s (FEV1) through week 24 (calcd. in percentage points); relative change in the percentage of the predicted FEV1 through week 24 (calcd. as a percentage) was a key secondary end point.  Of the 510 patients who underwent randomization, 509 received tezacaftor-ivacaftor or placebo, and 475 completed 24 wk of the trial regimen.  The mean FEV1 at baseline was 60.0% of the predicted value.  The effects on the abs. and relative changes in the percentage of the predicted FEV1 in favor of tezacaftor-ivacaftor over placebo were 4.0 percentage points and 6.8%, resp. (P<0.001 for both comparisons).  The rate of pulmonary exacerbation was 35% lower in the tezacaftor-ivacaftor group than in the placebo group (P = 0.005).  The incidence of adverse events was similar in the two groups.  Most adverse events were of mild severity (in 41.8% of patients overall) or moderate severity (in 40.9% overall), and serious adverse events were less frequent with tezacaftor-ivacaftor (12.4%) than with placebo (18.2%).  A total of 2.9% of patients discontinued the assigned regimen owing to adverse events.  Fewer patients in the tezacaftor-ivacaftor group than in the placebo group had respiratory adverse events, none of which led to discontinuation. conclusions The combination of tezacaftor and ivacaftor was efficacious and safe in patients 12 years of age or older who had cystic fibrosis and were homozygous for the CFTR Phe508del mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry28bA5s2HMrVg90H21EOLACvtfcHk0ljLi8zMnEKTyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFyr&md5=a8aec50415d3dec5202ce53b5176960d</span></div><a href="/servlet/linkout?suffix=cit200b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1709846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1709846%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor-Cousar%26aufirst%3DJ.%2BL.%26aulast%3DMunck%26aufirst%3DA.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3Dvan%2Bder%2BEnt%26aufirst%3DC.%2BK.%26aulast%3DMoeller%26aufirst%3DA.%26aulast%3DSimard%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%2BT.%26aulast%3DIngenito%26aufirst%3DE.%2BP.%26aulast%3DMcKee%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLekstrom-Himes%26aufirst%3DJ.%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26atitle%3DTezacaftor-Ivacaftor%2520in%2520Patients%2520with%2520Cystic%2520Fibrosis%2520Homozygous%2520for%2520Phe508del%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D2013%26epage%3D2023%26doi%3D10.1056%2FNEJMoa1709846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garg, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekstrom-Himes, J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1111/cts.12610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1111%2Fcts.12610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30694595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsFWitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=267-275&author=V.+Gargauthor=J.+Shenauthor=C.+Liauthor=S.+Agarwalauthor=A.+Gebreauthor=S.+Robertsonauthor=J.+Huangauthor=L.+Hanauthor=L.+Jiangauthor=K.+Stephanauthor=L.+T.+Wangauthor=J.+Lekstrom-Himes&title=Pharmacokinetic+and+Drug-Drug+Interaction+Profiles+of+the+Combination+of+Tezacaftor%2FIvacaftor&doi=10.1111%2Fcts.12610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor</span></div><div class="casAuthors">Garg, Varun; Shen, Jinshan; Li, Chonghua; Agarwal, Sagar; Gebre, Asfiha; Robertson, Sarah; Huang, Jiayin; Han, Linda; Jiang, Licong; Stephan, Kristin; Wang, Linda T.; Lekstrom-Himes, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-275</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Drug-drug interaction (DDI) studies are described for tezacaftor/ivacaftor, a new cystic fibrosis transmembrane conductance regulator modulator therapy for the treatment of cystic fibrosis.  Three phase I DDI studies were conducted in healthy subjects to characterize the DDI profile of tezacaftor/ivacaftor with cytochrome P 450 (CYP)3A substrates, CYP3A inhibitors, and a permeability glycoprotein (P-gp) substrate.  The effects of steady-state tezacaftor/ivacaftor on the pharmacokinetics (PKs) of digoxin (a P-gp substrate), midazolam, and ethinyl estradiol/norethindrone (CYP3A substrates) were evaluated.  Effects of strong (itraconazole) and moderate (ciprofloxacin) CYP3A inhibitors on tezacaftor/ivacaftor PKs were also detd.  Tezacaftor/ivacaftor increased digoxin area under the curve (AUC) by 30% but did not affect midazolam, ethinyl estradiol, or norethindrone exposures.  Itraconazole increased the AUC of tezacaftor 4-fold and ivacaftor 15.6-fold.  Ciprofloxacin had no significant effect on tezacaftor or ivacaftor exposure.  Coadministration of tezacaftor/ivacaftor may increase exposure of sensitive P-gp substrates.  Tezacaftor/ivacaftor is unlikely to impact exposure of drugs metabolized by CYP3A, including hormonal contraceptives.  Strong CYP3A inhibitors significantly increase the exposures of tezacaftor and ivacaftor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8u2x79NK5kbVg90H21EOLACvtfcHk0ljLi8zMnEKTyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsFWitro%253D&md5=41784952b7e6527fcfc33f2c62130344</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1111%2Fcts.12610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12610%26sid%3Dliteratum%253Aachs%26aulast%3DGarg%26aufirst%3DV.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DGebre%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DStephan%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%2BT.%26aulast%3DLekstrom-Himes%26aufirst%3DJ.%26atitle%3DPharmacokinetic%2520and%2520Drug-Drug%2520Interaction%2520Profiles%2520of%2520the%2520Combination%2520of%2520Tezacaftor%252FIvacaftor%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2019%26volume%3D12%26spage%3D267%26epage%3D275%26doi%3D10.1111%2Fcts.12610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F210491lbl.pdf+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><a href="https://www.drugs.com/newdrugs/fda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-underlying-cause-cf-children-ages-6-11-years-4996.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-underlying-cause-cf-children-ages-6-11-years-4996.html</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-underlying-cause-cf-children-ages-6-11-years-4996.html+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruah, S. H. S.</span>; <span class="NLM_string-name">Grootenhuis, P. D. J.</span>; <span class="NLM_string-name">Van Goor, F.</span>; <span class="NLM_string-name">Miller, M. T.</span>; <span class="NLM_string-name">McCartney, J.</span>; <span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Bear, B.</span>; <span class="NLM_string-name">Numa, M. M. D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Indolyl Cycloalkylcarboxamides as Modulators of ATP-Binding Cassette Transporters for Use as Drugs and Biological Tools</span>. <span class="NLM_patent">WO2010053471A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+H.+S.+Ruah&author=P.+D.+J.+Grootenhuis&author=F.+Van+Goor&author=M.+T.+Miller&author=J.+McCartney&author=J.+Zhou&author=B.+Bear&author=M.+M.+D.+Numa&title=Preparation+of+Indolyl+Cycloalkylcarboxamides+as+Modulators+of+ATP-Binding+Cassette+Transporters+for+Use+as+Drugs+and+Biological+Tools"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRuah%26aufirst%3DS.%2BH.%2BS.%26atitle%3DPreparation%2520of%2520Indolyl%2520Cycloalkylcarboxamides%2520as%2520Modulators%2520of%2520ATP-Binding%2520Cassette%2520Transporters%2520for%2520Use%2520as%2520Drugs%2520and%2520Biological%2520Tools%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit204b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Keshavarz-Shokri, A.</span>; <span class="NLM_string-name">Zhang, B.</span>; <span class="NLM_string-name">Alcacio, T. E.</span>; <span class="NLM_string-name">Lee, E. C.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Krawiec, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Benzodioxolyl-N-Indolyl Cyclopropanecarboxamide Derivatives for Use as CFTR Modulators</span>. <span class="NLM_patent">WO2011119984A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Keshavarz-Shokri&author=B.+Zhang&author=T.+E.+Alcacio&author=E.+C.+Lee&author=Y.+Zhang&author=M.+Krawiec&title=Preparation+of+Benzodioxolyl-N-Indolyl+Cyclopropanecarboxamide+Derivatives+for+Use+as+CFTR+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKeshavarz-Shokri%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520Benzodioxolyl-N-Indolyl%2520Cyclopropanecarboxamide%2520Derivatives%2520for%2520Use%2520as%2520CFTR%2520Modulators%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit204c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Alargova, R. G.</span>; <span class="NLM_string-name">Kadiyala, I. N.</span>; <span class="NLM_string-name">Zaman, N. T.</span></span> <span> </span><span class="NLM_article-title">Formulations of (R)-1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide for Treatment of Cystic Fibrosis</span>. <span class="NLM_patent">WO2012170061A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+G.+Alargova&author=I.+N.+Kadiyala&author=N.+T.+Zaman&title=Formulations+of+%28R%29-1-%282%2C2-Difluorobenzo%5Bd%5D%5B1%2C3%5Ddioxol-5-yl%29-N-%281-%282%2C3-dihydroxypropyl%29-6-fluoro-2-%281-hydroxy-2-methylpropan-2-yl%29-1h-indol-5-yl%29cyclopropanecarboxamide+for+Treatment+of+Cystic+Fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlargova%26aufirst%3DR.%2BG.%26atitle%3DFormulations%2520of%2520%2528R%2529-1-%25282%252C2-Difluorobenzo%255Bd%255D%255B1%252C3%255Ddioxol-5-yl%2529-N-%25281-%25282%252C3-dihydroxypropyl%2529-6-fluoro-2-%25281-hydroxy-2-methylpropan-2-yl%2529-1h-indol-5-yl%2529cyclopropanecarboxamide%2520for%2520Treatment%2520of%2520Cystic%2520Fibrosis%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit204d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Goor, F. F.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Compositions for the Treatment of CFTR-Mediated Disorders</span>. <span class="NLM_patent">WO2013185112A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+F.+Van+Goor&title=Pharmaceutical+Compositions+for+the+Treatment+of+CFTR-Mediated+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%2BF.%26atitle%3DPharmaceutical%2520Compositions%2520for%2520the%2520Treatment%2520of%2520CFTR-Mediated%2520Disorders%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit204e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Alargova, R. G.</span>; <span class="NLM_string-name">Dunbar, C. A.</span>; <span class="NLM_string-name">Kadiyala, I. N.</span></span> <span> </span><span class="NLM_article-title">Oral Compositions of (R)-1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide for Treatment of Cystic Fibrosis</span>. <span class="NLM_patent">WO2014014841A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+G.+Alargova&author=C.+A.+Dunbar&author=I.+N.+Kadiyala&title=Oral+Compositions+of+%28R%29-1-%282%2C2-Difluorobenzo%5Bd%5D%5B1%2C3%5Ddioxol-5-yl%29-N-%281-%282%2C3-dihydroxypropyl%29-6-fluoro-2-%281-hydroxy-2-methylpropan-2-yl%29-1h-indol-5-yl%29cyclopropanecarboxamide+for+Treatment+of+Cystic+Fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlargova%26aufirst%3DR.%2BG.%26atitle%3DOral%2520Compositions%2520of%2520%2528R%2529-1-%25282%252C2-Difluorobenzo%255Bd%255D%255B1%252C3%255Ddioxol-5-yl%2529-N-%25281-%25282%252C3-dihydroxypropyl%2529-6-fluoro-2-%25281-hydroxy-2-methylpropan-2-yl%2529-1h-indol-5-yl%2529cyclopropanecarboxamide%2520for%2520Treatment%2520of%2520Cystic%2520Fibrosis%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit204f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Phenix, B. D.</span>; <span class="NLM_string-name">Bagnol, L. J.-C.</span>; <span class="NLM_string-name">Brodeur, G. G.</span>; <span class="NLM_string-name">Chandran, S.</span>; <span class="NLM_string-name">Dokou, E.</span>; <span class="NLM_string-name">Ferris, L. A.</span>; <span class="NLM_string-name">Knezic, D.</span>; <span class="NLM_string-name">McCarty, K. L.</span>; <span class="NLM_string-name">Medek, A.</span>; <span class="NLM_string-name">Waggener, S. A.</span></span> <span> </span><span class="NLM_article-title">Method for Preparation of Quinolinone Carboxamides, Indole Carboxamides and Pharmaceutical Compositions Containing Them for the Treatment of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases</span>. <span class="NLM_patent">WO2015160787A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=B.+D.+Phenix&author=L.+J.-C.+Bagnol&author=G.+G.+Brodeur&author=S.+Chandran&author=E.+Dokou&author=L.+A.+Ferris&author=D.+Knezic&author=K.+L.+McCarty&author=A.+Medek&author=S.+A.+Waggener&title=Method+for+Preparation+of+Quinolinone+Carboxamides%2C+Indole+Carboxamides+and+Pharmaceutical+Compositions+Containing+Them+for+the+Treatment+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Mediated+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPhenix%26aufirst%3DB.%2BD.%26atitle%3DMethod%2520for%2520Preparation%2520of%2520Quinolinone%2520Carboxamides%252C%2520Indole%2520Carboxamides%2520and%2520Pharmaceutical%2520Compositions%2520Containing%2520Them%2520for%2520the%2520Treatment%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Mediated%2520Diseases%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit204g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Alcacio, T.</span>; <span class="NLM_string-name">Baek, M.</span>; <span class="NLM_string-name">Grootenhuis, P.</span>; <span class="NLM_string-name">Hadida Ruah, S. S.</span>; <span class="NLM_string-name">Hughes, R. M.</span>; <span class="NLM_string-name">Keshavarz-Shokri, A.</span>; <span class="NLM_string-name">McAuley-Aoki, R.</span>; <span class="NLM_string-name">McCartney, J.</span>; <span class="NLM_string-name">Miller, M. T.</span>; <span class="NLM_string-name">Van Goor, F.</span>; <span class="NLM_string-name">Zhang, B.</span>; <span class="NLM_string-name">Andreson, C.</span>; <span class="NLM_string-name">Cleveland, T.</span>; <span class="NLM_string-name">Frieman, B. A.</span>; <span class="NLM_string-name">Khatuya, H.</span>; <span class="NLM_string-name">Joshi, P. V.</span>; <span class="NLM_string-name">Krenitsky, P. J.</span>; <span class="NLM_string-name">Melillo, V.</span>; <span class="NLM_string-name">Pierre, F. J. D.</span>; <span class="NLM_string-name">Termin, A. P.</span>; <span class="NLM_string-name">Uy, J.</span>; <span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Abela, A. R.</span>; <span class="NLM_string-name">Busch, B. B.</span>; <span class="NLM_string-name">Paraselli, P.</span>; <span class="NLM_string-name">Siesel, D. A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Benzenesulfonylpyrazolylpyrrolidinylpyridinecarboxamide Derivatives and Analogs for Use as Cystic Fibrosis Transmembrane Conductance Regulator Modulators</span>. <span class="NLM_patent">WO2018064632A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=T.+Alcacio&author=M.+Baek&author=P.+Grootenhuis&author=S.+S.+Hadida+Ruah&author=R.+M.+Hughes&author=A.+Keshavarz-Shokri&author=R.+McAuley-Aoki&author=J.+McCartney&author=M.+T.+Miller&author=F.+Van+Goor&author=B.+Zhang&author=C.+Andreson&author=T.+Cleveland&author=B.+A.+Frieman&author=H.+Khatuya&author=P.+V.+Joshi&author=P.+J.+Krenitsky&author=V.+Melillo&author=F.+J.+D.+Pierre&author=A.+P.+Termin&author=J.+Uy&author=J.+Zhou&author=A.+R.+Abela&author=B.+B.+Busch&author=P.+Paraselli&author=D.+A.+Siesel&title=Preparation+of+Benzenesulfonylpyrazolylpyrrolidinylpyridinecarboxamide+Derivatives+and+Analogs+for+Use+as+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlcacio%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Benzenesulfonylpyrazolylpyrrolidinylpyridinecarboxamide%2520Derivatives%2520and%2520Analogs%2520for%2520Use%2520as%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Modulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, K. K.</span></span> <span> </span><span class="NLM_article-title">A New Year-Long Combination Hormonal Contraceptive</span>. <i>Nurs. Womens Health</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.nwh.2019.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.nwh.2019.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30836070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgs1Cjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=172-176&author=K.+K.+Blakely&title=A+New+Year-Long+Combination+Hormonal+Contraceptive&doi=10.1016%2Fj.nwh.2019.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">A New Year-Long Combination Hormonal Contraceptive</span></div><div class="casAuthors">Blakely Kala K</div><div class="citationInfo"><span class="NLM_cas:title">Nursing for women's health</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-176</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The U.S.  Food and Drug Administration approved a new combination hormonal contraceptive in August 2018.  Sold under the brand name Annovera, it is a combination of segesterone acetate and ethinyl estradiol, and it is the first multiuse vaginal contraceptive system that prevents ovulation for up to 13 menstrual cycles in a year.  Although there are several combination hormonal contraceptives on the market, this is the first single system that can be repeatedly used for an entire year and does not require placement by a health care provider.  This innovation gives women control over when to stop using the contraceptive, should they so desire.  Annovera is stored at room temperature when not in use, allowing women living in uncontrolled-temperature climates to use one contraceptive method for an entire year.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6YX09rUY9tWmbXvSEQle5fW6udTcc2eYUCT5P0vpHx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgs1Cjuw%253D%253D&md5=598b10d0d7f210768f00141b84342262</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2Fj.nwh.2019.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nwh.2019.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DK.%2BK.%26atitle%3DA%2520New%2520Year-Long%2520Combination%2520Hormonal%2520Contraceptive%26jtitle%3DNurs.%2520Womens%2520Health%26date%3D2019%26volume%3D23%26spage%3D172%26epage%3D176%26doi%3D10.1016%2Fj.nwh.2019.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gemzell-Danielsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitruk-Ware, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creinin, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plagianos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blithe, D.</span></span> <span> </span><span class="NLM_article-title">Segesterone Acetate/Ethinyl Estradiol 12-Month Contraceptive Vaginal System Safety Evaluation</span>. <i>Contraception</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/j.contraception.2019.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.contraception.2019.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30831102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlOhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2019&pages=323-328&author=K.+Gemzell-Danielssonauthor=R.+Sitruk-Wareauthor=M.+D.+Creininauthor=M.+Thomasauthor=K.+T.+Barnhartauthor=G.+Creasyauthor=H.+Sussmanauthor=M.+Alamiauthor=A.+E.+Burkeauthor=E.+Weisbergauthor=I.+Fraserauthor=M.+J.+Mirandaauthor=M.+Gilliamauthor=J.+Liuauthor=B.+R.+Carrauthor=M.+Plagianosauthor=K.+Robertsauthor=D.+Blithe&title=Segesterone+Acetate%2FEthinyl+Estradiol+12-Month+Contraceptive+Vaginal+System+Safety+Evaluation&doi=10.1016%2Fj.contraception.2019.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation</span></div><div class="casAuthors">Gemzell-Danielsson, Kristina; Sitruk-Ware, Regine; Creinin, Mitchell D.; Thomas, Michael; Barnhart, Kurt T.; Creasy, George; Sussman, Heather; Alami, Mohcine; Burke, Anne E.; Weisberg, Edith; Fraser, Ian; Miranda, Marie-Jose; Gilliam, Melissa; Liu, James; Carr, Bruce R.; Plagianos, Marlena; Roberts, Kevin; Blithe, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Contraception</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-328</span>CODEN:
                <span class="NLM_cas:coden">CCPTAY</span>;
        ISSN:<span class="NLM_cas:issn">0010-7824</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">To evaluate safety outcomes from clin. studies of a 12-mo contraceptive vaginal system (CVS) releasing an av. of segesterone acetate (SA) 150 mcg and ethinyl estradiol (EE) 13 mcg daily.  We integrated clin. safety data from nine studies in which women used the CVS for 21 consecutive days and removed it for 7 days of each 28-day cycle.  Four studies used the final manufd. CVS, including a 1-yr pharmacokinetic study, two 1-yr phase 3 trials and a second-year treatment extension study.  We assessed safety by evaluating adverse events women reported in a daily diary.  We also included data from focused safety studies evaluating endometrial biopsies, vaginal microbiol. and liver proteins from one of the phase 3 studies.  The combined studies included 3052 women; 2308 women [mean age 26.7±5.1 years; mean body mass index (BMI) 24.1±3.7 kg/m2] received the final manufd. CVS, of whom 999 (43.3%) completed 13 cycles of use.  Women using the final CVS most commonly reported adverse events of headache (n=601, 26%), nausea (n=420, 18%), vaginal discharge/vulvovaginal mycotic infection (n=242, 10%) and abdominal pain (n=225, 10%).  Few (<1.5%) women discontinued for these complaints.  Four (0.2%) women experienced venous thromboembolism (VTE), three of whom had risk factors for thrombosis [Factor V Leiden mutation (n=1); BMI>29 kg/m2 (n=2)].  During 21,482 treatment cycles in the phase 3 studies evaluable for expulsion, women reported partial expulsions in 4259 (19.5%) cycles and complete expulsions in 1509 (7%) cycles, most frequently in the initial cycle [499/2050 (24.3%) and 190/2050 (9.3%), resp.].  Safety-focused studies revealed no safety concerns.  The 1-yr SA/EE CVS has an acceptable safety profile.  Addnl. studies are warranted in obese women at higher risk of VTE.  This 1-yr contraceptive vaginal system represents a new long-term, user-controlled and procedure-free option with a safety profile similar to other combination hormonal contraceptives.  The same precautions currently used for combination hormonal contraceptive prescriptions apply to this new contraceptive vaginal system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUoXHrscP5r7Vg90H21EOLACvtfcHk0lgDj74QK6Ay-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlOhtbo%253D&md5=8ed0d7b0f76d698fda32b184c97a7bf4</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.contraception.2019.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.contraception.2019.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DGemzell-Danielsson%26aufirst%3DK.%26aulast%3DSitruk-Ware%26aufirst%3DR.%26aulast%3DCreinin%26aufirst%3DM.%2BD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DBarnhart%26aufirst%3DK.%2BT.%26aulast%3DCreasy%26aufirst%3DG.%26aulast%3DSussman%26aufirst%3DH.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DBurke%26aufirst%3DA.%2BE.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DMiranda%26aufirst%3DM.%2BJ.%26aulast%3DGilliam%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCarr%26aufirst%3DB.%2BR.%26aulast%3DPlagianos%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DBlithe%26aufirst%3DD.%26atitle%3DSegesterone%2520Acetate%252FEthinyl%2520Estradiol%252012-Month%2520Contraceptive%2520Vaginal%2520System%2520Safety%2520Evaluation%26jtitle%3DContraception%26date%3D2019%26volume%3D99%26spage%3D323%26epage%3D328%26doi%3D10.1016%2Fj.contraception.2019.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urquhart, L.</span></span> <span> </span><span class="NLM_article-title">Regulatory Watch: FDA New Drug Approvals in Q3 2018</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">779</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fnrd.2018.194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30374181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVaqt7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=779&author=L.+Urquhart&title=Regulatory+Watch%3A+FDA+New+Drug+Approvals+in+Q3+2018&doi=10.1038%2Fnrd.2018.194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory watch FDA new drug approvals in Q3 2018</span></div><div class="casAuthors">Urquhart, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">779</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjE_dMsHgqVrVg90H21EOLACvtfcHk0lgDj74QK6Ay-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVaqt7zL&md5=87a29e8402084122b834543ada7c7b4f</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.194%26sid%3Dliteratum%253Aachs%26aulast%3DUrquhart%26aufirst%3DL.%26atitle%3DRegulatory%2520Watch%253A%2520FDA%2520New%2520Drug%2520Approvals%2520in%2520Q3%25202018%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D779%26doi%3D10.1038%2Fnrd.2018.194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Ester Derivatives of Steroids</span>. <span class="NLM_patent">WO199713779</span>, <span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=F.+Li&title=Preparation+of+Ester+Derivatives+of+Steroids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26atitle%3DPreparation%2520of%2520Ester%2520Derivatives%2520of%2520Steroids%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehrhof, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irmscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, L.</span></span> <span> </span><span class="NLM_article-title">Synthesewege Zum 17a-Hydroxy-16-Methylen-19-nor-Progesteron Und Seinen Derivaten</span>. <i>Chem. Ber.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.1002/cber.19691020231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fcber.19691020231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=5802849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaF1MXovVSlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1969&pages=643-658&author=W.+Mehrhofauthor=K.+Irmscherauthor=R.+Erbauthor=L.+Pohl&title=Synthesewege+Zum+17a-Hydroxy-16-Methylen-19-nor-Progesteron+Und+Seinen+Derivaten&doi=10.1002%2Fcber.19691020231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Routes to the synthesis of 17α-hydroxy-16-methylene-19-norprogesterone and its derivatives</span></div><div class="casAuthors">Mehrhof, Werner; Irmscher, Klaus; Erb, Rolf; Pohl, Ludwig</div><div class="citationInfo"><span class="NLM_cas:title">Chemische Berichte</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">643-58</span>CODEN:
                <span class="NLM_cas:coden">CHBEAM</span>;
        ISSN:<span class="NLM_cas:issn">0009-2940</span>.
    </div><div class="casAbstract">17α-Hydroxy-3β-acetoxy-16-methylenepregn-5-en-20-one, prepd. by the method of G. Nomine et al. (1960), treated with N-bromoacetamide gave 5α-bromo-6β-hydroxy-3β-acetoxy-16α,17α-epoxy-16β-bromomethylpregnan-2-one which reacted with NOCl to give 5α-bromo-6β-nitrosooxy-3β-acetoxy-16α,17α-epoxy-16β-bromomethylpregnan-2-one (I).  The irradn. of I gave 5α-bromo-6β-hydroxy-3β-acetoxy-16α,17α-epoxy-19-oximino-16β-bromomethylpregnan-20-one which upon treatment with NaNO2 in AcOH gave 5α-bromo-6β-hydroxy-3β-acetoxy-16α,17α-epoxy-16β-bromomethylpregnane-19,20-dione 19 → 6 acetal (II).  Oxidn. of II with CrO3 gave the corresponding 20-oxopregnan-19-oic acid 19 → 6 lactone which was reduced with Zn to 17α-hydroxy-3β-acetoxy-20-oxo-16-methylenepregn-5-en-19-oic acid.  The latter refluxed with KOH gave 3β,17α-dihydroxy-20-oxo-16-methylenepregn-5-en-19-oic acid which upon oxidn. with CrO3 gave 17α-hydroxy-16-methylene-19-nor-progesterone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNP1PmHcQ6QLVg90H21EOLACvtfcHk0ljHPktYEwMS0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXovVSlsw%253D%253D&md5=31c7c278ed718e8939ec49878b3f2b64</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1002%2Fcber.19691020231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19691020231%26sid%3Dliteratum%253Aachs%26aulast%3DMehrhof%26aufirst%3DW.%26aulast%3DIrmscher%26aufirst%3DK.%26aulast%3DErb%26aufirst%3DR.%26aulast%3DPohl%26aufirst%3DL.%26atitle%3DSynthesewege%2520Zum%252017a-Hydroxy-16-Methylen-19-nor-Progesteron%2520Und%2520Seinen%2520Derivaten%26jtitle%3DChem.%2520Ber.%26date%3D1969%26volume%3D102%26spage%3D643%26epage%3D658%26doi%3D10.1002%2Fcber.19691020231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwars, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syhora, K.</span></span> <span> </span><span class="NLM_article-title">Steroid derivatives L. A Synthesis of 16-Methylene-17-a-Acetoxy-nor-Progesterone</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1925</span>– <span class="NLM_lpage">1929</span>, <span class="refDoi"> DOI: 10.1016/s0040-4039(00)90756-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0040-4039%2800%2990756-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1967&pages=1925-1929&author=V.+Schwarsauthor=J.+Zachovaauthor=K.+Syhora&title=Steroid+derivatives+L.+A+Synthesis+of+16-Methylene-17-a-Acetoxy-nor-Progesterone&doi=10.1016%2Fs0040-4039%2800%2990756-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2990756-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252990756-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchwars%26aufirst%3DV.%26aulast%3DZachova%26aufirst%3DJ.%26aulast%3DSyhora%26aufirst%3DK.%26atitle%3DSteroid%2520derivatives%2520L.%2520A%2520Synthesis%2520of%252016-Methylene-17-a-Acetoxy-nor-Progesterone%26jtitle%3DTetrahedron%2520Lett.%26date%3D1967%26volume%3D22%26spage%3D1925%26epage%3D1929%26doi%3D10.1016%2Fs0040-4039%2800%2990756-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, G.</span>; <span class="NLM_string-name">Gerardo, L.</span>; <span class="NLM_string-name">Rodriguez, S.-D.</span>; <span class="NLM_string-name">Miguel, C.</span></span> <span> </span><span class="NLM_article-title">Process for Alkynylating 16-Substituted 17-Keto Steroids</span>. <span class="NLM_patent">WO2013092668A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+Fuentes&author=L.+Gerardo&author=S.-D.+Rodriguez&author=C.+Miguel&title=Process+for+Alkynylating+16-Substituted+17-Keto+Steroids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFuentes%26aufirst%3DG.%26atitle%3DProcess%2520for%2520Alkynylating%252016-Substituted%252017-Keto%2520Steroids%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Vibegron: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1835</span>– <span class="NLM_lpage">1839</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1006-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1006-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30411311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cvotlWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1835-1839&author=S.+J.+Keam&title=Vibegron%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1006-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Vibegron: First Global Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1835-1839</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Vibegron is a selective beta 3 adrenergic receptor (β3AR) agonist that is being developed in Japan jointly by Kyorin Pharmaceutical Co., Ltd and Kissei Pharmaceutical Co., Ltd and in other regions worldwide (except in several other Asian countries) by Urovant Sciences for the treatment of overactive bladder (OAB).  Based on results from Japanese phase III trials, vibegron received approval in Japan in September 2018 for this indication.  This article summarizes the milestones in the development of vibegron leading to this first global approval for the treatment of OAB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKzA280ys79mgRQsDqrjW_fW6udTcc2eYaldaluolu0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvotlWqtQ%253D%253D&md5=c87f509175ef4659a61c49e4446e595f</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1006-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1006-3%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DVibegron%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1835%26epage%3D1839%26doi%3D10.1007%2Fs40265-018-1006-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kar, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salvo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagabukuro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacre-Salem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goble, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morriello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyes, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzmaurice, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenkl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gichuru, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jochnowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levorse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamlynny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struthers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of Vibegron: A Potent and Selective B3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyrurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=609-623&author=S.+D.+Edmondsonauthor=C.+Zhuauthor=N.+F.+Karauthor=J.+Di+Salvoauthor=H.+Nagabukuroauthor=B.+Sacre-Salemauthor=K.+Dingleyauthor=R.+Bergerauthor=S.+D.+Gobleauthor=G.+Morrielloauthor=B.+Harperauthor=C.+R.+Moyesauthor=D.-M.+Shenauthor=L.+Wangauthor=R.+Ballauthor=A.+Fitzmauriceauthor=T.+Frenklauthor=L.+N.+Gichuruauthor=S.+Haauthor=A.+L.+Hurleyauthor=N.+Jochnowitzauthor=D.+Levorseauthor=S.+Mistryauthor=R.+R.+Millerauthor=J.+Ormesauthor=G.+M.+Salituroauthor=A.+Sanfizauthor=A.+S.+Stevensonauthor=K.+Villaauthor=B.+Zamlynnyauthor=S.+Greenauthor=M.+Struthersauthor=A.+E.+Weber&title=Discovery+of+Vibegron%3A+A+Potent+and+Selective+B3+Adrenergic+Receptor+Agonist+for+the+Treatment+of+Overactive+Bladder&doi=10.1021%2Facs.jmedchem.5b01372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder</span></div><div class="casAuthors">Edmondson, Scott D.; Zhu, Cheng; Kar, Nam Fung; Di Salvo, Jerry; Nagabukuro, Hiroshi; Sacre-Salem, Beatrice; Dingley, Karen; Berger, Richard; Goble, Stephen D.; Morriello, Gregori; Harper, Bart; Moyes, Christopher R.; Shen, Dong-Ming; Wang, Liping; Ball, Richard; Fitzmaurice, Aileen; Frenkl, Tara; Gichuru, Loise N.; Ha, Sookhee; Hurley, Amanda L.; Jochnowitz, Nina; Levorse, Dorothy; Mistry, Shruty; Miller, Randy R.; Ormes, James; Salituro, Gino M.; Sanfiz, Anthony; Stevenson, Andra S.; Villa, Katherine; Zamlynny, Beata; Green, Stuart; Struthers, Mary; Weber, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described.  An early-generation clin. β3-AR agonist MK-0634 (3) exhibited efficacy in humans for the treatment of OAB, but development was discontinued due to unacceptable structure-based toxicity in preclin. species.  Optimization of a series of second-generation pyrrolidine-derived β3-AR agonists included reducing the risk for phospholipidosis, the risk of formation of disproportionate human metabolites, and the risk of formation of high levels of circulating metabolites in preclin. species.  These efforts resulted in the discovery of vibegron, which possesses improved druglike properties and an overall superior preclin. profile compared to MK-0634.  Structure-activity relationships leading to the discovery of vibegron and a summary of its preclin. profile are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTKGFhBOdMNbVg90H21EOLACvtfcHk0ljHPktYEwMS0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyrurjM&md5=89410d04a67540aa78e73e7312867ef3</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01372%26sid%3Dliteratum%253Aachs%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DKar%26aufirst%3DN.%2BF.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DNagabukuro%26aufirst%3DH.%26aulast%3DSacre-Salem%26aufirst%3DB.%26aulast%3DDingley%26aufirst%3DK.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DGoble%26aufirst%3DS.%2BD.%26aulast%3DMorriello%26aufirst%3DG.%26aulast%3DHarper%26aufirst%3DB.%26aulast%3DMoyes%26aufirst%3DC.%2BR.%26aulast%3DShen%26aufirst%3DD.-M.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBall%26aufirst%3DR.%26aulast%3DFitzmaurice%26aufirst%3DA.%26aulast%3DFrenkl%26aufirst%3DT.%26aulast%3DGichuru%26aufirst%3DL.%2BN.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DLevorse%26aufirst%3DD.%26aulast%3DMistry%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DOrmes%26aufirst%3DJ.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DSanfiz%26aufirst%3DA.%26aulast%3DStevenson%26aufirst%3DA.%2BS.%26aulast%3DVilla%26aufirst%3DK.%26aulast%3DZamlynny%26aufirst%3DB.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3DDiscovery%2520of%2520Vibegron%253A%2520A%2520Potent%2520and%2520Selective%2520B3%2520Adrenergic%2520Receptor%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Overactive%2520Bladder%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D609%26epage%3D623%26doi%3D10.1021%2Facs.jmedchem.5b01372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurose, T.</span></span> <span> </span><span class="NLM_article-title">Vibegron, a Novel Potent and Selective B3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study</span>. <i>Eur. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1016/j.eururo.2017.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.eururo.2017.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29366513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCkt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=783-790&author=M.+Yoshidaauthor=M.+Takedaauthor=M.+Gotohauthor=S.+Nagaiauthor=T.+Kurose&title=Vibegron%2C+a+Novel+Potent+and+Selective+B3-Adrenoreceptor+Agonist%2C+for+the+Treatment+of+Patients+with+Overactive+Bladder%3A+A+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Phase+3+Study&doi=10.1016%2Fj.eururo.2017.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214aR"><div class="casContent"><span class="casTitleNuber">214a</span><div class="casTitle"><span class="NLM_cas:atitle">Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study</span></div><div class="casAuthors">Yoshida, Masaki; Takeda, Masayuki; Gotoh, Momokazu; Nagai, Shinji; Kurose, Takafumi</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">783-790</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Vibegron is a novel, potent, and selective β3-adrenoreceptor agonist for the treatment of patients with overactive bladder (OAB).To evaluate the efficacy and safety of vibegron vs. placebo in Japanese OAB patients.Patients with OAB entered a 2-wk placebo run-in phase.  Once eligibility (≥8 micturition/d and either ≥1 urgency episodes/d or ≥1 urgency incontinence episodes/d) was confirmed, patients entered a 12-wk double-blind treatment phase.  The anticholinergic imidafenacin was used as an active ref.A total of 1232 patients were randomly assigned to one of the four 12-wk treatment groups: vibegron (50 mg or 100 mg once daily), placebo, or imidafenacin (0.1 mg twice daily).The primary endpoint was change in the mean no. of micturitions/d at wk 12 from baseline.  The secondary endpoints were changes from baselines in OAB symptom variables (daily episodes of urgency, urgency incontinence, incontinence, and nocturia, and voided vol./micturition).  Quality of life (QoL) and safety were assessed.  A constrained longitudinal data anal. model was used for anal. of efficacy.Patients taking vibegron 50 mg and 100 mg orally for 12 wk had significant improvements over the placebo in the primary and secondary endpoints.  The proportions of patients with normalization of micturition, resoln. of urgency, urgency incontinence, and incontinence were significantly greater than placebo.  Vibegron significantly improved QoL, with high patient satisfaction.  Incidences of drug-related adverse events with vibegron 50 mg and 100 mg were 7.6%, 5.4%, similar to placebo (5.1%), and less than imidafenacin (10.3%).  Treatment was for just 12 wk and a long-term study is needed.  The 12-wk treatment with vibegron is effective and well tolerated inpatients with OAB.  This randomized study demonstrated that vibegron is clin. useful for treatment of patients with OAB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3tRLvgD7ry7Vg90H21EOLACvtfcHk0ljMhyccj1NOTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCkt7nN&md5=8a0772a37e2b7a5c635652125a06992e</span></div><a href="/servlet/linkout?suffix=cit214a&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2017.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2017.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DGotoh%26aufirst%3DM.%26aulast%3DNagai%26aufirst%3DS.%26aulast%3DKurose%26aufirst%3DT.%26atitle%3DVibegron%252C%2520a%2520Novel%2520Potent%2520and%2520Selective%2520B3-Adrenoreceptor%2520Agonist%252C%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Overactive%2520Bladder%253A%2520A%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%25203%2520Study%26jtitle%3DEur.%2520Urol.%26date%3D2018%26volume%3D73%26spage%3D783%26epage%3D790%26doi%3D10.1016%2Fj.eururo.2017.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit214b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wein, A. J.</span></span> <span> </span><span class="NLM_article-title">Re: Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2018.04.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.juro.2018.04.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFSrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2018&pages=33-38&author=A.+J.+Wein&title=Re%3A+Pharmacological+Characterization+of+a+Novel+Beta+3+Adrenergic+Agonist%2C+Vibegron%3A+Evaluation+of+Antimuscarinic+Receptor+Selectivity+for+Combination+Therapy+for+Overactive+Bladder&doi=10.1016%2Fj.juro.2018.04.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214bR"><div class="casContent"><span class="casTitleNuber">214b</span><div class="casTitle"><span class="NLM_cas:atitle">Re: Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder</span></div><div class="casAuthors">Wein, Alan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-38</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review discussing the pharmacol. characterization of a novel beta 3 adrenergic agonist, Vibegron, and evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJV1yig2ClpbVg90H21EOLACvtfcHk0ljMhyccj1NOTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFSrsL8%253D&md5=eb52cd897e4a98c27c3bc10731881fcb</span></div><a href="/servlet/linkout?suffix=cit214b&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2018.04.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2018.04.052%26sid%3Dliteratum%253Aachs%26aulast%3DWein%26aufirst%3DA.%2BJ.%26atitle%3DRe%253A%2520Pharmacological%2520Characterization%2520of%2520a%2520Novel%2520Beta%25203%2520Adrenergic%2520Agonist%252C%2520Vibegron%253A%2520Evaluation%2520of%2520Antimuscarinic%2520Receptor%2520Selectivity%2520for%2520Combination%2520Therapy%2520for%2520Overactive%2520Bladder%26jtitle%3DJ.%2520Urol.%26date%3D2018%26volume%3D200%26spage%3D33%26epage%3D38%26doi%3D10.1016%2Fj.juro.2018.04.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit214c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salvo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagabukuro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickham, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzmaurice, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gichuru, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jochnowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamlynny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zycband, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenkl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struthers, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.237313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1124%2Fjpet.116.237313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27965369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVOjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2017&pages=346-355&author=J.+Di+Salvoauthor=H.+Nagabukuroauthor=L.+A.+Wickhamauthor=C.+Abbadieauthor=J.+A.+DeMartinoauthor=A.+Fitzmauriceauthor=L.+Gichuruauthor=A.+Kulickauthor=M.+J.+Donnellyauthor=N.+Jochnowitzauthor=A.+L.+Hurleyauthor=A.+Pereiraauthor=A.+Sanfizauthor=G.+Veroninauthor=K.+Villaauthor=J.+Woodsauthor=B.+Zamlynnyauthor=E.+Zycbandauthor=G.+M.+Salituroauthor=T.+Frenklauthor=A.+E.+Weberauthor=S.+D.+Edmondsonauthor=M.+Struthers&title=Pharmacological+Characterization+of+a+Novel+Beta+3+Adrenergic+Agonist%2C+Vibegron%3A+Evaluation+of+Antimuscarinic+Receptor+Selectivity+for+Combination+Therapy+for+Overactive+Bladder&doi=10.1124%2Fjpet.116.237313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214cR"><div class="casContent"><span class="casTitleNuber">214c</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectiviy for combination therapy for overactive bladder</span></div><div class="casAuthors">Di Salvo, J.; Nagabukuro, H.; Wickham, L. A.; Abbadie, C.; De Martino, J. A.; Fitzmaurice, A.; Gichuru, L.; Kulick, A.; Donnelly, M. J.; Jochnowitz, N.; Hurley, A. L.; Pereira, A.; Sanfiz, A.; Veronin, G.; Villa, K.; Woods, J.; Zamlynny, B.; Zycband, E.; Salituro, G. M.; Frenkl, T.; Weber, A. E.; Edmondson, S. D.; Struthers, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">346-355</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although the physiol. role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists for the treatment of overactive bladder are well established, the role of β3-adrenergic receptors (β3ARs) and their potential as therapeutics is just emerging.  In this manuscript, we characterized the pharmacol. of a novel β3AR agonist vibegron (MK-4618, KRP-114V) and explored mechanistic interactions of β3AR agonism and muscarinic antagonism in urinary bladder function.  Vibegron is a potent, selective full β3AR agonist across species, and it dose dependently increased bladder capacity, decreased micturition pressure, and increased bladder compliance in rhesus monkeys.  The relaxation effect of vibegron was enhanced when combined with muscarinic antagonists, but differentially influenced by muscarinic receptor subtype selectivity.  The effect was greater when vibegron was co-administered with tolterodine, a non-selective antagonist, compared with coadministration with darifenacin, a selective M3 antagonist.  Furthermore, a synergistic effect for bladder strip relaxation was obsd. with the combination of a β3AR agonist and tolterodine in contrast to simple additivity with darifenacin.  To det. expression in rhesus bladder, we employed a novel β3AR agonist probe, [3H]MRL-037, that selectively labels β3 receptors in both urothelium and detrusor smooth muscle.  Vibegron administration caused a dose-dependent increase in circulating glycerol and fatty acid levels in rhesus and rat in vivo, suggesting these circulating lipids can be surrogate biomarkers.  The translation of our observation to the clinic has yet to be detd., but the combination of β3AR agonists with M2/M3 antimuscarinics has the potential to redefine the std. of care for the pharmacol. treatment of overactive bladder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXNS-iTpZTkrVg90H21EOLACvtfcHk0ljuuQQn_1kVKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVOjs7k%253D&md5=28e4e907bef836e610d91619031289fa</span></div><a href="/servlet/linkout?suffix=cit214c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.237313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.237313%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DNagabukuro%26aufirst%3DH.%26aulast%3DWickham%26aufirst%3DL.%2BA.%26aulast%3DAbbadie%26aufirst%3DC.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26aulast%3DFitzmaurice%26aufirst%3DA.%26aulast%3DGichuru%26aufirst%3DL.%26aulast%3DKulick%26aufirst%3DA.%26aulast%3DDonnelly%26aufirst%3DM.%2BJ.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DSanfiz%26aufirst%3DA.%26aulast%3DVeronin%26aufirst%3DG.%26aulast%3DVilla%26aufirst%3DK.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DZamlynny%26aufirst%3DB.%26aulast%3DZycband%26aufirst%3DE.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DFrenkl%26aufirst%3DT.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DStruthers%26aufirst%3DM.%26atitle%3DPharmacological%2520Characterization%2520of%2520a%2520Novel%2520Beta%25203%2520Adrenergic%2520Agonist%252C%2520Vibegron%253A%2520Evaluation%2520of%2520Antimuscarinic%2520Receptor%2520Selectivity%2520for%2520Combination%2520Therapy%2520for%2520Overactive%2520Bladder%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D360%26spage%3D346%26epage%3D355%26doi%3D10.1124%2Fjpet.116.237313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosjek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabirol, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmond, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohel, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvizo, O.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High Ph Dynamic Kinetic Reduction</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6863</span>– <span class="NLM_lpage">6867</span>, <span class="refDoi"> DOI: 10.1002/anie.201802791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fanie.201802791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovFClu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=6863-6867&author=F.+Xuauthor=B.+Kosjekauthor=F.+L.+Cabirolauthor=H.+Chenauthor=R.+Desmondauthor=J.+Parkauthor=A.+P.+Gohelauthor=S.+J.+Collierauthor=D.+J.+Smithauthor=Z.+Liuauthor=J.+M.+Janeyauthor=J.+Y.+L.+Chungauthor=O.+Alvizo&title=Synthesis+of+Vibegron+Enabled+by+a+Ketoreductase+Rationally+Designed+for+High+Ph+Dynamic+Kinetic+Reduction&doi=10.1002%2Fanie.201802791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215aR"><div class="casContent"><span class="casTitleNuber">215a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High pH Dynamic Kinetic Reduction</span></div><div class="casAuthors">Xu, Feng; Kosjek, Birgit; Cabirol, Fabien L.; Chen, Haibin; Desmond, Richard; Park, Jeonghan; Gohel, Anupam P.; Collier, Steven J.; Smith, Derek J.; Liu, Zhuqing; Janey, Jacob M.; Chung, John Y. L.; Alvizo, Oscar</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6863-6867</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Described here is an efficient stereoselective synthesis of vibegron enabled by an enzymic dynamic kinetic redn. that proceeds in a high-pH environment.  To overcome enzyme performance limitations under these conditions, a ketoreductase (KRED) was evolved by a computationally and structurally aided strategy to increase cofactor stability through tighter binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRH49eLjY5XrVg90H21EOLACvtfcHk0ljuuQQn_1kVKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovFClu7g%253D&md5=c7d262c01344ade2489bd9b098eda32b</span></div><a href="/servlet/linkout?suffix=cit215a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201802791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201802791%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DF.%26aulast%3DKosjek%26aufirst%3DB.%26aulast%3DCabirol%26aufirst%3DF.%2BL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDesmond%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DGohel%26aufirst%3DA.%2BP.%26aulast%3DCollier%26aufirst%3DS.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJaney%26aufirst%3DJ.%2BM.%26aulast%3DChung%26aufirst%3DJ.%2BY.%2BL.%26aulast%3DAlvizo%26aufirst%3DO.%26atitle%3DSynthesis%2520of%2520Vibegron%2520Enabled%2520by%2520a%2520Ketoreductase%2520Rationally%2520Designed%2520for%2520High%2520Ph%2520Dynamic%2520Kinetic%2520Reduction%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D6863%26epage%3D6867%26doi%3D10.1002%2Fanie.201802791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit215b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Desmond, R.</span>; <span class="NLM_string-name">Park, J.</span>; <span class="NLM_string-name">Kalinin, A.</span>; <span class="NLM_string-name">Kosjek, B.</span>; <span class="NLM_string-name">Strotman, H.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Moncecchi, J.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Beta 3 Agonists and Intermediates</span>. <span class="NLM_patent">WO2014150639A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=F.+Xu&author=Z.+Liu&author=R.+Desmond&author=J.+Park&author=A.+Kalinin&author=B.+Kosjek&author=H.+Strotman&author=H.+Li&author=J.+Moncecchi&title=Process+for+Preparing+Beta+3+Agonists+and+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DF.%26atitle%3DProcess%2520for%2520Preparing%2520Beta%25203%2520Agonists%2520and%2520Intermediates%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit215c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Zhong, Y.-L.</span>; <span class="NLM_string-name">Chung, J. Y. L.</span>; <span class="NLM_string-name">Dunn, R. F.</span>; <span class="NLM_string-name">Maloney, K. M.</span>; <span class="NLM_string-name">Campos, K.</span>; <span class="NLM_string-name">Hoerrner, R. S.</span>; <span class="NLM_string-name">Lynch, J.</span>; <span class="NLM_string-name">Xu, F.</span>; <span class="NLM_string-name">Cleator, E.</span>; <span class="NLM_string-name">Gibson, A.</span>; <span class="NLM_string-name">Keen, S.</span>; <span class="NLM_string-name">Lieberman, D.</span>; <span class="NLM_string-name">Yoshikawa, N.</span></span> <span> </span><span class="NLM_article-title">Process for Making Beta 3 Agonists and Intermediates</span>. <span class="NLM_patent">WO2013062881A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=N.+Yasuda&author=Z.+Liu&author=Y.-L.+Zhong&author=J.+Y.+L.+Chung&author=R.+F.+Dunn&author=K.+M.+Maloney&author=K.+Campos&author=R.+S.+Hoerrner&author=J.+Lynch&author=F.+Xu&author=E.+Cleator&author=A.+Gibson&author=S.+Keen&author=D.+Lieberman&author=N.+Yoshikawa&title=Process+for+Making+Beta+3+Agonists+and+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DN.%26atitle%3DProcess%2520for%2520Making%2520Beta%25203%2520Agonists%2520and%2520Intermediates%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit215d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span>; <span class="NLM_string-name">Chang, L.</span>; <span class="NLM_string-name">Edmondson, S. D.</span>; <span class="NLM_string-name">Goble, S. D.</span>; <span class="NLM_string-name">Ha, S. N.</span>; <span class="NLM_string-name">Kar, N. F.</span>; <span class="NLM_string-name">Kopka, I. E.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Morriello, G. J.</span>; <span class="NLM_string-name">Moyes, C. R.</span>; <span class="NLM_string-name">Shen, D.-M.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Zhu, C.</span></span> <span> </span><span class="NLM_article-title">Hydroxymethyl Pyrrolidine as B3 Adrenoceptor Agonist</span>. <span class="NLM_patent">JP2012020961A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Berger&author=L.+Chang&author=S.+D.+Edmondson&author=S.+D.+Goble&author=S.+N.+Ha&author=N.+F.+Kar&author=I.+E.+Kopka&author=B.+Li&author=G.+J.+Morriello&author=C.+R.+Moyes&author=D.-M.+Shen&author=L.+Wang&author=C.+Zhu&title=Hydroxymethyl+Pyrrolidine+as+B3+Adrenoceptor+Agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DR.%26atitle%3DHydroxymethyl%2520Pyrrolidine%2520as%2520B3%2520Adrenoceptor%2520Agonist%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit215e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagabukuro, H.</span>; <span class="NLM_string-name">Edmondson, S. D.</span>; <span class="NLM_string-name">Sinharoy, M. S.</span>; <span class="NLM_string-name">Denney, W. S.</span>; <span class="NLM_string-name">Frenkl, T. L.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy Using a Beta 3 Adrenergic Receptor Agonist and an Antimuscarinic Agent</span>. <span class="NLM_patent">WO2011043942A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=H.+Nagabukuro&author=S.+D.+Edmondson&author=M.+S.+Sinharoy&author=W.+S.+Denney&author=T.+L.+Frenkl&title=Combination+Therapy+Using+a+Beta+3+Adrenergic+Receptor+Agonist+and+an+Antimuscarinic+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNagabukuro%26aufirst%3DH.%26atitle%3DCombination%2520Therapy%2520Using%2520a%2520Beta%25203%2520Adrenergic%2520Receptor%2520Agonist%2520and%2520an%2520Antimuscarinic%2520Agent%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit215f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span>; <span class="NLM_string-name">Chang, L.</span>; <span class="NLM_string-name">Edmondson, S. D.</span>; <span class="NLM_string-name">Goble, S. D.</span>; <span class="NLM_string-name">Ha, S. N.</span>; <span class="NLM_string-name">Kar, N. F.</span>; <span class="NLM_string-name">Kopka, I. E.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Morriello, G. J.</span>; <span class="NLM_string-name">Moyes, C. R.</span>; <span class="NLM_string-name">Shen, D.-M.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Zhu, C.</span></span> <span> </span><span class="NLM_article-title">Hydroxymethyl Pyrrolidines as Beta 3 Adrenergic Receptor Agonists</span>. <span class="NLM_patent">WO2009124167A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Berger&author=L.+Chang&author=S.+D.+Edmondson&author=S.+D.+Goble&author=S.+N.+Ha&author=N.+F.+Kar&author=I.+E.+Kopka&author=B.+Li&author=G.+J.+Morriello&author=C.+R.+Moyes&author=D.-M.+Shen&author=L.+Wang&author=C.+Zhu&title=Hydroxymethyl+Pyrrolidines+as+Beta+3+Adrenergic+Receptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DR.%26atitle%3DHydroxymethyl%2520Pyrrolidines%2520as%2520Beta%25203%2520Adrenergic%2520Receptor%2520Agonists%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyker, G.</span></span> <span> </span><span class="NLM_article-title">Amino Acid Derivatives by Multicomponent Reactions</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1702</span>, <span class="refDoi"> DOI: 10.1002/anie.199717001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fanie.199717001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK2sXmtVSjsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=1700-1702&author=G.+Dyker&title=Amino+Acid+Derivatives+by+Multicomponent+Reactions&doi=10.1002%2Fanie.199717001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acid derivatives by multicomponent reactions</span></div><div class="casAuthors">Dyker, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition in English</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1700-1702</span>CODEN:
                <span class="NLM_cas:coden">ACIEAY</span>;
        ISSN:<span class="NLM_cas:issn">0570-0833</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH</span>)
        </div><div class="casAbstract">A review with 12 refs. on the synthesis of amino acid derivs. by the Strecker synthesis, Ugi's four-component condensation, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnr3ZWzczxSLVg90H21EOLACvtfcHk0lhurk2QLuEAKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmtVSjsrY%253D&md5=0cfaa353be3768fd4f47b3f6e51e5970</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1002%2Fanie.199717001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.199717001%26sid%3Dliteratum%253Aachs%26aulast%3DDyker%26aufirst%3DG.%26atitle%3DAmino%2520Acid%2520Derivatives%2520by%2520Multicomponent%2520Reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1997%26volume%3D36%26spage%3D1700%26epage%3D1702%26doi%3D10.1002%2Fanie.199717001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d','cit2e','cit2f','cit2g','cit2h','cit2i','cit2j','cit2k','cit2l','cit2m','cit2n','cit2o','cit2p'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6a','cit6b','cit6c'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8a','cit8b','cit8c'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13a','cit13b','cit13c','cit13d','cit13e','cit13f','cit13g','cit13h','cit13i','cit13j'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b','cit18c'],'ref19':['cit19a','cit19b'],'ref20':['cit20a','cit20b','cit20c','cit20d'],'ref21':['cit21a','cit21b','cit21c','cit21d','cit21e','cit21f'],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['cit28a','cit28b','cit28c','cit28d'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31a','cit31b'],'ref32':['cit32a','cit32b'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38a','cit38b','cit38c'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43a','cit43b','cit43c','cit43d','cit43e','cit43f'],'ref44':['cit44'],'ref45':['cit45a','cit45b'],'ref46':['cit46a','cit46b'],'ref47':['cit47a','cit47b'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51a','cit51b'],'ref52':['cit52a','cit52b','cit52c','cit52d'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58a','cit58b'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63a','cit63b'],'ref64':['cit64'],'ref65':['cit65a','cit65b'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70a','cit70b','cit70c'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73a','cit73b','cit73c'],'ref74':['cit74'],'ref75':['cit75a','cit75b'],'ref76':['cit76a','cit76b','cit76c','cit76d','cit76e','cit76f','cit76g','cit76h'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82a','cit82b','cit82c'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89a','cit89b'],'ref90':['cit90a','cit90b'],'ref91':['cit91a','cit91b'],'ref92':['cit92a','cit92b'],'ref93':['cit93'],'ref94':['cit94a','cit94b'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101a','cit101b'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105a','cit105b'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109a','cit109b','cit109c'],'ref110':['cit110a','cit110b'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118a','cit118b','cit118c','cit118d','cit118e','cit118f'],'ref119':['cit119a','cit119b','cit119c','cit119d'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129a','cit129b'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132a','cit132b','cit132c'],'ref133':['cit133'],'ref134':['cit134a','cit134b'],'ref135':['cit135'],'ref136':['cit136a','cit136b'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146a','cit146b','cit146c','cit146d'],'ref147':['cit147a','cit147b'],'ref148':['cit148'],'ref149':['cit149a','cit149b'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153a','cit153b'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156a','cit156b'],'ref157':['cit157'],'ref158':['cit158a','cit158b'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162a','cit162b'],'ref163':['cit163a','cit163b'],'ref164':['cit164a','cit164b','cit164c'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178a','cit178b'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185a','cit185b'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190a','cit190b'],'ref191':['cit191'],'ref192':['cit192a','cit192b','cit192c','cit192d'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196a','cit196b'],'ref197':['cit197a','cit197b'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200a','cit200b'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204a','cit204b','cit204c','cit204d','cit204e','cit204f','cit204g'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214a','cit214b','cit214c'],'ref215':['cit215a','cit215b','cit215c','cit215d','cit215e','cit215f'],'ref216':['cit216']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved during 2019. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3604-3657. <a href="https://doi.org/10.1021/acs.jmedchem.1c00208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00208%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252Bduring%252B2019%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03022021%26date%3D30032021%26volume%3D64%26issue%3D7%26spage%3D3604%26epage%3D3657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shoji  Kobayashi</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclopentyl Methyl Ether (CPME) and 4-Methyltetrahydropyran (4-MeTHP) : Basic Chemical Properties and Applications as Next Generation Reaction Solvents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Synthetic Organic Chemistry, Japan</span><span> <strong>2021,</strong> <em>79 </em>
                                    (6)
                                     , 547-557. <a href="https://doi.org/10.5059/yukigoseikyokaishi.79.547" title="DOI URL">https://doi.org/10.5059/yukigoseikyokaishi.79.547</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5059/yukigoseikyokaishi.79.547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5059%2Fyukigoseikyokaishi.79.547%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Synthetic%2520Organic%2520Chemistry%252C%2520Japan%26atitle%3DCyclopentyl%252BMethyl%252BEther%252B%252528CPME%252529%252Band%252B4-Methyltetrahydropyran%252B%2525284-MeTHP%252529%252B%25253A%252BBasic%252BChemical%252BProperties%252Band%252BApplications%252Bas%252BNext%252BGeneration%252BReaction%252BSolvents%26aulast%3DKobayashi%26aufirst%3DShoji%26date%3D2021%26volume%3D79%26issue%3D6%26spage%3D547%26epage%3D557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hossein  Mousavi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive survey upon diverse and prolific applications of chitosan-based catalytic systems in one-pot multi-component synthesis of heterocyclic rings. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>57 </em><a href="https://doi.org/10.1016/j.ijbiomac.2021.06.123" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2021.06.123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2021.06.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2021.06.123%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DA%252Bcomprehensive%252Bsurvey%252Bupon%252Bdiverse%252Band%252Bprolific%252Bapplications%252Bof%252Bchitosan-based%252Bcatalytic%252Bsystems%252Bin%252Bone-pot%252Bmulti-component%252Bsynthesis%252Bof%252Bheterocyclic%252Brings%26aulast%3DMousavi%26aufirst%3DHossein%26date%3D2021%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-Han  Yuan</span>, <span class="hlFld-ContribAuthor ">Sai-Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiao-Bing  Chen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113218. <a href="https://doi.org/10.1016/j.ejmech.2021.113218" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113218%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFDA-approved%252Bpyrimidine-fused%252Bbicyclic%252Bheterocycles%252Bfor%252Bcancer%252Btherapy%25253A%252BSynthesis%252Band%252Bclinical%252Bapplication%26aulast%3DWang%26aufirst%3DShuai%26date%3D2021%26volume%3D214%26spage%3D113218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hsiu‐Hui  Wu</span>, <span class="hlFld-ContribAuthor ">Ho‐Lun  Chen</span>, <span class="hlFld-ContribAuthor ">Chih Ying  Hsu</span>, <span class="hlFld-ContribAuthor ">Chih‐Ling  Yeh</span>, <span class="hlFld-ContribAuthor ">Hsiu‐Fu  Hsu</span>, <span class="hlFld-ContribAuthor ">Chien‐Chung  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discotic material hexakis(4‐carboxyphenylethynyl)benzene inhibits
              
                Escherichia coli
              
              growth via the glycolysis pathway. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Chinese Chemical Society</span><span> <strong>2021,</strong> <em>68 </em>
                                    (2)
                                     , 239-244. <a href="https://doi.org/10.1002/jccs.202000508" title="DOI URL">https://doi.org/10.1002/jccs.202000508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jccs.202000508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjccs.202000508%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Chinese%2520Chemical%2520Society%26atitle%3DDiscotic%252Bmaterial%252Bhexakis%2525284%2525E2%252580%252590carboxyphenylethynyl%252529benzene%252Binhibits%252BEscherichia%252Bcoli%252Bgrowth%252Bvia%252Bthe%252Bglycolysis%252Bpathway%26aulast%3DWu%26aufirst%3DHsiu%25E2%2580%2590Hui%26date%3D2021%26date%3D2021%26volume%3D68%26issue%3D2%26spage%3D239%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amol  Thakkar</span>, <span class="hlFld-ContribAuthor ">Simon  Johansson</span>, <span class="hlFld-ContribAuthor ">Kjell  Jorner</span>, <span class="hlFld-ContribAuthor ">David  Buttar</span>, <span class="hlFld-ContribAuthor ">Jean-Louis  Reymond</span>, <span class="hlFld-ContribAuthor ">Ola  Engkvist</span>. </span><span class="cited-content_cbyCitation_article-title">Artificial intelligence and automation in computer aided synthesis planning. </span><span class="cited-content_cbyCitation_journal-name">Reaction Chemistry & Engineering</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     , 27-51. <a href="https://doi.org/10.1039/D0RE00340A" title="DOI URL">https://doi.org/10.1039/D0RE00340A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RE00340A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RE00340A%26sid%3Dliteratum%253Aachs%26jtitle%3DReaction%2520Chemistry%2520%2526%2520Engineering%26atitle%3DArtificial%252Bintelligence%252Band%252Bautomation%252Bin%252Bcomputer%252Baided%252Bsynthesis%252Bplanning%26aulast%3DThakkar%26aufirst%3DAmol%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1%26spage%3D27%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Garima  Tripathi</span>, <span class="hlFld-ContribAuthor ">Abhijeet  Kumar</span>, <span class="hlFld-ContribAuthor ">Sanchayita  Rajkhowa</span>, <span class="hlFld-ContribAuthor ">Vinod K.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of biologically relevant heterocyclic skeletons under solvent-free condition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 421-459. <a href="https://doi.org/10.1016/B978-0-12-820586-0.00013-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-820586-0.00013-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820586-0.00013-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820586-0.00013-3%26sid%3Dliteratum%253Aachs%26atitle%3DSynthesis%252Bof%252Bbiologically%252Brelevant%252Bheterocyclic%252Bskeletons%252Bunder%252Bsolvent-free%252Bcondition%26aulast%3DTripathi%26aufirst%3DGarima%26date%3D2021%26spage%3D421%26epage%3D459%26pub%3DElsevier%26atitle%3DGreen%252BSynthetic%252BApproaches%252Bfor%252BBiologically%252BRelevant%252BHeterocycles%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tejas M.  Dhameliya</span>, <span class="hlFld-ContribAuthor ">Hiren A.  Donga</span>, <span class="hlFld-ContribAuthor ">Punit V.  Vaghela</span>, <span class="hlFld-ContribAuthor ">Bhoomi G.  Panchal</span>, <span class="hlFld-ContribAuthor ">Dipen K.  Sureja</span>, <span class="hlFld-ContribAuthor ">Kunjan B.  Bodiwala</span>, <span class="hlFld-ContribAuthor ">Mahesh T.  Chhabria</span>. </span><span class="cited-content_cbyCitation_article-title">A decennary update on applications of metal nanoparticles (MNPs) in the synthesis of nitrogen- and oxygen-containing heterocyclic scaffolds. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (54)
                                     , 32740-32820. <a href="https://doi.org/10.1039/D0RA02272A" title="DOI URL">https://doi.org/10.1039/D0RA02272A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA02272A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA02272A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DA%252Bdecennary%252Bupdate%252Bon%252Bapplications%252Bof%252Bmetal%252Bnanoparticles%252B%252528MNPs%252529%252Bin%252Bthe%252Bsynthesis%252Bof%252Bnitrogen-%252Band%252Boxygen-containing%252Bheterocyclic%252Bscaffolds%26aulast%3DDhameliya%26aufirst%3DTejas%2BM.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D54%26spage%3D32740%26epage%3D32820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0076.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0076.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0001.jpeg" id="rightTab-gr72" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0002.jpeg" id="rightTab-GRAPHIC-d7e318-autogenerated" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0003.jpeg" id="rightTab-GRAPHIC-d7e319-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of 39 NCEs approved in 2018.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0001.jpeg jm0c00345_0002.jpeg jm0c00345_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0004.jpeg" id="rightTab-gr73" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Retrosynthetic approach to eravacycline.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Eravacycline Isoxazole <b>4</b> (<b>4</b>·Tartrate)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0016.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Construction of Eravacycline Tricyclic Michael Acceptor Enone <b>2</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0027.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Dibenzyl Amine Protected Coupling Partner <b>1</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0038.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Final Assembly of Eravacycline (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0049.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Ravuconazole (<b>35</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0060.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Fosravuconazole <span class="smallcaps smallerCapital">l</span>-Lysine Ethanolate (<b>II</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0071.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0071.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Omadacycline <b>III</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0071.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0074.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0074.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Plazomicin (<b>IV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0074.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0075.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0075.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Sarecycline Hydrochloride (<b>V</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0075.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Assembly of Baloxavir Piperazine Heterocyclic Core <b>59</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Construction of Baloxavir Benzothiepine <b>62</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Final Assembly of Baloxavir Marboxil (<b>VI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0009.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Bictegravir (<b>VII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0010.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Preparation of Bictegravir <i>syn</i>-Aminopentanol <b>78</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0011.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Preparation of Danoprevir Cyclopropyl Aminoester <b>87</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0012.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Danoprevir (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0013.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Doravirine (<b>IX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0014.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Moxidectin (<b>X</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0015.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Preparation of Tafenoquine Nitroquinoline Intermediate <b>115</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0017.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of Tafenoquine (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0018.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of Tecovirimat (<b>XII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch22" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0019.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of Avatrombopag Maleate (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch23" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0020.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Revefenacin (<b>XIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch24" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0021.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of Roxadustat (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch25" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0022.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. General Route to Elobixibat Sulfone <b>160</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch26" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0023.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of Elobixibat Hydrate (<b>XVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch27" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0024.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of Tegoprazan (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch28" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0025.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. Preparation of Tegoprazan Chromanol <b>174</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch29" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0026.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Synthesis of Elagolix Sodium (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch30" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0028.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. Synthesis of Fostamatinib (<b>XIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch31" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0029.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 31. Preparation of Fostamatinib <i>tert</i>-Butyl Phosphate <b>196</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch32" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0030.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 32. Synthesis of Evocalcet Aminopyrrolidines <b>204</b> and <b>205</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch33" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0031.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 33. Synthesis of Evocalcet (<b>XX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch34" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0032.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 34. Synthesis of Anlotinib (<b>XXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch35" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0033.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 35. Synthesis of Apalutamide (<b>XXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch36" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Scheme 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0034.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 36. Synthesis of Binimetinib (<b>XXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch37" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Scheme 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0035.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 37. Synthesis of Dacomitinib (<b>XXIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch38" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Scheme 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0036.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 38. Synthesis of Dacomitinib Butanoic Acid <b>243</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch39" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Scheme 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0037.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 39. Preparation of Duvelisib Purine <b>249</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch40" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Scheme 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0039.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 40. Synthesis of Duvelisib Monohydrate (<b>XXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch41" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Scheme 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0040.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 41. Synthesis of Encorafenib Carbamate <b>259</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch42" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Scheme 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0041.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 42. Synthesis of Encorafenib Boronate Ester <b>263</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch43" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Scheme 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0042.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 43. Synthesis of Encorafenib (<b>XXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch44" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Scheme 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0043.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 44. Synthesis of of Fruquintinib (<b>XXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch45" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Scheme 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0044.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 45. Synthesis of Gilteritinib (<b>XXVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch46" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Scheme 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0045.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 46. Synthesis of Glasdegib Piperidone <b>285</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch47" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Scheme 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0046.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 47. Transaminase Dynamic Kinetic Resolution (DKR) of Glasdegib Amine <b>286</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch48" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Scheme 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0047.jpeg" id="rightTab-gr48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 48. Synthesis of Glasdegib (<b>XXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch49" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Scheme 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0048.jpeg" id="rightTab-gr49" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 49. Synthesis of Ivosidenib (<b>XXX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch50" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Scheme 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0050.jpeg" id="rightTab-gr50" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 50. Synthesis of Ivosidenib Imine <b>292</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch51" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Scheme 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0051.jpeg" id="rightTab-gr51" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 51. Synthesis of Larotrectinib Pyrazolopyrimidine <b>304</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch51"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch52" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Scheme 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0052.jpeg" id="rightTab-gr52" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 52. Synthesis of Larotrectinib (<b>XXXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch53" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Scheme 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0053.jpeg" id="rightTab-gr53" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 53. Preparation of Lorlatinib Aminopyrazole Fragment <b>312</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch54" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Scheme 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0054.jpeg" id="rightTab-gr54" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 54. Synthesis of Lorlatinib (<b>XXXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch54"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch55" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Scheme 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0055.jpeg" id="rightTab-gr55" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 55. Assembly of Plitidepsin Peptidic Fragment <b>326</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch55"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch56" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Scheme 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0056.jpeg" id="rightTab-gr56" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 56. Preparation of Plitidepsin Ketoester Fragment <b>323</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch57" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Scheme 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0057.jpeg" id="rightTab-gr57" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 57. Preparation of Plitidepsin Carboxylic Acid <b>325</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch57"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch58" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Scheme 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0058.jpeg" id="rightTab-gr58" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 58. Construction of Plitidepsin Peptide Fragment <b>338</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch59" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Scheme 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0059.jpeg" id="rightTab-gr59" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 59. Final Assembly of Plitidepsin (<b>XXXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch60" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Scheme 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0061.jpeg" id="rightTab-gr60" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 60. Construction of Plitidepsin Amino Acid Derivative <b>344</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch60"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch61" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Scheme 61</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0062.jpeg" id="rightTab-gr61" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 61. Synthesis of Pyrotinib Maleate (<b>XXXIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch61"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch62" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Scheme 62</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0063.jpeg" id="rightTab-gr62" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 62. Synthesis of Pyrotinib Acid <b>348</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch62"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch63" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Scheme 63</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0064.jpeg" id="rightTab-gr63" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 63. Synthesis of Talazoparib Tosylate (<b>XXXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch63"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch64" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Scheme 64</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0065.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0065.jpeg" id="rightTab-gr64" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 64. Synthesis of Omidenepag Isopropyl (<b>XXXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch64"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch65" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Scheme 65</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0066.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0066.jpeg" id="rightTab-gr65" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 65. Synthesis of Omidenepag Isopropyl Chloromethylpyridine <b>361</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0066.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch65"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch66" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Scheme 66</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0067.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0067.jpeg" id="rightTab-gr66" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 66. Synthesis of Tezacaftor Cyclopropylacetic Acid <b>368</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch66"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch67" data-index="69" class="article__inlineFigure"><h2 class="fig-label">Scheme 67</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0068.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0068.jpeg" id="rightTab-gr67" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 67. Synthesis of Tezacaftor (<b>XXXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0068.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch67"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch68" data-index="70" class="article__inlineFigure"><h2 class="fig-label">Scheme 68</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0069.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0069.jpeg" id="rightTab-gr68" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 68. Synthesis of Tezacaftor Alkyne <b>373</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0069.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch68"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch69" data-index="71" class="article__inlineFigure"><h2 class="fig-label">Scheme 69</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0070.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0070.jpeg" id="rightTab-gr69" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 69. Synthesis of Segesterone Acetate (<b>XXXVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0070.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch69"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch70" data-index="72" class="article__inlineFigure"><h2 class="fig-label">Scheme 70</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0072.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0072.jpeg" id="rightTab-gr70" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 70. Synthesis of Vibegron Progenitor Aminoalcohol <b>386</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0072.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch70"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch71" data-index="73" class="article__inlineFigure"><h2 class="fig-label">Scheme 71</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/medium/jm0c00345_0073.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0073.jpeg" id="rightTab-gr71" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 71. Synthesis of Vibegron (<b>XXXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00345/20201001/images/large/jm0c00345_0073.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00345&amp;id=sch71"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i136">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 216 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raju, T. N. K.</span></span> <span> </span><span class="NLM_article-title">The Nobel Chronicles. 1988: James Whyte Black, (B 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1022</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)74775-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0140-6736%2805%2974775-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10768469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=1022&author=T.+N.+K.+Raju&title=The+Nobel+Chronicles.+1988%3A+James+Whyte+Black%2C+%28B+1924%29%2C+Gertrude+Elion+%281918-99%29%2C+and+George+H+Hitchings+%281905-98%29&doi=10.1016%2FS0140-6736%2805%2974775-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)</span></div><div class="casAuthors">Raju T N</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9208</span>),
    <span class="NLM_cas:pages">1022</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTWLVzWjiD66qcneEtCi92fW6udTcc2eb_d7LGdZ08Mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D&md5=c89d64b40317d0d0cb4a76c1cceecb58</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974775-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974775-9%26sid%3Dliteratum%253Aachs%26aulast%3DRaju%26aufirst%3DT.%2BN.%2BK.%26atitle%3DThe%2520Nobel%2520Chronicles.%25201988%253A%2520James%2520Whyte%2520Black%252C%2520%2528B%25201924%2529%252C%2520Gertrude%2520Elion%2520%25281918-99%2529%252C%2520and%2520George%2520H%2520Hitchings%2520%25281905-98%2529%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D1022%26doi%3D10.1016%2FS0140-6736%2805%2974775-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2002 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.2174/1389557043487457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F1389557043487457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=14965293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=207-233&author=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2002+New+Drugs&doi=10.2174%2F1389557043487457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2002 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-233</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  Therefore, it is important to be acquainted with these new structures as well as their syntheses.  To these ends, this review covers the syntheses of 28 NCEs marketed in 2002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGx8Y2c3smk7Vg90H21EOLACvtfcHk0lj3IM0wHxczmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D&md5=d93f443a242964b39e822ecb12ddacad</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.2174%2F1389557043487457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043487457%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202002%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D207%26epage%3D233%26doi%3D10.2174%2F1389557043487457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2003 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2174/1389557043402900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F1389557043402900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=15579116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1105-1125&author=K.+K.-C.+Liuauthor=J.+Liauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2003+New+Drugs&doi=10.2174%2F1389557043402900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2003 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Li, Jin; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1125</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing new future drugs.  To these ends, this review covers the syntheses of 23 NCEs marketed in 2003.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLauPqC1hEzbVg90H21EOLACvtfcHk0liU_f9RFSfF7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO&md5=f3f6acd4fefd93ede895369105d1cefb</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F1389557043402900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043402900%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202003%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1105%26epage%3D1125%26doi%3D10.2174%2F1389557043402900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2004 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1144</span>, <span class="refDoi"> DOI: 10.2174/138955705774933329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138955705774933329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=16375759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1133-1144&author=J.+Liauthor=K.+K.-C.+Liuauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2004+New+Drugs&doi=10.2174%2F138955705774933329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2004 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1144</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as leads for designing future drugs.  To this end, this review covers the syntheses of 12 NCEs marketed in 2004, such as azacitidine, duloxetine hydrochloride, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXh0-pEnN47Vg90H21EOLACvtfcHk0liU_f9RFSfF7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P&md5=9593b6bfb38f08160e1b198f53b70a53</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.2174%2F138955705774933329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774933329%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202004%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1133%26epage%3D1144%26doi%3D10.2174%2F138955705774933329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2005 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.2174/138955707780363800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138955707780363800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=17430228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-450&author=S.+M.+Sakyaauthor=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2005+New+Drugs&doi=10.2174%2F138955707780363800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2005 new drugs</span></div><div class="casAuthors">Sakya, Subas M.; Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-450</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 22 NCEs marketed in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_TvNK-ZG2LVg90H21EOLACvtfcHk0liU_f9RFSfF7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D&md5=cdbab18a11647fe6089fc6c6ded6ede9</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.2174%2F138955707780363800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707780363800%26sid%3Dliteratum%253Aachs%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202005%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D450%26doi%3D10.2174%2F138955707780363800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2006 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.2174/138955707782795629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138955707782795629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=18220978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1255-1269&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=J.+Li&title=Synthetic+Approaches+to+the+2006+New+Drugs&doi=10.2174%2F138955707782795629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2006 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1255-1269</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 16 NCEs marketed in 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX9HJKV9Z-pLVg90H21EOLACvtfcHk0lh03bg4NagAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K&md5=4d0a4be2d4e258c11f73792380a40078</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.2174%2F138955707782795629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707782795629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202006%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1255%26epage%3D1269%26doi%3D10.2174%2F138955707782795629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2007 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.2174/138955708786786435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138955708786786435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=19075810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1526-1548&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2007+New+Drugs&doi=10.2174%2F138955708786786435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2007 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1526-1548</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review covers the syntheses of 19 new chem. entities (NCEs) marketed in 2007.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These NCEs provide insights into mol. recognition and also serve as leads for designing future new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2ujHwEzjb7Vg90H21EOLACvtfcHk0lh03bg4NagAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D&md5=b2e378b89f153b6374a4aa375cf65fd7</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.2174%2F138955708786786435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708786786435%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202007%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1526%26epage%3D1548%26doi%3D10.2174%2F138955708786786435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2008 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1675</span>, <span class="refDoi"> DOI: 10.2174/138955709791012201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138955709791012201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20088782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1655-1675&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2008+New+Drugs&doi=10.2174%2F138955709791012201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2gR"><div class="casContent"><span class="casTitleNuber">2g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2008 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1655-1675</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 18 NCEs marketed in 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyNqyXXeUK7Vg90H21EOLACvtfcHk0lh03bg4NagAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D&md5=7c21b476dd957ab5b90c98502ee0ec2a</span></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.2174%2F138955709791012201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709791012201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202008%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1655%26epage%3D1675%26doi%3D10.2174%2F138955709791012201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2009 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2010.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=21256756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1136-1154&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=J.+Li&title=Synthetic+Approaches+to+the+2009+New+Drugs&doi=10.1016%2Fj.bmc.2010.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2hR"><div class="casContent"><span class="casTitleNuber">2h</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2009 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1154</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 21 NCEs marketed in 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhM07bPdVyP7Vg90H21EOLACvtfcHk0lh03bg4NagAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D&md5=132426fbdd026496e573cb26110b559b</span></div><a href="/servlet/linkout?suffix=cit2h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202009%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1136%26epage%3D1154%26doi%3D10.1016%2Fj.bmc.2010.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2010 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2011.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=22261026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1155-1174&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=H.+X.+Ding&title=Synthetic+Approaches+to+the+2010+New+Drugs&doi=10.1016%2Fj.bmc.2011.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2iR"><div class="casContent"><span class="casTitleNuber">2i</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2010 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Ding, Hong X.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1155-1174</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4x86l05yfrVg90H21EOLACvtfcHk0likbDUqGUB5vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D&md5=e4a5130168e87de1a00a090241a54412</span></div><a href="/servlet/linkout?suffix=cit2i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202010%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1155%26epage%3D1174%26doi%3D10.1016%2Fj.bmc.2011.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2011 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=23623674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&author=H.+X.+Dingauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2011+New+Drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2jR"><div class="casContent"><span class="casTitleNuber">2j</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2011 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2795-2825</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 26 NCEs that were launched in the world in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4leMAGdR_wLVg90H21EOLACvtfcHk0likbDUqGUB5vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D&md5=07079afb3ea7459e73455de425e5d756</span></div><a href="/servlet/linkout?suffix=cit2j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202011%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2k"><span><span class="NLM_label">(k) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2012 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2014.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=24629448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2005-2032&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2012+New+Drugs&doi=10.1016%2Fj.bmc.2014.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2kR"><div class="casContent"><span class="casTitleNuber">2k</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2012 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent a privileged structure for a particular biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two addnl. drugs which were launched at the end of 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C7y-_vIFErVg90H21EOLACvtfcHk0likbDUqGUB5vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D&md5=bb629a07ee4cfa5efe4f8b2ca0003410</span></div><a href="/servlet/linkout?suffix=cit2k&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202012%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2005%26epage%3D2032%26doi%3D10.1016%2Fj.bmc.2014.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2013 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2015.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=25797159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1895-1922&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2013+New+Drugs&doi=10.1016%2Fj.bmc.2015.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2lR"><div class="casContent"><span class="casTitleNuber">2l</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2013 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1895-1922</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83u4l4iyn9LVg90H21EOLACvtfcHk0lh1h71orZDM0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D&md5=b64a1ec20260b828d7f6de0e0a1319b0</span></div><a href="/servlet/linkout?suffix=cit2l&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202013%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D1895%26epage%3D1922%26doi%3D10.1016%2Fj.bmc.2015.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27020685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2mR"><div class="casContent"><span class="casTitleNuber">2m</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2014 new drugs</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1937-1980</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkq2WCDEAgbVg90H21EOLACvtfcHk0lh1h71orZDM0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D&md5=a5ce03081110edb2b616006c73d14650</span></div><a href="/servlet/linkout?suffix=cit2m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2015</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6480</span>– <span class="NLM_lpage">6515</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2n&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6480-6515&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2015&doi=10.1021%2Facs.jmedchem.7b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2nR"><div class="casContent"><span class="casTitleNuber">2n</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2015</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K. -C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6480-6515</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 29 new chem. entities (NCEs) that were approved for the first time in 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5OCn9h-Lu07Vg90H21EOLACvtfcHk0lh1h71orZDM0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D&md5=b10c1f677c2f4a216b11a4c89e8b3683</span></div><a href="/servlet/linkout?suffix=cit2n&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00010%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202015%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6480%26epage%3D6515%26doi%3D10.1021%2Facs.jmedchem.7b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2o"><span><span class="NLM_label">(o) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to New Drugs Approved During 2016</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7004</span>– <span class="NLM_lpage">7031</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2o&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7004-7031&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+New+Drugs+Approved+During+2016&doi=10.1021%2Facs.jmedchem.8b00260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2oR"><div class="casContent"><span class="casTitleNuber">2o</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to New Drugs Approved During 2016</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7004-7031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review discusses the published syntheses of the nineteen new chem. entities approved for the first time by a governing body anywhere in the world in 2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr16l1kfs1KlbVg90H21EOLACvtfcHk0ljOxLrSDPnHbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D&md5=183bbabe40dbfd7b7cfbcd94fd55f0d0</span></div><a href="/servlet/linkout?suffix=cit2o&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00260%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520New%2520Drugs%2520Approved%2520During%25202016%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7004%26epage%3D7031%26doi%3D10.1021%2Facs.jmedchem.8b00260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2p"><span><span class="NLM_label">(p) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInturff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2017</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7340</span>– <span class="NLM_lpage">7382</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2p&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Wqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7340-7382&author=A.+C.+Flickauthor=C.+A.+Leverettauthor=H.+X.+Dingauthor=E.+McInturffauthor=S.+J.+Finkauthor=C.+J.+Helalauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2017&doi=10.1021%2Facs.jmedchem.9b00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2pR"><div class="casContent"><span class="casTitleNuber">2p</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2017</span></div><div class="casAuthors">Flick, Andrew C.; Leverett, Carolyn A.; Ding, Hong X.; McInturff, Emma; Fink, Sarah J.; Helal, Christopher J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7340-7382</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 31 new chem. entities approved for the first time globally in 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozpSoktvArg7Vg90H21EOLACvtfcHk0ljOxLrSDPnHbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Wqt7g%253D&md5=83863eeaaadfcaab14c45e0ace932455</span></div><a href="/servlet/linkout?suffix=cit2p&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00196%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DMcInturff%26aufirst%3DE.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202017%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7340%26epage%3D7382%26doi%3D10.1021%2Facs.jmedchem.9b00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graul, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruces, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, M.</span></span> <span> </span><span class="NLM_article-title">The Year’s New Drugs & Biologics 2018: Part I</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">35</span>, <span class="refDoi"> DOI: 10.1358/dot.2019.55.1.2959663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdot.2019.55.1.2959663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cfhtFWqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=35&author=A.+I.+Graulauthor=P.+Pinaauthor=E.+Crucesauthor=M.+Stringer&title=The+Year%E2%80%99s+New+Drugs+%26+Biologics+2018%3A+Part+I&doi=10.1358%2Fdot.2019.55.1.2959663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The year's new drugs and biologics 2018: Part I</span></div><div class="casAuthors">Graul A I; Pina P; Cruces E; Stringer M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-87</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Sixty-four new drugs and biologics reached their first global markets in 2018, the greatest number in at least a decade.  In addition, 19 important new line extensions (new indications, new combinations or new formulations of previously marketed drugs) were introduced over the course of 2018.  Twenty-three other new products and new line extensions were approved but not launched before December 31.  As has been the trend in recent years, oncology was the most active therapeutic area in terms of new launches, with cancer drugs accounting for 25% of all novel drugs and biologics introduced worldwide last year.  Eight first-in-class agents were launched for the first time in 2018, including the first RNA interference agent as well as the photo-finish approval and rollout of the first three members of a radically different class of non-vasoconstricting antimigraine agents, the anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies.  Twenty-nine of the drugs launched last year were designated orphan drugs, reflecting the continued upswing in investment in the area of neglected diseases.  This is especially true in the U.S., which welcomed 25 of the newly launched orphan drugs.  Overall, the U.S. was the most active market for new drugs and biologics, accounting for two-thirds of all new launches in 2018.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa2AZtp5SCeIYPsCkJIw00fW6udTcc2eaRvFNackkamrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfhtFWqtg%253D%253D&md5=047c9e036c80b4dbb94c9bb6d144fabb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1358%2Fdot.2019.55.1.2959663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2019.55.1.2959663%26sid%3Dliteratum%253Aachs%26aulast%3DGraul%26aufirst%3DA.%2BI.%26aulast%3DPina%26aufirst%3DP.%26aulast%3DCruces%26aufirst%3DE.%26aulast%3DStringer%26aufirst%3DM.%26atitle%3DThe%2520Year%25E2%2580%2599s%2520New%2520Drugs%2520%2526%2520Biologics%25202018%253A%2520Part%2520I%26jtitle%3DDrugs%2520Today%26date%3D2019%26volume%3D55%26spage%3D35%26doi%3D10.1358%2Fdot.2019.55.1.2959663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span>For a more
detailed description of the medicinal chemistry strategy, preclinical
and clinical pharmacology of these drugs, see the following: <span> </span><span class="NLM_article-title">To Market, To Market—2018</span>. In  <i>2019
Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>, Ed.; <span class="NLM_publisher-name">ACS Division of Medicinal Chemistry</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, <span class="NLM_year">2019</span>; Vol.  <span class="NLM_volume">54</span>, pp  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">596</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=469-596&author=J.+J.+Bronson&title=2019%0AMedicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26atitle%3DTo%2520Market%252C%2520To%2520Market%25E2%2580%25942018%26btitle%3D2019%250AMedicinal%2520Chemistry%2520Reviews%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26pub%3DACS%2520Division%2520of%2520Medicinal%2520Chemistry%26date%3D2019%26volume%3D54%26spage%3D469%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, A.</span></span> <span> </span><span class="NLM_article-title">Eravacycline</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1358/dof.2014.039.04.2135181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdof.2014.039.04.2135181" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=247-256&author=S.+Chopraauthor=A.+Dasgupta&title=Eravacycline&doi=10.1358%2Fdof.2014.039.04.2135181"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1358%2Fdof.2014.039.04.2135181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2014.039.04.2135181%26sid%3Dliteratum%253Aachs%26aulast%3DChopra%26aufirst%3DS.%26aulast%3DDasgupta%26aufirst%3DA.%26atitle%3DEravacycline%26jtitle%3DDrugs%2520Future%26date%3D2014%26volume%3D39%26spage%3D247%26epage%3D256%26doi%3D10.1358%2Fdof.2014.039.04.2135181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Eravacycline: A Review in Complicated Intra-Abdominal Infections</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01067-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-01067-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30783960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=315-324&author=L.+J.+Scott&title=Eravacycline%3A+A+Review+in+Complicated+Intra-Abdominal+Infections&doi=10.1007%2Fs40265-019-01067-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Eravacycline: A Review in Complicated Intra-Abdominal Infections</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">315-324</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Eravacycline (Xerava), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-pos. and -neg. bacterial strains expressing certain common tetracycline-specific acquired resistance mechanisms.  In vitro, eravacycline exhibits potent activity against a broad spectrum of clin. relevant Gram-pos. and -neg. aerobic and anaerobic bacteria.  I.v. eravacycline is approved in several countries for the treatment of complicated intra-abdominal infections (cIAIs) in adult patients.  In two pivotal double-blind, multinational trials in this patient population, eravacycline (infusion ≈ 1 h) was noninferior to i.v. ertapenem or meropenem at the test-of-cure visit in terms of clin. response rates in all prespecified populations.  Eravacycline had an acceptable tolerability profile, with infusion site reactions, nausea, vomiting and diarrhoea the most commonly reported adverse reactions, most of which were of mild to moderate severity.  Given its broad spectrum of activity against common clin. relevant pathogens (including those expressing certain tetracycline- and other antibacterial-specific acquired resistance mechanisms) and its more potent in vitro activity and better tolerability profile than tigecycline, eravacycline provides a novel emerging option for the treatment of adult patients with cIAIs, esp. as empirical therapy when coverage of resistant pathogens is required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpakHQfiT0eebVg90H21EOLACvtfcHk0lgGnR8QljaOIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrY%253D&md5=3f0eef4a8789cc5a8dd0ff6ee9dc6a18</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01067-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01067-3%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DEravacycline%253A%2520A%2520Review%2520in%2520Complicated%2520Intra-Abdominal%2520Infections%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D315%26epage%3D324%26doi%3D10.1007%2Fs40265-019-01067-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenitsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorityala, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagace-Wiens, P. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoban, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlowsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0545-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-016-0545-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=26863149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=567-588&author=G.+G.+Zhanelauthor=D.+Cheungauthor=H.+Adamauthor=S.+Zelenitskyauthor=A.+Goldenauthor=F.+Schweizerauthor=B.+Gorityalaauthor=P.+R.+S.+Lagace-Wiensauthor=A.+Walktyauthor=A.+S.+Ginauthor=D.+J.+Hobanauthor=J.+A.+Karlowsky&title=Review+of+Eravacycline%2C+a+Novel+Fluorocycline+Antibacterial+Agent&doi=10.1007%2Fs40265-016-0545-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent</span></div><div class="casAuthors">Zhanel, George G.; Cheung, Doris; Adam, Heather; Zelenitsky, Sheryl; Golden, Alyssa; Schweizer, Frank; Gorityala, Bala; Lagace-Wiens, Philippe R. S.; Walkty, Andrew; Gin, Alfred S.; Hoban, Daryl J.; Karlowsky, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">567-588</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Eravacycline is an investigational, synthetic fluorocycline antibacterial agent that is structurally similar to tigecycline with two modifications to the D-ring of its tetracycline core: a fluorine atom replaces the dimethylamine moiety at C-7 and a pyrrolidinoacetamido group replaces the 2-tertiary-Bu glycylamido at C-9.  Like other tetracyclines, eravacycline inhibits bacterial protein synthesis through binding to the 30S ribosomal subunit.  Eravacycline demonstrates broad-spectrum antimicrobial activity against Gram-pos., Gram-neg., and anaerobic bacteria with the exception of Pseudomonas aeruginosa.  Eravacycline is two- to fourfold more potent than tigecycline vs. Gram-pos. cocci and two- to eightfold more potent than tigecycline vs. Gram-neg. bacilli.  I.v. eravacycline demonstrates linear pharmacokinetics that have been described by a four-compartment model.  Oral bioavailability of eravacycline is estd. at 28 % (range 26-32 %) and a single oral dose of 200 mg achieves a max. plasma concn. (Cmax) and area under the plasma concn.-time curve from 0 to infinity (AUC0-∞) of 0.23 ± 0.04 mg/L and 3.34 ± 1.11 mg·h/L, resp.  A population pharmacokinetic study of i.v. (IV) eravacycline demonstrated a mean steady-state vol. of distribution (Vss) of 320 L or 4.2 L/kg, a mean terminal elimination half-life (t1/2) of 48 h, and a mean total clearance (CL) of 13.5 L/h.  In a neutropenic murine thigh infection model, the pharmacodynamic parameter that demonstrated the best correlation with antibacterial response was the ratio of area under the plasma concn.-time curve over 24 h to the min. inhibitory concn. (AUC0-24h/MIC).  Several animal model studies including mouse systemic infection, thigh infection, lung infection, and pyelonephritis models have been published and demonstrated the in vivo efficacy of eravacycline.  A phase II clin. trial evaluating the efficacy and safety of eravacycline in the treatment of community-acquired complicated intra-abdominal infection (cIAI) has been published as well, and phase III clin. trials in cIAI and complicated urinary tract infection (cUTI) have been completed.  The eravacycline phase III program, known as IGNITE (Investigating Gram-Neg. Infections Treated with Eravacycline), investigated its safety and efficacy in cIAI (IGNITE 1) and cUTI (IGNITE 2).  Eravacycline met the primary endpoint in IGNITE 1, while data anal. for IGNITE 2 is currently ongoing.  Common adverse events reported in phase I-III studies included gastrointestinal effects such as nausea and vomiting.  Eravacycline is a promising i.v. and oral fluorocycline that may offer an alternative treatment option for patients with serious infections, particularly those caused by multidrug-resistant Gram-neg. pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppVXX7DWzsV7Vg90H21EOLACvtfcHk0lgGnR8QljaOIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGrsr8%253D&md5=ae7ad3f07bc0c2652e0b0257f63a5d52</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0545-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0545-8%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DCheung%26aufirst%3DD.%26aulast%3DAdam%26aufirst%3DH.%26aulast%3DZelenitsky%26aufirst%3DS.%26aulast%3DGolden%26aufirst%3DA.%26aulast%3DSchweizer%26aufirst%3DF.%26aulast%3DGorityala%26aufirst%3DB.%26aulast%3DLagace-Wiens%26aufirst%3DP.%2BR.%2BS.%26aulast%3DWalkty%26aufirst%3DA.%26aulast%3DGin%26aufirst%3DA.%2BS.%26aulast%3DHoban%26aufirst%3DD.%2BJ.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DReview%2520of%2520Eravacycline%252C%2520a%2520Novel%2520Fluorocycline%2520Antibacterial%2520Agent%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D567%26epage%3D588%26doi%3D10.1007%2Fs40265-016-0545-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brubaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, A. G.</span></span> <span> </span><span class="NLM_article-title">A Practical, Enantioselective Synthetic Route to a Key Precursor to the Tetracycline Antibiotics</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3523</span>– <span class="NLM_lpage">3525</span>, <span class="refDoi"> DOI: 10.1021/ol071377d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol071377d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovF2murs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=3523-3525&author=J.+D.+Brubakerauthor=A.+G.+Myers&title=A+Practical%2C+Enantioselective+Synthetic+Route+to+a+Key+Precursor+to+the+Tetracycline+Antibiotics&doi=10.1021%2Fol071377d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">A Practical, Enantioselective Synthetic Route to a Key Precursor to the Tetracycline Antibiotics</span></div><div class="casAuthors">Brubaker, Jason D.; Myers, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3523-3525</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonracemic dihydronaphthoisoxazoledione I (R = tert-butyldimethylsilyl), an intermediate in the convergent prepn. of tetracycline antibiotics and their analogs, is prepd. in five steps and 29% overall yield from 3-methoxy-2-furancarboxaldehyde (prepd. in one step from 3-methoxyfuran) and 3-benzyloxy-5-isoxazolecarboxaldehyde (II; prepd. in two steps from com. available material, no data); using this route, up to 40 g of material have been prepd. at a time.  Enantioselective addn. of divinylzinc to II in the presence of a nonracemic lithium morpholinylethanolate derived from (1S,2R)-norephedrine followed by mesylation of the nonracemic secondary alc. and substitution of the mesylate with dimethylamine provides α-vinylisoxazolemethylamine III (R1 = H) in 93% ee; divinylzinc is prepd. in situ from vinylmagnesium bromide and zinc chloride as a soln. which may be stored for up to 2 mo with no loss of yield or enantioselectivity in subsequent addn.  III (R1 = H) is also prepd. in five steps from II by addn. of vinylmagnesium bromide, enzymic resoln. of the racemic secondary alc. with Amano AK lipase and vinyl acetate, hydrolysis of the acetate, mesylation of the alc., and substitution of the mesylate with dimethylamine.  Regioselective lithiation of III (R1 = H) and addn. to 3-methoxy-2-furancarboxaldehyde, stereoselective thermal intramol. Diels-Alder cycloaddn. in the presence of diisopropylethylamine and 4-methyl-2,6-di-tert-butylphenol, and Swern oxidn. of the intermediate alcs. provides the nonracemic oxanaphthoisoxazolone IV in 57% yield; lithiation and iodination of III (R = H) to give III (R1 = I) followed by metalation with isopropylmagnesium chloride and addn. to 3-methoxy-2-furancarboxaldehyde gives the intermediate alcs. and their Diels-Alder adducts with higher diastereoselectivities than direct lithiation of III (R = H) followed by addn.  Boron trichloride-mediated cleavage of the Me and bicyclic ethers of IV followed by silylation yields I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgcix7f7WugLVg90H21EOLACvtfcHk0lgGnR8QljaOIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovF2murs%253D&md5=7bc12de97d04ee79631c7f38c0b15d91</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1021%2Fol071377d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol071377d%26sid%3Dliteratum%253Aachs%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DMyers%26aufirst%3DA.%2BG.%26atitle%3DA%2520Practical%252C%2520Enantioselective%2520Synthetic%2520Route%2520to%2520a%2520Key%2520Precursor%2520to%2520the%2520Tetracycline%2520Antibiotics%26jtitle%3DOrg.%2520Lett.%26date%3D2007%26volume%3D9%26spage%3D3523%26epage%3D3525%26doi%3D10.1021%2Fol071377d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Charest, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brubaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, A. G.</span></span> <span> </span><span class="NLM_article-title">A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1126/science.1109755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1126%2Fscience.1109755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=15831754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOnt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=395-398&author=M.+G.+Charestauthor=C.+D.+Lernerauthor=J.+D.+Brubakerauthor=D.+R.+Siegelauthor=A.+G.+Myers&title=A+Convergent+Enantioselective+Route+to+Structurally+Diverse+6-Deoxytetracycline+Antibiotics&doi=10.1126%2Fscience.1109755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics</span></div><div class="casAuthors">Charest, Mark G.; Lerner, Christian D.; Brubaker, Jason D.; Siegel, Dionicio R.; Myers, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5720</span>),
    <span class="NLM_cas:pages">395-398</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Complex antibiotics based on natural products are almost invariably prepd. by semisynthesis, or chem. transformation of the isolated natural products.  This approach greatly limits the range of accessible structures that might be studied as new antibiotic candidates.  Here the authors report a short and enantioselective synthetic route to a diverse range of 6-deoxytetracycline antibiotics, e.g. I·HCl.  The common feature of this class is a scaffold of four linearly fused rings, labeled A through D.  The authors targeted not a single compd. but a group of structures with the D ring as a site of structural variability.  A late-stage, diastereoselective C-ring construction was used to couple structurally varied D-ring precursors with an AB precursor contg. much of the essential functionality for binding to the bacterial ribosome.  Five derivs. were synthesized from benzoic acid in yields ranging from 5 to 7% over 14 to 15 steps, and a sixth, (-)-doxycycline hydrochloride (I·HCl), was synthesized in 8.3% yield over 18 steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr34sWE_oyu0LVg90H21EOLACvtfcHk0lh7mOkEm1EsaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOnt70%253D&md5=7050921817cf4f1bae760215eaf1a7b3</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1126%2Fscience.1109755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1109755%26sid%3Dliteratum%253Aachs%26aulast%3DCharest%26aufirst%3DM.%2BG.%26aulast%3DLerner%26aufirst%3DC.%2BD.%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DSiegel%26aufirst%3DD.%2BR.%26aulast%3DMyers%26aufirst%3DA.%2BG.%26atitle%3DA%2520Convergent%2520Enantioselective%2520Route%2520to%2520Structurally%2520Diverse%25206-Deoxytetracycline%2520Antibiotics%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D395%26epage%3D398%26doi%3D10.1126%2Fscience.1109755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, A. G.</span>; <span class="NLM_string-name">Kummer, D. A.</span>; <span class="NLM_string-name">Li, D.</span>; <span class="NLM_string-name">Hecker, E.</span>; <span class="NLM_string-name">Dion, A.</span>; <span class="NLM_string-name">Wright, P. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Tetracyclines and Intermediates for the Treatment of Infection</span>. <span class="NLM_patent">WO 2010126607A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=A.+G.+Myers&author=D.+A.+Kummer&author=D.+Li&author=E.+Hecker&author=A.+Dion&author=P.+M.+Wright&title=Synthesis+of+Tetracyclines+and+Intermediates+for+the+Treatment+of+Infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DA.%2BG.%26atitle%3DSynthesis%2520of%2520Tetracyclines%2520and%2520Intermediates%2520for%2520the%2520Treatment%2520of%2520Infection%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwoody, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyfe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plamondon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutcliffe, J. A.</span></span> <span> </span><span class="NLM_article-title">Fluorocyclines. 1. 7-Fluoro-9-Pyrrolidinoacetamido-6-Demethyl-6-Deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1021/jm201465w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201465w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Smu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=597-605&author=X.-Y.+Xiaoauthor=D.+K.+Huntauthor=J.+Zhouauthor=R.+B.+Clarkauthor=N.+Dunwoodyauthor=C.+Fyfeauthor=T.+H.+Grossmanauthor=W.+J.+O%E2%80%99Brienauthor=L.+Plamondonauthor=M.+Ronnauthor=C.+Sunauthor=W.-Y.+Zhangauthor=J.+A.+Sutcliffe&title=Fluorocyclines.+1.+7-Fluoro-9-Pyrrolidinoacetamido-6-Demethyl-6-Deoxytetracycline%3A+A+Potent%2C+Broad+Spectrum+Antibacterial+Agent&doi=10.1021%2Fjm201465w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent</span></div><div class="casAuthors">Xiao, Xiao-Yi; Hunt, Diana K.; Zhou, Jingye; Clark, Roger B.; Dunwoody, Nick; Fyfe, Corey; Grossman, Trudy H.; O'Brien, William J.; Plamondon, Louis; Ronn, Magnus; Sun, Cuixiang; Zhang, Wu-Yan; Sutcliffe, Joyce A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">597-605</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This and the accompanying report (DOI: 10.1021/jm201467r) describe the design, synthesis, and evaluation of a new generation of tetracycline antibacterial agents, 7-fluoro-9-substituted-6-demethyl-6-deoxytetracyclines ("fluorocyclines"), accessible through a recently developed total synthesis approach.  These fluorocyclines possess potent antibacterial activities against multidrug resistant (MDR) Gram-pos. and Gram-neg. pathogens.  One of the fluorocyclines, 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline (I, also known as TP-434, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference, Boston, MA, Sept. 12-15, 2010, poster F1-2157), is currently undergoing phase 2 clin. trials in patients with complicated intra-abdominal infections (cIAI).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ3aZPFmJBmrVg90H21EOLACvtfcHk0lh7mOkEm1EsaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Smu7fL&md5=b976b79734bf90689531f4f584b0f78c</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1021%2Fjm201465w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201465w%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DX.-Y.%26aulast%3DHunt%26aufirst%3DD.%2BK.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DR.%2BB.%26aulast%3DDunwoody%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DC.%26aulast%3DGrossman%26aufirst%3DT.%2BH.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DW.%2BJ.%26aulast%3DPlamondon%26aufirst%3DL.%26aulast%3DRonn%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.-Y.%26aulast%3DSutcliffe%26aufirst%3DJ.%2BA.%26atitle%3DFluorocyclines.%25201.%25207-Fluoro-9-Pyrrolidinoacetamido-6-Demethyl-6-Deoxytetracycline%253A%2520A%2520Potent%252C%2520Broad%2520Spectrum%2520Antibacterial%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D597%26epage%3D605%26doi%3D10.1021%2Fjm201465w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwoody, N.</span></span> <span> </span><span class="NLM_article-title">A Divergent Route to Eravacycline</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">936</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.6b02442</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.6b02442" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCgs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2017&pages=936-943&author=W.-Y.+Zhangauthor=Q.+Cheauthor=S.+Crawfordauthor=M.+Ronnauthor=N.+Dunwoody&title=A+Divergent+Route+to+Eravacycline&doi=10.1021%2Facs.joc.6b02442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">A Divergent Route to Eravacycline</span></div><div class="casAuthors">Zhang, Wu-Yan; Che, Qinglin; Crawford, Scott; Ronn, Magnus; Dunwoody, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">936-943</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A convergent route to eravacycline has been developed by employing Michael-Dieckmann cyclization between an enone and a fully built and protected left-hand piece (LHP).  After construction of the core eravacycline structure, a deprotection reaction was developed, allowing for the isoxazole ring opening and global deprotection to be achieved in one pot.  The LHP is synthesized from readily available 4-fluoro-3-methylphenol in six steps featuring a palladium-catalyzed Ph carboxylation in the last step.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondgEBWx4BQ7Vg90H21EOLACvtfcHk0lg8yjepovKPUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCgs77O&md5=af27209be4307456ae44237d9002e623</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.6b02442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.6b02442%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.-Y.%26aulast%3DChe%26aufirst%3DQ.%26aulast%3DCrawford%26aufirst%3DS.%26aulast%3DRonn%26aufirst%3DM.%26aulast%3DDunwoody%26aufirst%3DN.%26atitle%3DA%2520Divergent%2520Route%2520to%2520Eravacycline%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2017%26volume%3D82%26spage%3D936%26epage%3D943%26doi%3D10.1021%2Facs.joc.6b02442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Xiao, X.-Y.</span>; <span class="NLM_string-name">Plamondon, L.</span>; <span class="NLM_string-name">Hunt, D. K.</span>; <span class="NLM_string-name">Clark, R. B.</span>; <span class="NLM_string-name">Zahler, R. B.</span></span> <span> </span><span class="NLM_article-title">Preparation of C7-Fluoro Substituted Tetracycline Compounds as Antibacterial Agents</span>. <span class="NLM_patent">WO2010017470A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Zhou&author=X.-Y.+Xiao&author=L.+Plamondon&author=D.+K.+Hunt&author=R.+B.+Clark&author=R.+B.+Zahler&title=Preparation+of+C7-Fluoro+Substituted+Tetracycline+Compounds+as+Antibacterial+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520C7-Fluoro%2520Substituted%2520Tetracycline%2520Compounds%2520as%2520Antibacterial%2520Agents%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwoody, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilicky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.-Y.</span></span> <span> </span><span class="NLM_article-title">Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">838</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1021/op4000219</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op4000219" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=838-845&author=M.+Ronnauthor=Z.+Zhuauthor=P.+C.+Hoganauthor=W.-Y.+Zhangauthor=J.+Niuauthor=C.+E.+Katzauthor=N.+Dunwoodyauthor=O.+Gilickyauthor=Y.+Dengauthor=D.+K.+Huntauthor=M.+Heauthor=C.-L.+Chenauthor=C.+Sunauthor=R.+B.+Clarkauthor=X.-Y.+Xiao&title=Process+R%26D+of+Eravacycline%3A+The+First+Fully+Synthetic+Fluorocycline+in+Clinical+Development&doi=10.1021%2Fop4000219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development</span></div><div class="casAuthors">Ronn, Magnus; Zhu, Zhijian; Hogan, Philip C.; Zhang, Wu-Yan; Niu, John; Katz, Christopher E.; Dunwoody, Nicholas; Gilicky, Olga; Deng, Yonghong; Hunt, Diana K.; He, Minsheng; Chen, Chi-Li; Sun, Cuixiang; Clark, Roger B.; Xiao, Xiao-Yi</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">838-845</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Process research and development of the first fully synthetic broad spectrum 7-fluorotetracycline in clin. development is described.  The process utilizes two key intermediates in a convergent approach.  The key transformation is a Michael-Dieckmann reaction between a suitable substituted arom. moiety and a key cyclohexenone deriv.  Subsequent deprotection and acylation provide the desired active pharmaceutical ingredient in good overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXTEZ7pkV0WrVg90H21EOLACvtfcHk0lg8yjepovKPUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gs7s%253D&md5=d591ae52db9e104cae0839b2e3b348c7</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fop4000219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop4000219%26sid%3Dliteratum%253Aachs%26aulast%3DRonn%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHogan%26aufirst%3DP.%2BC.%26aulast%3DZhang%26aufirst%3DW.-Y.%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DKatz%26aufirst%3DC.%2BE.%26aulast%3DDunwoody%26aufirst%3DN.%26aulast%3DGilicky%26aufirst%3DO.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DHunt%26aufirst%3DD.%2BK.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DC.-L.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DClark%26aufirst%3DR.%2BB.%26aulast%3DXiao%26aufirst%3DX.-Y.%26atitle%3DProcess%2520R%2526D%2520of%2520Eravacycline%253A%2520The%2520First%2520Fully%2520Synthetic%2520Fluorocycline%2520in%2520Clinical%2520Development%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2013%26volume%3D17%26spage%3D838%26epage%3D845%26doi%3D10.1021%2Fop4000219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilicky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwoody, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, M.</span></span> <span> </span><span class="NLM_article-title">Process Research and Development of TP-808: A Key Intermediate for the Manufacture of Synthetic Tetracyclines</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVWht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=377-386&author=W.-Y.+Zhangauthor=C.-L.+Chenauthor=M.+Heauthor=Z.+Zhuauthor=P.+Hoganauthor=O.+Gilickyauthor=N.+Dunwoodyauthor=M.+Ronn&title=Process+Research+and+Development+of+TP-808%3A+A+Key+Intermediate+for+the+Manufacture+of+Synthetic+Tetracyclines&doi=10.1021%2Facs.oprd.7b00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Process Research and Development of TP-808: A Key Intermediate for the Manufacture of Synthetic Tetracyclines</span></div><div class="casAuthors">Zhang, Wu-Yan; Chen, Chi-Li; He, Minsheng; Zhu, Zhijian; Hogan, Philip; Gilicky, Olga; Dunwoody, Nicholas; Ronn, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">377-386</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Process research, development, and manuf. of TP-808 (I), a key intermediate for the discovery and manuf. of tetracycline analogs, is described.  The process used for the prepn. of I avoids chromatog. purifications and has been substantially improved over the previously reported prepn.  The robustness of the process was demonstrated in a 76.1 kg manufg. campaign with 56% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgcvtwzUdmn7Vg90H21EOLACvtfcHk0lg8yjepovKPUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVWht7c%253D&md5=39788986d026b955611ca5ee9376e8c7</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00003%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.-Y.%26aulast%3DChen%26aufirst%3DC.-L.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHogan%26aufirst%3DP.%26aulast%3DGilicky%26aufirst%3DO.%26aulast%3DDunwoody%26aufirst%3DN.%26aulast%3DRonn%26aufirst%3DM.%26atitle%3DProcess%2520Research%2520and%2520Development%2520of%2520TP-808%253A%2520A%2520Key%2520Intermediate%2520for%2520the%2520Manufacture%2520of%2520Synthetic%2520Tetracyclines%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D377%26epage%3D386%26doi%3D10.1021%2Facs.oprd.7b00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafrance, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilicky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwoody, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, M.</span></span> <span> </span><span class="NLM_article-title">Process Research and Development of an Enantiomerically Enriched Allylic Amine, One of the Key Intermediates for the Manufacture of Synthetic Tetracyclines</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1784</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.5b00274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=1784-1795&author=W.-Y.+Zhangauthor=P.+C.+Hoganauthor=C.-L.+Chenauthor=J.+Niuauthor=Z.+Wangauthor=D.+Lafranceauthor=O.+Gilickyauthor=N.+Dunwoodyauthor=M.+Ronn&title=Process+Research+and+Development+of+an+Enantiomerically+Enriched+Allylic+Amine%2C+One+of+the+Key+Intermediates+for+the+Manufacture+of+Synthetic+Tetracyclines&doi=10.1021%2Facs.oprd.5b00274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Process Research and Development of an Enantiomerically Enriched Allylic Amine, One of the Key Intermediates for the Manufacture of Synthetic Tetracyclines</span></div><div class="casAuthors">Zhang, Wu-Yan; Hogan, Philip C.; Chen, Chi-Li; Niu, John; Wang, Zhimin; Lafrance, Danny; Gilicky, Olga; Dunwoody, Nicholas; Ronn, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1784-1795</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A robust, cost-effective, and high yielding manufg. process for enantiomerically enriched (S)-allylic amine I, a key intermediate for fully synthetic tetracyclines have been developed.  Two novel and scalable asym. vinylations resulting in high-to-excellent stereoselectivity have been developed for the key step.  The final product is purified by an efficient crystn. of a L-tartaric salt.  The process described has been used to manuf. ∼350 kg of the tartaric salt of I with 99.0% ee in 8 steps (35% overall yield) from cheap and readily available di-Me maleate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpflsR7C6Ehf7Vg90H21EOLACvtfcHk0lhv2FUNq09XRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7jN&md5=5f46cd3c6b37577215c9372412850c39</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00274%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.-Y.%26aulast%3DHogan%26aufirst%3DP.%2BC.%26aulast%3DChen%26aufirst%3DC.-L.%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLafrance%26aufirst%3DD.%26aulast%3DGilicky%26aufirst%3DO.%26aulast%3DDunwoody%26aufirst%3DN.%26aulast%3DRonn%26aufirst%3DM.%26atitle%3DProcess%2520Research%2520and%2520Development%2520of%2520an%2520Enantiomerically%2520Enriched%2520Allylic%2520Amine%252C%2520One%2520of%2520the%2520Key%2520Intermediates%2520for%2520the%2520Manufacture%2520of%2520Synthetic%2520Tetracyclines%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D1784%26epage%3D1795%26doi%3D10.1021%2Facs.oprd.5b00274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><a href="https://www.eisai.com/news/2018/news201806.html" class="extLink">https://www.eisai.com/news/2018/news201806.html</a> (accessed Dec
3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.eisai.com%2Fnews%2F2018%2Fnews201806.html+%28accessed+Dec%0A3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span> <span> </span><span class="NLM_article-title">Potential of Ravuconazole and Its Prodrugs as the New Oraltherapeutics for Onychomycosis</span>. <i>Med. Mycol. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">E93</span>– <span class="NLM_lpage">E110</span>, <span class="refDoi"> DOI: 10.3314/mmj.16-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.3314%2Fmmj.16-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27904057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVClsbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=E93-E110&author=H.+Yamaguchi&title=Potential+of+Ravuconazole+and+Its+Prodrugs+as+the+New+Oraltherapeutics+for+Onychomycosis&doi=10.3314%2Fmmj.16-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Potential of ravuconazole and its prodrugs as the new oral therapeutics for onychomycosis</span></div><div class="casAuthors">Yamaguchi, Hideyo</div><div class="citationInfo"><span class="NLM_cas:title">Medical Mycology Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e93-e110</span>CODEN:
                <span class="NLM_cas:coden">MMJEB4</span>;
        ISSN:<span class="NLM_cas:issn">2185-6486</span>.
    
            (<span class="NLM_cas:orgname">Nippon Ishinkin Gakkai</span>)
        </div><div class="casAbstract">A review.  Onychomycosis is a fungal infection of the nail app. caused by dermatophytes, Candida and nondermatophytic molds.  It is highly prevalent in the general population worldwide and also responsible for significant morbidity and complications and does not usually cure itself.  Thus, the condition needs to be treated in view of phys. and psychol. problems produced.  Currently, oral medications using terbinafine are the most effective therapy, but it has relatively limited therapeutic success, particularly for long-term management.  Such existing oral therapies are assocd. with high recurrence rates and treatment failure, as well as with potential adverse events and drug-drug interactions.  In the light of these issues, development of more efficacious and safer alternatives for the treatment of onychomycosis is warranted.  Ravuconazole and its prodrugs are promising new drug candidates for oral therapy of onychomycosis, among which a water-sol. prodrug, mono-lysine phosphoester deriv. (E1224 or BFE1224) is in the most advanced stage of clin. development: a Phase II dose-finding study has been successfully completed and Phase III comparative studies are in progress in Japan.  This review aims to summarize our current status of knowledge and information on ravuconazole and its prodrugs, particularly BFE1224, as the potential oral treatment option for onychomycosis.  It also summarize the clin. features of onychomycosis with particular stress on its etiol., epidemiol., and current therapeutic options and their limitations.  Given its clin. usefulness.  BFE1224 may become a valuable addn. to the current armamentarium for the treatment of onychomycosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHkpAaDzjBlrVg90H21EOLACvtfcHk0lhv2FUNq09XRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVClsbzI&md5=8a12fc3102afed5c1eff2444a5180ce8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3314%2Fmmj.16-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3314%252Fmmj.16-00006%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DH.%26atitle%3DPotential%2520of%2520Ravuconazole%2520and%2520Its%2520Prodrugs%2520as%2520the%2520New%2520Oraltherapeutics%2520for%2520Onychomycosis%26jtitle%3DMed.%2520Mycol.%2520J.%26date%3D2016%26volume%3D57%26spage%3DE93%26epage%3DE110%26doi%3D10.3314%2Fmmj.16-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyosawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsu, K.</span></span> <span> </span><span class="NLM_article-title">In Vitro and in Vivo Antifungal Activities of ER-30346, a Novel Oral Triazole with a Broad Antifungal Spectrum</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2242</span>, <span class="refDoi"> DOI: 10.1128/AAC.40.10.2237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1128%2FAAC.40.10.2237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=8891121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK28XmtVCgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=2237-2242&author=K.+Hataauthor=J.+Kimuraauthor=H.+Mikiauthor=T.+Toyosawaauthor=T.+Nakamuraauthor=K.+Katsu&title=In+Vitro+and+in+Vivo+Antifungal+Activities+of+ER-30346%2C+a+Novel+Oral+Triazole+with+a+Broad+Antifungal+Spectrum&doi=10.1128%2FAAC.40.10.2237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum</span></div><div class="casAuthors">Hata, Katsura; Kimura, Junko; Miki, Hikari; Toyosawa, Toshio; Nakamura, Toshihiro; Katsu, Kanemasa</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2237-2242</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">ER-30346 is a novel oral triazole with a broad spectrum of potent activity against a wide range of fungi.  ER-30346, with MICs at which 90% of the strains tested are inhibited (MIC90s) ranging from 0.025 to 0.78 μg/mL, was 4 to 32 times more active than itraconazole, fluconazole, and amphotericin B against Candida albicans, Candida parapsilosis, and Candida glabrata.  Against Candida tropicalis, ER-30346, with an MIC90 of 12.5 μg/mL, was 2 to >8 times more active than itraconazole and fluconazole, but was 16 times less active than amphotericin B.  ER-30346 (MIC90, 0.78 μg/mL) was four to eight times more active than fluconazole and amphotericin B and had activity comparable to that of itraconazole against Trichosporon beigelli.  The MIC90s of ER-30346 were 0.10 μg/mL for Cryptococcus neoformans and 0.39 μg/mL for Aspergillus fumigatus.  ER-30346 was 2 to 8 times more active than itraconazole and amphotericin B and 32 to >256 times more active than fluconazole.  ER-30346 also showed good activity against dermatophytes, with MICs ranging from 0.05 to 0.39 μg/mL, and its activity was comparable to or 2 to 16 times higher than those of itraconazole and amphotericin B and >32 times higher an that of fluconazole.  In vivo activity was evaluated with systemic infections in mice.  Against systemic candidiasis and cryptococcosis, ER-30346 was comparable in efficacy to fluconazole and was more effective than itraconazole.  Of the drugs tested, ER-30346 was the most effective drug against systemic aspergillosis.  The authors studied the levels of ER-30346 in mouse plasma.  The max. concn. of drug in plasma and the area under the concn.-time curve for ER-30346 showed good linearity over a range of doses from 2 to 40 mg/kg of body wt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouenlKs4-WUrVg90H21EOLACvtfcHk0lhv2FUNq09XRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtVCgsb8%253D&md5=d73bc07b2ce8ab19b50220bcfc43b770</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.40.10.2237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.40.10.2237%26sid%3Dliteratum%253Aachs%26aulast%3DHata%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DJ.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DToyosawa%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DKatsu%26aufirst%3DK.%26atitle%3DIn%2520Vitro%2520and%2520in%2520Vivo%2520Antifungal%2520Activities%2520of%2520ER-30346%252C%2520a%2520Novel%2520Oral%2520Triazole%2520with%2520a%2520Broad%2520Antifungal%2520Spectrum%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26spage%3D2237%26epage%3D2242%26doi%3D10.1128%2FAAC.40.10.2237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubouchi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, A.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Fosravuconazole L-Lysine Ethanolate, a Novel Oral Triazole Antifungal Agent, for the Treatment of Onychomycosis: A Multicenter, Double-Blind, Randomized Phase III Study</span>. <i>J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1151</span>– <span class="NLM_lpage">1159</span>, <span class="refDoi"> DOI: 10.1111/1346-8138.14607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1111%2F1346-8138.14607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30156314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=1151-1159&author=S.+Watanabeauthor=I.+Tsubouchiauthor=A.+Okubo&title=Efficacy+and+Safety+of+Fosravuconazole+L-Lysine+Ethanolate%2C+a+Novel+Oral+Triazole+Antifungal+Agent%2C+for+the+Treatment+of+Onychomycosis%3A+A+Multicenter%2C+Double-Blind%2C+Randomized+Phase+III+Study&doi=10.1111%2F1346-8138.14607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study</span></div><div class="casAuthors">Watanabe, Shinichi; Tsubouchi, Ichiro; Okubo, Akihiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1151-1159</span>CODEN:
                <span class="NLM_cas:coden">JDMYAG</span>;
        ISSN:<span class="NLM_cas:issn">0385-2407</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Fosravuconazole L-lysine ethanolate (F-RVCZ) is a prodrug of ravuconazole, a novel triazole antifungal agent, exerting broad and potent antifungal activity.  The efficacy and safety of F-RVCZ, compared with a placebo, were investigated in a multicenter, double-blind, randomized study of Japanese onychomycosis patients with 25% or more clin. involvement of the target toenail.  Subjects (n = 153) were randomly assigned to receive F-RVCZ (100 mg RVCZ,n = 101) or placebo (n = 52) p.o. once daily for 12 wk.  The primary end-point was the rate of complete cure (clin. cure [0% clin. involvement of the target toenail] plus mycol. cure [neg. potassium hydroxide examn.]) at week 48 (36-wk post-treatment visit).  Secondary end-points were changes over time in the efficacy and mycol. effect of F-RVCZ.  Safety was also evaluated.  The complete cure rate at week 48 was significantly higher with F-RVCZ (59.4%, 60/101) than the placebo (5.8%, 3/52) in the full anal. set (P < 0.001).  The mycol. cure rate at week 48 was also significantly higher with F-RVCZ (82.0%, 73/89) than the placebo (20.0%, 10/50, P < 0.001).  Regarding safety, adverse events were obsd. in 83.2% (84/101) and 80.8% (42/52), and adverse drug reactions (ADR) in 23.8% (24/101) and 3.8% (2/52) of F-RVCZ and placebo subjects, resp.  ADR were mild to moderate in severity, with none being serious.  F-RVCZ (equiv. to 100 mg ravuconazole) administrated once daily for 12 wk was more effective than placebo and tolerable in patients with onychomycosis, suggesting it to be a promising drug for onychomycosis treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKwqaKpIELq7Vg90H21EOLACvtfcHk0lhP1I5QlN8cCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqt7%252FO&md5=716f4254981a5528fb4ac58ba997bbdc</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1111%2F1346-8138.14607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1346-8138.14607%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DS.%26aulast%3DTsubouchi%26aufirst%3DI.%26aulast%3DOkubo%26aufirst%3DA.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Fosravuconazole%2520L-Lysine%2520Ethanolate%252C%2520a%2520Novel%2520Oral%2520Triazole%2520Antifungal%2520Agent%252C%2520for%2520the%2520Treatment%2520of%2520Onychomycosis%253A%2520A%2520Multicenter%252C%2520Double-Blind%252C%2520Randomized%2520Phase%2520III%2520Study%26jtitle%3DJ.%2520Dermatol.%26date%3D2018%26volume%3D45%26spage%3D1151%26epage%3D1159%26doi%3D10.1111%2F1346-8138.14607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Torrico, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Vega, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinazo, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schijman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strub-Wourgaft, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, I.</span></span> <span> </span><span class="NLM_article-title">Treatment of Adult Chronic Indeterminate Chagas Disease with Benznidazole and Three E1224 Dosing Regimens: A Proof-of-Concept, Randomised, Placebo-Controlled Trial</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30538-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS1473-3099%2817%2930538-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29352704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=419-430&author=F.+Torricoauthor=J.+Gasconauthor=L.+Ortizauthor=C.+Alonso-Vegaauthor=M.-J.+Pinazoauthor=A.+Schijmanauthor=I.+C.+Almeidaauthor=F.+Alvesauthor=N.+Strub-Wourgaftauthor=I.+Ribeiro&title=Treatment+of+Adult+Chronic+Indeterminate+Chagas+Disease+with+Benznidazole+and+Three+E1224+Dosing+Regimens%3A+A+Proof-of-Concept%2C+Randomised%2C+Placebo-Controlled+Trial&doi=10.1016%2FS1473-3099%2817%2930538-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial</span></div><div class="casAuthors">Torrico, Faustino; Gascon, Joaquim; Ortiz, Lourdes; Alonso-Vega, Cristina; Pinazo, Maria-Jesus; Schijman, Alejandro; Almeida, Igor C.; Alves, Fabiana; Strub-Wourgaft, Nathalie; Ribeiro, Isabela</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chagas disease is a major neglected vector-borne disease.  In this study, we investigated the safety and efficacy of three oral E1224 (a water-sol. ravuconazole prodrug) regimens and benznidazole vs. placebo in adult chronic indeterminate Chagas disease.  In this proof-of-concept, double-blind, randomised phase 2 clin. trial, we recruited adults (18-50 years) with confirmed diagnosis of Trypanosoma cruzi infection from two outpatient units in Bolivia.  Patients were randomised with a computer-generated randomisation list, which was stratified by center and used a block size of ten.  Patients were randomly assigned (1:1:1:1:1) to five oral treatment groups: high-dose E1224 (duration 8 wk, total dose 4000 mg), low-dose E1224 (8 wk, 2000 mg), short-dose E1224 (4 wk + 4 wk placebo, 2400 mg), benznidazole (60 days, 5 mg/kg per day), or placebo (8 wk, E1224-matched tablets).  Double-blinding was limited to the E1224 and placebo arms, and assessors were masked to all treatment allocations.  The primary efficacy endpoint was parasitol. response to E1224 at the end of treatment, assessed by PCR.  The secondary efficacy endpoints were parasitol. response to benznidazole at end of treatment, assessed by PCR; sustainability of parasitol. response until 12 mo; parasite clearance and changes in parasite load; incidence of conversion to neg. response in conventional and non-conventional (antigen trypomastigote chemiluminescent ELISA [AT CL-ELISA]) serol. response; changes in levels of biomarkers; and complete response.  The primary anal. population consisted of all randomised patients by their assigned treatment arms.  This trial is registered with ClinicalTrials.gov, no. NCT01489228.  Between July 19, 2011, and July 26, 2012, we screened 560 participants with confirmed Chagas disease, of whom 231 were enrolled and assigned to high-dose E1224 (n = 45), low-dose E1224 (n = 48), short-dose E1224 (n = 46), benznidazole (n = 45), or placebo (n = 47).  Parasite clearance was obsd. with E1224 during the treatment phase, but no sustained response was seen with low-dose and short-dose regimens, whereas 13 patients (29%, 95% CI 16.4-44.3) had sustained response with the high-dose regimen compared with four (9%, 2.4-20.4) in the placebo group (p < 0.0001).  Benznidazole had a rapid and sustained effect on parasite clearance, with 37 patients (82%, 67.9-92.0) with sustained response at 12-mo follow-up.  After 1 wk of treatment, mean quant. PCR repeated measurements showed a significant redn. in parasite load in all treatment arms vs. placebo.  Parasite levels in the low-dose and short-dose E1224 groups gradually returned to placebo levels.  Both treatments were well tolerated.  Reversible, dose-dependent liver enzyme increases were seen with E1224 and benznidazole.  A 187 (81%) participants developed treatment-emergent adverse events and six (3%) developed treatment-emergent serious adverse events.  Treatment-emergent adverse events were headaches, nausea, pruritus, peripheral neuropathy, and hypersensitivity.  E1224 is the first new chem. entity developed for Chagas disease in decades.  E1224 displayed a transient, suppressive effect on parasite clearance, whereas benznidazole showed early and sustained efficacy until 12 mo of follow-up.  Despite PCR limitations, our results support increased diagnosis and access to benznidazole std. regimen, and provide a development roadmap for novel benznidazole regimens in monotherapy and in combinations with E1224.  Drugs for Neglected Diseases initiative.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqes8nnI-YsK7Vg90H21EOLACvtfcHk0lhP1I5QlN8cCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2hsbo%253D&md5=0d71e1af60fad81c14943af5e70ad8ad</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930538-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930538-8%26sid%3Dliteratum%253Aachs%26aulast%3DTorrico%26aufirst%3DF.%26aulast%3DGascon%26aufirst%3DJ.%26aulast%3DOrtiz%26aufirst%3DL.%26aulast%3DAlonso-Vega%26aufirst%3DC.%26aulast%3DPinazo%26aufirst%3DM.-J.%26aulast%3DSchijman%26aufirst%3DA.%26aulast%3DAlmeida%26aufirst%3DI.%2BC.%26aulast%3DAlves%26aufirst%3DF.%26aulast%3DStrub-Wourgaft%26aufirst%3DN.%26aulast%3DRibeiro%26aufirst%3DI.%26atitle%3DTreatment%2520of%2520Adult%2520Chronic%2520Indeterminate%2520Chagas%2520Disease%2520with%2520Benznidazole%2520and%2520Three%2520E1224%2520Dosing%2520Regimens%253A%2520A%2520Proof-of-Concept%252C%2520Randomised%252C%2520Placebo-Controlled%2520Trial%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2018%26volume%3D18%26spage%3D419%26epage%3D430%26doi%3D10.1016%2FS1473-3099%2817%2930538-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-Q.</span></span> <span> </span><span class="NLM_article-title">Improved Chiral Synthesis of Ravuconazole</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1611</span>– <span class="NLM_lpage">1625</span>, <span class="refDoi"> DOI: 10.1080/00397910802563420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F00397910802563420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFCisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=1611-1625&author=L.+Xuauthor=M.+R.+Mullerauthor=X.+Yuauthor=B.-Q.+Zhu&title=Improved+Chiral+Synthesis+of+Ravuconazole&doi=10.1080%2F00397910802563420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Improved chiral synthesis of ravuconazole</span></div><div class="casAuthors">Xu, Lin; Muller, Marc R.; Yu, Xiong; Zhu, Bao-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1611-1625</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A short, elegant, and high yielding synthesis of ravuconazole is presented.  The key step of this synthesis is an enantioselective palladium-catalyzed chiral zinc-allene addn. reaction.  The starting materials are 2-chloro-1-(2,4-difluorophenyl)-ethanone and (R)-4-phenylbutyn-2-ol obtained from enzymic resoln. of its racemate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSPw1AMDMdoLVg90H21EOLACvtfcHk0lhP1I5QlN8cCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFCisLs%253D&md5=38be319861dd2dcd71374b3a1bd0e813</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1080%2F00397910802563420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397910802563420%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DL.%26aulast%3DMuller%26aufirst%3DM.%2BR.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DB.-Q.%26atitle%3DImproved%2520Chiral%2520Synthesis%2520of%2520Ravuconazole%26jtitle%3DSynth.%2520Commun.%26date%3D2009%26volume%3D39%26spage%3D1611%26epage%3D1625%26doi%3D10.1080%2F00397910802563420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruoka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaku, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakinuma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antifungal Activity of Novel Thiazole-Containing Triazole Antifungals. II. Optically Active ER-30346 and Its Derivatives</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1248/cpb.46.623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1248%2Fcpb.46.623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=9579038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK1cXisl2ns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1998&pages=623-630&author=A.+Tsuruokaauthor=Y.+Kakuauthor=H.+Kakinumaauthor=I.+Tsukadaauthor=M.+Yanagisawaauthor=K.+Naraauthor=T.+Naito&title=Synthesis+and+Antifungal+Activity+of+Novel+Thiazole-Containing+Triazole+Antifungals.+II.+Optically+Active+ER-30346+and+Its+Derivatives&doi=10.1248%2Fcpb.46.623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives</span></div><div class="casAuthors">Tsuruoka, Akihiko; Kaku, Yumiko; Kakinuma, Hiroyuki; Tsukada, Itaru; Yanagisawa, Manabu; Nara, Kazumasa; Naito, Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-630</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A series of novel thiazole-contg. triazole antifungals, I (R1 = Ph, 4-FC6H4, Q, etc.) and II (X = CH, N, Y = Cl, F, CSNH2, etc.), was synthesized and evaluated for antifungal activity against a variety of clin. isolated pathogenic fungi in vitro and against systemic candidosis in vivo.  These compds. showed potent antifungal activities in vitro and in vivo.  In particular, (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1 ,2,4-triazol-1-yl)-2-butanol (ER-30346) showed potent and well-balanced in vitro activities and potent in vivo efficacy, and had a good safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAnG45DQnQu7Vg90H21EOLACvtfcHk0lj8LuXnCNFd0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisl2ns7Y%253D&md5=8d2a0ee78e21be39de46d661ebe5e588</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1248%2Fcpb.46.623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.46.623%26sid%3Dliteratum%253Aachs%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DKaku%26aufirst%3DY.%26aulast%3DKakinuma%26aufirst%3DH.%26aulast%3DTsukada%26aufirst%3DI.%26aulast%3DYanagisawa%26aufirst%3DM.%26aulast%3DNara%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520Antifungal%2520Activity%2520of%2520Novel%2520Thiazole-Containing%2520Triazole%2520Antifungals.%2520II.%2520Optically%2520Active%2520ER-30346%2520and%2520Its%2520Derivatives%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1998%26volume%3D46%26spage%3D623%26epage%3D630%26doi%3D10.1248%2Fcpb.46.623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibasaki, M.</span></span> <span> </span><span class="NLM_article-title">An Enantioselective Synthesis of the Key Intermediate for Triazole Antifungal Agents; Application to the Catalytic Asymmetric Synthesis of Efinaconazole (Jublia)</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">3272</span>– <span class="NLM_lpage">3278</span>, <span class="refDoi"> DOI: 10.1021/jo500369y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo500369y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=3272-3278&author=K.+Tamuraauthor=N.+Kumagaiauthor=M.+Shibasaki&title=An+Enantioselective+Synthesis+of+the+Key+Intermediate+for+Triazole+Antifungal+Agents%3B+Application+to+the+Catalytic+Asymmetric+Synthesis+of+Efinaconazole+%28Jublia%29&doi=10.1021%2Fjo500369y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">An Enantioselective Synthesis of the Key Intermediate for Triazole Antifungal Agents; Application to the Catalytic Asymmetric Synthesis of Efinaconazole (Jublia)</span></div><div class="casAuthors">Tamura, Keiji; Kumagai, Naoya; Shibasaki, Masakatsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3272-3278</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new synthetic route, the shortest reported to date, to access a key intermediate I for the synthesis of various triazole antifungal agents was developed.  The elusive tetrasubstituted stereogenic center that is essential in advanced triazole antifungal agents was constructed via the catalytic asym. cyanosilylation of a ketone.  The subsequent transformations were performed in two one-pot operations, enhancing the overall synthetic efficiency toward the intermediate.  This streamlined synthetic approach was successfully applied to efficient enantioselective syntheses of efinaconazole (II, Jublia) and ravuconazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUWAKjsfr3wbVg90H21EOLACvtfcHk0lj8LuXnCNFd0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itL0%253D&md5=f1ddf3693a5ab8363c81b0b7bf61eae0</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1021%2Fjo500369y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo500369y%26sid%3Dliteratum%253Aachs%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DKumagai%26aufirst%3DN.%26aulast%3DShibasaki%26aufirst%3DM.%26atitle%3DAn%2520Enantioselective%2520Synthesis%2520of%2520the%2520Key%2520Intermediate%2520for%2520Triazole%2520Antifungal%2520Agents%253B%2520Application%2520to%2520the%2520Catalytic%2520Asymmetric%2520Synthesis%2520of%2520Efinaconazole%2520%2528Jublia%2529%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D3272%26epage%3D3278%26doi%3D10.1021%2Fjo500369y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, M.</span></span> <span> </span><span class="NLM_article-title">Process for the Manufacture of Enantiomerically Pure Antifungal Azoles as Ravuconazole and Isavuconazole</span>. <span class="NLM_patent">US20110087030A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=M.+Soukup&title=Process+for+the+Manufacture+of+Enantiomerically+Pure+Antifungal+Azoles+as+Ravuconazole+and+Isavuconazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSoukup%26aufirst%3DM.%26atitle%3DProcess%2520for%2520the%2520Manufacture%2520of%2520Enantiomerically%2520Pure%2520Antifungal%2520Azoles%2520as%2520Ravuconazole%2520and%2520Isavuconazole%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, M.</span></span> <span> </span><span class="NLM_article-title">Intermediate Halophenyl Derivatives and Their Use in a Process for Preparing Azole Derivatives</span>. <span class="NLM_patent">WO2003002498A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+Soukup&title=Intermediate+Halophenyl+Derivatives+and+Their+Use+in+a+Process+for+Preparing+Azole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSoukup%26aufirst%3DM.%26atitle%3DIntermediate%2520Halophenyl%2520Derivatives%2520and%2520Their%2520Use%2520in%2520a%2520Process%2520for%2520Preparing%2520Azole%2520Derivatives%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A. S. D.</span></span> <span> </span><span class="NLM_article-title">Process for Selectively Preparing (1H-1,2,4-Triazol-1-yl)alkanols, Hydrazinyl Alkanol Compound Produced by Said Process and Use Thereof</span>. <span class="NLM_patent">WO2015058272A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+S.+D.+Souza&title=Process+for+Selectively+Preparing+%281H-1%2C2%2C4-Triazol-1-yl%29alkanols%2C+Hydrazinyl+Alkanol+Compound+Produced+by+Said+Process+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSouza%26aufirst%3DA.%2BS.%2BD.%26atitle%3DProcess%2520for%2520Selectively%2520Preparing%2520%25281H-1%252C2%252C4-Triazol-1-yl%2529alkanols%252C%2520Hydrazinyl%2520Alkanol%2520Compound%2520Produced%2520by%2520Said%2520Process%2520and%2520Use%2520Thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A. S. D.</span>; <span class="NLM_string-name">Mendes, B. L. D. M. E.</span></span> <span> </span><span class="NLM_article-title">Process for Selectively Preparing (1H-1,2,4-Triazol-1-yl)alkanols, Hydrazinyl Alkanol Compound Produced by Said Process and Use Thereof</span>. <span class="NLM_patent">BR102013027313B1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=A.+S.+D.+Souza&author=B.+L.+D.+M.+E.+Mendes&title=Process+for+Selectively+Preparing+%281H-1%2C2%2C4-Triazol-1-yl%29alkanols%2C+Hydrazinyl+Alkanol+Compound+Produced+by+Said+Process+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSouza%26aufirst%3DA.%2BS.%2BD.%26atitle%3DProcess%2520for%2520Selectively%2520Preparing%2520%25281H-1%252C2%252C4-Triazol-1-yl%2529alkanols%252C%2520Hydrazinyl%2520Alkanol%2520Compound%2520Produced%2520by%2520Said%2520Process%2520and%2520Use%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shalini, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drabu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P. K.</span></span> <span> </span><span class="NLM_article-title">Advances in Synthetic Approach to and Antifungal Activity of Triazoles</span>. <i>Beilstein J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.3762/bjoc.7.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.3762%2Fbjoc.7.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=21804864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvVKrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=668-677&author=K.+Shaliniauthor=N.+Kumarauthor=S.+Drabuauthor=P.+K.+Sharma&title=Advances+in+Synthetic+Approach+to+and+Antifungal+Activity+of+Triazoles&doi=10.3762%2Fbjoc.7.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13hR"><div class="casContent"><span class="casTitleNuber">13h</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in synthetic approach to and antifungal activity of triazoles</span></div><div class="casAuthors">Shalini, Kumari; Kumar, Nitin; Drabu, Sushma; Sharma, Pramod Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Beilstein Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">668-677, No. 79</span>CODEN:
                <span class="NLM_cas:coden">BJOCBH</span>;
        ISSN:<span class="NLM_cas:issn">1860-5397</span>.
    
            (<span class="NLM_cas:orgname">Beilstein-Institut zur Foerderung der Chemischen Wissenschaften</span>)
        </div><div class="casAbstract">A review.  Several five membered ring systems, e.g., triazole, oxadiazole dithiazole and thiadiazole with three heteroatoms at sym. or asym. positions have been studied because of their interesting pharmacol. properties.  In this article emphasis is placed on the synthetic development and pharmacol. activity of the triazole moiety which exhibits a broad spectrum of pharmacol. activity such as antifungal, antibacterial, anti-inflammatory and anticancer activity, etc.  Triazoles have increased our ability to treat many fungal infections, for example, candidiasis, cryptococcal meningitis, aspergillosis etc.  However, mortality due to these infections even with antifungal therapy is still unacceptably high.  Therefore, the development of new antifungal agents targeting specific fungal structures or functions is being actively pursued.  Rapid developments in mol. mycol. have led to a concd. search for more target antifungal agents.  Although a new era of antifungal therapy has begun, presenting challenges by systemic fungal diseases, the options for treatment will have greatly expanded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1hbxjMYkeALVg90H21EOLACvtfcHk0liQxu2N9NIMxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvVKrtbw%253D&md5=646e2ee7ddbf2b7bd9205a2b38a757a0</span></div><a href="/servlet/linkout?suffix=cit13h&amp;dbid=16384&amp;doi=10.3762%2Fbjoc.7.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3762%252Fbjoc.7.79%26sid%3Dliteratum%253Aachs%26aulast%3DShalini%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DDrabu%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DP.%2BK.%26atitle%3DAdvances%2520in%2520Synthetic%2520Approach%2520to%2520and%2520Antifungal%2520Activity%2520of%2520Triazoles%26jtitle%3DBeilstein%2520J.%2520Org.%2520Chem.%26date%3D2011%26volume%3D7%26spage%3D668%26epage%3D677%26doi%3D10.3762%2Fbjoc.7.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruoka, A.</span></span> <span> </span><span class="NLM_article-title">ER-30346. Triazole Antifungal</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1358/dof.1996.021.01.333681</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdof.1996.021.01.333681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK2sXjtVWktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1996&pages=20-24&author=T.+Naitoauthor=K.+Hataauthor=A.+Tsuruoka&title=ER-30346.+Triazole+Antifungal&doi=10.1358%2Fdof.1996.021.01.333681"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13iR"><div class="casContent"><span class="casTitleNuber">13i</span><div class="casTitle"><span class="NLM_cas:atitle">ER-30346. Triazole antifungal</span></div><div class="casAuthors">Naito, Toshihiko; Hata, Katsura; Tsuruoka, Akihiko</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-24</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous</span>)
        </div><div class="casAbstract">A review with 8 refs. of synthesis, pharmacol. actions, pharmacokinetics, drug interactions, and toxicity of triazole ER-30346.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw5bY56qrk9bVg90H21EOLACvtfcHk0liQxu2N9NIMxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtVWktg%253D%253D&md5=fbd11a57e6d4c3e809b07842f1b006a5</span></div><a href="/servlet/linkout?suffix=cit13i&amp;dbid=16384&amp;doi=10.1358%2Fdof.1996.021.01.333681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.1996.021.01.333681%26sid%3Dliteratum%253Aachs%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DHata%26aufirst%3DK.%26aulast%3DTsuruoka%26aufirst%3DA.%26atitle%3DER-30346.%2520Triazole%2520Antifungal%26jtitle%3DDrugs%2520Future%26date%3D1996%26volume%3D21%26spage%3D20%26epage%3D24%26doi%3D10.1358%2Fdof.1996.021.01.333681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindrud, M. D.</span>; <span class="NLM_string-name">Kim, S.</span>; <span class="NLM_string-name">Wei, C.</span></span> <span> </span><span class="NLM_article-title">Sonic Impinging Jet Crystallization Apparatus and Process</span>. <span class="NLM_patent">WO2000044468A1</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=M.+D.+Lindrud&author=S.+Kim&author=C.+Wei&title=Sonic+Impinging+Jet+Crystallization+Apparatus+and+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLindrud%26aufirst%3DM.%2BD.%26atitle%3DSonic%2520Impinging%2520Jet%2520Crystallization%2520Apparatus%2520and%2520Process%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pesti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DelMonte, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discordia, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doubleday, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kacsur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muslehiddinoglu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olzog, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoraval, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totleben, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanyo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemishetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasylak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span> <span> </span><span class="NLM_article-title">The Process Development of Ravuconazole: An Efficient Multikilogram Scale Preparation of an Antifungal Agent</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1021/op900065c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op900065c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotl2ht74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2009&pages=716-728&author=J.+Pestiauthor=C.-K.+Chenauthor=L.+Spanglerauthor=A.+J.+DelMonteauthor=S.+Benoitauthor=D.+Berglundauthor=J.+Bienauthor=P.+Brodfuehrerauthor=Y.+Chanauthor=E.+Corbettauthor=C.+Costelloauthor=P.+DeMenaauthor=R.+P.+Discordiaauthor=W.+Doubledayauthor=Z.+Gaoauthor=S.+Gingrasauthor=J.+Grossoauthor=O.+Haasauthor=D.+Kacsurauthor=C.+Laiauthor=S.+Leungauthor=M.+Millerauthor=J.+Muslehiddinogluauthor=N.+Nguyenauthor=J.+Qiuauthor=M.+Olzogauthor=E.+Reiffauthor=D.+Thoravalauthor=M.+Totlebenauthor=D.+Vanyoauthor=P.+Vemishettiauthor=J.+Wasylakauthor=C.+Wei&title=The+Process+Development+of+Ravuconazole%3A+An+Efficient+Multikilogram+Scale+Preparation+of+an+Antifungal+Agent&doi=10.1021%2Fop900065c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The Process Development of Ravuconazole: An Efficient Multikilogram Scale Preparation of an Antifungal Agent</span></div><div class="casAuthors">Pesti, Jaan; Chen, Chien-Kuang; Spangler, Lori; DelMonte, Albert J.; Benoit, Serge; Berglund, Derek; Bien, Jeffrey; Brodfuehrer, Paul; Chan, Yeung; Corbett, Elisabeth; Costello, Carrie; DeMena, Paul; Discordia, Robert P.; Doubleday, Wendel; Gao, Zhinong; Gingras, Stephane; Grosso, John; Haas, Oscar; Kacsur, David; Lai, Chiajen; Leung, Simon; Miller, Melanie; Muslehiddinoglu, Jale; Nguyen, Nina; Qiu, Jun; Olzog, Martina; Reiff, Emily; Thoraval, Dominique; Totleben, Michael; Vanyo, Dale; Vemishetti, Purushotham; Wasylak, John; Wei, Chenkou</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">716-728</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of a safe, robust process for the prepn. of ravuconazole (I), an antifungal agent, is described.  The discovery and development of procedures enabling the efficient synthesis of multikilogram quantities of I and the process demonstration through plant scale prepns. are presented.  A controlled means to prep. a Grignard reagent and utilization of Fourier Transform IR spectroscopy (FTIR) monitoring to safely conduct the reaction is featured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptVBPIsjDg3LVg90H21EOLACvtfcHk0liQxu2N9NIMxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotl2ht74%253D&md5=982f12e8bb7b3340606acb717e536eb6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fop900065c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop900065c%26sid%3Dliteratum%253Aachs%26aulast%3DPesti%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.-K.%26aulast%3DSpangler%26aufirst%3DL.%26aulast%3DDelMonte%26aufirst%3DA.%2BJ.%26aulast%3DBenoit%26aufirst%3DS.%26aulast%3DBerglund%26aufirst%3DD.%26aulast%3DBien%26aufirst%3DJ.%26aulast%3DBrodfuehrer%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DY.%26aulast%3DCorbett%26aufirst%3DE.%26aulast%3DCostello%26aufirst%3DC.%26aulast%3DDeMena%26aufirst%3DP.%26aulast%3DDiscordia%26aufirst%3DR.%2BP.%26aulast%3DDoubleday%26aufirst%3DW.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DGingras%26aufirst%3DS.%26aulast%3DGrosso%26aufirst%3DJ.%26aulast%3DHaas%26aufirst%3DO.%26aulast%3DKacsur%26aufirst%3DD.%26aulast%3DLai%26aufirst%3DC.%26aulast%3DLeung%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMuslehiddinoglu%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DQiu%26aufirst%3DJ.%26aulast%3DOlzog%26aufirst%3DM.%26aulast%3DReiff%26aufirst%3DE.%26aulast%3DThoraval%26aufirst%3DD.%26aulast%3DTotleben%26aufirst%3DM.%26aulast%3DVanyo%26aufirst%3DD.%26aulast%3DVemishetti%26aufirst%3DP.%26aulast%3DWasylak%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DC.%26atitle%3DThe%2520Process%2520Development%2520of%2520Ravuconazole%253A%2520An%2520Efficient%2520Multikilogram%2520Scale%2520Preparation%2520of%2520an%2520Antifungal%2520Agent%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2009%26volume%3D13%26spage%3D716%26epage%3D728%26doi%3D10.1021%2Fop900065c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span>; <span class="NLM_string-name">Chen, C.-P. H.</span>; <span class="NLM_string-name">Fakes, M. G.</span>; <span class="NLM_string-name">Pendri, Y. R.</span>; <span class="NLM_string-name">Kiau, S.</span>; <span class="NLM_string-name">Vakkalagadda, B.</span></span> <span> </span><span class="NLM_article-title">Preparation of Mono-Lysine Salts of Azole Compounds as Fungicides</span>. <span class="NLM_patent">WO2006118351A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=Q.+Gao&author=C.-P.+H.+Chen&author=M.+G.+Fakes&author=Y.+R.+Pendri&author=S.+Kiau&author=B.+Vakkalagadda&title=Preparation+of+Mono-Lysine+Salts+of+Azole+Compounds+as+Fungicides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DQ.%26atitle%3DPreparation%2520of%2520Mono-Lysine%2520Salts%2520of%2520Azole%2520Compounds%2520as%2520Fungicides%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estivill, C.</span></span> <span> </span><span class="NLM_article-title">Omadacycline: Tetracycline Antibiotic</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1358/dof.2009.034.01.1324393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdof.2009.034.01.1324393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvVWhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=11-15&author=Y.+Wangauthor=R.+Castanerauthor=J.+Bolosauthor=C.+Estivill&title=Omadacycline%3A+Tetracycline+Antibiotic&doi=10.1358%2Fdof.2009.034.01.1324393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Amadacycline: tetracycline antibiotic</span></div><div class="casAuthors">Wang, Y.; Castaner, R.; Bolos, J.; Estivill, C.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-15</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Amadacycline (PTK-0796) is an aminomethylcycline antibiotic with a broad spectrum of antibacterial activity.  The agent showed potent in vitro activity against multidrug-resistant and -susceptible Gram-pos., Gram-neg., anaerobic and atypical bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium and penicillin-resistant Streptococcus pneumoniae.  Amadacycline demonstrated superior in vivo activity to other antibiotics, including vancomycin, linezolid and minocycline, against infections caused by various bacterial pathogens and its activity was not affected by the presence of other antibiotics.  In patients with complicated skin and skin structure infections, amadacycline and linezolid showed comparable safety and efficacy profiles.  No discontinuations due to adverse events and no serious drug-related adverse events were reported in the amadacycline group.  Clin. trials of both oral and i.v. formulations of amadacycline have been completed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohbqe6FcpJSrVg90H21EOLACvtfcHk0lhkVDGlGEGLZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvVWhurs%253D&md5=d0bf100a0f78f80dd80bd81e9b1567b8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1358%2Fdof.2009.034.01.1324393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2009.034.01.1324393%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCastaner%26aufirst%3DR.%26aulast%3DBolos%26aufirst%3DJ.%26aulast%3DEstivill%26aufirst%3DC.%26atitle%3DOmadacycline%253A%2520Tetracycline%2520Antibiotic%26jtitle%3DDrugs%2520Future%26date%3D2009%26volume%3D34%26spage%3D11%26epage%3D15%26doi%3D10.1358%2Fdof.2009.034.01.1324393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Omadacycline: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1931</span>– <span class="NLM_lpage">1937</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1015-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1015-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30471003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3crkt1Grsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1931-1937&author=A.+Markhamauthor=S.+J.+Keam&title=Omadacycline%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1015-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Omadacycline: First Global Approval</span></div><div class="casAuthors">Markham Anthony; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1931-1937</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Paratek Pharmaceuticals are developing omadacycline (NUZYRA®), a first-in-class orally active aminomethylcycline antibacterial, as a treatment for various bacterial infections.  The drug, which is available in intravenous and oral formulations, has a broad spectrum of antibacterial activity and was recently approved in the USA as a treatment for the treatment of community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults.  This article summarizes the milestones in the development of omadacycline leading to this first global approval for the treatment of CABP and ABSSSI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUPapfSmV6s7esJRIHUP1ofW6udTcc2ebnpiYM1oxRUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crkt1Grsg%253D%253D&md5=7d2f58c3468e05a04e52a57dc7a200c6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1015-2%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DOmadacycline%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1931%26epage%3D1937%26doi%3D10.1007%2Fs40265-018-1015-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartner, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvetovich, R. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis Development of an Aminomethylcycline Antibiotic Via an Electronically Tuned Acyliminium Friedel-Crafts Reaction</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6095</span>– <span class="NLM_lpage">6100</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2008.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.tetlet.2008.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVyis7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=6095-6100&author=J.+Y.+L.+Chungauthor=F.+W.+Hartnerauthor=R.+J.+Cvetovich&title=Synthesis+Development+of+an+Aminomethylcycline+Antibiotic+Via+an+Electronically+Tuned+Acyliminium+Friedel-Crafts+Reaction&doi=10.1016%2Fj.tetlet.2008.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis development of an aminomethylcycline antibiotic via an electronically tuned acyliminium Friedel-Crafts reaction</span></div><div class="casAuthors">Chung, John Y. L.; Hartner, Frederick W.; Cvetovich, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">6095-6100</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">With the goal of improving the synthetic efficiency, the development of a convergent synthesis of minocycline deriv. PTK0796 via an intermol. acyliminium Friedel-Crafts reaction (Tscherniac-Einhorn reaction) is described.  The entire C9 neopentylaminomethyl side chain was installed in one step using an electronically optimized chloromethylacyliminium precursor in 83% yield.  Deprotection and re-equilibration to the C4 α-epimer in the presence of CaCl2 and ethanolamine or NaOH afforded the target aminomethylcycline antibiotic.  The corresponding cryst. tosylate salt was found to exhibit improved solid state stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreS-zW9M_3PrVg90H21EOLACvtfcHk0lhkVDGlGEGLZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVyis7%252FK&md5=1864f08e452659cd4004dceaabd72402</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2008.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2008.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DJ.%2BY.%2BL.%26aulast%3DHartner%26aufirst%3DF.%2BW.%26aulast%3DCvetovich%26aufirst%3DR.%2BJ.%26atitle%3DSynthesis%2520Development%2520of%2520an%2520Aminomethylcycline%2520Antibiotic%2520Via%2520an%2520Electronically%2520Tuned%2520Acyliminium%2520Friedel-Crafts%2520Reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D2008%26volume%3D49%26spage%3D6095%26epage%3D6100%26doi%3D10.1016%2Fj.tetlet.2008.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span>; <span class="NLM_string-name">Warchol, T.</span></span> <span> </span><span class="NLM_article-title">Methods for Synthesizing and Purifying Aminoalkyl Tetracycline Compounds</span>. <span class="NLM_patent">WO2008134048A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+Johnston&author=T.+Warchol&title=Methods+for+Synthesizing+and+Purifying+Aminoalkyl+Tetracycline+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%26atitle%3DMethods%2520for%2520Synthesizing%2520and%2520Purifying%2520Aminoalkyl%2520Tetracycline%2520Compounds%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steenbergen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villano, S.</span></span> <span> </span><span class="NLM_article-title">Discovery, Pharmacology, and Clinical Profile of Omadacycline, a Novel Aminomethylcycline Antibiotic</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6409</span>– <span class="NLM_lpage">6419</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.07.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2016.07.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27469981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cks7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=6409-6419&author=S.+K.+Tanakaauthor=J.+Steenbergenauthor=S.+Villano&title=Discovery%2C+Pharmacology%2C+and+Clinical+Profile+of+Omadacycline%2C+a+Novel+Aminomethylcycline+Antibiotic&doi=10.1016%2Fj.bmc.2016.07.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18cR"><div class="casContent"><span class="casTitleNuber">18c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic</span></div><div class="casAuthors">Tanaka, S. Ken; Steenbergen, Judith; Villano, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6409-6419</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Omadacycline is novel, aminomethyl tetracycline antibiotic being developed for oral and i.v. administration for the treatment of community-acquired bacterial infections.  Omadacycline is characterized by an aminomethyl substituent at the C9 position of the core 6-member ring.  Modifications at this position result in an improved spectrum of antimicrobial activity by overcoming resistance known to affect older generation tetracyclines via ribosomal protection proteins and efflux pump mechanisms.  In vitro, omadacycline has activity against Gram-pos. and Gram-neg. aerobes, anaerobes, and atypical pathogens including Legionella and Chlamydia spp.  Omadacycline offers once daily oral and IV dosing and a clin. tolerability and safety profile that compares favorably with contemporary antibiotics used across serious community-acquired infections where resistance has rendered many less effective.  In studies in patients with complicated skin and skin structure infections, including those with MRSA infections, omadacycline exhibited an efficacy and tolerability profile that was comparable to linezolid.  Ongoing and planned clin. studies are evaluating omadacycline as monotherapy for treating serious community-acquired bacterial infections including Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP).  This review provides an overview of the discovery, microbiol., nonclin. data, and available clin. safety and efficacy data for omadacycline, with ref. to other contemporary tetracycline-derived antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2DRA8vvaNmbVg90H21EOLACvtfcHk0liS-k0Zy6FaPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cks7nN&md5=d545e70f930e1213c2dc99f8142cdcc0</span></div><a href="/servlet/linkout?suffix=cit18c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.07.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.07.029%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DS.%2BK.%26aulast%3DSteenbergen%26aufirst%3DJ.%26aulast%3DVillano%26aufirst%3DS.%26atitle%3DDiscovery%252C%2520Pharmacology%252C%2520and%2520Clinical%2520Profile%2520of%2520Omadacycline%252C%2520a%2520Novel%2520Aminomethylcycline%2520Antibiotic%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D6409%26epage%3D6419%26doi%3D10.1016%2Fj.bmc.2016.07.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.fda.gov_drugs_new-2Ddrugs-2Dfda-2Dcders-2Dnew-2Dmolecular-2Dentities-2Dand-2Dnew-2Dtherapeutic-2Dbiological-2Dproducts_novel-2Ddrug-2Dapprovals-2D2018&amp;d=DwMFoQ&amp;c=UE1eNsedaKncO0Yl_u8bfw&amp;r=MKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s&amp;m=CVuOqytT8wbiBPnC7O4FpCDUO9pblLXS3us5ofOd6v4&amp;s=R3DCQACVOkMOAMrTxYddEgl3XJs1w-cCwklKJy_myRo&amp;e=" class="extLink">https://urldefense.proofpoint.com/v2/url?u=https-3A__www.fda.gov_drugs_new-2Ddrugs-2Dfda-2Dcders-2Dnew-2Dmolecular-2Dentities-2Dand-2Dnew-2Dtherapeutic-2Dbiological-2Dproducts_novel-2Ddrug-2Dapprovals-2D2018&d=DwMFoQ&c=UE1eNsedaKncO0Yl_u8bfw&r=MKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s&m=CVuOqytT8wbiBPnC7O4FpCDUO9pblLXS3us5ofOd6v4&s=R3DCQACVOkMOAMrTxYddEgl3XJs1w-cCwklKJy_myRo&e=</a> (accessed Dec 16, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__www.fda.gov_drugs_new-2Ddrugs-2Dfda-2Dcders-2Dnew-2Dmolecular-2Dentities-2Dand-2Dnew-2Dtherapeutic-2Dbiological-2Dproducts_novel-2Ddrug-2Dapprovals-2D2018%26d%3DDwMFoQ%26c%3DUE1eNsedaKncO0Yl_u8bfw%26r%3DMKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s%26m%3DCVuOqytT8wbiBPnC7O4FpCDUO9pblLXS3us5ofOd6v4%26s%3DR3DCQACVOkMOAMrTxYddEgl3XJs1w-cCwklKJy_myRo%26e%3D+%28accessed+Dec+16%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><a href="https://www.globenewswire.com/news-release/2019/06/06/1865709/0/en/Achaogen-Inc-Announces-Results-of-Auction-for-Substantially-All-Company-Assets.html" class="extLink">https://www.globenewswire.com/news-release/2019/06/06/1865709/0/en/Achaogen-Inc-Announces-Results-of-Auction-for-Substantially-All-Company-Assets.html</a> (accessed Jan 3, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2019%2F06%2F06%2F1865709%2F0%2Fen%2FAchaogen-Inc-Announces-Results-of-Auction-for-Substantially-All-Company-Assets.html+%28accessed+Jan+3%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Galani, I.</span></span> <span> </span><span class="NLM_article-title">Plazomicin: Aminoglycoside Antibiotic</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1358/dof.2014.039.01.2095267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdof.2014.039.01.2095267" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=25-35&author=I.+Galani&title=Plazomicin%3A+Aminoglycoside+Antibiotic&doi=10.1358%2Fdof.2014.039.01.2095267"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1358%2Fdof.2014.039.01.2095267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2014.039.01.2095267%26sid%3Dliteratum%253Aachs%26aulast%3DGalani%26aufirst%3DI.%26atitle%3DPlazomicin%253A%2520Aminoglycoside%2520Antibiotic%26jtitle%3DDrugs%2520Future%26date%3D2014%26volume%3D39%26spage%3D25%26epage%3D35%26doi%3D10.1358%2Fdof.2014.039.01.2095267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M. W.</span></span> <span> </span><span class="NLM_article-title">Plazomicin for the Treatment of Patients with Complicated Urinary Tract Infection</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1358/dot.2018.54.9.2874063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdot.2018.54.9.2874063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2017&pages=513-518&author=M.+W.+McCarthy&title=Plazomicin+for+the+Treatment+of+Patients+with+Complicated+Urinary+Tract+Infection&doi=10.1358%2Fdot.2018.54.9.2874063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1358%2Fdot.2018.54.9.2874063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2018.54.9.2874063%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DM.%2BW.%26atitle%3DPlazomicin%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Complicated%2520Urinary%2520Tract%2520Infection%26jtitle%3DDrugs%2520Today%26date%3D2017%26volume%3D54%26spage%3D513%26epage%3D518%26doi%3D10.1358%2Fdot.2018.54.9.2874063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Eljaaly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alharbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alshehri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogue, J. M.</span></span> <span> </span><span class="NLM_article-title">Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-1054-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-1054-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30723876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyis74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=243-269&author=K.+Eljaalyauthor=A.+Alharbiauthor=S.+Alshehriauthor=J.+K.+Ortwineauthor=J.+M.+Pogue&title=Plazomicin%3A+A+Novel+Aminoglycoside+for+the+Treatment+of+Resistant+Gram-Negative+Bacterial+Infections&doi=10.1007%2Fs40265-019-1054-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20cR"><div class="casContent"><span class="casTitleNuber">20c</span><div class="casTitle"><span class="NLM_cas:atitle">Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections</span></div><div class="casAuthors">Eljaaly, Khalid; Alharbi, Aisha; Alshehri, Samah; Ortwine, Jessica K.; Pogue, Jason M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">243-269</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Plazomicin is a novel semisynthetic parenteral aminoglycoside that inhibits bacterial protein synthesis.  It was approved by the United States Food and Drug Administration for use in adults with complicated urinary tract infections (cUTI), including pyelonephritis.  Plazomicin displays potent in vitro activity against Enterobacteriaceae, including both extended-spectrum β-lactamase-producing and carbapenem-resistant isolates.  Plazomicin's enhanced Enterobacteriaceae activity is due to its stability to commonly encountered aminoglycoside-modifying enzymes that compromise the activity of traditional aminoglycosides.  Plazomicin resistance in Enterobacteriaceae is via modification of the ribosomal binding site due to expression of 16S rRNA methyltransferases.  Plazomicin does not display improved activity over traditional aminoglycosides against other problematic resistant Gram-neg. bacteria, namely Pseudomonas aeruginosa and Acinetobacter baumannii.  Plazomicin has been assessed in two phase III randomized controlled trials.  The EPIC trial compared plazomicin and meropenem for the management of cUTI.  In this trial, plazomicin demonstrated superiority in composite cure (81.7% vs 70.1%; difference 11.6%; 95% confidence interval [CI] 2.7-25.7) at the test-of-cure visit, which was driven by enhanced sustained microbiol. eradication.  The CARE trial compared plazomicin-based and colistin-based combinations in patients with serious infections due to carbapenem-resistant Enterobacteriaceae (CRE).  In this anal., plazomicin-based combinations were assocd. with numerically decreased mortality or serious disease-related complications when compared with colistin-based combinations (23.5% vs 50%, resp.; 90% CI -0.7 to 51.2).  Furthermore, plazomicin was also assocd. with a lower incidence of nephrotoxicity than colistin.  However, small sample sizes limit the interpretation of the findings in the CARE trial.  Plazomicin is a novel aminoglycoside that offers clinicians an addnl. option for the management of CRE infections, with superior activity compared with traditional aminoglycosides and potentially improved efficacy and decreased toxicity compared with colistin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7IMMJ9KBAxLVg90H21EOLACvtfcHk0liS-k0Zy6FaPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyis74%253D&md5=e20938baf8656c6feb17be9e9c3e77b2</span></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-1054-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-1054-3%26sid%3Dliteratum%253Aachs%26aulast%3DEljaaly%26aufirst%3DK.%26aulast%3DAlharbi%26aufirst%3DA.%26aulast%3DAlshehri%26aufirst%3DS.%26aulast%3DOrtwine%26aufirst%3DJ.%2BK.%26aulast%3DPogue%26aufirst%3DJ.%2BM.%26atitle%3DPlazomicin%253A%2520A%2520Novel%2520Aminoglycoside%2520for%2520the%2520Treatment%2520of%2520Resistant%2520Gram-Negative%2520Bacterial%2520Infections%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D243%26epage%3D269%26doi%3D10.1007%2Fs40265-019-1054-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, P.-R.</span></span> <span> </span><span class="NLM_article-title">New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01112-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-01112-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30972660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWms7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=705-714&author=S.-S.+Jeanauthor=I.+M.+Gouldauthor=W.-S.+Leeauthor=P.-R.+Hsueh&title=New+Drugs+for+Multidrug-Resistant+Gram-Negative+Organisms%3A+Time+for+Stewardship&doi=10.1007%2Fs40265-019-01112-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20dR"><div class="casContent"><span class="casTitleNuber">20d</span><div class="casTitle"><span class="NLM_cas:atitle">New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship</span></div><div class="casAuthors">Jean, Shio-Shin; Gould, Ian M.; Lee, Wen-Sen; Hsueh, Po-Ren</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">705-714</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A gradual rise in drug-resistant trends among Gram-neg. organisms, esp. carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and extensively-drug-resistant (XDR) Acinetobacter baumannii, poses an enormous threat to healthcare systems worldwide.  In the last decade, many pharmaceutical companies have devoted enormous resources to the development of new potent antibiotics against XDR Gram-neg. pathogens, particularly CRE.  Some of these novel antibiotics against CRE strains are β-lactam/β-lactamase-inhibitor combination agents, while others belong to the non-β-lactam class.  Most of these antibiotics display good in vitro activity against the producers of Ambler class A, C, and D β-lactamase, although avibactam and vaborbactam are not active in vitro against metallo-β-lactamase (MβL) enzymes.  Nevertheless, in vitro efficacy against the producers of some or all class B enzymes (New Delhi MβL, Verona integron-encoded MβL, etc) has been shown with cefepime-zidebactam, aztreonam-avibactam, VNRX-5133, cefiderocol, plazomicin, and eravacycline.  As of Feburary 2019, drugs approved for treatment of some CRE-related infections by the US Food and Drug Administration included ceftazidime-avibactam, meropenem-vaborbactam, plazomicin, and eravacycline.  Although active against extended-spectrum and AmpC β-lactamase-producing Enterobacteriaceae, delafloxacin does not show in vitro activity against CRE.  Murepavadin is shown to be specifically active against CR- and colistin-resistant P. aeruginosa strains.  Despite successful development of novel antibiotics, strict implementation of an antibiotic stewardship policy in combination with the use of well-established phenotypic tests and novel multiplex PCR methods for detection of the most commonly encountered β-lactamases/carbapenemases in hospitals is important for prescribing effective antibiotics against CRE and decreasing the resistance burden due to CRE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9yoS5Y6hw97Vg90H21EOLACvtfcHk0lhY2zqb1VF4hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWms7nI&md5=e284e1d79d5a84abbb1418d00a153650</span></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01112-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01112-1%26sid%3Dliteratum%253Aachs%26aulast%3DJean%26aufirst%3DS.-S.%26aulast%3DGould%26aufirst%3DI.%2BM.%26aulast%3DLee%26aufirst%3DW.-S.%26aulast%3DHsueh%26aufirst%3DP.-R.%26atitle%3DNew%2520Drugs%2520for%2520Multidrug-Resistant%2520Gram-Negative%2520Organisms%253A%2520Time%2520for%2520Stewardship%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D705%26epage%3D714%26doi%3D10.1007%2Fs40265-019-01112-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagabhushan, T. L.</span></span> <span> </span><span class="NLM_article-title">Process for the Manufacture of 6′-N-Alkyl Derivatives of Sisomicin and Verdamicin; Novel Intermediates Useful Therein, and Novel 6′-N-Alkylverdamicins Prepared Thereby</span>. <span class="NLM_patent">US3997524A</span>, <span class="NLM_year">1976</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1976&author=T.+L.+Nagabhushan&title=Process+for+the+Manufacture+of+6%E2%80%B2-N-Alkyl+Derivatives+of+Sisomicin+and+Verdamicin%3B+Novel+Intermediates+Useful+Therein%2C+and+Novel+6%E2%80%B2-N-Alkylverdamicins+Prepared+Thereby"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNagabhushan%26aufirst%3DT.%2BL.%26atitle%3DProcess%2520for%2520the%2520Manufacture%2520of%25206%25E2%2580%25B2-N-Alkyl%2520Derivatives%2520of%2520Sisomicin%2520and%2520Verdamicin%253B%2520Novel%2520Intermediates%2520Useful%2520Therein%252C%2520and%2520Novel%25206%25E2%2580%25B2-N-Alkylverdamicins%2520Prepared%2520Thereby%26date%3D1976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggen, J.</span>; <span class="NLM_string-name">Goldblum, A. A.</span>; <span class="NLM_string-name">Linsell, M.</span>; <span class="NLM_string-name">Dozzo, P.</span>; <span class="NLM_string-name">Moser, H. E.</span>; <span class="NLM_string-name">Hildebrandt, D.</span>; <span class="NLM_string-name">Gliedt, M.</span></span> <span> </span><span class="NLM_article-title">Antibacterial Aminoglycoside Analogs</span>. <span class="NLM_patent">WO2009067692A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Aggen&author=A.+A.+Goldblum&author=M.+Linsell&author=P.+Dozzo&author=H.+E.+Moser&author=D.+Hildebrandt&author=M.+Gliedt&title=Antibacterial+Aminoglycoside+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAggen%26aufirst%3DJ.%26atitle%3DAntibacterial%2520Aminoglycoside%2520Analogs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Aggen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldblum, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dozzo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsell, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gliedt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrandt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlasichuk, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diokno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, H. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Spectrum of the Neoglycoside ACHN-490</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4642</span>, <span class="refDoi"> DOI: 10.1128/AAC.00572-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1128%2FAAC.00572-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20805391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCitrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=4636-4642&author=J.+B.+Aggenauthor=E.+S.+Armstrongauthor=A.+A.+Goldblumauthor=P.+Dozzoauthor=M.+S.+Linsellauthor=M.+J.+Gliedtauthor=D.+J.+Hildebrandtauthor=L.+A.+Feeneyauthor=A.+Kuboauthor=R.+D.+Matiasauthor=S.+Lopezauthor=M.+Gomezauthor=K.+B.+Wlasichukauthor=R.+Dioknoauthor=G.+H.+Millerauthor=H.+E.+Moser&title=Synthesis+and+Spectrum+of+the+Neoglycoside+ACHN-490&doi=10.1128%2FAAC.00572-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and spectrum of the neoglycoside ACHN-490</span></div><div class="casAuthors">Aggen, James B.; Armstrong, Eliana S.; Goldblum, Adam A.; Dozzo, Paola; Linsell, Martin S.; Gliedt, Micah J.; Hildebrandt, Darin J.; Feeney, Lee Ann; Kubo, Aya; Matias, Rowena D.; Lopez, Sara; Gomez, Marcela; Wlasichuk, Kenneth B.; Diokno, Raymond; Miller, George H.; Moser, Heinz E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4642</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">ACHN-490 is a neoglycoside, or "next-generation" aminoglycoside (AG), that has been identified as a potentially useful agent to combat drug-resistant bacteria emerging in hospitals and health care facilities around the world.  A focused medicinal chem. campaign produced a collection of over 400 sisomicin analogs from which ACHN-490 was selected.  The authors tested ACHN-490 against two panels of Gram-neg. and Gram-pos. pathogens, many of which harbored AG resistance mechanisms.  Unlike legacy AGs, ACHN-490 was active against strains expressing known AG-modifying enzymes, including the three most common such enzymes found in Enterobacteriaceae.  ACHN-490 inhibited the growth of AG-resistant Enterobacteriaceae (MIC90, ≤4 μg/mL), with the exception of Proteus mirabilis and indole-pos. Proteae (MIC90, 8 μg/mL and 16 μg/mL, resp.).  ACHN-490 was more active alone in vitro against Pseudomonas aeruginosa and Acinetobacter baumannii isolates with AG-modifying enzymes than against those with altered permeability/efflux.  The MIC90 of ACHN-490 against AG-resistant staphylococci was 2 μg/mL.  Due to its promising in vitro and in vivo profiles, ACHN-490 has been advanced into clin. development as a new antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqj0Wwd0mWDbVg90H21EOLACvtfcHk0lhY2zqb1VF4hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCitrzO&md5=c30682c90423c6e2dfcaadf11ad7787e</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1128%2FAAC.00572-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00572-10%26sid%3Dliteratum%253Aachs%26aulast%3DAggen%26aufirst%3DJ.%2BB.%26aulast%3DArmstrong%26aufirst%3DE.%2BS.%26aulast%3DGoldblum%26aufirst%3DA.%2BA.%26aulast%3DDozzo%26aufirst%3DP.%26aulast%3DLinsell%26aufirst%3DM.%2BS.%26aulast%3DGliedt%26aufirst%3DM.%2BJ.%26aulast%3DHildebrandt%26aufirst%3DD.%2BJ.%26aulast%3DFeeney%26aufirst%3DL.%2BA.%26aulast%3DKubo%26aufirst%3DA.%26aulast%3DMatias%26aufirst%3DR.%2BD.%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DM.%26aulast%3DWlasichuk%26aufirst%3DK.%2BB.%26aulast%3DDiokno%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DG.%2BH.%26aulast%3DMoser%26aufirst%3DH.%2BE.%26atitle%3DSynthesis%2520and%2520Spectrum%2520of%2520the%2520Neoglycoside%2520ACHN-490%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D4636%26epage%3D4642%26doi%3D10.1128%2FAAC.00572-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, J. B.</span>; <span class="NLM_string-name">Miller, G. H.</span>; <span class="NLM_string-name">Aggen, J. B.</span>; <span class="NLM_string-name">Armstrong, E. S.</span></span> <span> </span><span class="NLM_article-title">Treatment of Urinary Tract Infections with Antibacterial Aminoglycoside Compounds</span>. <span class="NLM_patent">WO2010132777A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+B.+Bruss&author=G.+H.+Miller&author=J.+B.+Aggen&author=E.+S.+Armstrong&title=Treatment+of+Urinary+Tract+Infections+with+Antibacterial+Aminoglycoside+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBruss%26aufirst%3DJ.%2BB.%26atitle%3DTreatment%2520of%2520Urinary%2520Tract%2520Infections%2520with%2520Antibacterial%2520Aminoglycoside%2520Compounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, J. B.</span>; <span class="NLM_string-name">Miller, G. H.</span>; <span class="NLM_string-name">Aggen, J. B.</span>; <span class="NLM_string-name">Armstrong, E. S.</span></span> <span> </span><span class="NLM_article-title">Treatment of Klebsiella Pneumoniae Infections with Antibacterial Aminoglycoside Compounds</span>. <span class="NLM_patent">WO2010132770A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+B.+Bruss&author=G.+H.+Miller&author=J.+B.+Aggen&author=E.+S.+Armstrong&title=Treatment+of+Klebsiella+Pneumoniae+Infections+with+Antibacterial+Aminoglycoside+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBruss%26aufirst%3DJ.%2BB.%26atitle%3DTreatment%2520of%2520Klebsiella%2520Pneumoniae%2520Infections%2520with%2520Antibacterial%2520Aminoglycoside%2520Compounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Trend, R.</span>; <span class="NLM_string-name">Dappen, M.</span>; <span class="NLM_string-name">Henry, C. E.</span>; <span class="NLM_string-name">Goldblum, A. A.</span>; <span class="NLM_string-name">Aggen, J. B.</span>; <span class="NLM_string-name">Mendonca, R. F. d. J. G.</span>; <span class="NLM_string-name">Sardinha, J. C. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Antibacterial Aminoglycoside Analogs</span>. <span class="NLM_patent">WO2019079613A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=R.+Trend&author=M.+Dappen&author=C.+E.+Henry&author=A.+A.+Goldblum&author=J.+B.+Aggen&author=R.+F.+d.+J.+G.+Mendonca&author=J.+C.+F.+Sardinha&title=Synthesis+of+Antibacterial+Aminoglycoside+Analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTrend%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520Antibacterial%2520Aminoglycoside%2520Analogs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Sarecycline: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-1053-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-1053-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30659422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=325-329&author=E.+D.+Deeks&title=Sarecycline%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-1053-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Sarecycline: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-329</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Sarecycline (Seysara) is an oral, once-daily, tetracycline-class drug for which a tablet formulation is approved in the USA for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥ 9 years.  The drug was developed by Paratek and Allergen and later acquired by Almirall S.  A. (a Barcelona-based pharmaceutical company focused on medical dermatol.).  Sarceycline tablets were approved in early Oct. 2018 and are planned to be available for patients in Jan. 2019.  Sarecycline capsules have also been studied in the USA, but no recent reports of development have been identified for this formulation.  There are currently no clin. trials underway assessing sarecycline in rosacea.  This article summarizes the milestones in the development of sarecycline leading to this first approval for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBZ4V-bGzXl7Vg90H21EOLACvtfcHk0ljxoZ7jSfQ6EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqt7o%253D&md5=e80aca5a735c13d2db53224be4844967</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-1053-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-1053-4%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DSarecycline%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D325%26epage%3D329%26doi%3D10.1007%2Fs40265-019-1053-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Abato, P.</span>; <span class="NLM_string-name">Assefa, H.</span>; <span class="NLM_string-name">Berniac, J.</span>; <span class="NLM_string-name">Bhatia, B.</span>; <span class="NLM_string-name">Bowser, T.</span>; <span class="NLM_string-name">Grier, M.</span>; <span class="NLM_string-name">Honeyman, L.</span>; <span class="NLM_string-name">Ismail, M.</span>; <span class="NLM_string-name">Kim, O. K.</span>; <span class="NLM_string-name">Nelson, M.</span>; <span class="NLM_string-name">Pan, J.</span>; <span class="NLM_string-name">Verma, A.</span></span> <span> </span><span class="NLM_article-title">Substituted Tetracycline Compounds for Treatment of Bacterial Infections and Neoplasms</span>. <span class="NLM_patent">WO2008079339A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+Abato&author=H.+Assefa&author=J.+Berniac&author=B.+Bhatia&author=T.+Bowser&author=M.+Grier&author=L.+Honeyman&author=M.+Ismail&author=O.+K.+Kim&author=M.+Nelson&author=J.+Pan&author=A.+Verma&title=Substituted+Tetracycline+Compounds+for+Treatment+of+Bacterial+Infections+and+Neoplasms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbato%26aufirst%3DP.%26atitle%3DSubstituted%2520Tetracycline%2520Compounds%2520for%2520Treatment%2520of%2520Bacterial%2520Infections%2520and%2520Neoplasms%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M. L.</span>; <span class="NLM_string-name">McIntyre, L.</span></span> <span> </span><span class="NLM_article-title">Preparation of 7-Substituted Fused Ring Tetracycline Compounds as Antibiotics</span>. <span class="NLM_patent">WO2001087824A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=M.+L.+Nelson&author=L.+McIntyre&title=Preparation+of+7-Substituted+Fused+Ring+Tetracycline+Compounds+as+Antibiotics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DM.%2BL.%26atitle%3DPreparation%2520of%25207-Substituted%2520Fused%2520Ring%2520Tetracycline%2520Compounds%2520as%2520Antibiotics%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seyedi, F.</span>; <span class="NLM_string-name">Warchol, T.</span>; <span class="NLM_string-name">Grier, M.</span></span> <span> </span><span class="NLM_article-title">Methods for Synthesizing Substituted Tetracycline Compounds</span>. <span class="NLM_patent">WO2009009042A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=F.+Seyedi&author=T.+Warchol&author=M.+Grier&title=Methods+for+Synthesizing+Substituted+Tetracycline+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSeyedi%26aufirst%3DF.%26atitle%3DMethods%2520for%2520Synthesizing%2520Substituted%2520Tetracycline%2520Compounds%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span> <span> </span><span class="NLM_article-title">Baloxavir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0899-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0899-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29623652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVejsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=693-697&author=Y.-A.+Heo&title=Baloxavir%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0899-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Baloxavir: First Global Approval</span></div><div class="casAuthors">Heo, Young-A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">693-697</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Baloxavir marboxil (Xofluza; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi.  The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis.  In Feb. 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections.  Phase III development is underway in the USA, EU and other countries for this indication.  This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV1eFMLv6ePLVg90H21EOLACvtfcHk0ljxoZ7jSfQ6EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVejsr0%253D&md5=1b11d92b5dc5807b6de1d1920ed1e4e5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0899-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0899-1%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26atitle%3DBaloxavir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D693%26epage%3D697%26doi%3D10.1007%2Fs40265-018-0899-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-influenza" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-influenza</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-drug-treat-influenza+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span> <span> </span><span class="NLM_article-title">Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1177/1060028019826565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1177%2F1060028019826565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30674196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2hsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=754-759&author=T.+Yang&title=Baloxavir+Marboxil%3A+The+First+Cap-Dependent+Endonuclease+Inhibitor+for+the+Treatment+of+Influenza&doi=10.1177%2F1060028019826565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza</span></div><div class="casAuthors">Yang, Tianrui</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">754-759</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To review the pharmacol., pharmacokinetics, clin. trials, and clin. implications of baloxavir marboxil.  Data Sources: A MEDLINE search was conducted using the terms baloxavir, baloxavir marboxil, cap-dependent endonuclease inhibitor, and polymerase acidic endonuclease inhibitor.  Addnl. data were obtained from the prescribing information and relevant guidelines.  Study Selection and Data Extn.: All clin. trials were included.  Data Synthesis: Baloxavir marboxil exploits a new mechanism of action of inhibiting cap-dependent endonuclease.  Baloxavir was shown to be superior compared with placebo and noninferior compared with oseltamivir with regard to the primary end point.  Baloxavir was well tolerated in the trials.  A second phase III study investigating high-risk patients was completed with pos. results.  However, the full article is not yet published.  Relevance to Patient Care and Clin. Practice: The small amt. of literature limits baloxavir's use in certain patient populations.  Baloxavir offers advantages such as single-dose regimen, eliminating adherence concerns and lack of cross-resistance, making it an alternative for resistant viruses.  Several uncertainties remain.  Baloxavir has not been studied in hospitalized patients, patients with symptoms for >48 h, or in combination with other antiviral agents.  Furthermore, resistance to baloxavir can develop after 1 dose.  Clin. studies are ongoing to evaluate baloxavir in young pediatric patients, hospitalized patients, and in combination therapy with neuraminidase inhibitors to further elucidate baloxavir's place in therapy.  Conclusion: Baloxavir is a new antiviral medication for the treatment of influenza.  Given the new mechanism of action, baloxavir may be useful in treating patients with resistant viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNvs3TXJOB27Vg90H21EOLACvtfcHk0ljxoZ7jSfQ6EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2hsrfP&md5=bdf7716d61f468afc888890da50c47a7</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1177%2F1060028019826565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028019826565%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26atitle%3DBaloxavir%2520Marboxil%253A%2520The%2520First%2520Cap-Dependent%2520Endonuclease%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Influenza%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2019%26volume%3D53%26spage%3D754%26epage%3D759%26doi%3D10.1177%2F1060028019826565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Splawn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. C.</span></span> <span> </span><span class="NLM_article-title">Baloxavir Marboxil: A Novel Cap-Dependent Endonuclease (CEN) Inhibitor for the Treatment of Acute Uncomplicated Influenza</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">359</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1358/dot.2019.55.6.2999889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdot.2019.55.6.2999889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3MzhvV2qtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=359-366&author=S.+C.+Lockeauthor=L.+M.+Splawnauthor=J.+C.+Cho&title=Baloxavir+Marboxil%3A+A+Novel+Cap-Dependent+Endonuclease+%28CEN%29+Inhibitor+for+the+Treatment+of+Acute+Uncomplicated+Influenza&doi=10.1358%2Fdot.2019.55.6.2999889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza</span></div><div class="casAuthors">Locke S C; Splawn L M; Cho J C</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">359-366</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Baloxavir marboxil is a newly approved antiviral agent with activity against influenza via a novel mechanism of action of inhibition of cap-dependent endonuclease (CEN).  The novel agent was approved in October of 2018 in the United States for the treatment of acute uncomplicated influenza A and B in patients aged 12 years or older.  Baloxavir is given as a single weight-based dose of 40 mg orally once for patients weighing less than 80 kg and 80 mg orally once for those weighing 80 kg or more within 48 hours of symptom onset.  In comparison with current therapy, baloxavir is as effective in decreasing time to symptom alleviation as the drug of choice, oseltamivir, and significantly reduces viral load 1 day after treatment compared with placebo and oseltamivir.  In safety analyses baloxavir was well tolerated with only mild adverse events reported (nausea, headache, diarrhea, bronchitis, nasopharyngitis), thus providing a safe and reliable alternative option to current therapy for acute uncomplicated influenza.  Further studies are being conducted to evaluate the use of baloxavir in additional patient populations including pediatric patients less than 12 years of age and patients who are at high risk of complications related to influenza.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmeHYKxCnC5NXdcedVHT5tfW6udTcc2eZAKEX96PMjt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzhvV2qtg%253D%253D&md5=e823e95a1a78fc9077331887c193e39a</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1358%2Fdot.2019.55.6.2999889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2019.55.6.2999889%26sid%3Dliteratum%253Aachs%26aulast%3DLocke%26aufirst%3DS.%2BC.%26aulast%3DSplawn%26aufirst%3DL.%2BM.%26aulast%3DCho%26aufirst%3DJ.%2BC.%26atitle%3DBaloxavir%2520Marboxil%253A%2520A%2520Novel%2520Cap-Dependent%2520Endonuclease%2520%2528CEN%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Acute%2520Uncomplicated%2520Influenza%26jtitle%3DDrugs%2520Today%26date%3D2019%26volume%3D55%26spage%3D359%26epage%3D366%26doi%3D10.1358%2Fdot.2019.55.6.2999889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, M.</span>; <span class="NLM_string-name">Tomita, K.</span>; <span class="NLM_string-name">Akiyama, T.</span>; <span class="NLM_string-name">Okano, A.</span>; <span class="NLM_string-name">Miyagawa, M.</span></span> <span> </span><span class="NLM_article-title">Substituted Polycyclic Pyridone Derivative and Prodrug Thereof</span>. <span class="NLM_patent">WO2016175224A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Kawai&author=K.+Tomita&author=T.+Akiyama&author=A.+Okano&author=M.+Miyagawa&title=Substituted+Polycyclic+Pyridone+Derivative+and+Prodrug+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DM.%26atitle%3DSubstituted%2520Polycyclic%2520Pyridone%2520Derivative%2520and%2520Prodrug%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shibahara, S.</span>; <span class="NLM_string-name">Fukui, N.</span>; <span class="NLM_string-name">Maki, T.</span>; <span class="NLM_string-name">Anan, K.</span></span> <span> </span><span class="NLM_article-title">Method for Producing Substituted Polycyclic Pyridone Derivative and Crystal of Same</span>. <span class="NLM_patent">WO2017221869A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Shibahara&author=N.+Fukui&author=T.+Maki&author=K.+Anan&title=Method+for+Producing+Substituted+Polycyclic+Pyridone+Derivative+and+Crystal+of+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShibahara%26aufirst%3DS.%26atitle%3DMethod%2520for%2520Producing%2520Substituted%2520Polycyclic%2520Pyridone%2520Derivative%2520and%2520Crystal%2520of%2520Same%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shishido, T.</span>; <span class="NLM_string-name">Noshi, T.</span>; <span class="NLM_string-name">Yamamoto, A.</span>; <span class="NLM_string-name">Kitano, M.</span></span> <span> </span><span class="NLM_article-title">Medicine for Treating Influenza Characterized by Comprising Combination of Cap-Dependent Endonuclease Inhibitor with Anti-Influenza Drug</span>. <span class="NLM_patent">WO2017104691A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=T.+Shishido&author=T.+Noshi&author=A.+Yamamoto&author=M.+Kitano&title=Medicine+for+Treating+Influenza+Characterized+by+Comprising+Combination+of+Cap-Dependent+Endonuclease+Inhibitor+with+Anti-Influenza+Drug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShishido%26aufirst%3DT.%26atitle%3DMedicine%2520for%2520Treating%2520Influenza%2520Characterized%2520by%2520Comprising%2520Combination%2520of%2520Cap-Dependent%2520Endonuclease%2520Inhibitor%2520with%2520Anti-Influenza%2520Drug%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, M.</span>; <span class="NLM_string-name">Tomita, K.</span>; <span class="NLM_string-name">Akiyama, T.</span>; <span class="NLM_string-name">Okano, A.</span>; <span class="NLM_string-name">Miyagawa, M.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Compositions Containing Substituted Polycyclic Pyridone Derivatives and Prodrug Thereof</span>. <span class="NLM_patent">US2019169206A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=M.+Kawai&author=K.+Tomita&author=T.+Akiyama&author=A.+Okano&author=M.+Miyagawa&title=Pharmaceutical+Compositions+Containing+Substituted+Polycyclic+Pyridone+Derivatives+and+Prodrug+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKawai%26aufirst%3DM.%26atitle%3DPharmaceutical%2520Compositions%2520Containing%2520Substituted%2520Polycyclic%2520Pyridone%2520Derivatives%2520and%2520Prodrug%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bam, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niedziela-Majka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yant, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukolj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazerwith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span> <span> </span><span class="NLM_article-title">Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7086</span>– <span class="NLM_lpage">7097</span>, <span class="refDoi"> DOI: 10.1128/AAC.01474-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1128%2FAAC.01474-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27645238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlWjt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=7086-7097&author=M.+Tsiangauthor=G.+S.+Jonesauthor=J.+Goldsmithauthor=A.+Mulatoauthor=D.+Hansenauthor=E.+Kanauthor=L.+Tsaiauthor=R.+A.+Bamauthor=G.+Stepanauthor=K.+M.+Strayauthor=A.+Niedziela-Majkaauthor=S.+R.+Yantauthor=H.+Yuauthor=G.+Kukoljauthor=T.+Cihlarauthor=S.+E.+Lazerwithauthor=K.+L.+Whiteauthor=H.+Jin&title=Antiviral+Activity+of+Bictegravir+%28GS-9883%29%2C+a+Novel+Potent+HIV-1+Integrase+Strand+Transfer+Inhibitor+with+an+Improved+Resistance+Profile&doi=10.1128%2FAAC.01474-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile</span></div><div class="casAuthors">Tsiang, Manuel; Jones, Gregg S.; Goldsmith, Joshua; Mulato, Andrew; Hansen, Derek; Kan, Elaine; Tsai, Luong; Bam, Rujuta A.; Stepan, George; Stray, Kirsten M.; Niedziela-Majka, Anita; Yant, Stephen R.; Yu, Helen; Kukolj, George; Cihlar, Tomas; Lazerwith, Scott E.; White, Kirsten L.; Jin, Haolun</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7086-7097</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concn. [IC50] of 7.5 ± 0.3 nM) and HIV-1 integration in cells.  BIC exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T lymphocytes, with 50% effective concns. ranging from 1.5 to 2.4 nM and selectivity indexes up to 8,700 relative to cytotoxicity.  BIC exhibits synergistic in vitro antiviral effects in pairwise combinations with tenofovir alafenamide, emtricitabine, or darunavir and maintains potent antiviral activity against HIV-1 variants resistant to other classes of antiretrovirals.  BIC displayed an in vitro resistance profile that was markedly improved compared to the integrase strand transfer inhibitors (INSTIs) raltegravir (RAL) and elvitegravir (EVG), and comparable to that of dolutegravir (DTG), against nine INSTI-resistant site-directed HIV-1 mutants.  BIC displayed statistically improved antiviral activity relative to EVG, RAL, and DTG against a panel of 47 patient-derived HIV-1 isolates with highlevel INSTI resistance; 13 of 47 tested isolates exhibited >2-fold lower resistance to BIC than DTG.  In dose-escalation expts. conducted in vitro, BIC and DTG exhibited higher barriers to resistance than EVG, selecting for HIV-1 variants with reduced phenotypic susceptibility at days 71, 87, and 20, resp.  A recombinant virus with the BIC-selected M50I/R263K dual mutations in IN exhibited only 2.8-fold reduced susceptibility to BIC compared to wild-type virus.  All BIC-selected variants exhibited low to intermediate levels of cross-resistance to RAL, DTG, and EVG (<8-fold) but remained susceptible to other classes of antiretrovirals.  A high barrier to in vitro resistance emergence for both BIC and DTG was also obsd. in viral breakthrough studies in the presence of const. clin. relevant drug concns.  The overall virol. profile of BIC supports its ongoing clin. investigation in combination with other antiretroviral agents for both treatment-naive and -experienced HIV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC24EKhD8sNbVg90H21EOLACvtfcHk0ljYFoR25kcH7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlWjt78%253D&md5=87a180a313ffaa8b03201b06a8c875ff</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.01474-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01474-16%26sid%3Dliteratum%253Aachs%26aulast%3DTsiang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DG.%2BS.%26aulast%3DGoldsmith%26aufirst%3DJ.%26aulast%3DMulato%26aufirst%3DA.%26aulast%3DHansen%26aufirst%3DD.%26aulast%3DKan%26aufirst%3DE.%26aulast%3DTsai%26aufirst%3DL.%26aulast%3DBam%26aufirst%3DR.%2BA.%26aulast%3DStepan%26aufirst%3DG.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DNiedziela-Majka%26aufirst%3DA.%26aulast%3DYant%26aufirst%3DS.%2BR.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DLazerwith%26aufirst%3DS.%2BE.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26aulast%3DJin%26aufirst%3DH.%26atitle%3DAntiviral%2520Activity%2520of%2520Bictegravir%2520%2528GS-9883%2529%252C%2520a%2520Novel%2520Potent%2520HIV-1%2520Integrase%2520Strand%2520Transfer%2520Inhibitor%2520with%2520an%2520Improved%2520Resistance%2520Profile%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D7086%26epage%3D7097%26doi%3D10.1128%2FAAC.01474-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1817</span>– <span class="NLM_lpage">1828</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1010-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1010-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30460547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1GgtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1817-1828&author=E.+D.+Deeks&title=Bictegravir%2FEmtricitabine%2FTenofovir+Alafenamide%3A+A+Review+in+HIV-1+Infection&doi=10.1007%2Fs40265-018-1010-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1817-1828</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Bictegravir is a new integrase strand transfer inhibitor (INSTI) with a high genetic barrier to the development of HIV-1 resistance.  The drug is co-formulated with the nucleos(t)ide reverse transcriptase inhibitors emtricitabine and tenofovir alafenamide (AF) in a single-tablet regimen (STR) for the once-daily treatment of HIV-1 infection in adults (bictegravir/emtricitabine/tenofovir AF; Biktarvy).  In phase 3 trials, bictegravir/emtricitabine/tenofovir AF was noninferior to dolutegravir-based therapy (dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir AF) in establishing virol. suppression in treatment-naive adults through 96 wk' treatment and, similarly, was noninferior to ongoing dolutegravir/abacavir/lamivudine or boosted elvitegravir- or protease inhibitor (PI)-based therapy in preventing virol. rebound over 48 wk in treatment-experienced patients.  No resistance emerged to any of the antiretrovirals in the STR.  Bictegravir/emtricitabine/tenofovir AF is generally well tolerated, requires no prior HLA-B*5701 testing (making it more suitable for 'rapid start' treatment), fulfils the antiretroviral regimen requirement for patients with hepatitis B virus (HBV) co-infection (i.e. contains tenofovir AF and emtricitabine, both of which are active against HBV) and can be used in renally impaired patients with creatinine clearance (CRCL) ≥ 30 mL/min.  Thus, although cost-effectiveness analyses would be beneficial, current data indicate that bictegravir/emtricitabine/tenofovir AF is a convenient initial and subsequent treatment option for adults with HIV-1 infection, including those co-infected with HBV, and provides the first non-pharmacol. boosted, INSTI-based, triple-combination STR suitable for patients with CRCL 30-50 mL/min.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9o4JdLQm3XLVg90H21EOLACvtfcHk0lj_WlBakqZa7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1GgtbbK&md5=ffec7739b3a4dda20f945a8dd3539422</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1010-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1010-7%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DBictegravir%252FEmtricitabine%252FTenofovir%2520Alafenamide%253A%2520A%2520Review%2520in%2520HIV-1%2520Infection%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1817%26epage%3D1828%26doi%3D10.1007%2Fs40265-018-1010-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biemmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisicaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogolino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sechi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotriffer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">From Ligand to Complexes. Part 2. Remarks on Human Immunodeficiency Virus Type 1 Integrase Inhibition by Beta-Diketo Acid Metal Complexes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7253</span>– <span class="NLM_lpage">7264</span>, <span class="refDoi"> DOI: 10.1021/jm800893q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800893q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlejtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7253-7264&author=A.+Bacchiauthor=M.+Biemmiauthor=M.+Carcelliauthor=F.+Cartaauthor=C.+Compariauthor=E.+Fisicaroauthor=D.+Rogolinoauthor=M.+Sechiauthor=M.+Sippelauthor=C.+A.+Sotrifferauthor=T.+W.+Sanchezauthor=N.+Neamati&title=From+Ligand+to+Complexes.+Part+2.+Remarks+on+Human+Immunodeficiency+Virus+Type+1+Integrase+Inhibition+by+Beta-Diketo+Acid+Metal+Complexes&doi=10.1021%2Fjm800893q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">From Ligand to Complexes. Part 2. Remarks on Human Immunodeficiency Virus type 1 Integrase Inhibition by β-Diketo Acid Metal Complexes</span></div><div class="casAuthors">Bacchi, Alessia; Biemmi, Mariano; Carcelli, Mauro; Carta, Fabrizio; Compari, Carlotta; Fisicaro, Emilia; Rogolino, Dominga; Sechi, Mario; Sippel, Martin; Sotriffer, Christoph A.; Sanchez, Tino W.; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7253-7264</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previously, the authors synthesized a series of β-diketo acid metal complexes as novel HIV-1 integrase (IN) inhibitors (J. Med. Chem.2006, 46, 4248-4260).  Herein, a further extension of this study is reported.  First, detailed docking studies were performed to investigate the mode of binding in the active site of the free ligands and of their metal complexes.  Second, a series of potentiometric measurements were conducted for two diketo acids chosen as model ligands, with Mn2+ and Ca2+, to outline a speciation model.  Third, the authors designed and synthesized a new set of complexes with different stoichiometries and tested them in an in vitro assay specific for IN.  Finally, the authors obtained the first x-ray structure of a metal complex with HIV-1 IN inhibition activity.  Anal. of these results supports the hypothesis that the diketo acids could act as complexes and form complexes with the metal ions on the active site of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb91JhwTAFFrVg90H21EOLACvtfcHk0lj_WlBakqZa7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlejtLvN&md5=db34155d02519041581c6021948172b8</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1021%2Fjm800893q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800893q%26sid%3Dliteratum%253Aachs%26aulast%3DBacchi%26aufirst%3DA.%26aulast%3DBiemmi%26aufirst%3DM.%26aulast%3DCarcelli%26aufirst%3DM.%26aulast%3DCarta%26aufirst%3DF.%26aulast%3DCompari%26aufirst%3DC.%26aulast%3DFisicaro%26aufirst%3DE.%26aulast%3DRogolino%26aufirst%3DD.%26aulast%3DSechi%26aufirst%3DM.%26aulast%3DSippel%26aufirst%3DM.%26aulast%3DSotriffer%26aufirst%3DC.%2BA.%26aulast%3DSanchez%26aufirst%3DT.%2BW.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DFrom%2520Ligand%2520to%2520Complexes.%2520Part%25202.%2520Remarks%2520on%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Integrase%2520Inhibition%2520by%2520Beta-Diketo%2520Acid%2520Metal%2520Complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7253%26epage%3D7264%26doi%3D10.1021%2Fjm800893q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sechi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisicaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogolino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gates, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derudas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mawsawi, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">From Ligand to Complexes: Inhibition of Human Immunodeficiency Virus Type 1 Integrase by Beta-Diketo Acid Metal Complexes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4248</span>– <span class="NLM_lpage">4260</span>, <span class="refDoi"> DOI: 10.1021/jm060193m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060193m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4248-4260&author=M.+Sechiauthor=A.+Bacchiauthor=M.+Carcelliauthor=C.+Compariauthor=E.+Duceauthor=E.+Fisicaroauthor=D.+Rogolinoauthor=P.+Gatesauthor=M.+Derudasauthor=L.+Q.+Al-Mawsawiauthor=N.+Neamati&title=From+Ligand+to+Complexes%3A+Inhibition+of+Human+Immunodeficiency+Virus+Type+1+Integrase+by+Beta-Diketo+Acid+Metal+Complexes&doi=10.1021%2Fjm060193m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">From Ligand to Complexes: Inhibition of Human Immunodeficiency Virus Type 1 Integrase by β-Diketo Acid Metal Complexes</span></div><div class="casAuthors">Sechi, Mario; Bacchi, Alessia; Carcelli, Mauro; Compari, Carlotta; Duce, Elenia; Fisicaro, Emilia; Rogolino, Dominga; Gates, Paul; Derudas, Marco; Al-Mawsawi, Laith Q.; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4248-4260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">β-Diketo acid-contg. compds. are a promising class of human immunodeficiency virus type 1 (HIV-1) integrase (IN) inhibitors.  Starting from the hypothesis that these inhibitors are able to coordinate ions in soln. before interacting on the active site, a series of potentiometric measurements have been performed to understand the coordination ability of the diketo acid pharmacophore toward the biol. relevant Mg2+.  Moreover, by using β-diketo acid/ester as model ligands with a set of divalent metal ions (Mg, Mn, Ni, Co, Cu, and Zn), the authors obtained a series of complexes and tested them for anti-HIV-1 IN activity.  Results demonstrate that the diketo acid functionality chelates divalent metal ions in soln., and complexes with metals in different stoichiometric ratios are isolated.  The authors postulate that the diketo acids act as complexes in their active form.  In particular, they predominantly form species such as Mg2L2+ and Mg2L2 (derived from diketo acids, H2L), and MgL+ and MgL2 (derived from diketo esters, HL) at physiol. pH.  Furthermore, the synthesized mono- and dimetallic complexes inhibited IN at a high nanomolar to low micromolar range, with metal dependency in the Ph diketo acid series.  Retrospective anal. suggests that the electronic properties of the arom. framework influence the metal-chelating ability of the diketo acid system.  Therefore, the difference in activities is related to the complexes they preferentially form in soln., and these findings are important for the design of a new generation of IN inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZMdzwfy_4y7Vg90H21EOLACvtfcHk0lj_WlBakqZa7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVSitrk%253D&md5=048fd84cfb2ec7652ed4dcdd9e160bb8</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1021%2Fjm060193m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060193m%26sid%3Dliteratum%253Aachs%26aulast%3DSechi%26aufirst%3DM.%26aulast%3DBacchi%26aufirst%3DA.%26aulast%3DCarcelli%26aufirst%3DM.%26aulast%3DCompari%26aufirst%3DC.%26aulast%3DDuce%26aufirst%3DE.%26aulast%3DFisicaro%26aufirst%3DE.%26aulast%3DRogolino%26aufirst%3DD.%26aulast%3DGates%26aufirst%3DP.%26aulast%3DDerudas%26aufirst%3DM.%26aulast%3DAl-Mawsawi%26aufirst%3DL.%2BQ.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DFrom%2520Ligand%2520to%2520Complexes%253A%2520Inhibition%2520of%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Integrase%2520by%2520Beta-Diketo%2520Acid%2520Metal%2520Complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4248%26epage%3D4260%26doi%3D10.1021%2Fjm060193m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, A.</span>; <span class="NLM_string-name">Enquist, J.</span>; <span class="NLM_string-name">Griggs, N.</span>; <span class="NLM_string-name">Hale, C.</span>; <span class="NLM_string-name">Ikemoto, N.</span>; <span class="NLM_string-name">Keaton, K. A.</span>; <span class="NLM_string-name">Kraft, M.</span>; <span class="NLM_string-name">Lazerwith, S. E.</span>; <span class="NLM_string-name">Leeman, M.</span>; <span class="NLM_string-name">Peng, Z.</span>; <span class="NLM_string-name">Schrier, K.</span>; <span class="NLM_string-name">Trinidad, J.</span>; <span class="NLM_string-name">van Herpt, J.</span>; <span class="NLM_string-name">Waltman, A. W.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Polycyclic-Carbamoylpyridone Compounds</span>. <span class="NLM_patent">US20150368264A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=A.+Chiu&author=J.+Enquist&author=N.+Griggs&author=C.+Hale&author=N.+Ikemoto&author=K.+A.+Keaton&author=M.+Kraft&author=S.+E.+Lazerwith&author=M.+Leeman&author=Z.+Peng&author=K.+Schrier&author=J.+Trinidad&author=J.+van+Herpt&author=A.+W.+Waltman&title=Synthesis+of+Polycyclic-Carbamoylpyridone+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChiu%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520Polycyclic-Carbamoylpyridone%2520Compounds%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Review of Synthetic Routes and Final Forms of Integrase Inhibitors Dolutegravir, Cabotegravir, and Bictegravir</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVSmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=716-729&author=D.+L.+Hughes&title=Review+of+Synthetic+Routes+and+Final+Forms+of+Integrase+Inhibitors+Dolutegravir%2C+Cabotegravir%2C+and+Bictegravir&doi=10.1021%2Facs.oprd.9b00031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Review of Synthetic Routes and Final Forms of Integrase Inhibitors Dolutegravir, Cabotegravir, and Bictegravir</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">716-729</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Bictegravir and dolutegravir are two recently approved integrase inhibitors for the treatment of HIV.  A third inhibitor, cabotegravir, is in Phase 3 development.  As a continuation of a series of articles on synthetic routes to newly approved drugs, the current article reviews the patent and journal literature regarding synthetic routes and final forms of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR2U-hP-ajqLVg90H21EOLACvtfcHk0ljzmRVR8Jc6rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVSmt74%253D&md5=06d1a446aa8ebd38a086a4c94434c953</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00031%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DReview%2520of%2520Synthetic%2520Routes%2520and%2520Final%2520Forms%2520of%2520Integrase%2520Inhibitors%2520Dolutegravir%252C%2520Cabotegravir%252C%2520and%2520Bictegravir%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26spage%3D716%26epage%3D729%26doi%3D10.1021%2Facs.oprd.9b00031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span>; <span class="NLM_string-name">Zeng, Q.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing (1r,3s)-3-Aminocyclopentanol Hydrochloride</span>. <span class="NLM_patent">CN108774145A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=F.+Ye&author=Q.+Zeng&title=Method+for+Preparing+%281r%2C3s%29-3-Aminocyclopentanol+Hydrochloride"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DF.%26atitle%3DMethod%2520for%2520Preparing%2520%25281r%252C3s%2529-3-Aminocyclopentanol%2520Hydrochloride%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michelin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgarbossa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strukul, G.</span></span> <span> </span><span class="NLM_article-title">The Baeyer-Villiger Oxidation of Ketones: A Paradigm for the Role of Soft Lewis Acidity in Homogeneous Catalysis</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.ccr.2009.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SlsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2010&pages=646-660&author=R.+A.+Michelinauthor=P.+Sgarbossaauthor=A.+Scarsoauthor=G.+Strukul&title=The+Baeyer-Villiger+Oxidation+of+Ketones%3A+A+Paradigm+for+the+Role+of+Soft+Lewis+Acidity+in+Homogeneous+Catalysis&doi=10.1016%2Fj.ccr.2009.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The Baeyer-Villiger oxidation of ketones: A paradigm for the role of soft Lewis acidity in homogeneous catalysis</span></div><div class="casAuthors">Michelin, Rino A.; Sgarbossa, Paolo; Scarso, Alessandro; Strukul, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">646-660</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The Baeyer-Villiger oxidn. of ketones to the corresponding esters or lactones is a valuable transformation that has been upgraded several times over the last century, from the original use of monopersulfuric acid as oxidant to more atom efficient and environmentally friendly oxidants such as hydrogen peroxide.  This review has concd. mainly on Pt complexes as catalysts for the Baeyer-Villiger oxidn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqglAAQ68pLXLVg90H21EOLACvtfcHk0ljzmRVR8Jc6rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SlsLnN&md5=d5301a283029f3b4028239edb92353be</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DMichelin%26aufirst%3DR.%2BA.%26aulast%3DSgarbossa%26aufirst%3DP.%26aulast%3DScarso%26aufirst%3DA.%26aulast%3DStrukul%26aufirst%3DG.%26atitle%3DThe%2520Baeyer-Villiger%2520Oxidation%2520of%2520Ketones%253A%2520A%2520Paradigm%2520for%2520the%2520Role%2520of%2520Soft%2520Lewis%2520Acidity%2520in%2520Homogeneous%2520Catalysis%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2010%26volume%3D254%26spage%3D646%26epage%3D660%26doi%3D10.1016%2Fj.ccr.2009.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Danoprevir: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1271</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0960-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0960-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30117020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFehsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1271-1276&author=A.+Markhamauthor=S.+J.+Keam&title=Danoprevir%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0960-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Danoprevir: First Global Approval</span></div><div class="casAuthors">Markham, Anthony; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1271-1276</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ascletis has developed danoprevir (Ganovo), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C.  Based on pos. results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently approved for marketing in China for the treatment of treatment-naive patients with non-cirrhotic genotype 1b chronic hepatitis C.  This article summarizes the milestones in the development of danoprevir leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfhWb3iJxXTLVg90H21EOLACvtfcHk0ljzmRVR8Jc6rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFehsrnE&md5=df4922b885606bbf29853228c0822908</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0960-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0960-0%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DDanoprevir%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1271%26epage%3D1276%26doi%3D10.1007%2Fs40265-018-0960-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gower, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razavi-Shearer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razavi, H.</span></span> <span> </span><span class="NLM_article-title">Global Epidemiology and Genotype Distribution of the Hepatitis C Virus Infection</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">S45</span>– <span class="NLM_lpage">S57</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2014.07.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.jhep.2014.07.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=25086286" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=S45-S57&author=E.+Gowerauthor=C.+Estesauthor=S.+Blachauthor=K.+Razavi-Shearerauthor=H.+Razavi&title=Global+Epidemiology+and+Genotype+Distribution+of+the+Hepatitis+C+Virus+Infection&doi=10.1016%2Fj.jhep.2014.07.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.07.027%26sid%3Dliteratum%253Aachs%26aulast%3DGower%26aufirst%3DE.%26aulast%3DEstes%26aufirst%3DC.%26aulast%3DBlach%26aufirst%3DS.%26aulast%3DRazavi-Shearer%26aufirst%3DK.%26aulast%3DRazavi%26aufirst%3DH.%26atitle%3DGlobal%2520Epidemiology%2520and%2520Genotype%2520Distribution%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520Infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D61%26spage%3DS45%26epage%3DS57%26doi%3D10.1016%2Fj.jhep.2014.07.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misialek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myszka, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiwert, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossen, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2559</span>– <span class="NLM_lpage">2568</span>, <span class="refDoi"> DOI: 10.1021/bi900038p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi900038p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFems7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=2559-2568&author=R.+Rajagopalanauthor=S.+Misialekauthor=S.+K.+Stevensauthor=D.+G.+Myszkaauthor=B.+J.+Brandhuberauthor=J.+A.+Ballardauthor=S.+W.+Andrewsauthor=S.+D.+Seiwertauthor=K.+Kossen&title=Inhibition+and+Binding+Kinetics+of+the+Hepatitis+C+Virus+NS3+Protease+Inhibitor+ITMN-191+Reveals+Tight+Binding+and+Slow+Dissociative+Behavior&doi=10.1021%2Fbi900038p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior</span></div><div class="casAuthors">Rajagopalan, Ravi; Misialek, Shawn; Stevens, Sarah K.; Myszka, David G.; Brandhuber, Barbara J.; Ballard, Joshua A.; Andrews, Steven W.; Seiwert, Scott D.; Kossen, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2559-2568</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The protease activity of hepatitis C virus nonstructural protein 3 (NS3) is essential for viral replication.  ITMN-191, a macrocyclic inhibitor of the NS3 protease active site, promotes rapid, multilog viral load redns. in chronic HCV patients.  Here, ITMN-191 is shown to be a potent inhibitor of NS3 with a two-step binding mechanism.  Progress curves are consistent with the formation of an initial collision complex (EI) that isomerizes to a highly stable complex (EI*) from which ITMN-191 dissocs. very slowly.  Ki, the dissocn. const. of EI, is 100 nM, and the rate const. for conversion of EI to EI* is 6.2 × 10-2 s-1.  Binding expts. using protein fluorescence confirm this isomerization rate.  From progress curve anal., the rate const. for dissocn. of ITMN-191 from the EI* complex is 3.8 × 10-5 s-1 with a calcd. complex half-life of ∼5 h and a true biochem. potency (Ki*) of ∼62 pM.  Surface plasmon resonance studies and assessment of enzyme reactivation following diln. of the EI* complex confirm slow dissocn. and suggest that the half-life may be considerably longer.  Abrogation of the tight binding and slow dissociative properties of ITMN-191 is obsd. with proteases that carry the R155K or D168A substitution, each of which is likely in drug resistant mutants.  Slow dissocn. is not obsd. with closely related macrocyclic inhibitors of NS3, suggesting that members of this class may display distinct binding kinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOY26vXOrtJrVg90H21EOLACvtfcHk0ljDjMNltAlIzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFems7k%253D&md5=5e985737f2627bd314b517f93b938336</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fbi900038p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900038p%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopalan%26aufirst%3DR.%26aulast%3DMisialek%26aufirst%3DS.%26aulast%3DStevens%26aufirst%3DS.%2BK.%26aulast%3DMyszka%26aufirst%3DD.%2BG.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DBallard%26aufirst%3DJ.%2BA.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DSeiwert%26aufirst%3DS.%2BD.%26aulast%3DKossen%26aufirst%3DK.%26atitle%3DInhibition%2520and%2520Binding%2520Kinetics%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520NS3%2520Protease%2520Inhibitor%2520ITMN-191%2520Reveals%2520Tight%2520Binding%2520and%2520Slow%2520Dissociative%2520Behavior%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D2559%26epage%3D2568%26doi%3D10.1021%2Fbi900038p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span>; <span class="NLM_string-name">Andrews, S. W.</span>; <span class="NLM_string-name">Condroski, K. R.</span>; <span class="NLM_string-name">Doherty, G. A.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Josey, J. A.</span>; <span class="NLM_string-name">Kennedy, A. L.</span>; <span class="NLM_string-name">Madduru, M. R.</span>; <span class="NLM_string-name">Stengel, P. J.</span>; <span class="NLM_string-name">Wenglowsky, S. M.</span>; <span class="NLM_string-name">Woodard, B. T.</span>; <span class="NLM_string-name">Woodard, L.</span></span> <span> </span><span class="NLM_article-title">Preparation of Macrocyclic Carboxylic Acid Derivatives as Inhibitors of HCV Replication</span>. <span class="NLM_patent">US20050267018A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=L.+M.+Blatt&author=S.+W.+Andrews&author=K.+R.+Condroski&author=G.+A.+Doherty&author=Y.+Jiang&author=J.+A.+Josey&author=A.+L.+Kennedy&author=M.+R.+Madduru&author=P.+J.+Stengel&author=S.+M.+Wenglowsky&author=B.+T.+Woodard&author=L.+Woodard&title=Preparation+of+Macrocyclic+Carboxylic+Acid+Derivatives+as+Inhibitors+of+HCV+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26atitle%3DPreparation%2520of%2520Macrocyclic%2520Carboxylic%2520Acid%2520Derivatives%2520as%2520Inhibitors%2520of%2520HCV%2520Replication%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span>; <span class="NLM_string-name">Wenglowsky, S. M.</span>; <span class="NLM_string-name">Andrews, S. W.</span>; <span class="NLM_string-name">Condroski, K. R.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Kennedy, A. L.</span>; <span class="NLM_string-name">Doherty, G. A.</span>; <span class="NLM_string-name">Josey, J. A.</span>; <span class="NLM_string-name">Stengel, P. J.</span>; <span class="NLM_string-name">Woodard, B. T.</span>; <span class="NLM_string-name">Madduru, M. R.</span></span> <span> </span><span class="NLM_article-title">Preparation of Macrocyclic Carboxylic Acids or Sulfonamides as Inhibitors of HCV Replication</span>. <span class="NLM_patent">WO2005095403A2</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=L.+M.+Blatt&author=S.+M.+Wenglowsky&author=S.+W.+Andrews&author=K.+R.+Condroski&author=Y.+Jiang&author=A.+L.+Kennedy&author=G.+A.+Doherty&author=J.+A.+Josey&author=P.+J.+Stengel&author=B.+T.+Woodard&author=M.+R.+Madduru&title=Preparation+of+Macrocyclic+Carboxylic+Acids+or+Sulfonamides+as+Inhibitors+of+HCV+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26atitle%3DPreparation%2520of%2520Macrocyclic%2520Carboxylic%2520Acids%2520or%2520Sulfonamides%2520as%2520Inhibitors%2520of%2520HCV%2520Replication%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit38c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L. M.</span>; <span class="NLM_string-name">Wenglowsky, S. M.</span>; <span class="NLM_string-name">Andrews, S. W.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Kennedy, A. L.</span>; <span class="NLM_string-name">Condroski, K. R.</span>; <span class="NLM_string-name">Josey, J. A.</span>; <span class="NLM_string-name">Stengel, P. J.</span>; <span class="NLM_string-name">Madduru, M. R.</span>; <span class="NLM_string-name">Doherty, G. A.</span>; <span class="NLM_string-name">Woodard, B. T.</span></span> <span> </span><span class="NLM_article-title">Preparation of Macrocyclic Carboxylic Acids and Acylsulfonamides as Inhibitors of HCV Replication</span>. <span class="NLM_patent">WO2005037214A2</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=L.+M.+Blatt&author=S.+M.+Wenglowsky&author=S.+W.+Andrews&author=Y.+Jiang&author=A.+L.+Kennedy&author=K.+R.+Condroski&author=J.+A.+Josey&author=P.+J.+Stengel&author=M.+R.+Madduru&author=G.+A.+Doherty&author=B.+T.+Woodard&title=Preparation+of+Macrocyclic+Carboxylic+Acids+and+Acylsulfonamides+as+Inhibitors+of+HCV+Replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlatt%26aufirst%3DL.%2BM.%26atitle%3DPreparation%2520of%2520Macrocyclic%2520Carboxylic%2520Acids%2520and%2520Acylsulfonamides%2520as%2520Inhibitors%2520of%2520HCV%2520Replication%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condroski, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serebryany, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenglowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madduru, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodard, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stengel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiwert, S. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4a Protease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1753</span>– <span class="NLM_lpage">1769</span>, <span class="refDoi"> DOI: 10.1021/jm400164c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400164c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFaku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1753-1769&author=Y.+Jiangauthor=S.+W.+Andrewsauthor=K.+R.+Condroskiauthor=B.+Buckmanauthor=V.+Serebryanyauthor=S.+Wenglowskyauthor=A.+L.+Kennedyauthor=M.+R.+Madduruauthor=B.+Wangauthor=M.+Lyonauthor=G.+A.+Dohertyauthor=B.+T.+Woodardauthor=C.+Lemieuxauthor=M.+G.+Doauthor=H.+Zhangauthor=J.+Ballardauthor=G.+Vigersauthor=B.+J.+Brandhuberauthor=P.+Stengelauthor=J.+A.+Joseyauthor=L.+Beigelmanauthor=L.+Blattauthor=S.+D.+Seiwert&title=Discovery+of+Danoprevir+%28ITMN-191%2FR7227%29%2C+a+Highly+Selective+and+Potent+Inhibitor+of+Hepatitis+C+Virus+%28HCV%29+NS3%2F4a+Protease&doi=10.1021%2Fjm400164c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease</span></div><div class="casAuthors">Jiang, Yutong; Andrews, Steven W.; Condroski, Kevin R.; Buckman, Brad; Serebryany, Vlad; Wenglowsky, Steve; Kennedy, April L.; Madduru, Machender R.; Wang, Bin; Lyon, Michael; Doherty, George A.; Woodard, Benjamin T.; Lemieux, Christine; Do, Mary Geck; Zhang, Hailong; Ballard, Joshua; Vigers, Guy; Brandhuber, Barbra J.; Stengel, Peter; Josey, John A.; Beigelman, Leonid; Blatt, Lawrence; Seiwert, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1753-1769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system.  Through structure-based drug design and optimization, macrocyclic peptidomimetic mols. bearing both a lipophilic P2 isoindoline carbamate and a P1/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepd. that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7).  Danoprevir (compd. 49) was selected as the clin. development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species.  X-ray crystallog. studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to the iterative structure-based design strategy of the authors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplS3sgoIBu_7Vg90H21EOLACvtfcHk0ljSHu6p0w2BXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFaku7w%253D&md5=2a979cd1202b9360bcef316dddd8382f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm400164c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400164c%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DS.%2BW.%26aulast%3DCondroski%26aufirst%3DK.%2BR.%26aulast%3DBuckman%26aufirst%3DB.%26aulast%3DSerebryany%26aufirst%3DV.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DKennedy%26aufirst%3DA.%2BL.%26aulast%3DMadduru%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLyon%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DG.%2BA.%26aulast%3DWoodard%26aufirst%3DB.%2BT.%26aulast%3DLemieux%26aufirst%3DC.%26aulast%3DDo%26aufirst%3DM.%2BG.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DStengel%26aufirst%3DP.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DBlatt%26aufirst%3DL.%26aulast%3DSeiwert%26aufirst%3DS.%2BD.%26atitle%3DDiscovery%2520of%2520Danoprevir%2520%2528ITMN-191%252FR7227%2529%252C%2520a%2520Highly%2520Selective%2520and%2520Potent%2520Inhibitor%2520of%2520Hepatitis%2520C%2520Virus%2520%2528HCV%2529%2520NS3%252F4a%2520Protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1753%26epage%3D1769%26doi%3D10.1021%2Fjm400164c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duceppe, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoneau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houpis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimroth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnaubelt, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (1r,2s)-1-Amino-2-Vinylcyclopropanecarboxylic Acid Vinyl-ACCA) Derivatives: Key Intermediates for the Preparation of Inhibitors of the Hepatitis C Virus NS3 Protease</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">5869</span>– <span class="NLM_lpage">5879</span>, <span class="refDoi"> DOI: 10.1021/jo050468q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo050468q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt12nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=5869-5879&author=P.+L.+Beaulieuauthor=J.+Gillardauthor=M.+D.+Baileyauthor=C.+Boucherauthor=J.-S.+Duceppeauthor=B.+Simoneauauthor=X.-J.+Wangauthor=L.+Zhangauthor=K.+Grozingerauthor=I.+Houpisauthor=V.+Farinaauthor=H.+Heimrothauthor=T.+Kruegerauthor=J.+Schnaubelt&title=Synthesis+of+%281r%2C2s%29-1-Amino-2-Vinylcyclopropanecarboxylic+Acid+Vinyl-ACCA%29+Derivatives%3A+Key+Intermediates+for+the+Preparation+of+Inhibitors+of+the+Hepatitis+C+Virus+NS3+Protease&doi=10.1021%2Fjo050468q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (1R,2S)-1-Amino-2-vinylcyclopropanecarboxylic Acid Vinyl-ACCA) Derivatives: Key Intermediates for the Preparation of Inhibitors of the Hepatitis C Virus NS3 Protease</span></div><div class="casAuthors">Beaulieu, Pierre L.; Gillard, James; Bailey, Murray D.; Boucher, Colette; Duceppe, Jean-Simon; Simoneau, Bruno; Wang, Xiao-Jun; Zhang, Li; Grozinger, Karl; Houpis, Ioannis; Farina, Vittorio; Heimroth, Heidi; Krueger, Thomas; Schnaubelt, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5869-5879</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(1R,2S)-1-Amino-2-vinylcyclopropanecarboxylic acid (vinyl-ACCA) is a key building block in the synthesis of BILN 2061, a potent inhibitor of hepatitis C virus NS3 and was recently shown to dramatically reduce viral load after administration to patients infected with HCV genotype 1.  The authors developed a scalable process that delivered derivs. of (1R,2S)-vinyl-ACCA in >99% enantiomeric excess.  The strategy included dialkylation of a glycine Schiff base using (E)-1,4-dibromo-2-butene as an electrophile to produce racemic vinyl-ACCA, which was subsequently resolved using a readily available, inexpensive esterase enzyme (Alcalase 2.4L).  Factors that affect diastereoselection in the initial dialkylation steps were examd. and the conditions were optimized to deliver the desired diastereomer selectively.  Product inhibition, which was encountered during the enzymic resoln. step, initially resulted in prolonged cycle times.  Enrichment of racemic vinyl-ACCA through a chem. resoln. via diastereomeric salt formation or the use of forcing conditions in the enzymic reaction both led to improvements in throughput and the development of a viable process.  Thus, multi-kilogram quantities of (1R,2S)-vinyl-ACCA were produced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMTSBIrZEPk7Vg90H21EOLACvtfcHk0ljSHu6p0w2BXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt12nur4%253D&md5=2165443a83201467dc3f8404758425cf</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjo050468q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo050468q%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DM.%2BD.%26aulast%3DBoucher%26aufirst%3DC.%26aulast%3DDuceppe%26aufirst%3DJ.-S.%26aulast%3DSimoneau%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DX.-J.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGrozinger%26aufirst%3DK.%26aulast%3DHoupis%26aufirst%3DI.%26aulast%3DFarina%26aufirst%3DV.%26aulast%3DHeimroth%26aufirst%3DH.%26aulast%3DKrueger%26aufirst%3DT.%26aulast%3DSchnaubelt%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%2520%25281r%252C2s%2529-1-Amino-2-Vinylcyclopropanecarboxylic%2520Acid%2520Vinyl-ACCA%2529%2520Derivatives%253A%2520Key%2520Intermediates%2520for%2520the%2520Preparation%2520of%2520Inhibitors%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520NS3%2520Protease%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D5869%26epage%3D5879%26doi%3D10.1021%2Fjo050468q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span>; <span class="NLM_string-name">Sherry, B. D.</span>; <span class="NLM_string-name">Gauthier, D. R.</span>; <span class="NLM_string-name">Campeau, L.-C.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Doravirine: An Investigational Next Generation Non-Nucleside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV</span>. In  <i>Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Magid, A. F.</span>; <span class="NLM_string-name">Pesti, J.</span>; <span class="NLM_string-name">Vaidyanathan, R.</span></span>, Eds.; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2016</span>; Vol.  <span class="NLM_volume">1239</span>, pp  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">205</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1239.ch007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=175-205&author=J.+D.+Burch&author=B.+D.+Sherry&author=D.+R.+Gauthier&author=L.-C.+Campeauauthor=A.+F.+Abdel-Magid&author=J.+Pesti&author=R.+Vaidyanathan&title=Comprehensive+Accounts+of+Pharmaceutical+Research+and+Development%3A+From+Discovery+to+Late-Stage+Process+Development+Volume+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1239.ch007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Fbk-2016-1239.ch007%26sid%3Dliteratum%253Aachs%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Doravirine%253A%2520An%2520Investigational%2520Next%2520Generation%2520Non-Nucleside%2520Reverse%2520Transcriptase%2520Inhibitor%2520%2528NNRTI%2529%2520for%2520the%2520Treatment%2520of%2520HIV%26btitle%3DComprehensive%2520Accounts%2520of%2520Pharmaceutical%2520Research%2520and%2520Development%253A%2520From%2520Discovery%2520to%2520Late-Stage%2520Process%2520Development%2520Volume%25201%26aulast%3DAbdel-Magid%26aufirst%3DA.%2BF.%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2016%26volume%3D1239%26spage%3D175%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colombier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. M.</span></span> <span> </span><span class="NLM_article-title">Doravirine: A Review</span>. <i>Curr. Opin. HIV AIDS</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1097/COH.0000000000000471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1097%2FCOH.0000000000000471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29794817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVemtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=308-314&author=M.+A.+Colombierauthor=J.+M.+Molina&title=Doravirine%3A+A+Review&doi=10.1097%2FCOH.0000000000000471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Doravirine: a review</span></div><div class="casAuthors">Colombier, Marie-Alice; Molina, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in HIV & AIDS</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">308-314</span>CODEN:
                <span class="NLM_cas:coden">COHABM</span>;
        ISSN:<span class="NLM_cas:issn">1746-630X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The current review addresses the role of doravirine (DOR), a novel once-daily nonnucleoside reverse transcriptase inhibitor (NNRTI) in first-line therapy at a time in which multiple options are available, and issues of antiviral efficacy, safety, simplicity and cost are crit. to make informed decisions.  DOR combination regimens have been tested in two large randomized double-blinded clin. trials in treatment-naive patients, showing noninferiority to ritonavir-boosted darunavir-based and efavirenz (EFV)-based regimens.  The main features of DOR are reviewed in this report including its antiviral activity, genetic barrier to resistance, safety, once-daily dosing and coformulation in a single tablet with tenofovir disoproxil fumarate and lamivudine.  DOR pharmacokinetics and drug-drug interactions are also reviewed as DOR can be given without food restriction and has no interaction with proton pump inhibitors.  DOR has shown a superior safety profile than EFV regarding neuropsychiatric and cutaneous adverse events.  DOR is currently being investigated in treatment-experienced patients and in those with transmitted NNRTI drug resistance.  DOR is a promising new NNRTI that could become the preferred drug in its class for treatment initiation.  DOR has shown excellent antiviral activity in treatment-naive patients, a better safety profile than EFV and a low potential for drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYEMuUgnObvbVg90H21EOLACvtfcHk0ljyEScxGjd-iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVemtrnF&md5=a3be79ea93dd338aaeadad905537df84</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1097%2FCOH.0000000000000471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOH.0000000000000471%26sid%3Dliteratum%253Aachs%26aulast%3DColombier%26aufirst%3DM.%2BA.%26aulast%3DMolina%26aufirst%3DJ.%2BM.%26atitle%3DDoravirine%253A%2520A%2520Review%26jtitle%3DCurr.%2520Opin.%2520HIV%2520AIDS%26date%3D2018%26volume%3D13%26spage%3D308%26epage%3D314%26doi%3D10.1097%2FCOH.0000000000000471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, D. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Characterization of Impurities of HIV NNRTI Doravirine by UHPLC-High Resolution Ms and Tandem Ms Analysis</span>. <i>J. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">968</span>, <span class="refDoi"> DOI: 10.1002/jms.3807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fjms.3807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27383410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs12gurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=959-968&author=L.+K.+Zhangauthor=R.+Yangauthor=H.+Shengauthor=R.+Helmyauthor=J.+Zhengauthor=Y.+Caoauthor=D.+R.+Gauthier&title=Characterization+of+Impurities+of+HIV+NNRTI+Doravirine+by+UHPLC-High+Resolution+Ms+and+Tandem+Ms+Analysis&doi=10.1002%2Fjms.3807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of impurities of HIV NNRTI Doravirine by UHPLC-high resolution MS and tandem MS analysis</span></div><div class="casAuthors">Zhang, Li-Kang; Yang, Ross; Sheng, Huaming; Helmy, Roy; Zheng, Jinjian; Cao, Yang; Gauthier, Donald R. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Mass Spectrometry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">959-968</span>CODEN:
                <span class="NLM_cas:coden">JMSPFJ</span>;
        ISSN:<span class="NLM_cas:issn">1076-5174</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">World Health Organization ests. that 34 million individuals globally are living with Human Immunodeficiency Virus (HIV).  Doravirine is a non-nucleoside reverse transcriptase inhibitors (NNRTI) being evaluated by Merck for the treatment of HIV-1 infection.  Drug regulation authorities require the purity of a pharmaceutical to be fully defined.  This is important to ensure that the pharmacol. and toxicol. effects are truly those of the drug substances and not because of the impurities.  Thus, understanding the drug impurity profiles is crit. to the safety and potency assessment of the drug candidate for clin. trials.  The impurity characterization can also provide useful information for crit. assessment of pharmaceutical processes.  Advances in mass spectrometry instrumentation and methods allow the identification of impurities in pharmaceuticals with a min. of sample material and increased sensitivity.  In this study, a rapid and sensitive method was developed for the structural detn. of the major impurities of doravirine.  The study utilizes ultra performance liq. chromatog.-high-resoln.-tandem mass spectrometry (UHPLC-HRMS/MS) techniques to perform structure elucidation of the unknown structures.  This approach has significant impact on impurity structural elucidation, and a total of five trace-level impurities of doravirine were characterized using the developed method.  Copyright © 2016 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkmg-gQgPhrVg90H21EOLACvtfcHk0lgHCd-wpU0YWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs12gurnF&md5=98e8c5b41e32e1a6537acd99c84367a6</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1002%2Fjms.3807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjms.3807%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%2BK.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DSheng%26aufirst%3DH.%26aulast%3DHelmy%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DGauthier%26aufirst%3DD.%2BR.%26atitle%3DCharacterization%2520of%2520Impurities%2520of%2520HIV%2520NNRTI%2520Doravirine%2520by%2520UHPLC-High%2520Resolution%2520Ms%2520and%2520Tandem%2520Ms%2520Analysis%26jtitle%3DJ.%2520Mass%2520Spectrom.%26date%3D2016%26volume%3D51%26spage%3D959%26epage%3D968%26doi%3D10.1002%2Fjms.3807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit43b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, D. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Journet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangion, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschaen, D. M.</span></span> <span> </span><span class="NLM_article-title">Highly Efficient Synthesis of HIV NNRTI Doravirine</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1021/ol503625z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol503625z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFKlurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=1353-1356&author=D.+R.+Gauthierauthor=B.+D.+Sherryauthor=Y.+Caoauthor=M.+Journetauthor=G.+Humphreyauthor=T.+Itohauthor=I.+Mangionauthor=D.+M.+Tschaen&title=Highly+Efficient+Synthesis+of+HIV+NNRTI+Doravirine&doi=10.1021%2Fol503625z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43bR"><div class="casContent"><span class="casTitleNuber">43b</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Efficient Synthesis of HIV NNRTI Doravirine</span></div><div class="casAuthors">Gauthier, Donald R., Jr.; Sherry, Benjamin D.; Cao, Yang; Journet, Michel; Humphrey, Guy; Itoh, Tetsuji; Mangion, Ian; Tschaen, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1353-1356</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) doravirine I was prepd. using the aldol addn. of (E)-F3CCOCH:CHOEt with the aryloxyacetate 3-Cl-5-NCC6H3OCH2CO2Et in a continuous flow app. followed by elimination with trifluoroacetic anhydride and cyclocondensation with ammonia to give aryloxypyridinone II as the key step.  Aldol addn. of 3-Cl-5-NCC6H3OCH2CO2Et to F3CCOCH:CHOEt in the presence of potassium tert-amyloxide using a flow reactor at -20° for 1-60 s and quenching with aq. dipotassium phosphate followed by a batch elimination with trifluoroacetic anhydride and triethylamine and cyclocondensation with ammonia yielded II in 68% yield; alkylation with a (chloromethyl)-1,2,4-triazolone (prepd. in four steps from Ph chloroformate and glycolic acid) using diisopropylethylamine in NMP/tert-amyl alc. yielded I.  Conditions for the continuous flow aldol reaction were derived using microbatch snapshots of the flow process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod9R1eNic2TbVg90H21EOLACvtfcHk0lgHCd-wpU0YWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFKlurk%253D&md5=4cb4a53d223195f05255992dfbac70e5</span></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.1021%2Fol503625z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol503625z%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DD.%2BR.%26aulast%3DSherry%26aufirst%3DB.%2BD.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DJournet%26aufirst%3DM.%26aulast%3DHumphrey%26aufirst%3DG.%26aulast%3DItoh%26aufirst%3DT.%26aulast%3DMangion%26aufirst%3DI.%26aulast%3DTschaen%26aufirst%3DD.%2BM.%26atitle%3DHighly%2520Efficient%2520Synthesis%2520of%2520HIV%2520NNRTI%2520Doravirine%26jtitle%3DOrg.%2520Lett.%26date%3D2015%26volume%3D17%26spage%3D1353%26epage%3D1356%26doi%3D10.1021%2Fol503625z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit43c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span>; <span class="NLM_string-name">Donald, R.</span>; <span class="NLM_string-name">Gauthier, J.</span>; <span class="NLM_string-name">Humphrey, G. R.</span>; <span class="NLM_string-name">Itoh, T.</span>; <span class="NLM_string-name">Journet, M.</span>; <span class="NLM_string-name">Qian, G.</span>; <span class="NLM_string-name">Sherry, B. D.</span>; <span class="NLM_string-name">Tschaen, D. M.</span></span> <span> </span><span class="NLM_article-title">Process for Making Reverse Transcriptase Inhibitors</span>. <span class="NLM_patent">WO2015084763A2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Cao&author=R.+Donald&author=J.+Gauthier&author=G.+R.+Humphrey&author=T.+Itoh&author=M.+Journet&author=G.+Qian&author=B.+D.+Sherry&author=D.+M.+Tschaen&title=Process+for+Making+Reverse+Transcriptase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26atitle%3DProcess%2520for%2520Making%2520Reverse%2520Transcriptase%2520Inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit43d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, T.</span>; <span class="NLM_string-name">Jeon, I.</span>; <span class="NLM_string-name">Mangion, I.</span>; <span class="NLM_string-name">Qian, G.</span>; <span class="NLM_string-name">Sherry, B. D.</span>; <span class="NLM_string-name">Gauthier, D. R.</span>; <span class="NLM_string-name">Cao, Y.</span></span> <span> </span><span class="NLM_article-title">Process for Making Reverse Transcriptase Inhibitors</span>. <span class="NLM_patent">WO2014089140A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=T.+Itoh&author=I.+Jeon&author=I.+Mangion&author=G.+Qian&author=B.+D.+Sherry&author=D.+R.+Gauthier&author=Y.+Cao&title=Process+for+Making+Reverse+Transcriptase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DT.%26atitle%3DProcess%2520for%2520Making%2520Reverse%2520Transcriptase%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit43e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asante-Appiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blouin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campeau, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauchon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chefson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromlish, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschenes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont-Gaudet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falgueyret, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forget, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvreau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plamondon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seliniotakis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Onge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truchon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducharme, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-1439, an Orally Bioavailable Non-Nucleoside Reverse Transcriptase Inhibitor Potent against a Wide Range of Resistant Mutant HIV Viruses</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmcl.2013.12.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=24412110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1yisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=917-922&author=B.+Coteauthor=J.+D.+Burchauthor=E.+Asante-Appiahauthor=C.+Baylyauthor=L.+Bedardauthor=M.+Blouinauthor=L.+C.+Campeauauthor=E.+Cauchonauthor=M.+Chanauthor=A.+Chefsonauthor=N.+Coulombeauthor=W.+Cromlishauthor=S.+Debnathauthor=D.+Deschenesauthor=K.+Dupont-Gaudetauthor=J.+P.+Falgueyretauthor=R.+Forgetauthor=S.+Gagneauthor=D.+Gauvreauauthor=M.+Girardinauthor=S.+Guiralauthor=E.+Langloisauthor=C.+S.+Liauthor=N.+Nguyenauthor=R.+Pappauthor=S.+Plamondonauthor=A.+Royauthor=S.+Royauthor=R.+Seliniotakisauthor=M.+St-Ongeauthor=S.+Ouelletauthor=P.+Tawaauthor=J.+F.+Truchonauthor=J.+Vaccaauthor=M.+Wronaauthor=Y.+Yanauthor=Y.+Ducharme&title=Discovery+of+MK-1439%2C+an+Orally+Bioavailable+Non-Nucleoside+Reverse+Transcriptase+Inhibitor+Potent+against+a+Wide+Range+of+Resistant+Mutant+HIV+Viruses&doi=10.1016%2Fj.bmcl.2013.12.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43eR"><div class="casContent"><span class="casTitleNuber">43e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses</span></div><div class="casAuthors">Cote, Bernard; Burch, Jason D.; Asante-Appiah, Ernest; Bayly, Chris; Bedard, Leanne; Blouin, Marc; Campeau, Louis-Charles; Cauchon, Elizabeth; Chan, Manuel; Chefson, Amandine; Coulombe, Nathalie; Cromlish, Wanda; Debnath, Smita; Deschenes, Denis; Dupont-Gaudet, Kristina; Falgueyret, Jean-Pierre; Forget, Robert; Gagne, Sebastien; Gauvreau, Danny; Girardin, Melina; Guiral, Sebastien; Langlois, Eric; Li, Chun Sing; Nguyen, Natalie; Papp, Rob; Plamondon, Serge; Roy, Amelie; Roy, Stephanie; Seliniotakis, Ria; St-Onge, Miguel; Ouellet, Stephane; Tawa, Paul; Truchon, Jean-Francois; Vacca, Joe; Wrona, Marc; Yan, Youwei; Ducharme, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">917-922</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of pyridone 36.  In cell cultures, this new NNRTI shows a superior potency profile against a range of wild type and clin. relevant, resistant mutant HIV viruses.  The overall favorable preclin. pharmacokinetic profile of 36 led to the prediction of a once daily low dose regimen in human.  NNRTI 36, now known as MK-1439, is currently in clin. development for the treatment of HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJff1LINDbQ7Vg90H21EOLACvtfcHk0lgHCd-wpU0YWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1yisw%253D%253D&md5=7d63ec63691d2d21eb29b8dd9c4c5e63</span></div><a href="/servlet/linkout?suffix=cit43e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.070%26sid%3Dliteratum%253Aachs%26aulast%3DCote%26aufirst%3DB.%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DBayly%26aufirst%3DC.%26aulast%3DBedard%26aufirst%3DL.%26aulast%3DBlouin%26aufirst%3DM.%26aulast%3DCampeau%26aufirst%3DL.%2BC.%26aulast%3DCauchon%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DM.%26aulast%3DChefson%26aufirst%3DA.%26aulast%3DCoulombe%26aufirst%3DN.%26aulast%3DCromlish%26aufirst%3DW.%26aulast%3DDebnath%26aufirst%3DS.%26aulast%3DDeschenes%26aufirst%3DD.%26aulast%3DDupont-Gaudet%26aufirst%3DK.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DForget%26aufirst%3DR.%26aulast%3DGagne%26aufirst%3DS.%26aulast%3DGauvreau%26aufirst%3DD.%26aulast%3DGirardin%26aufirst%3DM.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DLanglois%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DPapp%26aufirst%3DR.%26aulast%3DPlamondon%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DSeliniotakis%26aufirst%3DR.%26aulast%3DSt-Onge%26aufirst%3DM.%26aulast%3DOuellet%26aufirst%3DS.%26aulast%3DTawa%26aufirst%3DP.%26aulast%3DTruchon%26aufirst%3DJ.%2BF.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DWrona%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DDucharme%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520MK-1439%252C%2520an%2520Orally%2520Bioavailable%2520Non-Nucleoside%2520Reverse%2520Transcriptase%2520Inhibitor%2520Potent%2520against%2520a%2520Wide%2520Range%2520of%2520Resistant%2520Mutant%2520HIV%2520Viruses%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D917%26epage%3D922%26doi%3D10.1016%2Fj.bmcl.2013.12.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit43f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J.</span>; <span class="NLM_string-name">Cote, B.</span>; <span class="NLM_string-name">Nguyen, N.</span>; <span class="NLM_string-name">Li, C. S.</span>; <span class="NLM_string-name">St-Onge, M.</span>; <span class="NLM_string-name">Gauvreau, D.</span></span> <span> </span><span class="NLM_article-title">Non-Nucleoside Reverse Transcriptase Inhibitors</span>. <span class="NLM_patent">WO2011120133A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Burch&author=B.+Cote&author=N.+Nguyen&author=C.+S.+Li&author=M.+St-Onge&author=D.+Gauvreau&title=Non-Nucleoside+Reverse+Transcriptase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBurch%26aufirst%3DJ.%26atitle%3DNon-Nucleoside%2520Reverse%2520Transcriptase%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campeau, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvreau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardin, M. l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maligres, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, P. D.</span></span> <span> </span><span class="NLM_article-title">A Robust Kilo-Scale Synthesis of Doravirine</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1476</span>– <span class="NLM_lpage">1481</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00163</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00163" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSrtLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1476-1481&author=L.-C.+Campeauauthor=Q.+Chenauthor=D.+Gauvreauauthor=M.+l.+Girardinauthor=K.+Belykauthor=P.+Maligresauthor=G.+Zhouauthor=C.+Guauthor=W.+Zhangauthor=L.+Tanauthor=P.+D.+O%E2%80%99Shea&title=A+Robust+Kilo-Scale+Synthesis+of+Doravirine&doi=10.1021%2Facs.oprd.6b00163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Robust Kilo-Scale Synthesis of Doravirine</span></div><div class="casAuthors">Campeau, Louis-Charles; Chen, Qinghao; Gauvreau, Danny; Girardin, Melina; Belyk, Kevin; Maligres, Peter; Zhou, Guoyue; Gu, Chaozhan; Zhang, Wei; Tan, Lushi; O'Shea, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1476-1481</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Doravirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) currently in phase III clin. trials for the treatment of HIV infection.  Herein we describe a robust kilo-scale synthesis for its manuf.  The structure and origin of major impurities were detd. and their downstream fate-and-purge studied.  This resulted in a redesign of the route to introduce the key nitrile functionality via a copper mediated cyanation which allowed all impurities to be controlled to an acceptable level.  The improved synthesis was scaled to prep. ∼100 kg batches of doravirine to supply all preclin. and clin. studies up to phase III.  The synthesis affords high-quality material in a longest linear sequence of six steps and 37% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryg7zTXc5vMLVg90H21EOLACvtfcHk0ljoz6HgGQ3RCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSrtLvL&md5=6d2ff3a82e01b6ddfb9de06bb756e36f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00163%26sid%3Dliteratum%253Aachs%26aulast%3DCampeau%26aufirst%3DL.-C.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DGauvreau%26aufirst%3DD.%26aulast%3DGirardin%26aufirst%3DM.%2Bl.%26aulast%3DBelyk%26aufirst%3DK.%26aulast%3DMaligres%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DGu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DP.%2BD.%26atitle%3DA%2520Robust%2520Kilo-Scale%2520Synthesis%2520of%2520Doravirine%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1476%26epage%3D1481%26doi%3D10.1021%2Facs.oprd.6b00163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span>; <span class="NLM_string-name">Xu, L.</span>; <span class="NLM_string-name">Makha, M.</span>; <span class="NLM_string-name">Sandoval, C. A.</span>; <span class="NLM_string-name">Huang, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of 3-Chloromethyl-1,2,4-triazoline-5-one</span>. <span class="NLM_patent">CN104628663A</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=W.+Yang&author=L.+Xu&author=M.+Makha&author=C.+A.+Sandoval&author=C.+Huang&title=Synthesis+Method+of+3-Chloromethyl-1%2C2%2C4-triazoline-5-one"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26atitle%3DSynthesis%2520Method%2520of%25203-Chloromethyl-1%252C2%252C4-triazoline-5-one%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cowden, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottrell, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolling, U.-H.</span></span> <span> </span><span class="NLM_article-title">A New Synthesis of 1,2,4-Triazolin-5-ones: Application to the Convergent Synthesis of an NK1 Antagonist</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">8661</span>– <span class="NLM_lpage">8664</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)01548-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0040-4039%2800%2901548-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosVGhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2000&pages=8661-8664&author=C.+J.+Cowdenauthor=R.+D.+Wilsonauthor=B.+C.+Bishopauthor=I.+F.+Cottrellauthor=A.+J.+Daviesauthor=U.-H.+Dolling&title=A+New+Synthesis+of+1%2C2%2C4-Triazolin-5-ones%3A+Application+to+the+Convergent+Synthesis+of+an+NK1+Antagonist&doi=10.1016%2FS0040-4039%2800%2901548-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">A new synthesis of 1,2,4-triazolin-5-ones: application to the convergent synthesis of an NK1 antagonist</span></div><div class="casAuthors">Cowden, Cameron J.; Wilson, Robert D.; Bishop, Brian C.; Cottrell, Ian F.; Davies, Antony J.; Dolling, Ulf-H.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">8661-8664</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">3-Chloromethyl-1,2,4-triazolin-5-one (I) has been synthesized in a single step via the novel condensation of semicarbazide hydrochloride with ClCH2C(OMe)3.  Alkylation of the secondary amine fragment with I proceeds in 99% yield to afford the target NK1 antagonist II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxT3pfyW72z7Vg90H21EOLACvtfcHk0ljoz6HgGQ3RCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosVGhu7g%253D&md5=f1377f6291373f2c2afcb4b598d5ca49</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2901548-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252901548-3%26sid%3Dliteratum%253Aachs%26aulast%3DCowden%26aufirst%3DC.%2BJ.%26aulast%3DWilson%26aufirst%3DR.%2BD.%26aulast%3DBishop%26aufirst%3DB.%2BC.%26aulast%3DCottrell%26aufirst%3DI.%2BF.%26aulast%3DDavies%26aufirst%3DA.%2BJ.%26aulast%3DDolling%26aufirst%3DU.-H.%26atitle%3DA%2520New%2520Synthesis%2520of%25201%252C2%252C4-Triazolin-5-ones%253A%2520Application%2520to%2520the%2520Convergent%2520Synthesis%2520of%2520an%2520NK1%2520Antagonist%26jtitle%3DTetrahedron%2520Lett.%26date%3D2000%26volume%3D41%26spage%3D8661%26epage%3D8664%26doi%3D10.1016%2FS0040-4039%2800%2901548-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wilby, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eissa, N. A.</span></span> <span> </span><span class="NLM_article-title">Clinical Pharmacokinetics and Drug Interactions of Doravirine. <i>Eur</i></span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1007/s13318-018-0497-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs13318-018-0497-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30047107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVarurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=637-644&author=K.+J.+Wilbyauthor=N.+A.+Eissa&title=Clinical+Pharmacokinetics+and+Drug+Interactions+of+Doravirine.+Eur&doi=10.1007%2Fs13318-018-0497-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46aR"><div class="casContent"><span class="casTitleNuber">46a</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetics and Drug Interactions of Doravirine</span></div><div class="casAuthors">Wilby, Kyle John; Eissa, Nesma Ahmed</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">637-644</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Springer France</span>)
        </div><div class="casAbstract">A review.  Doravirine is a new HIV-1 non-nucleoside reverse transcriptase inhibitor that has demonstrated a good efficacy and safety profile in clin. trials.  It has a therapeutic profile that makes it an attractive option for treatment of HIV-1 infection.  As such, there has been an increase in the published literature regarding the pharmacokinetics of doravirine and potential for drug-drug interactions.  This review aimed to identify pharmacokinetic literature pertaining to doravirine, used findings from the literature to summarize its pharmacokinetic profile, and finally evaluated literature describing actual and potential drug interactions.  Review findings show doravirine is well-absorbed, exhibits moderate protein binding activity, and is extensively metabolized by cytochrome P 450 enzymes (specifically CYP3A).  It has an elimination half-life of 12-21 h.  Gender, age, moderate hepatic impairment, and co-administration with food did not greatly alter doravirine's pharmacokinetic profile.  Drug interaction studies have shown doravirine does not affect the pharmacokinetics of dolutegravir or atorvastatin but may have its pharmacokinetics altered by rifampicin (rifampin) and other rifamycins (CYP3A inducers) and ritonavir (CYP3A inhibitor).  No clin. significant interactions were noted between doravirine and an antacid (aluminum-magnesium), pantoprazole, ledipasvir/sofosbuvir, or elbasvir/grazoprevir.  Further study is needed to better understand doravirine's efficacy and safety profile when co-administered with other agents known to be CYP inducers or inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-xmCP56FHa7Vg90H21EOLACvtfcHk0libN2Rd7Qa-lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVarurfN&md5=cd86e9f9e6a4dc45fa54e4d9f6824623</span></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=10.1007%2Fs13318-018-0497-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13318-018-0497-3%26sid%3Dliteratum%253Aachs%26aulast%3DWilby%26aufirst%3DK.%2BJ.%26aulast%3DEissa%26aufirst%3DN.%2BA.%26atitle%3DClinical%2520Pharmacokinetics%2520and%2520Drug%2520Interactions%2520of%2520Doravirine.%2520Eur%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2018%26volume%3D43%26spage%3D637%26epage%3D644%26doi%3D10.1007%2Fs13318-018-0497-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit46b"><span><span class="NLM_label">(b) </span><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=210867" class="extLink">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210867</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdaf%2Findex.cfm%3Fevent%3Doverview.process%26ApplNo%3D210867+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Opoku, N. O</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakajika, D. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanza, E. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mambandu, G. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyathirombo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigo, M. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasonia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masembe, S. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumbere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kataliko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larbelee, J. P</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kpawor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolay, K. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolay, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attah, S. K</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olipoh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halleux, C. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuesel, A. C</span></span> <span> </span><span class="NLM_article-title">Single Dose Moxidectin Versus Ivermectin for Onchocerca Volvulus Infection in Ghana, Liberia, and the Democratic Republic of the Congo: A Randomised, Controlled, Double-Blind Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1207</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)32844-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0140-6736%2817%2932844-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29361335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVehs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1207-1216&author=N.+O+Opokuauthor=D.+K+Bakajikaauthor=E.+M+Kanzaauthor=H.+Howardauthor=G.+L+Mambanduauthor=A.+Nyathiromboauthor=M.+M+Nigoauthor=K.+Kasoniaauthor=S.+L+Masembeauthor=M.+Mumbereauthor=K.+Katalikoauthor=J.+P+Larbeleeauthor=M.+Kpaworauthor=K.+M+Bolayauthor=F.+Bolayauthor=S.+Asareauthor=S.+K+Attahauthor=G.+Olipohauthor=M.+Vaillantauthor=C.+M+Halleuxauthor=A.+C+Kuesel&title=Single+Dose+Moxidectin+Versus+Ivermectin+for+Onchocerca+Volvulus+Infection+in+Ghana%2C+Liberia%2C+and+the+Democratic+Republic+of+the+Congo%3A+A+Randomised%2C+Controlled%2C+Double-Blind+Phase+3+Trial&doi=10.1016%2FS0140-6736%2817%2932844-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial</span></div><div class="casAuthors">Opoku, Nicholas O.; Bakajika, Didier K.; Kanza, Eric M.; Howard, Hayford; Mambandu, Germain L.; Nyathirombo, Amos; Nigo, Maurice M.; Kasonia, Kambale; Masembe, Safari L.; Mumbere, Mupenzi; Kataliko, Kambale; Larbelee, Jemmah P.; Kpawor, Mawolo; Bolay, Kpehe M.; Bolay, Fatorma; Attah, Simon K.; Vaillant, Michel; Halleux, Christine M.; Kuesel, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10154</span>),
    <span class="NLM_cas:pages">1207-1216</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The morbidity and socioeconomic effects of onchocerciasis, a parasitic disease that is primarily endemic in sub-Saharan Africa, have motivated large morbidity and transmission control programs.  Annual community-directed ivermectin treatment has substantially reduced prevalence.  Elimination requires intensified efforts, including more efficacious treatments.  We compared parasitol. efficacy and safety of moxidectin and ivermectin.  This double-blind, parallel group, superiority trial was done in four sites in Ghana, Liberia, and the Democratic Republic of the Congo.  We enrolled participants (aged ≥12 years) with at least 10 Onchocerca volvulus microfilariae per mg skin who were not co-infected with Loa loa or lymphatic filariasis microfilaremic.  Participants were randomly allocated, stratified by sex and level of infection, to receive a single oral dose of 8 mg moxidectin or 150μg/kg ivermectin as overencapsulated oral tablets.  The primary efficacy outcome was skin microfilariae d. 12 mo post treatment.  We used a mixed-effects model to test the hypothesis that the primary efficacy outcome in the moxidectin group was 50% or less than that in the ivermectin group.  The primary efficacy anal. population were all participants who received the study drug and completed 12-mo follow-up (modified intention to treat).  This study is registered with ClinicalTrials.gov, no. NCT00790998.  Between Apr. 22, 2009, and Jan 23, 2011, we enrolled and allocated 998 participants to moxidectin and 501 participants to ivermectin. 978 received moxidectin and 494 ivermectin, of which 947 and 480 were included in primary efficacy outcome analyses.  At 12 mo, skin microfilarial d. (microfilariae per mg of skin) was lower in the moxidectin group (adjusted geometric mean 0·6 [95% CI 0·3-1·0]) than in the ivermectin group (4·5 [3·5-5·9]; difference 3·9 [3·2-4·9], p<0·0001; treatment difference 86%).  Mazzotti (ie, efficacy-related) reactions occurred in 967 (99%) of 978 moxidectin-treated participants and in 478 (97%) of 494 ivermectin-treated participants, including ocular reactions (moxidectin 113 [12%] participants and ivermectin 47 [10%] participants), lab. reactions (788 [81%] and 415 [84%]), and clin. reactions (944 [97%] and 446 [90%]).  No serious adverse events were considered to be related to treatment.  Skin microfilarial loads (ie, parasite transmission reservoir) are lower after moxidectin treatment than after ivermectin treatment.  Moxidectin would therefore be expected to reduce parasite transmission between treatment rounds more than ivermectin could, thus accelerating progress towards elimination.  UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7ainnG-wbBbVg90H21EOLACvtfcHk0libN2Rd7Qa-lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVehs7w%253D&md5=b0d562e50a7e90a2592d0985cda69da6</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2932844-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252932844-1%26sid%3Dliteratum%253Aachs%26aulast%3DOpoku%26aufirst%3DN.%2BO%26aulast%3DBakajika%26aufirst%3DD.%2BK%26aulast%3DKanza%26aufirst%3DE.%2BM%26aulast%3DHoward%26aufirst%3DH.%26aulast%3DMambandu%26aufirst%3DG.%2BL%26aulast%3DNyathirombo%26aufirst%3DA.%26aulast%3DNigo%26aufirst%3DM.%2BM%26aulast%3DKasonia%26aufirst%3DK.%26aulast%3DMasembe%26aufirst%3DS.%2BL%26aulast%3DMumbere%26aufirst%3DM.%26aulast%3DKataliko%26aufirst%3DK.%26aulast%3DLarbelee%26aufirst%3DJ.%2BP%26aulast%3DKpawor%26aufirst%3DM.%26aulast%3DBolay%26aufirst%3DK.%2BM%26aulast%3DBolay%26aufirst%3DF.%26aulast%3DAsare%26aufirst%3DS.%26aulast%3DAttah%26aufirst%3DS.%2BK%26aulast%3DOlipoh%26aufirst%3DG.%26aulast%3DVaillant%26aufirst%3DM.%26aulast%3DHalleux%26aufirst%3DC.%2BM%26aulast%3DKuesel%26aufirst%3DA.%2BC%26atitle%3DSingle%2520Dose%2520Moxidectin%2520Versus%2520Ivermectin%2520for%2520Onchocerca%2520Volvulus%2520Infection%2520in%2520Ghana%252C%2520Liberia%252C%2520and%2520the%2520Democratic%2520Republic%2520of%2520the%2520Congo%253A%2520A%2520Randomised%252C%2520Controlled%252C%2520Double-Blind%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1207%26epage%3D1216%26doi%3D10.1016%2FS0140-6736%2817%2932844-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit47b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Awadzi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opoku, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazdins-Helds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuesel, A. C.</span></span> <span> </span><span class="NLM_article-title">A Randomized, Single-Ascending-Dose, Ivermectin-Controlled, Double-Blind Study of Moxidectin in Onchocerca Volvulus Infection</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e2953</span>, (18 pp). <span class="refDoi"> DOI: 10.1371/journal.pntd.0002953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1371%2Fjournal.pntd.0002953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=24968000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ygtLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=e2953&author=K.+Awadziauthor=N.+O.+Opokuauthor=S.+K.+Attahauthor=J.+Lazdins-Heldsauthor=A.+C.+Kuesel&title=A+Randomized%2C+Single-Ascending-Dose%2C+Ivermectin-Controlled%2C+Double-Blind+Study+of+Moxidectin+in+Onchocerca+Volvulus+Infection&doi=10.1371%2Fjournal.pntd.0002953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection</span></div><div class="casAuthors">Awadzi, Kwablah; Opoku, Nicholas O.; Attah, Simon K.; Lazdins-Helds, Janis; Kuesel, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e2953/1-e2953/18, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Control of onchocerciasis as a public health problem in Africa relies on annual mass ivermectin distribution.  New tools are needed to achieve elimination of infection.  This study detd. in a small no. of Onchocerca volvulus infected individuals whether moxidectin, a veterinary anthelmintic, is safe enough to administer it in a future large study to further characterize moxidectin's safety and efficacy.  Effects on the parasite were also assessed.  Methodol./Principal Findings: Men and women from a forest area in South-eastern Ghana without ivermectin mass distribution received a single oral dose of 2 mg (N = 44), 4 mg (N = 45) or 8 mg (N = 38) moxidectin or 150 μg/kg ivermectin (N = 45) with 18 mo follow up.  All ivermectin and 97%-100% of moxidectin treated participants had Mazzotti reactions.  Statistically significantly higher percentages of participants treated with 8 mg moxidectin than participants treated with ivermectin experienced pruritus (87% vs. 56%), rash (63% vs. 42%), increased pulse rate (61% vs. 36%) and decreased mean arterial pressure upon 2 min standing still after ≥5 min supine relative to pre-treatment (61% vs. 27%).  These reactions resolved without treatment.  In the 8 mg moxidectin and ivermectin arms, the mean ± SD no. of microfilariae/mg skin were 22.9 ± 21.1 and 21.2 ± 16.4 pre-treatment and 0.0 ± 0.0 and 1.1 ± 4.2 at nadir reached 1 and 3 mo after treatment, resp.  At 6 mo, values were 0.0 ± 0.0 and 1.6 ± 4.5, at 12 mo 0.4 ± 0.9 and 3.4 ± 4.4 and at 18 mo 1.8 ± 3.3 and 4.0 ± 4.8, resp., in the 8 mg moxidectin and ivermectin arm.  The redn. from pre-treatment values was significantly higher after 8 mg moxidectin than after ivermectin treatment throughout follow up (p<0.01).  Conclusions/Significance: The 8 mg dose of moxidectin was safe enough to initiate the large study.  Provided its results confirm those from this study, availability of moxidectin to control programs could help them achieve onchocerciasis elimination objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt6NNNvsiF7LVg90H21EOLACvtfcHk0lgUoJBjNcQDKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ygtLbN&md5=83f752c91d9ea93e8c31cc8efe6416a2</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0002953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0002953%26sid%3Dliteratum%253Aachs%26aulast%3DAwadzi%26aufirst%3DK.%26aulast%3DOpoku%26aufirst%3DN.%2BO.%26aulast%3DAttah%26aufirst%3DS.%2BK.%26aulast%3DLazdins-Helds%26aufirst%3DJ.%26aulast%3DKuesel%26aufirst%3DA.%2BC.%26atitle%3DA%2520Randomized%252C%2520Single-Ascending-Dose%252C%2520Ivermectin-Controlled%252C%2520Double-Blind%2520Study%2520of%2520Moxidectin%2520in%2520Onchocerca%2520Volvulus%2520Infection%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2014%26volume%3D8%26spage%3De2953%26doi%3D10.1371%2Fjournal.pntd.0002953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cobb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckh, A.</span></span> <span> </span><span class="NLM_article-title">Moxidectin: A Review of Chemistry, Pharmacokinetics and Use in Horses</span>. <i>Parasites Vectors</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">S5</span>, <span class="refDoi"> DOI: 10.1186/1756-3305-2-S2-S5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1186%2F1756-3305-2-S2-S5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=19778466" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=S5&author=R.+Cobbauthor=A.+Boeckh&title=Moxidectin%3A+A+Review+of+Chemistry%2C+Pharmacokinetics+and+Use+in+Horses&doi=10.1186%2F1756-3305-2-S2-S5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1186%2F1756-3305-2-S2-S5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-3305-2-S2-S5%26sid%3Dliteratum%253Aachs%26aulast%3DCobb%26aufirst%3DR.%26aulast%3DBoeckh%26aufirst%3DA.%26atitle%3DMoxidectin%253A%2520A%2520Review%2520of%2520Chemistry%252C%2520Pharmacokinetics%2520and%2520Use%2520in%2520Horses%26jtitle%3DParasites%2520Vectors%26date%3D2009%26volume%3D2%26spage%3DS5%26doi%3D10.1186%2F1756-3305-2-S2-S5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prichard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lespine, A.</span></span> <span> </span><span class="NLM_article-title">Moxidectin and the Avermectins: Consanguinity but Not Identity</span>. <i>Int. J. Parasitol.: Drugs Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.ijpddr.2012.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.ijpddr.2012.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=24533275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BC2cfls1ehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=134-153&author=R.+Prichardauthor=C.+Menezauthor=A.+Lespine&title=Moxidectin+and+the+Avermectins%3A+Consanguinity+but+Not+Identity&doi=10.1016%2Fj.ijpddr.2012.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Moxidectin and the avermectins: Consanguinity but not identity</span></div><div class="casAuthors">Prichard Roger; Menez Cecile; Lespine Anne</div><div class="citationInfo"><span class="NLM_cas:title">International journal for parasitology. Drugs and drug resistance</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-53</span>
        ISSN:<span class="NLM_cas:issn">2211-3207</span>.
    </div><div class="casAbstract">The avermectins and milbemycins contain a common macrocyclic lactone (ML) ring, but are fermentation products of different organisms.  The principal structural difference is that avermectins have sugar groups at C13 of the macrocyclic ring, whereas the milbemycins are protonated at C13.  Moxidectin (MOX), belonging to the milbemycin family, has other differences, including a methoxime at C23.  The avermectins and MOX have broad-spectrum activity against nematodes and arthropods.  They have similar but not identical, spectral ranges of activity and some avermectins and MOX have diverse formulations for great user flexibility.  The longer half-life of MOX and its safety profile, allow MOX to be used in long-acting formulations.  Some important differences between MOX and avermectins in interaction with various invertebrate ligand-gated ion channels are known and could be the basis of different efficacy and safety profiles.  Modelling of IVM interaction with glutamate-gated ion channels suggest different interactions will occur with MOX.  Similarly, profound differences between MOX and the avermectins are seen in interactions with ABC transporters in mammals and nematodes.  These differences are important for pharmacokinetics, toxicity in animals with defective transporter expression, and probable mechanisms of resistance.  Resistance to the avermectins has become widespread in parasites of some hosts and MOX resistance also exists and is increasing.  There is some degree of cross-resistance between the avermectins and MOX, but avermectin resistance and MOX resistance are not identical.  In many cases when resistance to avermectins is noticed, MOX produces a higher efficacy and quite often is fully effective at recommended dose rates.  These similarities and differences should be appreciated for optimal decisions about parasite control, delaying, managing or reversing resistances, and also for appropriate anthelmintic combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSL5mESGuQZEE2yPDyEFiigfW6udTcc2eZB7yHiz_j1v7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfls1ehsQ%253D%253D&md5=960e3a7fb538f95e0a2772934af0929a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpddr.2012.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpddr.2012.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DPrichard%26aufirst%3DR.%26aulast%3DMenez%26aufirst%3DC.%26aulast%3DLespine%26aufirst%3DA.%26atitle%3DMoxidectin%2520and%2520the%2520Avermectins%253A%2520Consanguinity%2520but%2520Not%2520Identity%26jtitle%3DInt.%2520J.%2520Parasitol.%253A%2520Drugs%2520Drug%2520Resist.%26date%3D2012%26volume%3D2%26spage%3D134%26epage%3D153%26doi%3D10.1016%2Fj.ijpddr.2012.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lumaret, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errouissi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floate, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rombke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardhaugh, K.</span></span> <span> </span><span class="NLM_article-title">A Review on the Toxicity and Non-Target Effects of Macrocyclic Lactones in Terrestrial and Aquatic Environments</span>. <i>Curr. Pharm. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1004</span>– <span class="NLM_lpage">1060</span>, <span class="refDoi"> DOI: 10.2174/138920112800399257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F138920112800399257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=22039795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns1eltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=1004-1060&author=J.-P.+Lumaretauthor=F.+Errouissiauthor=K.+Floateauthor=J.+Rombkeauthor=K.+Wardhaugh&title=A+Review+on+the+Toxicity+and+Non-Target+Effects+of+Macrocyclic+Lactones+in+Terrestrial+and+Aquatic+Environments&doi=10.2174%2F138920112800399257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A review on the toxicity and non-target effects of macrocyclic lactones in terrestrial and aquatic environments</span></div><div class="casAuthors">Lumaret, Jean-Pierre; Errouissi, Faiek; Floate, Kevin; Rombke, Jorg; Wardhaugh, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1004-1060</span>CODEN:
                <span class="NLM_cas:coden">CPBUBP</span>;
        ISSN:<span class="NLM_cas:issn">1389-2010</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The avermectins, milbemycins and spinosyns are collectively referred to as macrocyclic lactones (MLs) which comprise several classes of chems. derived from cultures of soil micro-organisms.  These compds. are extensively and increasingly used in veterinary medicine and agriculture.  Due to their potential effects on non-target organisms, large amts. of information on their impact in the environment has been compiled in recent years, mainly caused by legal requirements related to their marketing authorization or registration.  The main objective of this paper is to critically review the present knowledge about the acute and chronic ecotoxicol. effects of MLs on organisms, mainly invertebrates, in the terrestrial and aquatic environment.  Detailed information is presented on the mode-of-action as well as the ecotoxicity of the most important compds. representing the three groups of MLs.  This information, based on more than 360 refs., is mainly provided in nine tables, presenting the effects of abamectin, ivermectin, eprinomectin, doramectin, emamectin, moxidectin, and spinosad on individual species of terrestrial and aquatic invertebrates as well as plants and algae.  Since dung dwelling organisms are particularly important non-targets, as they are exposed via dung from treated animals over their whole life-cycle, the information on the effects of MLs on dung communities is compiled in an addnl. table.  The results of this review clearly demonstrate that regarding environmental impacts many macrocyclic lactones are substances of high concern, particularly with larval instars of invertebrates.  Recent studies have also shown that susceptibility varies with life cycle stage and impacts can be mitigated by using MLs when these stages are not present.  However, information on the environmental impact of the MLs is scattered across a wide range of specialised scientific journals with research focusing mainly on ivermectin and to a lesser extent on abamectin doramectin and moxidectin.  By comparison, information on compds. such as eprinomectin, emamectin and selamectin is still relatively scarce.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXcE3YHuQiCLVg90H21EOLACvtfcHk0lgUoJBjNcQDKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns1eltLo%253D&md5=114cc1d8a05245f0cc5fb345b5091aac</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2174%2F138920112800399257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920112800399257%26sid%3Dliteratum%253Aachs%26aulast%3DLumaret%26aufirst%3DJ.-P.%26aulast%3DErrouissi%26aufirst%3DF.%26aulast%3DFloate%26aufirst%3DK.%26aulast%3DRombke%26aufirst%3DJ.%26aulast%3DWardhaugh%26aufirst%3DK.%26atitle%3DA%2520Review%2520on%2520the%2520Toxicity%2520and%2520Non-Target%2520Effects%2520of%2520Macrocyclic%2520Lactones%2520in%2520Terrestrial%2520and%2520Aquatic%2520Environments%26jtitle%3DCurr.%2520Pharm.%2520Biotechnol.%26date%3D2012%26volume%3D13%26spage%3D1004%26epage%3D1060%26doi%3D10.2174%2F138920112800399257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiala, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, D. B.</span></span> <span> </span><span class="NLM_article-title">Biosynthetic Origin of the Carbon Skeleton and Oxygen Atoms of the LL-F28249α, a Potent Antiparasitic Macrolide</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.42.398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.7164%2Fantibiotics.42.398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=2708133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaL1MXktVeru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1989&pages=398-406&author=H.+R.+Tsouauthor=Z.+H.+Ahmedauthor=R.+R.+Fialaauthor=M.+W.+Bullockauthor=G.+T.+Carterauthor=J.+J.+Goodmanauthor=D.+B.+Borders&title=Biosynthetic+Origin+of+the+Carbon+Skeleton+and+Oxygen+Atoms+of+the+LL-F28249%CE%B1%2C+a+Potent+Antiparasitic+Macrolide&doi=10.7164%2Fantibiotics.42.398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51aR"><div class="casContent"><span class="casTitleNuber">51a</span><div class="casTitle"><span class="NLM_cas:atitle">Biosynthetic origin of the carbon skeleton and oxygen atoms of the LL-F28249α, a potent antiparasitic macrolide</span></div><div class="casAuthors">Tsou, H. R.; Ahmed, Z. H.; Fiala, R. R.; Bullock, M. W.; Carter, G. T.; Goodman, J. J.; Borders, D. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">398-406</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">The biosynthesis of LL-F28249α (I) in a culture of Streptomyces cyanogriseus was studied using 13C-, 14C-, and 18O-labeled precursors.  A complete 13C-NMR spectrum of I was assigned.  Incorporation studies using 13-labeled precursors indicate that the C skeleton of I is derived from 7 acetate, 6 propionate, and one 2-methylpropionate units.  The origin of the O atoms of I was examd. by feeding [1-13C,18O2]acetate, [1-13C,18O2]propionate, [2-13C]acetate/18O2, and 18O2 sep. to the fermn. culture and analyzing the resulting labeled I samples by 13C-NMR, electron impact MS, and chem. ionization MS.  Of 8 O atoms in I, 4 are derived from acetate, 3 from propionate, and 1 from O2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrWVg6YkDLkLVg90H21EOLACvtfcHk0lhjlGI1FvLJ3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXktVeru7o%253D&md5=fb4d1f9e5d1e8a49fe9f883f6086d1b9</span></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.42.398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.42.398%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DAhmed%26aufirst%3DZ.%2BH.%26aulast%3DFiala%26aufirst%3DR.%2BR.%26aulast%3DBullock%26aufirst%3DM.%2BW.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26aulast%3DGoodman%26aufirst%3DJ.%2BJ.%26aulast%3DBorders%26aufirst%3DD.%2BB.%26atitle%3DBiosynthetic%2520Origin%2520of%2520the%2520Carbon%2520Skeleton%2520and%2520Oxygen%2520Atoms%2520of%2520the%2520LL-F28249%25CE%25B1%252C%2520a%2520Potent%2520Antiparasitic%2520Macrolide%26jtitle%3DJ.%2520Antibiot.%26date%3D1989%26volume%3D42%26spage%3D398%26epage%3D406%26doi%3D10.7164%2Fantibiotics.42.398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit51b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Enhancing Nemadectin Production by Streptomyces Cyaneogriseus Ssp. Noncyanogenus through Quantitative Evaluation and Optimization of Dissolved Oxygen and Shear Force</span>. <i>Bioresour. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">180</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1016/j.biortech.2017.09.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.biortech.2017.09.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29414165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKqtbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=2018&pages=180-188&author=X.+Songauthor=Y.+Zhangauthor=J.+Xueauthor=C.+Liauthor=Z.+Wangauthor=Y.+Wang&title=Enhancing+Nemadectin+Production+by+Streptomyces+Cyaneogriseus+Ssp.+Noncyanogenus+through+Quantitative+Evaluation+and+Optimization+of+Dissolved+Oxygen+and+Shear+Force&doi=10.1016%2Fj.biortech.2017.09.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51bR"><div class="casContent"><span class="casTitleNuber">51b</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing nemadectin production by Streptomyces cyaneogriseus ssp. noncyanogenus through quantitative evaluation and optimization of dissolved oxygen and shear force</span></div><div class="casAuthors">Song, Xiaoqing; Zhang, Yun; Xue, Jiayun; Li, Chao; Wang, Zejian; Wang, Yonghong</div><div class="citationInfo"><span class="NLM_cas:title">Bioresource Technology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">180-188</span>CODEN:
                <span class="NLM_cas:coden">BIRTEB</span>;
        ISSN:<span class="NLM_cas:issn">0960-8524</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In this study, effects of oxygen supply and shear stress on nemadectin prodn. by Streptomyces cyaneogriseus ssp. noncyanogenus (S. cyaneogriseus) fermn. were investigated in shake flasks and 5-L bioreactors.  Results showed sufficient dissolved oxygen level was essential for cells growth and nemadectin biosynthesis, while strong shear stress had neg. impacts on both cell growth and nemadectin synthesis.  Furthermore, when a combined paddle type was applied in culturing S. cyaneogriseus, the nemadectin prodn. was increased by 23.6%.  The influence of different agitation rates and paddle types on volumetric oxygen transfers coeff. (KLa) and shear stress were quant. studied through computational fluid dynamics simulation (CFD).  The results of CFD revealed that high KLa as well as low shear stress co-existed under the combined impeller configuration at 650 rpm.  This study is expected to be helpful to the scale-up of nemadectin fermn. and other stress-sensitive but high-oxygen-consumption filamentous microorganism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK2RC-OLYBuLVg90H21EOLACvtfcHk0lhjlGI1FvLJ3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKqtbfP&md5=3d7cd6a7ba3ddf49a5a671e5ab483cdf</span></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=10.1016%2Fj.biortech.2017.09.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biortech.2017.09.033%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DEnhancing%2520Nemadectin%2520Production%2520by%2520Streptomyces%2520Cyaneogriseus%2520Ssp.%2520Noncyanogenus%2520through%2520Quantitative%2520Evaluation%2520and%2520Optimization%2520of%2520Dissolved%2520Oxygen%2520and%2520Shear%2520Force%26jtitle%3DBioresour.%2520Technol.%26date%3D2018%26volume%3D255%26spage%3D180%26epage%3D188%26doi%3D10.1016%2Fj.biortech.2017.09.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Process for Eliminating Byproduct Dimethyl Sulfide from Production of Moxidectin</span>. <span class="NLM_patent">CN105294729A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Dai&author=H.+Li&author=R.+Wang&title=Process+for+Eliminating+Byproduct+Dimethyl+Sulfide+from+Production+of+Moxidectin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26atitle%3DProcess%2520for%2520Eliminating%2520Byproduct%2520Dimethyl%2520Sulfide%2520from%2520Production%2520of%2520Moxidectin%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit52b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Dai, Y.</span>; <span class="NLM_string-name">Wang, W.</span>; <span class="NLM_string-name">Zhao, D.</span>; <span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing High-Purity Moxidectin Using Membrane Separation</span>. <span class="NLM_patent">CN104356140A</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+Li&author=Y.+Dai&author=W.+Wang&author=D.+Zhao&author=R.+Wang&title=Method+for+Preparing+High-Purity+Moxidectin+Using+Membrane+Separation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26atitle%3DMethod%2520for%2520Preparing%2520High-Purity%2520Moxidectin%2520Using%2520Membrane%2520Separation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit52c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span>; <span class="NLM_string-name">Wen, J.</span>; <span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Moxidectin</span>. <span class="NLM_patent">CN104277050A</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+He&author=J.+Wen&author=H.+Zhang&title=Method+for+Preparing+Moxidectin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26atitle%3DMethod%2520for%2520Preparing%2520Moxidectin%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit52d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span>; <span class="NLM_string-name">Du, Z.</span>; <span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Preparation of Moxidectin</span>. <span class="NLM_patent">CN104017001B</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Dai&author=Z.+Du&author=R.+Wang&title=Preparation+of+Moxidectin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Moxidectin%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfitzner, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffatt, J. G.</span></span> <span> </span><span class="NLM_article-title">A New and Selective Oxidation of Alcohols</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">3027</span>– <span class="NLM_lpage">3028</span>, <span class="refDoi"> DOI: 10.1021/ja00902a036</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00902a036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaF3sXkvVantbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1963&pages=3027-3028&author=K.+E.+Pfitznerauthor=J.+G.+Moffatt&title=A+New+and+Selective+Oxidation+of+Alcohols&doi=10.1021%2Fja00902a036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The synthesis of nucleoside 5'-carboxaldehydes</span></div><div class="casAuthors">Pfitzner, K. E.; Moffatt, J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1963</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3027</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Addn. of dicyclohexylcarbodiimide (I) to an anhyd. soln. of pyridinium thymidine 5'-phosphate in Me2SO after 1 hr. at room temp. gave thymine (II) and inorg. phosphates.  A similar release of II resulted from P1,P2-dithymidine pyrophosphate, thymidine, and 5'-O-acetylthymidine, but not from 3'-O-acetylthymidine 5'phosphate, 3'-deoxythymidine 5'-phosphate, or the corresponding nucleosides in the presence of phosphate.  Treatment of 1 millimole 3'-O-acetylthymidine in 3 ml. anhyd. Me2SO contg. 0.5 millimole phosphoric acid with 3-5 millimoles I for several hrs. at room temp. gave no release of II, but rather 3'-O-acetyl thymidine 5'-carboxaldehyde (III), λ 267 mμ in H2O [2,4-di-nitrophenylhydrazone m. 233-34°,  (MeOH) 261 and 350 mμ (ε 19,300 and 21,650)], completely free of acidic nucleoside derivs. Redn. of III with NaBH4 gave II, while oxidn. of III with NaOI gave 3'-O-acetylthymidine 5'-carboxylic acid, which on alk. hydrolysis gave thymidine 5'-carboxylic acid. Similarly, the reaction of 2',3'-O-isopropylideneuridine and 2',3'-O-iso-propylideneadenosine with I and 0.5 mole-equiv. pyridinium trifluoroacetate or pyridinium phosphate in anhyd.  Me2SO, followed by treatment with 10% HOAc at 100° for 1 hr., gave uridine 5'carboxaldehyde and adenosine 5'-carboxaldehyde.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-8EJfx87wgbVg90H21EOLACvtfcHk0ljRgSO2tRkH-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3sXkvVantbY%253D&md5=3f46daf90e60de38496a7379b113674e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fja00902a036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00902a036%26sid%3Dliteratum%253Aachs%26aulast%3DPfitzner%26aufirst%3DK.%2BE.%26aulast%3DMoffatt%26aufirst%3DJ.%2BG.%26atitle%3DA%2520New%2520and%2520Selective%2520Oxidation%2520of%2520Alcohols%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1963%26volume%3D85%26spage%3D3027%26epage%3D3028%26doi%3D10.1021%2Fja00902a036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razzak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kassas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, S.</span></span> <span> </span><span class="NLM_article-title">Analytical Profile of Moxidectin</span>. <i>Profiles Drug Subst., Excipients, Relat. Methodol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-407691-4.00007-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FB978-0-12-407691-4.00007-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=23668407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ChtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=315-366&author=A.+Awasthiauthor=M.+Razzakauthor=R.+Al-Kassasauthor=J.+Harveyauthor=S.+Garg&title=Analytical+Profile+of+Moxidectin&doi=10.1016%2FB978-0-12-407691-4.00007-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Analytical profile of moxidectin</span></div><div class="casAuthors">Awasthi, Atul; Razzak, Majid; Al-Kassas, Raida; Harvey, Joanne; Garg, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Profiles of Drug Substances, Excipients, and Related Methodology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-366</span>CODEN:
                <span class="NLM_cas:coden">PDSEBJ</span>;
        ISSN:<span class="NLM_cas:issn">1871-5125</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Moxidectin or F28249α is a potent endectocide and semisynthetic methoxime deriv. of naturally occurring nemadectin.  It is well known for the novel mode of action against a broad range of nematode and anthropod animal parasites.  In this work, physicochem. and pharmaceutical aspects of moxidectin are described including stability, semisynthesis, purifn. processes, formulation compns., impurities, and degrdn. pathways.  Addnl. expts. such as DSC, XRD, and CHN anal. were carried out to complete the profile of moxidectin.  The importance of safety and quality of drug substances was highlighted by chronol. developments involving moxidectin and its analogs.  The information gathered from the literature was used to trace the origins of moxidectin-related substances presented in the European Pharmacopeia (EP) compendial monograph.  During the review, it was noticed that majority of impurities presented in the EP does not have any potential to increase with time in drug substance or formulated products; therefore, they do not require monitoring during stability studies.  This also showed the requirement for further characterization of the impurities obsd. during long-term storage and development of stability indicating methods distinguishing between process impurities and the true degrdn. products.  Furthermore, the stability of moxidectin in formulations is also reviewed in conjunction with known degrdn. routes and innovative ways to formulate products that are stable and effective at intended shelf life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI7xKWihUrArVg90H21EOLACvtfcHk0ljRgSO2tRkH-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ChtrrL&md5=0498df4db478ca73235464a0f702c3fa</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-407691-4.00007-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-407691-4.00007-1%26sid%3Dliteratum%253Aachs%26aulast%3DAwasthi%26aufirst%3DA.%26aulast%3DRazzak%26aufirst%3DM.%26aulast%3DAl-Kassas%26aufirst%3DR.%26aulast%3DHarvey%26aufirst%3DJ.%26aulast%3DGarg%26aufirst%3DS.%26atitle%3DAnalytical%2520Profile%2520of%2520Moxidectin%26jtitle%3DProfiles%2520Drug%2520Subst.%252C%2520Excipients%252C%2520Relat.%2520Methodol.%26date%3D2013%26volume%3D38%26spage%3D315%26epage%3D366%26doi%3D10.1016%2FB978-0-12-407691-4.00007-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, N. J.</span></span> <span> </span><span class="NLM_article-title">Tafenoquine - a Radical Improvement?</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1056/NEJMe1816383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1056%2FNEJMe1816383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30650321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cjitFaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=285-286&author=N.+J.+White&title=Tafenoquine+-+a+Radical+Improvement%3F&doi=10.1056%2FNEJMe1816383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Tafenoquine - A Radical Improvement?</span></div><div class="casAuthors">White Nicholas J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-286</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvc9lL5gewfEcLvDNbOD4DfW6udTcc2eZkNnU5wzsQr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjitFaksA%253D%253D&md5=0866617ff05aeab14b4d4e12f9365c4a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1816383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1816383%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DN.%2BJ.%26atitle%3DTafenoquine%2520-%2520a%2520Radical%2520Improvement%253F%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D285%26epage%3D286%26doi%3D10.1056%2FNEJMe1816383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blumbergs, P.</span>; <span class="NLM_string-name">LaMontagne, M. P.</span></span> <span> </span><span class="NLM_article-title">4-Methyl-5-[(Un)Substituted Phenoxy]-2,6-dimethoxy-8-(aminoalkylamino)quinolines</span>. <span class="NLM_patent">US4617394A</span>, <span class="NLM_year">1986</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&author=P.+Blumbergs&author=M.+P.+LaMontagne&title=4-Methyl-5-%5B%28Un%29Substituted+Phenoxy%5D-2%2C6-dimethoxy-8-%28aminoalkylamino%29quinolines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlumbergs%26aufirst%3DP.%26atitle%3D4-Methyl-5-%255B%2528Un%2529Substituted%2520Phenoxy%255D-2%252C6-dimethoxy-8-%2528aminoalkylamino%2529quinolines%26date%3D1986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vennerstrom, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuzum, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dande, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhous, W. K.</span></span> <span> </span><span class="NLM_article-title">8-Aminoquinolines Active against Blood Stage Plasmodium Falciparum in Vitro Inhibit Hematin Polymerization</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1128/AAC.43.3.598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1128%2FAAC.43.3.598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10049273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK1MXhsF2htbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1999&pages=598-602&author=J.+L.+Vennerstromauthor=E.+O.+Nuzumauthor=R.+E.+Millerauthor=A.+Dornauthor=L.+Gerenaauthor=P.+A.+Dandeauthor=W.+Y.+Ellisauthor=R.+G.+Ridleyauthor=W.+K.+Milhous&title=8-Aminoquinolines+Active+against+Blood+Stage+Plasmodium+Falciparum+in+Vitro+Inhibit+Hematin+Polymerization&doi=10.1128%2FAAC.43.3.598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization</span></div><div class="casAuthors">Vennerstrom, Jonathan L.; Nuzum, Edwin O.; Miller, Robert E.; Dorn, Arnulf; Gerena, Lucia; Dande, Prasad A.; Ellis, William Y.; Ridley, Robert G.; Milhous, Wilbur K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">598-602</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">From the Walter Reed Army Institute of Research (WRAIR) inventory, thirteen 8-aminoquinoline analogs of primaquine were selected for screening against a panel of seven Plasmodium falciparum clones and isolates.  Six of the 13 8-aminoquinolines, including I, II, and III, had av. 50% inhibitory concns. between 50 and 100 nM against these P. falciparum clones and were thus an order of magnitude more potent than primaquine.  However, excluding chloroquine-resistant clones and isolates, these 8-aminoquinolines were all an order of magnitude less potent than chloroquine.  None of the 8-aminoquinolines was cross resistant with either chloroquine or mefloquine.  In contrast to the inactive primaquine prototype, 8 of the 13 8-aminoquinolines inhibited hematin polymn. more efficiently than did chloroquine.  Although alkoxy or aryloxy substituents at position 5 uniquely endowed these 13 8-aminoquinolines with impressive schizontocidal activity, the structural specificity of inhibition of both parasite growth and hematin polymn. was low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosjpI6rzAadrVg90H21EOLACvtfcHk0li9qA9-q0ymrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsF2htbc%253D&md5=15467291ff3d1a7553190a14997228c9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1128%2FAAC.43.3.598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.43.3.598%26sid%3Dliteratum%253Aachs%26aulast%3DVennerstrom%26aufirst%3DJ.%2BL.%26aulast%3DNuzum%26aufirst%3DE.%2BO.%26aulast%3DMiller%26aufirst%3DR.%2BE.%26aulast%3DDorn%26aufirst%3DA.%26aulast%3DGerena%26aufirst%3DL.%26aulast%3DDande%26aufirst%3DP.%2BA.%26aulast%3DEllis%26aufirst%3DW.%2BY.%26aulast%3DRidley%26aufirst%3DR.%2BG.%26aulast%3DMilhous%26aufirst%3DW.%2BK.%26atitle%3D8-Aminoquinolines%2520Active%2520against%2520Blood%2520Stage%2520Plasmodium%2520Falciparum%2520in%2520Vitro%2520Inhibit%2520Hematin%2520Polymerization%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1999%26volume%3D43%26spage%3D598%26epage%3D602%26doi%3D10.1128%2FAAC.43.3.598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque-Ortega, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzano, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanys, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamarro, F.</span></span> <span> </span><span class="NLM_article-title">Tafenoquine, an Antiplasmodial 8-Aminoquinoline, Targets Leishmania Respiratory Complex III and Induces Apoptosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5344</span>– <span class="NLM_lpage">5351</span>, <span class="refDoi"> DOI: 10.1128/AAC.00790-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1128%2FAAC.00790-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20837758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5344-5351&author=L.+Carvalhoauthor=J.+R.+Luque-Ortegaauthor=J.+I.+Manzanoauthor=S.+Castanysauthor=L.+Rivasauthor=F.+Gamarro&title=Tafenoquine%2C+an+Antiplasmodial+8-Aminoquinoline%2C+Targets+Leishmania+Respiratory+Complex+III+and+Induces+Apoptosis&doi=10.1128%2FAAC.00790-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58aR"><div class="casContent"><span class="casTitleNuber">58a</span><div class="casTitle"><span class="NLM_cas:atitle">Tafenoquine, an antiplasmodial 8-aminoquinoline, targets Leishmania respiratory complex III and induces apoptosis</span></div><div class="casAuthors">Carvalho, Luis; Luque-Ortega, Juan Roman; Manzano, Jose Ignacio; Castanys, Santiago; Rivas, Luis; Gamarro, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5344-5351</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tafenoquine (TFQ), an 8-aminoquinoline analog of primaquine, which is under clin. trial (phase IIb/III) for the treatment and prevention of malaria, may represent an alternative treatment for leishmaniasis.  Here, the authors have studied the mechanism of action of TFQ against Leishmania parasites.  TFQ impaired the overall bioenergetic metab. of Leishmania promastigotes, causing a rapid drop in intracellular ATP levels without affecting plasma membrane permeability.  TFQ induced mitochondrial dysfunction through the inhibition of cytochrome c reductase (respiratory complex III) with a decrease in the oxygen consumption rate and depolarization of mitochondrial membrane potential.  This was accompanied by ROS prodn., elevation of intracellular Ca2+ levels and concomitant nuclear DNA fragmentation.  It is concluded that TFQ targets Leishmania mitochondria, leading to an apoptosis-like death process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqub4UUn4WPo7Vg90H21EOLACvtfcHk0li9qA9-q0ymrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FO&md5=966bb6693b6e5cf4a16482a642b5e9e4</span></div><a href="/servlet/linkout?suffix=cit58a&amp;dbid=16384&amp;doi=10.1128%2FAAC.00790-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00790-10%26sid%3Dliteratum%253Aachs%26aulast%3DCarvalho%26aufirst%3DL.%26aulast%3DLuque-Ortega%26aufirst%3DJ.%2BR.%26aulast%3DManzano%26aufirst%3DJ.%2BI.%26aulast%3DCastanys%26aufirst%3DS.%26aulast%3DRivas%26aufirst%3DL.%26aulast%3DGamarro%26aufirst%3DF.%26atitle%3DTafenoquine%252C%2520an%2520Antiplasmodial%25208-Aminoquinoline%252C%2520Targets%2520Leishmania%2520Respiratory%2520Complex%2520III%2520and%2520Induces%2520Apoptosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5344%26epage%3D5351%26doi%3D10.1128%2FAAC.00790-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit58b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lanners, H. N.</span></span> <span> </span><span class="NLM_article-title">Effect of the 8-Aminoquinoline Primaquine on Culture-Derived Gametocytes of the Malaria Parasite Plasmodium Falciparum</span>. <i>Z. Parasitenkd.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">478</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1007/BF00928413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2FBF00928413" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1991&pages=478-481&author=H.+N.+Lanners&title=Effect+of+the+8-Aminoquinoline+Primaquine+on+Culture-Derived+Gametocytes+of+the+Malaria+Parasite+Plasmodium+Falciparum&doi=10.1007%2FBF00928413"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58b&amp;dbid=16384&amp;doi=10.1007%2FBF00928413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00928413%26sid%3Dliteratum%253Aachs%26aulast%3DLanners%26aufirst%3DH.%2BN.%26atitle%3DEffect%2520of%2520the%25208-Aminoquinoline%2520Primaquine%2520on%2520Culture-Derived%2520Gametocytes%2520of%2520the%2520Malaria%2520Parasite%2520Plasmodium%2520Falciparum%26jtitle%3DZ.%2520Parasitenkd.%26date%3D1991%26volume%3D77%26spage%3D478%26epage%3D481%26doi%3D10.1007%2FBF00928413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayes, M.</span></span> <span> </span><span class="NLM_article-title">Tafenoquine Succinate: Antimalarial</span>. <i>Drugs Future</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1358/dof.2003.028.09.758545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdof.2003.028.09.758545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVKitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=859-869&author=J.+A.+McIntyreauthor=J.+Castanerauthor=M.+Bayes&title=Tafenoquine+Succinate%3A+Antimalarial&doi=10.1358%2Fdof.2003.028.09.758545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Tafenoquine succinate: Antimalarial</span></div><div class="casAuthors">McIntyre, J. A.; Castaner, J.; Bayes, M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">859-869</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Malaria is a significant public health problem in developing and third world countries.  Plasmodium falciparum and Plasmodium vivax parasites are responsible for the majority of cases of malaria infection.  Treatment focuses on both chemoprevention and treatment of acute infection, but the currently used drugs are threatened by drug-resistant species in many parts of the world.  Tatenoquine is a new 8-aminoquinoline with an improved therapeutic index and safety profile as compared to primaquine.  In pharmacol. studies, tafenoquine has been shown to be at least 10 times more potent than primaquine and has a much longer half-life, allowing less frequent dosing in chemoprophylactic regimens.  Its clin. efficacy has been demonstrated in a no. of studies, both as a chemoprophylactic agent for the prevention of P. falciparum infection and as an acute treatment against the liver stages of P. vivax.  Tafenoquine has the potential to become a widely used drug in the prevention and treatment of malaria infection and could replace some currently used drugs as resistant strains of Plasmodium species increase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIb_SpLEdDdrVg90H21EOLACvtfcHk0li9qA9-q0ymrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVKitb4%253D&md5=eced4bb3ff52010f67c6c82ad4afe4a0</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1358%2Fdof.2003.028.09.758545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2003.028.09.758545%26sid%3Dliteratum%253Aachs%26aulast%3DMcIntyre%26aufirst%3DJ.%2BA.%26aulast%3DCastaner%26aufirst%3DJ.%26aulast%3DBayes%26aufirst%3DM.%26atitle%3DTafenoquine%2520Succinate%253A%2520Antimalarial%26jtitle%3DDrugs%2520Future%26date%3D2003%26volume%3D28%26spage%3D859%26epage%3D869%26doi%3D10.1358%2Fdof.2003.028.09.758545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D.</span>; <span class="NLM_string-name">Davies, B. J.</span>; <span class="NLM_string-name">Kincey, P. M.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Quinoline Derivatives</span>. <span class="NLM_patent">WO2003093239A2</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=D.+Bell&author=B.+J.+Davies&author=P.+M.+Kincey&title=Process+for+the+Preparation+of+Quinoline+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DD.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Quinoline%2520Derivatives%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeds, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyavanagimatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, D. E.</span></span> <span> </span><span class="NLM_article-title">Development of ST-246 for Treatment of Poxvirus Infections</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2409</span>– <span class="NLM_lpage">2435</span>, <span class="refDoi"> DOI: 10.3390/v2112409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.3390%2Fv2112409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=21994624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVentbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=2409-2435&author=R.+Jordanauthor=J.+M.+Leedsauthor=S.+Tyavanagimattauthor=D.+E.+Hruby&title=Development+of+ST-246+for+Treatment+of+Poxvirus+Infections&doi=10.3390%2Fv2112409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Development of ST-246 for treatment of poxvirus infections</span></div><div class="casAuthors">Jordan, Robert; Leeds, Janet M.; Tyavanagimatt, Shanthakumar; Hruby, Dennis E.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2409-2435</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  ST-246 (Tecovirimat) is a small synthetic antiviral compd. being developed to treat pathogenic orthopoxvirus infections of humans.  The compd. was discovered as part of a high throughput screen designed to identify inhibitors of vaccinia virus-induced cytopathic effects.  The antiviral activity is specific for orthopoxviruses and the compd. does not inhibit the replication of other RNA- and DNA-contg. viruses or inhibit cell proliferation at concns. of compd. that are antiviral.  ST-246 targets vaccinia virus p37, a viral protein required for envelopment and secretion of extracellular forms of virus.  The compd. is orally bioavailable and protects multiple animal species from lethal orthopoxvirus challenge.  Preclin. safety pharmacol. studies in mice and non-human primates indicate that ST-246 is readily absorbed by the oral route and well tolerated with the no observable adverse effect level (NOAEL) in mice measured at 2000 mg/kg and the no observable effect level (NOEL) in non-human primates measured at 300 mg/kg.  Drug substance and drug product processes have been developed and com. scale batches have been produced using Good Manufg. Processes (GMP).  Human phase I clin. trials have shown that ST-246 is safe and well tolerated in healthy human volunteers.  Based on the results of the clin. evaluation, once a day dosing should provide plasma drug exposure in the range predicted to be antiviral based on data from efficacy studies in animal models of orthopoxvirus disease.  These data support the use of ST-246 as a therapeutic to treat pathogenic orthopoxvirus infections of humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmGadVchbhsbVg90H21EOLACvtfcHk0lj2G51_Zlcniw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVentbjM&md5=35bd35088ffa95b6a8346adb5d46891c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3390%2Fv2112409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv2112409%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DLeeds%26aufirst%3DJ.%2BM.%26aulast%3DTyavanagimatt%26aufirst%3DS.%26aulast%3DHruby%26aufirst%3DD.%2BE.%26atitle%3DDevelopment%2520of%2520ST-246%2520for%2520Treatment%2520of%2520Poxvirus%2520Infections%26jtitle%3DViruses%26date%3D2010%26volume%3D2%26spage%3D2409%26epage%3D2435%26doi%3D10.3390%2Fv2112409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Tecovirimat: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1382</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0967-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0967-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30120738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFCku7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1377-1382&author=S.+M.+Hoy&title=Tecovirimat%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0967-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Tecovirimat: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1377-1382</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Tecovirimat (TPOXX) is an orthopoxvirus-specific antiviral drug developed by SIGA Technologies in conjunction with the US Department of Health and Human Services' Biomedical Advances Research and Development Authority.  It acts by inhibiting the activity of the orthopoxvirus VP37 envelope wrapping protein, thereby preventing the formation of egress-competent enveloped virions, which are essential for dissemination of the virus in the host.  In July 2018, oral tecovirimat was approved in the USA for the treatment of human smallpox disease caused by variola virus in adults and paediatric patients weighing ≥ 13 kg.  Tecovirimat was approved under the US FDA's Animal Rule, in which marketing approval is based on its efficacy in relevant animal models.  An i.v. formulation of tecovirimat is undergoing phase I development for the treatment of smallpox infection.  This article summarises the milestones in the development of tecovirimat leading to this first approval for the treatment of human smallpox disease in adults and paediatric patients weighing ≥ 13 kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsN9oWSErgorVg90H21EOLACvtfcHk0lj2G51_Zlcniw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFCku7bF&md5=5824b1ec39cfd2be5d1915a25debae3a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0967-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0967-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DTecovirimat%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1377%26epage%3D1382%26doi%3D10.1007%2Fs40265-018-0967-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Merchlinsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albright, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiltz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkeley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challberg, M.</span></span> <span> </span><span class="NLM_article-title">The Development and Approval of Tecoviromat (TPOXX®), the First Antiviral against Smallpox</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.antiviral.2019.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=31181284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFOktLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=168-174&author=M.+Merchlinskyauthor=A.+Albrightauthor=V.+Olsonauthor=H.+Schiltzauthor=T.+Merkeleyauthor=C.+Hughesauthor=B.+Petersenauthor=M.+Challberg&title=The+Development+and+Approval+of+Tecoviromat+%28TPOXX%C2%AE%29%2C+the+First+Antiviral+against+Smallpox&doi=10.1016%2Fj.antiviral.2019.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63aR"><div class="casContent"><span class="casTitleNuber">63a</span><div class="casTitle"><span class="NLM_cas:atitle">The development and approval of tecoviromat (TPOXX), the first antiviral against smallpox</span></div><div class="casAuthors">Merchlinsky, Michael; Albright, Andrew; Olson, Victoria; Schiltz, Helen; Merkeley, Tyler; Hughes, Claiborne; Petersen, Brett; Challberg, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">168-174</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The classification of smallpox by the U.  S. Centers for Disease Control and Prevention (CDC) as a Category A Bioterrorism threat agent has resulted in the U.  S. Government investing significant funds to develop and stockpile a suite of medical countermeasures to ameliorate the consequences of a smallpox epidemic.  This stockpile includes both vaccines for prophylaxis and antivirals to treat symptomatic patients.  In this manuscript, we describe the path to approval for the first therapeutic against smallpox, identified during its development as ST-246, now known as tecovirimat and TPOXX, a small-mol. antiviral compd. sponsored by SIGA Technologies to treat symptomatic smallpox. Because the disease is no longer endemic, the development and approval of TPOXX was only possible under the U.  S. Food and Drug and Administration Animal Rule (FDA 2002).  In this article, we describe the combination of animal model studies and clin. trials that were used to satisfy the FDA requirements for the approval of TPOXX  under the Animal Rule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrraom8Rh5-irVg90H21EOLACvtfcHk0lj2G51_Zlcniw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFOktLfK&md5=a4ad1763632396c95698c9d0500e18fa</span></div><a href="/servlet/linkout?suffix=cit63a&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DMerchlinsky%26aufirst%3DM.%26aulast%3DAlbright%26aufirst%3DA.%26aulast%3DOlson%26aufirst%3DV.%26aulast%3DSchiltz%26aufirst%3DH.%26aulast%3DMerkeley%26aufirst%3DT.%26aulast%3DHughes%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DB.%26aulast%3DChallberg%26aufirst%3DM.%26atitle%3DThe%2520Development%2520and%2520Approval%2520of%2520Tecoviromat%2520%2528TPOXX%25C2%25AE%2529%252C%2520the%2520First%2520Antiviral%2520against%2520Smallpox%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D168%26spage%3D168%26epage%3D174%26doi%3D10.1016%2Fj.antiviral.2019.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit63b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Grosenbach, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honeychurch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinsangaram, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, D. E.</span></span> <span> </span><span class="NLM_article-title">Oral Tecovirimat for the Treatment of Smallpox</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1705688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1056%2FNEJMoa1705688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29972742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlert7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=44-53&author=D.+W.+Grosenbachauthor=K.+Honeychurchauthor=E.+A.+Roseauthor=J.+Chinsangaramauthor=A.+Frimmauthor=B.+Maitiauthor=C.+Lovejoyauthor=I.+Mearaauthor=P.+Longauthor=D.+E.+Hruby&title=Oral+Tecovirimat+for+the+Treatment+of+Smallpox&doi=10.1056%2FNEJMoa1705688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63bR"><div class="casContent"><span class="casTitleNuber">63b</span><div class="casTitle"><span class="NLM_cas:atitle">Oral tecovirimat for the treatment of smallpox</span></div><div class="casAuthors">Grosenbach, Douglas W.; Honeychurch, Kady; Rose, Eric A.; Chinsangaram, Jarasvech; Frimm, Annie; Maiti, Biswajit; Lovejoy, Candace; Meara, Ingrid; Long, Paul; Hruby, Dennis E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-53</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Smallpox was declared eradicated in 1980, but variola virus (VARV), which causes smallpox, still exists.  There is no known effective treatment for smallpox; therefore, tecovirimat is being developed as an oral smallpox therapy.  Because clin. trials in a context of natural disease are not possible, an alternative developmental path to evaluate efficacy and safety was needed. methods We investigated the efficacy of tecovirimat in nonhuman primate (monkeypox) and rabbit (rabbitpox) models in accordance with the Food and Drug Administration (FDA) Animal Efficacy Rule, which was interpreted for smallpox therapeutics by an expert advisory committee.  We also conducted a placebo-controlled pharmacokinetic and safety trial involving 449 adult volunteers. results The min. dose of tecovirimat required in order to achieve more than 90% survival in the monkeypox model was 10 mg per kg of body wt. for 14 days, and a dose of 40 mg per kg for 14 days was similarly efficacious in the rabbitpox model.  Although the ED per kg was higher in rabbits, exposure was lower, with a mean steady-state max., min., and av. (mean) concn. (Cmax, Cmin, and Cavg, resp.) of 374, 25, and 138 ng per mL, resp., in rabbits and 1444, 169, and 598 ng per mL in nonhuman primates, as well as an area under the concn.-time curve over 24 h (AUC0-24h) of 3318 ng × hours per mL in rabbits and 14,352 ng × hours per mL in nonhuman primates.  These findings suggested that the nonhuman primate was the more conservative model for the estn. of the required drug exposure in humans.  A dose of 600 mg twice daily for 14 days was selected for testing in humans and provided exposures in excess of those in nonhuman primates (mean steady-state Cmax, Cmin, and Cavg of 2209, 690, and 1270 ng per mL and AUC0-24h of 30,632 ng × hours per mL).  No pattern of troubling adverse events was obsd. conclusions On the basis of its efficacy in two animal models and pharmacokinetic and safety data in humans, tecovirimat is being advanced as a therapy for smallpox in accordance with the FDA Animal Rule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_dJtZ5rS5abVg90H21EOLACvtfcHk0linnrnZmXqQ2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlert7rJ&md5=2ba24cfcf5191d7d74a843bb3ce81313</span></div><a href="/servlet/linkout?suffix=cit63b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1705688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1705688%26sid%3Dliteratum%253Aachs%26aulast%3DGrosenbach%26aufirst%3DD.%2BW.%26aulast%3DHoneychurch%26aufirst%3DK.%26aulast%3DRose%26aufirst%3DE.%2BA.%26aulast%3DChinsangaram%26aufirst%3DJ.%26aulast%3DFrimm%26aufirst%3DA.%26aulast%3DMaiti%26aufirst%3DB.%26aulast%3DLovejoy%26aufirst%3DC.%26aulast%3DMeara%26aufirst%3DI.%26aulast%3DLong%26aufirst%3DP.%26aulast%3DHruby%26aufirst%3DD.%2BE.%26atitle%3DOral%2520Tecovirimat%2520for%2520the%2520Treatment%2520of%2520Smallpox%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D44%26epage%3D53%26doi%3D10.1056%2FNEJMoa1705688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Review of the Patent Literature: Synthesis and Final Forms of Antiviral Drugs Tecovirimat and Baloxavir Marboxil</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1298</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ensrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=1298-1307&author=D.+L.+Hughes&title=Review+of+the+Patent+Literature%3A+Synthesis+and+Final+Forms+of+Antiviral+Drugs+Tecovirimat+and+Baloxavir+Marboxil&doi=10.1021%2Facs.oprd.9b00144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Review of the Patent Literature: Synthesis and Final Forms of Antiviral Drugs Tecovirimat and Baloxavir Marboxil</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1298-1307</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article reviews synthetic routes and final polymorphic forms of two recently approved antiviral drugs, TPOXX (tecovirimat) for the treatment of smallpox and Xofluza (baloxavir marboxil), a treatment for influenza.  The patent literature was the source of information for synthetic routes and final forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo__fk1JmXM4rVg90H21EOLACvtfcHk0linnrnZmXqQ2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ensrrM&md5=1300a493cef08adecdd6009255967f71</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00144%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DReview%2520of%2520the%2520Patent%2520Literature%253A%2520Synthesis%2520and%2520Final%2520Forms%2520of%2520Antiviral%2520Drugs%2520Tecovirimat%2520and%2520Baloxavir%2520Marboxil%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26spage%3D1298%26epage%3D1307%26doi%3D10.1021%2Facs.oprd.9b00144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span>; <span class="NLM_string-name">Bailey, T. R.</span>; <span class="NLM_string-name">Rippin, S. R.</span>; <span class="NLM_string-name">Dai, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Isoindole Derivatives for Treatment and Prevention of Orthopoxvirus Infections</span>. <span class="NLM_patent">WO2008130348A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+Jordan&author=T.+R.+Bailey&author=S.+R.+Rippin&author=D.+Dai&title=Preparation+of+Isoindole+Derivatives+for+Treatment+and+Prevention+of+Orthopoxvirus+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DR.%26atitle%3DPreparation%2520of%2520Isoindole%2520Derivatives%2520for%2520Treatment%2520and%2520Prevention%2520of%2520Orthopoxvirus%2520Infections%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit65b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span>; <span class="NLM_string-name">Bailey, T. R.</span>; <span class="NLM_string-name">Rippin, S. R.</span>; <span class="NLM_string-name">Dai, D.</span></span> <span> </span><span class="NLM_article-title">Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases</span>. <span class="NLM_patent">US20120020922A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Jordan&author=T.+R.+Bailey&author=S.+R.+Rippin&author=D.+Dai&title=Compounds%2C+Compositions+and+Methods+for+Treatment+and+Prevention+of+Orthopoxvirus+Infections+and+Associated+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DR.%26atitle%3DCompounds%252C%2520Compositions%2520and%2520Methods%2520for%2520Treatment%2520and%2520Prevention%2520of%2520Orthopoxvirus%2520Infections%2520and%2520Associated%2520Diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyavanagimatt, S. R.</span>; <span class="NLM_string-name">Stone, M. A. C. L.</span>; <span class="NLM_string-name">Weimers, W. C.</span>; <span class="NLM_string-name">Nelson, D.</span>; <span class="NLM_string-name">Bolken, T. C.</span>; <span class="NLM_string-name">Hruby, D. E.</span>; <span class="NLM_string-name">O’Neill, M. H.</span>; <span class="NLM_string-name">Sweetapple, G.</span>; <span class="NLM_string-name">McCloughan, K. A.</span></span> <span> </span><span class="NLM_article-title">Polymorphic Forms ST-246</span>. <span class="NLM_patent">WO2011119698A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+R.+Tyavanagimatt&author=M.+A.+C.+L.+Stone&author=W.+C.+Weimers&author=D.+Nelson&author=T.+C.+Bolken&author=D.+E.+Hruby&author=M.+H.+O%E2%80%99Neill&author=G.+Sweetapple&author=K.+A.+McCloughan&title=Polymorphic+Forms+ST-246"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTyavanagimatt%26aufirst%3DS.%2BR.%26atitle%3DPolymorphic%2520Forms%2520ST-246%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avatrombopag-thrombocytopenia-adults-chronic-liver-disease" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avatrombopag-thrombocytopenia-adults-chronic-liver-disease</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-avatrombopag-thrombocytopenia-adults-chronic-liver-disease+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><a href="https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-doptelet_en.pdf" class="extLink">https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-doptelet_en.pdf</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.ema.europa.eu%2Fdocuments%2Fsmop-initial%2Fchmp-summary-positive-opinion-doptelet_en.pdf+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Avatrombopag: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1168</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0949-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0949-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29995177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlSjt7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1163-1168&author=M.+Shirley&title=Avatrombopag%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0949-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Avatrombopag: First Global Approval</span></div><div class="casAuthors">Shirley, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1163-1168</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Avatrombopag (Doptelet) is an orally bioavailable, small mol. thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.  In May 2018 avatrombopag received its first global approval, in the USA, for use in the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.  A Marketing Authorization Application for use of avatrombopag in this indication was submitted to the EMA in Apr. 2018.  Clin. development of avatrombopag in the treatment of other thrombocytopenic disorders, including immune thrombocytopenic purpura and chemotherapy-induced thrombocytopenia, is ongoing.  This article summarizes the milestones in the development of avatrombopag leading to this first approval for the treatment of thrombocytopenia in adult patients with CLD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJmYkB5ioYQbVg90H21EOLACvtfcHk0lgYFY0UF9fbBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlSjt7jL&md5=3759df7ee27fbb9f17a345115f755380</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0949-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0949-8%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DAvatrombopag%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1163%26epage%3D1168%26doi%3D10.1007%2Fs40265-018-0949-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugasawa, K.</span>; <span class="NLM_string-name">Watanuki, S.</span>; <span class="NLM_string-name">Koga, Y.</span>; <span class="NLM_string-name">Nagata, H.</span>; <span class="NLM_string-name">Obitsu, K.</span>; <span class="NLM_string-name">Wakayama, R.</span>; <span class="NLM_string-name">Hirayama, F.</span>; <span class="NLM_string-name">Suzuki, K.-I.</span></span> <span> </span><span class="NLM_article-title">2-Acylaminothiazole Derivative or Salt Thereof</span>. <span class="NLM_patent">WO2003062233A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=K.+Sugasawa&author=S.+Watanuki&author=Y.+Koga&author=H.+Nagata&author=K.+Obitsu&author=R.+Wakayama&author=F.+Hirayama&author=K.-I.+Suzuki&title=2-Acylaminothiazole+Derivative+or+Salt+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSugasawa%26aufirst%3DK.%26atitle%3D2-Acylaminothiazole%2520Derivative%2520or%2520Salt%2520Thereof%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit70b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugasawa, K.</span>; <span class="NLM_string-name">Koga, Y.</span>; <span class="NLM_string-name">Hirayama, F.</span>; <span class="NLM_string-name">Suzuki, K.-I.</span>; <span class="NLM_string-name">Awamura, Y.</span></span> <span> </span><span class="NLM_article-title">Novel Salt of 2-Acylaminothiazole Derivative</span>. <span class="NLM_patent">WO2004029049A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=K.+Sugasawa&author=Y.+Koga&author=F.+Hirayama&author=K.-I.+Suzuki&author=Y.+Awamura&title=Novel+Salt+of+2-Acylaminothiazole+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSugasawa%26aufirst%3DK.%26atitle%3DNovel%2520Salt%2520of%25202-Acylaminothiazole%2520Derivative%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit70c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugasawa, K.</span>; <span class="NLM_string-name">Miyafuji, A.</span>; <span class="NLM_string-name">Suzuki, K.</span>; <span class="NLM_string-name">Awamura, Y.</span></span> <span> </span><span class="NLM_article-title">2-Acylaminothiazole Compound Crystals</span>. <span class="NLM_patent">WO2013018362A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+Sugasawa&author=A.+Miyafuji&author=K.+Suzuki&author=Y.+Awamura&title=2-Acylaminothiazole+Compound+Crystals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSugasawa%26aufirst%3DK.%26atitle%3D2-Acylaminothiazole%2520Compound%2520Crystals%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-A.</span></span> <span> </span><span class="NLM_article-title">Revefenacin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1036-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1036-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30560478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=85-91&author=Y.-A.+Heo&title=Revefenacin%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1036-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Revefenacin: First Global Approval</span></div><div class="casAuthors">Heo, Young-A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-91</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Revefenacin (YUPELRI) inhalation soln., a long-acting muscarinic antagonist (i.e. an anticholinergic) developed by Theravance Biopharma and Mylan, is the first and currently the only once-daily, nebulized bronchodilator to be approved in the USA for the treatment of chronic obstructive pulmonary disease (COPD).  In Nov. 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD.  This article summarizes the milestones in the development of revefenacin leading to this first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreKt8JGiq2GLVg90H21EOLACvtfcHk0lgYFY0UF9fbBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F&md5=09384e244c9d6b3f9b4d39dd87705057</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1036-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1036-x%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.-A.%26atitle%3DRevefenacin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D85%26epage%3D91%26doi%3D10.1007%2Fs40265-018-1036-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1080/17512433.2019.1587292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F17512433.2019.1587292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30803279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlslemtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=293-298&author=F.+Liauthor=J.+Yang&title=Revefenacin+for+the+Treatment+of+Chronic+Obstructive+Pulmonary+Disease&doi=10.1080%2F17512433.2019.1587292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Revefenacin for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Li, Fuyuan; Yang, Junyi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-298</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Acetylcholine is the predominant parasympathetic neurotransmitter in the airways, and plays a key role in the pathophysiol. of chronic obstructive pulmonary disease (COPD).  Muscarinic receptors are found in smooth muscle cells and submucosal glands.  Binding of acetylcholine to muscarinic receptors could trigger bronchoconstriction.  Muscarinic antagonists prevent acetylcholine from binding to its receptors and produce bronchodilation.  Revefenacin is the first once-daily dosed nebulized long-acting muscarinic antagonist indicated for the maintenance treatment of patients with COPD.  In this paper, the chem. properties, mechanism of action, pharmacokinetics, clin. efficacy and safety of Revefenacin was introduced, and the evolution of muscarinic antagonists is also briefly described.  Revefenacin is a new M3 muscarinic receptor antagonist, which could prevent acetylcholine from binding with the muscarinic receptor, making bronchodilation and relieving COPD symptoms.  Revefenacin has a rapid onset of action, and the curative effect is to maintain a long time.  Clin. trials showed that Revefenacin could significantly increase forced expiratory vol. in 1 s (FEV1) in patients with COPD and improve their quality of life.  The recommended dose of Revefenacin inhalation soln. is 175μg once daily.  Adverse reactions were mild and the drug was well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXCbQy8bWgVbVg90H21EOLACvtfcHk0lgYFY0UF9fbBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlslemtbc%253D&md5=cf55198b6b6a62fb147722e4e0e753bb</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1080%2F17512433.2019.1587292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17512433.2019.1587292%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DRevefenacin%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Obstructive%2520Pulmonary%2520Disease%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2019%26volume%3D12%26spage%3D293%26epage%3D298%26doi%3D10.1080%2F17512433.2019.1587292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Axt, S.</span>; <span class="NLM_string-name">Church, T. J.</span>; <span class="NLM_string-name">Malathong, V.</span></span> <span> </span><span class="NLM_article-title">Crystalline Forms of a Biphenyl Compound</span>. <span class="NLM_patent">WO2006099165A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=S.+Axt&author=T.+J.+Church&author=V.+Malathong&title=Crystalline+Forms+of+a+Biphenyl+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAxt%26aufirst%3DS.%26atitle%3DCrystalline%2520Forms%2520of%2520a%2520Biphenyl%2520Compound%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit73b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Colson, P.-J.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing a Biphenyl-2-Ylcarbamic Acid</span>. <span class="NLM_patent">WO2012009166A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.-J.+Colson&title=Process+for+Preparing+a+Biphenyl-2-Ylcarbamic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DColson%26aufirst%3DP.-J.%26atitle%3DProcess%2520for%2520Preparing%2520a%2520Biphenyl-2-Ylcarbamic%2520Acid%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit73c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Mammen, M.</span>; <span class="NLM_string-name">Ji, Y.-H.</span>; <span class="NLM_string-name">Mu, Y.</span>; <span class="NLM_string-name">Husfeld, C.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Biphenyl Compounds Useful as Muscarinic Receptor Antagonists</span>. <span class="NLM_patent">US20050203133A1</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Mammen&author=Y.-H.+Ji&author=Y.+Mu&author=C.+Husfeld&author=L.+Li&title=Biphenyl+Compounds+Useful+as+Muscarinic+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMammen%26aufirst%3DM.%26atitle%3DBiphenyl%2520Compounds%2520Useful%2520as%2520Muscarinic%2520Receptor%2520Antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Roxadustat: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01077-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-01077-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30805897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=563-572&author=S.+Dhillon&title=Roxadustat%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01077-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Roxadustat: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">563-572</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Roxadustat (Ai Rui Zhuo in China) is an orally administered, small mol. hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that is being developed by FibroGen, in collaboration with Astellas and AstraZeneca, for the treatment of anemia in patients with dialysis-dependent chronic kidney disease (CKD), non-dialysis-dependent CKD and in patients with myelodysplastic syndromes.  The drug reversibly binds to and inhibits HIF-prolyl hydroxylase enzymes that are responsible for the degrdn. of transcription factors in the HIF family under normal oxygen conditions.  Inhibition of these enzymes reduces HIF breakdown and promotes HIF activity, leading to an increase in endogenous erythropoietin prodn., thereby enhancing erythropoiesis.  It also reduces the expression of the peptide hormone hepcidin, improves iron availability and increases Hb levels.  HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metab.  Roxadustat is approved in China and is under regulatory review in Japan for the treatment of anemia in patients with dialysis-dependent CKD.  Studies are underway to investigate long-term cardiovascular outcomes with roxadustat vs. placebo (for non-dialysis-dependent CKD) or std. of care (for dialysis-dependent CKD).  This article summarizes the milestones in the development of roxadustat leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ_JyPI6KLs7Vg90H21EOLACvtfcHk0lii-S8ll2fHZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyit7k%253D&md5=039b607bef7f12a73d9727d89f3df8e4</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01077-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01077-1%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DRoxadustat%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D563%26epage%3D572%26doi%3D10.1007%2Fs40265-019-01077-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Provenzano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besarab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durham, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cangiano, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saikali, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmerich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczech, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neff, T. B.</span></span> <span> </span><span class="NLM_article-title">Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD</span>. <i>Clin. J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">991</span>, <span class="refDoi"> DOI: 10.2215/CJN.06890615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2215%2FCJN.06890615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27094610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVSks7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=982-991&author=R.+Provenzanoauthor=A.+Besarabauthor=C.+H.+Sunauthor=S.+A.+Diamondauthor=J.+H.+Durhamauthor=J.+L.+Cangianoauthor=J.+R.+Aielloauthor=J.+E.+Novakauthor=T.+Leeauthor=R.+Leongauthor=B.+K.+Robertsauthor=K.+G.+Saikaliauthor=S.+Hemmerichauthor=L.+A.+Szczechauthor=K.-H.+P.+Yuauthor=T.+B.+Neff&title=Oral+Hypoxia-Inducible+Factor+Prolyl+Hydroxylase+Inhibitor+Roxadustat+%28FG-4592%29+for+the+Treatment+of+Anemia+in+Patients+with+CKD&doi=10.2215%2FCJN.06890615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75aR"><div class="casContent"><span class="casTitleNuber">75a</span><div class="casTitle"><span class="NLM_cas:atitle">Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD</span></div><div class="casAuthors">Provenzano, Robert; Besarab, Anatole; Sun, Chao H.; Diamond, Susan A.; Durham, John H.; Cangiano, Jose L.; Aiello, Joseph R.; Novak, James E.; Lee, Tyson; Leong, Robert; Roberts, Brian K.; Saikali, Khalil G.; Hemmerich, Stefan; Szczech, Lynda A.; Yu, Kin-Hung Peony; Neff, Thomas B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">982-991</span>CODEN:
                <span class="NLM_cas:coden">CJASC7</span>;
        ISSN:<span class="NLM_cas:issn">1555-9041</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Background and objectives: Roxadustat (FG-4592), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metab., and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with nondialysis CKD.  Design, setting, participants, & measurements: The 145 patients with nondialysis CKD and Hb ≤10.5 g/dL were randomized into one of six cohorts of approx. 24 patients each with varying roxadustat starting doses (tiered wt. and fixed amts.) and frequencies (two and three times weekly) followed by Hb maintenance with roxadustat one to three times weekly.  Treatment duration was 16 or 24 wk.  I.v. iron was prohibited.  The primary end point was the proportion of patients achieving Hb increase of ≥1.0 g/dL from baseline and Hb of ≥11.0 g/dL by week 17 (16 wk of treatment).  Secondary analyses included mean Hb change from baseline, iron utilization, and serum lipids.  Safety was evaluated by frequency/severity of adverse events.  Results: Of the 145 patients enrolled, 143 were evaluable for efficacy.  Overall, 92% of patients achieved Hb response.  Higher compared with lower starting doses led to earlier achievement of Hb response.  Roxadustat-induced Hb increases were independent of baseline C-reactive protein levels and iron repletion status.  Overall, over the first 16 treatment weeks, hepcidin levels decreased by 16.9% (P = 0.004), reticulocyte Hb content was maintained, and Hb increased by a mean (±SD) of 1.83 (±0.09) g/dL (P<0.001).  Overall mean total cholesterol level was reduced by a mean (±SD) of 26 (±30) mg/dL (P<0.001) after 8 wk of therapy, independent of the use of statins or other lipid-lowering agents.  No drug-related serious adverse events were reported.  Conclusions: In patients with nondialysis CKD who were anemic, various starting dose regimens of roxadustat were well tolerated and achieved anemia correction with reduced serum hepcidin levels.  After anemia correction, Hb was maintained by roxadustat at various dose frequencies without i.v. iron supplementation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVZ7-oE2mfNrVg90H21EOLACvtfcHk0lii-S8ll2fHZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVSks7bI&md5=710c58a01b4b7c6e2e610273ec82e26b</span></div><a href="/servlet/linkout?suffix=cit75a&amp;dbid=16384&amp;doi=10.2215%2FCJN.06890615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2215%252FCJN.06890615%26sid%3Dliteratum%253Aachs%26aulast%3DProvenzano%26aufirst%3DR.%26aulast%3DBesarab%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DC.%2BH.%26aulast%3DDiamond%26aufirst%3DS.%2BA.%26aulast%3DDurham%26aufirst%3DJ.%2BH.%26aulast%3DCangiano%26aufirst%3DJ.%2BL.%26aulast%3DAiello%26aufirst%3DJ.%2BR.%26aulast%3DNovak%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DLeong%26aufirst%3DR.%26aulast%3DRoberts%26aufirst%3DB.%2BK.%26aulast%3DSaikali%26aufirst%3DK.%2BG.%26aulast%3DHemmerich%26aufirst%3DS.%26aulast%3DSzczech%26aufirst%3DL.%2BA.%26aulast%3DYu%26aufirst%3DK.-H.%2BP.%26aulast%3DNeff%26aufirst%3DT.%2BB.%26atitle%3DOral%2520Hypoxia-Inducible%2520Factor%2520Prolyl%2520Hydroxylase%2520Inhibitor%2520Roxadustat%2520%2528FG-4592%2529%2520for%2520the%2520Treatment%2520of%2520Anemia%2520in%2520Patients%2520with%2520CKD%26jtitle%3DClin.%2520J.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2016%26volume%3D11%26spage%3D982%26epage%3D991%26doi%3D10.2215%2FCJN.06890615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit75b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) Protects against Cisplatin-Induced Acute Kidney Injury</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1042/CS20171625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1042%2FCS20171625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29581249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFamurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=825-838&author=Y.+Yangauthor=X.+Yuauthor=Y.+Zhangauthor=G.+Dingauthor=C.+Zhuauthor=S.+Huangauthor=Z.+Jiaauthor=A.+Zhang&title=Hypoxia-Inducible+Factor+Prolyl+Hydroxylase+Inhibitor+Roxadustat+%28FG-4592%29+Protects+against+Cisplatin-Induced+Acute+Kidney+Injury&doi=10.1042%2FCS20171625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75bR"><div class="casContent"><span class="casTitleNuber">75b</span><div class="casTitle"><span class="NLM_cas:atitle">Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury</span></div><div class="casAuthors">Yang, Yunwen; Yu, Xiaowen; Zhang, Yue; Ding, Guixia; Zhu, Chunhua; Huang, Songming; Jia, Zhanjun; Zhang, Aihua</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">825-838</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Renal hypoxia occurs in acute kidney injury (AKI) of various etiologies.  Activation of hypoxia-inducible transcription factor (HIF) has been identified as an important mechanism of cellular adaptation to low oxygen.  Preconditional HIF activation protects against AKI, suggesting a new approach in AKI treatment.  HIF is degraded under normoxic conditions mediated by oxygen-dependent hydroxylation of specific prolyl residues of the regulative α-subunits by HIF prolyl hydroxylases (PHD).  FG-4592 is a novel, orally active, small-mol. HIF PHD inhibitor for the treatment of anemia in patients with chronic kidney disease (CKD).  The current study aimed to evaluate the effect of FG-4592 (Roxadustat) on cis-diamminedichloroplatinum (cisplatin)-induced kidney injury.  In mice, pretreatment with FG-4592 markedly ameliorated cisplatin-induced kidney injury as shown by the improved renal function (blood urea nitrogen (BUN), serum creatinine (Scr), and cystatin C) and kidney morphol. (periodic acid-Schiff (PAS) staining) in line with a robust blockade of renal tubular injury markers of kidney injury mol. 1 (KIM-1) and neutrophil gelatinase-assocd. lipocalin (NGAL).  Meanwhile, the renal apoptosis and inflammation induced by cisplatin were also strikingly attenuated in FG-4592-treated mice.  Along with the protective effects shown above, FG-4592 pretreatment strongly enhanced HIF-1α in tubular cells, as well as the expressions of HIF target genes.  FG-4592 alone did not affect the renal function and morphol. in mice.  In vitro, FG-4592 treatment significantly up-regulated HIF-1α and protected the tubular cells against cisplatin-induced apoptosis.  In summary, FG-4592 treatment remarkably ameliorated the cisplatin-induced kidney injury possibly through the stabilization of HIF.  Thus, besides the role in treating CKD anemia, the clin. use of FG-4592 also could be extended to AKI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcKx-vnkcRmrVg90H21EOLACvtfcHk0liFE1m3IZKjFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFamurvE&md5=7232accbdd48f1d0186ee96ff512d94a</span></div><a href="/servlet/linkout?suffix=cit75b&amp;dbid=16384&amp;doi=10.1042%2FCS20171625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20171625%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DHypoxia-Inducible%2520Factor%2520Prolyl%2520Hydroxylase%2520Inhibitor%2520Roxadustat%2520%2528FG-4592%2529%2520Protects%2520against%2520Cisplatin-Induced%2520Acute%2520Kidney%2520Injury%26jtitle%3DClin.%2520Sci.%26date%3D2018%26volume%3D132%26spage%3D825%26epage%3D838%26doi%3D10.1042%2FCS20171625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span>; <span class="NLM_string-name">Jin, H.</span>; <span class="NLM_string-name">Zheng, Y.</span>; <span class="NLM_string-name">Huang, M.</span>; <span class="NLM_string-name">Meng, X.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Roxadustat Intermediate 4-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate for Treating Chronic Anemia</span>. <span class="NLM_patent">CN106478504A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=F.+Zhou&author=H.+Jin&author=Y.+Zheng&author=M.+Huang&author=X.+Meng&title=Preparation+Method+of+Roxadustat+Intermediate+4-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate+for+Treating+Chronic+Anemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26atitle%3DPreparation%2520Method%2520of%2520Roxadustat%2520Intermediate%25204-Hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate%2520for%2520Treating%2520Chronic%2520Anemia%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit76b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Roxadustat for Treatment of Chronic Nephrosis and Terminal Stage Nephrosis-Related Anaemia from 5-Nitrophenylethylamine</span>. <span class="NLM_patent">CN107602466A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=T.+Sun&title=Process+for+Preparation+of+Roxadustat+for+Treatment+of+Chronic+Nephrosis+and+Terminal+Stage+Nephrosis-Related+Anaemia+from+5-Nitrophenylethylamine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DT.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Roxadustat%2520for%2520Treatment%2520of%2520Chronic%2520Nephrosis%2520and%2520Terminal%2520Stage%2520Nephrosis-Related%2520Anaemia%2520from%25205-Nitrophenylethylamine%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit76c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Roxadustat for Treating Chronic Kidney Disease and Anemia Associated with End-Stage Renal Disease</span>. <span class="NLM_patent">CN107698505A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=T.+Sun&title=Preparation+Method+of+Roxadustat+for+Treating+Chronic+Kidney+Disease+and+Anemia+Associated+with+End-Stage+Renal+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DT.%26atitle%3DPreparation%2520Method%2520of%2520Roxadustat%2520for%2520Treating%2520Chronic%2520Kidney%2520Disease%2520and%2520Anemia%2520Associated%2520with%2520End-Stage%2520Renal%2520Disease%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit76d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span>; <span class="NLM_string-name">Liu, W.</span>; <span class="NLM_string-name">Wei, X.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Song, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Roxadustat</span>. <span class="NLM_patent">WO2018072662A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Yang&author=W.+Liu&author=X.+Wei&author=Y.+Wang&author=Y.+Song&title=Preparation+Method+of+Roxadustat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DM.%26atitle%3DPreparation%2520Method%2520of%2520Roxadustat%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit76e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, R.</span>; <span class="NLM_string-name">Li, C.</span>; <span class="NLM_string-name">Qiao, D.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Roxadustat</span>. <span class="NLM_patent">CN108017583A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=R.+Han&author=C.+Li&author=D.+Qiao&title=Method+for+Preparing+Roxadustat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DR.%26atitle%3DMethod%2520for%2520Preparing%2520Roxadustat%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit76f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Roxadustat</span>. <span class="NLM_patent">CN108383787A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Z.+Wang&title=Method+for+Preparing+Roxadustat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DMethod%2520for%2520Preparing%2520Roxadustat%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit76g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span>; <span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Roxadustat (Fg-459) for Treating Chronic Anaemia</span>. <span class="NLM_patent">CN108424388A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=X.+Zheng&author=Y.+Zhang&title=Preparation+Method+of+Roxadustat+%28Fg-459%29+for+Treating+Chronic+Anaemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DPreparation%2520Method%2520of%2520Roxadustat%2520%2528Fg-459%2529%2520for%2520Treating%2520Chronic%2520Anaemia%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit76h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of Roxadustat, and Intermediate Compound Thereof</span>. <span class="NLM_patent">CN108794397A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Xu&title=Synthesis+Method+of+Roxadustat%2C+and+Intermediate+Compound+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26atitle%3DSynthesis%2520Method%2520of%2520Roxadustat%252C%2520and%2520Intermediate%2520Compound%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arend, M. P.</span>; <span class="NLM_string-name">Flippin, L. A.</span>; <span class="NLM_string-name">Guenzler-Pukall, V.</span>; <span class="NLM_string-name">Ho, W.-B.</span>; <span class="NLM_string-name">Turtle, E. D.</span>; <span class="NLM_string-name">Du, X.</span></span> <span> </span><span class="NLM_article-title">Preparation of Isoquinolinecarboxamides and Their Use in Mediating Hypoxia Inducible Factor and Increasing Endogenous Erythropoietin</span>. <span class="NLM_patent">WO2004108681A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=M.+P.+Arend&author=L.+A.+Flippin&author=V.+Guenzler-Pukall&author=W.-B.+Ho&author=E.+D.+Turtle&author=X.+Du&title=Preparation+of+Isoquinolinecarboxamides+and+Their+Use+in+Mediating+Hypoxia+Inducible+Factor+and+Increasing+Endogenous+Erythropoietin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DArend%26aufirst%3DM.%2BP.%26atitle%3DPreparation%2520of%2520Isoquinolinecarboxamides%2520and%2520Their%2520Use%2520in%2520Mediating%2520Hypoxia%2520Inducible%2520Factor%2520and%2520Increasing%2520Endogenous%2520Erythropoietin%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witschi, C.</span>; <span class="NLM_string-name">Park, J. M.</span>; <span class="NLM_string-name">Thompson, M. D.</span>; <span class="NLM_string-name">Martinelli, M. J.</span>; <span class="NLM_string-name">Yeowell, D. A.</span>; <span class="NLM_string-name">Arend, M. P.</span></span> <span> </span><span class="NLM_article-title">Crystalline Forms of a Isoquinolinecarbonylaminoacetic Acid Derivative as a Prolyl Hydroxylase Inhibitor</span>. <span class="NLM_patent">WO2014014835A2</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+Witschi&author=J.+M.+Park&author=M.+D.+Thompson&author=M.+J.+Martinelli&author=D.+A.+Yeowell&author=M.+P.+Arend&title=Crystalline+Forms+of+a+Isoquinolinecarbonylaminoacetic+Acid+Derivative+as+a+Prolyl+Hydroxylase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWitschi%26aufirst%3DC.%26atitle%3DCrystalline%2520Forms%2520of%2520a%2520Isoquinolinecarbonylaminoacetic%2520Acid%2520Derivative%2520as%2520a%2520Prolyl%2520Hydroxylase%2520Inhibitor%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chedid, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayvargiya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camilleri, M.</span></span> <span> </span><span class="NLM_article-title">Elobixibat for the Treatment of Constipation</span>. <i>Expert Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">951</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1080/17474124.2018.1522248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F17474124.2018.1522248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30204504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKjurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=951-960&author=V.+Chedidauthor=P.+Vijayvargiyaauthor=M.+Camilleri&title=Elobixibat+for+the+Treatment+of+Constipation&doi=10.1080%2F17474124.2018.1522248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Elobixibat for the treatment of constipation</span></div><div class="casAuthors">Chedid, Victor; Vijayvargiya, Priya; Camilleri, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">951-960</span>CODEN:
                <span class="NLM_cas:coden">ERGHBD</span>;
        ISSN:<span class="NLM_cas:issn">1747-4124</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic idiopathic constipation (CC) is highly prevalent worldwide.  A subset of patients with CC have reduced fecal (and by inference, intra-colonic) bile acids (BA).  Elobixibat, a locally-acting ileal bile acid transporter (IBAT) inhibitor, leads to increased BA delivery to the colon and represents a new class of treatment for CC.  BAs accelerate colonic transit and increase colonic secretion.  Therefore, IBAT inhibitors have potential to treat patients with CC. : Rationale for IBAT inhibitor in therapeutics, and preclin. and clin. pharmacol. of elobixibat: In vitro, elobixibat is a highly potent, selective IBAT inhibitor.  In humans, elobixibat accelerated colonic transit.  In phase 2A, 2B and 3 studies in CC, elobixibat was efficacious, well tolerated and safe.  An open-label, phase 3 trial (52 wk) confirmed the safety of elobixibat.  Elobixibat reduces LDL cholesterol, increases serum GLP-1, and has potential in metabolic syndrome.: Uniquely among current treatments of CC, elobixibat stimulates both motor and secretory functions in the colon.  These dual effects suggest that, when approved, elobixibat may be a first-line choice for constipation assocd. with colonic BA deficiency and a second-line treatment for all patients with CC and constipation-predominant irritable bowel syndrome.  Further studies are required to confirm efficacy for relief of CC.  Once approved, elobixibat will likely become a second-line choice for treatment of CC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3b2aP_4FRrVg90H21EOLACvtfcHk0lhaq8OIZhLwUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKjurrM&md5=4a1ed28f27fc90216477dca9d62d6b35</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1080%2F17474124.2018.1522248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474124.2018.1522248%26sid%3Dliteratum%253Aachs%26aulast%3DChedid%26aufirst%3DV.%26aulast%3DVijayvargiya%26aufirst%3DP.%26aulast%3DCamilleri%26aufirst%3DM.%26atitle%3DElobixibat%2520for%2520the%2520Treatment%2520of%2520Constipation%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2018%26volume%3D12%26spage%3D951%26epage%3D960%26doi%3D10.1080%2F17474124.2018.1522248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camilleri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirapongsathorn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayvargiya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erwin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murad, M. H.</span></span> <span> </span><span class="NLM_article-title">Comparison of Efficacy of Pharmacological Treatments for Chronic Idiopathic Constipation: A Systematic Review and Network Meta-Analysis</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1611</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2016-311835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1136%2Fgutjnl-2016-311835" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27287486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVShurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1611&author=A.+D.+Nelsonauthor=M.+Camilleriauthor=S.+Chirapongsathornauthor=P.+Vijayvargiyaauthor=N.+Valentinauthor=A.+Shinauthor=P.+J.+Erwinauthor=Z.+Wangauthor=M.+H.+Murad&title=Comparison+of+Efficacy+of+Pharmacological+Treatments+for+Chronic+Idiopathic+Constipation%3A+A+Systematic+Review+and+Network+Meta-Analysis&doi=10.1136%2Fgutjnl-2016-311835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis</span></div><div class="casAuthors">Nelson, Alfred D.; Camilleri, Michael; Chirapongsathorn, Sakkarin; Vijayvargiya, Priya; Valentin, Nelson; Shin, Andrea; Erwin, Patricia J.; Wang, Zhen; Murad, M. Hassan</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1611-1623</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-anal.  Data sources We conducted searches (inception to May 2015) of MEDLINE, EMBASE, Scopus and Cochrane Central, as well as original data from authors or drug companies for the medications used for CIC.  Study selection Phase IIB and phase III randomised, placebo-controlled trials (RCT) of ≥4 wk' treatment for CIC in adults with Rome II or III criteria for functional constipation; trials included at least one of four end points.  Data extn. and synthesis Two investigators independently evaluated all full-text articles that met inclusion criteria and extd. data for primary and secondary end points, risk of bias and quality of evidence.  Outcomes Primary end points were ≥3 complete spontaneous bowel movements (CSBM)/wk and increase over baseline by ≥1 CSBM/wk.  Secondary end points were change from baseline (Δb) in the no. of SBM/wk and Δb CSBM/wk.  Results Twenty-one RCTs (9189 patients) met inclusion and end point criteria: 9 prucalopride, 3 lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium picosulfate (NaP).  All prespecified end points were unavailable in four polyethylene glycol studies.  Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥3 CSBM/wk end point.  No drug was superior at improving the primary end points on network metaanal.  Bisacodyl appeared superior to the other drugs for the secondary end point, Δb in no. of SBM/wk.  Conclusions Current drugs for CIC show similar efficacy.  Bisacodyl may be superior to prescription medications for Δb in the no. of SBM/wk in CIC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruhifelM1PN7Vg90H21EOLACvtfcHk0lhaq8OIZhLwUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVShurvE&md5=e2ee393680fd4ffddd9e96417db85be5</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2016-311835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2016-311835%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DA.%2BD.%26aulast%3DCamilleri%26aufirst%3DM.%26aulast%3DChirapongsathorn%26aufirst%3DS.%26aulast%3DVijayvargiya%26aufirst%3DP.%26aulast%3DValentin%26aufirst%3DN.%26aulast%3DShin%26aufirst%3DA.%26aulast%3DErwin%26aufirst%3DP.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMurad%26aufirst%3DM.%2BH.%26atitle%3DComparison%2520of%2520Efficacy%2520of%2520Pharmacological%2520Treatments%2520for%2520Chronic%2520Idiopathic%2520Constipation%253A%2520A%2520Systematic%2520Review%2520and%2520Network%2520Meta-Analysis%26jtitle%3DGut%26date%3D2017%26volume%3D66%26spage%3D1611%26doi%3D10.1136%2Fgutjnl-2016-311835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miner, P. B.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Elobixibat, the First-in-Class Ileal Bile Acid Transporter Inhibitor, for the Treatment of Chronic Idiopathic Constipation</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1381</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1080/14656566.2018.1508450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F14656566.2018.1508450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30129377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1381-1388&author=P.+B.+Miner&title=Elobixibat%2C+the+First-in-Class+Ileal+Bile+Acid+Transporter+Inhibitor%2C+for+the+Treatment+of+Chronic+Idiopathic+Constipation&doi=10.1080%2F14656566.2018.1508450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation</span></div><div class="casAuthors">Miner, Philip B. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1381-1388</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Elobixibat is the first in class ileal bile acid transporter (IBAT) inhibitor.  IBAT inhibitors block ileal absorption of bile acids by: (1) interrupting the enterohepatic circulation of bile resulting in a fall in serum cholesterol and (2) increasing the delivery of bile acids into the colon.  Increasing colonic bile acids causes mucosal fluid secretion and enhances colonic motor activity.  Changes in colonic physiol. may be useful in treating constipation.  In this review, the author reviews the prevalence and medical cost of Chronic Idiopathic Constipation (CIC) and the heterogeneity of the CIC patient population as a complicating factor in drug development and clin. care.  And also reviews the history of Bile Acid cathartics and the complex pharmacophysiol. of bile therapy with fluid and electrolyte shifts, colonic motor function changes and mucosal immunol. activation.  Finally, the author reviews elobixabat development and the clin. trials that demonstrate improvement in constipation.  The early phases of elobixibat development provide confirmation of high IBAT binding affinity which translates into the expected inhibition of enterohepatic bile acid circulation and enhanced delivery of ileal bile acids to the colon assocd. with expected physiol. changes.  Elobixibat as a treatment of CIC appears promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6CcsditpIz7Vg90H21EOLACvtfcHk0lhaq8OIZhLwUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLfF&md5=5ba00fab2446a3a735368df82bb5429a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1508450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1508450%26sid%3Dliteratum%253Aachs%26aulast%3DMiner%26aufirst%3DP.%2BB.%26atitle%3DElobixibat%252C%2520the%2520First-in-Class%2520Ileal%2520Bile%2520Acid%2520Transporter%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Idiopathic%2520Constipation%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26spage%3D1381%26epage%3D1388%26doi%3D10.1080%2F14656566.2018.1508450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Starke, I.</span>; <span class="NLM_string-name">Dahlstrom, M.</span>; <span class="NLM_string-name">Blomberg, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of N-[(8-Benzothiazepinyloxy)acetyl]phenylglycinates and Analogs as Ileal Bile Acid Transport Inhibitors</span>. <span class="NLM_patent">WO2002050051A1</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=I.+Starke&author=M.+Dahlstrom&author=D.+Blomberg&title=Preparation+of+N-%5B%288-Benzothiazepinyloxy%29acetyl%5Dphenylglycinates+and+Analogs+as+Ileal+Bile+Acid+Transport+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStarke%26aufirst%3DI.%26atitle%3DPreparation%2520of%2520N-%255B%25288-Benzothiazepinyloxy%2529acetyl%255Dphenylglycinates%2520and%2520Analogs%2520as%2520Ileal%2520Bile%2520Acid%2520Transport%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit82b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Starke, I.</span>; <span class="NLM_string-name">Dahlstrom, M.</span>; <span class="NLM_string-name">Blomberg, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of 1,5-Benzothiazepines for Use as Hypolipidemics</span>. <span class="NLM_patent">WO2001066533A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=I.+Starke&author=M.+Dahlstrom&author=D.+Blomberg&title=Preparation+of+1%2C5-Benzothiazepines+for+Use+as+Hypolipidemics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStarke%26aufirst%3DI.%26atitle%3DPreparation%2520of%25201%252C5-Benzothiazepines%2520for%2520Use%2520as%2520Hypolipidemics%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit82c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Starke, I.</span>; <span class="NLM_string-name">Dahlstrom, M. U. J.</span>; <span class="NLM_string-name">Blomberg, D.</span>; <span class="NLM_string-name">Alenfalk, S.</span>; <span class="NLM_string-name">Nordberg, P.</span>; <span class="NLM_string-name">Wallberg, A. C.</span>; <span class="NLM_string-name">Bostrom, S. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Benzothiazepine Derivatives for Potential Use as Ileal Bile Acid Transport Inhibitors for the Treatment of Hyperlipidemia</span>. <span class="NLM_patent">WO2003020710A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=I.+Starke&author=M.+U.+J.+Dahlstrom&author=D.+Blomberg&author=S.+Alenfalk&author=P.+Nordberg&author=A.+C.+Wallberg&author=S.+J.+Bostrom&title=Preparation+of+Benzothiazepine+Derivatives+for+Potential+Use+as+Ileal+Bile+Acid+Transport+Inhibitors+for+the+Treatment+of+Hyperlipidemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStarke%26aufirst%3DI.%26atitle%3DPreparation%2520of%2520Benzothiazepine%2520Derivatives%2520for%2520Potential%2520Use%2520as%2520Ileal%2520Bile%2520Acid%2520Transport%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Hyperlipidemia%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Take, Y.</span></span> <span> </span><span class="NLM_article-title">Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.244202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1124%2Fjpet.117.244202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29180359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2rtLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2018&pages=275-286&author=N.+Takahashiauthor=Y.+Take&title=Tegoprazan%2C+a+Novel+Potassium-Competitive+Acid+Blocker+to+Control+Gastric+Acid+Secretion+and+Motility&doi=10.1124%2Fjpet.117.244202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility</span></div><div class="casAuthors">Takahashi, Nobuyuki; Take, Yukinori</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-286</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Tegoprazan [(S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-carboxamide], a potassium-competitive acid blocker (P-CAB), is a novel potent and highly selective inhibitor of gastric H+/K+-ATPase.  Tegoprazan inhibited porcine, canine, and human H+/K+-ATPases in vitro with IC50 values ranging from 0.29 to 0.52μM, while that for canine kidney H+/K+-ATPase was more than 100μM.  A kinetic anal. revealed that tegoprazan inhibited H+/K+-ATPase in a potassium-competitive manner and the binding was reversible.  Oral single administrations of tegoprazan ranging from 0.3 to 30 mg/kg in dogs were well absorbed into the blood stream and distributed in gastric tissue/fluid higher than in plasma.  Tegoprazan potently inhibited histamine-induced gastric acid secretion in dogs, and a complete inhibition was obsd. at 1.0 mg/kg starting from 1 h after administration.  Moreover, an oral administration of tegoprazan at 1 and 3 mg/kg reversed the pentagastrin-induced acidified gastric pH to the neutral range.  Interestingly, 3 mg/kg tegoprazan immediately evoked a gastric phase III contraction of the migrating motor complex in pentagastrin-treated dogs and similar effects was obsd. with the other P-CAB, vonoprazan.  Tegoprazan is the novel P-CAB that may provide a new option for the therapy of gastric acid-related and motility-impaired diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8WdBeQ_mvpLVg90H21EOLACvtfcHk0lju2p_4i3q8Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2rtLbJ&md5=498d11b342041873399ec66ccfd5c5b3</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.244202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.244202%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DTake%26aufirst%3DY.%26atitle%3DTegoprazan%252C%2520a%2520Novel%2520Potassium-Competitive%2520Acid%2520Blocker%2520to%2520Control%2520Gastric%2520Acid%2520Secretion%2520and%2520Motility%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D364%26spage%3D275%26epage%3D286%26doi%3D10.1124%2Fjpet.117.244202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, I.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, I.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jee, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, P.-L.</span></span> <span> </span><span class="NLM_article-title">Randomised Phase 3 Trial: Tegoprazan, a Novel Potassium-Competitive Acid Blocker, Vs. Esomeprazole in Patients with Erosive Oesophagitis</span>. <i>Aliment. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1111/apt.15185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1111%2Fapt.15185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30843245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkslaitbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=864-872&author=K.+J.+Leeauthor=B.+K.+Sonauthor=G.+H.+Kimauthor=H.-K.+Jungauthor=H.-Y.+Jungauthor=I.-K.+Chungauthor=I.-K.+Sungauthor=J.+I.+Kimauthor=J.+H.+Kimauthor=J.+S.+Leeauthor=J.+G.+Kwonauthor=J.+H.+Parkauthor=K.+C.+Huhauthor=K.+S.+Parkauthor=M.-I.+Parkauthor=N.+Kimauthor=O.+Y.+Leeauthor=S.+R.+Jeeauthor=S.+K.+Leeauthor=S.+J.+Younauthor=S.+K.+Kimauthor=S.+T.+Leeauthor=S.+J.+Hongauthor=S.+C.+Choiauthor=T.+N.+Kimauthor=Y.+H.+Younauthor=H.+J.+Parkauthor=M.+J.+Kangauthor=C.+H.+Parkauthor=B.+T.+Kimauthor=S.+Younauthor=G.+S.+Songauthor=P.-L.+Rhee&title=Randomised+Phase+3+Trial%3A+Tegoprazan%2C+a+Novel+Potassium-Competitive+Acid+Blocker%2C+Vs.+Esomeprazole+in+Patients+with+Erosive+Oesophagitis&doi=10.1111%2Fapt.15185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis</span></div><div class="casAuthors">Lee, Kwang Jae; Son, Byoung Kwan; Kim, Gwang Ha; Jung, Hye-Kyung; Jung, Hwoon-Yong; Chung, Il-Kwun; Sung, In-Kyung; Kim, Jin Il; Kim, Jong Hyeok; Lee, Joon Seong; Kwon, Joong Goo; Park, Jung Ho; Huh, Kyu Chan; Park, Kyung Sik; Park, Moo-In; Kim, Nayoung; Lee, Oh Young; Jee, Sam Ryong; Lee, Sang Kil; Youn, Sei Jin; Kim, Sung Kook; Lee, Soo Teik; Hong, Su Jin; Choi, Suck Chei; Kim, Tae Nyeun; Youn, Young Hoon; Park, Hyo Ju; Kang, Min Ja; Park, Chi Hye; Kim, Bong Tae; Youn, Sangjun; Song, Geun Seog; Rhee, Poong-Lyul</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">864-872</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clin. benefit in acid-related disorders.  Aim : To confirm the non-inferiority of tegoprazan to esomeprazole in patients with erosive oesophagitis (EE).  Methods : In this multicentre, randomised, double-blind, parallel-group comparison study, 302 Korean patients with endoscopically confirmed EE (Los Angeles Classification Grades A-D) were randomly allocated to either tegoprazan (50 or 100 mg) or esomeprazole (40 mg) treatment groups for 4 or 8 wk.  The primary endpoint was the cumulative proportion of patients with healed EE confirmed by endoscopy up to 8 wk from treatment initiation.  Symptoms, safety and tolerability were also assessed.  Results : The cumulative healing rates at week 8 were 98.9% (91/92), 98.9% (90/91) and 98.9% (87/88) for tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg, resp.  Both doses of tegoprazan were non-inferior to esomeprazole 40 mg.  The incidence of adverse events was comparable among the groups, and tegoprazan was well-tolerated.  Conclusion : Once daily administration of tegoprazan 50 or 100 mg showed non-inferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZeNan9K-TibVg90H21EOLACvtfcHk0lju2p_4i3q8Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkslaitbc%253D&md5=889642f934ab5feac86f8812c8380062</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1111%2Fapt.15185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fapt.15185%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BJ.%26aulast%3DSon%26aufirst%3DB.%2BK.%26aulast%3DKim%26aufirst%3DG.%2BH.%26aulast%3DJung%26aufirst%3DH.-K.%26aulast%3DJung%26aufirst%3DH.-Y.%26aulast%3DChung%26aufirst%3DI.-K.%26aulast%3DSung%26aufirst%3DI.-K.%26aulast%3DKim%26aufirst%3DJ.%2BI.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DKwon%26aufirst%3DJ.%2BG.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DHuh%26aufirst%3DK.%2BC.%26aulast%3DPark%26aufirst%3DK.%2BS.%26aulast%3DPark%26aufirst%3DM.-I.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DO.%2BY.%26aulast%3DJee%26aufirst%3DS.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DYoun%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DS.%2BT.%26aulast%3DHong%26aufirst%3DS.%2BJ.%26aulast%3DChoi%26aufirst%3DS.%2BC.%26aulast%3DKim%26aufirst%3DT.%2BN.%26aulast%3DYoun%26aufirst%3DY.%2BH.%26aulast%3DPark%26aufirst%3DH.%2BJ.%26aulast%3DKang%26aufirst%3DM.%2BJ.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DKim%26aufirst%3DB.%2BT.%26aulast%3DYoun%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DG.%2BS.%26aulast%3DRhee%26aufirst%3DP.-L.%26atitle%3DRandomised%2520Phase%25203%2520Trial%253A%2520Tegoprazan%252C%2520a%2520Novel%2520Potassium-Competitive%2520Acid%2520Blocker%252C%2520Vs.%2520Esomeprazole%2520in%2520Patients%2520with%2520Erosive%2520Oesophagitis%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2019%26volume%3D49%26spage%3D864%26epage%3D872%26doi%3D10.1111%2Fapt.15185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanazawa, T.</span>; <span class="NLM_string-name">Koike, H.</span></span> <span> </span><span class="NLM_article-title">Chromane Substituted Benzimidazole Derivatives</span>. <span class="NLM_patent">US20070142448A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Hanazawa&author=H.+Koike&title=Chromane+Substituted+Benzimidazole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHanazawa%26aufirst%3DT.%26atitle%3DChromane%2520Substituted%2520Benzimidazole%2520Derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiaolong, Q.</span>; <span class="NLM_string-name">Lin, H.</span>; <span class="NLM_string-name">Wenbo, L.</span>; <span class="NLM_string-name">Ping, Z.</span>; <span class="NLM_string-name">Lingling, C.</span>; <span class="NLM_string-name">Xingang, Z.</span>; <span class="NLM_string-name">Ping, W.</span>; <span class="NLM_string-name">Donghui, W.</span>; <span class="NLM_string-name">Lei, C.</span>; <span class="NLM_string-name">Jun, C.</span></span> <span> </span><span class="NLM_article-title">Method for Synthetizing Tegoprazan Chiral Alcohol</span>. <span class="NLM_patent">CN109320485</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Q.+Xiaolong&author=H.+Lin&author=L.+Wenbo&author=Z.+Ping&author=C.+Lingling&author=Z.+Xingang&author=W.+Ping&author=W.+Donghui&author=C.+Lei&author=C.+Jun&title=Method+for+Synthetizing+Tegoprazan+Chiral+Alcohol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXiaolong%26aufirst%3DQ.%26atitle%3DMethod%2520for%2520Synthetizing%2520Tegoprazan%2520Chiral%2520Alcohol%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Elagolix: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1501</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0977-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0977-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30194661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ylsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1501-1508&author=Y.+N.+Lamb&title=Elagolix%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0977-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Elagolix: First Global Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1501-1508</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Elagolix (ORILISSA), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the treatment of reproductive hormone-dependent disorders in women.  In July 2018, the US FDA approved elagolix tablets for the management of moderate to severe pain assocd. with endometriosis.  This approval was based on pos. results in two replicate phase III trials; addnl. phase III trials in the USA, Canada and Puerto Rico are currently evaluating elagolix as both monotherapy and in combination with low-dose hormone add-back therapy in the same indication.  Elagolix with and without low-dose hormone add-back therapy is also undergoing phase III clin. development for heavy menstrual bleeding assocd. with uterine fibroids in the aforementioned locations.  This article summarizes the milestones in the development of elagolix leading to its first approval for the management of moderate to severe pain assocd. with endometriosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozwY9v1KHNcLVg90H21EOLACvtfcHk0ljPX14QSPSizw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ylsLzE&md5=984d0fcdfc38444ac282e0d6f519c1b7</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0977-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0977-4%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DElagolix%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1501%26epage%3D1508%26doi%3D10.1007%2Fs40265-018-0977-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barra, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scala, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, S.</span></span> <span> </span><span class="NLM_article-title">A Comprehensive Review of Hormonal and Biological Therapies for Endometriosis: Latest Developments</span>. <i>Expert Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1080/14712598.2019.1581761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F14712598.2019.1581761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30763525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFSku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=343-360&author=F.+Barraauthor=G.+Grandiauthor=M.+Tantariauthor=C.+Scalaauthor=F.+Facchinettiauthor=S.+Ferrero&title=A+Comprehensive+Review+of+Hormonal+and+Biological+Therapies+for+Endometriosis%3A+Latest+Developments&doi=10.1080%2F14712598.2019.1581761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of hormonal and biological therapies for endometriosis: latest developments</span></div><div class="casAuthors">Barra, Fabio; Grandi, Giovanni; Tantari, Matteo; Scala, Carolina; Facchinetti, Fabio; Ferrero, Simone</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">343-360</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Endometriosis is a chronic benign estrogen-dependent disease characterized by the presence of endometriotic glands and stroma outside the uterine cavity.  Although combined hormonal contraceptives and progestins, currently available first-line treatments for endometriosis, are efficacious and well tolerated for treating disease-related pain, some women experience partial or no improvement of pain or its recurrence is frequent after discontinuation of the therapies.  For these reasons, new drugs are under investigation for the treatment of endometriosis.: This review aims to give to the reader a complete and updated overview of hormonal and biol. therapies for the treatment of endometriosis, underlining the latest developments in this field of research.: Among the new drugs investigated, late clin. trials on gonadotropin-releasing hormone (GnRH) antagonists and aromatase inhibitors (AIs) have demonstrated the most promising results.  For this reason, elagolix, a new GnRH-antagonist, recently received the approval by the Food and Drug Administration (FDA) for treating pain assocd. to endometriosis.  Other drugs with innovative targets have been identified, but the majority of these compds. have only been evaluated in pre-clin. studies or early clin. trials.  Thus, a further extensive clin. research is necessary to better elucidate their pharmacol. characteristics, their efficacy, and safety for the treatment of this benign chronic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp27SZ7oHUK1LVg90H21EOLACvtfcHk0ljPX14QSPSizw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFSku7g%253D&md5=7fc04c9ff607504a28bdd191dce41ed0</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1080%2F14712598.2019.1581761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14712598.2019.1581761%26sid%3Dliteratum%253Aachs%26aulast%3DBarra%26aufirst%3DF.%26aulast%3DGrandi%26aufirst%3DG.%26aulast%3DTantari%26aufirst%3DM.%26aulast%3DScala%26aufirst%3DC.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DFerrero%26aufirst%3DS.%26atitle%3DA%2520Comprehensive%2520Review%2520of%2520Hormonal%2520and%2520Biological%2520Therapies%2520for%2520Endometriosis%253A%2520Latest%2520Developments%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2019%26volume%3D19%26spage%3D343%26epage%3D360%26doi%3D10.1080%2F14712598.2019.1581761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pokrzywinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snabes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surrey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, K. S.</span></span> <span> </span><span class="NLM_article-title">Impact of Elagolix on Work Loss Due to Endometriosis-Associated Pain: Estimates Based on the Results of Two Phase III Clinical Trials</span>. <i>Fertil. Steril.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1016/j.fertnstert.2019.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.fertnstert.2019.04.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=31227284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2kur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2019&pages=545-551&author=R.+M.+Pokrzywinskiauthor=A.+M.+Solimanauthor=J.+Chenauthor=M.+Snabesauthor=M.+P.+Diamondauthor=E.+Surreyauthor=K.+S.+Coyne&title=Impact+of+Elagolix+on+Work+Loss+Due+to+Endometriosis-Associated+Pain%3A+Estimates+Based+on+the+Results+of+Two+Phase+III+Clinical+Trials&doi=10.1016%2Fj.fertnstert.2019.04.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89aR"><div class="casContent"><span class="casTitleNuber">89a</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials</span></div><div class="casAuthors">Pokrzywinski, Robin M.; Soliman, Ahmed M.; Chen, Jun; Snabes, Michael; Diamond, Michael P.; Surrey, Eric; Coyne, Karin S.</div><div class="citationInfo"><span class="NLM_cas:title">Fertility and Sterility</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">545-551</span>CODEN:
                <span class="NLM_cas:coden">FESTAS</span>;
        ISSN:<span class="NLM_cas:issn">0015-0282</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">To est. the impact of elagolix on work loss due to endometriosis-assocd. pain.  Post hoc anal. of data from the Elaris I and II clin. trials.Not applicable.  Employed women ages 18-49 years with moderate-to-severe endometriosis-assocd. pain.  In the two trials, participants were randomized to 6 mo of treatment with placebo, elagolix 150 mg once a day, or elagolix 200 mg twice a day.  Data on planned work hours, presenteeism, absenteeism, and total work loss (absenteeism + presenteeism) at baseline and month 3 were collected using the Health-Related Productivity Questionnaire.  This anal. included employed participants from EM-I (n = 672) and EM-II (n = 626).  Between baseline and month 3, compared with participants treated with placebo, participants treated with elagolix 150 mg once a day gained > 2 h total work/wk (EM-I, 2.20 ± 1.03; EM-II, 2.65 ± 1.14).  Participants treated with 200 mg twice a day gained > 4 h total work/wk (EM-I, 4.91 ± 1.04; EM-II, 4.64 ± 1.14).  Both absenteeism and presenteeism were reduced, although most of the gain was due to reduced presenteeism.  Estd. cost savings after 6 mo of treatment with elagolix were > $1,500 U.  S. at 150 mg once a day and > $3,300 U.  S. at 200 mg twice a day.  Compared with placebo, treating moderate-to-severe endometriosis-assocd. pain with elagolix reduced absenteeism and improved productivity in employed women, which should result in cost savings.  NCT01620528 (EM-I) and NCT01931670 (EM-II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTDy7myDsC3LVg90H21EOLACvtfcHk0lgDUZYSb6JYTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2kur%252FJ&md5=9279bdbdaf942c635f245a9fb4b31574</span></div><a href="/servlet/linkout?suffix=cit89a&amp;dbid=16384&amp;doi=10.1016%2Fj.fertnstert.2019.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fertnstert.2019.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DPokrzywinski%26aufirst%3DR.%2BM.%26aulast%3DSoliman%26aufirst%3DA.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSnabes%26aufirst%3DM.%26aulast%3DDiamond%26aufirst%3DM.%2BP.%26aulast%3DSurrey%26aufirst%3DE.%26aulast%3DCoyne%26aufirst%3DK.%2BS.%26atitle%3DImpact%2520of%2520Elagolix%2520on%2520Work%2520Loss%2520Due%2520to%2520Endometriosis-Associated%2520Pain%253A%2520Estimates%2520Based%2520on%2520the%2520Results%2520of%2520Two%2520Phase%2520III%2520Clinical%2520Trials%26jtitle%3DFertil.%2520Steril.%26date%3D2019%26volume%3D112%26spage%3D545%26epage%3D551%26doi%3D10.1016%2Fj.fertnstert.2019.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit89b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sidduri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping Lou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huby, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwinge, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renzetti, L. M.</span></span> <span> </span><span class="NLM_article-title">N-Cycloalkanoyl-L-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2475</span>– <span class="NLM_lpage">2478</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00386-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0960-894X%2802%2900386-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=12161161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvVGjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=2475-2478&author=A.+Sidduriauthor=J.+W.+Tilleyauthor=K.+Hullauthor=J.+Ping+Louauthor=G.+Kaplanauthor=A.+Sheffronauthor=L.+Chenauthor=R.+Campbellauthor=R.+Guthrieauthor=T.-N.+Huangauthor=N.+Hubyauthor=K.+Rowanauthor=V.+Schwingeauthor=L.+M.+Renzetti&title=N-Cycloalkanoyl-L-Phenylalanine+Derivatives+as+VCAM%2FVLA-4+Antagonists&doi=10.1016%2FS0960-894X%2802%2900386-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89bR"><div class="casContent"><span class="casTitleNuber">89b</span><div class="casTitle"><span class="NLM_cas:atitle">N-Cycloalkanoyl-l-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists</span></div><div class="casAuthors">Sidduri, Achyutharao; Tilley, Jefferson W.; Hull, Kenneth; Lou, Jian Ping; Kaplan, Gerry; Sheffron, Allen; Chen, Li; Campbell, Robert; Guthrie, Robert; Huang, Tai-Nan; Huby, Nicholas; Rowan, Karen; Schwinge, Virginia; Renzetti, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2475-2478</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A systematic structure-activity relationship investigation of the lead compd., cycloalkanoyl phenylalanine deriv. resulted the identification of several N-[(substituted alkyl)cycloalkanoyl]-4-[((2,6-dichlorophenyl)carbonyl)amino]-l-phenylalanine derivs. as potent VCAM/VLA-4 antagonists.  The data are consistent with a model of these compds. in which these alkanoylphenylalanines reside in a compact gauche (-) bioactive conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOxvGLJqVLP7Vg90H21EOLACvtfcHk0lgDUZYSb6JYTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvVGjt7s%253D&md5=d94ec7757550db2569845abcf3dec5d3</span></div><a href="/servlet/linkout?suffix=cit89b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900386-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900386-4%26sid%3Dliteratum%253Aachs%26aulast%3DSidduri%26aufirst%3DA.%26aulast%3DTilley%26aufirst%3DJ.%2BW.%26aulast%3DHull%26aufirst%3DK.%26aulast%3DPing%2BLou%26aufirst%3DJ.%26aulast%3DKaplan%26aufirst%3DG.%26aulast%3DSheffron%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DR.%26aulast%3DGuthrie%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DT.-N.%26aulast%3DHuby%26aufirst%3DN.%26aulast%3DRowan%26aufirst%3DK.%26aulast%3DSchwinge%26aufirst%3DV.%26aulast%3DRenzetti%26aufirst%3DL.%2BM.%26atitle%3DN-Cycloalkanoyl-L-Phenylalanine%2520Derivatives%2520as%2520VCAM%252FVLA-4%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D2475%26epage%3D2478%26doi%3D10.1016%2FS0960-894X%2802%2900386-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucci, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pontillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozigian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struthers, R. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-Methoxyphenyl)-3-(2-Fluoro-6-[Trifluoromethyl]Benzyl)-4-Methyl-2,6-Dioxo-3,6-Dihydro-2h-Pyrimidin-1-Yl]-1-Phenylethylamino}Butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7478</span>– <span class="NLM_lpage">7485</span>, <span class="refDoi"> DOI: 10.1021/jm8006454</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8006454" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOrs73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7478-7485&author=C.+Chenauthor=D.+Wuauthor=Z.+Guoauthor=Q.+Xieauthor=G.+J.+Reinhartauthor=A.+Madanauthor=J.+Wenauthor=T.+Chenauthor=C.+Q.+Huangauthor=M.+Chenauthor=Y.+Chenauthor=F.+C.+Tucciauthor=M.+Rowbottomauthor=J.+Pontilloauthor=Y.-F.+Zhuauthor=W.+Wadeauthor=J.+Saundersauthor=H.+Bozigianauthor=R.+S.+Struthers&title=Discovery+of+Sodium+R-%28%2B%29-4-%7B2-%5B5-%282-Fluoro-3-Methoxyphenyl%29-3-%282-Fluoro-6-%5BTrifluoromethyl%5DBenzyl%29-4-Methyl-2%2C6-Dioxo-3%2C6-Dihydro-2h-Pyrimidin-1-Yl%5D-1-Phenylethylamino%7DButyrate+%28Elagolix%29%2C+a+Potent+and+Orally+Available+Nonpeptide+Antagonist+of+the+Human+Gonadotropin-Releasing+Hormone+Receptor&doi=10.1021%2Fjm8006454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90aR"><div class="casContent"><span class="casTitleNuber">90a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor</span></div><div class="casAuthors">Chen, Chen; Wu, Dongpei; Guo, Zhiqiang; Xie, Qiu; Reinhart, Greg J.; Madan, Ajay; Wen, Jenny; Chen, Takung; Huang, Charles Q.; Chen, Mi; Chen, Yongsheng; Tucci, Fabio C.; Rowbottom, Martin; Pontillo, Joseph; Zhu, Yun-Fei; Wade, Warren; Saunders, John; Bozigian, Haig; Struthers, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7478-7485</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of novel uracil phenylethylamines bearing a butyric acid as potent human gonadotropin-releasing hormone receptor (hGnRH-R) antagonists is described.  A major focus of this optimization was to improve the CYP3A4 inhibition liability of these uracils while maintaining their GnRH-R potency. R-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyric acid sodium salt, 10b (elagolix), was identified as a potent and selective hGnRH-R antagonist.  Oral administration of 10b suppressed LH in castrated macaques.  These efforts led to the identification of 10b as a clin. compd. for the treatment of endometriosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmNakYnE-bL7Vg90H21EOLACvtfcHk0lgDUZYSb6JYTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOrs73M&md5=d46a3b0801c6026cb9137cf6fffd9f54</span></div><a href="/servlet/linkout?suffix=cit90a&amp;dbid=16384&amp;doi=10.1021%2Fjm8006454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8006454%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DQ.%26aulast%3DReinhart%26aufirst%3DG.%2BJ.%26aulast%3DMadan%26aufirst%3DA.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DC.%2BQ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTucci%26aufirst%3DF.%2BC.%26aulast%3DRowbottom%26aufirst%3DM.%26aulast%3DPontillo%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DY.-F.%26aulast%3DWade%26aufirst%3DW.%26aulast%3DSaunders%26aufirst%3DJ.%26aulast%3DBozigian%26aufirst%3DH.%26aulast%3DStruthers%26aufirst%3DR.%2BS.%26atitle%3DDiscovery%2520of%2520Sodium%2520R-%2528%252B%2529-4-%257B2-%255B5-%25282-Fluoro-3-Methoxyphenyl%2529-3-%25282-Fluoro-6-%255BTrifluoromethyl%255DBenzyl%2529-4-Methyl-2%252C6-Dioxo-3%252C6-Dihydro-2h-Pyrimidin-1-Yl%255D-1-Phenylethylamino%257DButyrate%2520%2528Elagolix%2529%252C%2520a%2520Potent%2520and%2520Orally%2520Available%2520Nonpeptide%2520Antagonist%2520of%2520the%2520Human%2520Gonadotropin-Releasing%2520Hormone%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7478%26epage%3D7485%26doi%3D10.1021%2Fjm8006454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit90b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, D. J.</span>; <span class="NLM_string-name">Treiber, L. R.</span>; <span class="NLM_string-name">Hughes, R. M.</span>; <span class="NLM_string-name">Campopiano, O.</span>; <span class="NLM_string-name">Wang, P.</span>; <span class="NLM_string-name">Zhao, Y.</span>; <span class="NLM_string-name">Chou, S. K.</span>; <span class="NLM_string-name">Ouellette, M. A.</span>; <span class="NLM_string-name">Hettinger, D. N.</span></span> <span> </span><span class="NLM_article-title">Processes for the Preparation of Uracil Derivatives</span>. <span class="NLM_patent">US8765948B2</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+J.+Gallagher&author=L.+R.+Treiber&author=R.+M.+Hughes&author=O.+Campopiano&author=P.+Wang&author=Y.+Zhao&author=S.+K.+Chou&author=M.+A.+Ouellette&author=D.+N.+Hettinger&title=Processes+for+the+Preparation+of+Uracil+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGallagher%26aufirst%3DD.%2BJ.%26atitle%3DProcesses%2520for%2520the%2520Preparation%2520of%2520Uracil%2520Derivatives%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman-Kien, A. E.</span></span> <span> </span><span class="NLM_article-title">Disseminated Kaposi’s Sarcoma Syndrome in Young Homosexual Men</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">468</span>, <span class="refDoi"> DOI: 10.1016/S0190-9622(81)80010-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0190-9622%2881%2980010-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=7287964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADyaL38%252FjtFCjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1981&pages=468&author=A.+E.+Friedman-Kien&title=Disseminated+Kaposi%E2%80%99s+Sarcoma+Syndrome+in+Young+Homosexual+Men&doi=10.1016%2FS0190-9622%2881%2980010-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91aR"><div class="casContent"><span class="casTitleNuber">91a</span><div class="casTitle"><span class="NLM_cas:atitle">Disseminated Kaposi's sarcoma syndrome in young homosexual men</span></div><div class="casAuthors">Friedman-Kien A E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">468-71</span>
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8T9XkCStdIgqdek-gHSrIfW6udTcc2ea2nXkA5FqI-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL38%252FjtFCjsg%253D%253D&md5=0146de8d279b8cc66574d1fcc6485dfe</span></div><a href="/servlet/linkout?suffix=cit91a&amp;dbid=16384&amp;doi=10.1016%2FS0190-9622%2881%2980010-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0190-9622%252881%252980010-2%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman-Kien%26aufirst%3DA.%2BE.%26atitle%3DDisseminated%2520Kaposi%25E2%2580%2599s%2520Sarcoma%2520Syndrome%2520in%2520Young%2520Homosexual%2520Men%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D1981%26volume%3D5%26spage%3D468%26doi%3D10.1016%2FS0190-9622%2881%2980010-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit91b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0927-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0927-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29869203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=959-963&author=A.+Markham&title=Fostamatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0927-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91bR"><div class="casContent"><span class="casTitleNuber">91b</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">959-963</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Rigel Pharmaceuticals are developing the spleen tyrosine kinase (SYK) inhibitor fostamatinib (TAVALISSE) as a treatment for immune thrombocytopenia (ITP), autoimmune haemolytic anemia and IgA nephropathy.  Based on pos. results in the phase III FIT clin. trial program, the drug was recently approved in the US as a treatment for thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment.  This article summarizes the milestones in the development of fostamatinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgnmCw2LTVXrVg90H21EOLACvtfcHk0lgq6RwVxT1X2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsb7M&md5=e58fd226c946b7e2087a74d31eeba972</span></div><a href="/servlet/linkout?suffix=cit91b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0927-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0927-1%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DFostamatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D959%26epage%3D963%26doi%3D10.1007%2Fs40265-018-0927-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hymes, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prose, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubenstein, L. J.</span></span> <span> </span><span class="NLM_article-title">Kaposi’s Sarcoma in Homosexual Men-a Report of Eight Cases</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>318</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(81)92740-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0140-6736%2881%2992740-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=1981&pages=598-600&author=K.+B.+Hymesauthor=J.+B.+Greeneauthor=A.+Marcusauthor=D.+C.+Williamauthor=T.+Cheungauthor=N.+S.+Proseauthor=H.+Ballardauthor=L.+J.+Laubenstein&title=Kaposi%E2%80%99s+Sarcoma+in+Homosexual+Men-a+Report+of+Eight+Cases&doi=10.1016%2FS0140-6736%2881%2992740-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2881%2992740-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252881%252992740-9%26sid%3Dliteratum%253Aachs%26aulast%3DHymes%26aufirst%3DK.%2BB.%26aulast%3DGreene%26aufirst%3DJ.%2BB.%26aulast%3DMarcus%26aufirst%3DA.%26aulast%3DWilliam%26aufirst%3DD.%2BC.%26aulast%3DCheung%26aufirst%3DT.%26aulast%3DProse%26aufirst%3DN.%2BS.%26aulast%3DBallard%26aufirst%3DH.%26aulast%3DLaubenstein%26aufirst%3DL.%2BJ.%26atitle%3DKaposi%25E2%2580%2599s%2520Sarcoma%2520in%2520Homosexual%2520Men-a%2520Report%2520of%2520Eight%2520Cases%26jtitle%3DLancet%26date%3D1981%26volume%3D318%26spage%3D598%26epage%3D600%26doi%3D10.1016%2FS0140-6736%2881%2992740-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit92b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmann, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert-Guroff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyanaraman, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zolla-Pazner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibowitch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, M.</span></span> <span> </span><span class="NLM_article-title">Isolation of Human T-Cell Leukemia Virus in Acquired Immune Deficiency Syndrome (AIDS)</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>220</i></span>,  <span class="NLM_fpage">865</span>, <span class="refDoi"> DOI: 10.1126/science.6601823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1126%2Fscience.6601823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=6601823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADyaL3s7psleltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=220&publication_year=1983&pages=865&author=R.+C.+Galloauthor=P.+S.+Sarinauthor=E.+P.+Gelmannauthor=M.+Robert-Guroffauthor=E.+Richardsonauthor=V.+S.+Kalyanaramanauthor=D.+Mannauthor=G.+D.+Sidhuauthor=R.+E.+Stahlauthor=S.+Zolla-Paznerauthor=J.+Leibowitchauthor=M.+Popovic&title=Isolation+of+Human+T-Cell+Leukemia+Virus+in+Acquired+Immune+Deficiency+Syndrome+%28AIDS%29&doi=10.1126%2Fscience.6601823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92bR"><div class="casContent"><span class="casTitleNuber">92b</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)</span></div><div class="casAuthors">Gallo R C; Sarin P S; Gelmann E P; Robert-Guroff M; Richardson E; Kalyanaraman V S; Mann D; Sidhu G D; Stahl R E; Zolla-Pazner S; Leibowitch J; Popovic M</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">220</span>
        (<span class="NLM_cas:issue">4599</span>),
    <span class="NLM_cas:pages">865-7</span>
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Several isolates of a human type-C retrovirus belonging to one group, known as human T-cell leukemia virus (HTLV), have previously been obtained from patients with adult T-cell leukemia or lymphoma.  The T-cell tropism of HTLV and its prevalence in the Caribbean basin prompted a search for it in patients with the epidemic T-cell immune deficiency disorder known as AIDS.  Peripheral blood lymphocytes from one patient in the United States and two in France were cultured with T-cell growth factor (TCGF) an shown to express HTLV antigens.  Virus from the U.S. patient was isolated and characterized and shown to be related to HTLV subgroup I.  The virus was also transmitted into normal human T cells from umbilical cord blood of a newborn.  Whether or not HTLV-I or other retroviruses of this family with T-cell tropism cause AIDS, it is possible that patients from whom the virus can be isolated can also transmit it to others.  If the target cell of AIDS is the mature T cell as suspected, the methods used in these studies may prove useful for the long-term growth of these cells and for the identification of antigens specific for the etiological agent of AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtPEhazvKyxty3lHz94U-GfW6udTcc2ebf8iwZ6gfHsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s7psleltQ%253D%253D&md5=fd07e27fb89195143ef9aa8db269c871</span></div><a href="/servlet/linkout?suffix=cit92b&amp;dbid=16384&amp;doi=10.1126%2Fscience.6601823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6601823%26sid%3Dliteratum%253Aachs%26aulast%3DGallo%26aufirst%3DR.%2BC.%26aulast%3DSarin%26aufirst%3DP.%2BS.%26aulast%3DGelmann%26aufirst%3DE.%2BP.%26aulast%3DRobert-Guroff%26aufirst%3DM.%26aulast%3DRichardson%26aufirst%3DE.%26aulast%3DKalyanaraman%26aufirst%3DV.%2BS.%26aulast%3DMann%26aufirst%3DD.%26aulast%3DSidhu%26aufirst%3DG.%2BD.%26aulast%3DStahl%26aufirst%3DR.%2BE.%26aulast%3DZolla-Pazner%26aufirst%3DS.%26aulast%3DLeibowitch%26aufirst%3DJ.%26aulast%3DPopovic%26aufirst%3DM.%26atitle%3DIsolation%2520of%2520Human%2520T-Cell%2520Leukemia%2520Virus%2520in%2520Acquired%2520Immune%2520Deficiency%2520Syndrome%2520%2528AIDS%2529%26jtitle%3DScience%26date%3D1983%26volume%3D220%26spage%3D865%26doi%3D10.1126%2Fscience.6601823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bussel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trelinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homenda, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windyga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivcheva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalafallah, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaja, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovtsov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zayed, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duliege, A.-M.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase 3, Randomized, Placebo-Controlled Trials</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1002/ajh.25125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fajh.25125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29696684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ylur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2018&pages=921-930&author=J.+Busselauthor=D.+M.+Arnoldauthor=E.+Grossbardauthor=J.+Mayerauthor=J.+Trelinskiauthor=W.+Homendaauthor=A.+Hellmannauthor=J.+Windygaauthor=L.+Sivchevaauthor=A.+A.+Khalafallahauthor=F.+Zajaauthor=N.+Cooperauthor=V.+Markovtsovauthor=H.+Zayedauthor=A.-M.+Duliege&title=Fostamatinib+for+the+Treatment+of+Adult+Persistent+and+Chronic+Immune+Thrombocytopenia%3A+Results+of+Two+Phase+3%2C+Randomized%2C+Placebo-Controlled+Trials&doi=10.1002%2Fajh.25125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials</span></div><div class="casAuthors">Bussel, James; Arnold, Donald M.; Grossbard, Elliot; Mayer, Jiri; Trelinski, Jacek; Homenda, Wojciech; Hellmann, Andrzej; Windyga, Jerzy; Sivcheva, Liliya; Khalafallah, Alhossain A.; Zaja, Francesco; Cooper, Nichola; Markovtsov, Vadim; Zayed, Hany; Duliege, Anne-Marie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">921-930</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (Syk) signaling is central to phagocytosis-based, antibody-mediated platelet destruction in adults with immune thrombocytopenia (ITP).  Fostamatinib, an oral Syk inhibitor, produced sustained on-treatment responses in a phase 2 ITP study.  In two parallel, phase 3, multicenter, randomized, double-blind, placebo-controlled trials (FIT1 and FIT2), patients with persistent/chronic ITP were randomized 2:1 to fostamatinib (n = 101) or placebo (n = 49) at 100 mg BID for 24 wk with a dose increase in nonresponders to 150 mg BID after 4 wk.  The primary endpoint was stable response (platelets ≥50 000/μL at ≥4 of 6 biweekly visits, weeks 14-24, without rescue therapy).  Baseline median platelet count was 16 000/μL; median duration of ITP was 8.5 years.  Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P = .0003).  Overall responses (defined retrospectively as ≥1 platelet count ≥50 000/μL within the first 12 wk on treatment) occurred in 43% of patients on fostamatinib vs. 14% on placebo (P = .0006).  Median time to response was 15 days (on 100 mg bid), and 83% responded within 8 wk.  The most common adverse events were diarrhea (31% on fostamatinib vs. 15% on placebo), hypertension (28% vs. 13%), nausea (19% vs. 8%), dizziness (11% vs. 8%), and ALT increase (11% vs. 0%).  Most events were mild or moderate and resolved spontaneously or with medical management (antihypertensive, anti-motility agents).  Fostamatinib produced clin.-meaningful responses in ITP patients including those who failed splenectomy, thrombopoietic agents, and/or rituximab.  Fostamatinib is a novel ITP treatment option that targets an important mechanism of ITP pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXWLFmFwBPrLVg90H21EOLACvtfcHk0lg2QuockrXi4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ylur%252FF&md5=06dff53ac5d8e7752b760844f9f22384</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fajh.25125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.25125%26sid%3Dliteratum%253Aachs%26aulast%3DBussel%26aufirst%3DJ.%26aulast%3DArnold%26aufirst%3DD.%2BM.%26aulast%3DGrossbard%26aufirst%3DE.%26aulast%3DMayer%26aufirst%3DJ.%26aulast%3DTrelinski%26aufirst%3DJ.%26aulast%3DHomenda%26aufirst%3DW.%26aulast%3DHellmann%26aufirst%3DA.%26aulast%3DWindyga%26aufirst%3DJ.%26aulast%3DSivcheva%26aufirst%3DL.%26aulast%3DKhalafallah%26aufirst%3DA.%2BA.%26aulast%3DZaja%26aufirst%3DF.%26aulast%3DCooper%26aufirst%3DN.%26aulast%3DMarkovtsov%26aufirst%3DV.%26aulast%3DZayed%26aufirst%3DH.%26aulast%3DDuliege%26aufirst%3DA.-M.%26atitle%3DFostamatinib%2520for%2520the%2520Treatment%2520of%2520Adult%2520Persistent%2520and%2520Chronic%2520Immune%2520Thrombocytopenia%253A%2520Results%2520of%2520Two%2520Phase%25203%252C%2520Randomized%252C%2520Placebo-Controlled%2520Trials%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2018%26volume%3D93%26spage%3D921%26epage%3D930%26doi%3D10.1002%2Fajh.25125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payan, D. G.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3614</span>– <span class="NLM_lpage">3643</span>, <span class="refDoi"> DOI: 10.1021/jm201271b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201271b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3614-3643&author=R.+Singhauthor=E.+S.+Masudaauthor=D.+G.+Payan&title=Discovery+and+Development+of+Spleen+Tyrosine+Kinase+%28SYK%29+Inhibitors&doi=10.1021%2Fjm201271b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94aR"><div class="casContent"><span class="casTitleNuber">94a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors</span></div><div class="casAuthors">Singh, Rajinder; Masuda, Esteban S.; Payan, Donald G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3614-3643</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spleen tyrosine kinase (SYK) is a member of the cytoplasmic protein tyrosine kinase (PTK) family and has been identified as an important target for the development of therapeutics for the treatment of allergic and autoimmune diseases.  Maladies resulting from chronic inflammation and autoimmune dysfunction include, asthma, rheumatoid arthritis (RA), Crohn's disease, systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia purpura (ITP).  SYK has garnered substantial attention because of its importance as a key signal transduction regulator through antigen and Fc receptors in hematopoietic cells.  Recently SYK has entered the mainstream of potential pharmaceutical targets with a no. of inhibitor classes being reported in the literature.  The true potential as a validated target for inhibition by small mols. has been investigated in the last few years, with the emergence of advanced clin. trial data.  Structurally SYK possesses a tandem N-terminal Src homol. 2 domains (SH2), referred to as N-SH2 and C-SH2 domains, followed by a C-terminal kinase domain and most closely related to ZAP-70.  The multiple phosphorylation sites on SYK are fundamental structural prerequisites for its diverse functional activity.  Overall, these phosphorylation sites contribute to maintaining the kinase in an inactivated state.  In addn., they are implicated in events leading to primary activation of the kinase catalytic domain, amplification of this activity, and the orchestrated phosphorylation of multiple substrates.  Utilization of the numerous sites of phosphorylation on SYK leads to the activation of a multitude of signaling networks relevant to immune and autoimmune maladies.  SYK serves as a master regulator of inflammatory responses in a multitude of immune cells and as a result, inhibiting SYK activity dampens inflammation broadly and comprehensively.  The validation of SYK as an effective target for therapeutic intervention in autoimmune and inflammatory disorders has picked up pace over the last decade.  In particular, this has been attributable to the recognition of key biol. findings, coupled with successful small mol. inhibitors of SYK that have shown early indications of clin. efficacy in diverse autoimmune and inflammatory diseases.  SYK as a target has gained reinforcement with the successful completion of several Phase 2 clin. studies in RA, ITP and B-cell lymphoma.  Addnl. clin. studies are under way that may further emphasize the position of SYK as a therapeutically relevant target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp363qA4V4g-rVg90H21EOLACvtfcHk0lg2QuockrXi4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVOntw%253D%253D&md5=1b51e1b658842f2b562d533edb05e685</span></div><a href="/servlet/linkout?suffix=cit94a&amp;dbid=16384&amp;doi=10.1021%2Fjm201271b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201271b%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DMasuda%26aufirst%3DE.%2BS.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Spleen%2520Tyrosine%2520Kinase%2520%2528SYK%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3614%26epage%3D3643%26doi%3D10.1021%2Fjm201271b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit94b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mocsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tybulewicz, V. L. J.</span></span> <span> </span><span class="NLM_article-title">The SYK Tyrosine Kinase: A Crucial Player in Diverse Biological Functions</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1038/nri2765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fnri2765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20467426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=387-402&author=A.+Mocsaiauthor=J.+Rulandauthor=V.+L.+J.+Tybulewicz&title=The+SYK+Tyrosine+Kinase%3A+A+Crucial+Player+in+Diverse+Biological+Functions&doi=10.1038%2Fnri2765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94bR"><div class="casContent"><span class="casTitleNuber">94b</span><div class="casTitle"><span class="NLM_cas:atitle">The SYK tyrosine kinase: a crucial player in diverse biological functions</span></div><div class="casAuthors">Mocsai, Attila; Ruland, Jurgen; Tybulewicz, Victor L. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">387-402</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Spleen tyrosine kinase (SYK) is known to have a crucial role in adaptive immune receptor signalling.  However, recent reports indicate that SYK also mediates other, unexpectedly diverse biol. functions, including cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development.  SYK is activated by C-type lectins and integrins, and activates new targets, including the CARD9-BCL-10-MALT1 pathway and the NLRP3 inflammasome.  Studies using Drosophila melanogaster suggest that there is an evolutionarily ancient origin of SYK-mediated signalling.  Moreover, SYK has a crucial role in autoimmune diseases and haematol. malignancies.  This Review summarizes our current understanding of the diverse functions of SYK and how this is being translated for therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3YO5BcMqrf7Vg90H21EOLACvtfcHk0lha3Isdoy-kXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFOkurk%253D&md5=85857a2b9beb84e0fe74263a90fa8a53</span></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=10.1038%2Fnri2765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2765%26sid%3Dliteratum%253Aachs%26aulast%3DMocsai%26aufirst%3DA.%26aulast%3DRuland%26aufirst%3DJ.%26aulast%3DTybulewicz%26aufirst%3DV.%2BL.%2BJ.%26atitle%3DThe%2520SYK%2520Tyrosine%2520Kinase%253A%2520A%2520Crucial%2520Player%2520in%2520Diverse%2520Biological%2520Functions%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D10%26spage%3D387%26epage%3D402%26doi%3D10.1038%2Fnri2765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussel, J. B.</span></span> <span> </span><span class="NLM_article-title">Fostamatinib for Persistent/Chronic Adult Immune Thrombocytopenia</span>. <i>Immunotherapy</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.2217/imt-2017-0097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2217%2Fimt-2017-0097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28967793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=9-25&author=A.+Newlandauthor=E.-J.+Leeauthor=V.+McDonaldauthor=J.+B.+Bussel&title=Fostamatinib+for+Persistent%2FChronic+Adult+Immune+Thrombocytopenia&doi=10.2217%2Fimt-2017-0097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Fostamatinib for persistent/chronic adult immune thrombocytopenia</span></div><div class="casAuthors">Newland, Adrian; Lee, Eun-Ju; McDonald, Vickie; Bussel, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Immunotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-25</span>CODEN:
                <span class="NLM_cas:coden">IMMUCO</span>;
        ISSN:<span class="NLM_cas:issn">1750-7448</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by phagocytosis and destruction of autoantibody-coated platelets via spleen tyrosine kinase (Syk)-mediated signal transduction in macrophages.  Effectiveness of existing therapies varies, and even leading treatments (e.g., IVIg, splenectomy, rituximab, thrombopoietic agents) do not provide optimal management for a substantial no. of patients with chronic ITP.  Fostamatinib disodium is an orally-bioavailable investigational agent being developed for treatment of primary persistent/chronic adult ITP.  Fostamatinib inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis.  Promising findings have been described in several autoimmune diseases, including rheumatoid arthritis, and sustained responses with manageable adverse events obsd. with ongoing treatment in patients with heavily treated chronic ITP.  Fostamatinib represents an active therapy targeting a previously unexplored mechanism of ITP pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8Xq2q4K3g_rVg90H21EOLACvtfcHk0lha3Isdoy-kXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbnM&md5=586a0d541c4bd2ea226ea9e7667d61b3</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.2217%2Fimt-2017-0097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fimt-2017-0097%26sid%3Dliteratum%253Aachs%26aulast%3DNewland%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DE.-J.%26aulast%3DMcDonald%26aufirst%3DV.%26aulast%3DBussel%26aufirst%3DJ.%2BB.%26atitle%3DFostamatinib%2520for%2520Persistent%252FChronic%2520Adult%2520Immune%2520Thrombocytopenia%26jtitle%3DImmunotherapy%26date%3D2018%26volume%3D10%26spage%3D9%26epage%3D25%26doi%3D10.2217%2Fimt-2017-0097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweeny, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhamidipati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baluom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossbard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, D. T. W.</span></span> <span> </span><span class="NLM_article-title">Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1166</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.032151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1124%2Fdmd.110.032151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20371637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Klsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1166-1176&author=D.+J.+Sweenyauthor=W.+Liauthor=J.+Cloughauthor=S.+Bhamidipatiauthor=R.+Singhauthor=G.+Parkauthor=M.+Baluomauthor=E.+Grossbardauthor=D.+T.+W.+Lau&title=Metabolism+of+Fostamatinib%2C+the+Oral+Methylene+Phosphate+Prodrug+of+the+Spleen+Tyrosine+Kinase+Inhibitor+R406+in+Humans%3A+Contribution+of+Hepatic+and+Gut+Bacterial+Processes+to+the+Overall+Biotransformation&doi=10.1124%2Fdmd.110.032151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation</span></div><div class="casAuthors">Sweeny, David J.; Li, Weiqun; Clough, Jeffrey; Bhamidipati, Somasekhar; Singh, Rajinder; Park, Gary; Baluom, Muhammad; Grossbard, Elliott; Lau, David T.-W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1166-1176</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The metab. of the spleen tyrosine kinase inhibitor N4-(2,2-dimethyl-3-oxo-4-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethyoxyphenyl)-2,4-pyrimidinediamine (R406) and its oral prodrug N4-(2,2-dimethyl-4-[(dihydrogenphosphonoxy)methyl]-3-oxo-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethyoxyphenyl)-2,4-pyrimidinediamine disodium hexahydrate (R788, fostamatinib) was detd. in vitro and in humans.  R788 was rapidly converted to R406 by human intestinal microsomes, and only low levels of R788 were obsd. in plasma of human subjects after oral administration of 14C-R788.  R406 was the major drug-related compd. in plasma from human subjects, and only low levels of metabolites were obsd. in plasma.  The plasma metabolites of R406 were identified as a sulfate conjugate and glucuronide conjugate of the para-O-demethylated metabolite of R406 (R529) and a direct N-glucuronide conjugate of R406.  Elimination of drug-related material into the urine accounted for 19% of the administered dose, and the major metabolite in urine from all the human subjects was the lactam N-glucuronide of R406.  On av., 80% of the total drug was recovered in feces.  Two drug-related peaks were obsd.; one peak was identified as R406, and the other peak was identified as a unique 3,5-benzene diol metabolite of R406.  The 3,5-benzene diol metabolite appeared to result from the subsequent O-demethylations and dehydroxylation of R529 by anaerobic gut bacteria because only R529 was converted to this metabolite after the in vitro incubation with human fecal samples.  These data indicate that the major fecal metabolite of R406 obsd. in humans is a product of a hepatic cytochrome P 450-mediated O-demethylation and subsequent O-demethylations and dehydroxylation by gut bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjYey4HpvXGbVg90H21EOLACvtfcHk0lha3Isdoy-kXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Klsb0%253D&md5=391fda31851968948d538f70319979e1</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.032151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.032151%26sid%3Dliteratum%253Aachs%26aulast%3DSweeny%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DClough%26aufirst%3DJ.%26aulast%3DBhamidipati%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DG.%26aulast%3DBaluom%26aufirst%3DM.%26aulast%3DGrossbard%26aufirst%3DE.%26aulast%3DLau%26aufirst%3DD.%2BT.%2BW.%26atitle%3DMetabolism%2520of%2520Fostamatinib%252C%2520the%2520Oral%2520Methylene%2520Phosphate%2520Prodrug%2520of%2520the%2520Spleen%2520Tyrosine%2520Kinase%2520Inhibitor%2520R406%2520in%2520Humans%253A%2520Contribution%2520of%2520Hepatic%2520and%2520Gut%2520Bacterial%2520Processes%2520to%2520the%2520Overall%2520Biotransformation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1166%26epage%3D1176%26doi%3D10.1124%2Fdmd.110.032151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKeever, B.</span>; <span class="NLM_string-name">Diorazio, L. J.</span>; <span class="NLM_string-name">Jones, M. F.</span>; <span class="NLM_string-name">Ferris, L.</span>; <span class="NLM_string-name">Janbon, S. L. M.</span>; <span class="NLM_string-name">Siedlecki, P. S.</span>; <span class="NLM_string-name">Churchill, G. H.</span>; <span class="NLM_string-name">Crafts, P. A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pharmaceutical 2,4-Pyrimidinediamines in Large Scale</span>. <span class="NLM_patent">WO2015095765A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=B.+McKeever&author=L.+J.+Diorazio&author=M.+F.+Jones&author=L.+Ferris&author=S.+L.+M.+Janbon&author=P.+S.+Siedlecki&author=G.+H.+Churchill&author=P.+A.+Crafts&title=Preparation+of+Pharmaceutical+2%2C4-Pyrimidinediamines+in+Large+Scale"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeever%26aufirst%3DB.%26atitle%3DPreparation%2520of%2520Pharmaceutical%25202%252C4-Pyrimidinediamines%2520in%2520Large%2520Scale%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herring, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever-Abbas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R.</span></span> <span> </span><span class="NLM_article-title">Real-Time Monitoring and Control of Critical Process Impurities During the Manufacture of Fostamatinib Disodium</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.5b00008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFKlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=537-542&author=R.+Hartauthor=A.+Herringauthor=G.+P.+Howellauthor=B.+McKeever-Abbasauthor=N.+Pedgeauthor=R.+Woodward&title=Real-Time+Monitoring+and+Control+of+Critical+Process+Impurities+During+the+Manufacture+of+Fostamatinib+Disodium&doi=10.1021%2Facs.oprd.5b00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Real-Time Monitoring and Control of Critical Process Impurities during the Manufacture of Fostamatinib Disodium</span></div><div class="casAuthors">Hart, Richard; Herring, Adam; Howell, Gareth P.; McKeever-Abbas, Ben; Pedge, Nicholas; Woodward, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">537-542</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Process anal. technol. (PAT) was used to probe, monitor, and control the formation of process impurities during the synthesis of a pharmaceutical intermediate at 600 kg input scale.  An accurate detn. of end of reaction (EoR) was vital in limiting side-products, and a novel inline UV/vis-based approach was used where more traditional EoR techniques had failed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_IN2TK848BLVg90H21EOLACvtfcHk0lh6KRMoXvQwyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFKlsLg%253D&md5=b31da49d6176f9a4e2ae81da5319b124</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00008%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DR.%26aulast%3DHerring%26aufirst%3DA.%26aulast%3DHowell%26aufirst%3DG.%2BP.%26aulast%3DMcKeever-Abbas%26aufirst%3DB.%26aulast%3DPedge%26aufirst%3DN.%26aulast%3DWoodward%26aufirst%3DR.%26atitle%3DReal-Time%2520Monitoring%2520and%2520Control%2520of%2520Critical%2520Process%2520Impurities%2520During%2520the%2520Manufacture%2520of%2520Fostamatinib%2520Disodium%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D537%26epage%3D542%26doi%3D10.1021%2Facs.oprd.5b00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubota, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okabe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukumo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kifuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakairi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritani, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Evocalcet, a Next-Generation Calcium-Sensing Receptor Agonist for the Treatment of Hyperparathyroidism</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2055</span>– <span class="NLM_lpage">2060</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.04.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmcl.2018.04.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29724589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVCnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2055-2060&author=H.+Miyazakiauthor=Y.+Ikedaauthor=O.+Sakuraiauthor=T.+Miyakeauthor=R.+Tsubotaauthor=J.+Okabeauthor=M.+Kurodaauthor=Y.+Hisadaauthor=T.+Yanagidaauthor=H.+Yonedaauthor=Y.+Tsukumoauthor=S.+Tokunagaauthor=T.+Kawataauthor=R.+Ohashiauthor=H.+Fukudaauthor=K.+Kojimaauthor=A.+Kannamiauthor=T.+Kifujiauthor=N.+Satoauthor=A.+Ideiauthor=T.+Iguchiauthor=T.+Sakairiauthor=Y.+Moritani&title=Discovery+of+Evocalcet%2C+a+Next-Generation+Calcium-Sensing+Receptor+Agonist+for+the+Treatment+of+Hyperparathyroidism&doi=10.1016%2Fj.bmcl.2018.04.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism</span></div><div class="casAuthors">Miyazaki, Hiroshi; Ikeda, Yousuke; Sakurai, Osamu; Miyake, Tsutomu; Tsubota, Rie; Okabe, Jyunko; Kuroda, Masataka; Hisada, Yutaka; Yanagida, Tetsuya; Yoneda, Hikaru; Tsukumo, Yukihito; Tokunaga, Shin; Kawata, Takehisa; Ohashi, Rikiya; Fukuda, Hajime; Kojima, Koki; Kannami, Ayako; Kifuji, Takayuki; Sato, Naoya; Idei, Akiko; Iguchi, Taku; Sakairi, Tetsuya; Moritani, Yasunori</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2055-2060</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The calcium-sensing receptor (CaSR) plays an important role in sensing extracellular calcium ions and regulating parathyroid hormone secretion by parathyroid gland cells, and the receptor is a suitable target for the treatment of hyperparathyroidism.  Cinacalcet hydrochloride is a representative CaSR agonist which widely used for the hyperparathyroidism.  However, it has several issues to clin. use, such as nausea/vomiting and strong inhibition of CYP2D6.  We tried to improve these issues of cinacalcet for a new pharmaceutical agent as a preferable CaSR agonist.  Optimization from cinacalcet resulted in the identification of pyrrolidine compds. and successfully led to the discovery of evocalcet as an oral allosteric CaSR agonist.  Evocalcet, which exhibited highly favorable profiles such as CaSR agonistic activity and good DMPK profiles, will provide a novel therapeutic option for secondary hyperparathyroidism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3j0sLMaFRA7Vg90H21EOLACvtfcHk0lh6KRMoXvQwyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVCnsbk%253D&md5=4181ddd3deff7a144478d71e2d7d0899</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.04.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.04.055%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DH.%26aulast%3DIkeda%26aufirst%3DY.%26aulast%3DSakurai%26aufirst%3DO.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DTsubota%26aufirst%3DR.%26aulast%3DOkabe%26aufirst%3DJ.%26aulast%3DKuroda%26aufirst%3DM.%26aulast%3DHisada%26aufirst%3DY.%26aulast%3DYanagida%26aufirst%3DT.%26aulast%3DYoneda%26aufirst%3DH.%26aulast%3DTsukumo%26aufirst%3DY.%26aulast%3DTokunaga%26aufirst%3DS.%26aulast%3DKawata%26aufirst%3DT.%26aulast%3DOhashi%26aufirst%3DR.%26aulast%3DFukuda%26aufirst%3DH.%26aulast%3DKojima%26aufirst%3DK.%26aulast%3DKannami%26aufirst%3DA.%26aulast%3DKifuji%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DN.%26aulast%3DIdei%26aufirst%3DA.%26aulast%3DIguchi%26aufirst%3DT.%26aulast%3DSakairi%26aufirst%3DT.%26aulast%3DMoritani%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Evocalcet%252C%2520a%2520Next-Generation%2520Calcium-Sensing%2520Receptor%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Hyperparathyroidism%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2055%26epage%3D2060%26doi%3D10.1016%2Fj.bmcl.2018.04.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekercioglu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busse, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guyatt, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thabane, L.</span></span> <span> </span><span class="NLM_article-title">Cinacalcet Versus Standard Treatment for Chronic Kidney Disease: A Protocol for a Systematic Review and Meta-Analysis</span>. <i>Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2</span>, <span class="refDoi"> DOI: 10.1186/s13643-015-0177-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1186%2Fs13643-015-0177-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=26729302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BC28rntFOqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=2&author=N.+Sekerciogluauthor=J.+W.+Busseauthor=R.+A.+Mustafaauthor=G.+H.+Guyattauthor=L.+Thabane&title=Cinacalcet+Versus+Standard+Treatment+for+Chronic+Kidney+Disease%3A+A+Protocol+for+a+Systematic+Review+and+Meta-Analysis&doi=10.1186%2Fs13643-015-0177-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis</span></div><div class="casAuthors">Sekercioglu Nigar; Busse Jason W; Mustafa Reem A; Guyatt Gordon H; Thabane Lehana; Busse Jason W; Busse Jason W; Mustafa Reem A; Guyatt Gordon H; Thabane Lehana; Thabane Lehana; Thabane Lehana; Thabane Lehana</div><div class="citationInfo"><span class="NLM_cas:title">Systematic reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic kidney disease-mineral and bone disorders (CKD-MBD) have been associated with poor health outcomes, including diminished quality and length of life.  Standard management for CKD-MBD includes phosphate-restricted diet, active vitamin D, vitamin D analogs, and phosphate binders.  Persistently elevated parathyroid hormone (PTH) levels may require the addition of Cinacalcet hydrochloride (cinacalcet) which sensitizes calcium receptors on the parathyroid glands.  The objective of this systematic review is to compare the effect of cinacalcet versus standard treatment in patients with CKD-MBD.  METHODS/DESIGN:  Data sources will include MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, and Web of Science from 1996 to June 2015.  Teams of two reviewers will, independently and in duplicate, screen titles and abstracts and potentially eligible full text reports to determine eligibility, and subsequently abstract data and assess risk of bias in eligible trials.  We will calculate the effect estimates (risk ratios or mean differences) and 95 % confidence intervals, as well as statistical measures of variability in results across studies using random effect models for patient-important and intermediate outcomes.  We will use the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to rate the quality of evidence about estimates of effect on an outcome-by-outcome basis.  We will present our results with a GRADE summary table.  DISCUSSION:  Our review will explore the effect of cinacalcet versus standard treatment in patients with CKD-MBD.  The results of this systematic review will help guide management of this patient population, and identify targets for future research.  SYSTEMATIC REVIEW REGISTRATION:  PROSPERO CRD42015020318 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015020318.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHG2tAb9KNlvEeosoOnpOLfW6udTcc2ebbfpHGA2s6krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rntFOqsw%253D%253D&md5=775fa94550341d5c71af4ea8166f7311</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1186%2Fs13643-015-0177-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13643-015-0177-1%26sid%3Dliteratum%253Aachs%26aulast%3DSekercioglu%26aufirst%3DN.%26aulast%3DBusse%26aufirst%3DJ.%2BW.%26aulast%3DMustafa%26aufirst%3DR.%2BA.%26aulast%3DGuyatt%26aufirst%3DG.%2BH.%26aulast%3DThabane%26aufirst%3DL.%26atitle%3DCinacalcet%2520Versus%2520Standard%2520Treatment%2520for%2520Chronic%2520Kidney%2520Disease%253A%2520A%2520Protocol%2520for%2520a%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DSyst.%2520Rev.%26date%3D2016%26volume%3D5%26spage%3D2%26doi%3D10.1186%2Fs13643-015-0177-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fukagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimazaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akizawa, T.</span></span> <span> </span><span class="NLM_article-title">Evocalcet study, g. Head-to-Head Comparison of the New Calcimimetic Agent Evocalcet with Cinacalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">818</span>– <span class="NLM_lpage">825</span>, <span class="refDoi"> DOI: 10.1016/j.kint.2018.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.kint.2018.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30049473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2018&pages=818-825&author=M.+Fukagawaauthor=R.+Shimazakiauthor=T.+Akizawa&title=Evocalcet+study%2C+g.+Head-to-Head+Comparison+of+the+New+Calcimimetic+Agent+Evocalcet+with+Cinacalcet+in+Japanese+Hemodialysis+Patients+with+Secondary+Hyperparathyroidism&doi=10.1016%2Fj.kint.2018.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101aR"><div class="casContent"><span class="casTitleNuber">101a</span><div class="casTitle"><span class="NLM_cas:atitle">Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism</span></div><div class="casAuthors">Fukagawa, Masafumi; Shimazaki, Ryutaro; Akizawa, Tadao</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">818-825</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Secondary hyperparathyroidism (SHPT) leads to cardiovascular calcification, which affects survival and quality of life in patients with chronic kidney disease.  Cinacalcet is used to control SHPT, but it may induce gastrointestinal symptoms, resulting in lower adherence and insufficient dosages.  Therefore, a need exists to develop new calcimimetics that cause fewer gastrointestinal symptoms.  Here we conducted a phase 3, randomized, double-blind, double-dummy trial for a head-to-head comparison of the efficacy and safety of evocalcet, a new oral calcimimetic, to the established cinacalcet.  Japanese patients with SHPT on hemodialysis were randomized to receive evocalcet or cinacalcet (317 patients each) for 30 wk.  The primary efficacy endpoint was non-inferiority of evocalcet to cinacalcet in the proportion of patients achieving a mean intact parathyroid hormone level of 60 to 240 pg/mL from week 28 to 30 (non-inferiority margin, -15%, per protocol set analyses).  In the evocalcet and cinacalcet groups, 72.7% and 76.7%, resp., achieved the target intact parathyroid hormone level (between-group difference: -4.0% [95% confidence interval -11.4%, 3.5%], for non-inferiority).  The incidence of gastrointestinal-related adverse events was 18.6% and 32.8%, resp. (between-group difference: -14.2% [-20.9%, -7.5%], significant for superiority).  Thus, the non-inferiority of evocalcet to cinacalcet in suppressing intact parathyroid hormone with fewer gastrointestinal-related adverse events was demonstrated.  Hence, evocalcet may be a favorable alternative to existing calcimimetics for management of SHPT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Ydg7wWev1bVg90H21EOLACvtfcHk0lhr4m1bEwAxqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsrnF&md5=210c079361a6727058a399dbd6af385b</span></div><a href="/servlet/linkout?suffix=cit101a&amp;dbid=16384&amp;doi=10.1016%2Fj.kint.2018.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.kint.2018.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DFukagawa%26aufirst%3DM.%26aulast%3DShimazaki%26aufirst%3DR.%26aulast%3DAkizawa%26aufirst%3DT.%26atitle%3DEvocalcet%2520study%252C%2520g.%2520Head-to-Head%2520Comparison%2520of%2520the%2520New%2520Calcimimetic%2520Agent%2520Evocalcet%2520with%2520Cinacalcet%2520in%2520Japanese%2520Hemodialysis%2520Patients%2520with%2520Secondary%2520Hyperparathyroidism%26jtitle%3DKidney%2520Int.%26date%3D2018%26volume%3D94%26spage%3D818%26epage%3D825%26doi%3D10.1016%2Fj.kint.2018.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit101b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Wagenen, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balandrin, M. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Calcimimetic and Calcilytic Compounds</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/bs.pmch.2017.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fbs.pmch.2017.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29680147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BC1MjltFOgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1-86&author=E.+F.+Nemethauthor=B.+C.+Van+Wagenenauthor=M.+F.+Balandrin&title=Discovery+and+Development+of+Calcimimetic+and+Calcilytic+Compounds&doi=10.1016%2Fbs.pmch.2017.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101bR"><div class="casContent"><span class="casTitleNuber">101b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Calcimimetic and Calcilytic Compounds</span></div><div class="casAuthors">Nemeth Edward F; Van Wagenen Bradford C; Balandrin Manuel F</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-86</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">The extracellular calcium receptor (CaR) is a G protein-coupled receptor (GPCR) and the pivotal molecule regulating systemic Ca(2+) homeostasis.  The CaR was a challenging target for drug discovery because its physiological ligand is an inorganic ion (Ca(2+)) rather than a molecule so there was no structural template to guide medicinal chemistry.  Nonetheless, small molecules targeting this receptor were discovered.  Calcimimetics are agonists or positive allosteric modulators of the CaR, while calcilytics are antagonists and all to date are negative allosteric modulators.  The calcimimetic cinacalcet was the first allosteric modulator of a GPCR to achieve regulatory approval and is a first-in-class treatment for secondary hyperparathyroidism in patients on dialysis, and for hypercalcemia in some forms of primary hyperparathyroidism.  It is also useful in treating some rare genetic diseases that cause hypercalcemia.  Two other calcimimetics are now on the market (etelcalcetide) or under regulatory review (evocalcet).  Calcilytics stimulate the secretion of parathyroid hormone and were initially developed as treatments for osteoporosis.  Three different calcilytics of two different chemotypes failed in clinical trials due to lack of efficacy.  Calcilytics are now being repurposed and might be useful in treating hypoparathyroidism and several rare genetic diseases causing hypocalcemia.  The challenges ahead for medicinal chemists are to design compounds that select conformations of the CaR that preferentially target a particular signalling pathway and/or that affect the CaR in a tissue-selective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZ9pfcWWVZ5mPgL4LrC-0VfW6udTcc2ebbfpHGA2s6krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjltFOgsw%253D%253D&md5=a36b9f668aca3890332d63d0e628bcbc</span></div><a href="/servlet/linkout?suffix=cit101b&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2017.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2017.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DNemeth%26aufirst%3DE.%2BF.%26aulast%3DVan%2BWagenen%26aufirst%3DB.%2BC.%26aulast%3DBalandrin%26aufirst%3DM.%2BF.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Calcimimetic%2520and%2520Calcilytic%2520Compounds%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D57%26spage%3D1%26epage%3D86%26doi%3D10.1016%2Fbs.pmch.2017.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomoyuki, N.</span>; <span class="NLM_string-name">Yuusuke, M.</span>; <span class="NLM_string-name">Michihiro, M.</span>; <span class="NLM_string-name">Atsushi, H.</span></span> <span> </span><span class="NLM_article-title">Polyethylene Glycol Derivative</span>. <span class="NLM_patent">WO2018174283A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=N.+Tomoyuki&author=M.+Yuusuke&author=M.+Michihiro&author=H.+Atsushi&title=Polyethylene+Glycol+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTomoyuki%26aufirst%3DN.%26atitle%3DPolyethylene%2520Glycol%2520Derivative%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Anlotinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1057</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0939-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0939-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29943374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1aksL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1057-1062&author=Y.+Y.+Syed&title=Anlotinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0939-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Anlotinib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1057-1062</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Labs. are co-developing anlotinib (Focus V) for the treatment of advanced cancer.  Anlotinib is an oral small mol. inhibitor of multiple receptor tyrosine kinases, with a broad spectrum of inhibitory effects on tumor angiogenesis and growth.  Anlotinib is approved in China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have undergone progression or recurrence after ≥ 2 lines of systemic chemotherapy.  Anlotinib is also undergoing phase II and/or III clin. development for various sarcomas and carcinomas in China, USA and Italy.  This article summarizes the milestones in the development of anlotinib leading to this first approval for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqABdQcz5d4A7Vg90H21EOLACvtfcHk0lj7xVA87F91uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1aksL%252FL&md5=3d2f6b7b389292c75b6e5e1f95b3475a</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0939-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0939-x%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DAnlotinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1057%26epage%3D1062%26doi%3D10.1007%2Fs40265-018-0939-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span> <span> </span><span class="NLM_article-title">Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">120</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0664-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1186%2Fs13045-018-0664-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30231931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=120&author=G.+Shenauthor=F.+Zhengauthor=D.+Renauthor=F.+Duauthor=Q.+Dongauthor=Z.+Wangauthor=F.+Zhaoauthor=R.+Ahmadauthor=J.+Zhao&title=Anlotinib%3A+A+Novel+Multi-Targeting+Tyrosine+Kinase+Inhibitor+in+Clinical+Development&doi=10.1186%2Fs13045-018-0664-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development</span></div><div class="casAuthors">Shen, Guoshuang; Zheng, Fangchao; Ren, Dengfeng; Du, Feng; Dong, Qiuxia; Wang, Ziyi; Zhao, Fuxing; Ahmad, Raees; Zhao, Jiuda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120/1-120/11</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.  Compared to the effect of placebo, it improved both progression-free survival (PFS) and overall survival (OS) in a phase III trial in patients with advanced non-small-cell lung cancer (NSCLC), despite progression of the cancer after two lines of prior treatments.  Recently, the China Food and Drug Administration (CFDA) approved single agent anlotinib as a third-line treatment for patients with advanced NSCLC.  Moreover, a randomized phase IIB trial demonstrated that anlotinib significantly prolonged the median PFS in patients with advanced soft tissue sarcoma (STS).  Anlotinib also showed promising efficacy in patients with advanced medullary thyroid carcinoma and metastatic renal cell carcinoma (mRCC).  The tolerability profile of anlotinib is similar to that of other tyrosine kinase inhibitors that target VEGFR and other tyrosine kinase-mediated pathways; however, anlotinib has a significantly lower incidence of grade 3 or higher side effects compared to that of sunitinib.  We review the rationale, clin. evidence, and future perspectives of anlotinib for the treatment of multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCMhzvg4Az7bVg90H21EOLACvtfcHk0lj7xVA87F91uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsLo%253D&md5=31c4d8e23723484492a88b3272b5cb80</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0664-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0664-7%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DF.%26aulast%3DRen%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DAhmad%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26atitle%3DAnlotinib%253A%2520A%2520Novel%2520Multi-Targeting%2520Tyrosine%2520Kinase%2520Inhibitor%2520in%2520Clinical%2520Development%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D120%26doi%3D10.1186%2Fs13045-018-0664-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, L.</span></span> <span> </span><span class="NLM_article-title">Preclinical Characterization of Anlotinib, a Highly Potent and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1207</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.1111/cas.13536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1111%2Fcas.13536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29446853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlSqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=1207-1219&author=C.+Xieauthor=X.+Wanauthor=H.+Quanauthor=M.+Zhengauthor=L.+Fuauthor=Y.+Liauthor=L.+Lou&title=Preclinical+Characterization+of+Anlotinib%2C+a+Highly+Potent+and+Selective+Vascular+Endothelial+Growth+Factor+Receptor-2+Inhibitor&doi=10.1111%2Fcas.13536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105aR"><div class="casContent"><span class="casTitleNuber">105a</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor</span></div><div class="casAuthors">Xie, Chengying; Wan, Xiaozhe; Quan, Haitian; Zheng, Mingyue; Fu, Li; Li, Yun; Lou, Liguang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1207-1219</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Abrogating tumor angiogenesis by inhibiting vascular endothelial growth factor receptor-2 (VEGFR2) has been established as a therapeutic strategy for treating cancer.  However, because of their low selectivity, most small mol. inhibitors of VEGFR2 tyrosine kinase show unexpected adverse effects and limited anticancer efficacy.  In the present study, we detailed the pharmacol. properties of anlotinib, a highly potent and selective VEGFR2 inhibitor, in preclin. models.  Anlotinib occupied the ATP-binding pocket of VEGFR2 tyrosine kinase and showed high selectivity and inhibitory potency (IC50 <1 nmol/L) for VEGFR2 relative to other tyrosine kinases.  Concordant with this activity, anlotinib inhibited VEGF-induced signaling and cell proliferation in HUVEC with picomolar IC50 values.  However, micromolar concns. of anlotinib were required to inhibit tumor cell proliferation directly in vitro.  Anlotinib significantly inhibited HUVEC migration and tube formation; it also inhibited microvessel growth from explants of rat aorta in vitro and decreased vascular d. in tumor tissue in vivo.  Compared with the well-known tyrosine kinase inhibitor sunitinib, once-daily oral dose of anlotinib showed broader and stronger in vivo antitumor efficacy and, in some models, caused tumor regression in nude mice.  Collectively, these results indicate that anlotinib is a well-tolerated, orally active VEGFR2 inhibitor that targets angiogenesis in tumor growth, and support ongoing clin. evaluation of anlotinib for a variety of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNPRNZFdMmpLVg90H21EOLACvtfcHk0lj7xVA87F91uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlSqt70%253D&md5=e07c97d47bf00e0a7ca97e05d4d65b01</span></div><a href="/servlet/linkout?suffix=cit105a&amp;dbid=16384&amp;doi=10.1111%2Fcas.13536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13536%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DC.%26aulast%3DWan%26aufirst%3DX.%26aulast%3DQuan%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLou%26aufirst%3DL.%26atitle%3DPreclinical%2520Characterization%2520of%2520Anlotinib%252C%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor-2%2520Inhibitor%26jtitle%3DCancer%2520Sci.%26date%3D2018%26volume%3D109%26spage%3D1207%26epage%3D1219%26doi%3D10.1111%2Fcas.13536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit105b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, Y.</span></span> <span> </span><span class="NLM_article-title">Safety, Pharmacokinetics, and Antitumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Patients with Advanced Refractory Solid Tumors</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0332-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1186%2Fs13045-016-0332-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27716285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajsbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=105&author=Y.+Sunauthor=W.+Niuauthor=F.+Duauthor=C.+Duauthor=S.+Liauthor=J.+Wangauthor=L.+Liauthor=F.+Wangauthor=Y.+Haoauthor=C.+Liauthor=Y.+Chi&title=Safety%2C+Pharmacokinetics%2C+and+Antitumor+Properties+of+Anlotinib%2C+an+Oral+Multi-Target+Tyrosine+Kinase+Inhibitor%2C+in+Patients+with+Advanced+Refractory+Solid+Tumors&doi=10.1186%2Fs13045-016-0332-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105bR"><div class="casContent"><span class="casTitleNuber">105b</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors</span></div><div class="casAuthors">Sun, Yongkun; Niu, Wei; Du, Feng; Du, Chunxia; Li, Shuting; Wang, Jinwan; Li, Li; Wang, Fengqing; Hao, Yu; Li, Chuan; Chi, Yihebali</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105/1-105/9</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Anlotinib is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.  We aimed to evaluate the safety, pharmacokinetics, and antitumor activity of anlotinib in patients with advanced refractory solid tumors.  Methods: Anlotinib (5-16 mg) was orally administered in patients with solid tumor once a day on two schedules: (1) four consecutive weeks (4/0) or (2) 2-wk on/1-wk off (2/1).  Pharmacokinetic sampling was performed in all patients.  Twenty-one patients were further enrolled in an expanded cohort study on the recommended dose and schedule.  Preliminary tumor response was also assessed.  Results: On the 4/0 schedule, dose-limiting toxicity (DLT) was grade 3 hypertension at 10 mg.  On the 2/1 schedule, DLT was grade 3 hypertension and grade 3 fatigue at 16 mg.  Pharmacokinetic assessment indicated that anlotinib had long elimination half-lives and significant accumulation during multiple oral doses.  The 2/1 schedule was selected, with 12 mg once daily as the max. tolerated dose for the expanding study.  Twenty of the 21 patients (with colon adenocarcinoma, non-small cell lung cancer, renal clear cell cancer, medullary thyroid carcinoma, and soft tissue sarcoma) were assessable for antitumor activity of anlotinib: 3 patients had partial response, 14 patients had stable disease including 12 tumor burden shrinkage, and 3 had disease progression.  The main serious adverse effects were hypertension, triglyceride elevation, hand-foot skin reaction, and lipase elevation.  Conclusions: At the dose of 12 mg once daily at the 2/1 schedule, anlotinib displayed manageable toxicity, long circulation, and broad-spectrum antitumor potential, justifying the conduct of further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDNQUtYXwHILVg90H21EOLACvtfcHk0liISPNFZvu0ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajsbjN&md5=38e37bd976e43f78f9d2ddae6fe61c97</span></div><a href="/servlet/linkout?suffix=cit105b&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0332-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0332-8%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChi%26aufirst%3DY.%26atitle%3DSafety%252C%2520Pharmacokinetics%252C%2520and%2520Antitumor%2520Properties%2520of%2520Anlotinib%252C%2520an%2520Oral%2520Multi-Target%2520Tyrosine%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Refractory%2520Solid%2520Tumors%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D105%26doi%3D10.1186%2Fs13045-016-0332-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syrigos, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saif, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karapanagiotou, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikonomopoulos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marinis, F.</span></span> <span> </span><span class="NLM_article-title">The Need for Third-Line Treatment in Non-Small Cell Lung Cancer: An Overview of New Options</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=21378351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BC3M3ktlOgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=649-659&author=K.+N.+Syrigosauthor=M.+W.+Saifauthor=E.+M.+Karapanagiotouauthor=G.+Oikonomopoulosauthor=F.+De+Marinis&title=The+Need+for+Third-Line+Treatment+in+Non-Small+Cell+Lung+Cancer%3A+An+Overview+of+New+Options"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The need for third-line treatment in non-small cell lung cancer: an overview of new options</span></div><div class="casAuthors">Syrigos Kostas N; Saif Muhammad W; Karapanagiotou Eleni M; Oikonomopoulos George; De Marinis Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">649-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As a result of improved effectiveness of first-, second-line and maintenance therapeutic regimens in non-small cell lung cancer, there is need for new options as third-line treatment.  Erlotinib and gefitinib are currently the only drugs of proven efficacy in the third-line setting.  Chemotherapy drugs, such as pemetrexed, are being investigated, as are many new agents, such as cetuximab, sunitinib, sorafenib, everolimus, enzastaurin, afilbercept.  These novel targeted therapies seem to improve response rates and progression-free survival and their toxicity is tolerable.  In an effort to prolong survival while maintaining quality of life, large prospective studies are needed to examine the effectiveness and safety of third-line regimens in these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShxxgwn_cICo3yKPtYViAGfW6udTcc2eaq4Q_24V-XDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3ktlOgtQ%253D%253D&md5=1dd65e85411730c21951f8baab1efb07</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSyrigos%26aufirst%3DK.%2BN.%26aulast%3DSaif%26aufirst%3DM.%2BW.%26aulast%3DKarapanagiotou%26aufirst%3DE.%2BM.%26aulast%3DOikonomopoulos%26aufirst%3DG.%26aulast%3DDe%2BMarinis%26aufirst%3DF.%26atitle%3DThe%2520Need%2520for%2520Third-Line%2520Treatment%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520An%2520Overview%2520of%2520New%2520Options%26jtitle%3DAnticancer%2520Res.%26date%3D2011%26volume%3D31%26spage%3D649%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span> <span> </span><span class="NLM_article-title">Anlotinib Inhibits Angiogenesis Via Suppressing the Activation of VEGFR2, PDGFRβ and FGFR1</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>654</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.gene.2018.02.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.gene.2018.02.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29454091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=654&publication_year=2018&pages=77-86&author=B.+Linauthor=X.+Songauthor=D.+Yangauthor=D.+Baiauthor=Y.+Yaoauthor=N.+Lu&title=Anlotinib+Inhibits+Angiogenesis+Via+Suppressing+the+Activation+of+VEGFR2%2C+PDGFR%CE%B2+and+FGFR1&doi=10.1016%2Fj.gene.2018.02.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1</span></div><div class="casAuthors">Lin, Binyan; Song, Xiuming; Yang, Dawei; Bai, Dongsheng; Yao, Yuyuan; Lu, Na</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">654</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tumor cells recruit vascular endothelial cells and circulating endothelial progenitor cells to form new vessels to support their own growth and metastasis.  VEGF, PDGF-BB and FGF-2 are three major pro-angiogenic factors and applied to promote angiogenesis.  In this research, we demonstrated that anlotinib, a potent multi-tyrosine kinases inhibitor (TKI), showed a significant inhibitory effect on VEGF/PDGF-BB/FGF-2-induced angiogenesis in vitro and in vivo.  Wound healing assay, chamber directional migration assay and tube formation assay indicated that anlotinib inhibited VEGF/PDGF-BB/FGF-2-induced cell migration and formation of capillary-like tubes in endothelial cells.  Furthermore, anlotinib suppressed blood vessels sprout and microvessel d. in rat aortic ring assay and chicken chorioallantoic membrane (CAM) assay.  Importantly, according to our study, the anti-angiogenic effect of anlotinib is superior to sunitinib, sorafenib and nintedanib, which are three main anti-angiogenesis drugs in clinic.  Mechanistically, anlotinib inhibits the activation of VEGFR2, PDGFRβ and FGFR1 as well their common downstream ERK signaling.  Therefore, anlotinib is a potential agent to inhibit angiogenesis and be applied to tumor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ1_1sUZdru7Vg90H21EOLACvtfcHk0liISPNFZvu0ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFeitrw%253D&md5=57b3bebdd38f455cd470a812a78b479f</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2018.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2018.02.026%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DB.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DBai%26aufirst%3DD.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DN.%26atitle%3DAnlotinib%2520Inhibits%2520Angiogenesis%2520Via%2520Suppressing%2520the%2520Activation%2520of%2520VEGFR2%252C%2520PDGFR%25CE%25B2%2520and%2520FGFR1%26jtitle%3DGene%26date%3D2018%26volume%3D654%26spage%3D77%26epage%3D86%26doi%3D10.1016%2Fj.gene.2018.02.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span> <span> </span><span class="NLM_article-title">Anlotinib as a Third-Line Therapy in Patients with Refractory Advanced Non-Small-Cell Lung Cancer: A Multicentre, Randomised Phase II Trial (ALTER0302)</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1038/bjc.2017.478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fbjc.2017.478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29438373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=654-661&author=B.+Hanauthor=K.+Liauthor=Y.+Zhaoauthor=B.+Liauthor=Y.+Chengauthor=J.+Zhouauthor=Y.+Luauthor=Y.+Shiauthor=Z.+Wangauthor=L.+Jiangauthor=Y.+Luoauthor=Y.+Zhangauthor=C.+Huangauthor=Q.+Liauthor=G.+Wu&title=Anlotinib+as+a+Third-Line+Therapy+in+Patients+with+Refractory+Advanced+Non-Small-Cell+Lung+Cancer%3A+A+Multicentre%2C+Randomised+Phase+II+Trial+%28ALTER0302%29&doi=10.1038%2Fbjc.2017.478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)</span></div><div class="casAuthors">Han, Baohui; Li, Kai; Zhao, Yizhuo; Li, Baolan; Cheng, Ying; Zhou, Jianying; Lu, You; Shi, Yuankai; Wang, Zhehai; Jiang, Liyan; Luo, Yi; Zhang, Yiping; Huang, Cheng; Li, Qiang; Wu, Guoming</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">654-661</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumor angiogenesis and proliferative signalling.  The objective of this study was to assess the safety and efficacy of third-line anlotinib for patients with refractory advanced non-small-cell lung cancer (RA-NSCLC).  Methods: Eligible patients were randomized 1 : 1 to receive anlotinib (12 mg per day, per os; days 1-14; 21 days per cycle) or a placebo.  The primary end point was progression-free survival (PFS).  Results: A total of 117 eligible patients enrolled from 13 clin. centers in China were analyzed in the full anal. set.  No patients received immune check-point inhibitors and epidermal growth factor receptor status was unknown in 60.7% of the population.  PFS was better with anlotinib compared with the placebo (4.8 vs 1.2 mo; hazard ratio (HR)=0.32; 95% confidence interval (CI), 0.20-0.51; P<0.0001), as well as overall response rate (ORR) (10.0%; 95% CI, 2.4-17.6% vs 0%; 95% CI, 0-6.27%; P=0.028).  The median overall survival (OS) was 9.3 mo (95% CI, 6.8-15.1) for the anlotinib group and 6.3 mo (95% CI, 4.3-10.5) for the placebo group (HR=0.78; 95% CI, 0.51-1.18; P=0.2316).  Adverse events were more frequent in the anlotinib than the placebo group.  The percentage of grade 3-4 treatment-related adverse events was 21.67% in the anlotinib group.  Conclusions: Anlotinib as a third-line treatment provided significant PFS benefits to patients with RA-NSCLC when compared with the placebo, and the toxicity profiles showed good tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri6DYDQBnPr7Vg90H21EOLACvtfcHk0lgtAGvhI1jjuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSgsbk%253D&md5=6fee39699543db9ae2aafe82da90c188</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.478%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DG.%26atitle%3DAnlotinib%2520as%2520a%2520Third-Line%2520Therapy%2520in%2520Patients%2520with%2520Refractory%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%253A%2520A%2520Multicentre%252C%2520Randomised%2520Phase%2520II%2520Trial%2520%2528ALTER0302%2529%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D654%26epage%3D661%26doi%3D10.1038%2Fbjc.2017.478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. P.</span></span> <span> </span><span class="NLM_article-title">Substituted Quinoline Compounds as Angiogenesis Inhibitors and Their Preparation and Use in the Treatment of Angiogenesis and Cancer</span>. <span class="NLM_patent">WO2008112407A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=G.+P.+Chen&title=Substituted+Quinoline+Compounds+as+Angiogenesis+Inhibitors+and+Their+Preparation+and+Use+in+the+Treatment+of+Angiogenesis+and+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%2BP.%26atitle%3DSubstituted%2520Quinoline%2520Compounds%2520as%2520Angiogenesis%2520Inhibitors%2520and%2520Their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Angiogenesis%2520and%2520Cancer%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit109b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. P. C.</span></span> <span> </span><span class="NLM_article-title">Kinase Inhibitors for the Treatment of Disease Associated with Angiogenesis</span>. <span class="NLM_patent">WO2010021918A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=G.+P.+C.+Chen&title=Kinase+Inhibitors+for+the+Treatment+of+Disease+Associated+with+Angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%2BP.%2BC.%26atitle%3DKinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Disease%2520Associated%2520with%2520Angiogenesis%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit109c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G. P.</span>; <span class="NLM_string-name">Yan, C.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing an Anti-Cancer Agent, 1-{[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy]methyl}cyclopropanamine, Its Crystalline Form and Its Salts</span>. <span class="NLM_patent">WO2016179123A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=G.+P.+Chen&author=C.+Yan&title=Process+for+Preparing+an+Anti-Cancer+Agent%2C+1-%7B%5B4-%284-Fluoro-2-methyl-1H-indol-5-yloxy%29-6-methoxyquinolin-7-yloxy%5Dmethyl%7Dcyclopropanamine%2C+Its+Crystalline+Form+and+Its+Salts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%2BP.%26atitle%3DProcess%2520for%2520Preparing%2520an%2520Anti-Cancer%2520Agent%252C%25201-%257B%255B4-%25284-Fluoro-2-methyl-1H-indol-5-yloxy%2529-6-methoxyquinolin-7-yloxy%255Dmethyl%257Dcyclopropanamine%252C%2520Its%2520Crystalline%2520Form%2520and%2520Its%2520Salts%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span>; <span class="NLM_string-name">Zhang, X.</span>; <span class="NLM_string-name">Gao, Y.</span>; <span class="NLM_string-name">Chen, G.</span>; <span class="NLM_string-name">Wang, Q.</span>; <span class="NLM_string-name">Chen, Z.</span>; <span class="NLM_string-name">Dong, P.</span>; <span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Crystal of Quinoline Derivative and Preparation Method Thereof</span>. <span class="NLM_patent">CN102344438A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Zhao&author=X.+Zhang&author=Y.+Gao&author=G.+Chen&author=Q.+Wang&author=Z.+Chen&author=P.+Dong&author=J.+Jin&title=Crystal+of+Quinoline+Derivative+and+Preparation+Method+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DR.%26atitle%3DCrystal%2520of%2520Quinoline%2520Derivative%2520and%2520Preparation%2520Method%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit110b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Jiang, H.</span>; <span class="NLM_string-name">Tian, X.</span>; <span class="NLM_string-name">Yang, L.</span></span> <span> </span><span class="NLM_article-title">Quinoline Derivative for Treatment of Neuroendocrine Tumors</span>. <span class="NLM_patent">WO2019052520A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=X.+Zhang&author=X.+Wang&author=H.+Jiang&author=X.+Tian&author=L.+Yang&title=Quinoline+Derivative+for+Treatment+of+Neuroendocrine+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DQuinoline%2520Derivative%2520for%2520Treatment%2520of%2520Neuroendocrine%2520Tumors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinhold, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Claire, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehrman, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span> <span> </span><span class="NLM_article-title">3′-Azido-3′-Deoxythymidine (BW A509U): An Antiviral Agent That Inhibits the Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus in Vitro</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">7096</span>, <span class="refDoi"> DOI: 10.1073/pnas.82.20.7096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1073%2Fpnas.82.20.7096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=2413459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaL2MXlvV2htbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1985&pages=7096&author=H.+Mitsuyaauthor=K.+J.+Weinholdauthor=P.+A.+Furmanauthor=M.+H.+St.+Claireauthor=S.+N.+Lehrmanauthor=R.+C.+Galloauthor=D.+Bolognesiauthor=D.+W.+Barryauthor=S.+Broder&title=3%E2%80%B2-Azido-3%E2%80%B2-Deoxythymidine+%28BW+A509U%29%3A+An+Antiviral+Agent+That+Inhibits+the+Infectivity+and+Cytopathic+Effect+of+Human+T-Lymphotropic+Virus+Type+III%2FLymphadenopathy-Associated+Virus+in+Vitro&doi=10.1073%2Fpnas.82.20.7096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">3'-Azido-3'-deoxythymidine (BW A509U):  an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro</span></div><div class="casAuthors">Mitsuya, Hiroaki; Weinhold, Kent J.; Furman, Phillip A.; St. Clair, Marty H.; Lehrman, Sandra Nusinoff; Gallo, Robert C.; Bolognesi, Dani; Barry, David W.; Broder, Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7096-100</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The antiviral effects of a thymidine analog, 3'-azido-3'-deoxythymidine (BW A509U)(I)  [30516-87-1], which, as a triphosphate, inhibits the reverse transcriptase of human T-lymphotropic virus type III (HTLV-III)/lymphadenopathy-assocd. virus (LAV) was detd.  This agent blocked the expression of the p24 gag protein of HTLV-III/LAV in H9 cells following exposure to virus.  The drug also inhibited the cytopathic effect of HTLV-IIIB (a virus derived from a pool of American patients) and HTLV-III/RF-II (an isolate obtained from a Haitian patient that differs by about 20% in the amino acid sequence of the envelope gene from several isolates of HTLV-III/LAV, including HTLV-IIIB, analyzed so far).  3'-Azido-3'-deoxythymidine also completely blocked viral replication as assessed by reverse transcriptase prodn. in normal human peripheral blood mononuclear cells exposed to HTLV-III.  Finally, at concns. of 3'-azido-3'-deoxythymidine that block the in vitro infectively and cytopathic effect of HTLV-IIIB, the in vitro immune functions of normal T cells remain basically intact.  These results are relevant to the treatment of AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6ef2jfFgGQbVg90H21EOLACvtfcHk0lgtAGvhI1jjuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlvV2htbk%253D&md5=f56aaaed3c081c9a393e5fa8893f769c</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1073%2Fpnas.82.20.7096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.82.20.7096%26sid%3Dliteratum%253Aachs%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DWeinhold%26aufirst%3DK.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DSt.%2BClaire%26aufirst%3DM.%2BH.%26aulast%3DLehrman%26aufirst%3DS.%2BN.%26aulast%3DGallo%26aufirst%3DR.%2BC.%26aulast%3DBolognesi%26aufirst%3DD.%26aulast%3DBarry%26aufirst%3DD.%2BW.%26aulast%3DBroder%26aufirst%3DS.%26atitle%3D3%25E2%2580%25B2-Azido-3%25E2%2580%25B2-Deoxythymidine%2520%2528BW%2520A509U%2529%253A%2520An%2520Antiviral%2520Agent%2520That%2520Inhibits%2520the%2520Infectivity%2520and%2520Cytopathic%2520Effect%2520of%2520Human%2520T-Lymphotropic%2520Virus%2520Type%2520III%252FLymphadenopathy-Associated%2520Virus%2520in%2520Vitro%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1985%26volume%3D82%26spage%3D7096%26doi%3D10.1073%2Fpnas.82.20.7096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span> <span> </span><span class="NLM_article-title">Apalutamide: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0900-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0900-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29626324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsVaqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=699-705&author=Z.+T.+Al-Salama&title=Apalutamide%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0900-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Apalutamide: First Global Approval</span></div><div class="casAuthors">Al-Salama, Zaina T.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">699-705</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Apalutamide (ErleadaTM) is a next-generation oral androgen receptor (AR) inhibitor that is being developed by Janssen for the treatment of prostate cancer (PC).  It binds directly to the ligand-binding domain of the AR and blocks the effects of androgens.  In Feb. 2018, apalutamide received its first global approval in the USA for the treatment of non-metastatic castration-resistant PC (nmCRPC).  Apalutamide is undergoing phase III investigation in chemotherapy-naive patients with metastatic CRPC (in combination with abiraterone acetate plus prednisone), patients with high-risk localized or locally advanced PC receiving primary radiation therapy, and in patients with metastatic hormone-sensitive PC and biochem.-relapsed PC.  This article summarizes the milestones in the development of apalutamide leading to this first approval in nmCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfajxysBf-c7Vg90H21EOLACvtfcHk0lhh3tihKUMAHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsVaqtr8%253D&md5=b6a8295485956422287476b4192ee789</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0900-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0900-z%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26atitle%3DApalutamide%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D699%26epage%3D705%26doi%3D10.1007%2Fs40265-018-0900-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span>; <span class="NLM_string-name">Yoo, D.</span>; <span class="NLM_string-name">Sawyers, C. L.</span>; <span class="NLM_string-name">Tran, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of Diarylthiohydantoins as Androgen Receptor Antagonists for the Treatment of Hormone Refractory Prostate Cancer</span>. <span class="NLM_patent">US20070254933A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Jung&author=D.+Yoo&author=C.+L.+Sawyers&author=C.+Tran&title=Preparation+of+Diarylthiohydantoins+as+Androgen+Receptor+Antagonists+for+the+Treatment+of+Hormone+Refractory+Prostate+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Diarylthiohydantoins%2520as%2520Androgen%2520Receptor%2520Antagonists%2520for%2520the%2520Treatment%2520of%2520Hormone%2520Refractory%2520Prostate%2520Cancer%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebenek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, T. A.</span></span> <span> </span><span class="NLM_article-title">The Accuracy of Reverse Transcriptase from HIV-1</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>242</i></span>,  <span class="NLM_fpage">1171</span>, <span class="refDoi"> DOI: 10.1126/science.2460925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1126%2Fscience.2460925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=2460925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaL1MXjs1SmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=242&publication_year=1988&pages=1171&author=J.+D.+Robertsauthor=K.+Bebenekauthor=T.+A.+Kunkel&title=The+Accuracy+of+Reverse+Transcriptase+from+HIV-1&doi=10.1126%2Fscience.2460925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The accuracy of reverse transcriptase from HIV-1</span></div><div class="casAuthors">Roberts, John D.; Bebenek, Katarzyna; Kunkel, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">242</span>
        (<span class="NLM_cas:issue">4882</span>),
    <span class="NLM_cas:pages">1171-3</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A study was conducted to det. the fidelity of DNA synthesis catalyzed in vitro by the reverse transcriptase from a human immunodeficiency virus type 1 (HIV-1).  Like other retroviral reverse transcriptases, the HIV-1 enzyme does not correct errors by exonucleolytic proofreading.  Measurements with M13mp2-based fidelity assays indicated that the HIV-1 enzyme, isolated either from virus particles or from Escherichia coli cells infected with a plasmid expressing the cloned gene, was exceptionally inaccurate, having an av. error rate per detectable nucleotide incorporated of 1/1700.  It was, in fact, the least accurate reverse transcriptase described to date, one-tenth as accurate as the polymerases isolated from avian myeloblastosis or murine leukemia viruses, which have av. error rates of ∼1/17,000 and ∼1/30,000, resp.  DNA sequence analyses of mutations generated by HIV-1 polymerase showed that base substitution, addn., and deletion errors were all produced.  Certain template positions were mutational hotspots where the error rate could be as high as 1 per 70 polymd. nucleotides.  The data are consistent with the notion that the exceptional diversity of the HIV-1 genome results from error-prone reverse transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraUU7LzeJgzrVg90H21EOLACvtfcHk0lhh3tihKUMAHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXjs1SmsQ%253D%253D&md5=c8c40b64b883d6ae14d445f07a243e59</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1126%2Fscience.2460925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2460925%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DJ.%2BD.%26aulast%3DBebenek%26aufirst%3DK.%26aulast%3DKunkel%26aufirst%3DT.%2BA.%26atitle%3DThe%2520Accuracy%2520of%2520Reverse%2520Transcriptase%2520from%2520HIV-1%26jtitle%3DScience%26date%3D1988%26volume%3D242%26spage%3D1171%26doi%3D10.1126%2Fscience.2460925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isaacsson Velho, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carducci, M. A.</span></span> <span> </span><span class="NLM_article-title">Investigational Therapies Targeting the Androgen Signaling Axis and the Androgen Receptor and in Prostate Cancer - Recent Developments and Future Directions</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">811</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1080/13543784.2018.1513490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F13543784.2018.1513490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30118330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GktL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=811-822&author=P.+Isaacsson+Velhoauthor=M.+A.+Carducci&title=Investigational+Therapies+Targeting+the+Androgen+Signaling+Axis+and+the+Androgen+Receptor+and+in+Prostate+Cancer+-+Recent+Developments+and+Future+Directions&doi=10.1080%2F13543784.2018.1513490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions</span></div><div class="casAuthors">Isaacsson Velho, Pedro; Carducci, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">811-822</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Despite the heterogeneity of prostate cancer (PCa), androgen stimulation is fundamental to its development, growth, and lethality.  Therefore, the blockade of androgen receptor (AR) signaling is crit. to controlling the disease, even after progression with castrate levels of androgens.  We review the current understanding of new ways to block the AR, using novel antiandrogen inhibitors, which act on different parts of the AR signaling pathway in PCa.  We also review new approaches, such as the use of poly(ADP-ribose) polymerase (PARP) inhibitors, targeting both the AR and the DNA repair pathway, potentially adding synergy and improving efficacy and the combination of AR inhibitors and immunotherapy.  Bipolar androgen therapy (BAT), an innovative strategy to target the AR, has shown early evidence of efficacy in PCa is also discussed in detail.  We highlight some of the key ongoing studies of greatest relevance to this topic.: Clin. trials investigating new AR-targeted therapies should be encouraged in patients with PCa.  While it is unlikely that one AR inhibitor will produce long-lasting responses in a substantial proportion of patients, there is evidence that some strategies, such as the BAT could resensitize the AR to antiandrogens, alternating therapies and delaying time to progression, maximizing benefit to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod_gi-9BnoLLVg90H21EOLACvtfcHk0lhh3tihKUMAHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GktL7E&md5=2659edaa5397a0ee6fe46e6651e2ce6a</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1080%2F13543784.2018.1513490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2018.1513490%26sid%3Dliteratum%253Aachs%26aulast%3DIsaacsson%2BVelho%26aufirst%3DP.%26aulast%3DCarducci%26aufirst%3DM.%2BA.%26atitle%3DInvestigational%2520Therapies%2520Targeting%2520the%2520Androgen%2520Signaling%2520Axis%2520and%2520the%2520Androgen%2520Receptor%2520and%2520in%2520Prostate%2520Cancer%2520-%2520Recent%2520Developments%2520and%2520Future%2520Directions%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2018%26volume%3D27%26spage%3D811%26epage%3D822%26doi%3D10.1080%2F13543784.2018.1513490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bambury, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathkopf, D. E.</span></span> <span> </span><span class="NLM_article-title">Novel and Next-Generation Androgen Receptor-Directed Therapies for Prostate Cancer: Beyond Abiraterone and Enzalutamide</span>. <i>Urol. Oncol.: Semin. Orig. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1016/j.urolonc.2015.05.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.urolonc.2015.05.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=26162486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=348-355&author=R.+M.+Bamburyauthor=D.+E.+Rathkopf&title=Novel+and+Next-Generation+Androgen+Receptor-Directed+Therapies+for+Prostate+Cancer%3A+Beyond+Abiraterone+and+Enzalutamide&doi=10.1016%2Fj.urolonc.2015.05.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide</span></div><div class="casAuthors">Bambury, Richard M.; Rathkopf, Dana E.</div><div class="citationInfo"><span class="NLM_cas:title">Urologic Oncology: Seminars and Original Investigations</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">348-355</span>CODEN:
                <span class="NLM_cas:coden">UOSOAA</span>;
        ISSN:<span class="NLM_cas:issn">1078-1439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The approval of abiraterone and enzalutamide for the treatment of advanced castration-resistant prostate cancer heralded a paradigm shift in the management of this disease.  Nevertheless, new and improved treatments are needed since the disease remains incurable for the majority of these patients.  In this article, we review the biol. of castration-resistant disease as well as emerging therapeutic compds. directed at the androgen receptor, including galeterone, VT-464, ARN-509, and ODM-201.  Mechanisms of action, early clin. data, and ongoing clin. studies for these compds. are all reviewed.  The need to find optimal sequencing and combination strategies as well as the need for predictive biomarkers of response to these agents is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq18y5Xt5wFGrVg90H21EOLACvtfcHk0lgOitCi4RdMRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygsrbL&md5=f16bb4806d79d9030f52f2e4c170e448</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2015.05.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2015.05.025%26sid%3Dliteratum%253Aachs%26aulast%3DBambury%26aufirst%3DR.%2BM.%26aulast%3DRathkopf%26aufirst%3DD.%2BE.%26atitle%3DNovel%2520and%2520Next-Generation%2520Androgen%2520Receptor-Directed%2520Therapies%2520for%2520Prostate%2520Cancer%253A%2520Beyond%2520Abiraterone%2520and%2520Enzalutamide%26jtitle%3DUrol.%2520Oncol.%253A%2520Semin.%2520Orig.%2520Invest.%26date%3D2016%26volume%3D34%26spage%3D348%26epage%3D355%26doi%3D10.1016%2Fj.urolonc.2015.05.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadaschik, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainwaring, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Gitlitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espina, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rackoff, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, E. J.</span></span> <span> </span><span class="NLM_article-title">Apalutamide Treatment and Metastasis-Free Survival in Prostate Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1408</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1715546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1056%2FNEJMoa1715546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29420164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVCmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1408-1418&author=M.+R.+Smithauthor=F.+Saadauthor=S.+Chowdhuryauthor=S.+Oudardauthor=B.+A.+Hadaschikauthor=J.+N.+Graffauthor=D.+Olmosauthor=P.+N.+Mainwaringauthor=J.+Y.+Leeauthor=H.+Uemuraauthor=A.+Lopez-Gitlitzauthor=G.+C.+Trudelauthor=B.+M.+Espinaauthor=Y.+Shuauthor=Y.+C.+Parkauthor=W.+R.+Rackoffauthor=M.+K.+Yuauthor=E.+J.+Small&title=Apalutamide+Treatment+and+Metastasis-Free+Survival+in+Prostate+Cancer&doi=10.1056%2FNEJMoa1715546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Apalutamide treatment and metastasis-free survival in prostate cancer</span></div><div class="casAuthors">Smith, Matthew R.; Saad, Fred; Chowdhury, Simon; Oudard, Stephane; Hadaschik, Boris A.; Graff, Julie N.; Olmos, David; Mainwaring, Paul N.; Lee, Ji Youl; Uemura, Hiroji; Lopez-Gitlitz, Angela; Trudel, Geralyn C.; Espina, Byron M.; Shu, Youyi; Park, Youn C.; Rackoff, Wayne R.; Yu, Margaret K.; Small, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1408-1418</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer.  We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis. methods We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 mo or less.  Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo.  All the patients continued to receive androgen-deprivation therapy.  The primary end point was metastasis-free survival, which was defined as the time from randomization to the first detection of distant metastasis on imaging or death. results A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo group).  In the planned primary anal., which was performed after 378 events had occurred, median metastasis-free survival was 40.5 mo in the apalutamide group as compared with 16.2 mo in the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 0.35; P<0.001).  Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001).  The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group.  The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%). conclusions Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0nCARi0YWC7Vg90H21EOLACvtfcHk0lgOitCi4RdMRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVCmurk%253D&md5=ef5fead8f1f12720031f124b412c937a</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1715546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1715546%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BR.%26aulast%3DSaad%26aufirst%3DF.%26aulast%3DChowdhury%26aufirst%3DS.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DHadaschik%26aufirst%3DB.%2BA.%26aulast%3DGraff%26aufirst%3DJ.%2BN.%26aulast%3DOlmos%26aufirst%3DD.%26aulast%3DMainwaring%26aufirst%3DP.%2BN.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DUemura%26aufirst%3DH.%26aulast%3DLopez-Gitlitz%26aufirst%3DA.%26aulast%3DTrudel%26aufirst%3DG.%2BC.%26aulast%3DEspina%26aufirst%3DB.%2BM.%26aulast%3DShu%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DY.%2BC.%26aulast%3DRackoff%26aufirst%3DW.%2BR.%26aulast%3DYu%26aufirst%3DM.%2BK.%26aulast%3DSmall%26aufirst%3DE.%2BJ.%26atitle%3DApalutamide%2520Treatment%2520and%2520Metastasis-Free%2520Survival%2520in%2520Prostate%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D1408%26epage%3D1418%26doi%3D10.1056%2FNEJMoa1715546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Bian, J.</span>; <span class="NLM_string-name">Yu, J.</span>; <span class="NLM_string-name">Wang, M.</span>; <span class="NLM_string-name">Dai, X.</span></span> <span> </span><span class="NLM_article-title">Preparation of Apalutamide</span>. <span class="NLM_patent">CN107501237A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Qin&author=Y.+Chen&author=J.+Bian&author=J.+Yu&author=M.+Wang&author=X.+Dai&title=Preparation+of+Apalutamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Apalutamide%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit118b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span>; <span class="NLM_string-name">Yang, J.</span>; <span class="NLM_string-name">Nie, F.</span>; <span class="NLM_string-name">Yang, Y.</span>; <span class="NLM_string-name">Jiang, X.</span></span> <span> </span><span class="NLM_article-title">Preparation of Diaryl Thiohydantoin Compound Apalutamide</span>. <span class="NLM_patent">CN108047200A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=H.+Bian&author=J.+Yang&author=F.+Nie&author=Y.+Yang&author=X.+Jiang&title=Preparation+of+Diaryl+Thiohydantoin+Compound+Apalutamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBian%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520Diaryl%2520Thiohydantoin%2520Compound%2520Apalutamide%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit118c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span>; <span class="NLM_string-name">Wei, D.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Preparing Method of Apalutamide and Intermediates</span>. <span class="NLM_patent">CN108069869A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Z.+Hu&author=D.+Wei&author=X.+Zhu&author=S.+Wang&title=Preparing+Method+of+Apalutamide+and+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DZ.%26atitle%3DPreparing%2520Method%2520of%2520Apalutamide%2520and%2520Intermediates%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit118d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, A. R.</span>; <span class="NLM_string-name">Kanniah, S. L.</span>; <span class="NLM_string-name">Arote, N. D.</span>; <span class="NLM_string-name">Bhagwat, O. V.</span>; <span class="NLM_string-name">Sonar, J. K.</span>; <span class="NLM_string-name">Poundkar, V. B.</span>; <span class="NLM_string-name">Wagh, Y. D.</span></span> <span> </span><span class="NLM_article-title">Solid State Forms of Apalutamide</span>. <span class="NLM_patent">WO2018112001A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+R.+Muthusamy&author=S.+L.+Kanniah&author=N.+D.+Arote&author=O.+V.+Bhagwat&author=J.+K.+Sonar&author=V.+B.+Poundkar&author=Y.+D.+Wagh&title=Solid+State+Forms+of+Apalutamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMuthusamy%26aufirst%3DA.%2BR.%26atitle%3DSolid%2520State%2520Forms%2520of%2520Apalutamide%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit118e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-H.</span>; <span class="NLM_string-name">Guo, J.-C.</span>; <span class="NLM_string-name">Shih, W.-L.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Apalutamide</span>. <span class="NLM_patent">US20180201601A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.-H.+Chen&author=J.-C.+Guo&author=W.-L.+Shih&title=Process+for+Preparing+Apalutamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.-H.%26atitle%3DProcess%2520for%2520Preparing%2520Apalutamide%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit118f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Pawar, A. A.</span>; <span class="NLM_string-name">Subba Reddy, P. R.</span>; <span class="NLM_string-name">Mudapaka, V. K.</span>; <span class="NLM_string-name">Gopi, S. P.</span>; <span class="NLM_string-name">Reddy, K. R. S.</span>; <span class="NLM_string-name">Verma, H.</span></span> <span> </span><span class="NLM_article-title">Amorphous Solid Dispersions of Apalutamide and Process for the Preparation Thereof</span>. <span class="NLM_patent">WO2019016747A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+A.+Pawar&author=P.+R.+Subba+Reddy&author=V.+K.+Mudapaka&author=S.+P.+Gopi&author=K.+R.+S.+Reddy&author=H.+Verma&title=Amorphous+Solid+Dispersions+of+Apalutamide+and+Process+for+the+Preparation+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPawar%26aufirst%3DA.%2BA.%26atitle%3DAmorphous%2520Solid%2520Dispersions%2520of%2520Apalutamide%2520and%2520Process%2520for%2520the%2520Preparation%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span>; <span class="NLM_string-name">Bonnefous, C.</span>; <span class="NLM_string-name">Julien, J. D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Spiro Thiohydantoin Compounds as Androgen Receptor Modulators</span>. <span class="NLM_patent">WO2011103202A2</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+D.+Smith&author=C.+Bonnefous&author=J.+D.+Julien&title=Preparation+of+Spiro+Thiohydantoin+Compounds+as+Androgen+Receptor+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DPreparation%2520of%2520Spiro%2520Thiohydantoin%2520Compounds%2520as%2520Androgen%2520Receptor%2520Modulators%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit119b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Haim, C. B.</span>; <span class="NLM_string-name">Horvath, A.</span>; <span class="NLM_string-name">Weerts, J. E. E.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Apalutamide</span>. <span class="NLM_patent">WO2016100652A2</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=C.+B.+Haim&author=A.+Horvath&author=J.+E.+E.+Weerts&title=Process+for+the+Preparation+of+Apalutamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHaim%26aufirst%3DC.%2BB.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Apalutamide%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit119c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Haim, C. B.</span>; <span class="NLM_string-name">Horvath, A.</span>; <span class="NLM_string-name">Weerts, J. E. E.</span>; <span class="NLM_string-name">Albaneze-Walker, J.</span></span> <span> </span><span class="NLM_article-title">Processes for the Preparation of a Diarylthiohydantoin Compound</span>. <span class="NLM_patent">WO2016100645A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=C.+B.+Haim&author=A.+Horvath&author=J.+E.+E.+Weerts&author=J.+Albaneze-Walker&title=Processes+for+the+Preparation+of+a+Diarylthiohydantoin+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHaim%26aufirst%3DC.%2BB.%26atitle%3DProcesses%2520for%2520the%2520Preparation%2520of%2520a%2520Diarylthiohydantoin%2520Compound%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit119d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bignan, G.</span>; <span class="NLM_string-name">Connolly, P. J.</span>; <span class="NLM_string-name">Hickson, I.</span>; <span class="NLM_string-name">Meerpoel, L.</span>; <span class="NLM_string-name">Pande, V.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Branch, J.</span>; <span class="NLM_string-name">Rocaboy, C.</span>; <span class="NLM_string-name">Trabalon Escolar, L. B.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Thiohydantoin Derivatives as Androgen Receptor Antagonists</span>. <span class="NLM_patent">WO2017123542A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Bignan&author=P.+J.+Connolly&author=I.+Hickson&author=L.+Meerpoel&author=V.+Pande&author=Z.+Zhang&author=J.+Branch&author=C.+Rocaboy&author=L.+B.+Trabalon+Escolar&title=Preparation+of+Substituted+Thiohydantoin+Derivatives+as+Androgen+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBignan%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Substituted%2520Thiohydantoin%2520Derivatives%2520as%2520Androgen%2520Receptor%2520Antagonists%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, M.</span></span> <span> </span><span class="NLM_article-title">Selective Catalytic Hydrogenation of Functionalized Nitroarenes: An Update</span>. <i>ChemCatChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1002/cctc.200900129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fcctc.200900129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1amt7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=210-221&author=H.-U.+Blaserauthor=H.+Steinerauthor=M.+Studer&title=Selective+Catalytic+Hydrogenation+of+Functionalized+Nitroarenes%3A+An+Update&doi=10.1002%2Fcctc.200900129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Catalytic Hydrogenation of Functionalized Nitroarenes: An Update</span></div><div class="casAuthors">Blaser, Hans-Ulrich; Steiner, Heinz; Studer, Martin</div><div class="citationInfo"><span class="NLM_cas:title">ChemCatChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-221</span>CODEN:
                <span class="NLM_cas:coden">CHEMK3</span>;
        ISSN:<span class="NLM_cas:issn">1867-3880</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Progress made in the last decade for the selective catalytic hydrogenation of nitroarenes in the presence of other reducible functions is reviewed.  The main focus is on catalytic systems capable of reducing nitro groups with very high chemoselectivity in substrates contg. carbon-carbon or carbon-nitrogen double or triple bonds, carbonyl or benzyl groups, and multiple Cl, Br, or I substituents.  The performance of new catalyst types is described, most notably of gold-based catalysts, but also of modified classical Pt, Pd, and Ni catalysts, as well as homogeneous catalysts.  The best results for the various chemoselectivity problems are compiled and assessed with regard to their versatility and synthetic viability.  In addn., progress in understanding mechanistic aspects are briefly described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZbqcwraSCLbVg90H21EOLACvtfcHk0lhIhBQA_yNCdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1amt7nM&md5=1044185cf70d0c5bd48031a26a62c437</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1002%2Fcctc.200900129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcctc.200900129%26sid%3Dliteratum%253Aachs%26aulast%3DBlaser%26aufirst%3DH.-U.%26aulast%3DSteiner%26aufirst%3DH.%26aulast%3DStuder%26aufirst%3DM.%26atitle%3DSelective%2520Catalytic%2520Hydrogenation%2520of%2520Functionalized%2520Nitroarenes%253A%2520An%2520Update%26jtitle%3DChemCatChem%26date%3D2009%26volume%3D1%26spage%3D210%26epage%3D221%26doi%3D10.1002%2Fcctc.200900129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rose, A. A. N.</span></span> <span> </span><span class="NLM_article-title">Encorafenib and Binimetinib for the Treatment of BRAF V600E/K-Mutated Melanoma</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1358/dot.2019.55.4.2958476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1358%2Fdot.2019.55.4.2958476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3M7hvFOqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=247-264&author=A.+A.+N.+Rose&title=Encorafenib+and+Binimetinib+for+the+Treatment+of+BRAF+V600E%2FK-Mutated+Melanoma&doi=10.1358%2Fdot.2019.55.4.2958476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma</span></div><div class="casAuthors">Rose A A N</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">247-264</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">BRAF is a constituent of the mitogen-activated protein kinase (MAPK) signaling pathway, which serves to activate downstream MEK, and is one of the most commonly mutated oncogenes in human tumors.  Indeed, BRAF V600 mutations are present in approximately 40% of metastatic melanoma tumors.  Encorafenib (LGX-818, Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK, respectively.  BRAF and MEK inhibitors have been shown to improve overall and progression-free survival among patients with metastatic melanoma.  Of these inhibitors, encorafenib and binimetinib are the newest combination, which received approval by the Food and Drug Administration (FDA) for the treatment of BRAF V600E/K-mutated melanoma in June 2018.  This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF V600-mutated melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzgEWjSIiY6SM8MEzWGjS9fW6udTcc2eb_4oWiYPFbNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7hvFOqug%253D%253D&md5=0a6adb92ca9611aa52a5ca5c5bf9240e</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1358%2Fdot.2019.55.4.2958476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2019.55.4.2958476%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DA.%2BA.%2BN.%26atitle%3DEncorafenib%2520and%2520Binimetinib%2520for%2520the%2520Treatment%2520of%2520BRAF%2520V600E%252FK-Mutated%2520Melanoma%26jtitle%3DDrugs%2520Today%26date%3D2019%26volume%3D55%26spage%3D247%26epage%3D264%26doi%3D10.1358%2Fdot.2019.55.4.2958476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Liberal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span> <span> </span><span class="NLM_article-title">BRAF and MEK Inhibition for the Treatment of Advanced BRAF Mutant Melanoma</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1297</span>, <span class="refDoi"> DOI: 10.1517/14656566.2015.1044971</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1517%2F14656566.2015.1044971" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=26001180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptFait78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1285-1297&author=J.+Richmanauthor=J.+Martin-Liberalauthor=S.+Diemauthor=J.+Larkin&title=BRAF+and+MEK+Inhibition+for+the+Treatment+of+Advanced+BRAF+Mutant+Melanoma&doi=10.1517%2F14656566.2015.1044971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma</span></div><div class="casAuthors">Richman, Juliet; Martin-Liberal, Juan; Diem, Stefan; Larkin, James</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1285-1297</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: BRAF inhibition alone has achieved unprecedented efficacy results in patients affected by BRAF-mutated advanced melanoma.  Since these findings, it was postulated that dual inhibition of BRAF and other components of the RAS/RAF/MEK/ERK MAPK pathway (such as MEK) would be superior to BRAF inhibition as monotherapy.  A series of recent clin. trials have confirmed this hypothesis.  Areas covered: In this article, the biol. rationale for both single and concomitant inhibitions of the MAPK pathway in BRAF mutant melanoma is provided.  Moreover, available clin. data on the efficacy and toxicity of BRAF and MEK inhibition as single agents and in combination are extensively reviewed.  Expert opinion: Dual BRAF and MEK inhibition in advanced BRAF-mutated melanoma is superior to single inhibition in terms of efficacy without significant increase in toxicity.  Therefore, BRAF plus MEK inhibition is expected to supersede single-agent BRAF inhibition in these patients in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1FrIWkBI77bVg90H21EOLACvtfcHk0liZXBLr5vjItQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptFait78%253D&md5=ead554efadd66f2c617dbfd9baa4e2d3</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1044971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1044971%26sid%3Dliteratum%253Aachs%26aulast%3DRichman%26aufirst%3DJ.%26aulast%3DMartin-Liberal%26aufirst%3DJ.%26aulast%3DDiem%26aufirst%3DS.%26aulast%3DLarkin%26aufirst%3DJ.%26atitle%3DBRAF%2520and%2520MEK%2520Inhibition%2520for%2520the%2520Treatment%2520of%2520Advanced%2520BRAF%2520Mutant%2520Melanoma%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D1285%26epage%3D1297%26doi%3D10.1517%2F14656566.2015.1044971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krajsova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loquai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moutouh-de Parseval, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickard, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma (COLUMBUS): A Multicentre, Open-Label, Randomised Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30142-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS1470-2045%2818%2930142-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29573941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlslKltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=603-615&author=R.+Dummerauthor=P.+A.+Asciertoauthor=H.+J.+Gogasauthor=A.+Aranceauthor=M.+Mandalaauthor=G.+Liszkayauthor=C.+Garbeauthor=D.+Schadendorfauthor=I.+Krajsovaauthor=R.+Gutzmerauthor=V.+Chiarion-Sileniauthor=C.+Dutriauxauthor=J.+W.+B.+de+Grootauthor=N.+Yamazakiauthor=C.+Loquaiauthor=L.+A.+Moutouh-de+Parsevalauthor=M.+D.+Pickardauthor=V.+Sandorauthor=C.+Robertauthor=K.+T.+Flaherty&title=Encorafenib+Plus+Binimetinib+Versus+Vemurafenib+or+Encorafenib+in+Patients+with+BRAF-Mutant+Melanoma+%28COLUMBUS%29%3A+A+Multicentre%2C+Open-Label%2C+Randomised+Phase+3+Trial&doi=10.1016%2FS1470-2045%2818%2930142-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial</span></div><div class="casAuthors">Dummer, Reinhard; Ascierto, Paolo A.; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A.; Pickard, Michael D.; Sandor, Victor; Robert, Caroline; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">603-615</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Combined BRAF-MEK inhibitor therapy is the std. of care for BRAFV600-mutant advanced melanoma.  We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, vs. vemurafenib in patients with advanced BRAFV600-mutant melanoma.  COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries.  Eligible patients were aged 18 years or older and had histol. confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a BRAFV600E or BRAFV600K mutation; an Eastern Cooperative Oncol. Group (ECOG) performance status of 0 or 1; and were treatment naive or had progressed on or after previous first-line immunotherapy.  In part 1 of the study, patients were randomly assigned (1:1:1) via interactive response technol. to receive either oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group).  The primary endpoint was progression-free survival by blinded independent central review for encorafenib plus binimetinib vs. vemurafenib.  Efficacy analyses were by intention-to-treat.  Safety was analyzed in patients who received at least one dose of study drug and one postbaseline safety assessment.  The results of part 2 will be published sep.  This study is registered with ClinicalTrials.gov, no. NCT01909453, and EudraCT, no. 2013-001176-38.  Between Dec 30, 2013, and Apr. 10, 2015, 577 of 1345 screened patients were randomly assigned to either the encorafenib plus binimetinib group (n=192), the encorafenib group (n=194), or the vemurafenib group (n=191).  With a median follow-up of 16·6 mo (95% CI 14·8-16·9), median progression-free survival was 14·9 mo (95% CI 11·0-18·5) in the encorafenib plus binimetinib group and 7·3 mo (5·6-8·2) in the vemurafenib group (hazard ratio [HR] 0·54, 95% CI 0·41-0·71; two-sided p<0·0001).  The most common grade 3-4 adverse events seen in more than 5% of patients in the encorafenib plus binimetinib group were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased creatine phosphokinase (13 [7%]), and hypertension (11 [6%]); in the encorafenib group they were palmoplantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and in the vemurafenib group it was arthralgia (11 [6%] of 186 patients).  There were no treatment-related deaths except for one death in the combination group, which was considered possibly related to treatment by the investigator.  Encorafenib plus binimetinib and encorafenib monotherapy showed favorable efficacy compared with vemurafenib.  Overall, encorafenib plus binimetinib appears to have an improved tolerability profile compared with encorafenib or vemurafenib.  Encorafenib plus binimetinib could represent a new treatment option for patients with BRAF-mutant melanoma.Array BioPharma, Novartis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjPYLzOZ57s7Vg90H21EOLACvtfcHk0liZXBLr5vjItQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlslKltr4%253D&md5=4570e5b6091c5683a5f8a2d09110d541</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930142-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930142-6%26sid%3Dliteratum%253Aachs%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DGogas%26aufirst%3DH.%2BJ.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DKrajsova%26aufirst%3DI.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BW.%2BB.%26aulast%3DYamazaki%26aufirst%3DN.%26aulast%3DLoquai%26aufirst%3DC.%26aulast%3DMoutouh-de%2BParseval%26aufirst%3DL.%2BA.%26aulast%3DPickard%26aufirst%3DM.%2BD.%26aulast%3DSandor%26aufirst%3DV.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DEncorafenib%2520Plus%2520Binimetinib%2520Versus%2520Vemurafenib%2520or%2520Encorafenib%2520in%2520Patients%2520with%2520BRAF-Mutant%2520Melanoma%2520%2528COLUMBUS%2529%253A%2520A%2520Multicentre%252C%2520Open-Label%252C%2520Randomised%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D603%26epage%3D615%26doi%3D10.1016%2FS1470-2045%2818%2930142-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Synthesizing Method for Binimetinib</span>. <span class="NLM_patent">CN105820124A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Chen&title=Synthesizing+Method+for+Binimetinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DSynthesizing%2520Method%2520for%2520Binimetinib%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krell, C. M.</span>; <span class="NLM_string-name">Misun, M.</span>; <span class="NLM_string-name">Niederer, D. A.</span>; <span class="NLM_string-name">Pachinger, W. H.</span>; <span class="NLM_string-name">Wolf, M.-C.</span>; <span class="NLM_string-name">Zimmermann, D.</span>; <span class="NLM_string-name">Liu, W.</span>; <span class="NLM_string-name">Stengel, P. J.</span>; <span class="NLM_string-name">Nichols, P.</span></span> <span> </span><span class="NLM_article-title">Preparation of and Formulation Comprising a Mek Inhibitor</span>. <span class="NLM_patent">WO2014063024A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=C.+M.+Krell&author=M.+Misun&author=D.+A.+Niederer&author=W.+H.+Pachinger&author=M.-C.+Wolf&author=D.+Zimmermann&author=W.+Liu&author=P.+J.+Stengel&author=P.+Nichols&title=Preparation+of+and+Formulation+Comprising+a+Mek+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKrell%26aufirst%3DC.%2BM.%26atitle%3DPreparation%2520of%2520and%2520Formulation%2520Comprising%2520a%2520Mek%2520Inhibitor%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1947</span>– <span class="NLM_lpage">1953</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1028-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1028-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30506139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3crnslGgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1947-1953&author=M.+Shirley&title=Dacomitinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1028-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib: First Global Approval</span></div><div class="casAuthors">Shirley Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1947-1953</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dacomitinib (Vizimpro(®)) is an orally administered, small-molecule irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid tumours.  In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.  Registration applications for the use of dacomitinib as first-line treatment for patients with EGFR-mutation-positive metastatic NSCLC have also been submitted in the EU and Japan.  This article summarizes the milestones in the development of dacomitinib leading to this first approval for the first-line treatment of patients with EGFR-mutated metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA4VT-ypttQfSAs_PE1QvifW6udTcc2eaXXa7hFPCtOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnslGgsw%253D%253D&md5=0e035cd4b47b60f40c2af1d3c1fb5add</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1028-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1028-x%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DDacomitinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1947%26epage%3D1953%26doi%3D10.1007%2Fs40265-018-1028-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Díaz-Serrano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugazagoitia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, L. P.-A.</span></span> <span> </span><span class="NLM_article-title">Targeting EGFR in Lung Cancer: Current Standards and Developments</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0916-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0916-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29915896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1aksr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=893-911&author=A.+D%C3%ADaz-Serranoauthor=P.+Gellaauthor=E.+Jim%C3%A9nezauthor=J.+Zugazagoitiaauthor=L.+P.-A.+Rodr%C3%ADguez&title=Targeting+EGFR+in+Lung+Cancer%3A+Current+Standards+and+Developments&doi=10.1007%2Fs40265-018-0916-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting EGFR in Lung Cancer: Current Standards and Developments</span></div><div class="casAuthors">Diaz-Serrano, Asuncion; Gella, Pablo; Jimenez, Elisabeth; Zugazagoitia, Jon; Paz-Ares Rodriguez, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">893-911</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Lung cancer is the second most common malignant tumor and the leading cause of cancer death.  Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a distinct subtype of lung cancer comprising approx. 15-40% of non-squamous tumors.  The development of first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) has been a significant step forward in the treatment of patients with EGFR-mutant tumors, and over the last few years has been the therapy of choice in the initial management of patients with activating mutations in EGFR, with some differences in efficacy and toxicity profile.  Up to 50% of patients treated with first- and second-generation TKIs develop an EGFR exon 20 T790M mutation at the time of progression.  In this context, osimertinib has shown a great benefit in terms of progression-free survival (PFS) in the second-line setting, including central nervous system metastasis control.  The FLAURA trial, which compared osimertinib to first-generation inhibitors as first-line therapy, showed a clear PFS advantage for osimertinib and a trend towards an increased overall survival (OS) assessed by investigator review.  Although T790M mutation is the most common mechanism of resistance to first- and second-generation EGFR TKIs, other EGFR-dependent and -independent mechanisms have been described, such as HER2 and MET amplifications or BRAF and MEK mutations.  Some mechanisms of resistance to osimertinib and other third-generation TKIs have also been described.  Several fourth-generation TKIs, targeted drug combinations and immunotherapy strategies are under investigation to overcome resistance to EGFR TKIs in order to improve EGFR-mutant NSCLC patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJpVCr1NbkELVg90H21EOLACvtfcHk0liqJiGKB9h8Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1aksr3J&md5=e5223d828d256d44256bd5db029306b5</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0916-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0916-4%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25ADaz-Serrano%26aufirst%3DA.%26aulast%3DGella%26aufirst%3DP.%26aulast%3DJim%25C3%25A9nez%26aufirst%3DE.%26aulast%3DZugazagoitia%26aufirst%3DJ.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DL.%2BP.-A.%26atitle%3DTargeting%2520EGFR%2520in%2520Lung%2520Cancer%253A%2520Current%2520Standards%2520and%2520Developments%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D893%26epage%3D911%26doi%3D10.1007%2Fs40265-018-0916-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbar, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR-Mutation-Positive Non-Small-Cell Lung Cancer (ARCHER 1050): A Randomised, Open-Label, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30608-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS1470-2045%2817%2930608-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28958502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1454-1466&author=Y.-L.+Wuauthor=Y.+Chengauthor=X.+Zhouauthor=K.+H.+Leeauthor=K.+Nakagawaauthor=S.+Nihoauthor=F.+Tsujiauthor=R.+Linkeauthor=R.+Rosellauthor=J.+Corralauthor=M.+R.+Migliorinoauthor=A.+Pluzanskiauthor=E.+I.+Sbarauthor=T.+Wangauthor=J.+L.+Whiteauthor=S.+Nadanacivaauthor=R.+Sandinauthor=T.+S.+Mok&title=Dacomitinib+Versus+Gefitinib+as+First-Line+Treatment+for+Patients+with+EGFR-Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28ARCHER+1050%29%3A+A+Randomised%2C+Open-Label%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2817%2930608-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; Sbar, Eric I.; Wang, Tao; White, Jane Liang; Nadanaciva, Sashi; Sandin, Rickard; Mok, Tony S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1466</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.  We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-pos. non-small-cell lung cancer (NSCLC).  In this international, multicenter, randomized, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centers and university hospitals in seven countries or special administrative regions.  We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met.  Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system.  The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population.  Safety was assessed in all patients who received at least one dose of study treatment.  This study is registered with ClinicalTrials.gov, no. NCT01774721, and is ongoing but no longer recruiting patients.  Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225).  Median duration of follow-up for progression-free survival was 22·1 mo (95% CI 20·3-23·9).  Median progression-free survival according to masked independent review was 14·7 mo (95% CI 11·1-16·6) in the dacomitinib group and 9·2 mo (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001).  The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).  Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib.  Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).  Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-pos. NSCLC and should be considered as a new treatment option for this population.  SFJ Pharmaceuticals Group and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqZ8AKr7cDZLVg90H21EOLACvtfcHk0liqJiGKB9h8Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI&md5=89eb8749060bfa3dfe79a84537b2b27b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930608-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930608-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DTsuji%26aufirst%3DF.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DMigliorino%26aufirst%3DM.%2BR.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DJ.%2BL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSandin%26aufirst%3DR.%26aulast%3DMok%26aufirst%3DT.%2BS.%26atitle%3DDacomitinib%2520Versus%2520Gefitinib%2520as%2520First-Line%2520Treatment%2520for%2520Patients%2520with%2520EGFR-Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528ARCHER%25201050%2529%253A%2520A%2520Randomised%252C%2520Open-Label%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D1454%26epage%3D1466%26doi%3D10.1016%2FS1470-2045%2817%2930608-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakhoury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, F. O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivault, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-D]Pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8103</span>– <span class="NLM_lpage">8124</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8103-8124&author=J.+B.+Smaillauthor=A.+J.+Gonzalesauthor=J.+A.+Spicerauthor=H.+Leeauthor=J.+E.+Reedauthor=K.+Sextonauthor=I.+W.+Althausauthor=T.+Zhuauthor=S.+L.+Blackauthor=A.+Blaserauthor=W.+A.+Dennyauthor=P.+A.+Ellisauthor=S.+Fakhouryauthor=P.+J.+Harveyauthor=K.+Hookauthor=F.+O.+J.+McCarthyauthor=B.+D.+Palmerauthor=F.+Rivaultauthor=K.+Schlosserauthor=T.+Ellisauthor=A.+M.+Thompsonauthor=E.+Trachetauthor=R.+T.+Wintersauthor=H.+Tecleauthor=A.+Bridges&title=Tyrosine+Kinase+Inhibitors.+20.+Optimization+of+Substituted+Quinazoline+and+Pyrido%5B3%2C4-D%5DPyrimidine+Derivatives+as+Orally+Active%2C+Irreversible+Inhibitors+of+the+Epidermal+Growth+Factor+Receptor+Family&doi=10.1021%2Facs.jmedchem.6b00883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129aR"><div class="casContent"><span class="casTitleNuber">129a</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family</span></div><div class="casAuthors">Smaill, Jeff B.; Gonzales, Andrea J.; Spicer, Julie A.; Lee, Helen; Reed, Jessica E.; Sexton, Karen; Althaus, Irene W.; Zhu, Tong; Black, Shannon L.; Blaser, Adrian; Denny, William A.; Ellis, Paul A.; Fakhoury, Stephen; Harvey, Patricia J.; Hook, Ken; McCarthy, Florence O. J.; Palmer, Brian D.; Rivault, Freddy; Schlosser, Kevin; Ellis, Teresa; Thompson, Andrew M.; Trachet, Erin; Winters, R. Thomas; Tecle, Haile; Bridges, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8103-8124</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationships for inhibition of erbB1, erbB2 and erbB4 were detd. for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogs of the irreversible pan-erbB inhibitor, canertinib.  Cyclic amine bearing crotonamides were detd. to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays.  The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated.  Several anilines were identified as providing potent, reversible pan-erbB inhibition.  Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo.  Quinazoline I and pyrido[3,4-d]pyrimidine II were identified as clearly superior to canertinib.  Both compds. possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents resp.  Pharmacokinetic comparison of compds. I and II across three species selected compd. I as the preferred candidate.  Compd. I (PF-00299804) has been assigned the nomenclature of dacomitinib and is currently under clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0-NpOmVq10bVg90H21EOLACvtfcHk0lj0qfi9hgXDrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM&md5=442afda669a5c1b7a190cd82b77bee33</span></div><a href="/servlet/linkout?suffix=cit129a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DSpicer%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DSexton%26aufirst%3DK.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBlack%26aufirst%3DS.%2BL.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DFakhoury%26aufirst%3DS.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DHook%26aufirst%3DK.%26aulast%3DMcCarthy%26aufirst%3DF.%2BO.%2BJ.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRivault%26aufirst%3DF.%26aulast%3DSchlosser%26aufirst%3DK.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%26atitle%3DTyrosine%2520Kinase%2520Inhibitors.%252020.%2520Optimization%2520of%2520Substituted%2520Quinazoline%2520and%2520Pyrido%255B3%252C4-D%255DPyrimidine%2520Derivatives%2520as%2520Orally%2520Active%252C%2520Irreversible%2520Inhibitors%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8103%26epage%3D8124%26doi%3D10.1021%2Facs.jmedchem.6b00883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit129b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. E.</span>; <span class="NLM_string-name">Smaill, J. B.</span></span> <span> </span><span class="NLM_article-title">The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor</span>. In  <i>Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Magid, A. F.</span>, <span class="NLM_string-name">Pesti, J. A.</span>, <span class="NLM_string-name">Vaidyanathan, R.</span></span>, Eds.; <span class="NLM_publisher-name">ACS Publications</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">233</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1239.ch008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=207-233&author=J.+E.+Reed&author=J.+B.+Smaillauthor=A.+F.+Abdel-Magid&author=J.+A.+Pesti&author=R.+Vaidyanathan&title=Comprehensive+Accounts+of+Pharmaceutical+Research+and+Development%3A+From+Discovery+to+Late-Stage+Process+Development+Volume+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129b&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1239.ch008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Fbk-2016-1239.ch008%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DJ.%2BE.%26atitle%3DThe%2520Discovery%2520of%2520Dacomitinib%252C%2520a%2520Potent%2520Irreversible%2520EGFR%2520Inhibitor%26btitle%3DComprehensive%2520Accounts%2520of%2520Pharmaceutical%2520Research%2520and%2520Development%253A%2520From%2520Discovery%2520to%2520Late-Stage%2520Process%2520Development%2520Volume%25201%26aulast%3DAbdel-Magid%26aufirst%3DA.%2BF.%26pub%3DACS%2520Publications%26date%3D2016%26spage%3D207%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span>; <span class="NLM_string-name">Dirat, O.</span></span> <span> </span><span class="NLM_article-title">Early and Late Stage Process Development for the Manufacture of Dacomitinib</span>. In  <i>Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdel-Magid, A. F.</span>, <span class="NLM_string-name">Pesti, J. A.</span>, <span class="NLM_string-name">Vaidyanathan, R.</span></span>, Eds.; <span class="NLM_publisher-name">ACS Publications</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">252</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/bk-2016-1239.ch009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=235-252&author=S.+Yu&author=O.+Diratauthor=A.+F.+Abdel-Magid&author=J.+A.+Pesti&author=R.+Vaidyanathan&title=Comprehensive+Accounts+of+Pharmaceutical+Research+and+Development%3A+From+Discovery+to+Late-Stage+Process+Development+Volume+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fbk-2016-1239.ch009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1021%252Fbk-2016-1239.ch009%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DS.%26atitle%3DEarly%2520and%2520Late%2520Stage%2520Process%2520Development%2520for%2520the%2520Manufacture%2520of%2520Dacomitinib%26btitle%3DComprehensive%2520Accounts%2520of%2520Pharmaceutical%2520Research%2520and%2520Development%253A%2520From%2520Discovery%2520to%2520Late-Stage%2520Process%2520Development%2520Volume%25201%26aulast%3DAbdel-Magid%26aufirst%3DA.%2BF.%26pub%3DACS%2520Publications%26date%3D2016%26spage%3D235%26epage%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span>; <span class="NLM_string-name">Mo, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of EGFR (Epidermal Growth Factor Receptor) Inhibitor Dacomitinib</span>. <span class="NLM_patent">CN103304492A</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+Lin&author=G.+Mo&title=Synthesis+Method+of+EGFR+%28Epidermal+Growth+Factor+Receptor%29+Inhibitor+Dacomitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DK.%26atitle%3DSynthesis%2520Method%2520of%2520EGFR%2520%2528Epidermal%2520Growth%2520Factor%2520Receptor%2529%2520Inhibitor%2520Dacomitinib%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Krajczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boryski, J.</span></span> <span> </span><span class="NLM_article-title">Dimroth Rearrangement-Old but Not Outdated</span>. <i>Curr. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2515</span>– <span class="NLM_lpage">2529</span>, <span class="refDoi"> DOI: 10.2174/1385272821666170427125720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2174%2F1385272821666170427125720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=2515-2529&author=A.+Krajczykauthor=J.+Boryski&title=Dimroth+Rearrangement-Old+but+Not+Outdated&doi=10.2174%2F1385272821666170427125720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132aR"><div class="casContent"><span class="casTitleNuber">132a</span><div class="casTitle"><span class="NLM_cas:atitle">Dimroth Rearrangement-Old but not Outdated</span></div><div class="casAuthors">Krajczyk, Anna; Boryski, Jerzy</div><div class="citationInfo"><span class="NLM_cas:title">Current Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2515-2529</span>CODEN:
                <span class="NLM_cas:coden">CORCFE</span>;
        ISSN:<span class="NLM_cas:issn">1385-2728</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The aim of this review is to present a general outlook on the Dimroth rearrangement along with the situations in which it may occur, and to briefly describe its potential applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_ENWP1DHSFrVg90H21EOLACvtfcHk0lipEl9_B1p3KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOgtr8%253D&md5=6089af4dae3823a833ac73f3f6761f9c</span></div><a href="/servlet/linkout?suffix=cit132a&amp;dbid=16384&amp;doi=10.2174%2F1385272821666170427125720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1385272821666170427125720%26sid%3Dliteratum%253Aachs%26aulast%3DKrajczyk%26aufirst%3DA.%26aulast%3DBoryski%26aufirst%3DJ.%26atitle%3DDimroth%2520Rearrangement-Old%2520but%2520Not%2520Outdated%26jtitle%3DCurr.%2520Org.%2520Chem.%26date%3D2017%26volume%3D21%26spage%3D2515%26epage%3D2529%26doi%3D10.2174%2F1385272821666170427125720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit132b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">El Ashry, E. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadeem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Kilany, Y.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Dimroth Rearrangement: A Valuable Tool for the Synthesis of Heterocycles</span>. <i>Adv. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/S0065-2725(10)01005-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0065-2725%2810%2901005-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSksLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2010&pages=161-228&author=E.+S.+H.+El+Ashryauthor=S.+Nadeemauthor=M.+R.+Shahauthor=Y.+El+Kilany&title=Recent+Advances+in+the+Dimroth+Rearrangement%3A+A+Valuable+Tool+for+the+Synthesis+of+Heterocycles&doi=10.1016%2FS0065-2725%2810%2901005-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132bR"><div class="casContent"><span class="casTitleNuber">132b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the Dimroth rearrangement: a valuable tool for the synthesis of heterocycles</span></div><div class="casAuthors">El Ashry, El Sayed H.; Nadeem, Said; Shah, Muhammad Raza; El Kilany, Yeldez</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161-228</span>CODEN:
                <span class="NLM_cas:coden">AHTCAG</span>;
        ISSN:<span class="NLM_cas:issn">0065-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review was given covering recent advances in Dimroth rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc9ADjRpXbf7Vg90H21EOLACvtfcHk0lipEl9_B1p3KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSksLvI&md5=516baf2204fea17ef557004202be72fd</span></div><a href="/servlet/linkout?suffix=cit132b&amp;dbid=16384&amp;doi=10.1016%2FS0065-2725%2810%2901005-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2725%252810%252901005-6%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BAshry%26aufirst%3DE.%2BS.%2BH.%26aulast%3DNadeem%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DM.%2BR.%26aulast%3DEl%2BKilany%26aufirst%3DY.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Dimroth%2520Rearrangement%253A%2520A%2520Valuable%2520Tool%2520for%2520the%2520Synthesis%2520of%2520Heterocycles%26jtitle%3DAdv.%2520Heterocycl.%2520Chem.%26date%3D2010%26volume%3D101%26spage%3D161%26epage%3D228%26doi%3D10.1016%2FS0065-2725%2810%2901005-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit132c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">El Ashry, E. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Kilany, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assafir, H.</span></span> <span> </span><span class="NLM_article-title">Dimroth Rearrangement: Translocation of Heteroatoms in Heterocyclic Rings and Its Role in Ring Transformations of Heterocycles</span>. <i>Adv. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/S0065-2725(08)60984-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0065-2725%2808%2960984-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVKntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1999&pages=79-165&author=E.+S.+H.+El+Ashryauthor=Y.+El+Kilanyauthor=N.+Rashedauthor=H.+Assafir&title=Dimroth+Rearrangement%3A+Translocation+of+Heteroatoms+in+Heterocyclic+Rings+and+Its+Role+in+Ring+Transformations+of+Heterocycles&doi=10.1016%2FS0065-2725%2808%2960984-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132cR"><div class="casContent"><span class="casTitleNuber">132c</span><div class="casTitle"><span class="NLM_cas:atitle">Dimroth rearrangement: Translocation of heteroatoms in heterocyclic rings and its role in ring transformations of heterocycles</span></div><div class="casAuthors">El Ashry, E. S. H.; El Kilany, Y.; Rashed, N.; Assafir, H.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">79-167</span>CODEN:
                <span class="NLM_cas:coden">AHTCAG</span>;
        ISSN:<span class="NLM_cas:issn">0065-2725</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with many refs. covering rearrangements in rings of fused systems and translocations of exo- and endocyclic heteroatoms in heterocyclic rings.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM45QBxKFI0bVg90H21EOLACvtfcHk0lipEl9_B1p3KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVKntQ%253D%253D&md5=1099d48f4dc9bf6fdc5724f9e2e1ccc6</span></div><a href="/servlet/linkout?suffix=cit132c&amp;dbid=16384&amp;doi=10.1016%2FS0065-2725%2808%2960984-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2725%252808%252960984-8%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BAshry%26aufirst%3DE.%2BS.%2BH.%26aulast%3DEl%2BKilany%26aufirst%3DY.%26aulast%3DRashed%26aufirst%3DN.%26aulast%3DAssafir%26aufirst%3DH.%26atitle%3DDimroth%2520Rearrangement%253A%2520Translocation%2520of%2520Heteroatoms%2520in%2520Heterocyclic%2520Rings%2520and%2520Its%2520Role%2520in%2520Ring%2520Transformations%2520of%2520Heterocycles%26jtitle%3DAdv.%2520Heterocycl.%2520Chem.%26date%3D1999%26volume%3D75%26spage%3D79%26epage%3D165%26doi%3D10.1016%2FS0065-2725%2808%2960984-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span>; <span class="NLM_string-name">Wang, Q.</span>; <span class="NLM_string-name">Su, R.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Huo, X.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib Solvate, Novel Crystalline Form of Dacomitinib and Preparation Method and Use of Dacomitinib in Novel Crystalline Form</span>. <span class="NLM_patent">CN107793368A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Q.+Wang&author=Q.+Wang&author=R.+Su&author=H.+Li&author=X.+Huo&author=L.+Wang&author=J.+Wang&title=Dacomitinib+Solvate%2C+Novel+Crystalline+Form+of+Dacomitinib+and+Preparation+Method+and+Use+of+Dacomitinib+in+Novel+Crystalline+Form"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26atitle%3DDacomitinib%2520Solvate%252C%2520Novel%2520Crystalline%2520Form%2520of%2520Dacomitinib%2520and%2520Preparation%2520Method%2520and%2520Use%2520of%2520Dacomitinib%2520in%2520Novel%2520Crystalline%2520Form%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagrillo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, C. A. M.</span></span> <span> </span><span class="NLM_article-title">Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">69</span>, <span class="refDoi"> DOI: 10.3390/ph12020069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.3390%2Fph12020069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKksLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=69&author=D.+A.+Rodriguesauthor=F.+S.+Sagrilloauthor=C.+A.+M.+Fraga&title=Duvelisib%3A+A+2018+Novel+FDA-Approved+Small+Molecule+Inhibiting+Phosphoinositide+3-Kinases&doi=10.3390%2Fph12020069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134aR"><div class="casContent"><span class="casTitleNuber">134a</span><div class="casTitle"><span class="NLM_cas:atitle">Duvelisib: a 2018 novel FDA-approved small molecule inhibiting phosphoinositide 3-kinases</span></div><div class="casAuthors">Rodrigues, Daniel A.; Sagrillo, Fernanda S.; Fraga, Carlos A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Duvelisib (Copiktra) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ).  In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) after at least two prior therapies.  Duvelisib has also been approved under accelerated track for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.  In this review, we provide a series of information about duvelisib, such as the development of clin. trials for LLC/SLL and FL and the steps used for its synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKfwFmy1g2D7Vg90H21EOLACvtfcHk0ljYdQU-AW3eIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKksLvO&md5=2eed3f6f628369e9551d7c0d1a4476b5</span></div><a href="/servlet/linkout?suffix=cit134a&amp;dbid=16384&amp;doi=10.3390%2Fph12020069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph12020069%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DD.%2BA.%26aulast%3DSagrillo%26aufirst%3DF.%2BS.%26aulast%3DFraga%26aufirst%3DC.%2BA.%2BM.%26atitle%3DDuvelisib%253A%2520A%25202018%2520Novel%2520FDA-Approved%2520Small%2520Molecule%2520Inhibiting%2520Phosphoinositide%25203-Kinases%26jtitle%3DPharmaceuticals%26date%3D2019%26volume%3D12%26spage%3D69%26doi%3D10.3390%2Fph12020069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit134b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vangapandu, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V.</span></span> <span> </span><span class="NLM_article-title">Duvelisib: A Phosphoinositide-3 Kinase Delta/Gamma Inhibitor for Chronic Lymphocytic Leukemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1312338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F13543784.2017.1312338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28388280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVeqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=625-632&author=H.+V.+Vangapanduauthor=N.+Jainauthor=V.+Gandhi&title=Duvelisib%3A+A+Phosphoinositide-3+Kinase+Delta%2FGamma+Inhibitor+for+Chronic+Lymphocytic+Leukemia&doi=10.1080%2F13543784.2017.1312338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134bR"><div class="casContent"><span class="casTitleNuber">134b</span><div class="casTitle"><span class="NLM_cas:atitle">Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia</span></div><div class="casAuthors">Vangapandu, Hima V.; Jain, Nitin; Gandhi, Varsha</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">625-632</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity.  Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse.  Therefore, for the past few years, development of targeted therapies is on the rise.  PI3K is a major player in the B-cell receptor (BCR) signaling axis, which is crit. for the survival and maintenance of B cells.  Duvelisib, a PI3K δ/γ dual isoform specific inhibitor that induces apoptosis and reduces cytokine and chemokine levels in vitro, holds promise for CLL.  Herein, we review PI3K isoforms and their inhibitors in general, and duvelisib in particular; examine literature on preclin. investigations, pharmacokinetics and clin. studies of duvelisib either as single agent or in combination, for patients with CLL and other lymphoid malignancies.  Duvelisib targets the PI3K δ isoform, which is necessary for cell proliferation and survival, and γ isoform, which is crit. for cytokine signaling and pro-inflammatory responses from the microenvironment.  In phase I clin. trials, duvelisib as a single agent showed promise for CLL and other lymphoid malignancies.  Phase II and III trials of duvelisib alone or in combination with other agents are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6_pe9x-0X77Vg90H21EOLACvtfcHk0ljYdQU-AW3eIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVeqsLg%253D&md5=acb74fe8a63bb3941b7e1b565a509d77</span></div><a href="/servlet/linkout?suffix=cit134b&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1312338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1312338%26sid%3Dliteratum%253Aachs%26aulast%3DVangapandu%26aufirst%3DH.%2BV.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DGandhi%26aufirst%3DV.%26atitle%3DDuvelisib%253A%2520A%2520Phosphoinositide-3%2520Kinase%2520Delta%252FGamma%2520Inhibitor%2520for%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D625%26epage%3D632%26doi%3D10.1080%2F13543784.2017.1312338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaneda, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messer, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ralainirina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leem, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorjestani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueiredo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foubert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rausch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazer, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varner, J. A.</span></span> <span> </span><span class="NLM_article-title">PI3Kgamma Is a Molecular Switch That Controls Immune Suppression</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>539</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">442</span>, <span class="refDoi"> DOI: 10.1038/nature19834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fnature19834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27642729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvV2it7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=539&publication_year=2016&pages=437-442&author=M.+M.+Kanedaauthor=K.+S.+Messerauthor=N.+Ralainirinaauthor=H.+Liauthor=C.+J.+Leemauthor=S.+Gorjestaniauthor=G.+Wooauthor=A.+V.+Nguyenauthor=C.+C.+Figueiredoauthor=P.+Foubertauthor=M.+C.+Schmidauthor=M.+Pinkauthor=D.+G.+Winklerauthor=M.+Rauschauthor=V.+J.+Palombellaauthor=J.+Kutokauthor=K.+McGovernauthor=K.+A.+Frazerauthor=X.+Wuauthor=M.+Karinauthor=R.+Sasikauthor=E.+E.+Cohenauthor=J.+A.+Varner&title=PI3Kgamma+Is+a+Molecular+Switch+That+Controls+Immune+Suppression&doi=10.1038%2Fnature19834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kγ is a molecular switch that controls immune suppression</span></div><div class="casAuthors">Kaneda, Megan M.; Messer, Karen S.; Ralainirina, Natacha; Li, Hongying; Leem, Christopher J.; Gorjestani, Sara; Woo, Gyunghwi; Nguyen, Abraham V.; Figueiredo, Camila C.; Foubert, Philippe; Schmid, Michael C.; Pink, Melissa; Winkler, David G.; Rausch, Matthew; Palombella, Vito J.; Kutok, Jeffery; McGovern, Karen; Frazer, Kelly A.; Wu, Xuefeng; Karin, Michael; Sasik, Roman; Cohen, Ezra E. W.; Varner, Judith A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">539</span>
        (<span class="NLM_cas:issue">7629</span>),
    <span class="NLM_cas:pages">437-442</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Macrophages play crit., but opposite, roles in acute and chronic inflammation and cancer.  In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T cells, whereas macrophages in neoplastic and parasitic diseases express anti-inflammatory cytokines that induce immune suppression and may promote resistance to T cell checkpoint inhibitors.  Here we show that macrophage PI 3-kinase γ controls a crit. switch between immune stimulation and suppression during inflammation and cancer.  PI3Kγ signalling through Akt and mTor inhibits NFκB activation while stimulating C/EBPβ activation, thereby inducing a transcriptional program that promotes immune suppression during inflammation and tumor growth.  By contrast, selective inactivation of macrophage PI3Kγ stimulates and prolongs NFκB activation and inhibits C/EBPβ activation, thus promoting an immunostimulatory transcriptional program that restores CD8+ T cell activation and cytotoxicity.  PI3Kγ synergizes with checkpoint inhibitor therapy to promote tumor regression and increased survival in mouse models of cancer.  In addn., PI3Kγ-directed, anti-inflammatory gene expression can predict survival probability in cancer patients.  Our work thus demonstrates that therapeutic targeting of intracellular signalling pathways that regulate the switch between macrophage polarization states can control immune suppression in cancer and other disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMN1E8I633erVg90H21EOLACvtfcHk0ljYdQU-AW3eIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvV2it7fL&md5=89edbf1f65665684c8360de9350f9195</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fnature19834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19834%26sid%3Dliteratum%253Aachs%26aulast%3DKaneda%26aufirst%3DM.%2BM.%26aulast%3DMesser%26aufirst%3DK.%2BS.%26aulast%3DRalainirina%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLeem%26aufirst%3DC.%2BJ.%26aulast%3DGorjestani%26aufirst%3DS.%26aulast%3DWoo%26aufirst%3DG.%26aulast%3DNguyen%26aufirst%3DA.%2BV.%26aulast%3DFigueiredo%26aufirst%3DC.%2BC.%26aulast%3DFoubert%26aufirst%3DP.%26aulast%3DSchmid%26aufirst%3DM.%2BC.%26aulast%3DPink%26aufirst%3DM.%26aulast%3DWinkler%26aufirst%3DD.%2BG.%26aulast%3DRausch%26aufirst%3DM.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DKutok%26aufirst%3DJ.%26aulast%3DMcGovern%26aufirst%3DK.%26aulast%3DFrazer%26aufirst%3DK.%2BA.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKarin%26aufirst%3DM.%26aulast%3DSasik%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DVarner%26aufirst%3DJ.%2BA.%26atitle%3DPI3Kgamma%2520Is%2520a%2520Molecular%2520Switch%2520That%2520Controls%2520Immune%2520Suppression%26jtitle%3DNature%26date%3D2016%26volume%3D539%26spage%3D437%26epage%3D442%26doi%3D10.1038%2Fnature19834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ram, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span> <span> </span><span class="NLM_article-title">Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">988</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1038/nrd1902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fnrd1902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=16341064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=988-1004&author=B.+T.+Hennessyauthor=D.+L.+Smithauthor=P.+T.+Ramauthor=Y.+Luauthor=G.+B.+Mills&title=Exploiting+the+PI3K%2FAKT+Pathway+for+Cancer+Drug+Discovery&doi=10.1038%2Fnrd1902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136aR"><div class="casContent"><span class="casTitleNuber">136a</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery</span></div><div class="casAuthors">Hennessy, Bryan T.; Smith, Debra L.; Ram, Prahlad T.; Lu, Yiling; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">988-1004</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy.  Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway.  This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq40Fg-hLrrMbVg90H21EOLACvtfcHk0lhUdyva2qPTCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI&md5=faecabc3a6799137d133afb37d139ceb</span></div><a href="/servlet/linkout?suffix=cit136a&amp;dbid=16384&amp;doi=10.1038%2Fnrd1902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1902%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DRam%26aufirst%3DP.%2BT.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DExploiting%2520the%2520PI3K%252FAKT%2520Pathway%2520for%2520Cancer%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D988%26epage%3D1004%26doi%3D10.1038%2Fnrd1902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit136b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Phosphoinositide 3-Kinase Pathway in Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+Phosphoinositide+3-Kinase+Pathway+in+Cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136bR"><div class="casContent"><span class="casTitleNuber">136b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0lhUdyva2qPTCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit136b&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520Phosphoinositide%25203-Kinase%2520Pathway%2520in%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastasia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, G.</span></span> <span> </span><span class="NLM_article-title">Novel Drugs in Follicular Lymphoma</span>. <i>Mediterr. J. Hematol. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e2016061</span>, <span class="refDoi"> DOI: 10.4084/mjhid.2016.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.4084%2Fmjhid.2016.061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=e2016061&author=A.+Anastasiaauthor=G.+Rossi&title=Novel+Drugs+in+Follicular+Lymphoma&doi=10.4084%2Fmjhid.2016.061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.4084%2Fmjhid.2016.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4084%252Fmjhid.2016.061%26sid%3Dliteratum%253Aachs%26aulast%3DAnastasia%26aufirst%3DA.%26aulast%3DRossi%26aufirst%3DG.%26atitle%3DNovel%2520Drugs%2520in%2520Follicular%2520Lymphoma%26jtitle%3DMediterr.%2520J.%2520Hematol.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D8%26spage%3De2016061%26doi%3D10.4084%2Fmjhid.2016.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span>; <span class="NLM_string-name">Martin, M.</span>; <span class="NLM_string-name">Isbester, P.</span>; <span class="NLM_string-name">Lane, B.</span>; <span class="NLM_string-name">Kropp, J.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Isoquinolines and Solid Forms of Isoquinolines</span>. <span class="NLM_patent">WO2012097000A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+Ren&author=M.+Martin&author=P.+Isbester&author=B.+Lane&author=J.+Kropp&title=Process+for+Preparing+Isoquinolines+and+Solid+Forms+of+Isoquinolines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DP.%26atitle%3DProcess%2520for%2520Preparing%2520Isoquinolines%2520and%2520Solid%2520Forms%2520of%2520Isoquinolines%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Encorafenib and Binimetinib: First Global Approvals</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1277</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0963-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0963-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30117021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFehsrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1277-1284&author=M.+Shirley&title=Encorafenib+and+Binimetinib%3A+First+Global+Approvals&doi=10.1007%2Fs40265-018-0963-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Encorafenib and Binimetinib: First Global Approvals</span></div><div class="casAuthors">Shirley, Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1277-1284</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Encorafenib (Braftovi), a BRAF inhibitor, and binimetinib (Mektovi), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPharma.  In June 2018 they each received their first global approval, in the USA, for use in combination, for patients with unresectable or metastatic melanoma with a BRAFV600E or -V600K mutation as detected by an FDA-approved test.  Registration applications for encorafenib and binimetinib for use in combination in the treatment of BRAF-mutation-pos. advanced melanoma have also been submitted in the EU, Australia, Switzerland and Japan, with the EMA Committee for Medicinal Products for Human Use adopting a pos. opinion in July 2018 towards granting the drugs marketing authorizations in the EU.  Encorafenib plus binimetinib combination therapy is also in ongoing phase III clin. development in the treatment of metastatic colorectal cancer.  This article summarizes the milestones in the development of encorafenib and binimetinib leading to these first approvals for the treatment of BRAFV600E or -V600K-mutation-pos. unresectable or metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2LM_GzUpVoLVg90H21EOLACvtfcHk0lhUdyva2qPTCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFehsrnK&md5=13c3b196d9db53a4b7a6e870d2f69e32</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0963-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0963-x%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DEncorafenib%2520and%2520Binimetinib%253A%2520First%2520Global%2520Approvals%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1277%26epage%3D1284%26doi%3D10.1007%2Fs40265-018-0963-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Cancer Genome Atlas Network.</span> <span> </span><span class="NLM_article-title">Genomic Classification of Cutaneous
Melanoma</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">1681</span>– <span class="NLM_lpage">1696</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2015.05.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.cell.2015.05.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=26091043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2015&pages=1681-1696&author=Cancer+Genome+Atlas+Network.&title=Genomic+Classification+of+Cutaneous%0AMelanoma&doi=10.1016%2Fj.cell.2015.05.044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.05.044%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGenomic%2520Classification%2520of%2520Cutaneous%250AMelanoma%26jtitle%3DCell%26date%3D2015%26volume%3D161%26spage%3D1681%26epage%3D1696%26doi%3D10.1016%2Fj.cell.2015.05.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span> <span> </span><span class="NLM_article-title">BRAF and MEK Inhibitors in the Era of Immunotherapy in Melanoma Patients</span>. <i>Wspolczesna Onkol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.5114/wo.2018.73890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.5114%2Fwo.2018.73890" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=68-72&author=J.+Mackiewiczauthor=A.+Mackiewicz&title=BRAF+and+MEK+Inhibitors+in+the+Era+of+Immunotherapy+in+Melanoma+Patients&doi=10.5114%2Fwo.2018.73890"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.5114%2Fwo.2018.73890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Fwo.2018.73890%26sid%3Dliteratum%253Aachs%26aulast%3DMackiewicz%26aufirst%3DJ.%26aulast%3DMackiewicz%26aufirst%3DA.%26atitle%3DBRAF%2520and%2520MEK%2520Inhibitors%2520in%2520the%2520Era%2520of%2520Immunotherapy%2520in%2520Melanoma%2520Patients%26jtitle%3DWspolczesna%2520Onkol.%26date%3D2018%26volume%3D22%26spage%3D68%26epage%3D72%26doi%3D10.5114%2Fwo.2018.73890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span>; <span class="NLM_string-name">Jin, X.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Poon, D.</span>; <span class="NLM_string-name">Tellew, J.</span>; <span class="NLM_string-name">Wan, Y.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Xie, Y.</span></span> <span> </span><span class="NLM_article-title">Compounds and Compositions as Protein Kinase Inhibitors</span>. <span class="NLM_patent">WO2011025927A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Huang&author=X.+Jin&author=Z.+Liu&author=D.+Poon&author=J.+Tellew&author=Y.+Wan&author=X.+Wang&author=Y.+Xie&title=Compounds+and+Compositions+as+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DS.%26atitle%3DCompounds%2520and%2520Compositions%2520as%2520Protein%2520Kinase%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Fruquintinib, a Potent and Highly Selective Small Molecule Inhibitor of Vegfr 1, 2, 3 Tyrosine Kinases for Cancer Therapy</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1635</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.4161/15384047.2014.964087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.4161%2F15384047.2014.964087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=25482937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1635-1645&author=Q.+Sunauthor=J.+Zhouauthor=Z.+Zhangauthor=M.+Guoauthor=J.+Liangauthor=F.+Zhouauthor=J.+Longauthor=W.+Zhangauthor=F.+Yinauthor=H.+Caiauthor=H.+Yangauthor=W.+Zhangauthor=Y.+Guauthor=L.+Niauthor=Y.+Saiauthor=Y.+Cuiauthor=M.+Zhangauthor=M.+Hongauthor=J.+Sunauthor=Z.+Yangauthor=W.+Qingauthor=W.+Suauthor=Y.+Ren&title=Discovery+of+Fruquintinib%2C+a+Potent+and+Highly+Selective+Small+Molecule+Inhibitor+of+Vegfr+1%2C+2%2C+3+Tyrosine+Kinases+for+Cancer+Therapy&doi=10.4161%2F15384047.2014.964087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy</span></div><div class="casAuthors">Sun, Qiaoling; Zhou, Jinghong; Zhang, Zheng; Guo, Mingchuan; Liang, Junqing; Zhou, Feng; Long, Jingwen; Zhang, Wei; Yin, Fang; Cai, Huaqing; Yang, Haibin; Zhang, Weihan; Gu, Yi; Ni, Liang; Sai, Yang; Cui, Yumin; Zhang, Meifang; Hong, Minhua; Sun, Junen; Yang, Zheng; Qing, Weiguo; Su, Weiguo; Ren, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1635-1645</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">VEGF/VEGFR signal axis has been proven to be an important target for development of novel cancer therapies.  One challenging aspect in small mol. VEGFR inhibitors is to achieve sustained target inhibition at tolerable doses previously seen only with the long-acting biologics.  It would require high potency (low effective drug concns.) and sufficient drug exposures at tolerated doses so that the drug concn. can be maintained above effective drug concn. for target inhibition within the dosing period.  Fruquintinib (HMPL-013) is a small mol. inhibitor with strong potency and high selectivity against VEGFR family currently in Phase II clin. studies.  Anal. of Phase I pharmacokinetic data revealed that at the max. tolerated dose of once daily oral administration fruquintinib achieved complete VEGFR2 suppression (drug concns. were maintained above that required to produce >85% inhibition of VEGFR2 phosphorylation in mouse) for 24 h/day.  In this article, the preclin. data for fruquintinib will be described, including kinase enzyme activity and selectivity, cellular VEGFR inhibition and VEGFR-driven functional activity, in vivo VEGFR phosphorylation inhibition in the lung tissue in mouse and tumor growth inhibition in a panel of tumor xenograft and patient derive xenograft models in mouse.  Pharmacokinetic and target inhibition data are also presented to provide a correlation between target inhibition and tumor growth inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj6Wfr9ByAXrVg90H21EOLACvtfcHk0lj5FfGwl5tRcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslertLc%253D&md5=6007c07007eba7cffd680b48db6e7fae</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.4161%2F15384047.2014.964087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F15384047.2014.964087%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DF.%26aulast%3DCai%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DSai%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DHong%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DQing%26aufirst%3DW.%26aulast%3DSu%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Fruquintinib%252C%2520a%2520Potent%2520and%2520Highly%2520Selective%2520Small%2520Molecule%2520Inhibitor%2520of%2520Vegfr%25201%252C%25202%252C%25203%2520Tyrosine%2520Kinases%2520for%2520Cancer%2520Therapy%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2014%26volume%3D15%26spage%3D1635%26epage%3D1645%26doi%3D10.4161%2F15384047.2014.964087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Fruquintinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1761</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0998-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0998-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30357594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cvivFKgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1757-1761&author=M.+Shirley&title=Fruquintinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0998-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Fruquintinib: First Global Approval</span></div><div class="casAuthors">Shirley Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1757-1761</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fruquintinib (Elunate(®)) is an orally available, potent and highly selective small molecule inhibitor of VEGFR-1, -2 and -3 that was discovered and developed by Hutchison MediPharma for the treatment of solid tumours.  In September 2018, fruquintinib received its first global approval, in China, for use in the treatment of metastatic colorectal cancer (CRC) in patients who have failed at least two prior systemic anti-neoplastic therapies.  Fruquintinib is in ongoing phase III clinical development for use in the treatment of advanced NSCLC and advanced gastric cancer.  This article summarizes the milestones in the development of fruquintinib leading to this first approval for the treatment of metastatic CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgv6IkRgnDqbmQt-ICR3qNfW6udTcc2eZc874ydZRZsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvivFKgsQ%253D%253D&md5=d3a7bc508dbcd87aacfc547ba27284e0</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0998-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0998-z%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DFruquintinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1757%26epage%3D1761%26doi%3D10.1007%2Fs40265-018-0998-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span>; <span class="NLM_string-name">Li, W.</span>; <span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">Crystalline Forms of 6-((6,7-Dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide</span>. <span class="NLM_patent">WO2016037550A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Z.+Wu&author=W.+Li&author=Y.+Chu&title=Crystalline+Forms+of+6-%28%286%2C7-Dimethoxyquinazolin-4-yl%29oxy%29-N%2C2-dimethylbenzofuran-3-carboxamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DCrystalline%2520Forms%2520of%25206-%2528%25286%252C7-Dimethoxyquinazolin-4-yl%2529oxy%2529-N%252C2-dimethylbenzofuran-3-carboxamide%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span>; <span class="NLM_string-name">Li, W.</span>; <span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">6-(6,7-Dimethoxyquinazoline-4-yloxy)-N, 2-Dimethyl Benzofuran-3-Methane Amide Crystal Form</span>. <span class="NLM_patent">CN105461702A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Z.+Wu&author=W.+Li&author=Y.+Chu&title=6-%286%2C7-Dimethoxyquinazoline-4-yloxy%29-N%2C+2-Dimethyl+Benzofuran-3-Methane+Amide+Crystal+Form"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26atitle%3D6-%25286%252C7-Dimethoxyquinazoline-4-yloxy%2529-N%252C%25202-Dimethyl%2520Benzofuran-3-Methane%2520Amide%2520Crystal%2520Form%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit146b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Yi, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Quinazoline Derivative Crystal Form B</span>. <span class="NLM_patent">CN105777723A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Yu&author=J.+Chen&author=D.+Yi&title=Preparation+of+Quinazoline+Derivative+Crystal+Form+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Quinazoline%2520Derivative%2520Crystal%2520Form%2520B%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit146c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Yi, D.</span></span> <span> </span><span class="NLM_article-title">Preparation and Application of Fruquintinib Crystal Form C</span>. <span class="NLM_patent">CN105777722A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Yu&author=J.+Chen&author=D.+Yi&title=Preparation+and+Application+of+Fruquintinib+Crystal+Form+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26atitle%3DPreparation%2520and%2520Application%2520of%2520Fruquintinib%2520Crystal%2520Form%2520C%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit146d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span>; <span class="NLM_string-name">Chen, J.</span>; <span class="NLM_string-name">Yi, D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Crystal Form a of 6-[(6,7-Dimethoxy-4-quinazolinyl)oxy]-N,2-Dimethyl-3-benzofurancarboxamide</span>. <span class="NLM_patent">CN105777721A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Yu&author=J.+Chen&author=D.+Yi&title=Preparation+of+Crystal+Form+a+of+6-%5B%286%2C7-Dimethoxy-4-quinazolinyl%29oxy%5D-N%2C2-Dimethyl-3-benzofurancarboxamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Crystal%2520Form%2520a%2520of%25206-%255B%25286%252C7-Dimethoxy-4-quinazolinyl%2529oxy%255D-N%252C2-Dimethyl-3-benzofurancarboxamide%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-G.</span>; <span class="NLM_string-name">Zhang, W.</span>; <span class="NLM_string-name">Yan, X.</span>; <span class="NLM_string-name">Cui, Y.</span>; <span class="NLM_string-name">Ren, Y.</span>; <span class="NLM_string-name">Duan, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Quinazoline Derivatives as KDR Inhibitors</span>. <span class="NLM_patent">WO2009137797A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=W.-G.+Su&author=W.+Zhang&author=X.+Yan&author=Y.+Cui&author=Y.+Ren&author=J.+Duan&title=Preparation+of+Quinazoline+Derivatives+as+KDR+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DW.-G.%26atitle%3DPreparation%2520of%2520Quinazoline%2520Derivatives%2520as%2520KDR%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit147b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.</span>; <span class="NLM_string-name">Zhang, W.</span>; <span class="NLM_string-name">Yan, X.</span>; <span class="NLM_string-name">Cui, Y.</span>; <span class="NLM_string-name">Ren, Y.</span>; <span class="NLM_string-name">Duan, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Quinazoline Derivatives as Angiogenesis Inhibitors</span>. <span class="NLM_patent">CN101575333A</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=W.+Su&author=W.+Zhang&author=X.+Yan&author=Y.+Cui&author=Y.+Ren&author=J.+Duan&title=Preparation+of+Quinazoline+Derivatives+as+Angiogenesis+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DW.%26atitle%3DPreparation%2520of%2520Quinazoline%2520Derivatives%2520as%2520Angiogenesis%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-1062-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-019-1062-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30721452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=331-339&author=S.+Dhillon&title=Gilteritinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-1062-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-339</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Gilteritinib (Xospata) is an orally available small mol. receptor tyrosine kinase inhibitor developed by Astellas Pharma in collaboration with Kotobuki Pharmaceutical for the treatment of acute myeloid leukemia (AML) harbouring FMS-like tyrosine kinase 3 (FLT3) mutations.  Gilteritinib inhibits FLT3 (STK1 or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246).  Gilteritinib inhibits FLT3 signalling in cells expressing FLT3 internal tandem duplication (ITD), tyrosine kinase domain mutation FLT3-D835Y and the double mutant FLT3-ITD-D835Y, thereby inducing apoptosis.  Gilteritinib also binds to and inhibits the wild-type and mutated forms of ALK, resulting in reduced tumor cell proliferation in cancer cell types that overexpress the mutation.  Gilteritinib is approved in Japan for the treatment of relapsed or refractory AML with FLT3 mutation.  Recently, it was also approved in the USA for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation, as detected by an FDA-approved test.  Clin. development of gilteritinib is underway in several countries worldwide.  Development for non-small cell lung cancer and solid tumors has been discontinued.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4eM9A80qh7Vg90H21EOLACvtfcHk0lgWPgKgk07vJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyis78%253D&md5=54765ef94cdc6b66d133f2728755dd6b</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-1062-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-1062-3%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DGilteritinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D331%26epage%3D339%26doi%3D10.1007%2Fs40265-019-1062-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromitsu, S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib, a FLT3/Axl Inhibitor, Shows Antileukemic Activity in Mouse Models of FLT3 Mutated Acute Myeloid Leukemia</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1007/s10637-017-0470-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs10637-017-0470-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28516360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=556-565&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=M.+Yamadaauthor=R.+Tanakaauthor=R.+Saitoauthor=I.+Shimadaauthor=K.+Moriauthor=S.+Kuromitsu&title=Gilteritinib%2C+a+FLT3%2FAxl+Inhibitor%2C+Shows+Antileukemic+Activity+in+Mouse+Models+of+FLT3+Mutated+Acute+Myeloid+Leukemia&doi=10.1007%2Fs10637-017-0470-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149aR"><div class="casContent"><span class="casTitleNuber">149a</span><div class="casTitle"><span class="NLM_cas:atitle">Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</span></div><div class="casAuthors">Mori, Masamichi; Kaneko, Naoki; Ueno, Yoko; Yamada, Masaki; Tanaka, Ruriko; Saito, Rika; Shimada, Itsuro; Mori, Kenichi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">556-565</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Advances in the understanding of the mol. basis for acute myeloid leukemia (AML) have generated new potential targets for treatment.  Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are assocd. with poor overall survival.  AXL plays a role in the activation of FLT3 and has been implicated in the pathogenesis of AML.  The studies reported here evaluated the ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and animal models of AML.  Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity against c-KIT.  Gilteritinib demonstrated potent inhibitory activity against the internal tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3.  Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these assays.  Furthermore, gilteritinib decreased the phosphorylation levels of FLT3 and its downstream targets in both cellular and animal models.  In vivo, gilteritinib was distributed at high levels in xenografted tumors after oral administration.  The decreased FLT3 activity and high intratumor distribution of gilteritinib translated to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML.  No overt toxicity was seen in mouse models treated with gilteritinib.  These results indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in the treatment of FLT3 mutation-pos. AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMaOcOB0-DOrVg90H21EOLACvtfcHk0lgWPgKgk07vJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvV2isrc%253D&md5=ffdf8ee1887cd2c6623dda70bb98a464</span></div><a href="/servlet/linkout?suffix=cit149a&amp;dbid=16384&amp;doi=10.1007%2Fs10637-017-0470-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-017-0470-z%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DGilteritinib%252C%2520a%2520FLT3%252FAxl%2520Inhibitor%252C%2520Shows%2520Antileukemic%2520Activity%2520in%2520Mouse%2520Models%2520of%2520FLT3%2520Mutated%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26spage%3D556%26epage%3D565%26doi%3D10.1007%2Fs10637-017-0470-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit149b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span> <span> </span><span class="NLM_article-title">Gilteritinib for the Treatment of Patients with FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia</span>. <i>Expert Rev. Precis. Med. Drug. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1080/23808993.2019.1612709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F23808993.2019.1612709" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=105-112&author=E.+S.+Wang&title=Gilteritinib+for+the+Treatment+of+Patients+with+FLT3+Mutated+Relapsed+or+Refractory+Acute+Myeloid+Leukemia&doi=10.1080%2F23808993.2019.1612709"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149b&amp;dbid=16384&amp;doi=10.1080%2F23808993.2019.1612709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F23808993.2019.1612709%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DE.%2BS.%26atitle%3DGilteritinib%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520FLT3%2520Mutated%2520Relapsed%2520or%2520Refractory%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DExpert%2520Rev.%2520Precis.%2520Med.%2520Drug.%2520Dev.%26date%3D2019%26volume%3D4%26spage%3D105%26epage%3D112%26doi%3D10.1080%2F23808993.2019.1612709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, I.</span>; <span class="NLM_string-name">Kurosawa, K.</span>; <span class="NLM_string-name">Matsuya, T.</span>; <span class="NLM_string-name">Iikubo, K.</span>; <span class="NLM_string-name">Kondoh, Y.</span>; <span class="NLM_string-name">Kamikawa, A.</span>; <span class="NLM_string-name">Tomiyama, H.</span>; <span class="NLM_string-name">Iwai, Y.</span></span> <span> </span><span class="NLM_article-title">Diamino Heterocyclic Carboxamide Compound</span>. <span class="NLM_patent">US8969336</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=I.+Shimada&author=K.+Kurosawa&author=T.+Matsuya&author=K.+Iikubo&author=Y.+Kondoh&author=A.+Kamikawa&author=H.+Tomiyama&author=Y.+Iwai&title=Diamino+Heterocyclic+Carboxamide+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DI.%26atitle%3DDiamino%2520Heterocyclic%2520Carboxamide%2520Compound%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Q.</span>; <span class="NLM_string-name">Zhou, Z.</span>; <span class="NLM_string-name">Gao, Q.</span>; <span class="NLM_string-name">Zheng, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of 3,5-Disubstituted-Pyrazine-2-formamide Compound</span>. <span class="NLM_patent">CN106083821A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Q.+Yue&author=Z.+Zhou&author=Q.+Gao&author=B.+Zheng&title=Synthesis+Method+of+3%2C5-Disubstituted-Pyrazine-2-formamide+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DQ.%26atitle%3DSynthesis%2520Method%2520of%25203%252C5-Disubstituted-Pyrazine-2-formamide%2520Compound%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwight, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parillon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4948</span>– <span class="NLM_lpage">4964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4948-4964&author=W.-S.+Huangauthor=S.+Liuauthor=D.+Zouauthor=M.+Thomasauthor=Y.+Wangauthor=T.+Zhouauthor=J.+Romeroauthor=A.+Kohlmannauthor=F.+Liauthor=J.+Qiauthor=L.+Caiauthor=T.+A.+Dwightauthor=Y.+Xuauthor=R.+Xuauthor=R.+Doddauthor=A.+Tomsauthor=L.+Parillonauthor=X.+Luauthor=R.+Anjumauthor=S.+Zhangauthor=F.+Wangauthor=J.+Keatsauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=Q.+Xuauthor=L.+E.+Moranauthor=Q.+K.+Mohemmadauthor=H.+G.+Jangauthor=T.+Clacksonauthor=N.+I.+Narasimhanauthor=V.+M.+Riveraauthor=X.+Zhuauthor=D.+Dalgarnoauthor=W.+C.+Shakespeare&title=Discovery+of+Brigatinib+%28AP26113%29%2C+a+Phosphine+Oxide-Containing%2C+Potent%2C+Orally+Active+Inhibitor+of+Anaplastic+Lymphoma+Kinase&doi=10.1021%2Facs.jmedchem.6b00306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></div><div class="casAuthors">Huang, Wei-Sheng; Liu, Shuangying; Zou, Dong; Thomas, Mathew; Wang, Yihan; Zhou, Tianjun; Romero, Jan; Kohlmann, Anna; Li, Feng; Qi, Jiwei; Cai, Lisi; Dwight, Timothy A.; Xu, Yongjin; Xu, Rongsong; Dodd, Rory; Toms, Angela; Parillon, Lois; Lu, Xiaohui; Anjum, Rana; Zhang, Sen; Wang, Frank; Keats, Jeffrey; Wardwell, Scott D.; Ning, Yaoyu; Xu, Qihong; Moran, Lauren E.; Mohemmad, Qurish K.; Jang, Hyun Gyung; Clackson, Tim; Narasimhan, Narayana I.; Rivera, Victor M.; Zhu, Xiaotian; Dalgarno, David; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4948-4964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of echinoderm microtubule-assocd. protein-like 4 (EML4)-anaplastic lymphoma kinase pos. (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors.  This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clin. candidate brigatinib.  A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addn. to favorable ADME properties.  Brigatinib displayed low nanomolar IC50s against native ALK and all tested clin. relevant ALK mutants in both enzyme-based biochem. and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).  Brigatinib represents the most clin. advanced phosphine oxide-contg. drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5_iqprSA4QbVg90H21EOLACvtfcHk0ljay--S4Nx1ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCgur8%253D&md5=4cb93ff587579c97fda8aff0c7d43317</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DDwight%26aufirst%3DT.%2BA.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DToms%26aufirst%3DA.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoran%26aufirst%3DL.%2BE.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DJang%26aufirst%3DH.%2BG.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%2520Brigatinib%2520%2528AP26113%2529%252C%2520a%2520Phosphine%2520Oxide-Containing%252C%2520Potent%252C%2520Orally%2520Active%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4948%26epage%3D4964%26doi%3D10.1021%2Facs.jmedchem.6b00306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Glasdegib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1047-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1047-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30666593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=207-213&author=S.+M.+Hoy&title=Glasdegib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1047-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153aR"><div class="casContent"><span class="casTitleNuber">153a</span><div class="casTitle"><span class="NLM_cas:atitle">Glasdegib: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-213</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Glasdegib (DAURISMO) is an oral inhibitor of the Hedgehog signalling pathway, the activation of which is assocd. with a no. of malignancies.  It has been developed by Pfizer and was approved in Nov. 2018 in the USA for use in combination with low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in patients aged = 75 years or those who have comorbidities that preclude use of intensive induction chemotherapy.  Glasdegib is the first Hedgehog pathway inhibitor to be approved for AML in the USA.  It received orphan designation for the treatment of AML in the USA in June 2017 and in the EU in Oct. 2017, and for the treatment of myelodysplastic syndrome (MDS) in the USA in Oct. 2017.  It is also undergoing clin. development for use in select haematol. and other malignancies, including MDS, in various countries worldwide.  This article summarizes the milestones in the development of glasdegib leading to its use in combination with low-dose cytarabine for the treatment of newly-diagnosed AML in patients aged = 75 years or those who have comorbidities that preclude use of intensive induction chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeH-czMi5FQrVg90H21EOLACvtfcHk0ljay--S4Nx1ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqtLs%253D&md5=8ca00a70ef07e03b24e52fa57638867e</span></div><a href="/servlet/linkout?suffix=cit153a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1047-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1047-7%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DGlasdegib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D207%26epage%3D213%26doi%3D10.1007%2Fs40265-018-1047-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit153b"><span><span class="NLM_label">(b) </span><a href="https://www.fda.gov/Drugs/Fda-Approves-Glasdegib-Aml-Adults-Age-75-or-Older-or-Who-Have-Comorbidities" class="extLink">https://www.fda.gov/Drugs/Fda-Approves-Glasdegib-Aml-Adults-Age-75-or-Older-or-Who-Have-Comorbidities</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2FDrugs%2FFda-Approves-Glasdegib-Aml-Adults-Age-75-or-Older-or-Who-Have-Comorbidities+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidel, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montesinos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DesJardins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeremski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuser, M.</span></span> <span> </span><span class="NLM_article-title">Randomized Comparison of Low Dose Cytarabine with or without Glasdegib in Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">389</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0312-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fs41375-018-0312-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30555165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=379-389&author=J.+E.+Cortesauthor=F.+H.+Heidelauthor=A.+Hellmannauthor=W.+Fiedlerauthor=B.+D.+Smithauthor=T.+Robakauthor=P.+Montesinosauthor=D.+A.+Pollyeaauthor=P.+DesJardinsauthor=O.+Ottmannauthor=W.+W.+Maauthor=M.+N.+Shaikauthor=A.+D.+Lairdauthor=M.+Zeremskiauthor=A.+O%E2%80%99Connellauthor=G.+Chanauthor=M.+Heuser&title=Randomized+Comparison+of+Low+Dose+Cytarabine+with+or+without+Glasdegib+in+Patients+with+Newly+Diagnosed+Acute+Myeloid+Leukemia+or+High-Risk+Myelodysplastic+Syndrome&doi=10.1038%2Fs41375-018-0312-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome</span></div><div class="casAuthors">Cortes, Jorge E.; Heidel, Florian H.; Hellmann, Andrzej; Fiedler, Walter; Smith, B. Douglas; Robak, Tadeusz; Montesinos, Pau; Pollyea, Daniel A.; DesJardins, Pierre; Ottmann, Oliver; Ma, Weidong Wendy; Shaik, M. Naveed; Laird, A. Douglas; Zeremski, Mirjana; O'Connell, Ashleigh; Chan, Geoffrey; Heuser, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">379-389</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Glasdegib is a Hedgehog pathway inhibitor.  This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy.  Glasdegib 100 mg (oral, QD) was administered continuously in 28-day cycles; LDAC 20 mg (s.c., BID) was administered for 10 per 28 days.  Patients (stratified by cytogenetic risk) were randomized (2:1) to receive glasdegib/LDAC or LDAC.  The primary endpoint was overall survival.  Eighty-eight and 44 patients were randomized to glasdegib/LDAC and LDAC, resp.  Median (80% confidence interval [CI]) overall survival was 8.8 (6.9-9.9) months with glasdegib/LDAC and 4.9 (3.5-6.0) months with LDAC (hazard ratio, 0.51; 80% CI, 0.39-0.67, P = 0.0004).  Fifteen (17.0%) and 1 (2.3%) patients in the glasdegib/LDAC and LDAC arms, resp., achieved complete remission (P < 0.05).  Nonhematol. grade 3/4 all-causality adverse events included pneumonia (16.7%) and fatigue (14.3%) with glasdegib/LDAC and pneumonia (14.6%) with LDAC.  Clin. efficacy was evident across patients with diverse mutational profiles.  Glasdegib plus LDAC has a favorable benefit-risk profile and may be a promising option for AML patients unsuitable for intensive chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokx5onjXmKwLVg90H21EOLACvtfcHk0lgr_NlQ9MhoUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitLjL&md5=8f40182c7f9b69a2fdc6d2ab558d9723</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0312-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0312-9%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26aulast%3DHellmann%26aufirst%3DA.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DMontesinos%26aufirst%3DP.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DDesJardins%26aufirst%3DP.%26aulast%3DOttmann%26aufirst%3DO.%26aulast%3DMa%26aufirst%3DW.%2BW.%26aulast%3DShaik%26aufirst%3DM.%2BN.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DZeremski%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DHeuser%26aufirst%3DM.%26atitle%3DRandomized%2520Comparison%2520of%2520Low%2520Dose%2520Cytarabine%2520with%2520or%2520without%2520Glasdegib%2520in%2520Patients%2520with%2520Newly%2520Diagnosed%2520Acute%2520Myeloid%2520Leukemia%2520or%2520High-Risk%2520Myelodysplastic%2520Syndrome%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26spage%3D379%26epage%3D389%26doi%3D10.1038%2Fs41375-018-0312-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shavnya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzillo, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyden, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaGreca, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alsina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tkalcevic, G. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">106</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1021/ml2002423</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml2002423" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=106-111&author=M.+J.+Munchhofauthor=Q.+Liauthor=A.+Shavnyaauthor=G.+V.+Borzilloauthor=T.+L.+Boydenauthor=C.+S.+Jonesauthor=S.+D.+LaGrecaauthor=L.+Martinez-Alsinaauthor=N.+Patelauthor=K.+Pelletierauthor=L.+A.+Reiterauthor=M.+D.+Robbinsauthor=G.+T.+Tkalcevic&title=Discovery+of+PF-04449913%2C+a+Potent+and+Orally+Bioavailable+Inhibitor+of+Smoothened&doi=10.1021%2Fml2002423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened</span></div><div class="casAuthors">Munchhof, Michael J.; Li, Qifang; Shavnya, Andrei; Borzillo, Gary V.; Boyden, Tracey L.; Jones, Christopher S.; LaGreca, Susan D.; Martinez-Alsina, Luis; Patel, Nandini; Pelletier, Kathleen; Reiter, Larry A.; Robbins, Michael D.; Tkalcevic, George T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">106-111</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hedgehog signaling pathway have generated a great deal of interest in the oncol. area due to the mounting evidence of their potential to provide promising therapeutic options for patients.  Herein, we describe the discovery strategy to overcome the issues inherent in lead structure 1 that resulted in the identification of Smoothened inhibitor 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea (PF-04449913, 26), which has been advanced to human clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCSrORZG_pxbVg90H21EOLACvtfcHk0lgr_NlQ9MhoUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GhsLnO&md5=298ea79230c119359512b1ad07900557</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Fml2002423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml2002423%26sid%3Dliteratum%253Aachs%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DShavnya%26aufirst%3DA.%26aulast%3DBorzillo%26aufirst%3DG.%2BV.%26aulast%3DBoyden%26aufirst%3DT.%2BL.%26aulast%3DJones%26aufirst%3DC.%2BS.%26aulast%3DLaGreca%26aufirst%3DS.%2BD.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DPelletier%26aufirst%3DK.%26aulast%3DReiter%26aufirst%3DL.%2BA.%26aulast%3DRobbins%26aufirst%3DM.%2BD.%26aulast%3DTkalcevic%26aufirst%3DG.%2BT.%26atitle%3DDiscovery%2520of%2520PF-04449913%252C%2520a%2520Potent%2520and%2520Orally%2520Bioavailable%2520Inhibitor%2520of%2520Smoothened%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D106%26epage%3D111%26doi%3D10.1021%2Fml2002423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triche, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, A. A.</span></span> <span> </span><span class="NLM_article-title">GLI3 Repressor Determines Hedgehog Pathway Activation and Is Required for Response to SMO Antagonist Glasdegib in AML</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">3465</span>– <span class="NLM_lpage">3475</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-05-718585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1182%2Fblood-2016-05-718585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28487292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFamt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=3465-3475&author=P.+Chaudhryauthor=M.+Singhauthor=T.+J.+Tricheauthor=M.+Guzmanauthor=A.+A.+Merchant&title=GLI3+Repressor+Determines+Hedgehog+Pathway+Activation+and+Is+Required+for+Response+to+SMO+Antagonist+Glasdegib+in+AML&doi=10.1182%2Fblood-2016-05-718585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156aR"><div class="casContent"><span class="casTitleNuber">156a</span><div class="casTitle"><span class="NLM_cas:atitle">GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML</span></div><div class="casAuthors">Chaudhry, Parvesh; Singh, Mohan; Triche, Timothy J.; Guzman, Monica; Merchant, Akil A.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3465-3475</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Hedgehog (Hh) signaling pathway is activated in many cancers and is a promising target for therapeutic development.  Deletions in the receptor Patched (PTCH) or activating mutations in Smoothened (SMO) have been reported in basal cell carcinoma and medulloblastoma, but are largely absent in most tumor types.  Therefore, the mechanism of pathway activation in most cancers, including hematol. malignancies, remains unknown.  In normal tissues, Hh pathway activation via PTCH/SMO causes an increase in the downstream transcriptional activator GLI1 and a decrease in the GLI3 transcriptional repressor (GLI3R).  In this article,weconfirm that theHhpathway is active in acute myeloid leukemia (AML), however, this activity is largely independent of SMO.  Epigenetic and gene expression anal. of The Cancer Genome Atlas AML data set reveals that GLI3 expression is silenced in mostAMLpatient samples, and the GLI3 locus is abnormally methylated.Weshow that GLI3R is required for the therapeutic effect of SMO antagonists in AML samples and restoration of GLI3R suppresses the growth of AML.  We addnl. demonstrate that GLI3R repressesAMLgrowth by downregulatingAKTexpression.  In summary,this study provides the first evidence that GLI3R plays an essential role in SMO-independent Hh signaling in AML, and suggests that GLI3R could serve as a potential biomarker for patient selection in SMO antagonist clin. trials.  Furthermore, these data support rational combinations of hypomethylating agents with SMO antagonists in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwpV6MABYMMLVg90H21EOLACvtfcHk0liIxMP7r2jZdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFamt7rK&md5=32db4f56b56b90e8a32b675018a4610f</span></div><a href="/servlet/linkout?suffix=cit156a&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-05-718585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-05-718585%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhry%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DTriche%26aufirst%3DT.%2BJ.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DMerchant%26aufirst%3DA.%2BA.%26atitle%3DGLI3%2520Repressor%2520Determines%2520Hedgehog%2520Pathway%2520Activation%2520and%2520Is%2520Required%2520for%2520Response%2520to%2520SMO%2520Antagonist%2520Glasdegib%2520in%2520AML%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D3465%26epage%3D3475%26doi%3D10.1182%2Fblood-2016-05-718585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit156b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W.</span></span> <span> </span><span class="NLM_article-title">Activation of the Hedgehog Pathway in Chronic Myelogeneous Leukemia Patients</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1186/1756-9966-30-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1186%2F1756-9966-30-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=21235817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Klu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=8&author=B.+Longauthor=H.+Zhuauthor=C.+Zhuauthor=T.+Liuauthor=W.+Meng&title=Activation+of+the+Hedgehog+Pathway+in+Chronic+Myelogeneous+Leukemia+Patients&doi=10.1186%2F1756-9966-30-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156bR"><div class="casContent"><span class="casTitleNuber">156b</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the hedgehog pathway in chronic myelogeneous leukemia patients</span></div><div class="casAuthors">Long, Bing; Zhu, Huanling; Zhu, Cuixia; Liu, Ting; Meng, Wentong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Hedgehog (Hh) signaling pathway is involved in regulation of many tissues development and oncogenesis.  Recently, Hh signaling has been identified as a required functional pathway for leukemia stem cells(LSCs), and loss of this pathway impairs leukemia progression.  Objectives: The aim of this study was to det. the expression of Hedgehog signaling mols. in Chronic Myelogeneous Leukemia (CML) patients and normal people by semiquant. polymerase chain reaction (PCR) and to correlate mRNA expression to patients' clin. data.  Results: Here, we showed that Sonic hedgehog (Shh), Smoothened (Smo), and Gli1 genes of Hh signaling were significantly upregulated in CML patients when compared with normal people (P<0.001).  The levels of Shh, Smo mRNA in chronic phase of CML patients were obviously lower than that in blast crisis (p<0.05).  There were no significant differences of Shh, Ptch1, Smo, Gli1 mRNA expression found when comparing CML patients of chronic phase(CP) with imatinib(IM) treated or not(p>0.05).  Conclusions: These findings suggested that activation of the Hh pathway maybe assocd. with CML progression.  Treatment of CML with imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase inhibitor, has no significant influence on the inhibition of Hh pathway of CML-CP patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgyBC327KiFrVg90H21EOLACvtfcHk0liIxMP7r2jZdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Klu7s%253D&md5=bcd89f1907b8535ee3d151fda6cb51c6</span></div><a href="/servlet/linkout?suffix=cit156b&amp;dbid=16384&amp;doi=10.1186%2F1756-9966-30-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-9966-30-8%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DMeng%26aufirst%3DW.%26atitle%3DActivation%2520of%2520the%2520Hedgehog%2520Pathway%2520in%2520Chronic%2520Myelogeneous%2520Leukemia%2520Patients%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D30%26spage%3D8%26doi%3D10.1186%2F1756-9966-30-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heretsch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzagkaroulaki, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannis, A.</span></span> <span> </span><span class="NLM_article-title">Modulators of the Hedgehog Signaling Pathway</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6613</span>– <span class="NLM_lpage">6624</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.bmc.2010.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20708941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFamtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=6613-6624&author=P.+Heretschauthor=L.+Tzagkaroulakiauthor=A.+Giannis&title=Modulators+of+the+Hedgehog+Signaling+Pathway&doi=10.1016%2Fj.bmc.2010.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Modulators of the hedgehog signaling pathway</span></div><div class="casAuthors">Heretsch, Philipp; Tzagkaroulaki, Lito; Giannis, Athanassios</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6613-6624</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since its discovery by C. Nuesslein-Volhard and E. F. Wieschaus, hedgehog (hh) signaling has come a long way.  Today it is regarded as a key regulator in embryogenesis where it governs processes like cell proliferation, differentiation, and tissue patterning.  Furthermore, in adults it is involved in the maintenance of stem cells, and in tissue repair and regeneration.  But hh signaling has a second-much darker-face: it plays an important role in several types of human cancers where it promotes growth and enables proliferation of tumor stem cells.  The etiol. of medulloblastoma and basal cell carcinoma is tightly linked to aberrant hh activity, but also cancers of the prostate, the pancreas, the colon, the breasts, rhabdomyosarcoma, and leukemia, are dependent on irregular hh activity.  Recent clin. studies have shown that hh signaling can be the basis of an important new class of therapeutic agents with far-reaching implications in oncol.  Thus, modulation of hh signaling by means of small mols. has emerged as a valuable tool in combating these hh-dependent cancers.  Cyclopamine, a unique natural product with a fascinating history, was the first identified inhibitor of hh signaling and its story is closely linked to the progress in the whole field.  In this review we will trace the story of cyclopamine, give an overview on the biol. modes of hh signaling both in untransformed and malignant cells, and finally present potent modulators of the hh pathway-many of them already in clin. studies.  For more than 30 years now the knowledge on hh signaling has grown steadily-an end to this development is far from being conceivable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphJz_mK5dDvbVg90H21EOLACvtfcHk0liIxMP7r2jZdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFamtrfO&md5=3187f3b583e2094cd0cfd1690ffe3071</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DHeretsch%26aufirst%3DP.%26aulast%3DTzagkaroulaki%26aufirst%3DL.%26aulast%3DGiannis%26aufirst%3DA.%26atitle%3DModulators%2520of%2520the%2520Hedgehog%2520Signaling%2520Pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D6613%26epage%3D6624%26doi%3D10.1016%2Fj.bmc.2010.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiesslich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neureiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neureiter, D.</span></span> <span> </span><span class="NLM_article-title">Thoughts on Investigational Hedgehog Pathway Inhibitors for the Treatment of Cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1274392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F13543784.2017.1274392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28004600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=133-136&author=T.+Jagerauthor=M.+Ockerauthor=T.+Kiesslichauthor=E.+Neureiterauthor=D.+Neureiter&title=Thoughts+on+Investigational+Hedgehog+Pathway+Inhibitors+for+the+Treatment+of+Cancer&doi=10.1080%2F13543784.2017.1274392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158aR"><div class="casContent"><span class="casTitleNuber">158a</span><div class="casTitle"><span class="NLM_cas:atitle">Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer</span></div><div class="casAuthors">Jager Tarkan; Ocker Matthias; Ocker Matthias; Kiesslich Tobias; Kiesslich Tobias; Neureiter Elen; Neureiter Daniel; Neureiter Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on investigational drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-136</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5cBz8zkyS2JPlX7E30qdzfW6udTcc2eaFCnW-qhplfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FnsVKntQ%253D%253D&md5=a1fbfd34b2de5e49f4a1828c7d7e3943</span></div><a href="/servlet/linkout?suffix=cit158a&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1274392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1274392%26sid%3Dliteratum%253Aachs%26aulast%3DJager%26aufirst%3DT.%26aulast%3DOcker%26aufirst%3DM.%26aulast%3DKiesslich%26aufirst%3DT.%26aulast%3DNeureiter%26aufirst%3DE.%26aulast%3DNeureiter%26aufirst%3DD.%26atitle%3DThoughts%2520on%2520Investigational%2520Hedgehog%2520Pathway%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D133%26epage%3D136%26doi%3D10.1080%2F13543784.2017.1274392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit158b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller-Moslin, K.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">500</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201000011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fcmdc.201000011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=20229564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFyqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=500-512&author=S.+Peukertauthor=K.+Miller-Moslin&title=Small-Molecule+Inhibitors+of+the+Hedgehog+Signaling+Pathway+as+Cancer+Therapeutics&doi=10.1002%2Fcmdc.201000011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158bR"><div class="casContent"><span class="casTitleNuber">158b</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics</span></div><div class="casAuthors">Peukert, Stefan; Miller-Moslin, Karen</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">500-512</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Inhibitors of the Hedgehog (Hh) mol. signaling pathway have emerged in recent years as a promising new class of potential therapeutics for cancer treatment.  Numerous drug discovery efforts have resulted in the identification of a wide variety of small mols. that target different members of this pathway, including Smoothened (Smo), Sonic hedgehog protein (Shh), and Gli1.  Several Smo inhibitors have now entered human clin. trials, and successful proof-of-concept studies have been carried out in patients with defined genetic mutations in the Hh pathway.  This review provides a general overview of three main topics in this rapidly expanding area: (1) the various types of biol. assays and in vivo models that have been employed for the identification and optimization of Hh pathway inhibitors; (2) Smo inhibitors reported to date, including recent clin. results where available; and (3) efforts toward the identification and characterization of inhibitors of other members of the Hh pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwPNA0A-NVA7Vg90H21EOLACvtfcHk0lgKuk0NSB07-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFyqt7o%253D&md5=429705c283818ba2af09f66aceea2ff3</span></div><a href="/servlet/linkout?suffix=cit158b&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000011%26sid%3Dliteratum%253Aachs%26aulast%3DPeukert%26aufirst%3DS.%26aulast%3DMiller-Moslin%26aufirst%3DK.%26atitle%3DSmall-Molecule%2520Inhibitors%2520of%2520the%2520Hedgehog%2520Signaling%2520Pathway%2520as%2520Cancer%2520Therapeutics%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D500%26epage%3D512%26doi%3D10.1002%2Fcmdc.201000011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puchlopek-Dermenci, A. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, H. J.</span></span> <span> </span><span class="NLM_article-title">Development of a Concise, Asymmetric Synthesis of a Smoothened Receptor (SMO) Inhibitor: Enzymatic Transamination of a 4-Piperidinone with Dynamic Kinetic Resolution</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">860</span>– <span class="NLM_lpage">863</span>, <span class="refDoi"> DOI: 10.1021/ol403630g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol403630g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=860-863&author=Z.+Pengauthor=J.+W.+Wongauthor=E.+C.+Hansenauthor=A.+L.+A.+Puchlopek-Dermenciauthor=H.+J.+Clarke&title=Development+of+a+Concise%2C+Asymmetric+Synthesis+of+a+Smoothened+Receptor+%28SMO%29+Inhibitor%3A+Enzymatic+Transamination+of+a+4-Piperidinone+with+Dynamic+Kinetic+Resolution&doi=10.1021%2Fol403630g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Concise, Asymmetric Synthesis of a Smoothened Receptor (SMO) Inhibitor: Enzymatic Transamination of a 4-Piperidinone with Dynamic Kinetic Resolution</span></div><div class="casAuthors">Peng, Zhihui; Wong, John W.; Hansen, Eric C.; Puchlopek-Dermenci, Angela L. A.; Clarke, Hugh J.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">860-863</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A concise, asym. synthesis of a smoothened receptor inhibitor I is described.  The synthesis features an enzymic transamination with concurrent dynamic kinetic resoln. (DKR) of a 4-piperidone II to establish the two stereogenic centers required in a single step.  This efficient reaction affords the desired anti amine III in >10:1 dr and >99% ee.  The title compd. is prepd. in only five steps with 40% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqszZmrhpvptrVg90H21EOLACvtfcHk0lgKuk0NSB07-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKktrk%253D&md5=4cb54842346c8cb6f16460612599f6ee</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1021%2Fol403630g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol403630g%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DJ.%2BW.%26aulast%3DHansen%26aufirst%3DE.%2BC.%26aulast%3DPuchlopek-Dermenci%26aufirst%3DA.%2BL.%2BA.%26aulast%3DClarke%26aufirst%3DH.%2BJ.%26atitle%3DDevelopment%2520of%2520a%2520Concise%252C%2520Asymmetric%2520Synthesis%2520of%2520a%2520Smoothened%2520Receptor%2520%2528SMO%2529%2520Inhibitor%253A%2520Enzymatic%2520Transamination%2520of%2520a%25204-Piperidinone%2520with%2520Dynamic%2520Kinetic%2520Resolution%26jtitle%3DOrg.%2520Lett.%26date%3D2014%26volume%3D16%26spage%3D860%26epage%3D863%26doi%3D10.1021%2Fol403630g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, E. C.</span>; <span class="NLM_string-name">Seadeek, C. S.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Crystalline Forms of 1-((2r,4r)-2-(1h-Benzo[D]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea Maleate</span>. <span class="NLM_patent">WO2016170451A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.+C.+Hansen&author=C.+S.+Seadeek&title=Process+for+Preparing+Crystalline+Forms+of+1-%28%282r%2C4r%29-2-%281h-Benzo%5BD%5Dimidazol-2-yl%29-1-methylpiperidin-4-yl%29-3-%284-cyanophenyl%29urea+Maleate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DE.%2BC.%26atitle%3DProcess%2520for%2520Preparing%2520Crystalline%2520Forms%2520of%25201-%2528%25282r%252C4r%2529-2-%25281h-Benzo%255BD%255Dimidazol-2-yl%2529-1-methylpiperidin-4-yl%2529-3-%25284-cyanophenyl%2529urea%2520Maleate%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Ivosidenib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1509</span>– <span class="NLM_lpage">1516</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0978-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0978-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30209701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSnu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1509-1516&author=S.+Dhillon&title=Ivosidenib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0978-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Ivosidenib: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1509-1516</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Ivosidenib (Tibsovo) is a small mol., orally available inhibitor of mutated cytosolic isocitrate dehydrogenase 1 (IDH1) that is being developed by Agios Pharmaceuticals for the treatment of cancer in patients with IDH1 mutations.  The mutated form of the IDH1 enzyme produces a metabolite, 2-hydroxyglutarate (2-HG), which is thought to play a role in the formation and progression of acute myeloid leukemia (AML), gliomas and other cancers.  Elevated 2-HG levels interfere with cellular metab. and epigenetic regulation, thereby contributing to oncogenesis.  Ivosidenib targets the IDH1 metabolic pathway to prevent a build-up of the oncometabolite 2-HG.  This article summarizes the milestones in the development of ivosidenib leading to this first approval in the USA for the treatment of patients with relapsed or refractory AML with a susceptible IDH1 mutation.  Clin. development for AML, cholangiocarcinoma, glioma, myelodysplastic syndromes and solid tumors is ongoing worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr2rLroCG57LVg90H21EOLACvtfcHk0lizpqmIJ2TKjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSnu7rJ&md5=e18b0f17ef1376e1730ced8864dd5f1c</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0978-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0978-3%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DIvosidenib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1509%26epage%3D1516%26doi%3D10.1007%2Fs40265-018-0978-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Boddu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of Isocitrate Dehydrogenase Mutant AML</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1317745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1080%2F13543784.2017.1317745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28388242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlSmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=525-530&author=P.+Bodduauthor=G.+Borthakur&title=Therapeutic+Targeting+of+Isocitrate+Dehydrogenase+Mutant+AML&doi=10.1080%2F13543784.2017.1317745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162aR"><div class="casContent"><span class="casTitleNuber">162a</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of isocitrate dehydrogenase mutant AML</span></div><div class="casAuthors">Boddu, Prajwal; Borthakur, Gautam</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525-530</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The present article relates to mIDH inhibitors currently undergoing active development in clin. trials and also incorporate a section outlining agents targeting other simultaneously dysregulated pathways uniquely operational in IDH-mutated acute myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4-tiAS8V0ObVg90H21EOLACvtfcHk0lizpqmIJ2TKjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlSmu70%253D&md5=56f64f762e556aafeaecf6cc2af2da03</span></div><a href="/servlet/linkout?suffix=cit162a&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1317745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1317745%26sid%3Dliteratum%253Aachs%26aulast%3DBoddu%26aufirst%3DP.%26aulast%3DBorthakur%26aufirst%3DG.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Isocitrate%2520Dehydrogenase%2520Mutant%2520AML%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D525%26epage%3D530%26doi%3D10.1080%2F13543784.2017.1317745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit162b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nassereddine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lap, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haroun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabbara, I.</span></span> <span> </span><span class="NLM_article-title">The Role of Mutant IDH1 and IDH2 Inhibitors in the Treatment of Acute Myeloid Leukemia</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1983</span>– <span class="NLM_lpage">1991</span>, <span class="refDoi"> DOI: 10.1007/s00277-017-3161-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs00277-017-3161-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29090344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslCmtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=1983-1991&author=S.+Nassereddineauthor=C.+J.+Lapauthor=F.+Harounauthor=I.+Tabbara&title=The+Role+of+Mutant+IDH1+and+IDH2+Inhibitors+in+the+Treatment+of+Acute+Myeloid+Leukemia&doi=10.1007%2Fs00277-017-3161-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162bR"><div class="casContent"><span class="casTitleNuber">162b</span><div class="casTitle"><span class="NLM_cas:atitle">The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Nassereddine, Samah; Lap, Coen J.; Haroun, Faysal; Tabbara, Imad</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1983-1991</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">For decades, researchers have looked into the pathophysiol. of acute myeloid leukemia (AML).  With the advances in mol. techniques, the two-hit hypothesis was replaced by a multi-hit model, which also emphasizes the importance of aberrant epigenetic regulation in the pathogenesis of AML.  IDH1 and IDH2 are two isoforms of isocitrate dehydrogenase that perform crucial roles in cellular metab.  Somatic mutations in either of these two genes impart a neomorphic enzymic activity upon the encoded enzymes resulting in the ability to convert α-ketoglutarate (αKG) into the oncometabolite R2-hydroxyglutarate (R2-HG), which can competitively inhibit multiple αKG-dependent dioxygenases.  Inhibition of various classes of αKG-dependent dioxygenases results in dramatic epigenetic changes in hematopoietic cells, which has been found to directly impair differentiation.  In addn. to a global dysregulation of gene expression, other mechanisms have been described through which R2-HG promotes leukemic transformation including the induction of B cell lymphoma 2 dependency and stimulation of the EglN family of prolyl 4-hydroxylases (EglN).  Due to the fact that mutations in IDH1 and IDH2 are acquired early during AML clonal evolution as well as because these mutations tend to remain stable during AML progression, the pharmaceutical industry has prompted the development of specific mutant IDH enzyme inhibitors.  More recently, the FDA approved the first mutant IDH2 inhibitor, enasidenib (AG-221), for patients with relapsed or refractory IDH2-mutated AML (RR-AML).  This has brought a lot of excitement to researchers, clinicians, and patients, esp. because the treatment of AML remains challenging and is still assocd. with a high mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0MoaTYhzKz7Vg90H21EOLACvtfcHk0lizpqmIJ2TKjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslCmtrrL&md5=8b84f1581f0beef64cf14e6bf9f1a7c0</span></div><a href="/servlet/linkout?suffix=cit162b&amp;dbid=16384&amp;doi=10.1007%2Fs00277-017-3161-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-017-3161-0%26sid%3Dliteratum%253Aachs%26aulast%3DNassereddine%26aufirst%3DS.%26aulast%3DLap%26aufirst%3DC.%2BJ.%26aulast%3DHaroun%26aufirst%3DF.%26aulast%3DTabbara%26aufirst%3DI.%26atitle%3DThe%2520Role%2520of%2520Mutant%2520IDH1%2520and%2520IDH2%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DAnn.%2520Hematol.%26date%3D2017%26volume%3D96%26spage%3D1983%26epage%3D1991%26doi%3D10.1007%2Fs00277-017-3161-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quivoron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadrzadeh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gliser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saada, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agresta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penard-Lacronique, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K.</span></span> <span> </span><span class="NLM_article-title">AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3734</span>, <span class="refDoi"> DOI: 10.1182/blood.V124.21.3734.3734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1182%2Fblood.V124.21.3734.3734" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3734&author=E.+Hansenauthor=C.+Quivoronauthor=K.+Straleyauthor=R.+M.+Lemieuxauthor=J.+Popovici-Mullerauthor=H.+Sadrzadehauthor=A.+T.+Fathiauthor=C.+Gliserauthor=M.+Davidauthor=V.+Saadaauthor=J.+Micolauthor=O.+Bernardauthor=M.+Dorschauthor=H.+Yangauthor=M.+Suauthor=S.+Agrestaauthor=S.+de+Bottonauthor=V.+Penard-Lacroniqueauthor=K.+Yen&title=AG-120%2C+an+Oral%2C+Selective%2C+First-in-Class%2C+Potent+Inhibitor+of+Mutant+IDH1%2C+Reduces+Intracellular+2HG+and+Induces+Cellular+Differentiation+in+TF-1+R132H+Cells+and+Primary+Human+IDH1+Mutant+AML+Patient+Samples+Treated+Ex+Vivo&doi=10.1182%2Fblood.V124.21.3734.3734"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163a&amp;dbid=16384&amp;doi=10.1182%2Fblood.V124.21.3734.3734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V124.21.3734.3734%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DE.%26aulast%3DQuivoron%26aufirst%3DC.%26aulast%3DStraley%26aufirst%3DK.%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DSadrzadeh%26aufirst%3DH.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DGliser%26aufirst%3DC.%26aulast%3DDavid%26aufirst%3DM.%26aulast%3DSaada%26aufirst%3DV.%26aulast%3DMicol%26aufirst%3DJ.%26aulast%3DBernard%26aufirst%3DO.%26aulast%3DDorsch%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DAgresta%26aufirst%3DS.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DPenard-Lacronique%26aufirst%3DV.%26aulast%3DYen%26aufirst%3DK.%26atitle%3DAG-120%252C%2520an%2520Oral%252C%2520Selective%252C%2520First-in-Class%252C%2520Potent%2520Inhibitor%2520of%2520Mutant%2520IDH1%252C%2520Reduces%2520Intracellular%25202HG%2520and%2520Induces%2520Cellular%2520Differentiation%2520in%2520TF-1%2520R132H%2520Cells%2520and%2520Primary%2520Human%2520IDH1%2520Mutant%2520AML%2520Patient%2520Samples%2520Treated%2520Ex%2520Vivo%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D3734%26doi%3D10.1182%2Fblood.V124.21.3734.3734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit163b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">DiNardo, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roboz, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mims, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swords, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannis, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollyea, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnellan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fathi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigneux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prince, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foran, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arellano, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekeres, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willekens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapsalis, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldwasser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agresta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">2386</span>– <span class="NLM_lpage">2398</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1716984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1056%2FNEJMoa1716984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29860938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1WjsrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=2386-2398&author=C.+D.+DiNardoauthor=E.+M.+Steinauthor=S.+de+Bottonauthor=G.+J.+Robozauthor=J.+K.+Altmanauthor=A.+S.+Mimsauthor=R.+Swordsauthor=R.+H.+Collinsauthor=G.+N.+Mannisauthor=D.+A.+Pollyeaauthor=W.+Donnellanauthor=A.+T.+Fathiauthor=A.+Pigneuxauthor=H.+P.+Erbaauthor=G.+T.+Princeauthor=A.+S.+Steinauthor=G.+L.+Uyauthor=J.+M.+Foranauthor=E.+Traerauthor=R.+K.+Stuartauthor=M.+L.+Arellanoauthor=J.+L.+Slackauthor=M.+A.+Sekeresauthor=C.+Willekensauthor=S.+Choeauthor=H.+Wangauthor=V.+Zhangauthor=K.+E.+Yenauthor=S.+M.+Kapsalisauthor=H.+Yangauthor=D.+Daiauthor=B.+Fanauthor=M.+Goldwasserauthor=H.+Liuauthor=S.+Agrestaauthor=B.+Wuauthor=E.+C.+Attarauthor=M.+S.+Tallmanauthor=R.+M.+Stoneauthor=H.+M.+Kantarjian&title=Durable+Remissions+with+Ivosidenib+in+IDH1-Mutated+Relapsed+or+Refractory+AML&doi=10.1056%2FNEJMoa1716984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163bR"><div class="casContent"><span class="casTitleNuber">163b</span><div class="casTitle"><span class="NLM_cas:atitle">Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML</span></div><div class="casAuthors">DiNardo, C. D.; Stein, E. M.; de Botton, S.; Roboz, G. J.; Altman, J. K.; Mims, A. S.; Swords, R.; Collins, R. H.; Mannis, G. N.; Pollyea, D. A.; Donnellan, W.; Fathi, A. T.; Pigneux, A.; Erba, H. P.; Prince, G. T.; Stein, A. S.; Uy, G. L.; Foran, J. M.; Traer, E.; Stuart, R. K.; Arellano, M. L.; Slack, J. L.; Sekeres, M. A.; Willekens, C.; Choe, S.; Wang, H.; Zhang, V.; Yen, K. E.; Kapsalis, S. M.; Yang, H.; Dai, D.; Fan, B.; Goldwasser, M.; Liu, H.; Agresta, S.; Wu, B.; Attar, E. C.; Tallman, M. S.; Stone, R. M.; Kantarjian, H. M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2386-2398</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in 6 to 10% of patients with acute myeloid leukemia (AML).  Ivosidenib (AG-120) is an oral, targeted, small-mol. inhibitor of mutant IDH1.  We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1-mutated AML.  Safety and efficacy were assessed in all treated patients.  The primary efficacy population included patients with relapsed or refractory AML receiving 500 mg of ivosidenib daily with at least 6 mo of follow-up.  Overall, 258 patients received ivosidenib and had safety outcomes assessed.  Among patients with relapsed or refractory AML (179 patients), treatment-related adverse events of grade 3 or higher that occurred in at least 3 patients were prolongation of the QT interval (in 7.8% of the patients), the IDH differentiation syndrome (in 3.9%), anemia (in 2.2%), thrombocytopenia or a decrease in the platelet count (in 3.4%), and leukocytosis (in 1.7%).  In the primary efficacy population (125 patients), the rate of complete remission or complete remission with partial hematol. recovery was 30.4% (95% confidence interval [CI], 22.5 to 39.3), the rate of complete remission was 21.6% (95% CI, 14.7 to 29.8), and the overall response rate was 41.6% (95% CI, 32.9 to 50.8).  The median durations of these responses were 8.2 mo (95% CI, 5.5 to 12.0), 9.3 mo (95% CI, 5.6 to 18.3), and 6.5 mo (95% CI, 4.6 to 9.3), resp.  Transfusion independence was attained in 29 of 84 patients (35%), and patients who had a response had fewer infections and febrile neutropenia episodes than those who did not have a response.  Among 34 patients who had a complete remission or complete remission with partial hematol. recovery, 7 (21%) had no residual detectable IDH1 mutations on digital polymerase-chain-reaction assay.  No preexisting co-occurring single gene mutation predicted clin. response or resistance to treatment.  In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was assocd. with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and mol. remissions in some patients with complete remission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAH6OFnOLWHbVg90H21EOLACvtfcHk0lgPZgSGMPs5Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1WjsrnO&md5=d60a1161c02f7d4aa39c8fbf6ed2dea1</span></div><a href="/servlet/linkout?suffix=cit163b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1716984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1716984%26sid%3Dliteratum%253Aachs%26aulast%3DDiNardo%26aufirst%3DC.%2BD.%26aulast%3DStein%26aufirst%3DE.%2BM.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DMims%26aufirst%3DA.%2BS.%26aulast%3DSwords%26aufirst%3DR.%26aulast%3DCollins%26aufirst%3DR.%2BH.%26aulast%3DMannis%26aufirst%3DG.%2BN.%26aulast%3DPollyea%26aufirst%3DD.%2BA.%26aulast%3DDonnellan%26aufirst%3DW.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DPigneux%26aufirst%3DA.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DPrince%26aufirst%3DG.%2BT.%26aulast%3DStein%26aufirst%3DA.%2BS.%26aulast%3DUy%26aufirst%3DG.%2BL.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DTraer%26aufirst%3DE.%26aulast%3DStuart%26aufirst%3DR.%2BK.%26aulast%3DArellano%26aufirst%3DM.%2BL.%26aulast%3DSlack%26aufirst%3DJ.%2BL.%26aulast%3DSekeres%26aufirst%3DM.%2BA.%26aulast%3DWillekens%26aufirst%3DC.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DV.%26aulast%3DYen%26aufirst%3DK.%2BE.%26aulast%3DKapsalis%26aufirst%3DS.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DB.%26aulast%3DGoldwasser%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DAgresta%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DAttar%26aufirst%3DE.%2BC.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26atitle%3DDurable%2520Remissions%2520with%2520Ivosidenib%2520in%2520IDH1-Mutated%2520Relapsed%2520or%2520Refractory%2520AML%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D2386%26epage%3D2398%26doi%3D10.1056%2FNEJMoa1716984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span>; <span class="NLM_string-name">Popovici-Muller, J.</span>; <span class="NLM_string-name">Travins, J.</span>; <span class="NLM_string-name">Cai, Z.</span>; <span class="NLM_string-name">Cui, D.</span>; <span class="NLM_string-name">Ding, Z.</span></span> <span> </span><span class="NLM_article-title">Therapeutically Active Compounds and Their Methods of Use</span>. <span class="NLM_patent">WO2013107291A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+M.+Lemieux&author=J.+Popovici-Muller&author=J.+Travins&author=Z.+Cai&author=D.+Cui&author=Z.+Ding&title=Therapeutically+Active+Compounds+and+Their+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26atitle%3DTherapeutically%2520Active%2520Compounds%2520and%2520Their%2520Methods%2520of%2520Use%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit164b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span>; <span class="NLM_string-name">Popovici-Muller, J.</span>; <span class="NLM_string-name">Travins, J.</span>; <span class="NLM_string-name">Cai, Z.</span>; <span class="NLM_string-name">Cui, D.</span>; <span class="NLM_string-name">Ding, Z.</span></span> <span> </span><span class="NLM_article-title">Therapeutically Active Compounds and Their Methods of Use</span>. <span class="NLM_patent">WO2015010297A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=R.+M.+Lemieux&author=J.+Popovici-Muller&author=J.+Travins&author=Z.+Cai&author=D.+Cui&author=Z.+Ding&title=Therapeutically+Active+Compounds+and+Their+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26atitle%3DTherapeutically%2520Active%2520Compounds%2520and%2520Their%2520Methods%2520of%2520Use%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit164c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianchetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penard-Lacronique, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quivoron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saada, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Botton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaharski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.-S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00421</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00421" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=300-305&author=J.+Popovici-Mullerauthor=R.+M.+Lemieuxauthor=E.+Artinauthor=J.+O.+Saundersauthor=F.+G.+Salituroauthor=J.+Travinsauthor=G.+Cianchettaauthor=Z.+Caiauthor=D.+Zhouauthor=D.+Cuiauthor=P.+Chenauthor=K.+Straleyauthor=E.+Tobinauthor=F.+Wangauthor=M.+D.+Davidauthor=V.+Penard-Lacroniqueauthor=C.+Quivoronauthor=V.+Saadaauthor=S.+de+Bottonauthor=S.+Grossauthor=L.+Dangauthor=H.+Yangauthor=L.+Utleyauthor=Y.+Chenauthor=H.+Kimauthor=S.+Jinauthor=Z.+Guauthor=G.+Yaoauthor=Z.+Luoauthor=X.+Lvauthor=C.+Fangauthor=L.+Yanauthor=A.+Olaharskiauthor=L.+Silvermanauthor=S.+Billerauthor=S.-S.+M.+Suauthor=K.+Yen&title=Discovery+of+AG-120+%28Ivosidenib%29%3A+A+First-in-Class+Mutant+IDH1+Inhibitor+for+the+Treatment+of+IDH1+Mutant+Cancers&doi=10.1021%2Facsmedchemlett.7b00421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164cR"><div class="casContent"><span class="casTitleNuber">164c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers</span></div><div class="casAuthors">Popovici-Muller, Janeta; Lemieux, Rene M.; Artin, Erin; Saunders, Jeffrey O.; Salituro, Francesco G.; Travins, Jeremy; Cianchetta, Giovanni; Cai, Zhenwei; Zhou, Ding; Cui, Dawei; Chen, Ping; Straley, Kimberly; Tobin, Erica; Wang, Fang; David, Muriel D.; Penard-Lacronique, Virginie; Quivoron, Cyril; Saada, Veronique; de Botton, Stephane; Gross, Stefan; Dang, Lenny; Yang, Hua; Utley, Luke; Chen, Yue; Kim, Hyeryun; Jin, Shengfang; Gu, Zhiwei; Yao, Gui; Luo, Zhiyong; Lv, Xiaobing; Fang, Cheng; Yan, Liping; Olaharski, Andrew; Silverman, Lee; Biller, Scott; Su, Shin-San M.; Yen, Katharine</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">300-305</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the prodn. of D-2-hydroxyglutarate (2-HG), an oncometabolite.  Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation.  IDH1 mutations have been described in an array of hematol. malignancies and solid tumors.  Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo.  Preliminary data from phase 1 clin. trials enrolling patients with cancers harboring an IDH1 mutation indicate that AG-120 has an acceptable safety profile and clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmTLcR37BiPrVg90H21EOLACvtfcHk0lg1grZDt_v28Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrurw%253D&md5=730ac2faa6844e4abe3fd9a360d74d29</span></div><a href="/servlet/linkout?suffix=cit164c&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00421%26sid%3Dliteratum%253Aachs%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26aulast%3DArtin%26aufirst%3DE.%26aulast%3DSaunders%26aufirst%3DJ.%2BO.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DTravins%26aufirst%3DJ.%26aulast%3DCianchetta%26aufirst%3DG.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DStraley%26aufirst%3DK.%26aulast%3DTobin%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DDavid%26aufirst%3DM.%2BD.%26aulast%3DPenard-Lacronique%26aufirst%3DV.%26aulast%3DQuivoron%26aufirst%3DC.%26aulast%3DSaada%26aufirst%3DV.%26aulast%3Dde%2BBotton%26aufirst%3DS.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DDang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DUtley%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DOlaharski%26aufirst%3DA.%26aulast%3DSilverman%26aufirst%3DL.%26aulast%3DBiller%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DS.-S.%2BM.%26aulast%3DYen%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520AG-120%2520%2528Ivosidenib%2529%253A%2520A%2520First-in-Class%2520Mutant%2520IDH1%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520IDH1%2520Mutant%2520Cancers%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D300%26epage%3D305%26doi%3D10.1021%2Facsmedchemlett.7b00421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, A. R.</span>; <span class="NLM_string-name">Singh, A.</span>; <span class="NLM_string-name">Yazali, V. S.</span>; <span class="NLM_string-name">Luthra, P. K.</span>; <span class="NLM_string-name">Vasoya, S. L.</span>; <span class="NLM_string-name">Patil, B. T.</span>; <span class="NLM_string-name">Taneja, A. K.</span>; <span class="NLM_string-name">Srivastav, N. C.</span>; <span class="NLM_string-name">Singh, R.</span>; <span class="NLM_string-name">Rengasamy, V.</span>; <span class="NLM_string-name">Tyagi, A.</span></span> <span> </span><span class="NLM_article-title">Solid State Forms of Ivosidenib</span>. <span class="NLM_patent">WO2019104318A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+R.+Muthusamy&author=A.+Singh&author=V.+S.+Yazali&author=P.+K.+Luthra&author=S.+L.+Vasoya&author=B.+T.+Patil&author=A.+K.+Taneja&author=N.+C.+Srivastav&author=R.+Singh&author=V.+Rengasamy&author=A.+Tyagi&title=Solid+State+Forms+of+Ivosidenib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMuthusamy%26aufirst%3DA.%2BR.%26atitle%3DSolid%2520State%2520Forms%2520of%2520Ivosidenib%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Larotrectinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1044-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1044-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30635837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=201-206&author=L.+J.+Scott&title=Larotrectinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1044-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib: First Global Approval</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-206</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Larotrectinib (Vitrakvi) is an orally administered, small mol., highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncol. in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbor neurotrophic receptor tyrosine kinase (NTRK) gene fusions.  In Nov. 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.  A registration application for the use of larotrectinib in pediatric and adult patients with locally advanced or metastatic solid tumors with NTRK gene fusion proteins has been submitted in the EU.  This article summarizes the milestones in the development of larotrectinib leading to its first approval for the treatment of adult and pediatric patients with solid tumors that have NTRK gene fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMpwdBG0H7ELVg90H21EOLACvtfcHk0lg1grZDt_v28Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsb8%253D&md5=8c3d442665ece609cc09422052903696</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1044-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1044-x%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DLarotrectinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D201%26epage%3D206%26doi%3D10.1007%2Fs40265-018-1044-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span> <span> </span><span class="NLM_article-title">NTRK Fusion-Positive Cancers and TRK Inhibitor Therapy</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/s41571-018-0113-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fs41571-018-0113-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30333516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCrsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=731-747&author=E.+Coccoauthor=M.+Scaltritiauthor=A.+Drilon&title=NTRK+Fusion-Positive+Cancers+and+TRK+Inhibitor+Therapy&doi=10.1038%2Fs41571-018-0113-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">NTRK fusion-positive cancers and TRK inhibitor therapy</span></div><div class="casAuthors">Cocco, Emiliano; Scaltriti, Maurizio; Drilon, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">731-747</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, resp.) are oncogenic drivers of various adult and paediatric tumor types.  These fusions can be detected in the clinic using a variety of methods, including tumor DNA and RNA sequencing and plasma cell-free DNA profiling.  The treatment of patients with NTRK fusion-pos. cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is assocd. with high response rates (>75%), regardless of tumor histol.  First-generation TRK inhibitors are well tolerated by most patients, with toxicity profiles characterized by occasional off-tumor, on-target adverse events (attributable to TRK inhibition in non-malignant tissues).  Despite durable disease control in many patients, advanced-stage NTRK fusion-pos. cancers eventually become refractory to TRK inhibition; resistance can be mediated by the acquisition of NTRK kinase domain mutations.  Fortunately, certain resistance mutations can be overcome by second-generation TRK inhibitors, including LOXO-195 and TPX-0005 that are being explored in clin. trials.  In this Review, we discuss the biol. of NTRK fusions, strategies to target these drivers in the treatment-naive and acquired-resistance disease settings, and the unique safety profile of TRK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2tGShkjX-5LVg90H21EOLACvtfcHk0lg1grZDt_v28Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCrsLnO&md5=fbc1f5b0de3614008f1b1f1e2e6167ce</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fs41571-018-0113-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41571-018-0113-0%26sid%3Dliteratum%253Aachs%26aulast%3DCocco%26aufirst%3DE.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DDrilon%26aufirst%3DA.%26atitle%3DNTRK%2520Fusion-Positive%2520Cancers%2520and%2520TRK%2520Inhibitor%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26spage%3D731%26epage%3D747%26doi%3D10.1038%2Fs41571-018-0113-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span> <span> </span><span class="NLM_article-title">Larotrectinib in NTRK-Rearranged Solid Tumors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1557</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00126</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00126" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks1Chsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=1555-1557&author=F.+H.+Wilsonauthor=R.+S.+Herbst&title=Larotrectinib+in+NTRK-Rearranged+Solid+Tumors&doi=10.1021%2Facs.biochem.9b00126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Larotrectinib in NTRK-Rearranged Solid Tumors</span></div><div class="casAuthors">Wilson, Frederick H.; Herbst, Roy S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1555-1557</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Larotrectinib (LOXO-101 and ARRY470) is an orally available, potent, and selective ATP-competitive pan-tropomyosin receptor tyrosine kinase (TRK) inhibitor with low nanomolar 50% inhibitory concns.  Early phase clin. trials for safety and efficacy of larotrectinib in adult and pediatric patients with diverse TRK fusion-pos. malignancies were recently reported.  Responses were obsd. in 75% of patients regardless of patient age, tumor type, TRK family member, or identity of the TRK fusion partner.  On the basis of these findings, the Food and Drug Administration granted accelerated approval to larotrectinib in Nov. 2018 for the treatment of adult and pediatric patients with advanced solid tumors harboring an NTRK gene fusion.  Using structural insights derived from X-ray crystallog. of TRK proteins and in silico modeling of addnl. structurally distinct TRK inhibitors, a second TRK inhibitor called LOXO195 was identified as a candidate compd. with potential activity against secondary mutations conferring resistance to larotrectinib.  On the basis of prior experience with acquired resistance to other kinase-directed therapies, LOXO-195 was developed nearly in parallel with larotrectinib in anticipation of acquired resistance to larotrectinib in treated patients.  A phase 1/2 clin. trial evaluating the safety and preliminary efficacy of LOXO-195 in adults and children with TRK-driven solid tumors refractory to a prior TRK inhibitor is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7SElFd-Ty17Vg90H21EOLACvtfcHk0liz0FBPfvtCCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks1Chsb0%253D&md5=d92f8170ae3bd22f4c5e76bf058d8edc</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00126%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DF.%2BH.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26atitle%3DLarotrectinib%2520in%2520NTRK-Rearranged%2520Solid%2520Tumors%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D1555%26epage%3D1557%26doi%3D10.1021%2Facs.biochem.9b00126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F. Y.</span></span> <span> </span><span class="NLM_article-title">A Tumor-Agnostic NTRK (TRK) Inhibitor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.02.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.cell.2019.02.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30901551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVWgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2019&pages=8&author=F.+W.+Huangauthor=F.+Y.+Feng&title=A+Tumor-Agnostic+NTRK+%28TRK%29+Inhibitor&doi=10.1016%2Fj.cell.2019.02.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">A Tumor-Agnostic NTRK (TRK) Inhibitor</span></div><div class="casAuthors">Huang, Franklin W.; Feng, Felix Y.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Larotrectinib is a small-mol. kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer.  Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights.  To view this Bench to Bedside, open or download the PDF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOCr1TgE8Pl7Vg90H21EOLACvtfcHk0liz0FBPfvtCCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVWgtLg%253D&md5=339c53baa9365f3eefc6948b4fc2cfaf</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.02.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.02.049%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DF.%2BW.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26atitle%3DA%2520Tumor-Agnostic%2520NTRK%2520%2528TRK%2529%2520Inhibitor%26jtitle%3DCell%26date%3D2019%26volume%3D177%26spage%3D8%26doi%3D10.1016%2Fj.cell.2019.02.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, M.</span>; <span class="NLM_string-name">Eary, C. T.</span>; <span class="NLM_string-name">Spencer, S.</span>; <span class="NLM_string-name">Juengst, D.</span>; <span class="NLM_string-name">Hache, B.</span>; <span class="NLM_string-name">Jiang, Y.</span>; <span class="NLM_string-name">Haas, J.</span>; <span class="NLM_string-name">Andrews, S. W.</span></span> <span> </span><span class="NLM_article-title">Preparation of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide</span>. <span class="NLM_patent">WO2017201241A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+Reynolds&author=C.+T.+Eary&author=S.+Spencer&author=D.+Juengst&author=B.+Hache&author=Y.+Jiang&author=J.+Haas&author=S.+W.+Andrews&title=Preparation+of+%28S%29-N-%285-%28%28R%29-2-%282%2C5-Difluorophenyl%29pyrrolidin-1-yl%29pyrazolo%5B1%2C5-a%5Dpyrimidin-3-yl%29-3-hydroxypyrrolidine-1-carboxamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReynolds%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520%2528S%2529-N-%25285-%2528%2528R%2529-2-%25282%252C5-Difluorophenyl%2529pyrrolidin-1-yl%2529pyrazolo%255B1%252C5-a%255Dpyrimidin-3-yl%2529-3-hydroxypyrrolidine-1-carboxamide%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryser, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diebold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautschi, O.</span></span> <span> </span><span class="NLM_article-title">Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Update and Perspectives</span>. <i>Curr. Opin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1097/CCO.0000000000000494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1097%2FCCO.0000000000000494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30394941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlCmtrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2019&pages=8-12&author=C.+O.+Ryserauthor=J.+Dieboldauthor=O.+Gautschi&title=Treatment+of+Anaplastic+Lymphoma+Kinase-Positive+Non-Small+Cell+Lung+Cancer%3A+Update+and+Perspectives&doi=10.1097%2FCCO.0000000000000494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives</span></div><div class="casAuthors">Ryser, Christoph Oliver; Diebold, Joachim; Gautschi, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-12</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: We describe recent developments in the rapidly evolving field of anaplastic lymphoma kinase-targeting agents.  Recent findings: Five targeted drugs are currently available in the clinic via regular approval or named patient programs, including crizotinib, ceritinib, alectinib, brigatinib and lorlatinib.  This review summarizes published data, together with drug-specific information on dosing and toxicity.  Moreover, we discuss different clin. scenarios and potential treatment options in patients with tumor progression, based on current literature and our own experience.  Summary: Patients with metastatic, anaplastic lymphoma kinase-rearranged nonsmall cell lung cancer should be managed by interdisciplinary expert teams.  New drugs with enhanced brain activity are available, and some patients may benefit from local therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMSqOqWnTEdrVg90H21EOLACvtfcHk0liz0FBPfvtCCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlCmtrrK&md5=fe23a33e86c430f7eb71be1dd441812d</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1097%2FCCO.0000000000000494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0000000000000494%26sid%3Dliteratum%253Aachs%26aulast%3DRyser%26aufirst%3DC.%2BO.%26aulast%3DDiebold%26aufirst%3DJ.%26aulast%3DGautschi%26aufirst%3DO.%26atitle%3DTreatment%2520of%2520Anaplastic%2520Lymphoma%2520Kinase-Positive%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Update%2520and%2520Perspectives%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2019%26volume%3D31%26spage%3D8%26epage%3D12%26doi%3D10.1097%2FCCO.0000000000000494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Lorlatinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1041-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1041-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30604291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=93-98&author=Y.+Y.+Syed&title=Lorlatinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1041-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-98</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Lorlatinib is an oral small mol. inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-pos. non-small cell lung cancer (NSCLC).  Based on results from a phase I/II trial, lorlatinib received approval in Japan in Sept. 2018 and in the USA in Nov. 2018 for the treatment of ALK-pos. NSCLC.  This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU4Wwiia48VbVg90H21EOLACvtfcHk0liag2Hd6pTxrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqsr4%253D&md5=f041ba0200e2d607bb2a014884455990</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1041-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1041-0%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DLorlatinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D93%26epage%3D98%26doi%3D10.1007%2Fs40265-018-1041-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10r)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2h-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]-Benzoxadiazacyclotetradecine-3-Carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Ros Oncogene 1 (Ros1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810r%29-7-Amino-12-Fluoro-2%2C10%2C16-Trimethyl-15-Oxo-10%2C15%2C16%2C17-Tetrahydro-2h-8%2C4-%28Metheno%29Pyrazolo%5B4%2C3-H%5D%5B2%2C5%2C11%5D-Benzoxadiazacyclotetradecine-3-Carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+C-Ros+Oncogene+1+%28Ros1%29+with+Preclinical+Brain+Exposure+and+Broad-Spectrum+Potency+against+ALK-Resistant+Mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0liag2Hd6pTxrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810r%2529-7-Amino-12-Fluoro-2%252C10%252C16-Trimethyl-15-Oxo-10%252C15%252C16%252C17-Tetrahydro-2h-8%252C4-%2528Metheno%2529Pyrazolo%255B4%252C3-H%255D%255B2%252C5%252C11%255D-Benzoxadiazacyclotetradecine-3-Carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520C-Ros%2520Oncogene%25201%2520%2528Ros1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-Spectrum%2520Potency%2520against%2520ALK-Resistant%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satouchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.-F.</span></span> <span> </span><span class="NLM_article-title">ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1370</span>– <span class="NLM_lpage">1379</span>, <span class="refDoi"> DOI: 10.1200/JCO.18.02236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1200%2FJCO.18.02236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30892989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cbmt1yntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=1370-1379&author=A.+T.+Shawauthor=B.+J.+Solomonauthor=B.+Besseauthor=T.+M.+Bauerauthor=C.-C.+Linauthor=R.+A.+Sooauthor=G.+J.+Rielyauthor=S.-H.+I.+Ouauthor=J.+S.+Clancyauthor=S.+Liauthor=A.+Abbattistaauthor=H.+Thurmauthor=M.+Satouchiauthor=D.+R.+Camidgeauthor=S.+Kaoauthor=R.+Chiariauthor=S.+M.+Gadgeelauthor=E.+Felipauthor=J.-F.+Martini&title=ALK+Resistance+Mutations+and+Efficacy+of+Lorlatinib+in+Advanced+Anaplastic+Lymphoma+Kinase-Positive+Non-Small-Cell+Lung+Cancer&doi=10.1200%2FJCO.18.02236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Shaw Alice T; Solomon Benjamin J; Besse Benjamin; Bauer Todd M; Lin Chia-Chi; Soo Ross A; Riely Gregory J; Ou Sai-Hong Ignatius; Clancy Jill S; Li Sherry; Thurm Holger; Martini Jean-Francois; Abbattista Antonello; Satouchi Miyako; Camidge D Ross; Kao Steven; Chiari Rita; Gadgeel Shirish M; Felip Enriqueta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1370-1379</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non-small-cell lung cancer, including in patients who have failed prior ALK TKIs.  Molecular determinants of response to lorlatinib have not been established, but preclinical data suggest that ALK resistance mutations may represent a biomarker of response in previously treated patients.  PATIENTS AND METHODS:  Baseline plasma and tumor tissue samples were collected from 198 patients with ALK-positive non-small-cell lung cancer from the registrational phase II study of lorlatinib.  We analyzed plasma DNA for ALK mutations using Guardant360.  Tumor tissue DNA was analyzed using an ALK mutation-focused next-generation sequencing assay.  Objective response rate, duration of response, and progression-free survival were evaluated according to ALK mutation status.  RESULTS:  Approximately one quarter of patients had ALK mutations detected by plasma or tissue genotyping.  In patients with crizotinib-resistant disease, the efficacy of lorlatinib was comparable among patients with and without ALK mutations using plasma or tissue genotyping.  In contrast, in patients who had failed 1 or more second-generation ALK TKIs, objective response rate was higher among patients with ALK mutations (62% v 32% [plasma]; 69% v 27% [tissue]).  Progression-free survival was similar in patients with and without ALK mutations on the basis of plasma genotyping (median, 7.3 months v 5.5 months; hazard ratio, 0.81) but significantly longer in patients with ALK mutations identified by tissue genotyping (median, 11.0 months v 5.4 months; hazard ratio, 0.47).  CONCLUSION:  In patients who have failed 1 or more second-generation ALK TKIs, lorlatinib shows greater efficacy in patients with ALK mutations compared with patients without ALK mutations.  Tumor genotyping for ALK mutations after failure of a second-generation TKI may identify patients who are more likely to derive clinical benefit from lorlatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSncho2_xqX8ULxIEhxUjPfW6udTcc2earWT-3HhDTwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbmt1yntg%253D%253D&md5=66ac31b67ead0ec2ab21309b875a081f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1200%2FJCO.18.02236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.18.02236%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DClancy%26aufirst%3DJ.%2BS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DSatouchi%26aufirst%3DM.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DKao%26aufirst%3DS.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DMartini%26aufirst%3DJ.-F.%26atitle%3DALK%2520Resistance%2520Mutations%2520and%2520Efficacy%2520of%2520Lorlatinib%2520in%2520Advanced%2520Anaplastic%2520Lymphoma%2520Kinase-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D1370%26epage%3D1379%26doi%3D10.1200%2FJCO.18.02236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbattista, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peltz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S.-H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Lorlatinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer: Results from a Global Phase 2 Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1654</span>– <span class="NLM_lpage">1667</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30649-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS1470-2045%2818%2930649-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30413378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFamt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1654-1667&author=B.+J.+Solomonauthor=B.+Besseauthor=T.+M.+Bauerauthor=E.+Felipauthor=R.+A.+Sooauthor=D.+R.+Camidgeauthor=R.+Chiariauthor=A.+Bearzauthor=C.-C.+Linauthor=S.+M.+Gadgeelauthor=G.+J.+Rielyauthor=E.+H.+Tanauthor=T.+Setoauthor=L.+P.+Jamesauthor=J.+S.+Clancyauthor=A.+Abbattistaauthor=J.-F.+Martiniauthor=J.+Chenauthor=G.+Peltzauthor=H.+Thurmauthor=S.-H.+I.+Ouauthor=A.+T.+Shaw&title=Lorlatinib+in+Patients+with+ALK-Positive+Non-Small-Cell+Lung+Cancer%3A+Results+from+a+Global+Phase+2+Study&doi=10.1016%2FS1470-2045%2818%2930649-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study</span></div><div class="casAuthors">Solomon, Benjamin J.; Besse, Benjamin; Bauer, Todd M.; Felip, Enriqueta; Soo, Ross A.; Camidge, D. Ross; Chiari, Rita; Bearz, Alessandra; Lin, Chia-Chi; Gadgeel, Shirish M.; Riely, Gregory J.; Tan, Eng Huat; Seto, Takashi; James, Leonard P.; Clancy, Jill S.; Abbattista, Antonello; Martini, Jean-Francois; Chen, Joseph; Peltz, Gerson; Thurm, Holger; Ignatius Ou, Sai-Hong; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1654-1667</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations.  In a phase 1 study, activity was seen in patients with ALK-pos. non-small-cell lung cancer, most of whom had CNS metastases and progression after ALK-directed therapy.  We aimed to analyze the overall and intracranial antitumor activity of lorlatinib in patients with ALK-pos., advanced non-small-cell lung cancer.  In this phase 2 study, patients with histol. or cytol. ALK-pos. or ROS1-pos., advanced, non-small-cell lung cancer, with or without CNS metastases, with an Eastern Cooperative Oncol. Group performance status of 0, 1, or 2, and adequate end-organ function were eligible.  Patients were enrolled into six different expansion cohorts (EXP1-6) on the basis of ALK and ROS1 status and previous therapy, and were given lorlatinib 100 mg orally once daily continuously in 21-day cycles.  The primary endpoint was overall and intracranial tumor response by independent central review, assessed in pooled subgroups of ALK-pos. patients.  Analyses of activity and safety were based on the safety anal. set (ie, all patients who received at least one dose of lorlatinib) as assessed by independent central review.  Patients with measurable CNS metastases at baseline by independent central review were included in the intracranial activity analyses.  In this report, we present lorlatinib activity data for the ALK-pos. patients (EXP1-5 only), and safety data for all treated patients (EXP1-6).  This study is ongoing and is registered with ClinicalTrials.gov, no. NCT01970865.  Between Sept 15, 2015, and Oct 3, 2016, 276 patients were enrolled: 30 who were ALK pos. and treatment naive (EXP1); 59 who were ALK pos. and received previous crizotinib without (n=27; EXP2) or with (n=32; EXP3A) previous chemotherapy; 28 who were ALK pos. and received one previous non-crizotinib ALK tyrosine kinase inhibitor, with or without chemotherapy (EXP3B); 112 who were ALK pos. with two (n=66; EXP4) or three (n=46; EXP5) previous ALK tyrosine kinase inhibitors with or without chemotherapy; and 47 who were ROS1 pos. with any previous treatment (EXP6).  One patient in EXP4 died before receiving lorlatinib and was excluded from the safety anal. set.  In treatment-naive patients (EXP1), an objective response was achieved in 27 (90·0%; 95% CI 73·5-97·9) of 30 patients.  Three patients in EXP1 had measurable baseline CNS lesions per independent central review, and objective intracranial responses were obsd. in two (66·7%; 95% CI 9·4-99·2).  In ALK-pos. patients with at least one previous ALK tyrosine kinase inhibitor (EXP2-5), objective responses were achieved in 93 (47·0%; 39·9-54·2) of 198 patients and objective intracranial response in those with measurable baseline CNS lesions in 51 (63·0%; 51·5-73·4) of 81 patients.  Objective response was achieved in 41 (69·5%; 95% CI 56·1-80·8) of 59 patients who had only received previous crizotinib (EXP2-3A), nine (32·1%; 15·9-52·4) of 28 patients with one previous non-crizotinib ALK tyrosine kinase inhibitor (EXP3B), and 43 (38·7%; 29·6-48·5) of 111 patients with two or more previous ALK tyrosine kinase inhibitors (EXP4-5).  Objective intracranial response was achieved in 20 (87·0%; 95% CI 66·4-97·2) of 23 patients with measurable baseline CNS lesions in EXP2-3A, five (55·6%; 21·2-86·3) of nine patients in EXP3B, and 26 (53·1%; 38·3-67·5) of 49 patients in EXP4-5.  The most common treatment-related adverse events across all patients were hypercholesterolemia (224 [81%] of 275 patients overall and 43 [16%] grade 3-4) and hypertriglyceridemia (166 [60%] overall and 43 [16%] grade 3-4).  Serious treatment-related adverse events occurred in 19 (7%) of 275 patients and seven patients (3%) permanently discontinued treatment because of treatment-related adverse events.  No treatment-related deaths were reported.  Consistent with its broad ALK mutational coverage and CNS penetration, lorlatinib showed substantial overall and intracranial activity both in treatment-naive patients with ALK-pos. non-small-cell lung cancer, and in those who had progressed on crizotinib, second-generation ALK tyrosine kinase inhibitors, or after up to three previous ALK tyrosine kinase inhibitors.  Thus, lorlatinib could represent an effective treatment option for patients with ALK-pos. non-small-cell lung cancer in first-line or subsequent therapy.Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13AyVlJJCKrVg90H21EOLACvtfcHk0lgPtz-h-xnA7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFamt7zF&md5=0d47716d988ee784448e5cfc599cdef9</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930649-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930649-1%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DChiari%26aufirst%3DR.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DJames%26aufirst%3DL.%2BP.%26aulast%3DClancy%26aufirst%3DJ.%2BS.%26aulast%3DAbbattista%26aufirst%3DA.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DPeltz%26aufirst%3DG.%26aulast%3DThurm%26aufirst%3DH.%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DLorlatinib%2520in%2520Patients%2520with%2520ALK-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%253A%2520Results%2520from%2520a%2520Global%2520Phase%25202%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D1654%26epage%3D1667%26doi%3D10.1016%2FS1470-2045%2818%2930649-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugger, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makowski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colon-Cruz, R.</span></span> <span> </span><span class="NLM_article-title">Developing an Asymmetric Transfer Hydrogenation Process for (S)-5-Fluoro-3-Methylisobenzofuran-1(3h)-One, a Key Intermediate to Lorlatinib</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1340</span>– <span class="NLM_lpage">1348</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00187</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00187" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1340-1348&author=S.+Duanauthor=B.+Liauthor=R.+W.+Duggerauthor=B.+Conwayauthor=R.+Kumarauthor=C.+Martinezauthor=T.+Makowskiauthor=R.+Pearsonauthor=M.+Olivierauthor=R.+Colon-Cruz&title=Developing+an+Asymmetric+Transfer+Hydrogenation+Process+for+%28S%29-5-Fluoro-3-Methylisobenzofuran-1%283h%29-One%2C+a+Key+Intermediate+to+Lorlatinib&doi=10.1021%2Facs.oprd.7b00187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Developing an Asymmetric Transfer Hydrogenation Process for (S)-5-Fluoro-3-methylisobenzofuran-1(3H)-one, a Key Intermediate to Lorlatinib</span></div><div class="casAuthors">Duan, Shengquan; Li, Bryan; Dugger, Robert W.; Conway, Brian; Kumar, Rajesh; Martinez, Carlos; Makowski, Teresa; Pearson, Robert; Olivier, Mark; Colon-Cruz, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1340-1348</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthesis of (S)-5-fluoro-3-methylisobenzofuran-1(3H)-one (I), a key intermediate to lorlatinib, is described.  A few synthetic methodologies, i.e., boron redn., enzymic redn., asym. hydrogenation, and asym. transfer hydrogenation, were evaluated for the chiral redn. of the substituted acetophenone intermediate.  A manufg. process, on the basis of the asym. transfer hydrogenation, was developed.  This process was successfully scaled up to prep. 400 kg of I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUZVVRYmmYYrVg90H21EOLACvtfcHk0lgPtz-h-xnA7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurrF&md5=ffd07ec1715c2f1ede2708c2c67d2f0f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00187%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DDugger%26aufirst%3DR.%2BW.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DMartinez%26aufirst%3DC.%26aulast%3DMakowski%26aufirst%3DT.%26aulast%3DPearson%26aufirst%3DR.%26aulast%3DOlivier%26aufirst%3DM.%26aulast%3DColon-Cruz%26aufirst%3DR.%26atitle%3DDeveloping%2520an%2520Asymmetric%2520Transfer%2520Hydrogenation%2520Process%2520for%2520%2528S%2529-5-Fluoro-3-Methylisobenzofuran-1%25283h%2529-One%252C%2520a%2520Key%2520Intermediate%2520to%2520Lorlatinib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D1340%26epage%3D1348%26doi%3D10.1021%2Facs.oprd.7b00187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nematalla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raggon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, J.</span></span> <span> </span><span class="NLM_article-title">Exploratory Process Development of Lorlatinib</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.8b00210</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.8b00210" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=1289-1293&author=B.+Liauthor=R.+W.+Barnhartauthor=J.+E.+Hoffmanauthor=A.+Nematallaauthor=J.+Raggonauthor=P.+Richardsonauthor=N.+Sachauthor=J.+Weaver&title=Exploratory+Process+Development+of+Lorlatinib&doi=10.1021%2Facs.oprd.8b00210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Exploratory Process Development of Lorlatinib</span></div><div class="casAuthors">Li, Bryan; Barnhart, Richard W.; Hoffman, Jacqui E.; Nematalla, Asaad; Raggon, Jeffrey; Richardson, Paul; Sach, Neal; Weaver, John</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1289-1293</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The original synthesis of lorlatinib (I) was applied and improved in the first GMP campaign.  In this approach, a slow addn. of the boronate ester was crit. in suppressing the formation of a homocoupled impurity in the Suzuki-Miyaura coupling, and the chemoselective hydrolysis of Me ester was accomplished by potassium trimethylsilanoate.  The synthesis was completed with macrocyclic amidation followed by deprotection of the Boc groups.  A thorough process safety evaluation of HATU enabled its use as the coupling reagent for the macrocyclic amidation, which improved the yield and eliminated the only chromatog. operation in the synthetic sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRVJZSwiHBgrVg90H21EOLACvtfcHk0lhOaozqCcTchg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVWrsLfI&md5=4bb70a5071d2a8cb45661a3d223fb96f</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.8b00210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.8b00210%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DBarnhart%26aufirst%3DR.%2BW.%26aulast%3DHoffman%26aufirst%3DJ.%2BE.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DRaggon%26aufirst%3DJ.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DWeaver%26aufirst%3DJ.%26atitle%3DExploratory%2520Process%2520Development%2520of%2520Lorlatinib%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2018%26volume%3D22%26spage%3D1289%26epage%3D1293%26doi%3D10.1021%2Facs.oprd.8b00210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bharate, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, R. A.</span></span> <span> </span><span class="NLM_article-title">Kinase Inhibitors of Marine Origin</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">6761</span>– <span class="NLM_lpage">6815</span>, <span class="refDoi"> DOI: 10.1021/cr300410v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr300410v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVGiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2013&pages=6761-6815&author=S.+B.+Bharateauthor=S.+D.+Sawantauthor=P.+P.+Singhauthor=R.+A.+Vishwakarma&title=Kinase+Inhibitors+of+Marine+Origin&doi=10.1021%2Fcr300410v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178aR"><div class="casContent"><span class="casTitleNuber">178a</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitors of Marine Origin</span></div><div class="casAuthors">Bharate, Sandip B.; Sawant, Sanghapal D.; Singh, Parvinder Pal; Vishwakarma, Ram A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6761-6815</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The primary aim of this review is to discuss and critically analyze marine-derived small-mol. inhibitors of protein and lipid kinases, with an emphasis on medicinal chem., lead optimization, patent literature, preclin. profiling and clin. development (354 compds. are described and 717 refs. are provided).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraZAF-t78hZrVg90H21EOLACvtfcHk0lhOaozqCcTchg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVGiur8%253D&md5=9ab17c0a26a7144ec729aab8383a7436</span></div><a href="/servlet/linkout?suffix=cit178a&amp;dbid=16384&amp;doi=10.1021%2Fcr300410v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr300410v%26sid%3Dliteratum%253Aachs%26aulast%3DBharate%26aufirst%3DS.%2BB.%26aulast%3DSawant%26aufirst%3DS.%2BD.%26aulast%3DSingh%26aufirst%3DP.%2BP.%26aulast%3DVishwakarma%26aufirst%3DR.%2BA.%26atitle%3DKinase%2520Inhibitors%2520of%2520Marine%2520Origin%26jtitle%3DChem.%2520Rev.%26date%3D2013%26volume%3D113%26spage%3D6761%26epage%3D6815%26doi%3D10.1021%2Fcr300410v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit178b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Rinehart, K. L.</span>; <span class="NLM_string-name">Lithgow-Bertelloni, A. M.</span></span> <span> </span><span class="NLM_article-title">Dehydrodidemnin B</span>. <span class="NLM_patent">WO9104985A1</span>, <span class="NLM_year">1991</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1991&author=K.+L.+Rinehart&author=A.+M.+Lithgow-Bertelloni&title=Dehydrodidemnin+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRinehart%26aufirst%3DK.%2BL.%26atitle%3DDehydrodidemnin%2520B%26date%3D1991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urdiales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morata, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Castro, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Jiménez, F.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative Effect of Dehydrodidemnin B (DDB), a Depsipeptide Isolated from Mediterranean Tunicates</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/0304-3835(96)04151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2F0304-3835%2896%2904151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=8603376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK28Xhslejurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1996&pages=31-37&author=J.+Urdialesauthor=P.+Morataauthor=I.+N.+De+Castroauthor=F.+S%C3%A1nchez-Jim%C3%A9nez&title=Antiproliferative+Effect+of+Dehydrodidemnin+B+%28DDB%29%2C+a+Depsipeptide+Isolated+from+Mediterranean+Tunicates&doi=10.1016%2F0304-3835%2896%2904151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates</span></div><div class="casAuthors">Urdiales, Jose L.; Morata, Pilar; Nunez De Castro, Ignacio; Sanchez-Jimenez, Francisca</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">31-7</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The biol. effects of dehydrodidemnin B (DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB).  Daily administration of DB or DDB (2.5 μg/mouse) almost duplicated the animal life-span and total no. of tumor cells decreased by 70-90%.  Results suggest a major effect of DDB when administered in the lag phase of growth.  DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by the DDB-treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfkvs5GBkoS7Vg90H21EOLACvtfcHk0lhOaozqCcTchg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xhslejurc%253D&md5=e8b33a94cc19d5036368d2ead4ff8556</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2F0304-3835%2896%2904151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3835%252896%252904151-1%26sid%3Dliteratum%253Aachs%26aulast%3DUrdiales%26aufirst%3DJ.%26aulast%3DMorata%26aufirst%3DP.%26aulast%3DDe%2BCastro%26aufirst%3DI.%2BN.%26aulast%3DS%25C3%25A1nchez-Jim%25C3%25A9nez%26aufirst%3DF.%26atitle%3DAntiproliferative%2520Effect%2520of%2520Dehydrodidemnin%2520B%2520%2528DDB%2529%252C%2520a%2520Depsipeptide%2520Isolated%2520from%2520Mediterranean%2520Tunicates%26jtitle%3DCancer%2520Lett.%26date%3D1996%26volume%3D102%26spage%3D31%26epage%3D37%26doi%3D10.1016%2F0304-3835%2896%2904151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Losada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Alonso, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Murcia, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Leal, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domínguez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gago, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galmarini, C. M.</span></span> <span> </span><span class="NLM_article-title">Translation Elongation Factor eEF1A2 Is a Novel Anticancer Target for the Marine Natural Product Plitidepsin</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">35100</span>, <span class="refDoi"> DOI: 10.1038/srep35100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fsrep35100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27713531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Cgtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=35100&author=A.+Losadaauthor=M.+J.+Mu%C3%B1oz-Alonsoauthor=C.+Garc%C3%ADaauthor=P.+A.+S%C3%A1nchez-Murciaauthor=J.+F.+Mart%C3%ADnez-Lealauthor=J.+M.+Dom%C3%ADnguezauthor=M.+P.+Lilloauthor=F.+Gagoauthor=C.+M.+Galmarini&title=Translation+Elongation+Factor+eEF1A2+Is+a+Novel+Anticancer+Target+for+the+Marine+Natural+Product+Plitidepsin&doi=10.1038%2Fsrep35100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin</span></div><div class="casAuthors">Losada, Alejandro; Munoz-Alonso, Maria Jose; Garcia, Carolina; Sanchez-Murcia, Pedro A.; Martinez-Leal, Juan Fernando; Dominguez, Juan Manuel; Lillo, M. Pilar; Gago, Federico; Galmarini, Carlos M.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35100</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">EEF1A2 is one of the isoforms of the alpha subunit of the eukaryotic Elongation Factor 1.  It is overexpressed in human tumors and is endowed with oncogenic properties, favoring tumor cell proliferation while inhibiting apoptosis.  We demonstrate that plitidepsin, an antitumor agent of marine origin that has successfully completed a phase-III clin. trial for multiple myeloma, exerts its antitumor activity by targeting eEF1A2.  The drug interacts with eEF1A2 with a KD of 80 nM and a target residence time of circa 9 min.  This protein was also identified as capable of binding [14C]-plitidepsin in a cell lysate from K-562 tumor cells.  A mol. modeling approach was used to identify a favorable binding site for plitidepsin at the interface between domains 1 and 2 of eEF1A2 in the GTP conformation.  Three tumor cell lines selected for at least 100-fold more resistance to plitidepsin than their resp. parental cells showed reduced levels of eEF1A2 protein.  Ectopic expression of eEF1A2 in resistant cells restored the sensitivity to plitidepsin.  FLIM-phasor FRET expts. demonstrated that plitidepsin localizes in tumor cells sufficiently close to eEF1A2 as to suggest the formation of drug-protein complexes in living cells.  Altogether, our results strongly suggest that eEF1A2 is the primary target of plitidepsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodS9RXtf_pNLVg90H21EOLACvtfcHk0li-rzRKNY9x9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Cgtb7M&md5=ed7bdf2fb20ed615dd71fab64bdce05c</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fsrep35100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep35100%26sid%3Dliteratum%253Aachs%26aulast%3DLosada%26aufirst%3DA.%26aulast%3DMu%25C3%25B1oz-Alonso%26aufirst%3DM.%2BJ.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DC.%26aulast%3DS%25C3%25A1nchez-Murcia%26aufirst%3DP.%2BA.%26aulast%3DMart%25C3%25ADnez-Leal%26aufirst%3DJ.%2BF.%26aulast%3DDom%25C3%25ADnguez%26aufirst%3DJ.%2BM.%26aulast%3DLillo%26aufirst%3DM.%2BP.%26aulast%3DGago%26aufirst%3DF.%26aulast%3DGalmarini%26aufirst%3DC.%2BM.%26atitle%3DTranslation%2520Elongation%2520Factor%2520eEF1A2%2520Is%2520a%2520Novel%2520Anticancer%2520Target%2520for%2520the%2520Marine%2520Natural%2520Product%2520Plitidepsin%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D35100%26doi%3D10.1038%2Fsrep35100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greil, R.</span></span> <span> </span><span class="NLM_article-title">Plitidepsin: A Potential New Treatment for Relapsed/Refractory Multiple Myeloma</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.2217/fon-2018-0492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.2217%2Ffon-2018-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30111169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=109-120&author=M.+Leischauthor=A.+Egleauthor=R.+Greil&title=Plitidepsin%3A+A+Potential+New+Treatment+for+Relapsed%2FRefractory+Multiple+Myeloma&doi=10.2217%2Ffon-2018-0492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma</span></div><div class="casAuthors">Leisch, Michael; Egle, Alexander; Greil, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-120</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Plitidepsin is a marine-derived anticancer compd. isolated from the Mediterranean tunicate Applidium albicans.  It exerts pleiotropic effects on cancer cells, most likely by binding to the eukaryotic translation eEF1A2.  This ultimately leads to cell-cycle arrest, growth inhibition and induction of apoptosis via multiple pathway alterations.  Recently, a Phase III randomized trial in patients with relapsed/refractory multiple myeloma reported outcomes for plitidepsin plus dexamethasone compared with dexamethasone.  Median progression-free survival was 3.8 mo in the plitidepsin arm and 1.9 mo in the dexamethasone arm (HR: 0.611; p = 0.0048).  Here, we review preclin. data regarding plitidepsins mechanism of action, give an overview of clin. trial results across different tumor types as well as the latest results in multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreQ2wJUJXILbVg90H21EOLACvtfcHk0li-rzRKNY9x9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGis7k%253D&md5=011f4da81faa52d1a59279093753f05d</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.2217%2Ffon-2018-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2018-0492%26sid%3Dliteratum%253Aachs%26aulast%3DLeisch%26aufirst%3DM.%26aulast%3DEgle%26aufirst%3DA.%26aulast%3DGreil%26aufirst%3DR.%26atitle%3DPlitidepsin%253A%2520A%2520Potential%2520New%2520Treatment%2520for%2520Relapsed%252FRefractory%2520Multiple%2520Myeloma%26jtitle%3DFuture%2520Oncol.%26date%3D2019%26volume%3D15%26spage%3D109%26epage%3D120%26doi%3D10.2217%2Ffon-2018-0492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, I.</span>; <span class="NLM_string-name">Polanco, C.</span>; <span class="NLM_string-name">Cuevas, F.</span>; <span class="NLM_string-name">Mandez, P.</span>; <span class="NLM_string-name">Cuevas, C.</span>; <span class="NLM_string-name">Gallego, P.</span>; <span class="NLM_string-name">Munt, S.</span>; <span class="NLM_string-name">Manzanares, I.</span></span> <span> </span><span class="NLM_article-title">Synthetic Methods for Aplidine and New Antitumoral Derivatives, Methods of Making and Using Them</span>. <span class="NLM_patent">WO2002002596A2</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=I.+Rodriguez&author=C.+Polanco&author=F.+Cuevas&author=P.+Mandez&author=C.+Cuevas&author=P.+Gallego&author=S.+Munt&author=I.+Manzanares&title=Synthetic+Methods+for+Aplidine+and+New+Antitumoral+Derivatives%2C+Methods+of+Making+and+Using+Them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DI.%26atitle%3DSynthetic%2520Methods%2520for%2520Aplidine%2520and%2520New%2520Antitumoral%2520Derivatives%252C%2520Methods%2520of%2520Making%2520and%2520Using%2520Them%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Pyrotinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1751</span>– <span class="NLM_lpage">1755</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-0997-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-0997-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30341682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cvhtlyjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1751-1755&author=H.+A.+Blair&title=Pyrotinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-0997-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrotinib: First Global Approval</span></div><div class="casAuthors">Blair Hannah A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1751-1755</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours.  Based on positive results in a phase II trial, the drug recently received conditional approval in China for use in combination with capecitabine for the treatment of HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy.  This article summarizes the milestones in the development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSojcxi5hdr-Zw7prLlxLOzfW6udTcc2eZQUUD1TepW3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvhtlyjtQ%253D%253D&md5=89ed6376fc6a528100a00d18737d37ec</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-0997-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-0997-0%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DPyrotinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1751%26epage%3D1755%26doi%3D10.1007%2Fs40265-018-0997-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Pyrotinib: A Novel Irreversible EGFR/HER2 Dual Tyrosine Kinase Inhibitor with Favorable Safety Profiles for the Treatment of Breast Cancer</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.01.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.ejps.2017.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28115222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1Wqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2017&pages=51-61&author=X.+Liauthor=C.+Yangauthor=H.+Wanauthor=G.+Zhangauthor=J.+Fengauthor=L.+Zhangauthor=X.+Chenauthor=D.+Zhongauthor=L.+Louauthor=W.+Taoauthor=L.+Zhang&title=Discovery+and+Development+of+Pyrotinib%3A+A+Novel+Irreversible+EGFR%2FHER2+Dual+Tyrosine+Kinase+Inhibitor+with+Favorable+Safety+Profiles+for+the+Treatment+of+Breast+Cancer&doi=10.1016%2Fj.ejps.2017.01.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer</span></div><div class="casAuthors">Li, Xin; Yang, Changyong; Wan, Hong; Zhang, Ge; Feng, Jun; Zhang, Lei; Chen, Xiaoyan; Zhong, Dafang; Lou, Liguang; Tao, Weikang; Zhang, Lianshan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-61</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery and development of a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor SHR1258 (pyrotinib) for the treatment of HER2-postive breast cancer is presented.  The structure-activity relationship of lead series and their pharmacokinetic properties were evaluated to identify the potential candidates for further in vivo efficacy studies and preclin. safety assessments.  Metabolic pathway and drug-drug interaction were also investigated in preclin. settings.  In particular, major metabolites in human and animal species were assessed with regard to potential toxicity or off-target side effects.  Overall, the potent and selective EGFR/HER2 dual inhibitor, pyrotinib, displayed robust anti-tumor effects on HER2-overexpressing xenograft models and sufficiently safety windows in animals as well as favorable pharmacokinetic properties in human, which substantially ensures current clin. development.  Finally, recent advances of pyrotinib in clin. studies are highlighted with very encouraging outcomes in patients with HER2-postive advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdbJnY0jwOjLVg90H21EOLACvtfcHk0liKbdpQxz_WhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1Wqsrw%253D&md5=12f13882a32cfb56959f58deaadadce8</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DD.%26aulast%3DLou%26aufirst%3DL.%26aulast%3DTao%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Pyrotinib%253A%2520A%2520Novel%2520Irreversible%2520EGFR%252FHER2%2520Dual%2520Tyrosine%2520Kinase%2520Inhibitor%2520with%2520Favorable%2520Safety%2520Profiles%2520for%2520the%2520Treatment%2520of%2520Breast%2520Cancer%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D110%26spage%3D51%26epage%3D61%26doi%3D10.1016%2Fj.ejps.2017.01.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chew, W.</span>; <span class="NLM_string-name">Cheal, G. K.</span>; <span class="NLM_string-name">Lunetta, J. F.</span></span> <span> </span><span class="NLM_article-title">Methods of Synthesizing Substituted 3-Cyanoquinolines and Intermediates Thereof</span>. <span class="NLM_patent">WO2006127207A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=W.+Chew&author=G.+K.+Cheal&author=J.+F.+Lunetta&title=Methods+of+Synthesizing+Substituted+3-Cyanoquinolines+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChew%26aufirst%3DW.%26atitle%3DMethods%2520of%2520Synthesizing%2520Substituted%25203-Cyanoquinolines%2520and%2520Intermediates%2520Thereof%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit185b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chew, W.</span>; <span class="NLM_string-name">Papamichelakis, M.</span></span> <span> </span><span class="NLM_article-title">Methods of Preparing 3-Cyano-Quinolines and Intermediates Made Thereby</span>. <span class="NLM_patent">WO2006127205A2</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=W.+Chew&author=M.+Papamichelakis&title=Methods+of+Preparing+3-Cyano-Quinolines+and+Intermediates+Made+Thereby"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChew%26aufirst%3DW.%26atitle%3DMethods%2520of%2520Preparing%25203-Cyano-Quinolines%2520and%2520Intermediates%2520Made%2520Thereby%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span>; <span class="NLM_string-name">Zhang, Q.</span>; <span class="NLM_string-name">Cao, Y.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Tyrosine Kinase Inhibitor and Derivative Thereof</span>. <span class="NLM_patent">WO2017186140A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Wu&author=Q.+Zhang&author=Y.+Cao&title=Method+for+Preparing+Tyrosine+Kinase+Inhibitor+and+Derivative+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26atitle%3DMethod%2520for%2520Preparing%2520Tyrosine%2520Kinase%2520Inhibitor%2520and%2520Derivative%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutically Acceptable Salt of (E)-N-[4-[[3-Chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide, Preparation Method Therefor, and Medical Use Thereof</span>. <span class="NLM_patent">WO2012122865A2</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=X.+Li&author=B.+Wang&title=Pharmaceutically+Acceptable+Salt+of+%28E%29-N-%5B4-%5B%5B3-Chloro-4-%282-pyridylmethoxy%29phenyl%5Damino%5D-3-cyano-7-ethoxy-6-quinolyl%5D-3-%5B%282r%29-1-methylpyrrolidin-2-yl%5Dprop-2-enamide%2C+Preparation+Method+Therefor%2C+and+Medical+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26atitle%3DPharmaceutically%2520Acceptable%2520Salt%2520of%2520%2528E%2529-N-%255B4-%255B%255B3-Chloro-4-%25282-pyridylmethoxy%2529phenyl%255Damino%255D-3-cyano-7-ethoxy-6-quinolyl%255D-3-%255B%25282r%2529-1-methylpyrrolidin-2-yl%255Dprop-2-enamide%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Medical%2520Use%2520Thereof%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Talazoparib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1939</span>– <span class="NLM_lpage">1946</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1026-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1026-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30506138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3crnslGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1939-1946&author=S.+M.+Hoy&title=Talazoparib%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1026-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Talazoparib: First Global Approval</span></div><div class="casAuthors">Hoy Sheridan M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1939-1946</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Talazoparib (TALZENNA®) is an oral inhibitor of the polyadenosine 5'-diphosphoribose polymerase (PARP) enzymes, which play a critical role in repairing DNA single-strand breaks.  It has been developed by Pfizer and was recently approved in the USA for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer (as detected by a US FDA-approved assay).  A regulatory assessment for talazoparib in this patient population is underway in the EU, with talazoparib also undergoing development for use in metastatic castration-resistant prostate cancer and various solid tumours, and as neoadjuvant therapy in early triple negative breast cancer.  This article summarizes the milestones in the development of talazoparib leading to its first approval for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative, locally advanced or metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA4VT-ypttQZNiNltV31zlfW6udTcc2eZWzT3giI_kHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnslGgsg%253D%253D&md5=e5799d67f592d4e449e18f09fc727a4b</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1026-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1026-z%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DTalazoparib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1939%26epage%3D1946%26doi%3D10.1007%2Fs40265-018-1026-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sulai, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. R.</span></span> <span> </span><span class="NLM_article-title">Development of Poly(ADP-ribose) Polymerase Inhibitors in the Treatment of BRCA-Mutated Breast Cancer</span>. <i>Clin. Adv. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30067621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ktFSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=491-501&author=N.+H.+Sulaiauthor=A.+R.+Tan&title=Development+of+Poly%28ADP-ribose%29+Polymerase+Inhibitors+in+the+Treatment+of+BRCA-Mutated+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer</span></div><div class="casAuthors">Sulai Nanna H; Tan Antoinette R</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">491-501</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">The poly(ADP-ribose) polymerases (PARPs) 1 and 2 are DNA-binding enzymes that play a critical role in the repair of DNA.  The use of PARP inhibitors is a rational therapeutic approach to selectively killing a subset of cancer cells with deficiencies in DNA repair pathways.  PARP inhibitors that have undergone clinical investigation in the treatment of breast cancer include olaparib, talazoparib, veliparib, niraparib, and rucaparib.  The antitumor activity of PARP inhibitors as single agents has been demonstrated in BRCA-associated metastatic breast cancer.  In 2018, olaparib became the first oral PARP inhibitor to receive approval in the United States for the treatment of advanced BRCA-mutated breast cancer, an approval that represents a major change in the treatment paradigm for this subtype of breast cancer.  PARP inhibition plus chemotherapy and PARP inhibition plus immunotherapy are novel approaches undergoing extensive study in breast cancer.  This review focuses on the clinical development of PARP inhibitors administered singly or in combination with other agents for early-stage and metastatic BRCA-mutated breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRNVLPSo_8ek0EgZCMqtRBifW6udTcc2eZWzT3giI_kHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ktFSquw%253D%253D&md5=93140138e625e5aba394ab0e9b2b24ad</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSulai%26aufirst%3DN.%2BH.%26aulast%3DTan%26aufirst%3DA.%2BR.%26atitle%3DDevelopment%2520of%2520Poly%2528ADP-ribose%2529%2520Polymerase%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520BRCA-Mutated%2520Breast%2520Cancer%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D16%26spage%3D491%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">5588</span>– <span class="NLM_lpage">5599</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-2753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1158%2F0008-5472.CAN-12-2753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=23118055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=5588-5599&author=J.+Muraiauthor=S.-y.+N.+Huangauthor=B.+B.+Dasauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+H.+Doroshowauthor=J.+Jiauthor=S.+Takedaauthor=Y.+Pommier&title=Trapping+of+PARP1+and+PARP2+by+Clinical+PARP+Inhibitors&doi=10.1158%2F0008-5472.CAN-12-2753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190aR"><div class="casContent"><span class="casTitleNuber">190a</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-yin N.; Das, Benu Brata; Renaud, Amelie; Zhang, Yiping; Doroshow, James H.; Ji, Jiuping; Takeda, Shunichi; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5588-5599</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These findings indicate that PARP inhibitors in clin. trials not only block catalytic function but also trap PARP enzymes on DNA, illuminating the mechanistic basis for their cytotoxic activity in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW3m55HXn9ObVg90H21EOLACvtfcHk0lhvnQrMLD96bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE&md5=81c590b6a4fbb9efc9c64f7de5e89524</span></div><a href="/servlet/linkout?suffix=cit190a&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-2753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-2753%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.-y.%2BN.%26aulast%3DDas%26aufirst%3DB.%2BB.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DTrapping%2520of%2520PARP1%2520and%2520PARP2%2520by%2520Clinical%2520PARP%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D5588%26epage%3D5599%26doi%3D10.1158%2F0008-5472.CAN-12-2753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit190b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1158%2F1535-7163.MCT-13-0803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=24356813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=433-443&author=J.+Muraiauthor=S.-Y.+N.+Huangauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+Jiauthor=S.+Takedaauthor=J.+Morrisauthor=B.+A.+Teicherauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Stereospecific+PARP+Trapping+by+BMN+673+and+Comparison+with+Olaparib+and+Rucaparib&doi=10.1158%2F1535-7163.MCT-13-0803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190bR"><div class="casContent"><span class="casTitleNuber">190b</span><div class="casTitle"><span class="NLM_cas:atitle">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-Yin N.; Renaud, Amelie; Zhang, Yiping; Ji, Jiuping; Takeda, Shunichi; Morris, Joel; Teicher, Beverly; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks.  We recently reported that several PARP inhibitors have an addnl. cytotoxic mechanism by trapping PARP-DNA complexes, and that both olaparib and niraparib act as PARP poisons at pharmacol. concns.  Therefore, we have proposed that PARP inhibitors should be evaluated based both on catalytic PARP inhibition and PARP-DNA trapping.  Here, we evaluated the novel PARP inhibitor, BMN 673, and compared its effects on PARP1 and PARP2 with two other clin. PARP inhibitors, olaparib and rucaparib, using biochem. and cellular assays in genetically modified chicken DT40 and human cancer cell lines.  Although BMN 673, olaparib, and rucaparib are comparable at inhibiting PARP catalytic activity, BMN 673 is ∼100-fold more potent at trapping PARP-DNA complexes and more cytotoxic as single agent than olaparib, whereas olaparib and rucaparib show similar potencies in trapping PARP-DNA complexes.  The high level of resistance of PARP1/2 knockout cells to BMN 673 demonstrates the selectivity of BMN 673 for PARP1/2.  Moreover, we show that BMN 673 acts by stereospecific binding to PARP1 as its enantiomer, LT674, is several orders of magnitude less efficient.  BMN 673 is also approx. 100-fold more cytotoxic than olaparib and rucaparib in combination with the DNA alkylating agents Me methane sulfonate (MMS) and temozolomide.  Our study demonstrates that BMN 673 is the most potent clin. PARP inhibitor tested to date with the highest efficiency at trapping PARP-DNA complexes.  Mol Cancer Ther; 13(2); 433-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8p5YTwAneh7Vg90H21EOLACvtfcHk0lj60Yxy3m9DEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D&md5=513c544d1cb5c2203e7696af76201afd</span></div><a href="/servlet/linkout?suffix=cit190b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0803%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.-Y.%2BN.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DStereospecific%2520PARP%2520Trapping%2520by%2520BMN%2520673%2520and%2520Comparison%2520with%2520Olaparib%2520and%2520Rucaparib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D433%26epage%3D443%26doi%3D10.1158%2F1535-7163.MCT-13-0803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyagi-Scharber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, L. E.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of (8s, 9r)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1 H-1, 2, 4-Triazol-5-Yl)-2, 7, 8, 9-Tetrahydro-3 H-Pyrido [4, 3, 2-De] Phthalazin-3-One (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly (ADP-Ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01498</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01498" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=335-357&author=B.+Wangauthor=D.+Chuauthor=Y.+Fengauthor=Y.+Shenauthor=M.+Aoyagi-Scharberauthor=L.+E.+Post&title=Discovery+and+Characterization+of+%288s%2C+9r%29-5-Fluoro-8-%284-Fluorophenyl%29-9-%281-Methyl-1+H-1%2C+2%2C+4-Triazol-5-Yl%29-2%2C+7%2C+8%2C+9-Tetrahydro-3+H-Pyrido+%5B4%2C+3%2C+2-De%5D+Phthalazin-3-One+%28BMN+673%2C+Talazoparib%29%2C+a+Novel%2C+Highly+Potent%2C+and+Orally+Efficacious+Poly+%28ADP-Ribose%29+Polymerase-1%2F2+Inhibitor%2C+as+an+Anticancer+Agent&doi=10.1021%2Facs.jmedchem.5b01498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent</span></div><div class="casAuthors">Wang, Bing; Chu, Daniel; Feng, Ying; Shen, Yuqiao; Aoyagi-Scharber, Mika; Post, Leonard E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">335-357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors.  Lead optimization led to the identification of (I) (talazoparib; BMN 673; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one).  The novel stereospecific dual chiral-center-embedded structure of this compd. has enabled extensive and unique binding interactions with PARP1/2 proteins. I demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity with Ki = 1.2 and 0.87 nM, resp.  It inhibits PARP-mediated PARylation in a whole-cell assay with an EC50 of 2.51 nM and prevents proliferation of cancer cells carrying mutant BRCA1/2, with EC50 = 0.3 nM (MX-1) and 5 nM (Capan-1), resp. I is orally available, displaying favorable pharmacokinetic (PK) properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as a single-agent or in combination with chemotherapy agents such as temozolomide and cisplatin. I has completed phase 1 clin. trial and is currently being studied in phase 2 and 3 clin. trials for the treatment of locally advanced and/or metastatic breast cancer with germline BRCA1/2 deleterious mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBpTb90_rQhLVg90H21EOLACvtfcHk0lj60Yxy3m9DEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rN&md5=443bfeb7aeda6c6522d41ab52793931a</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01498%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DPost%26aufirst%3DL.%2BE.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520%25288s%252C%25209r%2529-5-Fluoro-8-%25284-Fluorophenyl%2529-9-%25281-Methyl-1%2520H-1%252C%25202%252C%25204-Triazol-5-Yl%2529-2%252C%25207%252C%25208%252C%25209-Tetrahydro-3%2520H-Pyrido%2520%255B4%252C%25203%252C%25202-De%255D%2520Phthalazin-3-One%2520%2528BMN%2520673%252C%2520Talazoparib%2529%252C%2520a%2520Novel%252C%2520Highly%2520Potent%252C%2520and%2520Orally%2520Efficacious%2520Poly%2520%2528ADP-Ribose%2529%2520Polymerase-1%252F2%2520Inhibitor%252C%2520as%2520an%2520Anticancer%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D335%26epage%3D357%26doi%3D10.1021%2Facs.jmedchem.5b01498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span>; <span class="NLM_string-name">Chu, D.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Jiang, Q.</span>; <span class="NLM_string-name">Lu, L.</span></span> <span> </span><span class="NLM_article-title">Processes of Synthesizing Dihydropyridophthalazinone Derivatives</span>. <span class="NLM_patent">WO2011097602A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=B.+Wang&author=D.+Chu&author=Y.+Liu&author=Q.+Jiang&author=L.+Lu&title=Processes+of+Synthesizing+Dihydropyridophthalazinone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26atitle%3DProcesses%2520of%2520Synthesizing%2520Dihydropyridophthalazinone%2520Derivatives%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit192b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span>; <span class="NLM_string-name">Chu, D.</span>; <span class="NLM_string-name">Liu, Y.</span>; <span class="NLM_string-name">Peng, S.</span></span> <span> </span><span class="NLM_article-title">Crystalline (8s,9r)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one Tosylate Salt</span>. <span class="NLM_patent">WO2012054698A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=B.+Wang&author=D.+Chu&author=Y.+Liu&author=S.+Peng&title=Crystalline+%288s%2C9r%29-5-Fluoro-8-%284-fluorophenyl%29-9-%281-methyl-1h-1%2C2%2C4-triazol-5-yl%29-8%2C9-dihydro-2h-pyrido%5B4%2C3%2C2-de%5Dphthalazin-3%287h%29-one+Tosylate+Salt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26atitle%3DCrystalline%2520%25288s%252C9r%2529-5-Fluoro-8-%25284-fluorophenyl%2529-9-%25281-methyl-1h-1%252C2%252C4-triazol-5-yl%2529-8%252C9-dihydro-2h-pyrido%255B4%252C3%252C2-de%255Dphthalazin-3%25287h%2529-one%2520Tosylate%2520Salt%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit192c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span>; <span class="NLM_string-name">Gutierrez, A. A.</span>; <span class="NLM_string-name">Shen, Y.</span>; <span class="NLM_string-name">Wang, E. W.</span>; <span class="NLM_string-name">Okhamafe, A. O.</span>; <span class="NLM_string-name">Price, C. P.</span>; <span class="NLM_string-name">Chou, T.</span></span> <span> </span><span class="NLM_article-title">Dihydropyridophthalazinone Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) for the Treatment of Multiple Myeloma</span>. <span class="NLM_patent">WO2013028495A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Feng&author=A.+A.+Gutierrez&author=Y.+Shen&author=E.+W.+Wang&author=A.+O.+Okhamafe&author=C.+P.+Price&author=T.+Chou&title=Dihydropyridophthalazinone+Inhibitors+of+Poly+%28Adp-Ribose%29+Polymerase+%28Parp%29+for+the+Treatment+of+Multiple+Myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%26atitle%3DDihydropyridophthalazinone%2520Inhibitors%2520of%2520Poly%2520%2528Adp-Ribose%2529%2520Polymerase%2520%2528Parp%2529%2520for%2520the%2520Treatment%2520of%2520Multiple%2520Myeloma%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit192d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M.</span></span> <span> </span><span class="NLM_article-title">Triazole Intermediates Useful in the Synthesis of Protected N-Alkyltriazolecarbaldehydes</span>. <span class="NLM_patent">WO2015069851A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+Henderson&title=Triazole+Intermediates+Useful+in+the+Synthesis+of+Protected+N-Alkyltriazolecarbaldehydes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DM.%26atitle%3DTriazole%2520Intermediates%2520Useful%2520in%2520the%2520Synthesis%2520of%2520Protected%2520N-Alkyltriazolecarbaldehydes%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span>; <span class="NLM_string-name">Yohi, P. W.</span>; <span class="NLM_string-name">Xu, M.</span>; <span class="NLM_string-name">Cruise, D.</span>; <span class="NLM_string-name">Huang, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Parpinhibitor Talazoparib</span>. <span class="NLM_patent">WO2017215166A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Xu&author=P.+W.+Yohi&author=M.+Xu&author=D.+Cruise&author=L.+Huang&title=Synthesis+of+Parpinhibitor+Talazoparib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520Parpinhibitor%2520Talazoparib%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><a href="https://www.prnewswire.com/news-releases/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension-300735092.html" class="extLink">https://www.prnewswire.com/news-releases/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension-300735092.html</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fsanten-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension-300735092.html+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okanari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odani-Kawabata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shams, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, K.</span></span> <span> </span><span class="NLM_article-title">Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and Its Prodrug Omidenepag Isopropyl</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6869</span>– <span class="NLM_lpage">6891</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlSmu7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6869-6891&author=R.+Iwamuraauthor=M.+Tanakaauthor=E.+Okanariauthor=T.+Kiriharaauthor=N.+Odani-Kawabataauthor=N.+Shamsauthor=K.+Yoneda&title=Identification+of+a+Selective%2C+Non-Prostanoid+EP2+Receptor+Agonist+for+the+Treatment+of+Glaucoma%3A+Omidenepag+and+Its+Prodrug+Omidenepag+Isopropyl&doi=10.1021%2Facs.jmedchem.8b00808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl</span></div><div class="casAuthors">Iwamura, Ryo; Tanaka, Masayuki; Okanari, Eiji; Kirihara, Tomoko; Odani-Kawabata, Noriko; Shams, Naveed; Yoneda, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6869-6891</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EP2 receptor agonists are expected to be effective ocular hypotensive agents; however, it has been suggested that agonism to other EP receptor subtypes may lead to undesirable effects.  Through medicinal chem. efforts, we identified a scaffold bearing a (pyridin-2-ylamino)acetic acid moiety as a promising EP2-selective receptor agonist. (6-((4-(Pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-ylamino)acetic acid 13ax (omidenepag, OMD) exerted potent and selective activity toward the human EP2 receptor (h-EP2).  Low doses of omidenepag iso-Pr (OMDI), a prodrug of 13ax, lowered intraocular pressure (IOP) in ocular normotensive monkeys.  OMDI was selected as a clin. candidate for the treatment of glaucoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlk0pJferBArVg90H21EOLACvtfcHk0lhawGPPTX4HKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlSmu7zI&md5=d7fc57da815da074427a656c40fb65e3</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00808%26sid%3Dliteratum%253Aachs%26aulast%3DIwamura%26aufirst%3DR.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DOkanari%26aufirst%3DE.%26aulast%3DKirihara%26aufirst%3DT.%26aulast%3DOdani-Kawabata%26aufirst%3DN.%26aulast%3DShams%26aufirst%3DN.%26aulast%3DYoneda%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520a%2520Selective%252C%2520Non-Prostanoid%2520EP2%2520Receptor%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Glaucoma%253A%2520Omidenepag%2520and%2520Its%2520Prodrug%2520Omidenepag%2520Isopropyl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6869%26epage%3D6891%26doi%3D10.1021%2Facs.jmedchem.8b00808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. D.</span></span> <span> </span><span class="NLM_article-title">A Novel, Non-Prostanoid EP2 Receptor-Selective Prostaglandin E2 Agonist Stimulates Local Bone Formation and Enhances Fracture Healing</span>. <i>J. Bone Miner. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2033</span>– <span class="NLM_lpage">2042</span>, <span class="refDoi"> DOI: 10.1359/jbmr.2003.18.11.2033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1359%2Fjbmr.2003.18.11.2033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=14606517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVyiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=2033-2042&author=M.+Liauthor=H.+Z.+Keauthor=H.+Qiauthor=D.+R.+Healyauthor=Y.+Liauthor=D.+T.+Crawfordauthor=V.+M.+Paralkarauthor=T.+A.+Owenauthor=K.+O.+Cameronauthor=B.+A.+Lefkerauthor=T.+A.+Brownauthor=D.+D.+Thompson&title=A+Novel%2C+Non-Prostanoid+EP2+Receptor-Selective+Prostaglandin+E2+Agonist+Stimulates+Local+Bone+Formation+and+Enhances+Fracture+Healing&doi=10.1359%2Fjbmr.2003.18.11.2033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196aR"><div class="casContent"><span class="casTitleNuber">196a</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing</span></div><div class="casAuthors">Li, Mei; Ke, Hua Zhu; Qi, Hong; Healy, David R.; Li, Yan; Crawford, D. Todd; Paralkar, Vishwas M.; Owen, Thomas A.; Cameron, Kimberly O.; Lefker, Bruce A.; Brown, Thomas A.; Thompson, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2033-2042</span>CODEN:
                <span class="NLM_cas:coden">JBMREJ</span>;
        ISSN:<span class="NLM_cas:issn">0884-0431</span>.
    
            (<span class="NLM_cas:orgname">American Society for Bone and Mineral Research</span>)
        </div><div class="casAbstract">CP-533,536, a newly discovered, non-prostanoid EP2 receptor-selective PGE2 agonist, stimulates local bone formation and enhances fracture healing in rat models.  There is a significant medical need for agents that can stimulate local bone formation and enhance fracture healing.  The authors tested the effects of CP-533,536, a newly discovered, non-prostanoid EP2 receptor-selective PGE2 agonist, in stimulating local bone formation and enhancing fracture healing in rat models.  In the first model, a single injection of CP-533,536 at doses of 0.3, 1, or 3 mg/kg to the proximal tibial metaphysis of 6-wk-old male rats was given on day 1, and the local bone anabolic effect was detd. on day 7.  The authors then tested the effects of this compd. in inducing bone formation on rat periosteum of the femur.  A single dose of 0.3 mg of CP-533,536 incorporated in a poly-(DL-lactide-co-glycolide) (PLGH) matrix was injected onto the periosteum of the femur in 3-wk-old male rats, and local bone formation was detd. on day 14.  Finally, the ability of CP-533,536 in PLGH matrix in enhancing fracture healing was tested using the rat femoral fracture model.  CP-533,536 in PLGH matrix at doses of 0.05, 0.5, or 5 mg was delivered to the local fracture site on the same day of fracture, and its efficacy was evaluated on day 21.  A single injection of CP-533,536 at doses of 0.3, 1, or 3 mg/kg to the proximal tibial metaphysis dose-dependently stimulated local lamellar bone formation on trabecular, endocortical, and periosteal surfaces, and thus increased bone mineral content and bone strength at the injected site.  Similarly, a single injection of 0.3 mg of CP-533,536 incorporated in PLGH matrix onto the periosteum of the femur induced significantly local bone formation.  In the rat femoral fracture model, CP-533,536 in PLGH matrix at doses of 0.05, 0.5, and 5 mg dose-dependently increased callus size, d., and strength compared with PLGH matrix alone.  These results show that CP-533,536 stimulates new bone formation on trabecular, endocortical, and periosteal surfaces and enhances fracture healing.  These data reveal that EP2 receptor-selective agonists provide therapeutic potential for local bone augmentation, bone repair, and bone healing in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-eB8GOoJsErVg90H21EOLACvtfcHk0liuIFBG1ESrVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVyiu7o%253D&md5=96d5d5fca5c87a121edda85af9cdbb9b</span></div><a href="/servlet/linkout?suffix=cit196a&amp;dbid=16384&amp;doi=10.1359%2Fjbmr.2003.18.11.2033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1359%252Fjbmr.2003.18.11.2033%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DKe%26aufirst%3DH.%2BZ.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DHealy%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCrawford%26aufirst%3DD.%2BT.%26aulast%3DParalkar%26aufirst%3DV.%2BM.%26aulast%3DOwen%26aufirst%3DT.%2BA.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26aulast%3DLefker%26aufirst%3DB.%2BA.%26aulast%3DBrown%26aufirst%3DT.%2BA.%26aulast%3DThompson%26aufirst%3DD.%2BD.%26atitle%3DA%2520Novel%252C%2520Non-Prostanoid%2520EP2%2520Receptor-Selective%2520Prostaglandin%2520E2%2520Agonist%2520Stimulates%2520Local%2520Bone%2520Formation%2520and%2520Enhances%2520Fracture%2520Healing%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2003%26volume%3D18%26spage%3D2033%26epage%3D2042%26doi%3D10.1359%2Fjbmr.2003.18.11.2033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit196b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borovecki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasser, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva-Jardine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korsmeyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowchalk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukicevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. D.</span></span> <span> </span><span class="NLM_article-title">An EP2 Receptor-Selective Prostaglandin E2 Agonist Induces Bone Healing</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">6736</span>– <span class="NLM_lpage">6740</span>, <span class="refDoi"> DOI: 10.1073/pnas.1037343100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1073%2Fpnas.1037343100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=12748385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktlygsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=6736-6740&author=V.+M.+Paralkarauthor=F.+Boroveckiauthor=H.+Z.+Keauthor=K.+O.+Cameronauthor=B.+Lefkerauthor=W.+A.+Grasserauthor=T.+A.+Owenauthor=M.+Liauthor=P.+DaSilva-Jardineauthor=M.+Zhouauthor=R.+L.+Dunnauthor=F.+Dumontauthor=R.+Korsmeyerauthor=P.+Krasneyauthor=T.+A.+Brownauthor=D.+Plowchalkauthor=S.+Vukicevicauthor=D.+D.+Thompson&title=An+EP2+Receptor-Selective+Prostaglandin+E2+Agonist+Induces+Bone+Healing&doi=10.1073%2Fpnas.1037343100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196bR"><div class="casContent"><span class="casTitleNuber">196b</span><div class="casTitle"><span class="NLM_cas:atitle">An EP2 receptor-selective prostaglandin E2 agonist induces bone healing</span></div><div class="casAuthors">Paralkar, V. M.; Borovecki, F.; Ke, H. Z.; Cameron, K. O.; Lefker, B.; Grasser, W. A.; Owen, T. A.; Li, M.; Da Silva-Jardine, P.; Zhou, M.; Dunn, R. L.; Dumont, F.; Korsmeyer, R.; Krasney, P.; Brown, T. A.; Plowchalk, D.; Vukicevic, S.; Thompson, D. D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6736-6740</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The morbidity and mortality assocd. with impaired/delayed fracture healing remain high.  Our objective was to identify a small nonpeptidyl mol. with the ability to promote fracture healing and prevent malunions.  Prostaglandin E2 (PGE2) causes significant increases in bone mass and bone strength when administered systemically or locally to the skeleton.  However, due to side effects, PGE2 is an unacceptable therapeutic option for fracture healing.  PGE2 mediates its tissue-specific pharmacol. activity via four different G protein-coupled receptor subtypes, EP1, -2, -3, and -4.  The anabolic action of PGE2 in bone has been linked to an elevated level of cAMP, thereby implicating the EP2 and/or EP4 receptor subtypes in bone formation.  We identified an EP2 selective agonist, CP-533,536, which has the ability to heal canine long bone segmental and fracture model defects without the objectionable side effects of PGE2, suggesting that the EP2 receptor subtype is a major contributor to PGE2's local bone anabolic activity.  The potent bone anabolic activity of CP-533,536 offers a therapeutic alternative for the treatment of fractures and bone defects in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDrg8xp8EmpbVg90H21EOLACvtfcHk0liuIFBG1ESrVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktlygsLk%253D&md5=22efaca07d0dbad4a3da8b52ef37b21e</span></div><a href="/servlet/linkout?suffix=cit196b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1037343100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1037343100%26sid%3Dliteratum%253Aachs%26aulast%3DParalkar%26aufirst%3DV.%2BM.%26aulast%3DBorovecki%26aufirst%3DF.%26aulast%3DKe%26aufirst%3DH.%2BZ.%26aulast%3DCameron%26aufirst%3DK.%2BO.%26aulast%3DLefker%26aufirst%3DB.%26aulast%3DGrasser%26aufirst%3DW.%2BA.%26aulast%3DOwen%26aufirst%3DT.%2BA.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DDaSilva-Jardine%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DDunn%26aufirst%3DR.%2BL.%26aulast%3DDumont%26aufirst%3DF.%26aulast%3DKorsmeyer%26aufirst%3DR.%26aulast%3DKrasney%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DT.%2BA.%26aulast%3DPlowchalk%26aufirst%3DD.%26aulast%3DVukicevic%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DD.%2BD.%26atitle%3DAn%2520EP2%2520Receptor-Selective%2520Prostaglandin%2520E2%2520Agonist%2520Induces%2520Bone%2520Healing%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D6736%26epage%3D6740%26doi%3D10.1073%2Fpnas.1037343100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamura, R.</span>; <span class="NLM_string-name">Tanaka, M.</span>; <span class="NLM_string-name">Katsube, T.</span>; <span class="NLM_string-name">Shigetomi, M.</span>; <span class="NLM_string-name">Okanari, E.</span>; <span class="NLM_string-name">Tokunaga, Y.</span>; <span class="NLM_string-name">Fujiwara, H.</span></span> <span> </span><span class="NLM_article-title">Pyridylaminoacetic Acid Compound</span>. <span class="NLM_patent">WO2009113600A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Iwamura&author=M.+Tanaka&author=T.+Katsube&author=M.+Shigetomi&author=E.+Okanari&author=Y.+Tokunaga&author=H.+Fujiwara&title=Pyridylaminoacetic+Acid+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIwamura%26aufirst%3DR.%26atitle%3DPyridylaminoacetic%2520Acid%2520Compound%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit197b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span>; <span class="NLM_string-name">Oue, M.</span>; <span class="NLM_string-name">Wada, Y.</span></span> <span> </span><span class="NLM_article-title">N-Substituted Sulfonamide Compound and Method for Producing Same</span>. <span class="NLM_patent">WO2015190507A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Yamamoto&author=M.+Oue&author=Y.+Wada&title=N-Substituted+Sulfonamide+Compound+and+Method+for+Producing+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DN-Substituted%2520Sulfonamide%2520Compound%2520and%2520Method%2520for%2520Producing%2520Same%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><a href="https://www.drugbank.ca/drugs/DB08820" class="extLink">https://www.drugbank.ca/drugs/DB08820</a> (accessed Jul 28, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB08820+%28accessed+Jul+28%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><a href="https://www.drugs.com/newdrugs/fda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-cystic-fibrosis-ages-12-older-certain-mutations-4693.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-cystic-fibrosis-ages-12-older-certain-mutations-4693.html</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-cystic-fibrosis-ages-12-older-certain-mutations-4693.html+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilewski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanathan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tullis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekstrom-Himes, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. T.</span></span> <span> </span><span class="NLM_article-title">Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1164/rccm.201704-0717OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1164%2Frccm.201704-0717OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=28930490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFClt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2018&pages=214-224&author=S.+H.+Donaldsonauthor=J.+M.+Pilewskiauthor=M.+Grieseauthor=J.+Cookeauthor=L.+Viswanathanauthor=E.+Tullisauthor=J.+C.+Daviesauthor=J.+A.+Lekstrom-Himesauthor=L.+T.+Wang&title=Tezacaftor%2FIvacaftor+in+Subjects+with+Cystic+Fibrosis+and+F508del%2FF508del-CFTR+or+F508del%2FG551D-CFTR&doi=10.1164%2Frccm.201704-0717OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200aR"><div class="casContent"><span class="casTitleNuber">200a</span><div class="casTitle"><span class="NLM_cas:atitle">Tezacaftor/ivacaftor in subjects with cystic fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR</span></div><div class="casAuthors">Donaldson, Scott H.; Pilewski, Joseph M.; Griese, Matthias; Cooke, Jon; Viswanathan, Lakshmi; Tullis, Elizabeth; Davies, Jane C.; Lekstrom-Himes, Julie A.; Wang, Linda T.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-224</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Tezacaftor (formerly VX-661) is an investigational small mol. that improves processing and trafficking of the cystic fibrosis transmembrane conductance regulator (CFTR) in vitro, and improves CFTR function alone and in combination with ivacaftor.  To evaluate the safety and efficacy of tezacaftor monotherapy and of tezacaftor/ivacaftor combination therapy in subjects with cystic fibrosis homozygous for F508del or compd. heterozygous for F508del and G551D.  This was a randomized, placebo-controlled, double-blind, multicenter, phase 2 study (NCT01531673).  Subjects homozygous for F508del received tezacaftor (10 to 150 mg) every day alone or in combination with ivacaftor (150 mg every 12 h) in a dose escalation phase, as well as in a dosage regimen testing phase.  Subjects compd. heterozygous for F508del and G551D, taking physician-prescribed ivacaftor, received tezacaftor (100 mg every day).  Primary endpoints were safety through Day 56 and change in sweat chloride from baseline through Day 28.  Secondary endpoints included change in percent predicted FEV1 (ppFEV1) from baseline through Day 28 and pharmacokinetics.  The incidence of adverse events was similar across treatment arms.  Tezacaftor (100 mg every day)/ivacaftor (150 mg every 12 h) resulted in a 6.04 mmol/L decrease in sweat chloride and 3.75 percentage point increase in ppFEV1 in subjects homozygous for F508del, and a 7.02 mmol/L decrease in sweat chloride and 4.60 percentage point increase in ppFEV1 in subjects compd. heterozygous for F508del and G551D from baseline through Day 28 (P<0.05 for all).  These results support continued clin. development of tezacaftor (100 mg every day) in combination with ivacaftor (150 mg every 12 h) in subjects with cystic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTXp3OwI7Y2bVg90H21EOLACvtfcHk0lj1eSd2pq1ESA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFClt7%252FI&md5=b04a30024a61f63458b3aaea8bd51b18</span></div><a href="/servlet/linkout?suffix=cit200a&amp;dbid=16384&amp;doi=10.1164%2Frccm.201704-0717OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201704-0717OC%26sid%3Dliteratum%253Aachs%26aulast%3DDonaldson%26aufirst%3DS.%2BH.%26aulast%3DPilewski%26aufirst%3DJ.%2BM.%26aulast%3DGriese%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DJ.%26aulast%3DViswanathan%26aufirst%3DL.%26aulast%3DTullis%26aufirst%3DE.%26aulast%3DDavies%26aufirst%3DJ.%2BC.%26aulast%3DLekstrom-Himes%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DL.%2BT.%26atitle%3DTezacaftor%252FIvacaftor%2520in%2520Subjects%2520with%2520Cystic%2520Fibrosis%2520and%2520F508del%252FF508del-CFTR%2520or%2520F508del%252FG551D-CFTR%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2018%26volume%3D197%26spage%3D214%26epage%3D224%26doi%3D10.1164%2Frccm.201704-0717OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit200b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor-Cousar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKone, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Ent, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingenito, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekstrom-Himes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span> <span> </span><span class="NLM_article-title">Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1709846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1056%2FNEJMoa1709846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29099344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFyr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=2013-2023&author=J.+L.+Taylor-Cousarauthor=A.+Munckauthor=E.+F.+McKoneauthor=C.+K.+van+der+Entauthor=A.+Moellerauthor=C.+Simardauthor=L.+T.+Wangauthor=E.+P.+Ingenitoauthor=C.+McKeeauthor=Y.+Luauthor=J.+Lekstrom-Himesauthor=J.+S.+Elborn&title=Tezacaftor-Ivacaftor+in+Patients+with+Cystic+Fibrosis+Homozygous+for+Phe508del&doi=10.1056%2FNEJMoa1709846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200bR"><div class="casContent"><span class="casTitleNuber">200b</span><div class="casTitle"><span class="NLM_cas:atitle">Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del</span></div><div class="casAuthors">Taylor-Cousar, Jennifer L.; Munck, Anne; McKone, Edward F.; van der Ent, Cornelis K.; Moeller, Alexander; Simard, Christopher; Wang, Linda T.; Ingenito, Edward P.; McKee, Charlotte; Lu, Yimeng; Lekstrom-Himes, Julie; Elborn, J. Stuart</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2013-2023</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Combination treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators tezacaftor (VX-661) and ivacaftor (VX-770) was designed to target the underlying cause of disease in patients with cystic fibrosis.  In this phase 3, randomized, double-blind, multicenter, placebo-controlled, parallel-group trial, we evaluated combination therapy with tezacaftor and ivacaftor in patients 12 years of age or older who had cystic fibrosis and were homozygous for the CFTR Phe508del mutation.  Patients were randomly assigned in a 1:1 ratio to receive either 100 mg of tezacaftor once daily and 150 mg of ivacaftor twice daily or matched placebo for 24 wk.  The primary end point was the abs. change in the percentage of the predicted forced expiratory vol. in 1 s (FEV1) through week 24 (calcd. in percentage points); relative change in the percentage of the predicted FEV1 through week 24 (calcd. as a percentage) was a key secondary end point.  Of the 510 patients who underwent randomization, 509 received tezacaftor-ivacaftor or placebo, and 475 completed 24 wk of the trial regimen.  The mean FEV1 at baseline was 60.0% of the predicted value.  The effects on the abs. and relative changes in the percentage of the predicted FEV1 in favor of tezacaftor-ivacaftor over placebo were 4.0 percentage points and 6.8%, resp. (P<0.001 for both comparisons).  The rate of pulmonary exacerbation was 35% lower in the tezacaftor-ivacaftor group than in the placebo group (P = 0.005).  The incidence of adverse events was similar in the two groups.  Most adverse events were of mild severity (in 41.8% of patients overall) or moderate severity (in 40.9% overall), and serious adverse events were less frequent with tezacaftor-ivacaftor (12.4%) than with placebo (18.2%).  A total of 2.9% of patients discontinued the assigned regimen owing to adverse events.  Fewer patients in the tezacaftor-ivacaftor group than in the placebo group had respiratory adverse events, none of which led to discontinuation. conclusions The combination of tezacaftor and ivacaftor was efficacious and safe in patients 12 years of age or older who had cystic fibrosis and were homozygous for the CFTR Phe508del mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry28bA5s2HMrVg90H21EOLACvtfcHk0lj1eSd2pq1ESA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFyr&md5=a8aec50415d3dec5202ce53b5176960d</span></div><a href="/servlet/linkout?suffix=cit200b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1709846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1709846%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor-Cousar%26aufirst%3DJ.%2BL.%26aulast%3DMunck%26aufirst%3DA.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3Dvan%2Bder%2BEnt%26aufirst%3DC.%2BK.%26aulast%3DMoeller%26aufirst%3DA.%26aulast%3DSimard%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%2BT.%26aulast%3DIngenito%26aufirst%3DE.%2BP.%26aulast%3DMcKee%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLekstrom-Himes%26aufirst%3DJ.%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26atitle%3DTezacaftor-Ivacaftor%2520in%2520Patients%2520with%2520Cystic%2520Fibrosis%2520Homozygous%2520for%2520Phe508del%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D2013%26epage%3D2023%26doi%3D10.1056%2FNEJMoa1709846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garg, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekstrom-Himes, J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1111/cts.12610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1111%2Fcts.12610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30694595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsFWitro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=267-275&author=V.+Gargauthor=J.+Shenauthor=C.+Liauthor=S.+Agarwalauthor=A.+Gebreauthor=S.+Robertsonauthor=J.+Huangauthor=L.+Hanauthor=L.+Jiangauthor=K.+Stephanauthor=L.+T.+Wangauthor=J.+Lekstrom-Himes&title=Pharmacokinetic+and+Drug-Drug+Interaction+Profiles+of+the+Combination+of+Tezacaftor%2FIvacaftor&doi=10.1111%2Fcts.12610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor</span></div><div class="casAuthors">Garg, Varun; Shen, Jinshan; Li, Chonghua; Agarwal, Sagar; Gebre, Asfiha; Robertson, Sarah; Huang, Jiayin; Han, Linda; Jiang, Licong; Stephan, Kristin; Wang, Linda T.; Lekstrom-Himes, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-275</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Drug-drug interaction (DDI) studies are described for tezacaftor/ivacaftor, a new cystic fibrosis transmembrane conductance regulator modulator therapy for the treatment of cystic fibrosis.  Three phase I DDI studies were conducted in healthy subjects to characterize the DDI profile of tezacaftor/ivacaftor with cytochrome P 450 (CYP)3A substrates, CYP3A inhibitors, and a permeability glycoprotein (P-gp) substrate.  The effects of steady-state tezacaftor/ivacaftor on the pharmacokinetics (PKs) of digoxin (a P-gp substrate), midazolam, and ethinyl estradiol/norethindrone (CYP3A substrates) were evaluated.  Effects of strong (itraconazole) and moderate (ciprofloxacin) CYP3A inhibitors on tezacaftor/ivacaftor PKs were also detd.  Tezacaftor/ivacaftor increased digoxin area under the curve (AUC) by 30% but did not affect midazolam, ethinyl estradiol, or norethindrone exposures.  Itraconazole increased the AUC of tezacaftor 4-fold and ivacaftor 15.6-fold.  Ciprofloxacin had no significant effect on tezacaftor or ivacaftor exposure.  Coadministration of tezacaftor/ivacaftor may increase exposure of sensitive P-gp substrates.  Tezacaftor/ivacaftor is unlikely to impact exposure of drugs metabolized by CYP3A, including hormonal contraceptives.  Strong CYP3A inhibitors significantly increase the exposures of tezacaftor and ivacaftor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8u2x79NK5kbVg90H21EOLACvtfcHk0lj1eSd2pq1ESA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsFWitro%253D&md5=41784952b7e6527fcfc33f2c62130344</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1111%2Fcts.12610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12610%26sid%3Dliteratum%253Aachs%26aulast%3DGarg%26aufirst%3DV.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DGebre%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DStephan%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%2BT.%26aulast%3DLekstrom-Himes%26aufirst%3DJ.%26atitle%3DPharmacokinetic%2520and%2520Drug-Drug%2520Interaction%2520Profiles%2520of%2520the%2520Combination%2520of%2520Tezacaftor%252FIvacaftor%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2019%26volume%3D12%26spage%3D267%26epage%3D275%26doi%3D10.1111%2Fcts.12610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F210491lbl.pdf+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><a href="https://www.drugs.com/newdrugs/fda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-underlying-cause-cf-children-ages-6-11-years-4996.html" class="extLink">https://www.drugs.com/newdrugs/fda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-underlying-cause-cf-children-ages-6-11-years-4996.html</a> (accessed Dec 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.drugs.com%2Fnewdrugs%2Ffda-approves-symdeko-tezacaftor-ivacaftor-ivacaftor-underlying-cause-cf-children-ages-6-11-years-4996.html+%28accessed+Dec+3%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruah, S. H. S.</span>; <span class="NLM_string-name">Grootenhuis, P. D. J.</span>; <span class="NLM_string-name">Van Goor, F.</span>; <span class="NLM_string-name">Miller, M. T.</span>; <span class="NLM_string-name">McCartney, J.</span>; <span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Bear, B.</span>; <span class="NLM_string-name">Numa, M. M. D.</span></span> <span> </span><span class="NLM_article-title">Preparation of Indolyl Cycloalkylcarboxamides as Modulators of ATP-Binding Cassette Transporters for Use as Drugs and Biological Tools</span>. <span class="NLM_patent">WO2010053471A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+H.+S.+Ruah&author=P.+D.+J.+Grootenhuis&author=F.+Van+Goor&author=M.+T.+Miller&author=J.+McCartney&author=J.+Zhou&author=B.+Bear&author=M.+M.+D.+Numa&title=Preparation+of+Indolyl+Cycloalkylcarboxamides+as+Modulators+of+ATP-Binding+Cassette+Transporters+for+Use+as+Drugs+and+Biological+Tools"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRuah%26aufirst%3DS.%2BH.%2BS.%26atitle%3DPreparation%2520of%2520Indolyl%2520Cycloalkylcarboxamides%2520as%2520Modulators%2520of%2520ATP-Binding%2520Cassette%2520Transporters%2520for%2520Use%2520as%2520Drugs%2520and%2520Biological%2520Tools%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit204b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Keshavarz-Shokri, A.</span>; <span class="NLM_string-name">Zhang, B.</span>; <span class="NLM_string-name">Alcacio, T. E.</span>; <span class="NLM_string-name">Lee, E. C.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Krawiec, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Benzodioxolyl-N-Indolyl Cyclopropanecarboxamide Derivatives for Use as CFTR Modulators</span>. <span class="NLM_patent">WO2011119984A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Keshavarz-Shokri&author=B.+Zhang&author=T.+E.+Alcacio&author=E.+C.+Lee&author=Y.+Zhang&author=M.+Krawiec&title=Preparation+of+Benzodioxolyl-N-Indolyl+Cyclopropanecarboxamide+Derivatives+for+Use+as+CFTR+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKeshavarz-Shokri%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520Benzodioxolyl-N-Indolyl%2520Cyclopropanecarboxamide%2520Derivatives%2520for%2520Use%2520as%2520CFTR%2520Modulators%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit204c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Alargova, R. G.</span>; <span class="NLM_string-name">Kadiyala, I. N.</span>; <span class="NLM_string-name">Zaman, N. T.</span></span> <span> </span><span class="NLM_article-title">Formulations of (R)-1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide for Treatment of Cystic Fibrosis</span>. <span class="NLM_patent">WO2012170061A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+G.+Alargova&author=I.+N.+Kadiyala&author=N.+T.+Zaman&title=Formulations+of+%28R%29-1-%282%2C2-Difluorobenzo%5Bd%5D%5B1%2C3%5Ddioxol-5-yl%29-N-%281-%282%2C3-dihydroxypropyl%29-6-fluoro-2-%281-hydroxy-2-methylpropan-2-yl%29-1h-indol-5-yl%29cyclopropanecarboxamide+for+Treatment+of+Cystic+Fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlargova%26aufirst%3DR.%2BG.%26atitle%3DFormulations%2520of%2520%2528R%2529-1-%25282%252C2-Difluorobenzo%255Bd%255D%255B1%252C3%255Ddioxol-5-yl%2529-N-%25281-%25282%252C3-dihydroxypropyl%2529-6-fluoro-2-%25281-hydroxy-2-methylpropan-2-yl%2529-1h-indol-5-yl%2529cyclopropanecarboxamide%2520for%2520Treatment%2520of%2520Cystic%2520Fibrosis%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit204d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Goor, F. F.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Compositions for the Treatment of CFTR-Mediated Disorders</span>. <span class="NLM_patent">WO2013185112A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+F.+Van+Goor&title=Pharmaceutical+Compositions+for+the+Treatment+of+CFTR-Mediated+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%2BF.%26atitle%3DPharmaceutical%2520Compositions%2520for%2520the%2520Treatment%2520of%2520CFTR-Mediated%2520Disorders%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit204e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Alargova, R. G.</span>; <span class="NLM_string-name">Dunbar, C. A.</span>; <span class="NLM_string-name">Kadiyala, I. N.</span></span> <span> </span><span class="NLM_article-title">Oral Compositions of (R)-1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide for Treatment of Cystic Fibrosis</span>. <span class="NLM_patent">WO2014014841A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+G.+Alargova&author=C.+A.+Dunbar&author=I.+N.+Kadiyala&title=Oral+Compositions+of+%28R%29-1-%282%2C2-Difluorobenzo%5Bd%5D%5B1%2C3%5Ddioxol-5-yl%29-N-%281-%282%2C3-dihydroxypropyl%29-6-fluoro-2-%281-hydroxy-2-methylpropan-2-yl%29-1h-indol-5-yl%29cyclopropanecarboxamide+for+Treatment+of+Cystic+Fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlargova%26aufirst%3DR.%2BG.%26atitle%3DOral%2520Compositions%2520of%2520%2528R%2529-1-%25282%252C2-Difluorobenzo%255Bd%255D%255B1%252C3%255Ddioxol-5-yl%2529-N-%25281-%25282%252C3-dihydroxypropyl%2529-6-fluoro-2-%25281-hydroxy-2-methylpropan-2-yl%2529-1h-indol-5-yl%2529cyclopropanecarboxamide%2520for%2520Treatment%2520of%2520Cystic%2520Fibrosis%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit204f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Phenix, B. D.</span>; <span class="NLM_string-name">Bagnol, L. J.-C.</span>; <span class="NLM_string-name">Brodeur, G. G.</span>; <span class="NLM_string-name">Chandran, S.</span>; <span class="NLM_string-name">Dokou, E.</span>; <span class="NLM_string-name">Ferris, L. A.</span>; <span class="NLM_string-name">Knezic, D.</span>; <span class="NLM_string-name">McCarty, K. L.</span>; <span class="NLM_string-name">Medek, A.</span>; <span class="NLM_string-name">Waggener, S. A.</span></span> <span> </span><span class="NLM_article-title">Method for Preparation of Quinolinone Carboxamides, Indole Carboxamides and Pharmaceutical Compositions Containing Them for the Treatment of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases</span>. <span class="NLM_patent">WO2015160787A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=B.+D.+Phenix&author=L.+J.-C.+Bagnol&author=G.+G.+Brodeur&author=S.+Chandran&author=E.+Dokou&author=L.+A.+Ferris&author=D.+Knezic&author=K.+L.+McCarty&author=A.+Medek&author=S.+A.+Waggener&title=Method+for+Preparation+of+Quinolinone+Carboxamides%2C+Indole+Carboxamides+and+Pharmaceutical+Compositions+Containing+Them+for+the+Treatment+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Mediated+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPhenix%26aufirst%3DB.%2BD.%26atitle%3DMethod%2520for%2520Preparation%2520of%2520Quinolinone%2520Carboxamides%252C%2520Indole%2520Carboxamides%2520and%2520Pharmaceutical%2520Compositions%2520Containing%2520Them%2520for%2520the%2520Treatment%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Mediated%2520Diseases%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit204g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Alcacio, T.</span>; <span class="NLM_string-name">Baek, M.</span>; <span class="NLM_string-name">Grootenhuis, P.</span>; <span class="NLM_string-name">Hadida Ruah, S. S.</span>; <span class="NLM_string-name">Hughes, R. M.</span>; <span class="NLM_string-name">Keshavarz-Shokri, A.</span>; <span class="NLM_string-name">McAuley-Aoki, R.</span>; <span class="NLM_string-name">McCartney, J.</span>; <span class="NLM_string-name">Miller, M. T.</span>; <span class="NLM_string-name">Van Goor, F.</span>; <span class="NLM_string-name">Zhang, B.</span>; <span class="NLM_string-name">Andreson, C.</span>; <span class="NLM_string-name">Cleveland, T.</span>; <span class="NLM_string-name">Frieman, B. A.</span>; <span class="NLM_string-name">Khatuya, H.</span>; <span class="NLM_string-name">Joshi, P. V.</span>; <span class="NLM_string-name">Krenitsky, P. J.</span>; <span class="NLM_string-name">Melillo, V.</span>; <span class="NLM_string-name">Pierre, F. J. D.</span>; <span class="NLM_string-name">Termin, A. P.</span>; <span class="NLM_string-name">Uy, J.</span>; <span class="NLM_string-name">Zhou, J.</span>; <span class="NLM_string-name">Abela, A. R.</span>; <span class="NLM_string-name">Busch, B. B.</span>; <span class="NLM_string-name">Paraselli, P.</span>; <span class="NLM_string-name">Siesel, D. A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Benzenesulfonylpyrazolylpyrrolidinylpyridinecarboxamide Derivatives and Analogs for Use as Cystic Fibrosis Transmembrane Conductance Regulator Modulators</span>. <span class="NLM_patent">WO2018064632A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=T.+Alcacio&author=M.+Baek&author=P.+Grootenhuis&author=S.+S.+Hadida+Ruah&author=R.+M.+Hughes&author=A.+Keshavarz-Shokri&author=R.+McAuley-Aoki&author=J.+McCartney&author=M.+T.+Miller&author=F.+Van+Goor&author=B.+Zhang&author=C.+Andreson&author=T.+Cleveland&author=B.+A.+Frieman&author=H.+Khatuya&author=P.+V.+Joshi&author=P.+J.+Krenitsky&author=V.+Melillo&author=F.+J.+D.+Pierre&author=A.+P.+Termin&author=J.+Uy&author=J.+Zhou&author=A.+R.+Abela&author=B.+B.+Busch&author=P.+Paraselli&author=D.+A.+Siesel&title=Preparation+of+Benzenesulfonylpyrazolylpyrrolidinylpyridinecarboxamide+Derivatives+and+Analogs+for+Use+as+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlcacio%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Benzenesulfonylpyrazolylpyrrolidinylpyridinecarboxamide%2520Derivatives%2520and%2520Analogs%2520for%2520Use%2520as%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Modulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, K. K.</span></span> <span> </span><span class="NLM_article-title">A New Year-Long Combination Hormonal Contraceptive</span>. <i>Nurs. Womens Health</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.nwh.2019.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.nwh.2019.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30836070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgs1Cjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=172-176&author=K.+K.+Blakely&title=A+New+Year-Long+Combination+Hormonal+Contraceptive&doi=10.1016%2Fj.nwh.2019.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">A New Year-Long Combination Hormonal Contraceptive</span></div><div class="casAuthors">Blakely Kala K</div><div class="citationInfo"><span class="NLM_cas:title">Nursing for women's health</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">172-176</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The U.S.  Food and Drug Administration approved a new combination hormonal contraceptive in August 2018.  Sold under the brand name Annovera, it is a combination of segesterone acetate and ethinyl estradiol, and it is the first multiuse vaginal contraceptive system that prevents ovulation for up to 13 menstrual cycles in a year.  Although there are several combination hormonal contraceptives on the market, this is the first single system that can be repeatedly used for an entire year and does not require placement by a health care provider.  This innovation gives women control over when to stop using the contraceptive, should they so desire.  Annovera is stored at room temperature when not in use, allowing women living in uncontrolled-temperature climates to use one contraceptive method for an entire year.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6YX09rUY9tWmbXvSEQle5fW6udTcc2eYwGfof4hEYr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgs1Cjuw%253D%253D&md5=598b10d0d7f210768f00141b84342262</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2Fj.nwh.2019.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nwh.2019.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DK.%2BK.%26atitle%3DA%2520New%2520Year-Long%2520Combination%2520Hormonal%2520Contraceptive%26jtitle%3DNurs.%2520Womens%2520Health%26date%3D2019%26volume%3D23%26spage%3D172%26epage%3D176%26doi%3D10.1016%2Fj.nwh.2019.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gemzell-Danielsson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitruk-Ware, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creinin, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creasy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plagianos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blithe, D.</span></span> <span> </span><span class="NLM_article-title">Segesterone Acetate/Ethinyl Estradiol 12-Month Contraceptive Vaginal System Safety Evaluation</span>. <i>Contraception</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/j.contraception.2019.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.contraception.2019.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30831102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlOhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2019&pages=323-328&author=K.+Gemzell-Danielssonauthor=R.+Sitruk-Wareauthor=M.+D.+Creininauthor=M.+Thomasauthor=K.+T.+Barnhartauthor=G.+Creasyauthor=H.+Sussmanauthor=M.+Alamiauthor=A.+E.+Burkeauthor=E.+Weisbergauthor=I.+Fraserauthor=M.+J.+Mirandaauthor=M.+Gilliamauthor=J.+Liuauthor=B.+R.+Carrauthor=M.+Plagianosauthor=K.+Robertsauthor=D.+Blithe&title=Segesterone+Acetate%2FEthinyl+Estradiol+12-Month+Contraceptive+Vaginal+System+Safety+Evaluation&doi=10.1016%2Fj.contraception.2019.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation</span></div><div class="casAuthors">Gemzell-Danielsson, Kristina; Sitruk-Ware, Regine; Creinin, Mitchell D.; Thomas, Michael; Barnhart, Kurt T.; Creasy, George; Sussman, Heather; Alami, Mohcine; Burke, Anne E.; Weisberg, Edith; Fraser, Ian; Miranda, Marie-Jose; Gilliam, Melissa; Liu, James; Carr, Bruce R.; Plagianos, Marlena; Roberts, Kevin; Blithe, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Contraception</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-328</span>CODEN:
                <span class="NLM_cas:coden">CCPTAY</span>;
        ISSN:<span class="NLM_cas:issn">0010-7824</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">To evaluate safety outcomes from clin. studies of a 12-mo contraceptive vaginal system (CVS) releasing an av. of segesterone acetate (SA) 150 mcg and ethinyl estradiol (EE) 13 mcg daily.  We integrated clin. safety data from nine studies in which women used the CVS for 21 consecutive days and removed it for 7 days of each 28-day cycle.  Four studies used the final manufd. CVS, including a 1-yr pharmacokinetic study, two 1-yr phase 3 trials and a second-year treatment extension study.  We assessed safety by evaluating adverse events women reported in a daily diary.  We also included data from focused safety studies evaluating endometrial biopsies, vaginal microbiol. and liver proteins from one of the phase 3 studies.  The combined studies included 3052 women; 2308 women [mean age 26.7±5.1 years; mean body mass index (BMI) 24.1±3.7 kg/m2] received the final manufd. CVS, of whom 999 (43.3%) completed 13 cycles of use.  Women using the final CVS most commonly reported adverse events of headache (n=601, 26%), nausea (n=420, 18%), vaginal discharge/vulvovaginal mycotic infection (n=242, 10%) and abdominal pain (n=225, 10%).  Few (<1.5%) women discontinued for these complaints.  Four (0.2%) women experienced venous thromboembolism (VTE), three of whom had risk factors for thrombosis [Factor V Leiden mutation (n=1); BMI>29 kg/m2 (n=2)].  During 21,482 treatment cycles in the phase 3 studies evaluable for expulsion, women reported partial expulsions in 4259 (19.5%) cycles and complete expulsions in 1509 (7%) cycles, most frequently in the initial cycle [499/2050 (24.3%) and 190/2050 (9.3%), resp.].  Safety-focused studies revealed no safety concerns.  The 1-yr SA/EE CVS has an acceptable safety profile.  Addnl. studies are warranted in obese women at higher risk of VTE.  This 1-yr contraceptive vaginal system represents a new long-term, user-controlled and procedure-free option with a safety profile similar to other combination hormonal contraceptives.  The same precautions currently used for combination hormonal contraceptive prescriptions apply to this new contraceptive vaginal system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUoXHrscP5r7Vg90H21EOLACvtfcHk0lhWhXnBzzeTJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlOhtbo%253D&md5=8ed0d7b0f76d698fda32b184c97a7bf4</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.contraception.2019.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.contraception.2019.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DGemzell-Danielsson%26aufirst%3DK.%26aulast%3DSitruk-Ware%26aufirst%3DR.%26aulast%3DCreinin%26aufirst%3DM.%2BD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DBarnhart%26aufirst%3DK.%2BT.%26aulast%3DCreasy%26aufirst%3DG.%26aulast%3DSussman%26aufirst%3DH.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DBurke%26aufirst%3DA.%2BE.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DFraser%26aufirst%3DI.%26aulast%3DMiranda%26aufirst%3DM.%2BJ.%26aulast%3DGilliam%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCarr%26aufirst%3DB.%2BR.%26aulast%3DPlagianos%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DBlithe%26aufirst%3DD.%26atitle%3DSegesterone%2520Acetate%252FEthinyl%2520Estradiol%252012-Month%2520Contraceptive%2520Vaginal%2520System%2520Safety%2520Evaluation%26jtitle%3DContraception%26date%3D2019%26volume%3D99%26spage%3D323%26epage%3D328%26doi%3D10.1016%2Fj.contraception.2019.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urquhart, L.</span></span> <span> </span><span class="NLM_article-title">Regulatory Watch: FDA New Drug Approvals in Q3 2018</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">779</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1038%2Fnrd.2018.194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30374181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVaqt7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=779&author=L.+Urquhart&title=Regulatory+Watch%3A+FDA+New+Drug+Approvals+in+Q3+2018&doi=10.1038%2Fnrd.2018.194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory watch FDA new drug approvals in Q3 2018</span></div><div class="casAuthors">Urquhart, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">779</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjE_dMsHgqVrVg90H21EOLACvtfcHk0lhWhXnBzzeTJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVaqt7zL&md5=87a29e8402084122b834543ada7c7b4f</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.194%26sid%3Dliteratum%253Aachs%26aulast%3DUrquhart%26aufirst%3DL.%26atitle%3DRegulatory%2520Watch%253A%2520FDA%2520New%2520Drug%2520Approvals%2520in%2520Q3%25202018%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D779%26doi%3D10.1038%2Fnrd.2018.194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Ester Derivatives of Steroids</span>. <span class="NLM_patent">WO199713779</span>, <span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=F.+Li&title=Preparation+of+Ester+Derivatives+of+Steroids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26atitle%3DPreparation%2520of%2520Ester%2520Derivatives%2520of%2520Steroids%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehrhof, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irmscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, L.</span></span> <span> </span><span class="NLM_article-title">Synthesewege Zum 17a-Hydroxy-16-Methylen-19-nor-Progesteron Und Seinen Derivaten</span>. <i>Chem. Ber.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">658</span>, <span class="refDoi"> DOI: 10.1002/cber.19691020231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fcber.19691020231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=5802849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaF1MXovVSlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1969&pages=643-658&author=W.+Mehrhofauthor=K.+Irmscherauthor=R.+Erbauthor=L.+Pohl&title=Synthesewege+Zum+17a-Hydroxy-16-Methylen-19-nor-Progesteron+Und+Seinen+Derivaten&doi=10.1002%2Fcber.19691020231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Routes to the synthesis of 17α-hydroxy-16-methylene-19-norprogesterone and its derivatives</span></div><div class="casAuthors">Mehrhof, Werner; Irmscher, Klaus; Erb, Rolf; Pohl, Ludwig</div><div class="citationInfo"><span class="NLM_cas:title">Chemische Berichte</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">643-58</span>CODEN:
                <span class="NLM_cas:coden">CHBEAM</span>;
        ISSN:<span class="NLM_cas:issn">0009-2940</span>.
    </div><div class="casAbstract">17α-Hydroxy-3β-acetoxy-16-methylenepregn-5-en-20-one, prepd. by the method of G. Nomine et al. (1960), treated with N-bromoacetamide gave 5α-bromo-6β-hydroxy-3β-acetoxy-16α,17α-epoxy-16β-bromomethylpregnan-2-one which reacted with NOCl to give 5α-bromo-6β-nitrosooxy-3β-acetoxy-16α,17α-epoxy-16β-bromomethylpregnan-2-one (I).  The irradn. of I gave 5α-bromo-6β-hydroxy-3β-acetoxy-16α,17α-epoxy-19-oximino-16β-bromomethylpregnan-20-one which upon treatment with NaNO2 in AcOH gave 5α-bromo-6β-hydroxy-3β-acetoxy-16α,17α-epoxy-16β-bromomethylpregnane-19,20-dione 19 → 6 acetal (II).  Oxidn. of II with CrO3 gave the corresponding 20-oxopregnan-19-oic acid 19 → 6 lactone which was reduced with Zn to 17α-hydroxy-3β-acetoxy-20-oxo-16-methylenepregn-5-en-19-oic acid.  The latter refluxed with KOH gave 3β,17α-dihydroxy-20-oxo-16-methylenepregn-5-en-19-oic acid which upon oxidn. with CrO3 gave 17α-hydroxy-16-methylene-19-nor-progesterone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNP1PmHcQ6QLVg90H21EOLACvtfcHk0lgJKjBhLFwDAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXovVSlsw%253D%253D&md5=31c7c278ed718e8939ec49878b3f2b64</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1002%2Fcber.19691020231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19691020231%26sid%3Dliteratum%253Aachs%26aulast%3DMehrhof%26aufirst%3DW.%26aulast%3DIrmscher%26aufirst%3DK.%26aulast%3DErb%26aufirst%3DR.%26aulast%3DPohl%26aufirst%3DL.%26atitle%3DSynthesewege%2520Zum%252017a-Hydroxy-16-Methylen-19-nor-Progesteron%2520Und%2520Seinen%2520Derivaten%26jtitle%3DChem.%2520Ber.%26date%3D1969%26volume%3D102%26spage%3D643%26epage%3D658%26doi%3D10.1002%2Fcber.19691020231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwars, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syhora, K.</span></span> <span> </span><span class="NLM_article-title">Steroid derivatives L. A Synthesis of 16-Methylene-17-a-Acetoxy-nor-Progesterone</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1925</span>– <span class="NLM_lpage">1929</span>, <span class="refDoi"> DOI: 10.1016/s0040-4039(00)90756-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2FS0040-4039%2800%2990756-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1967&pages=1925-1929&author=V.+Schwarsauthor=J.+Zachovaauthor=K.+Syhora&title=Steroid+derivatives+L.+A+Synthesis+of+16-Methylene-17-a-Acetoxy-nor-Progesterone&doi=10.1016%2Fs0040-4039%2800%2990756-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2990756-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252990756-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchwars%26aufirst%3DV.%26aulast%3DZachova%26aufirst%3DJ.%26aulast%3DSyhora%26aufirst%3DK.%26atitle%3DSteroid%2520derivatives%2520L.%2520A%2520Synthesis%2520of%252016-Methylene-17-a-Acetoxy-nor-Progesterone%26jtitle%3DTetrahedron%2520Lett.%26date%3D1967%26volume%3D22%26spage%3D1925%26epage%3D1929%26doi%3D10.1016%2Fs0040-4039%2800%2990756-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, G.</span>; <span class="NLM_string-name">Gerardo, L.</span>; <span class="NLM_string-name">Rodriguez, S.-D.</span>; <span class="NLM_string-name">Miguel, C.</span></span> <span> </span><span class="NLM_article-title">Process for Alkynylating 16-Substituted 17-Keto Steroids</span>. <span class="NLM_patent">WO2013092668A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+Fuentes&author=L.+Gerardo&author=S.-D.+Rodriguez&author=C.+Miguel&title=Process+for+Alkynylating+16-Substituted+17-Keto+Steroids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFuentes%26aufirst%3DG.%26atitle%3DProcess%2520for%2520Alkynylating%252016-Substituted%252017-Keto%2520Steroids%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Vibegron: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1835</span>– <span class="NLM_lpage">1839</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1006-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1007%2Fs40265-018-1006-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=30411311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A280%3ADC%252BB3cvotlWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1835-1839&author=S.+J.+Keam&title=Vibegron%3A+First+Global+Approval&doi=10.1007%2Fs40265-018-1006-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Vibegron: First Global Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1835-1839</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Vibegron is a selective beta 3 adrenergic receptor (β3AR) agonist that is being developed in Japan jointly by Kyorin Pharmaceutical Co., Ltd and Kissei Pharmaceutical Co., Ltd and in other regions worldwide (except in several other Asian countries) by Urovant Sciences for the treatment of overactive bladder (OAB).  Based on results from Japanese phase III trials, vibegron received approval in Japan in September 2018 for this indication.  This article summarizes the milestones in the development of vibegron leading to this first global approval for the treatment of OAB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKzA280ys79mgRQsDqrjW_fW6udTcc2eZKkD9btKfZWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvotlWqtQ%253D%253D&md5=c87f509175ef4659a61c49e4446e595f</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1006-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1006-3%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DVibegron%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1835%26epage%3D1839%26doi%3D10.1007%2Fs40265-018-1006-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kar, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salvo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagabukuro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacre-Salem, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goble, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morriello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyes, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzmaurice, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenkl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gichuru, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jochnowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levorse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamlynny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struthers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery of Vibegron: A Potent and Selective B3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyrurjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=609-623&author=S.+D.+Edmondsonauthor=C.+Zhuauthor=N.+F.+Karauthor=J.+Di+Salvoauthor=H.+Nagabukuroauthor=B.+Sacre-Salemauthor=K.+Dingleyauthor=R.+Bergerauthor=S.+D.+Gobleauthor=G.+Morrielloauthor=B.+Harperauthor=C.+R.+Moyesauthor=D.-M.+Shenauthor=L.+Wangauthor=R.+Ballauthor=A.+Fitzmauriceauthor=T.+Frenklauthor=L.+N.+Gichuruauthor=S.+Haauthor=A.+L.+Hurleyauthor=N.+Jochnowitzauthor=D.+Levorseauthor=S.+Mistryauthor=R.+R.+Millerauthor=J.+Ormesauthor=G.+M.+Salituroauthor=A.+Sanfizauthor=A.+S.+Stevensonauthor=K.+Villaauthor=B.+Zamlynnyauthor=S.+Greenauthor=M.+Struthersauthor=A.+E.+Weber&title=Discovery+of+Vibegron%3A+A+Potent+and+Selective+B3+Adrenergic+Receptor+Agonist+for+the+Treatment+of+Overactive+Bladder&doi=10.1021%2Facs.jmedchem.5b01372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder</span></div><div class="casAuthors">Edmondson, Scott D.; Zhu, Cheng; Kar, Nam Fung; Di Salvo, Jerry; Nagabukuro, Hiroshi; Sacre-Salem, Beatrice; Dingley, Karen; Berger, Richard; Goble, Stephen D.; Morriello, Gregori; Harper, Bart; Moyes, Christopher R.; Shen, Dong-Ming; Wang, Liping; Ball, Richard; Fitzmaurice, Aileen; Frenkl, Tara; Gichuru, Loise N.; Ha, Sookhee; Hurley, Amanda L.; Jochnowitz, Nina; Levorse, Dorothy; Mistry, Shruty; Miller, Randy R.; Ormes, James; Salituro, Gino M.; Sanfiz, Anthony; Stevenson, Andra S.; Villa, Katherine; Zamlynny, Beata; Green, Stuart; Struthers, Mary; Weber, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described.  An early-generation clin. β3-AR agonist MK-0634 (3) exhibited efficacy in humans for the treatment of OAB, but development was discontinued due to unacceptable structure-based toxicity in preclin. species.  Optimization of a series of second-generation pyrrolidine-derived β3-AR agonists included reducing the risk for phospholipidosis, the risk of formation of disproportionate human metabolites, and the risk of formation of high levels of circulating metabolites in preclin. species.  These efforts resulted in the discovery of vibegron, which possesses improved druglike properties and an overall superior preclin. profile compared to MK-0634.  Structure-activity relationships leading to the discovery of vibegron and a summary of its preclin. profile are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTKGFhBOdMNbVg90H21EOLACvtfcHk0lhH8NZMdpWbQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyrurjM&md5=89410d04a67540aa78e73e7312867ef3</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01372%26sid%3Dliteratum%253Aachs%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DKar%26aufirst%3DN.%2BF.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DNagabukuro%26aufirst%3DH.%26aulast%3DSacre-Salem%26aufirst%3DB.%26aulast%3DDingley%26aufirst%3DK.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DGoble%26aufirst%3DS.%2BD.%26aulast%3DMorriello%26aufirst%3DG.%26aulast%3DHarper%26aufirst%3DB.%26aulast%3DMoyes%26aufirst%3DC.%2BR.%26aulast%3DShen%26aufirst%3DD.-M.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBall%26aufirst%3DR.%26aulast%3DFitzmaurice%26aufirst%3DA.%26aulast%3DFrenkl%26aufirst%3DT.%26aulast%3DGichuru%26aufirst%3DL.%2BN.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DLevorse%26aufirst%3DD.%26aulast%3DMistry%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DOrmes%26aufirst%3DJ.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DSanfiz%26aufirst%3DA.%26aulast%3DStevenson%26aufirst%3DA.%2BS.%26aulast%3DVilla%26aufirst%3DK.%26aulast%3DZamlynny%26aufirst%3DB.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3DDiscovery%2520of%2520Vibegron%253A%2520A%2520Potent%2520and%2520Selective%2520B3%2520Adrenergic%2520Receptor%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Overactive%2520Bladder%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D609%26epage%3D623%26doi%3D10.1021%2Facs.jmedchem.5b01372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurose, T.</span></span> <span> </span><span class="NLM_article-title">Vibegron, a Novel Potent and Selective B3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study</span>. <i>Eur. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1016/j.eururo.2017.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.eururo.2017.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=29366513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVCkt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=783-790&author=M.+Yoshidaauthor=M.+Takedaauthor=M.+Gotohauthor=S.+Nagaiauthor=T.+Kurose&title=Vibegron%2C+a+Novel+Potent+and+Selective+B3-Adrenoreceptor+Agonist%2C+for+the+Treatment+of+Patients+with+Overactive+Bladder%3A+A+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Phase+3+Study&doi=10.1016%2Fj.eururo.2017.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214aR"><div class="casContent"><span class="casTitleNuber">214a</span><div class="casTitle"><span class="NLM_cas:atitle">Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study</span></div><div class="casAuthors">Yoshida, Masaki; Takeda, Masayuki; Gotoh, Momokazu; Nagai, Shinji; Kurose, Takafumi</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">783-790</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Vibegron is a novel, potent, and selective β3-adrenoreceptor agonist for the treatment of patients with overactive bladder (OAB).To evaluate the efficacy and safety of vibegron vs. placebo in Japanese OAB patients.Patients with OAB entered a 2-wk placebo run-in phase.  Once eligibility (≥8 micturition/d and either ≥1 urgency episodes/d or ≥1 urgency incontinence episodes/d) was confirmed, patients entered a 12-wk double-blind treatment phase.  The anticholinergic imidafenacin was used as an active ref.A total of 1232 patients were randomly assigned to one of the four 12-wk treatment groups: vibegron (50 mg or 100 mg once daily), placebo, or imidafenacin (0.1 mg twice daily).The primary endpoint was change in the mean no. of micturitions/d at wk 12 from baseline.  The secondary endpoints were changes from baselines in OAB symptom variables (daily episodes of urgency, urgency incontinence, incontinence, and nocturia, and voided vol./micturition).  Quality of life (QoL) and safety were assessed.  A constrained longitudinal data anal. model was used for anal. of efficacy.Patients taking vibegron 50 mg and 100 mg orally for 12 wk had significant improvements over the placebo in the primary and secondary endpoints.  The proportions of patients with normalization of micturition, resoln. of urgency, urgency incontinence, and incontinence were significantly greater than placebo.  Vibegron significantly improved QoL, with high patient satisfaction.  Incidences of drug-related adverse events with vibegron 50 mg and 100 mg were 7.6%, 5.4%, similar to placebo (5.1%), and less than imidafenacin (10.3%).  Treatment was for just 12 wk and a long-term study is needed.  The 12-wk treatment with vibegron is effective and well tolerated inpatients with OAB.  This randomized study demonstrated that vibegron is clin. useful for treatment of patients with OAB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3tRLvgD7ry7Vg90H21EOLACvtfcHk0lhH8NZMdpWbQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVCkt7nN&md5=8a0772a37e2b7a5c635652125a06992e</span></div><a href="/servlet/linkout?suffix=cit214a&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2017.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2017.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DGotoh%26aufirst%3DM.%26aulast%3DNagai%26aufirst%3DS.%26aulast%3DKurose%26aufirst%3DT.%26atitle%3DVibegron%252C%2520a%2520Novel%2520Potent%2520and%2520Selective%2520B3-Adrenoreceptor%2520Agonist%252C%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Overactive%2520Bladder%253A%2520A%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%25203%2520Study%26jtitle%3DEur.%2520Urol.%26date%3D2018%26volume%3D73%26spage%3D783%26epage%3D790%26doi%3D10.1016%2Fj.eururo.2017.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit214b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wein, A. J.</span></span> <span> </span><span class="NLM_article-title">Re: Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2018.04.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1016%2Fj.juro.2018.04.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFSrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=2018&pages=33-38&author=A.+J.+Wein&title=Re%3A+Pharmacological+Characterization+of+a+Novel+Beta+3+Adrenergic+Agonist%2C+Vibegron%3A+Evaluation+of+Antimuscarinic+Receptor+Selectivity+for+Combination+Therapy+for+Overactive+Bladder&doi=10.1016%2Fj.juro.2018.04.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214bR"><div class="casContent"><span class="casTitleNuber">214b</span><div class="casTitle"><span class="NLM_cas:atitle">Re: Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder</span></div><div class="casAuthors">Wein, Alan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-38</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review discussing the pharmacol. characterization of a novel beta 3 adrenergic agonist, Vibegron, and evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJV1yig2ClpbVg90H21EOLACvtfcHk0lhH8NZMdpWbQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFSrsL8%253D&md5=eb52cd897e4a98c27c3bc10731881fcb</span></div><a href="/servlet/linkout?suffix=cit214b&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2018.04.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2018.04.052%26sid%3Dliteratum%253Aachs%26aulast%3DWein%26aufirst%3DA.%2BJ.%26atitle%3DRe%253A%2520Pharmacological%2520Characterization%2520of%2520a%2520Novel%2520Beta%25203%2520Adrenergic%2520Agonist%252C%2520Vibegron%253A%2520Evaluation%2520of%2520Antimuscarinic%2520Receptor%2520Selectivity%2520for%2520Combination%2520Therapy%2520for%2520Overactive%2520Bladder%26jtitle%3DJ.%2520Urol.%26date%3D2018%26volume%3D200%26spage%3D33%26epage%3D38%26doi%3D10.1016%2Fj.juro.2018.04.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit214c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Di Salvo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagabukuro, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickham, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbadie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzmaurice, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gichuru, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jochnowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamlynny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zycband, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenkl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struthers, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.237313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1124%2Fjpet.116.237313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=27965369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVOjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2017&pages=346-355&author=J.+Di+Salvoauthor=H.+Nagabukuroauthor=L.+A.+Wickhamauthor=C.+Abbadieauthor=J.+A.+DeMartinoauthor=A.+Fitzmauriceauthor=L.+Gichuruauthor=A.+Kulickauthor=M.+J.+Donnellyauthor=N.+Jochnowitzauthor=A.+L.+Hurleyauthor=A.+Pereiraauthor=A.+Sanfizauthor=G.+Veroninauthor=K.+Villaauthor=J.+Woodsauthor=B.+Zamlynnyauthor=E.+Zycbandauthor=G.+M.+Salituroauthor=T.+Frenklauthor=A.+E.+Weberauthor=S.+D.+Edmondsonauthor=M.+Struthers&title=Pharmacological+Characterization+of+a+Novel+Beta+3+Adrenergic+Agonist%2C+Vibegron%3A+Evaluation+of+Antimuscarinic+Receptor+Selectivity+for+Combination+Therapy+for+Overactive+Bladder&doi=10.1124%2Fjpet.116.237313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214cR"><div class="casContent"><span class="casTitleNuber">214c</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectiviy for combination therapy for overactive bladder</span></div><div class="casAuthors">Di Salvo, J.; Nagabukuro, H.; Wickham, L. A.; Abbadie, C.; De Martino, J. A.; Fitzmaurice, A.; Gichuru, L.; Kulick, A.; Donnelly, M. J.; Jochnowitz, N.; Hurley, A. L.; Pereira, A.; Sanfiz, A.; Veronin, G.; Villa, K.; Woods, J.; Zamlynny, B.; Zycband, E.; Salituro, G. M.; Frenkl, T.; Weber, A. E.; Edmondson, S. D.; Struthers, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">346-355</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although the physiol. role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists for the treatment of overactive bladder are well established, the role of β3-adrenergic receptors (β3ARs) and their potential as therapeutics is just emerging.  In this manuscript, we characterized the pharmacol. of a novel β3AR agonist vibegron (MK-4618, KRP-114V) and explored mechanistic interactions of β3AR agonism and muscarinic antagonism in urinary bladder function.  Vibegron is a potent, selective full β3AR agonist across species, and it dose dependently increased bladder capacity, decreased micturition pressure, and increased bladder compliance in rhesus monkeys.  The relaxation effect of vibegron was enhanced when combined with muscarinic antagonists, but differentially influenced by muscarinic receptor subtype selectivity.  The effect was greater when vibegron was co-administered with tolterodine, a non-selective antagonist, compared with coadministration with darifenacin, a selective M3 antagonist.  Furthermore, a synergistic effect for bladder strip relaxation was obsd. with the combination of a β3AR agonist and tolterodine in contrast to simple additivity with darifenacin.  To det. expression in rhesus bladder, we employed a novel β3AR agonist probe, [3H]MRL-037, that selectively labels β3 receptors in both urothelium and detrusor smooth muscle.  Vibegron administration caused a dose-dependent increase in circulating glycerol and fatty acid levels in rhesus and rat in vivo, suggesting these circulating lipids can be surrogate biomarkers.  The translation of our observation to the clinic has yet to be detd., but the combination of β3AR agonists with M2/M3 antimuscarinics has the potential to redefine the std. of care for the pharmacol. treatment of overactive bladder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXNS-iTpZTkrVg90H21EOLACvtfcHk0ljZfaQgE1Cktw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVOjs7k%253D&md5=28e4e907bef836e610d91619031289fa</span></div><a href="/servlet/linkout?suffix=cit214c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.237313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.237313%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DNagabukuro%26aufirst%3DH.%26aulast%3DWickham%26aufirst%3DL.%2BA.%26aulast%3DAbbadie%26aufirst%3DC.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26aulast%3DFitzmaurice%26aufirst%3DA.%26aulast%3DGichuru%26aufirst%3DL.%26aulast%3DKulick%26aufirst%3DA.%26aulast%3DDonnelly%26aufirst%3DM.%2BJ.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DSanfiz%26aufirst%3DA.%26aulast%3DVeronin%26aufirst%3DG.%26aulast%3DVilla%26aufirst%3DK.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DZamlynny%26aufirst%3DB.%26aulast%3DZycband%26aufirst%3DE.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DFrenkl%26aufirst%3DT.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DStruthers%26aufirst%3DM.%26atitle%3DPharmacological%2520Characterization%2520of%2520a%2520Novel%2520Beta%25203%2520Adrenergic%2520Agonist%252C%2520Vibegron%253A%2520Evaluation%2520of%2520Antimuscarinic%2520Receptor%2520Selectivity%2520for%2520Combination%2520Therapy%2520for%2520Overactive%2520Bladder%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D360%26spage%3D346%26epage%3D355%26doi%3D10.1124%2Fjpet.116.237313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosjek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabirol, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmond, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohel, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvizo, O.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High Ph Dynamic Kinetic Reduction</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6863</span>– <span class="NLM_lpage">6867</span>, <span class="refDoi"> DOI: 10.1002/anie.201802791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fanie.201802791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovFClu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=6863-6867&author=F.+Xuauthor=B.+Kosjekauthor=F.+L.+Cabirolauthor=H.+Chenauthor=R.+Desmondauthor=J.+Parkauthor=A.+P.+Gohelauthor=S.+J.+Collierauthor=D.+J.+Smithauthor=Z.+Liuauthor=J.+M.+Janeyauthor=J.+Y.+L.+Chungauthor=O.+Alvizo&title=Synthesis+of+Vibegron+Enabled+by+a+Ketoreductase+Rationally+Designed+for+High+Ph+Dynamic+Kinetic+Reduction&doi=10.1002%2Fanie.201802791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215aR"><div class="casContent"><span class="casTitleNuber">215a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High pH Dynamic Kinetic Reduction</span></div><div class="casAuthors">Xu, Feng; Kosjek, Birgit; Cabirol, Fabien L.; Chen, Haibin; Desmond, Richard; Park, Jeonghan; Gohel, Anupam P.; Collier, Steven J.; Smith, Derek J.; Liu, Zhuqing; Janey, Jacob M.; Chung, John Y. L.; Alvizo, Oscar</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6863-6867</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Described here is an efficient stereoselective synthesis of vibegron enabled by an enzymic dynamic kinetic redn. that proceeds in a high-pH environment.  To overcome enzyme performance limitations under these conditions, a ketoreductase (KRED) was evolved by a computationally and structurally aided strategy to increase cofactor stability through tighter binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRH49eLjY5XrVg90H21EOLACvtfcHk0ljZfaQgE1Cktw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovFClu7g%253D&md5=c7d262c01344ade2489bd9b098eda32b</span></div><a href="/servlet/linkout?suffix=cit215a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201802791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201802791%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DF.%26aulast%3DKosjek%26aufirst%3DB.%26aulast%3DCabirol%26aufirst%3DF.%2BL.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDesmond%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DGohel%26aufirst%3DA.%2BP.%26aulast%3DCollier%26aufirst%3DS.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJaney%26aufirst%3DJ.%2BM.%26aulast%3DChung%26aufirst%3DJ.%2BY.%2BL.%26aulast%3DAlvizo%26aufirst%3DO.%26atitle%3DSynthesis%2520of%2520Vibegron%2520Enabled%2520by%2520a%2520Ketoreductase%2520Rationally%2520Designed%2520for%2520High%2520Ph%2520Dynamic%2520Kinetic%2520Reduction%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D6863%26epage%3D6867%26doi%3D10.1002%2Fanie.201802791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit215b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Desmond, R.</span>; <span class="NLM_string-name">Park, J.</span>; <span class="NLM_string-name">Kalinin, A.</span>; <span class="NLM_string-name">Kosjek, B.</span>; <span class="NLM_string-name">Strotman, H.</span>; <span class="NLM_string-name">Li, H.</span>; <span class="NLM_string-name">Moncecchi, J.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Beta 3 Agonists and Intermediates</span>. <span class="NLM_patent">WO2014150639A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=F.+Xu&author=Z.+Liu&author=R.+Desmond&author=J.+Park&author=A.+Kalinin&author=B.+Kosjek&author=H.+Strotman&author=H.+Li&author=J.+Moncecchi&title=Process+for+Preparing+Beta+3+Agonists+and+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DF.%26atitle%3DProcess%2520for%2520Preparing%2520Beta%25203%2520Agonists%2520and%2520Intermediates%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit215c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Zhong, Y.-L.</span>; <span class="NLM_string-name">Chung, J. Y. L.</span>; <span class="NLM_string-name">Dunn, R. F.</span>; <span class="NLM_string-name">Maloney, K. M.</span>; <span class="NLM_string-name">Campos, K.</span>; <span class="NLM_string-name">Hoerrner, R. S.</span>; <span class="NLM_string-name">Lynch, J.</span>; <span class="NLM_string-name">Xu, F.</span>; <span class="NLM_string-name">Cleator, E.</span>; <span class="NLM_string-name">Gibson, A.</span>; <span class="NLM_string-name">Keen, S.</span>; <span class="NLM_string-name">Lieberman, D.</span>; <span class="NLM_string-name">Yoshikawa, N.</span></span> <span> </span><span class="NLM_article-title">Process for Making Beta 3 Agonists and Intermediates</span>. <span class="NLM_patent">WO2013062881A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=N.+Yasuda&author=Z.+Liu&author=Y.-L.+Zhong&author=J.+Y.+L.+Chung&author=R.+F.+Dunn&author=K.+M.+Maloney&author=K.+Campos&author=R.+S.+Hoerrner&author=J.+Lynch&author=F.+Xu&author=E.+Cleator&author=A.+Gibson&author=S.+Keen&author=D.+Lieberman&author=N.+Yoshikawa&title=Process+for+Making+Beta+3+Agonists+and+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DN.%26atitle%3DProcess%2520for%2520Making%2520Beta%25203%2520Agonists%2520and%2520Intermediates%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit215d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span>; <span class="NLM_string-name">Chang, L.</span>; <span class="NLM_string-name">Edmondson, S. D.</span>; <span class="NLM_string-name">Goble, S. D.</span>; <span class="NLM_string-name">Ha, S. N.</span>; <span class="NLM_string-name">Kar, N. F.</span>; <span class="NLM_string-name">Kopka, I. E.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Morriello, G. J.</span>; <span class="NLM_string-name">Moyes, C. R.</span>; <span class="NLM_string-name">Shen, D.-M.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Zhu, C.</span></span> <span> </span><span class="NLM_article-title">Hydroxymethyl Pyrrolidine as B3 Adrenoceptor Agonist</span>. <span class="NLM_patent">JP2012020961A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Berger&author=L.+Chang&author=S.+D.+Edmondson&author=S.+D.+Goble&author=S.+N.+Ha&author=N.+F.+Kar&author=I.+E.+Kopka&author=B.+Li&author=G.+J.+Morriello&author=C.+R.+Moyes&author=D.-M.+Shen&author=L.+Wang&author=C.+Zhu&title=Hydroxymethyl+Pyrrolidine+as+B3+Adrenoceptor+Agonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DR.%26atitle%3DHydroxymethyl%2520Pyrrolidine%2520as%2520B3%2520Adrenoceptor%2520Agonist%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit215e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagabukuro, H.</span>; <span class="NLM_string-name">Edmondson, S. D.</span>; <span class="NLM_string-name">Sinharoy, M. S.</span>; <span class="NLM_string-name">Denney, W. S.</span>; <span class="NLM_string-name">Frenkl, T. L.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy Using a Beta 3 Adrenergic Receptor Agonist and an Antimuscarinic Agent</span>. <span class="NLM_patent">WO2011043942A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=H.+Nagabukuro&author=S.+D.+Edmondson&author=M.+S.+Sinharoy&author=W.+S.+Denney&author=T.+L.+Frenkl&title=Combination+Therapy+Using+a+Beta+3+Adrenergic+Receptor+Agonist+and+an+Antimuscarinic+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNagabukuro%26aufirst%3DH.%26atitle%3DCombination%2520Therapy%2520Using%2520a%2520Beta%25203%2520Adrenergic%2520Receptor%2520Agonist%2520and%2520an%2520Antimuscarinic%2520Agent%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit215f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span>; <span class="NLM_string-name">Chang, L.</span>; <span class="NLM_string-name">Edmondson, S. D.</span>; <span class="NLM_string-name">Goble, S. D.</span>; <span class="NLM_string-name">Ha, S. N.</span>; <span class="NLM_string-name">Kar, N. F.</span>; <span class="NLM_string-name">Kopka, I. E.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Morriello, G. J.</span>; <span class="NLM_string-name">Moyes, C. R.</span>; <span class="NLM_string-name">Shen, D.-M.</span>; <span class="NLM_string-name">Wang, L.</span>; <span class="NLM_string-name">Zhu, C.</span></span> <span> </span><span class="NLM_article-title">Hydroxymethyl Pyrrolidines as Beta 3 Adrenergic Receptor Agonists</span>. <span class="NLM_patent">WO2009124167A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=R.+Berger&author=L.+Chang&author=S.+D.+Edmondson&author=S.+D.+Goble&author=S.+N.+Ha&author=N.+F.+Kar&author=I.+E.+Kopka&author=B.+Li&author=G.+J.+Morriello&author=C.+R.+Moyes&author=D.-M.+Shen&author=L.+Wang&author=C.+Zhu&title=Hydroxymethyl+Pyrrolidines+as+Beta+3+Adrenergic+Receptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DR.%26atitle%3DHydroxymethyl%2520Pyrrolidines%2520as%2520Beta%25203%2520Adrenergic%2520Receptor%2520Agonists%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyker, G.</span></span> <span> </span><span class="NLM_article-title">Amino Acid Derivatives by Multicomponent Reactions</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1702</span>, <span class="refDoi"> DOI: 10.1002/anie.199717001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=10.1002%2Fanie.199717001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;key=1%3ACAS%3A528%3ADyaK2sXmtVSjsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=1700-1702&author=G.+Dyker&title=Amino+Acid+Derivatives+by+Multicomponent+Reactions&doi=10.1002%2Fanie.199717001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acid derivatives by multicomponent reactions</span></div><div class="casAuthors">Dyker, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition in English</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1700-1702</span>CODEN:
                <span class="NLM_cas:coden">ACIEAY</span>;
        ISSN:<span class="NLM_cas:issn">0570-0833</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH</span>)
        </div><div class="casAbstract">A review with 12 refs. on the synthesis of amino acid derivs. by the Strecker synthesis, Ugi's four-component condensation, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnr3ZWzczxSLVg90H21EOLACvtfcHk0lht4nqlYJX0Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmtVSjsrY%253D&md5=0cfaa353be3768fd4f47b3f6e51e5970</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1002%2Fanie.199717001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.199717001%26sid%3Dliteratum%253Aachs%26aulast%3DDyker%26aufirst%3DG.%26atitle%3DAmino%2520Acid%2520Derivatives%2520by%2520Multicomponent%2520Reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1997%26volume%3D36%26spage%3D1700%26epage%3D1702%26doi%3D10.1002%2Fanie.199717001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-19%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00345%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00345" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677acc13feec3ddd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
